Inflammation/Immunology

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

(+)-(3R,8S)-Falcarindiol

((3R,8S)-Falcarindiol; 3(R),8(S),9(Z)-Falcarindiol) Cat. No.: HY-N1976

(+)-(3R,8S)-Falcarindiol is a polyacetylene found in carrots, has **antimycobacterial** activity, with an IC_{50} of 6 μM and MIC of 24 μM against Mycobacterium tuberculosis H37Ra. Antineoplastic and anti-inflammatory activity.



Purity: 97.48%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(+)-Balanophonin

Cat. No.: HY-N5089

(+)-Balanophonin is a phenolic compound that could be isolated from Passiflora edulis. (+)-Balanophonin possesses anti-oxidant, anticholinesterase, anti-inflammatory, anticancer, and antineurodegenerative activities.
.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(+)-Columbianetin

((S)-Columbianetin) Cat. No.: HY-N0363

(+)-Columbianetin is an isomer of Columbianetin. Columbianetin is a phytoalexin associated with celery (Apium graveolens) resistance to pathogens during storage. Columbianetin exhibits excellent anti-fungal and anti-inflammatory activity.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

(+)-Columbianetin acetate

((S)-Columbianetin acetate) Cat. No.: HY-N0363A

(S)-Columbianetin acetate is an isomer of Columbianetin. Columbianetin is a phytoalexin associated with celery (Apium graveolens) resistance to pathogens during storage. Columbianetin exhibits excellent anti-fungal and anti-inflammatory activity.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

(+)-DHMEQ ((1R,2R,6R)-Dehydroxymethylepoxyquinomicin; (1R,2R,6R)-DHMEQ)

Cat. No.: HY-14645A

(+)-DHMEQ is an activator of antioxidant transcription factor **Nrf2**. (+)-DHMEQ is the enantiomer of (-)-DHMEQ. (-)-DHMEQ inhibits NF-kB than its enantiomer (+)-DHMEQ.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

(+)-Isolariciresinol

((+)-Cyclolariciresinol) Cat. No.: HY-14579

(+)-Isolariciresinol ((+)-Cyclolariciresinol) can be used for the research of rheumatitis. Anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(+)-Medioresinol Di-O-β-D-glucopyranoside

Cat. No.: HY-N8209

(+)-Medioresinol Di-O-β-D-glucopyranoside is a lignan glucoside with strong inhibitory activity of **3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(+)-Schisandrin B

Cat. No.: HY-N2267

(+)-Schisandrin B is an enantiomer of Schisandrin B. Schisandrin B is an active dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, has antioxidant effect on rodent liver and heart.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(-)-Alkannin

Cat. No.: HY-N6012

(-)-Alkannin, found in Alkanna tinctoria, is used as a food coloring. (-)-Alkannin shows anticancer activity, arrests cell cycle, and induces **apoptosis**. (-)-Alkannin improves hepatic inflammation in a Rho-kinase pathway.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(-)-Anomalin

((-)-Praeruptorin B) Cat. No.: HY-N0947

(-)-Anomalin ((-)-Praeruptorin B) is a coumarin derivative isolated from the root of S. resinosum.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

(-)-Butin

Cat. No.: HY-N6020

(-)-Butin is the S enantiomer of Butin. Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera, with strong antioxidant, antiplatelet and anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(-)-Corypalmine

(Discretinine)

Cat. No.: HY-N3636

(-)-Corypalmine (Discretinine), an alkaloid that could be isolated from the stem of Guatteriopsis friesiana, possesses antimicrobial activity.
.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(-)-Curine

Cat. No.: HY-N2569

(-)-Curine is an orally active bisbenzylisoquinoline alkaloid isolated from Chondrodendron platyphyllum. (-)-Curine presents anti-inflammatory and analgesic effects at nontoxic doses, at least in part, resulting from the inhibition of **prostaglandin E2** production.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(-)-DHMEQ

(Dehydroxymethylepoxyquinomicin)

Cat. No.: HY-14645

(-)-DHMEQ (Dehydroxymethylepoxyquinomicin) is a potent, selective and irreversible **NF-κB** inhibitor that covalently binds to a cysteine residue. (-)-DHMEQ inhibits nuclear translocation of **NF-κB** and shows anti-inflammatory and anticancer activity.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

(-)-Epicatechin

((-)-Epicatechol; Epicatechin; epi-Catechin)

Cat. No.: HY-N0001

(-)-Epicatechin inhibits cyclooxygenase-1 (**COX-1**) with an IC_{50} of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the p65 subunit of NF-κB.



Purity: 99.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

(-)-Ibuprofenamide

((R)-Ibuprofenamide)

Cat. No.: HY-111950

(-)-Ibuprofenamide is an amide prodrug of Ibuprofen with anti-inflammatory activity. Ibuprofen is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(-)-Integerrimine

Cat. No.: HY-122772

(-)-Integerrimine, a pyrrolizidine alkaloid, has antiulcerogenic activity. (-)-Integerrimine is also a mutagenic and weakly clastogenic agent in Drosophila.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(-)-Ketoconazole

((-)-Ketoconazol; (-)-R 41400)

Cat. No.: HY-B0105B

(-)-Ketoconazole ((-)-R 41400) is one of the enantiomer of Ketoconazole. Ketoconazole is a racemic mixture of two enantiomers, levoketoconazole ((2S,4R)-(−)-ketoconazole) and dextroketoconazole ((2R,4S)-(+)-ketoconazole).



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

(-)-Taxifolin

((-)-Dihydroquercetin)

Cat. No.: HY-N0136B

(-)-Taxifolin is the less active enantiomer of Taxifolin. Taxifolin exhibits important anti-**tyrosinase** activity. Taxifolin exhibits significant inhibitory activity against **collagenase** with an IC_{50} value of 193.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(-)-Zeylenol

(Zeylenol)

Cat. No.: HY-N2052

(-)-Zeylenol, isaolated from stems of Uvaria grandiflora, possesses anti-inflammatory and anticancer activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(2-Chloropyridin-4-yl)methanamine hydrochloride

Cat. No.: HY-101771A

(2-Chloropyridin-4-yl)methanamine hydrochloride is a selective **LOXL2** inhibitor with an IC_{50} of 126 nM.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

(2R,5S)-Ritlecitinib

((2R,5S)-PF-06651600)

Cat. No.: HY-100754B

(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective **JAK3** inhibitor (IC_{50}=144.8 nM) extracted from patent US20150158864A1, example 68.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 5 mg

(2S)-2'-Methoxykurarinone

(2'-O-Methylkurarinone)

Cat. No.: HY-N1746

(2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

(3R,4S)-Tofacitinib

Cat. No.: HY-40354D

(3R,4S)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib inhibits **JAK3** with IC_{50} of 1 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

(3R,5S)-Atorvastatin sodium

Cat. No.: HY-135374

(3R,5S)-Atorvastatin sodium is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC_{50}s of 0.39 μM and 2.39 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(3S,4R)-Tofacitinib

Cat. No.: HY-40354B

(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib inhibits **JAK3** with IC_{50} of 1 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

(3S,4S)-Tofacitinib

Cat. No.: HY-40354C

(3S,4S)-Tofacitinib is the less active S-enantiomer of Tofacitinib. Tofacitinib inhibits **JAK3** with IC_{50} of 1 nM.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 1 mg

(3β,7β,12β,20Z)-3,7,12-Trihydroxy-11,15,23-trioxo-lanost-8,20-dien-26-oic acid

Cat. No.: HY-N8090

(3β,7β,12β,20Z)-3,7,12-Trihydroxy-11,15,23-trioxo-lanost-8,20-dien-26-oic acid, a lanostane triterpenoids, exhibits obvious NO inhibitory activity on n LPS-induced BV-2 microglia cells with an IC_{50} of 9.55 uM. (3β,7β,12β,20Z)-3,7,12-Tri.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(5R,6E)-5-Hydroxy-1,7-diphenyl-6-hepten-3-one

((5R)-trans-1,7-diphenyl-5-hydroxy-6-hepten-3-one)

Cat. No.: HY-N2185

(5R,6E)-5-Hydroxy-1,7-diphenyl-6-hepten-3-one is the methylene chloride extract of Alpinia nutans, has antioxidant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

(5α)-Stigmastane-3,6-dione

Cat. No.: HY-N1203

(5α)-Stigmastane-3,6-dione is a naturally occurring sterol that could be isolated from fruits of Ailanthus altissima Swingle. Antimicrobial Activity..
.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 5 mg

(E)-Ethyl p-methoxycinnamate

Cat. No.: HY-N0346A

(E)-Ethyl p-methoxycinnamate is a natural product found in Kaempferia galangal with anti-inflammatory, anti-neoplastic and anti-microbial effects.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

(E)-m-Coumaric acid

Cat. No.: HY-N7127

(E)-m-Coumaric acid (3-Hydroxycinnamic acid) is an aromatic acid that highly abundant in food.
(E)-m-Coumaric acid (3-Hydroxycinnamic acid) is an antioxidant.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

(E)-SIS3

Cat. No.: HY-13013

(E)-SIS3 is a potent and selective inhibitor of **Smad3** with an IC_{50} of 3 μM for Smad3 phosphorylation. (E)-SIS3 inhibits the myofibroblast differentiation of fibroblasts by TGF-β1.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

(E/Z)-BCI

(NSC 150117)

Cat. No.: HY-126390

(E/Z)-BCI (NSC 150117) is a **dual-specificity phosphatase 6 (DUSP6)** inhibitor with anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-Demethoxycurcumin

(p-Hydroxycinnamoyl-feruloylmethane)

Cat. No.: HY-N0006A

(E/Z)-Demethoxycurcumin (p-Hydroxycinnamoyl-feruloylmethane) is a curcuminoid isolated from curcuma species, with anticoagulative active.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-IT-603

Cat. No.: HY-121508

(E/Z)-IT-603 is a mixture of E-IT-603 and Z-IT-603 (IT-603). IT-603 is a **c-Rel** inhibitor with an IC_{50} of 3 μM. IT-603 has anti-tumor activity.
(E/Z)-IT-603 is a promising modulator of T-cell responses in the context of graft-versus-host disease (GVHD) and malignant diseases.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(E/Z)-Methyl mycophenolate

Cat. No.: HY-113972A

(E/Z)-Methyl mycophenolate is a racemic compound of (Z)-Methyl mycophenolate and (E)-Methyl mycophenolate isomers. Methyl mycophenolate is a methyl ester of mycophenolic acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-Polydatin

((E/Z)-Piceid)

Cat. No.: HY-N0120

(E/Z)-Polydatin ((E/Z)-Piceid) is a monocrystalline compound originally isolated from the root and rhizome of Polygonum cuspidatum.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

(E/Z)-Sivopixant

((E/Z)-S-600918)

Cat. No.: HY-137451A

(E/Z)-Sivopixant ((E/Z)-S-600918) is a potent **P2X3 receptor** antagonist with an IC_{50} of 4 nM. (E/Z)-Sivopixant can be used for respiratory diseases research.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(R)-(+)-Anatabine

Cat. No.: HY-126047B

(R)-(+)-Anatabine is an less active R-enantiomer of Anatabine. Anatabine is a potent **α4β2 nAChR** agonist. Anatabine inhibits **NF-κB** activation lower **amyloid-β (Aβ)** production by preventing the β-cleavage of amyloid precursor protein (APP).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-(-)-Ibuprofen

((R)-Ibuprofen) Cat. No.: HY-78131B

(R)-(-)-Ibuprofen is the R enantiomer of Ibuprofen, inactive on COX, inhibits **NF-κB** activation; (R)-(-)-Ibuprofen exhibits anti-inflammatory and antinociceptive effects.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg

(R)-Apremilast

((R)-CC-10004) Cat. No.: HY-I0636

(R)-Apremilast ((R)-CC-10004) is a enantiomer of Apremilast.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(R)-BPO-27

Cat. No.: HY-19778

(R)-BPO-27, the R enantiomer of BPO-27, is a potent, orally active and ATP-competitive **CFTR** inhibitor with an IC_{50} of 4 nM.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

(R)-Citronellol

(D-Citronellol; (R)-(+)-β-Citronellol) Cat. No.: HY-124257

(R)-Citronellol (D-Citronellol) is an alcoholic monoterpene found in geranium essential oil. (R)-Citronellol inhibits degranulation of mast cells and does not affect caffeine bitterness perception.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

(R)-Fangchinoline

(Thalrugosine; Thaligine) Cat. No.: HY-N1372

(R)-Fangchinoline (Thalrugosine), a alkaloids from genus Stephaniaexhibits antimicrobial and hypotensive activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-Lansoprazole

(Dexlansoprazole) Cat. No.: HY-13662B

(R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid.



Purity: 95.04%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

(R)-Lisofylline

((R)-Lisophylline) Cat. No.: HY-109854A

(R)-Lisofylline ((R)-Lisophylline) is a (R)-enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 5 mg

(R)-NVS-ZP7-4

Cat. No.: HY-114395A

(R)-NVS-ZP7-4 is the R-isomer of NVS-ZP7-4. NVS-ZP7-4 is a Zinc transporter SLC39A7 **(ZIP7)** inhibitor that is also the first reported chemical tool to probe the impact of modulating ER zinc levels and investigate ZIP7 as a novel druggable node in the Notch pathway.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(R)-Posenacaftor sodium

((R)-PTI-801 sodium) Cat. No.: HY-109187B

(R)-Posenacaftor (R)-PTI-801) sodium is the R enantiomer of Posenacaftor. Posenacaftor is a **cystic fibrosis transmembrane regulator (CFTR) protein** modulator that corrects the folding and trafficking of CFTR protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(R,R)-CXCR2-IN-2

Cat. No.: HY-120878A

(R,R)-CXCR2-IN-2, diastereoisomer of CXCR2-IN-2 (compound 68), is a brain penetrant **CXCR2** antagonist with a pIC_{50} of 9 and 6.8 in the Tango assay and d in the HWB Gro-α induced CD11b expression assay, respectively.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(R,R)-Palonosetron Hydrochloride

Cat. No.: HY-A0021C

(R,R)-Palonosetron Hydrochloride is the active enantiomer of Palonosetron.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R,R)-Secoisolariciresinol diglucoside

((R,R)-SDG; (R,R)-LGM2605)

Cat. No.: HY-N6937

(R,R)-Secoisolariciresinol diglucoside ((R,R)-SDG) is the minor isomer of Secoisolariciresinol diglucoside in flaxseed.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

(R,S)-Anatabine

Cat. No.: HY-126047A

(R,S)-Anatabine is a a minor tobacco alkaloid found in the Solanaceae family of plants that can be used as a specific marker for the detection of tobacco use.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

(Rac)-Apremilast D5

((Rac)-CC-10004 D5)

Cat. No.: HY-12085S2

(Rac)-Apremilast D5 ((Rac)-CC-10004 D5) is a deuterium labeled (R)-Apremilast. (R)-Apremilast ((R)-CC-10004) is a enantiomer of Apremilast.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-Benpyrine

Cat. No.: HY-133807A

(Rac)-Benpyrine, a racemate of Benpyrine, is a potent and orally active **TNF-α** inhibitor. (Rac)-Benpyrine has the potential for **TNF-α** mediated inflammatory and autoimmune disease research.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(rac)-Etodolac-d3

Cat. No.: HY-76251S1

(Rac)-Etodolac-d3 ((Rac)-AY-24236-d3) is a labelled racemic Etodolac. Etodolac (AY-24236) is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC_{50}=53.5 nM).



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

(Rac)-HAMI 3379

Cat. No.: HY-112248

(Rac)-HAMI 3379 is the racemate of HAMI 3379. HAMI 3379 is a potent and selective **Cysteinyl leukotriene ($CysLT_2$) receptor** antagonist.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

(Rac)-Indoximod

(1-Methyl-DL-tryptophan; (Rac)-NLG-8189)

Cat. No.: HY-133897

(Rac)-Indoximod (1-Methyl-DL-tryptophan) is an indoleamine 2,3-dioxygenase (**IDO**) inhibitor.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

(Rac)-MGV354

Cat. No.: HY-117917

(Rac)-MGV354 is the racemate of MGV354. MGV354 is a soluble guanylate cyclase (sGC) activator with EC_{50}s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-Modipafant

(UK-74505)

Cat. No.: HY-108908

(Rac)-Modipafant (UK-74505) is an orally active, selective, long-acting irreversible **platelet activating factor receptor (PAFR)** antagonist. (Rac)-Modipafant prevents dengue infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

(rac)-Modipafant-d4

Cat. No.: HY-108908S

(rac)-Modipafant-d4 (UK-74505-d4) is the deuterium labeled (Rac)-Modipafant. (Rac)-Modipafant (UK-74505) is an orally active, selective, long-acting irreversible **platelet activating factor receptor (PAFR)** antagonist. (Rac)-Modipafant prevents dengue infection.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg, 25 mg, 100 mg

(Rac)-Mono(3,5,5-trimethylhexyl) phthalate

Cat. No.: HY-133672

(Rac)-Mono(3,5,5-trimethylhexyl) phthalate is a important metabolite of commonly used phthalate plasticizers. (Rac)-Mono(3,5,5-trimethylhexyl) phthalate has immuno-suppressive effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-Myrislignan

Cat. No.: HY-N0608A

(Rac)-Myrislignan is the racemate of Myrislignan. Myrislignan, a lignan isolated from Myristica fragrans Houtt, possesses anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-PF-06250112

Cat. No.: HY-117900A

(Rac)-PF-0625011 is a racemate of PF-06250112. PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor and shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-Telmesteine

Cat. No.: HY-108285

(Rac)-Telmesteine is a **protease** inhibitor and is thus a suitable enzyme stabilizer extracted from patent WO 2017220302 A1, compound II-1. (Rac)-Telmesteine can be used as an enzyme stabilizer in protease-containing detergents and cleaning agents.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg

(rel)-Atorvastatin

Cat. No.: HY-B0589A

(rel)-Atorvastatin, a relative configuration of Atorvastatin. Atorvastatin is an orally active **HMG-CoA** reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC_{50}s of 0.39 μM and 2.39 μM, respectively.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

(rel)-Myrislignan

Cat. No.: HY-N0608B

(rel)-Myrislignan, a relative configuration of Myrislignan. Myrislignan is a lignan isolated from Myristica fragrans Houtt.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

(S)-(+)-Dimethindene maleate

Cat. No.: HY-107647

(S)-(+)-Dimethindene maleate, an enantiomer, is a potent M_2-selective muscarinic receptor antagonist (pA_2 = 7.86/7.74; pK_i = 7.78).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-(+)-Ibuprofen

((S)-Ibuprofen)

Cat. No.: HY-78131A

(S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent **COX-1** and **COX-2** inhibitor with IC_{50}s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

(S)-(+)-Ibuprofen D3

((S)-Ibuprofen D3)

Cat. No.: HY-78131AS

(S)-(+)-Ibuprofen D3 ((S)-Ibuprofen D3) is a deuterium labeled (S)-(+)-Ibuprofen. (S)-(+)-Ibuprofen is the S(+)-enantiomer of Ibuprofen that inhibits **COX-1** and **COX-2** activity with IC_{50}s of 2.1 μM and 1.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

(S)-(+)-Rolipram

((+)-Rolipram; (S)-Rolipram)

Cat. No.: HY-B0392



(S)-(+)-Rolipram ((+)-Rolipram) is a cyclic AMP(cAMP)-specific **phosphodiesterase 4 (PDE4)** inhibitor, with an IC_{50} of 1100 nM. (S)-(+)-Rolipram can suppresse tumor necrosis factor-alpha (TNFα) production by human mononuclear cells.

Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

(S)-(-)-Propranolol hydrochloride

Cat. No.: HY-B0573A



(S)-(-)-Propranolol hydrochloride is a **β-adrenergic receptor** antagonist with log K_d values of -8.16, -9.08, and -6.93 for β_1, β_2, and β_3, respectively.

Purity: ≥97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL,

(S)-BI 665915

Cat. No.: HY-12995A



(S)-BI 665915 is an orally active oxadiazole-containing **5-lipoxygenase-activating protein (FLAP)** inhibitor with an IC_{50} of 1.7 nM for FLAP binding. (S)-BI 665915 inhibits FLAP functional in human whole blood with an IC_{50} of 45 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-Coriolic acid

(13(S)-HODE)

Cat. No.: HY-113884B



(S)-Coriolic acid (13(S)-HODE), the product of 15-lipoxygenase (15-LOX) metabolism of linoleic acid, functions as the endogenous ligand to activate **PPARγ**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-Flurbiprofen

(Esflurbiprofen)

Cat. No.: HY-15123



(S)-Flurbiprofen is an active enantiomer of Flurbiprofen, with IC_{50} values of 0.48 μM and 0.47 μM for **COX-1** and **COX-2**, respectively.

Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg

(S)-Ketorolac

((-)-Ketorolac)

Cat. No.: HY-B0580A



(S)-Ketorolac is a nonsteroidal anti-inflammatory agent. (S)-ketorolac exhibits potent **COX1** and **COX2** enzyme inhibition.

Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

(S)-Thalidomide

((S)-(-)-Thalidomide)

Cat. No.: HY-14658A



(S)-Thalidomide ((S)-(-)-Thalidomide) is the S-enantiomer of Thalidomide. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic and pro-apoptotic effects. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN) .

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C6-NH2 dihydrochloride

(VH032-C6-NH2 dihydrochloride)

Cat. No.: HY-136006



(S,R,S)-AHPC-C6-NH2 dihydrochloride (VH032-C6-NH2 dihydrochloride) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for **AKT** PROTAC degrader.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C6-NH2 hydrochloride

(VH032-C6-NH2 hydrochloride)

Cat. No.: HY-136006A



(S,R,S)-AHPC-C6-NH2 hydrochloride (VH032-C6-NH2 hydrochloride) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for **AKT** PROTAC degrader.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C8-NH2

(VH032-C8-NH2)

Cat. No.: HY-133487B



(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for **AKT** PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1.

Purity: 95.05%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

(S,R,S)-AHPC-C8-NH2 dihydrochloride

(VH032-C8-NH2 dihydrochloride) Cat. No.: HY-133487

(S,R,S)-AHPC-C8-NH2 dihydrochloride (VH032-C8-NH2 dihydrochloride) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for **AKT** PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Z)-Lafutidine

((Z)-FRG-8813) Cat. No.: HY-121406

(Z)-Lafutidine ((Z)-FRG-8813) is a potent **histamine H2 receptor** antagonist. (Z)-Lafutidine shows anti-secretory and gastroprotective activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Z)-Lanoconazole

Cat. No.: HY-14282A

(Z)-Lanoconazole is the Z configuration of Lanoconazole. Lanoconazole is a potent and orally active imidazole **antifungal** agent, shows a broad spectrum of activity against fungi in vitro and in vivo.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

(±)-Catechin

(rel-Cianidanol; rel-Catechuic acid) Cat. No.: HY-B1890

(±)-Catechin (rel-Cianidanol) is the racemate of Catechin. (±)-Catechin has two steric forms of (+)-Catechin and its enantiomer (-)-Catechin. (+)-Catechin inhibits cyclooxygenase-1 (COX-1) with an IC_{50} of 1.4 μM.



Relative stereochemistry

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(±)-CPSI-1306

Cat. No.: HY-110095

(±)-CPSI-1306 is an orally available antagonist of macrophage migration inhibitory factor **(MIF)**.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

(±)-Evodiamine

Cat. No.: HY-N0114A

(±)-Evodiamine, a quinazolinocarboline alkaloid, is a **Top1** inhibitor. Evodiamine exhibits anti-inflammatory, antiobesity, and antitumor effects. (±)-Evodiamine inhibits the proliferation of a wide variety of tumor cells by inducing their **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg, 1 g

(±)-Naproxen-d3

((Rac)-Naproxen-d3) Cat. No.: HY-15029S

(±)-Naproxen-d3 ((Rac)-Naproxen-d3) is the deuterium labeled (±)-Naproxen. (±)-Naproxen is a non-steroidal anti-inflammatory drug (NSAID).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(±)-Norcantharidin

((±)-NCTD) Cat. No.: HY-N0291

(±)-Norcantharidin ((±)-NCTD) is a compound possessing anti-angiogenetic activity with potential use in anti-cancertherapy.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

(±)-Taxifolin

((±)-Dihydroquercetin) Cat. No.: HY-N0136A

(±)-Taxifolin ((±)-Dihydroquercetin) is the racemate of Taxifolin. Taxifolin exhibits important anti-**tyrosinase** activity. Taxifolin exhibits significant inhibitory activity against **collagenase** with an IC_{50} value of 193.3 μM.



Relative stereochemistry

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

(±)11(12)-EET

(11,12-EET) Cat. No.: HY-130494

(±)11(12)-EET is a NLRP3 inflammasome inhibitor. (±)11(12)-EET can be used for the research of anti-inflammatory, angiogenic and cardioprotective.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 μg, 50 μg

(±)-Vasicine

((±)-Peganine) Cat. No.: HY-N7031

(±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H^+-K^+-ATPase activity in vitro with an IC_{50} of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and cytoprotective effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1,2-Dihydrotanshinone

(1,2-Dihydrotanshinquinone) Cat. No.: HY-122970

1,2-Dihydrotanshinone (1,2-Dihydrotanshinquinone) is an abietane diterpene. 1,2-Dihydrotanshinone inhibits the formation of the pathogenic complex formed between (CUG)n-RNA and the splicing-factor muscleblind-like 1 (MBNL1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine

(DOPE) Cat. No.: HY-112005

1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) is a neutral **helper lipid** for cationic liposome and combines with cationic phospholipids to improve transfection efficiency of naked siRNA.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 250 mg

1,3,5,8-Tetrahydroxyxanthone

(Desmethylbellidifolin) Cat. Cat. No.: HY-N2050

1,3,5,8-Tetrahydroxyxanthone (Desmethylbellidifolin) is a natural xanthone extracted from Gentianella acuta. 1,3,5,8-Tetrahydroxyxanthone has antispasmodic effect and anti-inflammatory activity.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1,4-Cineole

Cat. No.: HY-N7117

1,4-Cineole is a widely distributed, natural, oxygenated monoterpene. 1,4-Cineole, present in eucalyptus oil, activates both human **TRPM8** and human **TRPA1**.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

1,4-Dicaffeoylquinic acid

(1,4-DCQA) Cat. No.: HY-N0358

1,4-Dicaffeoylquinic acid (1,4-DCQA) is a phenylpropanoid from Xanthii fructus, inhibits LPS-stimulated TNF-α production.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

1-(4-Chlorophenyl)biguanide-d4 hydrochloride

Cat. No.: HY-W129818S



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

1-beta-D-Arabinofuranosyluracil

(Uracil 1-β-D-arabinofuranoside) Cat. No.: HY-N6652

1-beta-D-Arabinofuranosyluracil (Uracil 1-β-D-arabinofuranoside) isolated from the Caribbean sponge Tectitethya crypta, is a methoxyadenosine derivative.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

1-Eicosanol

(Arachidyl alcohol) Cat. No.: HY-W004263

1-Eicosanol is a natural compound with antioxidant activity isolated from Hypericum carinatum.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 500 mg

1-Heptadecanol

Cat. No.: HY-W004296

1-Heptadecanol is a long-chain primary alcohol with antibacterial activity from Solena amplexicaulis leaves.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

1-Hydroxy-2-butanone

Cat. No.: HY-W005327

1-Hydroxy-2-butanone is a natural compound isolated from Bomboo Juice with antitubercular activity.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg

1-Hydroxy-2-methylanthraquinone

Cat. No.: HY-N1625

1-Hydroxy-2-methylanthraquinone exhibits antimicrobial, antioxidant, pesticidal, and anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1-Hydroxy-ibuprofen

Cat. No.: HY-136592

1-Hydroxy Ibuprofen is a **metabolite** of Ibuprofen in P. australis. Ibuprofen is an anti-inflammatory inhibitor targeting **COX-1** and **COX-2** with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

1-Methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid

Cat. No.: HY-N4226

1-Methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid is from Cordyceps bassiana, which is one of Cordyceps species with anti-oxidative, anti-cancer, anti-inflammatory, anti-diabetic, anti-obesity, anti-angiogenic, and anti-nociceptive...



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

1-Naphthalenemethanol

(1-Hydroxymethylnaphthalene)

Cat. No.: HY-W017241

1-Naphthalenemethanol is a natural compound the root bark extracts of Annona senegalensis with antibacterial activity.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

1-Pentadecanol

Cat. No.: HY-W004295

1-Pentadecanol is a naturally occurring antiacne agent.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

1-Tetradecanol

Cat. No.: HY-W004294

1-Tetradecanol, isolated from Myristica fragrans, is a straight-chain saturated fatty alcohol. 1-Tetradecanol possesses antibacterial and anti-inflammatory (periodontitis) activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

10-DEBC hydrochloride

Cat. No.: HY-100654

10-DEBC hydrochloride is a selective **Akt** inhibitor, with an IC_{50} of 1.28 μM. 10-DEBC hydrochloride is a novel anti-TB compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

10-Gingerol

Cat. No.: HY-N0448

10-Gingerol is a major pungent constituent in the ginger oleoresin from fresh rhizome, with anti-inflammatory, antioxidant and anti-proliferative activities. 10-Gingerol inhibits the proliferation of MDA-MB-231 tumor cell line with an IC_{50} of 12.1 μM.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

10-Hydroxydecanoic acid

(NSC 15139)

Cat. No.: HY-Y0148

10-Hydroxydecanoic acid (NSC 15139) is a saturated fatty acid of 10-hydroxy-trans-2-decenoic acid from royal jelly, with anti-inflammatory activity.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

10-Nitrooleic acid

(CXA-10)

Cat. No.: HY-101559

10-Nitrooleic acid (CXA-10), a nitro fatty acid, has potential effects in disease states in which oxidative stress, inflammation, fibrosis, and/or direct tissue toxicity play significant roles.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

11(α)-Methoxysaikosaponin F

Cat. No.: HY-N4215

11(α)-Methoxysaikosaponin F is a triterpenoid saponin isolated from Bupleurum marginatum Wall.ex DC(ZYCH) which is a promising therapeutic for liver fibrosis. 11(α)-Methoxysaikosaponin F has an IC_{50} of 387.7 nM with viability of hepatic stellate cells-T6 (HSCs-T6).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

12-Epinapelline

Cat. No.: HY-N2162

12-Epinapelline is a diterpene alkaloid isolated from Aconitum baikalense. 12-Epinapelline exhibits Anti-inflammatory activity and stimulates the growth of colonies from fibroblast precursors.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

12-HETE

Cat. No.: HY-113439

12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell **apoptosis** in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

12S-HHT

(12(S)-HHTrE)

Cat. No.: HY-113330

12S-HHT (12(S)-HHTrE) is an enzymatic product of prostaglandin H_2 (PGH_2) derived from cyclooxygenase (COX)-mediated arachidonic acid metabolism. 12S-HHT is an endogenous ligand for **BLT2** that fully activates **BLT2** in vivo.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

13-cis Acitretin D3

(Isoacitretin D3; Ro 13-7652 D3)

Cat. No.: HY-129240S

13-cis Acitretin D3 Isoacitretin D3 is a deuterium labeled 13-cis Acitretin. 13-cis Acitretin is the metabolite of Acitretin after chronic administration. Acitretin(Ro 10-1670) is a second-generation, systemic retinoid that has been used in the treatment of psoriasis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

13-cis-N-[4-(Ethoxycarbonyl)phenyl]retinamide

Cat. No.: HY-112077

13-cis-N-[4-(Ethoxycarbonyl)phenyl]retinamide is a derivative of Retinoic acid.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

14-Deoxy-11,12-didehydroandrographolide

(14-dehydro Andrographolide; AP10)

Cat. No.: HY-N1490

14-Deoxy-11,12-didehydroandrographolide is an analogue of Andrographolide. 14-Deoxy-11,12-didehydroandrographolide inhibits **NF-κB** activation.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

1400W Dihydrochloride

Cat. No.: HY-18731

1400W dihydrochloride is a potent and selective inhibitor of human inducible **NO synthase** with K_i values of 7 nM.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

15-Deoxy-Δ-12,14-prostaglandin J2

(15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2)

Cat. No.: HY-108568

15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective **PPARγ** (EC_{50} of 2 μM) and a covalent **PPARδ** agonist.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg

15-LOX-1 inhibitor 1

Cat. No.: HY-138989

15-LOX-1 inhibitor 1 is a potent inhibitor of **15-LOX-1** (15-lipoxygenase-1) with an IC_{50} value of 0.19 μM. 15-LOX-1 inhibitor 1 protects macrophages from lipopolysaccharide-induced cytotoxicity. 15-LOX-1 inhibitor 1 inhibits NO formation and lipid peroxidation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

15a-Hydroxy-3,11,23-trioxo-lanost-8,20-dien-26-oic acid

Cat. No.: HY-N8104

15a-Hydroxy-3,11,23-trioxo-lanost-8,20-dien-26-oic acid, a Lanostane triterpenoid, possesses NO production inhibitory activities of LPS-induced microglia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

16,16-Dimethyl prostaglandin E2

(16,16-dimethyl PGE2)

Cat. No.: HY-106420

16,16-Dimethyl prostaglandin E2 (16,16-dimethyl PGE2) is an orally active vertebrate **Hematopoietic stem cells (HSCs)** homeostasis critical regulator. 16,16-Dimethyl prostaglandin E2 can act through **EP2/EP4** and has an interaction with the Wnt pathway.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

16α-Hydroxydehydrotrametenolic acid

(3β,16α-Dihydroxylanosta-7,9(11),24-trien-21-oic acid)

Cat. No.: HY-N2990

16α-Hydroxydehydrotrametenolic acid is a triterpene Acid in fermented mycelia of edible fungus Poria cocos.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

16α-Hydroxyprednisolone

(OH-PRED)

Cat. No.: HY-117580

16α-Hydroxyprednisolone is a stereoselective metabolite of the 22(R) epimer of the glucocorticoid budesonide via cytochrome P450 3A (CYP3A) enzymes.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

17-Hydroxyisolathyrol

Cat. No.: HY-N4132

17-Hydroxyisolathyrol is a macrocychc lathyrol derivative isolated from seeds of Euphorbla luthyrrs.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

18α-Glycyrrhetinic acid

Cat. No.: HY-N0375

18α-Glycyrrhetinic acid, a diet-derived compound, is an inhibitor of **NF-kB** and an activator of **proteasome**, which serves as pro-longevity and anti-aggregation factor in a multicellular organism. 18α-Glycyrrhetinic acid induces **apoptosis**.



Purity: 99.32%
Clinical Data: Launched
Size: 100 mg, 500 mg

18β-Glycyrrhetinic acid

Cat. No.: HY-N0180

18β-Glycyrrhetinic acid is the major bioactive component of Glycyrrhizae Radix and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g

19α-Hydroxyasiatic acid

Cat. No.: HY-N8164

19α-Hydroxyasiatic acid, a natural triterpenoid, possesses anti-elastase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1beta-Hydroxyalantolactone

Cat. No.: HY-124670

1beta-Hydroxyalantolactone modulate many processes that influence inflammatory reactions.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 5 mg

2"-O-Galloylhyperin

Cat. No.: HY-N0526

2"-O-Galloylhyperin, an active compound isolated from Pyrola incarnate Fisch., possesses anti-oxidative and anti-inflammatory activities. 2"-O-Galloylhyperin has hepatoprotective effect against oxidative stress-induced liver damage.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

2'-Aminoacetophenone

Cat. No.: HY-I0501

2'-Aminoacetophenone is an aromatic compound containing a ketone substituted by one alkyl group, and a phenyl group. 2'-Aminoacetophenone can be used as a **breath biomarker** for the detection of Ps. Aeruginosa infections in the cystic fibrosis lung.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

2'-Hydroxy-2-methoxychalcone

Cat. No.: HY-128452

2'-Hydroxy-2-methoxychalcone (compound 3b) is a synthetic chalcone, with antimicrobial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2'MeO6MF

Cat. No.: HY-131997

2'MeO6MF is a brain-penetrant positive allosteric modulator at **α2β1γ2L** and all **α1**-containing **$GABA_A$ receptors**. 2'MeO6MF also can directly activate **α2β2/3** and **α2β2/3γ2L $GABA_A$ receptors**. 2'MeO6MF has anxiolytic and sedative effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2,3,4,5-Tetracaffeoyl-D-Glucaric acid

Cat. No.: HY-N4311

2,3,4,5-Tetracaffeoyl-D-Glucaric acid is a caffeoyl-D-glucaric acid derivative isolated from the Genus Gnaphalium.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2,4,6-Trichlorol-3-methyl-5-methoxy-phenol 1-O-β-d-glucopyranosyl-(1 → 6)-β-d-glucopyranoside

Cat. No.: HY-N8132

2,4,6-Trichlorol-3-methyl-5-methoxy-phenol 1-O-β-d-glucopyranosyl-(1 6)-β-d-glucopyranoside is a chlorophenyl glycoside found in the bulbs of Lilium brownie var. viridulum.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2,4,7-Trihydroxy-9,10-dihydrophenanthrene

Cat. No.: HY-N7155

2,4,7-Trihydroxy-9,10-dihydrophenanthrene is a dihydrophenanthrene derivative that can be isolated from the air-dried whole plant of Pholidota chinensis Lindl..



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2,4-Diamino-6-hydroxypyrimidine

Cat. No.: HY-100954

2,4-Diamino-6-hydroxypyrimidine is a specific **GTP cyclohydrolase I** inhibitor (the rate-limiting enzyme in de novo pterin synthesis). 2,4-Diamino-6-hydroxypyrimidine blocks Tetrahydrobiopterin (BH4) synthesis and suppresses **NO** production.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

2,5-Di-tert-butylhydroquinone

Cat. No.: HY-W012399

2,5-Di-tert-butylhydroquinone (DTBHQ), the indirect food additive, regulates the activity of **5-lipoxygenase** as well as the activity of **COX-2** (IC_{50}=1.8 and 14.1 μM for 5-LO and COX-2, respectively) .



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

2,5-Dihydroxyacetophenone

Cat. No.: HY-W001174

2,5-Dihydroxyacetophenone, isolated from Rehmanniae Radix Preparata, inhibits the production of inflammatory mediators in activated macrophages by blocking the **ERK1/2** and **NF-κB** signaling pathways.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide

Cat. No.: HY-120469

GDC-046 is a potent, selective, and orally bioavailable **TYK2** inhibitor with K_is of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

2-(Phosphonooxy)benzoic acid

Cat. No.: HY-N7138

2-(Phosphonooxy)benzoic acid is a non-acetylated salicylic acid derivative which has the potential for inflammatory disease as well as in analgesic therapy.



Purity: ≥97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

2-Acetamidophenol

(Orthocetamol)

Cat. No.: HY-W015600

Paracetamol (4-acetamidophenol). 2-Acetamidophenol is a promising analgesic and an anti-arthritic agent.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 500 mg

2-Furoyl-LIGRLO-amide

Cat. No.: HY-P1314

2-Furoyl-LIGRLO-amide is a potent and selective **proteinase-activated receptor 2 (PAR2)** agonist with a **pD_2** value of 7.0.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

2-Furoyl-LIGRLO-amide TFA

Cat. No.: HY-P1314A

2-Furoyl-LIGRLO-amide TFA is a potent and selective **proteinase-activated receptor 2 (PAR2)** agonist with a **pD_2** value of 7.0.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

2-Heptanol

Cat. No.: HY-W015879

2-Heptanol is one of chemical constituents identified in the essential oil of rhizome of Curcuma angustifolia and Curcuma zedoaria. Rhizome essential oil exhibited good **antimicrobial** and antioxidant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

2-Hydroxy Ibuprofen

((±)-2-Hydroxy Ibuprofen)

Cat. No.: HY-126121

2-Hydroxy Ibuprofen is a metabolite of Ibuprofen. Ibuprofen is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

2-Hydroxy-1-methoxyanthraquinone

Cat. No.: HY-N5125

2-Hydroxy-1-methoxyanthraquinone could be isolated from the stem bark of Morinda lucida Benth. (Rubiaceae) and possesses antibacterial activity.
.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-Methoxy-4-vinylphenol

Cat. No.: HY-W019940

2-Methoxy-4-vinylphenol (2M4VP), a naturally Germination inhibitor, exerts potent anti-inflammatory effects.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

20(R)-Ginsenoside Rh2

Cat. No.: HY-N1401

20(R)-Ginsenoside Rh2, a **matrix metalloproteinase (MMP)** inhibitor, acts as a cell antiproliferator. It has anticancer effects via blocking cell proliferation and causing G1 phase arrest.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

20(S)-Ginsenoside Rg3

(20(S)-Propanaxadiol; S-ginsenoside Rg3)

Cat. No.: HY-N0603



20(S)-Ginsenoside Rg3 is the main component of Red ginseng. Ginsenoside Rg3 inhibits **Na^+** and **hKv1.4** channel with IC_{50}s of 32.2±4.5 and 32.6±2.2 μM, respectively. 20(S)-Ginsenoside Rg3 also inhibits **Aβ** levels, **NF-κB** activity, and **COX-2** expression.

Purity: 98.10%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

20-Deoxyingenol

Cat. No.: HY-N0866



20-Deoxyingenol, a diterpene, is isolated from the roots of Euphorbia kansui. 20-Deoxyingenol can promote autophagy and lysosomal biogenesis by promoting the nuclear translocation of transcription factor EB (TFEB) in vitro.

Purity: 97.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

20-Hydroxyganoderic Acid G

Cat. No.: HY-N7018



20-Hydroxyganoderic Acid G is a lanostane triterpenoid obtained from the EtOH extract of fruiting bodies of the Ganoderma curtisii. 20-Hydroxyganoderic Acid G inhibits BV-2 microglia cells activated by LPS with an IC_{50} of 21.33 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione

Cat. No.: HY-136340



21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione is an **intermediate** of delta 9,11 steroids synthesis, for example, Vamorolone (HY-109017). The delta 9,11 steroids are modifications of glucocorticoids and has **anti-inflammatory** properties.

Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg

21-Desacetyldeflazacort-D5

Cat. No.: HY-100085S



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

24-Norursodeoxycholic acid

(Norucholic acid; nor-UDCA)

Cat. No.: HY-101737



24-norursodeoxycholic acid (Norucholic acid) is a side chain-shortened C_{23} homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory and anti-fibrotic properties.

Purity: ≥98.0%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

25(S)-Ruscogenin-1-O-α-L-rhamnopyranosyl (1→2)-β-D-xylopyranoside

Cat. No.: HY-N5051



25(S)-Ruscogenin-1-O-α-L-rhamnopyranosyl (12)-β-D-xylopyranoside shows inhibitory activity of neutrophil respiratory burst stimulated by PMA(phorbol myristate acetate).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

25-Hydroxycholesterol

Cat. No.: HY-113134



25-Hydroxycholesterol is a metabolite of cholesterol that is produced and secreted by macrophages in response to Toll-like receptor (TLR) activation. 25-hydroxycholesterol is a potent (EC_{50}≈65 nM) and selective suppressor of IgA production by B cells.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

25S-Inokosterone

Cat. No.: HY-N4130



25S-Inokosterone is a phytoecdysone in the roots of two same species of A. bidentata Blume and A. japonica Nakai, and two different species of C. capitata Moq and C. officinalis Kuan. 25S-Inokosterone has the potential for the LPS-induced acute kidney injury research.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

27-O-Acetyl-withaferin A

Cat. No.: HY-N5046



27-O-Acetyl-withaferin A is found in Withania aristata.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

28-O-β-D-Glucopyranosyl pomolic acid

Cat. No.: HY-N1533

28-O-β-D-Glucopyranosyl pomolic acid is a **urokinase plasminogen activator** inhibitor with **IC_{50}** at 37.82 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3'-Azido-3'-deoxy-5-fluorocytidine

Cat. No.: HY-111641

3'-Azido-3'-deoxy-5-fluorocytidine (Compound 12) is a cytidine derivative.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

3'-Hydroxypuerarin

Cat. No.: HY-N1980

3'-Hydroxypuerarin is an isoflavone isolated from the roots of Pueraria lobata (Willd.) Ohwi. 3'-Hydroxypuerarin is a antioxidant, which shows marked ONOO(-), NO•, total ROS scavenging activities.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

3'-O-Methylorobol

Cat. No.: HY-N1859

3'-O-Methylorobol, an antioxidant flavonoid, exhibits moderate antioxidant activity in the 2,2-diphenyl-1-picrylhydrazyl free radical scavenging assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3,11,15,23-Tetraoxo-27ξ-lanosta-8,16-dien-26-oic acid

Cat. No.: HY-N9327

3,11,15,23-Tetraoxo-27ξ-lanosta-8,16-dien-26-oic acid, a lanostane-type triterpenoid, is isolated from Antrodia camphorate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3,4,5-Tricaffeoylquinic acid

(3,4,5-triCQA)

Cat. No.: HY-N6588

3,4,5-Tricaffeoylquinic acid (3,4,5-triCQA) inhibits tumor necrosis factor-α-stimulated production of inflammatory mediators in keratinocytes via suppression of Akt- and NF-κB-pathways.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3,4-Benzocoumarin

Cat. No.: HY-109714

3,4-Benzocoumarin is a kind of the expanded structure of coumarin derivatives.Coumarin is a chemical compound in the benzopyrone chemical class that can be found in many natural species.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3,4-O-Isopropylidene-shikimic acid

Cat. No.: HY-N1782

3,4-O-Isopropylidene-shikimicn acid is a natural product that can be isolated from the whole plants of Hypericum wightianum. 3,4-O-Isopropylidene-shikimic acid has anti-inflammatory effect and antioxidant activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3,5-Dimethoxybenzoic acid

Cat. No.: HY-W001251

3,5-Dimethoxybenzoic acid, isolated from Melia azedarach L. leaves with antifungal activity, is an intermediate in organic synthesis.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

3-Acetamidocoumarin

Cat. No.: HY-W014750

3-Acetamidocoumarin plays an important role in biology and medicine. 3-Acetamidocoumarin has physiological effects and has been used for many diseases such as treatment of burns, brucellosis-rheumatic diseases and cancer.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 25 mg

3-Acetyl-beta-boswellic acid

Cat. No.: HY-N2075

3-Acetyl-beta-boswellic acid is a boswellic acid isolated from Boswellia serrata gum resin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Carene

Cat. No.: HY-N6663

3-Carene is a bicyclic monoterpene in essential oils extracted from pine trees. 3-Carene inhibits nociceptive stimulus-induced inflammatory infiltrates and COX-2 overexpression, and with antinociceptive effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Deazaadenosine

Cat. No.: HY-W013332

3-Deazaadenosine is an inhibitor of **S-adenosylhomocysteine hydrolase**, with a K_i of 3.9 μM; 3-Deazaadenosine has anti-inflammatory, anti-proliferative and anti-**HIV** activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Deazaadenosine hydrochloride

Cat. No.: HY-W013332A

3-Deazaadenosine (hydrochloride) is an inhibitor of **S-adenosylhomocysteine hydrolase**, with a K_i of 3.9 μM; 3-Deazaadenosine has anti-inflammatory, anti-proliferative and anti-**HIV** activity.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

3-Demethylcolchicine

Cat. No.: HY-W021267

3-Demethylcolchicine, a colchicine metabolite, possesses a hydroxy-group on its carbon ring that could participate in radical scavenging and markedly inhibits the carrageenin edema.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

3-Deoxysappanchalcone

Cat. No.: HY-N1745A

3-Deoxysappanchalcone is a naturally-occurring chalcone compound isolated from Caesalpinia sappan L. (Leguminosae), which possesses anti-allergic, antiviral, anti-inflammatory and antioxidant activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Epioleanolic acid

Cat. No.: HY-N4290

3-Epioleanolic acid is an active component of Verbena officinalis Linn, with anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

3-Hydroxy-4-methoxyacetophenone

(Acetoisovanillone; Isoacetovanillone)

Cat. No.: HY-W002484

3-Hydroxy-4-methoxyacetophenone(Acetoisovanillone; Isoacetovanillone) is an active compound isolated from P. spinosa. Isoacetovanillone possesses anti-inflammatory activity and prevented injuries due to administration of acetic acid in the colon.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

3-O-Acetyl-16α-hydroxydehydrotrametenolic acid

Cat. No.: HY-N2989

3-O-Acetyl-16α-hydroxydehydrotrametenolic acid, an anti-inflammatory triterpenoid, inhibits NO production and iNOS expression in LPS-stimulated Raw264.7 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-O-Acetyl-α-boswellic acid

(α-Boswellic acid acetate)

Cat. No.: HY-N3037

3-O-Acetyl-α-boswellic acid suppresses T cell function.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-O-Methylellagic acid

Cat. No.: HY-N7430

3-O-Methylellagic acid is a nature product that can be isolated from Myrciaria cauliflora, with anti-inflammatory activity. 3-O-Methylellagic acid shows an inhibitory effect on glucose transport assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

3-O-Methylquercetin

Cat. No.: HY-N1860

3-O-Methylquercetin (3-MQ), a main constituent of Rhamnus nakaharai, inhibits total cAMP and **cGMP-phosphodiesterase (PDE)** of guinea pig trachealis. 3-O-Methylquercetin (3-MQ) exhibits IC_{50} values of 31.9 μM 86.9 μM 18.6 μM and 1.6 μM for PDE1, PDE5, PDE2 and PDE4, respectively.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Oxo-5β-cholanoic acid

(Dehydrolithocholic acid; 3-oxoLCA)

Cat. No.: HY-125801

3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of **TH17** cells by directly binding to the key transcription factor **RORγt** (K_d=1.13 μM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

3M-011

Cat. No.: HY-121496

3M-011 is a potent dual **toll-like receptor TLR7/8** agonist and a cytokine inducer. 3M-011 significantly inhibits **H3N2 influenza viral** replication in the nasal cavity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3β,7β,15β-Trihydroxy-11-oxo-lanosta-8-en-24→20 lactone

Cat. No.: HY-N2277

3β,7β,15β-Trihydroxy-11-oxo-lanosta-8-en-2420 lactone is a natural compound that could be isolated from G. lucidum with antimycobacterial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4''-methyloxy-Daidzin

(Daidzein 7-O-B-D-glucoside 4''-O-methylate)

Cat. No.: HY-N4128

4''-methyloxy-Daidzin (Daidzein 7-O-B-D-glucoside 4''-O-methylate), an isoflavone methyl-glycoside, is isolated from Cordyceps militaris grown on germinated soybeans. Isoflavones possess immunomodulating and antiallergic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

4''-methyloxy-Genistin

Cat. No.: HY-N4129

4''-methyloxy-Genistin, an isoflavone methyl-glycoside, is isolated from Cordyceps militaris grown on germinated soybeans. Isoflavones possess immunomodulating and antiallergic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

4'-Ethynyl-2'-deoxyadenosine

Cat. No.: HY-125810

4'-Ethynyl-2'-deoxyadenosine (4'-E-dA), a nucleoside **reverse transcriptase (RT)** inhibitor, is an antiretroviral agent which is potent against drug-resistant HIV variants, with an EC_{50} of 98 nM in MT-4 cells for anti-HIV-1 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4'-Hydroxy diclofenac

Cat. No.: HY-15550

4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 5 mg

4'-Hydroxy diclofenac-d4

Cat. No.: HY-15550S

4'-Hydroxy diclofenac D4 is the deuterium labeled 4'-Hydroxy diclofenac. 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4'-Hydroxychalcone

Cat. No.: HY-N7056

4'-Hydroxychalcone is a chalcone isolated from licorice root, with hepatoprotective activity. 4'-Hydroxychalcone inhibits TNFα-induced NF-κB activation via **proteasome** inhibition.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

4'-Methoxyresveratrol

(4'-O-Methylresveratrol)

Cat. No.: HY-N2485

4'-Methoxyresveratrol (4'-O-Methylresveratrol) is a polyphenol derived from Dipterocarpaceae, with antiandrogenic, antifungal and anti-inflammatory activities.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

4'-O-Methylochnaflavone

Cat. No.: HY-N4300

4'-O-Methylochnaflavone is a biflavonoid isolated from Lonicera japonica, suppresses mouse lymphocyte proliferation.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

4(3H)-Quinazolinone

Cat. No.: HY-W018800

4(3H)-Quinazolinone is a building block in chemical synthesis. Biologically active nitrogen heterocyclic compounds. Possesses a wide spectrum of biological properties like antibacterial, antifungal, anticonvulsant, anti-inflammatory, anti-HIV, anticancerous and analgesic activities.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone

Cat. No.: HY-N8184

4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone exhibits **COX-1** and **COX-2** inhibitory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4,6-Dichloroguaiacol

Cat. No.: HY-133608

4,6-Dichloroguaiacol induces biochemical and morphological changes in human peripheral blood lymphocytes in vitro.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4-Acetamidophenyl acetate

Cat. No.: HY-66004

4-Acetamidophenyl acetate is an impurity of Acetaminophen (paracetamol). Acetaminophen, an analgesic drug, is a selective COX-2 inhibitor (IC_{50}=25.8 μM), and is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4-Aminosalicylic acid

Cat. No.: HY-I0447

4-Aminosalicylic acid (ASA) is an orally active antibiotic and has the potential to treat tuberculosis.



Purity: 97.32%
Clinical Data: Launched
Size: 500 mg

4-Hydroperoxy cyclophosphamide

Cat. No.: HY-117433

4-Hydroperoxy cyclophosphamide is the active metabolite form of the prodrug Cyclophosphamide.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

4-Hydroperoxy Cyclophosphamide-d4

Cat. No.: HY-117433S

4-Hydroperoxy Cyclophosphamide-d4 is the deuterium labeled 4-Hydroperoxy cyclophosphamide. 4-Hydroperoxy cyclophosphamide is the active metabolite form of the prodrug Cyclophosphamide.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

4-Hydroxyacetophenone

(P-hydroxyacetophenone)

Cat. No.: HY-Y0073

4-Hydroxyacetophenone (P-hydroxyacetophenone) is a key hepatoprotective and choleretic compound in Artemisia capillaris and A. morrisonensis, also has an anti-hepatitis B virus effect and anti-inflammatory effect.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

4-Hydroxyacetophenone oxime

Cat. No.: HY-135325

4-Hydroxyacetophenone oxime is an impurity of Acetaminophen (Paracetamol). Acetaminophen is a potent cyclooxygenase-2 (COX-2) and hepatic N-acetyltransferase 2 (NAT2) inhibitor, and used antipyretic and analgesic drug.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4-Hydroxybenzyl alcohol

Cat. No.: HY-Y0892

4-Hydroxybenzyl alcohol is a phenolic compound widely distributed in various kinds of plants. Anti-inflammatory, anti-oxidant, anti-nociceptive activity. Neuroprotective effect. Inhibitor of tumor angiogenesis and growth.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

4-Hydroxychalcone

Cat. No.: HY-107818

4-Hydroxychalcone is a chalcone metabolite with anti-angiogenic and anti-inflammatory activities. 4-Hydroxychalcone suppresses angiogenesis by suppression of growth factor pathway with no signs of cytotoxicity.



Purity: 99.65%
Clinical Data:
Size: 10 mM × 1 mL, 100 mg

4-Hydroxylonchocarpin

Cat. No.: HY-N2208

4-Hydroxylonchocarpin is a chalcone compound from an extract of Psoralea corylifolia. 4-Hydroxylonchocarpin increases phosphorylation of p38 MAPK, JNK and ERK.



Purity: 92.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

4-Hydroxyphenyl Carvedilol-d5

(4-Hydroxycarvedilol-d5)

Cat. No.: HY-12767S

4-Hydroxyphenyl Carvedilol D5 is the deuterium labeled 4-Hydroxyphenyl Carvedilol.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4-Methoxycinnamic acid

Cat. No.: HY-N1387

4-Methoxycinnamic acid is detected as natural phenylpropanoid in A. preissii.



Purity: 96.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 1 g

4-Methylamino antipyrine

Cat. No.: HY-135731

4-Methylamino antipyrine is an active metabolite of Metamizole. Metamizole is a pyrazolone non-steroidal anti-inflammatory drug (NSAID) and inhibits **COX**. Metamizole is an nonopioid analgesic drug and can be used for pain and fever.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

4-Methylamino antipyrine hydrochloride

Cat. No.: HY-135731A

4-Methylamino antipyrine hydrochloride is an active metabolite of Metamizole. Metamizole is a pyrazolone non-steroidal anti-inflammatory drug (NSAID) and inhibits **COX**. Metamizole is an nonopioid analgesic drug and can be used for pain and fever.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

4-Methylesculetin

Cat. No.: HY-N4288

4-Methylesculetin is an orally active natural coumarin derivative, with potent anti-oxidant and anti-inflammatory activities. 4-Methylesculetin inhibits **myeloperoxidase** activity and reduces IL-6 level.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

4-O-Cinnamoylquinic acid

Cat. No.: HY-N8217

4-O-Cinnamoylquinic acid could inhibit superoxide anion generation in human neutrophils.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4-O-Methyl honokiol

Cat. No.: HY-U00450

4-O-Methyl honokiol is a natural neolignan isolated from Magnolia officinalis, acts as a **PPARγ** agonist, and inhibtis **NF-κB** activity, used for cancer and inflammation research.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

4-Octyl Itaconate

Cat. No.: HY-112675

4-Octyl Itaconate is a cell-permeable Itaconate derivative. Itaconate is an anti-inflammatory metabolite that activates **Nrf2** via alkylation of KEAP1.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

4-Phenyl-7,8-dihydroxycoumarin

Cat. No.: HY-128410

4-Phenyl-7,8-dihydroxycoumarin is a coumarin derivative and can be used for bronchiectasiss research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4-Propionamidophenol

Cat. No.: HY-135326

4-Propionamidophenol is a p-acetamidophenol analog.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

48740 RP

(RP-55778)

Cat. No.: HY-100153

48740 RP (RP-55778) is a platelet-activating factor (**PAF**) antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5(S)-HPETE

Cat. No.: HY-125770

5(S)-HpETE is a monohydroperoxy polyunsaturated fatty acid (**PUFA**) produced by the action of 5-LO on arachidonic acid. 5(S)-HpETE is metabolized to leukotriene A4 (LTA4), a key intermediate in the formation of LTs.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5,6,7-Trimethoxyflavone

(Baicalein trimethyl ether)

Cat. No.: HY-110398

5,6,7-Trimethoxyflavone is a novel **p38-α MAPK** inhibitor with an anti-inflammatory effect. 5,6,7-Trimethoxyflavone is isolated from several plants including Zeyhera tuberculosa, Callicarpa japonica, and Kickxia lanigera.



Purity: 98.76%
Clinical Data:
Size: 10 mg

5,6-Didehydroginsenoside Rd

Cat. No.: HY-N4263

5,6-Didehydroginsenoside Rd is a dammarane-type saponin isolated from the dried roots of Panax notoginseng.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5,6-Dihydroxyindole

Cat. No.: HY-W018025

5,6-Dihydroxyindole, a melanin precursor, has a broad-spectrum **antibacterial**, **antifungal**, **antiviral**, **antiparasitic** activity. 5,6-Dihydroxyindole has cytotoxic effects and is strongly toxic against various pathogens.



Purity: 95.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

5,7,4'-Trihydroxy-8-Methylflavanone

(8-Methyl-naringenine) Cat. No.: HY-N2210

5,7,4'-Trihydroxy-8-Methylflavanone (Compound 2) is a flavanone isolated from Qualea grandiflora.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5,7,8-Trimethoxyflavone

(Norwogonin 5,7,8-trimethyl ether) Cat. No.: HY-N7656

5,7,8-Trimethoxyflavone (Norwogonin 5,7,8-trimethyl ether), isolated from Andrographis echioides, inhibits **NO** with an IC_{50} of 39.1 μM. 5,7,8-Trimethoxyflavone has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

5,7-Dimethoxyflavanone

Cat. No.: HY-N5054

5,7-Dimethoxyflavanone shows potent antimutagenic activity against MeIQ mutagenesis in Ames test using the S. typhimurium TA100 and TA98 strains. And 5,7-Dimethoxyflavanone significantly and dose-dependently inhibits the inflammatory mediato.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5,7-Dimethoxyflavone

Cat. No.: HY-N5011

5,7-Dimethoxyflavone is one of the major components of Kaempferia parviflora, has anti-obesity, anti-inflammatory, and antineoplastic effects. 5,7-Dimethoxyflavone inhibits cytochrome **P450 (CYP) 3As**.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg

5-A-RU-PABC-Val-Cit-Fmoc

Cat. No.: HY-131296

5-A-RU-PABC-Val-Cit-Fmoc is the prodrug of 5-A-RU. 5-A-RU, a precursor of bacterial Riboflavin, is a **mucosal-associated invariant T (MAIT) cells** activator.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

5-Acetylsalicylic acid

Cat. No.: HY-107831

5-Acetylsalicylic acid has anti-inflammatory and is considered to be the active agent in inflammatory bowel disease (IBD).



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

5-Aminosalicylic Acid

(Mesalamine; 5-ASA; Mesalazine) Cat. No.: HY-15027

5-Aminosalicylic acid (Mesalamine) acts as a specific **PPARγ** agonist and also inhibits p21-activated kinase 1 (**PAK1**) and **NF-κB**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

5-Aminosalicylic Acid-D3 hydrochloride (Mesalamine-D3 hydrochloride; 5-ASA-D3 hydrochloride; ...)

Cat. No.: HY-15027S

5-Aminosalicylic Acid-D3 (Mesalamine-D3) hydrochloride is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific **PPARγ** agonist and also inhibits p21-activated kinase 1 (**PAK1**) and **NF-κB**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

5-Desmethylsinensetin

Cat. No.: HY-N7632

5-desmethylsinensetin, isolated from Stevia satureiifolia var. satureiifolia, possesses antiprotozoal activity. 5-desmethylsinensetin shows IC_{50} values of 0.4 μg/mL on T. cruzi epimastigotes and 75.1 μg/mL on trypomastigotes, respectively.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 1 mg

5-Hydroxy-8-methoxypsoralen

(5-Hydroxyxanthotoxin) Cat. No.: HY-134039

5-Hydroxy-8-methoxypsoralen (5-Hydroxyxanthotoxin) is a metabolite of Xanthotoxin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-Lipoxygenase-In-1

Cat. No.: HY-U00308

5-Lipoxygenase-In-1 is a **5-Lipoxygenase** inhibitor extracted from patent EP 331232 A2, table 4, compound example 4.10.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

5-O-Demethylnobiletin

(5-Demethylnobiletin)

Cat. No.: HY-N1942

5-O-Demethylnobiletin (5-Demethylnobiletin), a polymethoxyflavone isolated from Sideritis tragoriganum, is a direct inhibition of 5-LOX (IC_{50}=0.1 μM), without affecting the expression of COX-2.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

5Z-7-Oxozeaenol

(FR148083; L783279; LL-Z 1640-2)

Cat. No.: HY-12686

5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of **TAK1** and **VEGF-R2**, with IC_{50}s of 8 nM and 52 nM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

5β-Dutasteride

Cat. No.: HY-135386

5β-Dutasteride is the S configuration of Dutasteride. 5β-Dutasteride is a potent inhibitor of both **5 alpha-reductase isozymes**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

6"-O-Malonyldaidzin

Cat. No.: HY-N4073

6"-O-Malonyldaidzin is a malonylated isoflavone isolated from soybean seeds. 6"-O-Malonyldaidzin may has protective effect on eye.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

6''-O-Malonylgenistin

(Malonylgenistin; Genistin malonate)

Cat. No.: HY-N0917

6''-O-Malonylgenistin(Malonylgenistin) is an isoflavone derivative.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

6-Aminochrysene

(6-Chrysenamine)

Cat. No.: HY-108315

6-Aminochrysene (6-Aminochrysene) is an aromatic amine used as a chemotherapeutic agent in the treatment of splenomegaly, myeloid leukemia, and breast cancer.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg

6-Demethoxytangeretin

Cat. No.: HY-N4126

6-Demethoxytangeretin is a citrus flavonoid isolated from Citrus depressa.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

6-Formyl-isoophiopogonanone A

Cat. No.: HY-N2220

6-Formyl-isoophiopogonanone A is a homoisoflavonoidal extracted from Ophiopogon japonicas, with antioxidant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

6-Hydroxycoumarin

Cat. No.: HY-N6656

6-Hydroxycoumarin is a coumarin which has anti-inflammatory, anti-pyretic, anti-oxidant, vasodilator, anti-amoebic, anti-bacterial, anti-fungal, bacteriostatic and antitumor activity.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 100 mg

6-Hydroxyflavone

Cat. No.: HY-N7110

6-Hydroxyflavone is a naturally occurring flavone, with anti-inflammatory activity. 6-Hydroxyflavone exhibits inhibitory effect towards bovine hemoglobin (BHb) glycation.



Purity: 99.88%
Clinical Data:
Size: 10 mM × 1 mL, 100 mg

6-Hydroxyluteolin 7-glucoside

Cat. No.: HY-129529

6-Hydroxyluteolin 7-glucoside is a flavonoid from Tanacetum parthenium and T. vulgare. 6-Hydroxyluteolin 7-glucoside inhibits the major pathways of arachidonate metabolism in leukocytes. 6-Hydroxyluteolin 7-glucoside has anti-inflammatory effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

6-Hydroxyrubiadin

Cat. No.: HY-N2714

6-Hydroxyrubiadin, a natural anthraquinone, may be a potential therapeutic candidate for the treatment of inflammation and inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

6-O-Methyl Guanosine

Cat. No.: HY-111648

6-O-Methyl Guanosine is a modified nucleoside. 6-O-Methyl Guanosine (6-methylguanosine) inhibit colony-forming ability in a malignant xeroderma pigmentosum cell line.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

6-OAU

(GTPL5846)

Cat. No.: HY-12764

6-OAU(GTPL5846; 6-n-octylaminouracil) is a surrogate agonist of GPR84; activates human GPR84 in the presence of Gqi5 chimera in HEK293 cells with an EC50 of 105 nM in the PI assay.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

6-Thioguanine

(Thioguanine; 2-Amino-6-purinethiol)

Cat. No.: HY-13765

6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (**PLpros**) and also potently inhibits **USP2** activity, with IC_{50}s of 25 μM and 40 μM for Plpros and recombinant human...



Purity: ≥99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

6α-Methylprednisolone 21-hemisuccinate sodium salt

(Methylprednisolone sodium succinate; ...)

Cat. No.: HY-B1060

6α-Methylprednisolone 21-hemisuccinate sodium salt is a glucocorticoid of slightly longer half-life than that of Prednisolone. It has potential uses in antiinflammatory agents.



Purity: 98.01%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

7,3',4'-Tri-O-methylluteolin

(5-Hydroxy-3',4',7-trimethoxyflavone)

Cat. No.: HY-N7012

7,3',4'-Tri-O-methylluteolin (5-Hydroxy-3',4',7-trimethoxyflavone) is a flavonoid from the herb Lippia nodiflora L.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

7,4'-Di-O-methylapigenin

(4',7-Dimethoxy-5-Hydroxyflavone)

Cat. No.: HY-N2144

The compound 7,4'-Di-O-methylapigenin may be partly responsible for the reported antifungal activity of C. zeyheri, and may serve as a potential source of lead compounds that can be developed as antifungal phytomedicines.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg

7,4'-Dihydroxyflavone

Cat. No.: HY-N2609

7,4'-Dihydroxyflavone (7,4'-DHF) is a flavonoid isolated from Glycyrrhiza uralensis, the **eotaxin/CCL11** inhibitor, has the ability to consistently suppress eotaxin production and prevent dexamethasone (Dex)paradoxical adverse effects on eotaxin...



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

7,8-Dihydroneopterin

Cat. No.: HY-136341

7,8-Dihydroneopterin, an inflammation marker, induces cellular **apoptosis** in astrocytes and neurons via enhancement of nitric oxide synthase (**iNOS**) expression. 7,8-Dihydroneopterin can be used in the research of neurodegenerative diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

7,8-Dimethoxycoumarin

Cat. No.: HY-N4280

7,8-Dimethoxycoumarin (Daphnetin dimethyl ether) is a coumarin from Artemisia caruifolia.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

7-Acetyllycopsamine

Cat. No.: HY-122916

7-Acetyllycopsamine, a pyrrolizidine alkaloid, is a mild hepatotoxin. 7-Acetyllycopsamine can induce liver inflammation in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7-Hydroxyaristolochic acid A

Cat. No.: HY-N2012

7-Hydroxyaristolochic acid A is an aristolochic acid analogue found in Aristolochia plants. Aristolochic acid can be used as an anti-inflammatory agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7-Hydroxyflavone

Cat. No.: HY-N7108

7-Hydroxyflavone is a flavonoid isolated from M. indica, with anti-inflammatory activity. 7-Hydroxyflavone protects renal cells from nicotine (NIC)-associated cytotoxicity via the ERK/Nrf2/HO-1 pathway.



Purity: >98%
Clinical Data:
Size: 10 mg, 50 mg, 100 mg

7-Hydroxymethotrexate

Cat. No.: HY-130569

7-Hydroxymethotrexate is a major metabolite of Methotrexate (MTX; HY-14519). Methotrexate, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7-Methylguanosine

Cat. No.: HY-122524

7-Methylguanosine is a novel cNIIIB nucleotidase inhibitor with IC_{50} value of 87.8 ± 7.5 μM.



Purity: 96.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

7-O-Demethyl rapamycin

Cat. No.: HY-123691

7-O-Demethyl rapamycin, a derivative of Rapamycin (HY-10219), has antifungal activity and immunosuppressant properties. 7-O-Demethyl rapamycin has useful tumor cell growth-inhibiting activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

7-O-Methylaloeresin A

Cat. No.: HY-N2214

7-O-Methylaloeresin A is 5-methylchromone glycoside isolated from Commiphora socotrana (Burseraceae).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7α,25-Dihydroxycholesterol

(7α,25-OHC)

Cat. No.: HY-113962

7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor **EBI2 (GPR183)**. 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC_{50}=140 pM; K_d=450 pM).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

8-Azaadenosine

Cat. No.: HY-115686



8-Azaadenosine is a potent **ADAR1** inhibitor and an A-to-I editing inhibitor. 8-Azaadenosine blocks RNA editing and inhibits proliferation, 3D growth, invasion, and migration in thyroid cancer cells.

Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

8-CPT-Cyclic AMP sodium

(8-CPT-cAMP sodium; 8-(p-Chlorophenylthio)-cAMP sodium) Cat. No.: HY-111673



8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of **cyclic AMP-dependent protein kinase (PKA)**. 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase **(PDE VA)** with an IC_{50} of 0.9 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

8-Gingerol

Cat. No.: HY-N0447



8-Gingerol, found in the rhizomes of ginger (Z. officinale) with oral bioavailability, activates **TRPV1**, with an EC_{50} of 5.0 μM. 8-Gingerol inhibits COX-2, and inhibits the growth of H. pylori in vitro.

Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

8-Methylsulfinyloctyl isothiocyanate

Cat. No.: HY-115770



8-Methylsulfinyloctyl isothiocyanate, an isothiocyanate, has antimicrobial activity and remarkable inhibitory activity against plant growth. 8-Methylsulfinyloctyl isothiocyanate impair COX-2 mediated inflammatory responses in LPS stimulated raw macrophages.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

8-O-Acetylharpagide

Cat. No.: HY-N0757



8-O-Acetylharpagide is an iridoid isolated from Ajuga reptans with antitumoral, antiviral, antibacterial, and anti-inflammatory activities. 8-O-Acetylharpagide also has a biological activity on isolated smooth muscle preparations from guinea pig.

Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

9-cis-Retinoic acid

(ALRT1057) Cat. No.: HY-15128



9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent **RAR/RXR** agonist. 9-cis-Retinoic acid induces **apoptosis**, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities.

Purity: 95.15%
Clinical Data: Launched
Size: 5 mg

9-cis-Retinoic acid-d5

Cat. No.: HY-132334S



9-cis-Retinoic acid-d5 (ALRT1057-d5) is the deuterium labeled 9-cis-Retinoic acid. 9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent **RAR/RXR** agonist.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

A 839977

Cat. No.: HY-13954



A 839977 is a **P2X7** selective antagonist; it blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC_{50} values are 20 nM, 42 nM and 150 nM respectively) and reduces inflammatory and neuropathic pain in animal models; the antihyperalgesic effects...

Purity: 98.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

A-205804

Cat. No.: HY-100226



A-205804 is an orally bioavailable, potent and selective lead inhibitor of **E-selectin** and **ICAM-1** expression, with an IC_{50} of 20 nM and 25 nM for E-selectin and ICAM-1, respectively. A-205804 can be used in the research of chronic inflammatory diseases.

Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

A-286982

Cat. No.: HY-107587



A-286982 is a potent and allosteric **LFA-1/ICAM-1 interaction** inhibitor with IC_{50}s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding and LFA-1-mediated cellular adhesion assay, respectively.

Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

A-317491

Cat. No.: HY-15568

A-317491 is a potent, selective and non-nucleotide antagonist of **$P2X_3$** and **$P2X_{2/3}$ receptors**, with K_is of 22, 22, 9, and 92 nM for **$hP2X_3$**, **$rP2X_3$**, **$hP2X_{2/3}$**, and **$rP2X_{2/3}$**, respectively.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

A-317491 sodium salt hydrate

Cat. No.: HY-15568A

A-317491 sodium salt hydrate is a potent, selective and non-nucleotide antagonist of **$P2X_3$** and **$P2X_{2/3}$ receptors**, with K_is of 22, 22, 9, and 92 nM for **$hP2X_3$**, **$rP2X_3$**, **$hP2X_{2/3}$**, and **$rP2X_{2/3}$**, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

A-69412

Cat. No.: HY-101945

A-69412 is a reversible, specific inhibitor of the **5-lipoxygenase** (**5-LO**). A-69412 has the potential to treat asthma and ulcerative colitis, and possibly other inflammatory and allergic conditions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A-770041

Cat. No.: HY-11011

A-770041 is selective and orally active Src-family Lck inhibitor; A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

A-803467

Cat. No.: HY-11079

A-803467 is a potent and selective tetrodotoxin-resistant **$Na_v1.8$ sodium channel** blocker (**IC_{50}**=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models.



Purity: 98.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

A-967079

Cat. No.: HY-108463

A-967079 is a selective **TRPA1** receptor antagonist with **IC_{50}**s of 67 nM and 289 nM at human and rat TRPA1 receptors, respectively, and has good penetration into the CNS.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

A-9758

Cat. No.: HY-126252

A-9758 is a RORγ ligand and a potent, selective **RORγt** inverse agonist (**IC_{50}**=5 nM), and exhibits robust potency against **IL-17A** release. A-9758 is effective in suppressing both Th17 differentiation and Th17 effector function.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A-987306

Cat. No.: HY-14364

A-987306 is a potent and oral bioavailable histamine **H_4** antagonist, with **K_i**s of 3.4 nM and 5.8 nM for rat H_4, and human H_4. A-987306 shows anti-inflammatory activity in mice peritonitis model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A2B receptor antagonist 1

Cat. No.: HY-U00321

A2B receptor antagonist 1 is a potent **A2B adenosine receptor** antagonist extracted from patent WO 2009157938 A1 EXAMPLE 9B.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AB928

Cat. No.: HY-129393

AB928 is an orally bioavailable, selective dual adenosine receptor **(A2aR/A2bR)** antagonist. AB928 relieves adenosine-mediated immune suppression. AB928 has immunomodulatory and antitumor activities.



Purity: 99.79%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Abatacept

(CTLA4Ig; BMS-188667)

Cat. No.: HY-108829

Abatacept (CTLA4Ig) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein drug for the autoimmune diseases.

Abatacept

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

ABBV-744

Cat. No.: HY-112090

ABBV-744 is a first-in-class, orally active and selective inhibitor of the **BDII domain** of BET family proteins with IC_{50} values ranging from 4 to 18 nM for BRD2, BRD3, BRD4 and BRDT.



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Abietic acid

Cat. No.: HY-N6871

Abietic acid, a diterpene isolated from Pimenta racemosa var. grissea, possesses antiproliferative, antibacterial, and anti-obesity properties. Abietic acid inhibits lipoxygenase activity for allergy treatment.



Purity: 81.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

ABR-238901

Cat. No.: HY-141537

ABR-238901 is an orally active and potent **S100A8/A9** blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Abrocitinib

(PF-04965842)

Cat. No.: HY-107429

Abrocitinib (PF-04965842) is a potent, orally active and selective **JAK1** inhibitor, with IC_{50}s of 29 and 803 nM for JAK1 and JAK2, respectively.



Purity: 99.26%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

ABT-702 dihydrochloride

Cat. No.: HY-103161

ABT-702 dihydrochloride is a potent **adenosine kinase** (**AK**) inhibitor (IC_{50}=1.7 nM).



Purity: 96.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AC-264613

Cat. No.: HY-14351

AC-264613 is a potent and selective protease-activated receptor (**PAR-2**) agonist with a pEC_{50} of 7.5.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ac-FLTD-CMK

Cat. No.: HY-111675

Ac-FLTD-CMK, a gasdermin D (GSDMD)-derived inhibitor, is a specific **inflammatory caspases** inhibitor.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 1 mg

Ac-IEPD-AFC

Cat. No.: HY-P1092

Ac-IEPD-AFC is a substrate of Granzyme B.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ac-YVAD-CHO

(L-709049)

Cat. No.: HY-120019

Ac-YVAD-CHO (L-709049) is a potent, reversible, specific tetrapeptide interleukin-Iβ converting enzyme (**ICE**) inhibitor with mouse and human K_i values of 3.0 and 0.76 nM. Ac-YVAD-CHO can suppress the production of mature IL-Iβ.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ac2-12

Cat. No.: HY-P1099

Ac2-12, an annexin/lipocortin 1 (LC1)-mimetic peptide, inhibit neutrophil extravasation. Ac2-12 has antimigratory action and inhibits recruitment of neutrophils in experimental inflammation models.

Ac-AMVSEFLKQAW

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ac2-12 TFA

Cat. No.: HY-P1099A

Ac2-12 TFA, an annexin/lipocortin 1 (LC1)-mimetic peptide, inhibit neutrophil extravasation. Ac2-12 TFA has antimigratory action and inhibits recruitment of neutrophils in experimental inflammation models.

Ac-AMVSEFLKQAW (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ac2-26

Cat. No.: HY-P1098

Ac2-26, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue.

Ac-AMVSEFLKQAWFIENEEQEYVQTVK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ac2-26 TFA

Cat. No.: HY-P1098A

Ac2-26 TFA, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue.

Ac-AMVSEFLKQAWFIENEEQEYVQTVK (TFA salt)

Purity: 96.48%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Ac9-25

Cat. No.: HY-P1118

Ac9-25, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR.

Ac-QAWFIENEEQEYVQTVK

Purity: 98.54%
Clinical Data: No Development Reported
Size: 1 mg

Ac9-25 TFA

Cat. No.: HY-P1118A

Ac9-25 TFA, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor **(FPR)** agonist and activates the neutrophil NADPH oxidase through FPR.

Ac-QAWFIENEEQEYVQTVK (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acacetin

(5,7-Dihydroxy-4'-methoxyflavone)

Cat. No.: HY-N0451

Acacetin (5,7-Dihydroxy-4'-methoxyflavone) is an orally active flavonoid derived from Tephroseris kirilowii (Turcz.) Holub. Acacetin docks in the ATP binding pocket of PI3Kγ. Acacetin causes cell cycle arrest and induces **apoptosis** and **autophagy** in cancer cells.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Acanthoside B

Cat. No.: HY-N2807

Acanthoside B is a potential bioactive lignan with anti-inflammatory and anti-amnesic activities. Acanthoside B can be used for alzheimer's disease and lung inflammation research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACAT-IN-10

Cat. No.: HY-139027

ACAT-IN-10 is an **acyl-Coenzyme A:cholesterol acyltransferase (ACAT)** inhibitor extracted from patent EP1236468A1, example 197. ACAT-IN-10 weakly inhibits NF-κB mediated transcription.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACAT-IN-10 dihydrochloride

Cat. No.: HY-139027A

ACAT-IN-10 dihydrochloride is an **acyl-Coenzyme A:cholesterol acyltransferase (ACAT)** inhibitor extracted from patent EP1236468A1, example 197. ACAT-IN-10 dihydrochloride weakly inhibits NF-κB mediated transcription.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACAT-IN-2

Cat. No.: HY-139019

ACAT-IN-2 is an **acyl-Coenzyme A:cholesterol acyltransferase (ACAT)** inhibitor extracted from patent EP1236468A1, example 187. ACAT-IN-2 inhibits NF-κB mediated transcription.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACAT-IN-3

Cat. No.: HY-139020

ACAT-IN-3 is an **acyl-Coenzyme A:cholesterol acyltransferase (ACAT)** inhibitor. ACAT-IN-3 inhibits NF-κB mediated transcription.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACAT-IN-4

Cat. No.: HY-139021

ACAT-IN-4 (Example 208) is an **acyl-Coenzyme A:cholesterol acyltransferase (ACAT)** inhibitor. ACAT-IN-4 inhibits NF-κB mediated transcription.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACAT-IN-4 hydrochloride

Cat. No.: HY-139021A

ACAT-IN-4 hydrochloride (Example 208) is an **acyl-Coenzyme A:cholesterol acyltransferase (ACAT)** inhibitor. ACAT-IN-4 hydrochloride inhibits NF-κB mediated transcription.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACAT-IN-5

Cat. No.: HY-139022

ACAT-IN-5 (example 19) is an **acyl-Coenzyme A:cholesterol acyltransferase (ACAT)** inhibitor. ACAT-IN-5 inhibits NF-κB mediated transcription.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACAT-IN-6

Cat. No.: HY-139023

ACAT-IN-6 is an **acyl-Coenzyme A:cholesterol acyltransferase (ACAT)** inhibitor extracted from patent EP1236468A1, example 200. ACAT-IN-6 potently inhibits NF-κB mediated transcription.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACAT-IN-7

Cat. No.: HY-139024

ACAT-IN-7 is an **acyl-Coenzyme A:cholesterol acyltransferase (ACAT)** inhibitor. ACAT-IN-7 inhibits NF-κB mediated transcription.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACAT-IN-8

Cat. No.: HY-139025

ACAT-IN-8 (example 206) is an **acyl-Coenzyme A:cholesterol acyltransferase (ACAT)** inhibitor. ACAT-IN-8 inhibits NF-κB mediated transcription.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACAT-IN-9

Cat. No.: HY-139026

ACAT-IN-9 is an **acyl-Coenzyme A:cholesterol acyltransferase (ACAT)** inhibitor extracted from patent EP1236468A1, example 207. ACAT-IN-9 inhibits NF-κB mediated transcription.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acebilustat

(CTX-4430)

Cat. No.: HY-17625

Acebilustat (CTX-4430) is a leukotriene A4 hydrolase inhibitor, used for an oral antiinflammatory drug.



Purity: 99.72%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Aceclofenac

Cat. No.: HY-B0634

Aceclofenac is an orally active nonsteroidal anti-inflammatory drug (NSAID), with analgesic and anti-inflammatory properties. Aceclofenac is used for the research of osteoarthritis, ankylosing spondylitis, rheumatoid arthritis.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Acemetacin

(TVX 1322)

Cat. No.: HY-B0482

Acemetacin (TVX 1322) is a non-steroidal anti-inflammatory drug and a glycolic acid ester of indometacin that is a cyclooxygenase inhibitor.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Acetaminophen

(Paracetamol; 4-Acetamidophenol; 4'-Hydroxyacetanilide)

Cat. No.: HY-66005

Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (**COX-2**) inhibitor with an IC_{50} of 25.8 μM; is a widely used antipyretic and analgesic agent. Acetaminophen is a potent **hepatic N-acetyltransferase 2 (NAT2)** inhibitor.



Purity: 99.96%
Clinical Data: Launched
Size: 500 mg, 5 g, 10 g

Acetaminophen metabolite 3-hydroxy-acetaminophen

(3-Hydroxyacetaminophen)

Cat. No.: HY-G0004

3-hydroxy-acetaminophen is a metabolite of Acetaminophen, which is a pain medicine.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Acetyl-Calpastatin(184-210)(human)

Cat. No.: HY-P1081

Acetyl-Calpastatin(184-210)(human) is a potent, selective and reversible **calpain** inhibitor with K_i values of 0.2 nM and 6 μM for μ-calpain and cathepsin L, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acetyl-Calpastatin(184-210)(human) TFA

Cat. No.: HY-P1081A

Acetyl-Calpastatin(184-210)(human) TFA is a potent, selective and reversible **calpain** inhibitor with K_i values of 0.2 nM and 6 μM for μ-calpain and cathepsin L, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acetylcorynoline

Cat. No.: HY-N0759

Acetylcorynoline is the major alkaloid component derived from Corydalis bungeana, and has anti-inflammatory properties.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Acetylshengmanol Arabinoside

Cat. No.: HY-N2170

Acetylshengmanol Arabinoside is isolated from Cimicifugae rhizoma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acetylshikonin

Cat. No.: HY-N2181

Acetylshikonin, derived from the root of Lithospermum erythrorhizon, has anti-cancer and antiinflammation activity. Acetylshikonin is a non-selective **cytochrome P450** inhibitor against all P450s (IC_{50} values range from 1.4-4.0 μM).



Purity: 98.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

ACHP Hydrochloride

(IKK-2 Inhibitor VIII)

Cat. No.: HY-13060

ACHP Hydrochloride (IKK-2 Inhibitor VIII) is a highly potent and selective **IKK-β** inhibitor with an IC_{50} of 8.5 nM.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Acid secretion-IN-1

Cat. No.: HY-136301

Acid secretion-IN-1 is a polycyclic compound extracted from patent WO2018024188A1, Compound Example 17.4. Acid secretion-IN-1 is synthesized and used in the IDO inhibitor synthetic experiment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acitretin

(Ro 10-1670)

Cat. No.: HY-B0107

Acitretin (Ro 10-1670) is a second-generation, systemic retinoid that has been used in the treatment of psoriasis. Acitretin also can be used for the research of Alzheimer's disease.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Acitretin sodium

(Ro 10-1670 sodium)

Cat. No.: HY-B0107A

Acitretin (Ro 10-1670) sodium is a second-generation, systemic retinoid that has been used in the treatment of psoriasis. Acitretin sodium also can be used for the research of Alzheimer's disease.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Aclidinium Bromide

(LAS 34273; LAS-W 330)

Cat. No.: HY-14144

Aclidinium Bromide (LAS 34273; LAS-W 330) is a long-acting, inhaled **muscarinic** antagonist. Aclidinium Bromide has the potential for chronic obstructive pulmonary disease (COPD) research.



Purity: 98.08%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Aconine

(Jesaconine)

Cat. No.: HY-N0277

Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced **NF-κB** activation.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

ACP-105

Cat. No.: HY-112256

ACP-105 is an orally available, selective amd potent **androgen receptor** modulator (SARM), with **pEC_{50}s** of 9.0 and 9.3 for AR wild type and T877A mutant, respectively.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Acrivastine

(BW825C)

Cat. No.: HY-B1510

Acrivastine (BW825C) is a short acting **histamine 1** receptor antagonist for the treatment of allergic rhinitis.



Purity: 99.37%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Acrivastine D7

(BW825C D7)

Cat. No.: HY-B1510S

Acrivastine D7 (BW825C D7) is a deuterium labeled Acrivastine. Acrivastine is a short acting histamine 1 receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACT-389949

Cat. No.: HY-124071

ACT-389949 is a first-in-class, potent and selective and agonist of **formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX)**, with an **EC_{50}** of 3 nM for FPR2/ALX internalization into monocytes.



Purity: 98.42%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ACT-678689

Cat. No.: HY-19572

ACT-678689 (Compound Example 1.53.4) is a **tryptophan hydroxylase** (**TPH**) inhibitor with an **IC_{50}** of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACT001

Cat. No.: HY-128861A

ACT001 is an orally active **PAI-1** inhibitor by inhibiting the phosphorylation of **PI3K** and **AKT**. ACT001 inhibits the phosphorylation of STAT3 and PD-L1 expression by directly binding to **STAT3**.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Actarit

(4-Acetylaminophenylacetic acid; MS-932)

Cat. No.: HY-76938

Actarit, an orally active antirheumatic compound, has the potential to treat type II collagen-induced arthritis.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

ACTH (1-13)

(Adrenocorticotropic Hormone (1-13))

Cat. No.: HY-P1555

ACTH (1-13) is a 13-aa peptide, with cytoprotective effects in the model of ethanol induced gastric lesions in rats.

SYSMEHFRWGKPV

Purity: 99.57%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

ACTH (11-24)

(Adrenocorticotropic Hormone (11-24))

Cat. No.: HY-P1558

ACTH (11-24) is a fragment of adrenocorticotrophin, acts as an antagonist of **adrenocorticotropic hormone (ACTH) receptor**, and induces cortisol release.

KPVGKKRRPVKVYP

Purity: 95.40%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Acumapimod

(BCT197)

Cat. No.: HY-16715

Acumapimod (BCT197) is an orally active **p38 MAP** kinase inhibitor, with an IC_{50} of less than 1 μM for p38α.



Purity: 99.03%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AD 0261

Cat. No.: HY-U00005

AD 0261 is a radical scavenger which displays strong inhibitory action on the generation of lipid peroxides and superoxide anions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adalimumab

(Anti-Human TNF-alpha, Human Antibody)

Cat. No.: HY-P9908

Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factorα (**TNF-α**).

Adalimumab

Purity: 99.62%
Clinical Data: Phase 4
Size: 1 mg, 5 mg, 25 mg, 50 mg

ADAMTS-5 Inhibitor

Cat. No.: HY-114996

ADAMTS-5 Inhibitor is a potent **ADAMTS-5 (aggrecanase-2)** inhibitor, with an IC_{50} of 1.1 μM. ADAMTS-5 Inhibitor shows >40-fold functional selectivity over ADAMTS-4 (aggrecanase-1).



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Adapalene

(CD271)

Cat. No.: HY-B0091

Adapalene (CD271), a third-generation synthetic retinoid, is widely used for the research of acne. Adapalene is a potent **RAR** agonist, with AC_{50}s of 2.3 nM, 9.3 nM, and 22 nM for **RARβ**, **RARγ**, **RARα**, respectively.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Adapalene sodium salt

(CD 271 sodium salt)

Cat. No.: HY-B0091A

Adapalene (CD271) sodium salt, a third-generation synthetic retinoid, is widely used for the research of acne. Adapalene sodium salt is a potent **RAR** agonist, with AC_{50}s of 2.3 nM, 9.3 nM, and 22 nM for **RARβ**, **RARγ**, **RARα**, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Adavivint

(SM04690; Lorecivivint)

Cat. No.: HY-109049

Adavivint (SM04690; Lorecivivint) is a potent and selective inhibitor of canonical **Wnt** signaling, with an EC_{50} of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells.



Purity: ≥98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Adelmidrol

Cat. No.: HY-B1026

Adelmidrol exerts important anti-inflammatory effects that are partly dependent on **PPARγ**. Adelmidrol reduces **NF-κB** translocation, and **COX-2** expression.



Purity: ≥98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 100 mg

Adenosine A1 receptor activator T62

Cat. No.: HY-106199

Adenosine A1 receptor activator T62 is an allosteric enhancer of **adenosine A1 receptor**. Adenosine A1 receptor activator T62 produces antinociception in animal models of acute pain and also reduces hypersensitivity in models of inflammatory and nerve-injury pain.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Adenosine amine congener

(ADAC)

Cat. No.: HY-128064

Adenosine amine congener (ADAC) is a selective **A1 adenosine receptor** agonist, can ameliorate noise- and Cisplatin-induced cochlear injury. Adenosine amine congener also has neuroprotective effects.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Adenosine deaminase

Cat. No.: HY-114175

Adenosine deaminase is an enzyme that catalyzes the irreversible deamination of adenosine and 2'-deoxyadenosine to inosine and 2'-deoxyinosine, respectively.

Adenosine deaminase

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adezmapimod

(SB 203580; RWJ 64809)

Cat. No.: HY-10256

Adezmapimod (SB 203580) is a selective and ATP-competitive **p38 MAPK** inhibitor with IC_{50}s of 50 nM and 500 nM for **SAPK2a/p38** and **SAPK2b/p38β2**, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC_{50}s of 100-500-fold higher than that for SAPK2a/p38.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Adezmapimod hydrochloride

(SB 203580 hydrochloride; RWJ 64809 hydrochloride)

Cat. No.: HY-10256A

Adezmapimod (SB 203580) hydrochloride is a selective and ATP-competitive **p38 MAPK** inhibitor with IC_{50}s of 50 nM and 500 nM for **SAPK2a/p38** and **SAPK2b/p38β2**, respectively.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Adrenic Acid

(cis-7,10,13,16-Docosatetraenoic acid)

Cat. No.: HY-W013215

Adrenic Acid (cis-7,10,13,16-Docosatetraenoic acid) is a naturally polyunsaturated fatty acid in the adrenal gland, brain, kidney, and vasculature. Adrenic Acid can regulate the vascular tone in arteries of the adrenal cortex.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mg (300 mM * 100 μL in Ethanol),

Adriforant hydrochloride

(PF-3893787 hydrochloride)

Cat. No.: HY-19705B

Adriforant hydrochloride (PF-3893787 hydrochloride) is a novel **histamine H4 receptor** antagonist binding affinity (K_i=2.4 nM) and is also a functional (K_i=1.56 nM) antagonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ADU-S100

(MIW815; ML RR-S2 CDA)

Cat. No.: HY-12885

ADU-S100 (MIW815), an activator of stimulator of interferon genes (**STING**), leads to potent and systemic tumor regression and immunity.



Purity: 99.53%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

ADU-S100 ammonium salt

(MIW815 ammonium salt; ML RR-S2 CDA ammonium salt) Cat. No.: HY-12885B

ADU-S100 ammonium salt (MIW815 ammonium salt), an activator of stimulator of interferon genes (**STING**), leads to potent and systemic tumor regression and immunity.



Purity: 99.53%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

ADU-S100 disodium salt

(MIW815 disodium salt; ML RR-S2 CDA disodium salt) Cat. No.: HY-12885A

ADU-S100 disodium salt (MIW815 disodium salt) is an activator of stimulator of interferon genes (**STING**).



Purity: 98.83%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

ADU-S100 enantiomer ammonium salt (MIW815 enantiomer ammonium salt; ML RR-S2 CDA enantiomer ammonium salt)

Cat. No.: HY-12885C

ADU-S100 enantiomer ammonium salt (MIW815 enantiomer ammonium salt) is the less active enantiomer of ADU-S100. ADU-S100 is an activator of stimulator of interferon genes (STING).



Purity: 98.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

AE-3763

Cat. No.: HY-19406

AE-3763 is a peptide-based **human neutrophil elastase** inhibitor with an $\mathbf{IC_{50}}$ of 29 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Aeruginosin 865

Cat. No.: HY-130994

Aeruginosin 865, isolated from terrestrial cyanobacterium Nostoc sp. Lukešová 30/93, is the first aeruginosin-type peptide containing both a fatty acid and a carbohydrate moiety. Aeruginosin 865 inhibits translocation of **NF-kB** to the nucleus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AF12198

Cat. No.: HY-P1110

AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) ($\mathrm{IC_{50}}$=8 nM) but not the human type II receptor ($\mathrm{IC_{50}}$=6.7 μM) or the murine type I receptor ($\mathrm{IC_{50}}$>200 μM).

Purity: 99.61%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Afimetoran

(BMS-986256) Cat. No.: HY-139567

Afimetoran is a **toll-like receptor** antagonist, which can be used in the research of inflammatory and autoimmune diseases.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Afzelin

(Kaempferol-3-O-rhamnoside) Cat. No.: HY-N1441

Afzelin (Kaempferol-3-O-rhamnoside) is is a flavonol glycoside found in Houttuynia cordata Thunberg and is widely used in the preparation of antibacterial and antipyretic agents, detoxicants and for the treatment of inflammation.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

AG-09/1

Cat. No.: HY-128113

AG-09/1 is a specific formyl peptide receptor 1 (**FPR1**) agonist. N-formyl peptide receptors (FPR) are important in host defense.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AG-825

(Tyrphostin AG-825) Cat. No.: HY-15844

AG-825 (Tyrphostin AG-825) is a selective and ATP-competitive **ErbB2** inhibitor which suppresses tyrosine phosphorylation, with an $\mathbf{IC_{50}}$ of 0.35 μM. AG-825 displays anti-cancer activity. AG825 significantly accelerates apoptosis of human neutrophils.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AG126

(Tyrphostin AG126) Cat. No.: HY-108330

AG126 is a **tyrosine kinase inhibitor** which can prevent the activation of mitogen-activated protein kinase **p42MAPK** (**ERK2**).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Aganepag

(AGN 210937) Cat. No.: HY-19864

Aganepag is a potent **Prostanoid EP2 receptor** agonist, with an EC_{50} of 0.19 nM, and shows no activity at EP4 receptor. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AGN 210676

(Simenepag) Cat. No.: HY-14898

AGN 210676 is a selective prostaglandin EP_2 agonist extracted from patent US20070203222A1, Compound example 23, has an EC_{50} of 5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AGN194204

(IRX4204; NRX194204; VTP 194204) Cat. No.: HY-13717

AGN194204 (IRX4204) is an orally active and selective **RXR** agonist with K_d values 0.4 nM, 3.6 nM and 3.8 nM and EC_{50}s of 0.2 nM, 0.8 nM and 0.08 nM for **RXRα**, **RXRβ** and **RXRγ**, respectively. AGN194204 is inactive against RAR.



Purity: ≥99.0%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Agnuside

(Agnoside) Cat. No.: HY-N2518

Agnuside is a compound isolated from Vitex negundo, down-regulates pro-inflammatory mediators **PGE2** and **LTB4**, and reduces the expression of cytokines, with anti-arthritic activity.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

AH 6809

Cat. No.: HY-10418

AH 6809 is an antagonist of **EP** and **DP receptor**, with K_is of 1217, 1150, 1597, and 1415 nM for the cloned **human** EP_1, EP_2, EP_3-**III**, and **DP receptor** respectively. AH 6809 has a K_i of 350 nM for **mouse** EP_2 **receptor**.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ailanthone

(Δ13-Dehydrochaparrinone) Cat. No.: HY-N1943

Ailanthone (Δ13-Dehydrochaparrinone) is a potent inhibitor of both full-length **androgen receptor (AR)** (IC_{50}=69nM) and constitutively active truncated AR splice variants (AR_{1-651} IC_{50}=309nM).



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ajugasterone C

Cat. No.: HY-N2196

Ajugasterone C is an ecdysteroid isolated from Leuzea carthamoides. Ajugasterone C shows significant inhibitory effect at 100 mg/kg dose on rat paw oedema development due to Carrageenan-induced inflammation in Sprague Dawley rats.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Akuammidine

Cat. No.: HY-N7437

Akuammidine, isolated from the seeds of Picralima nitida, shows a preference for **μ-opioid** binding sites with K_i values of 0.6, 2.4 and 8.6 μM at μ-, σ- and κ-opioid binding sites, respectively. Akuammidine possesses anti-inflammatory and anti-asthmatic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AL 8697

Cat. No.: HY-108645

AL 8697 is a specific and orally active **p38α MAPK** inhibitor with an IC_{50} of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC_{50}=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Albendazole sulfoxide D3

(Ricobendazole D3; Albendazole oxide D3)

Cat. No.: HY-12785S

Albendazole sulfoxide D3 is deuterium labeled Albendazole sulfoxide, which is a broad-spectrum anthelmintic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Albiflorin

Cat. No.: HY-N0037

Albiflorin, a major constituent contained in peony root, is a monoterpene glycoside with neuroprotective effects. Albiflorin also has anti-inflammatory, antioxidant and antinociceptive effects.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

ALC-0159

Cat. No.: HY-138300

ALC-0159, a polyethylene glycol (PEG) lipid conjugate, could be used as vaccine excipient.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Alcaftadine

(R89674)

Cat. No.: HY-17039

Alcaftadine (R89674) is a **histamine H1 receptor** antagonist, which is used to prevent eye irritation brought on by allergic conjunctivitis.



Purity: 99.42%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Alcaftadine-D3

(R89674-D3)

Cat. No.: HY-17039S

Alcaftadine-D3 (R89674-D3) is a deuterium labeled Alcaftadine. Alcaftadine (HY-17039) is a H1 histamine receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alclometasone

(7a-Chloro-16a-methyl prednisolone)

Cat. No.: HY-A0150

Alclometasone (7a-Chloro-16a-methyl prednisolone) is a **glucocorticoid** and inhibits the release of pro-inflammatory mediators from leukocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alimemazine

(Trimeprazine)

Cat. No.: HY-12752

Alimemazine is a phenothiazine derivative that is generally used as an antipruritic agent and also a **hemagglutinin (HA)-receptor** antagonist.Alimemazine (Trimeprazine) is also acts as a partial agonist against the histamine H1 receptor (H1R) and other GPCRs.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Alimemazine D6

(Trimeprazine D6)

Cat. No.: HY-12752S

Alimemazine D6 is deuterium labeled Alimemazine, which is an antihistamine.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alimemazine hemitartrate

(Trimeprazine hemitartrate)

Cat. No.: HY-12752A

Alimemazine hemitartrate is a phenothiazine derivative that is generally used as an antipruritic agent and also a **hemagglutinin (HA)-receptor** antagonist.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Alisporivir intermediate-1

Cat. No.: HY-P1358

Alisporivir intermediate-1 is an intermediate in the synthesis of Alisporivir. Alisporivir is used for the treatment of inflammatory and viral diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK4290

(AKST4290)

Cat. No.: HY-136788

ALK4290 (AKST4290) is a potent and orally actively **CCR3** inhibitor extracted from patent US20130261153A1, compound Example 2, with a K_i of 3.2 nM for hCCR3. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Allantoin

(5-Ureidohydantoin)

Cat. No.: HY-N0543

Allantoin is a skin conditioning agent that promotes healthy skin, stimulates new and healthy tissue growth.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Alliin

Cat. No.: HY-N0661

Alliin, an orally active sulfoxide compound derived from garlic, exhibits hypoglycemic, antioxidant and anti-inflammatory activities.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Allosecurinine

(Phyllochrysine)

Cat. No.: HY-N2377

Allosecurinine (Phyllochrysine) is a Securinega alkaloid isolated from M.indica and M.discoidea.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Alminoprofen

(EB-382)

Cat. No.: HY-17485

Alminoprofen (EB-382) is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class. Alminoprofen possesses a dual anti-inflammatory action, by inhibiting both **secretory phospholipase A_2 ($sPLA_2$)** and **COX-2**.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Alniditan

(Alnitidan)

Cat. No.: HY-101698

Alniditan (Alnitidan) is a potent **5-HT_{1B}** and **5-HT_{1D} receptors** agonist, with **IC_{50}**s of 1.7 nM and 1.3 nM for **h5-HT_{1B}** and **h5-HT_{1D} receptors** in HEK293 cells, respectively. Alniditan has migraine-preventive effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alniditan dihydrochloride

(Alnitidan dihydrochloride)

Cat. No.: HY-101698B

Alniditan (Alnitidan) dihydrochloride is a potent **5-HT_{1B}** and **5-HT_{1D} receptors** agonist, with **IC_{50}**s of 1.7 nM and 1.3 nM for **h5-HT_{1B}** and **h5-HT_{1D} receptors** in HEK293 cells, respectively. Alniditan dihydrochloride has migraine-preventive effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Alnustone

Cat. No.: HY-N0558

Alnustone, a non-phenolic diarylheptanoid found in herbs and spices, is a constituent of Curcuma xanthorrhiza. Alnustone displays anti-emetic and anti-inflammatory activities.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Aloesin

(Aloeresin)

Cat. No.: HY-N2460

Aloesin (Aloeresin) is an active constituent of the herb aloe vera and displays anti-inflammatory activity, ultraviolet protection, and antibacterium effects. Aloesin exerts its anticancer effect through the MAPK signaling pathway.



Purity: 99.92%
Clinical Data:
Size: 10 mM × 1 mL, 500 μg, 1 mg, 5 mg, 10 mg

Alogliptin

(SYR-322 free base)

Cat. No.: HY-A0023A

Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of **DPP-4** with an **IC_{50}** of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin can be used for the research of type 2 diabetes.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Alogliptin Benzoate

(SYR 322)

Cat. No.: HY-A0023

Alogliptin Benzoate (SYR-322) is a potent, selective and orally active inhibitor of **DPP-4** with an IC_{50} of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin Benzoate can be used for the research of type 2 diabetes.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Aloin(mixture of A&B)

Cat. No.: HY-N6013

Aloin (mixture of A&B) is anthraquinone derivative isolated from Aloe vera. Aloin (mixture of A&B) has diverse biological activities such as anti-inflammatory, immunity, antidiabetic, antioxidant, antibacterial, antifungal, and antitumor activities.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Aloisine A

(RP107)

Cat. No.: HY-112363

Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC_{50}s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC_{50}=0.5 μM) and GSK-3β (IC_{50}=1.5 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aloperine

Cat. No.: HY-13516

Aloperine is an alkaloid in sophora plants such as Sophora alopecuroides L, which has shown anti-cancer, anti-inflammatory and anti-virus properties. Aloperine is widely used to treat patients with allergic contact dermatitis eczema and other skin inflammation in China.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Alosetron

(GR 68755; GR 68755X)

Cat. No.: HY-70050A

Alosetron (GR 68755) is a potent and highly selective serotonin **5-HT3 receptor** antagonist. Alosetron is used for the research of irritable bowel syndrome (IBS).



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Alosetron ((Z)-2-butenedioate) (GR 68755 ((Z)-2-butenedioate); GR 68755X ((Z)-2-butenedioate))

Cat. No.: HY-70050B

Alosetron (GR 68755) (Z)-2-butenedioate is a potent and highly selective serotonin **5-HT3 receptor** antagonist. Alosetron (Z)-2-butenedioate is used for the research of irritable bowel syndrome (IBS).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Alosetron (Hydrochloride(1:X)) (GR 68755 (Hydrochloride(1:X)); GR 68755X (Hydrochloride(1:X)))

Cat. No.: HY-70050

Alosetron (GR 68755) Hydrochloride(1:X) is a potent and highly selective serotonin **5-HT3 receptor** antagonist. Alosetron Hydrochloride(1:X) is used for the research of irritable bowel syndrome (IBS).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

alpha-Boswellic acid

(α-Boswellic acid)

Cat. No.: HY-N0611

alpha-Boswellic acid (α-Boswellic acid) is a pentacyclic triterpene compound from extracts of Frankincense, has anticonvulsant and anti-cancer properties.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

alpha-Cyperone

(α-Cyperone; (+)-α-Cyperone)

Cat. No.: HY-N0710

alpha-Cyperone (α-Cyperone) is associated with the down-regulation of COX-2, IL-6, Nck-2, Cdc42 and Rac1, resulting in reduction of inflammation, which would be highly beneficial for treatment of inflammatory diseases such as AD.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Alpha-Estradiol

(Alfatradiol; Epiestradiol; Epiestrol)

Cat. No.: HY-B0141A

Alpha-Estradiol is a weak estrogen and a **5α-reductase** inhibitor which is used as a topical medication in the treatment of androgenic alopecia.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Alpinetin

Cat. No.: HY-N0625A

Alpinetin is a flavonoid isolated from Alpinia katsumadai Hayata, activates activates **PPAR-γ**, with potent anti-inflammatory activity.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Aluminum Hydroxide

Cat. No.: HY-B1521

Aluminum Hydroxide is an orally active main form of aluminum used as adjuvant. Aluminum hydroxide-based adjuvant researches include the repository effect, pro-phagocytic effect, and activation of the pro-inflammatory NLRP3 pathway.

$Al(OH)_3$

Purity: >98%
Clinical Data: Launched
Size: 500 mg, 1 g

Alvelestat

(AZD9668)

Cat. No.: HY-15651

Alvelestat (AZD9668) is an orally bioavailable, affinity and selective inhibitor of **neutrophil elastase (NE)** with a pIC_{50} value of 7.9 nM, a K_i value of 9.4 nM and a K_d value of 9.5 nM.



Purity: 99.27%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AM-0902

Cat. No.: HY-108329

AM-0902 is a potent, selective transient receptor potential A1 (**TRPA1**) antagonist with IC_{50}s of 71 and 131 nM for **rTRPA1** and **hTRPA1**, respectively.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AM095

Cat. No.: HY-16039

AM095 is a selective LPA_1 receptor antagonist. The IC_{50} for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA_1-transfected CHO cells is 0.025 and 0.023 μM, respectively.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

AM095 free acid

Cat. No.: HY-16040

AM095 (free acid) is a potent **LPA1** receptor antagonist with IC_{50} values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

AM103

Cat. No.: HY-14163

AM 103 is a potent and selective **FLAP** inhibitor, with an IC_{50} value of 4.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AM211

(AM211 free acid)

Cat. No.: HY-13213

AM211 is a potent, selective and orally bioavailable **prostaglandin D2 (PGD2) receptor type 2 (DP2)** antagonist, with IC_{50}s of 4.9 nM, 7.8 nM, 4.9 nM, 10.4 nM for human, mouse, guinea pig, and rat DP2, respectively.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AM679

Cat. No.: HY-14460

AM679 is a potent, selective **5-lipoxygenase-activating protein (FLAP)** inhibitor with an IC_{50} of 2 nM in a human FLAP membrane binding assay.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AM966

Cat. No.: HY-15277

AM966 is a high affinity, selective, oral LPA_1-antagonist, inhibits LPA-stimulated intracellular calcium release (IC_{50}=17 nM).



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AMARA peptide

Cat. No.: HY-P1576

AMARA peptide is a substrate for SIK and AMPK.

AMARAASAAALARRR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amaroswerin

Cat. No.: HY-N9337

Amaroswerin is a bioactive secoiridoid glucoside from Swertia mussotii. Amaroswerin has anti-inflammatory, antidiabetic, antiviral, anticholinergic and immunomodulatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ambutonium bromide

(BL700)

Cat. No.: HY-U00067

Ambutonium bromide is an acetylcholine antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amcinonide

(CL-34699)

Cat. No.: HY-B1197

Amcinonide inhibit NO release from activated microglia with IC50 3.38 nM. Amcinonide has affinity for the glucocorticoid receptor.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Amdizalisib

Cat. No.: HY-132807

Amdizalisib is a **PI3K** inhibitor and used for the research of inflammatory disease, autoimmune disease or cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amebucort

Cat. No.: HY-U00298

Amebucort is a synthetic glucocorticoid corticosteroid, may used for the research of inflammatory disorders.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Amelubant

(BIIL 284)

Cat. No.: HY-19304

Amelubant (BIIL 284) is a potent, oral and long acting **LTB_4 receptor** antagonist, negligibly binds to LTB_4 receptor, with **K_i**s of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a prodrug of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amfenac Sodium Hydrate

Cat. No.: HY-17479A

Amfenac Sodium Hydrate is a **COX-2** inhibitor.



Purity: 98.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

AMG 487

Cat. No.: HY-15319

AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 **(CXCR3)** which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with **IC_{50}**s of 8.0 and 8.2 nM, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AMG-009

Cat. No.: HY-19499

AMG-009 is a potent antagonist of **prostaglandin D2**, with **IC_{50}** of 3 nM and 12 nM for CRTH2 and DP receptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AMG-47a

Cat. No.: HY-18303

AMG-47a is a potent and orally active **lymphocyte-specific protein tyrosine kinase (Lck)** inhibitor, with an IC_{50} of 0.2 nM. AMG-47a also inhibits **VEGF2**, **p38α**, **Jak3** and **MLR** and **IL-2** with IC_{50}s of 1 nM, 3 nM, 72 nM, 30 nM and 21 nM, respectively.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AMG-548

Cat. No.: HY-108642

AMG-548, an orally active and selective **p38α** inhibitor (K_i=0.5 nM), shows slightly selective over **p38β** (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG 548 is also extremely potent in the inhibition of whole blood LPS stimulated **TNFα** (IC_{50}=3 nM).



Purity: ≥99.0%
Clinical Data:
Size: 1 mg, 5 mg

AMG-548 dihydrochloride

Cat. No.: HY-108642B

AMG-548 dihydrochloride, an orally active and selective **p38α** inhibitor (K_i=0.5 nM), shows slightly selective over **p38β** (K_i=36 nM) and >1000 fold selective against p38γ and p38δ.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

AMG-548 hydrochloride

Cat. No.: HY-108642A

AMG-548 hydrochloride, an orally active and selective **p38α** inhibitor (K_i=0.5 nM), shows slightly selective over **p38β** (K_i=36 nM) and >1000 fold selective against p38γ and p38δ.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AMG2850

Cat. No.: HY-104059

AMG2850 is a potent, orally bioavailable and selective **transient receptor potential melastatin 8 (TRPM8)** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminochlorthenoxazin

(ICI 350)

Cat. No.: HY-U00152

Aminochlorthenoxazin is an antipyretic and analgesic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aminophylline

Cat. No.: HY-B0140

Aminophylline is a competitive and non-selective **phosphodiesterase (PDE)** inhibitor. Aminophylline is a competitive **adenosine receptor** antagonist. Aminophylline has apulmonary vasodilator action as well as a bronchodilator action and has the potential for asthma research.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Aminopterin

(4-Aminofolic acid; APGA)

Cat. No.: HY-14518

Aminopterin (4-Aminofolic acid), the 4-amino derivative of folic acid, is a **folic acid** antagonist. Aminopterin catalyses the reduction of folic acid to tetrahydrofolic acid, and competitively inhibits dihydrofolate reductase **(DHFR)** with a K_i of 3.7 pM.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ammonium glycyrrhizinate (Monoammonium glycyrrhizinate; Glycyrrhizic acid ammonium salt; Ammonium glycyrrhizate)

Cat. No.: HY-76225

Ammonium glycyrrhizinate (Monoammonium glycyrrhizinate) has various pharmacological actions such as anti-inflammatory, antiallergic, antigastriculcer, and antihepatitis activities.



Purity: 97.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

Amodiaquine

(Amodiaquin)

Cat. No.: HY-B1322A

Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active **histamine N-methyltransferase** inhibitor.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Amodiaquine dihydrochloride

(Amodiaquin dihydrochloride) Cat. No.: HY-B1322B

Amodiaquine dihydrochloride (Amodiaquin dihydrochloride), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active **histamine N-methyltransferase** inhibitor with a K_i of 18.6 nM.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Amodiaquine dihydrochloride dihydrate

(Amodiaquin dihydrochloride dihydrate) Cat. No.: HY-B1322

Amodiaquine dihydrochloride dihydrate (Amodiaquin dihydrochloride dihydrate), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active **histamine N-methyltransferase** inhibitor.



Purity: 99.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Amotosalen hydrochloride

(S-59) Cat. No.: HY-107004A

Amotosalen hydrochloride (S-59) is a light-activated, DNA-, RNA-crosslinking psoralen compound, which is used to neutralise pathogens.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Amphotericin B trihydrate

Cat. No.: HY-B0221A

Amphotericin B trihydrate, a polyene antibiotic, is first isolated from fermenter cultures of Streptomyces nodosus. Amphotericin B trihydrate also possesses antileishmanial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ampiroxicam

(CP 65703) Cat. No.: HY-17484

Ampiroxicam(CP65703) is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug. Target: COX Ampiroxicam is a non-steroidal anti-inflammatory drug. It is a prodrug of piroxicam.



Purity: 97.12%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

AMXT-1501 tetrahydrochloride

Cat. No.: HY-124617A

AMXT-1501 tetrahydrochloride is an orally active **polyamine transport** inhibitor. AMXT1501 blocks tumor growth in immunocompetent mice but not in athymic nude mice lacking T cells. Combination of DFMO and AMXT1501 induces caspase3 mediated apoptosis in NB cell lines.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg

AMY-101

(Cp40) Cat. No.: HY-P1717

AMY-101 (Cp40), a peptidic inhibitor of the central **complement component C3** (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs).



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

AMY-101 acetate

(Cp40 acetate) Cat. No.: HY-P1717B

AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central **complement component C3** (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs).



Purity: 99.93%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

AMY-101 TFA

(Cp40 TFA) Cat. No.: HY-P1717A

AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central **complement component C3** (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs).



Purity: 99.94%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

AN-3485

Cat. No.: HY-18325

AN-3485 is a benzoxaborole analog, **Toll-Like Receptor(TLR)** inhibitor with IC_{50} values ranging from 18 to 580 nM.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg

AN3199

Cat. No.: HY-19830

AN3199 is a **PDE4** inhibitor with an IC_{50} of 94.5 nM. AN3199 can be used for the research of inflammation-associated diseases such as asthma and chronic obstructive pulmonary disease (COPD).



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Anagrelide hydrochloride

(BL4162A)

Cat. No.: HY-B0523A

Anagrelide hydrochloride (BL4162A) is a drug used for the treatment of essential thrombocytosis.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Anatabine dicitrate

Cat. No.: HY-19918A

Anatabine dicitrate is a tobacco alkaloid that can cross the blood-brain barrier. Anatabine dicitrate is a potent **α4β2 nAChR** agonist.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Andrograpanin

Cat. No.: HY-N9388

Andrograpanin, a bioactive compound from Andrographis paniculata, exhibits **anti-inflammatory** and anti-infectious properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Andrographolide

(Andrographis)

Cat. No.: HY-N0191

Andrographolide is a **NF-κB** inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on **p50** in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.



Purity: 98.57%
Clinical Data: Launched
Size: 100 mg, 500 mg

Andropanolide

Cat. No.: HY-N1912

Andrographolide (Andro) is a small antagonist for NF-κB activation by covalent modifying reduced cysteine 62 of p50. Andrographolide is a bicyclic diterpenoid lactone mainly produced from the plant Andrographis (Andrographis paniculate).



Purity: 98.78%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Androsin

Cat. No.: HY-N1399

Androsin is an active compound isolated from Picrorhiza Kurroa Royle ex Benth, with anti-asthmatic effects.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Anemarrhenasaponin Ia

Cat. No.: HY-N7576

Anemarrhenasaponin Ia, isolated from Anemarrhenae rhizome, inhibits N-formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide generation. Anemarrhenasaponin Ia is an useful anti-inflammation reagent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anemarsaponin B

Cat. No.: HY-N0811

Anemarsaponin B is a steroidal saponin. Anemarsaponin B decreases the protein and mRNA levels of **iNOS** and **COX-2**. Anemarsaponin B reduces the expressions and productions of pro-inflammatory cytokines, including TNF-a and IL-6.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Anemarsaponin E

Cat. No.: HY-N0813

Anemarsaponin E is extracted from Anemarrhena asphodeloides Bunge and has anti-inflammatory activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Angelicain
(Norcimifugin)

Cat. No.: HY-N6941

Angelicain (Norcimifugin) is a constituent of Cimicifuga foetida with anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Angelol B

Cat. No.: HY-N4235

Angelol B is a coumarin isolated from the roots of Angelica pubescens f. biserrata, which is passive diffusion as the dominating process in Caco-2 cell monolayer model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Angelol K

Cat. No.: HY-N4234

Angelol K is a natural product from Chinese angelica.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Angeloylgomisin O

Cat. No.: HY-N2271

Angeloylgomisin O, a lignin extract of Schisandra rubriflora. Anti-inflammatory properties.



Purity: 97.57%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Angiotensin (1-7)
(Ang-(1-7))

Cat. No.: HY-12403

Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine **ACE** activity (IC_{50}=0.65 μM).



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Angiotensin (1-7) (acetate)
(Ang-(1-7) (acetate))

Cat. No.: HY-12403A

Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Anisodamine hydrobromide
(6-Hydroxyhyoscyamine hydrobromide)

Cat. No.: HY-N0584A

Anisodamine hydrobromide (6-Hydroxyhyoscyamine hydrobromide), a belladonna alkaloid, is a non-subtype-selective **muscarinic** and a **nicotinic cholinoceptor** antagonist. Anisodamine hydrobromide shows antioxidant, anti-inflammatory properties.



Purity: 98.35%
Clinical Data: Launched
Size: 1 mg, 5 mg

Anitrazafen
(LY 122512)

Cat. No.: HY-17350

Anitrazafen is a topically effective antiinflammatory agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ankaflavin

Cat. No.: HY-N6642

Ankaflavin, isolated from Monascus-Fermented red rice, is a **PPARγ** agonist with anti-inlfammatory activity. Ankaflavin exhibits selective cytotoxic effect and induces cell death on cancer cells.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Ansofaxine hydrochloride
(LY03005; LPM570065)

Cat. No.: HY-U00096

Ansofaxine hydrochloride (LY03005; LPM570065) is a triple reuptake inhibitor; inhibits **serotonin**, **dopamine** and **norepinephrine** reuptake with IC_{50} values of 723, 491 and 763 nM, respectively.



Purity: 99.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Antennapedia Peptide(TFA)

Cat. No.: HY-P0307A

Antennapedia Peptide is a 16 amino acid peptide, originally derived from the 60 amino acid long homeodomain of the Drosophila transcription factor Antennapedia and is a member of the family of Cell-penetrating peptides.

RQIKIWFQNRRMKWKK (TFA salt)

Purity: 99.09%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Anthraquinone-2-carboxylic acid

Cat. No.: HY-W031757

Anthraquinone-2-carboxylic acid is a major anthraquinone isolated from Brazilian taheebo, with anti-inflammatory activity and antinociceptive.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg, 500 mg

Anti-inflammatory agent 1

Cat. No.: HY-U00273

Anti-inflammatory agent 1 is an anti-inflammatory agent extracted from patent WO 2009003229 A1, example 36.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anti-inflammatory agent 5

Cat. No.: HY-N10066

Anti-inflammatory agent 5 displays potent inhibition of NO generation in lipopolysaccharide-induced BV-2 microglial cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anti-inflammatory agent 6

Cat. No.: HY-139833

Anti-inflammatory agent 6 blocks the phosphorylation of **I kappa b kinase α/β (IKKα/β)**, **IκBα**, and **nuclear factor kB p65 (NF-κB p65)** which is a key controller of inflammation, thereby showing anti-inflammatory potential.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anti-inflammatory agent 7

Cat. No.: HY-139844

Anti-inflammatory agent 7 inhibits proinflammatory cytokines by blocking the **NF-κB/MAPK** signaling pathway in LPS-treated RAW 264.7 cells as well as mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anti-SARS-CoV-2 Spike mAb (CR3022)

(SARS-CR3022; SARS-CoV-2 Antibody-CR3022)

Cat. No.: HY-P9807

Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein.

Anti-SARS-CoV-2 Spike mAb (CR3022)

Purity: 95.00%
Clinical Data: No Development Reported
Size: 100 μg, 500 μg

Antiallergic agent-1

Cat. No.: HY-115723

Antiallergic agent-1, a **Src-family kinase** inhibitor, may serve as a new valuable lead compound for future antiallergic drug discovery.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antiasthmatic Compound 1

Cat. No.: HY-U00409

Antiasthmatic Compound 1 is an antiasthmatic agent, which has the potential for allergic asthma treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 40

Cat. No.: HY-139757

Antibacterial agent 40 is an antibacterial agent (extracted from patent WO2015159265A1, compound C) .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 41

Cat. No.: HY-139758

Antibacterial agent 41 (example 3) is a **antibacterial** agent (extracted from patent WO2013030735A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 52

Cat. No.: HY-139769

Antibacterial agent 52 (example 18) is a **antibacterial** agent (extracted from patent WO2013030735A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 53

Cat. No.: HY-139770

Antibacterial agent 53 (example 19) is a **antibacterial** agent (extracted from patent WO2013030735A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 54

Cat. No.: HY-139771

Antibacterial agent 54 (example 20) is a **antibacterial** agent (extracted from patent WO2013030735A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 55

Cat. No.: HY-139772

Antibacterial agent 55 (example 21) is a **antibacterial** agent (extracted from patent WO2013030735A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 56

Cat. No.: HY-139773

Antibacterial agent 56 (example 22) is a **antibacterial** agent (extracted from patent WO2013030735A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 57

Cat. No.: HY-139774

Antibacterial agent 57 (example 25) is a **antibacterial** agent (extracted from patent WO2013030735A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 59

Cat. No.: HY-139776

Antibacterial agent 59 (example 24) is a **antibacterial** agent (extracted from patent WO2013030735A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antibacterial agent 61

Cat. No.: HY-139778

Antibacterial agent 61 (example 27) is a **antibacterial** agent (extracted from patent WO2013030735A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antileukinate

Cat. No.: HY-125567

Antileukinate, a hexapeptide, is a potent inhibitor of **CXC-chemokine receptor (CXCR)**. Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antipyrine

(Phenazone; Phenazon)

Cat. No.: HY-B0171

Antipyrine (Phenazone) is an antipyretic and analgesic. Antipyrine can be used as a probe drug for oxidative drug metabolism. Antipyrine has been widely used in assessment of hepatic oxidative capacity.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Antitumor agent-2

Cat. No.: HY-128934

Antitumor agent-2 is sourced from patent CN102250203, compound 6a-r, has antitumor action and anti-inflammatory action.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Antitumor agent-21

Cat. No.: HY-107470

Antitumor agent-21 is an aryl-quinolin derivative, with potential anticancer, anti-inflammatory, anti-proliferative, anti-hormonal effects and inhibition of vasculogenic mimicry .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antiulcer Agent 1

Cat. No.: HY-U00122

Antiulcer Agent 1 is a 2-(3,4-dimethoxyphenyl)ethylamine derivative for oral administration at an exploratory stage of new drug development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AP-1/NF-κB activation inhibitor 1

Cat. No.: HY-133987

AP-1/NF-κB activation inhibitor 1 is a potent **AP-1** and **NF-κB** mediated transcriptional activation inhibitor (IC_{50}=1 μM), without blocking basal transcription driven by the β-actin promoter.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Apafant

(WEB 2086)

Cat. No.: HY-108634

Apafant (WEB 2086), a potent **platelet-activating factor (PAF)** antagonist, inhibits PAF binding to human PAF receptors with a K_i of 9.9 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Apamin

(Apamine)

Cat. No.: HY-P0256

Apamin (Apamine) is an 18 amino acid peptide neurotoxin found in apitoxin (bee venom), is known as a specifically selective blocker of **Ca^{2+}**-activated **K^+** (SK) channels and exhibits anti-inflammatory and anti-fibrotic activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

Apamin TFA

(Apamine TFA)

Cat. No.: HY-P0256A

Apamin TFA (Apamine TFA) is an 18 amino acid peptide neurotoxin found in apitoxin (bee venom), is known as a specifically selective blocker of **Ca^{2+}**-activated **K^+** (SK) channels and exhibits anti-inflammatory and anti-fibrotic activity.

Purity: 96.59%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

APETx2

Cat. No.: HY-P1346

APETx2, a sea anemone peptide from Anthopleura elegantissima, is a selective and reversible **ASIC3** inhibitor, with an IC_{50} of 63 nM. APETx2 directly inhibits the ASIC3 channel by acting at its external side. APETx2 could reverses acidinduced and inflammatory pain.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

APETx2 TFA

Cat. No.: HY-P1346A

APETx2 TFA, a sea anemone peptide from Anthopleura elegantissima, is a selective and reversible **ASIC3** inhibitor, with an IC_{50} of 63 nM. APETx2 directly inhibits the ASIC3 channel by acting at its external side. APETx2 could reverses acidinduced and inflammatory pain.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aphidicolin

Cat. No.: HY-N6733

Aphidicolin is an inhibitor of **DNA** polymerase α and δ, prevents mitotic cell division by interfering with the activity of DNA polymerase. Aphidicolin is an antibiotic produced by the mold Cephalosporium aphidicola.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Apigenin (4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1)

Cat. No.: HY-N1201

Apigenin (4',5,7-Trihydroxyflavone) is a competitive **CYP2C9** inhibitor with a K_i of 2 μM.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Apigenin-7-diglucuronide

Cat. No.: HY-N7270

Apigenin-7-diglucuronide is a flavonoid glycoside and is present in an assortment of medicinal plants with anti-inflammatory or ant-oxidant activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apiin

Cat. No.: HY-N0577

Apiin, a major constituent of Apium graveolens leaves with anti-inflammatory properties. Apiin shows significant inhibitory activity on nitrite (NO) production (IC_{50} = 0.08 mg/mL) in-vitro and iNOS expression (IC_{50} = 0.049 mg/ mL) in LPS-activated J774.A1 cells.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Apilimod

(STA 5326)

Cat. No.: HY-14644

Apilimod (STA 5326) is a potent **IL-12/IL-23** inhibitor, and strongly inhibits IL-12 with **IC_{50}**s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively. Apilimod is a potent and highly selective **PIKfyve** inhibitor.



Purity: 99.55%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Apilimod mesylate

(STA 5326 mesylate)

Cat. No.: HY-14644A

Apilimod (STA 5326) mesylate is a potent **IL-12/IL-23** inhibitor, and strongly inhibits IL-12 with **IC_{50}**s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively. Apilimod is a potent and highly selective **PIKfyve** inhibitor.



Purity: 99.40%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Apiopaeonoside

Cat. No.: HY-N2161

Apiopaeonoside is a natural product isolated from the root of Paeonia suffruticosa.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Apremilast

(CC-10004)

Cat. No.: HY-12085

Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (**PDE-4**) with an **IC_{50}** of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC_{50} of 104 nM.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Apremilast-d5

(CC-10004-d5)

Cat. No.: HY-12085S

Apremilast D5 (CC-10004 D5) is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (**PDE-4**) with an **IC_{50}** of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC_{50} of 104 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

APTO-253

(LOR-253; LT-253)

Cat. No.: HY-16291

APTO-253 (LOR-253) is a small molecule that inhibits **c-Myc** expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and **apoptosis** in acute myeloid leukemia cells.



Purity: 98.15%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

APX-115

(Ewha-18278) Cat. No.: HY-120801

APX-115 (Ewha-18278) is a potent, orally active pan **NADPH oxidase (Nox)** inhibitor with K_i values of 1.08 μM, 0.57 μM, and 0.63 μM for **Nox1**, **Nox2** and **Nox4**, respectively. APX-115 effectively prevents kidney injury.



Purity: ≥98.0%
Clinical Data:
Size: 1 mg

APX-115 free base

(Ewha-18278 free base) Cat. No.: HY-120801A

APX-115 free base (Ewha-18278 free base) is a potent, orally active pan **NADPH oxidase (Nox)** inhibitor with K_i values of 1.08 μM, 0.57 μM, and 0.63 μM for **Nox1**, **Nox2** and **Nox4**, respectively. APX-115 free base effectively prevents kidney injury.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

APY0201

Cat. No.: HY-15982

APY0201 is a potent **PIKfyve** inhibitor, which inhibits the conversion of PtdIns3P to PtdIns(3,5)P_2 in the presence of in the presence of [^{33}P]ATP with an IC_{50} of 5.2 nM. APY0201 also inhibits **IL-12/IL-23** production.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Apyramide

Cat. No.: HY-U00046

Apyramide is an **anti-inflammatory agent (NSAID)** and behaves as a prodrug of indomethacin (HY-14397). Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

AQX-435

Cat. No.: HY-136268

AQX-435 is a potent **SHIP1 phosphatase** activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AR-C102222 hydrochloride

Cat. No.: HY-12122A

AR-C102222 hydrochloride is a potent, competitive, orally active and highly selective **inducible nitric oxide synthase (iNOS)** inhibitor, with an IC_{50} of 37 nM. AR-C102222 hydrochloride has antinociception and anti-inflammatory activities.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

AR-C141990 hydrochloride

Cat. No.: HY-119996A

AR-C141990 hydrochloride is a potent **lactate transporters (monocarboxylate transporters; MCTs)** inhibitor with pK_i values of 7.6, 6.6 for MCT-1 and MCT-2, respectively. AR-C141990 hydrochloride has immunosuppressive properties and inhibits graft versus host response.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ar-Turmerone

((+)-ar-Turmerone) Cat. No.: HY-N6703

ar-Turmerone ((+)-ar-Turmerone) is a major bioactive compound of the herb Curcuma longa with anti-tumorigenesis and anti-inflammatory activities. ar-Turmerone activates apoptotic protein in human lymphoma U937 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Arachidonic acid

(Immunocytophyt) Cat. No.: HY-109590

Arachidonic acid is an essential fatty acid and a major constituent of biomembranes.

Purity: 99.50%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg

Arazine

(N-Acetyl-S-farnesyl-L-cysteine) Cat. No.: HY-133021

Arazine (N-Acetyl-S-farnesyl-L-cysteine) is a cell-permeable modulator of **G protein and G-protein coupled receptor** signaling. Arazine can be a a substrate for isoprenylcysteine methyltransferase by competing with prenylated G protein or its receptors site.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg (27.2 mM * 500 μL in Methyl acetate),

Arctigenin

((-)-Arctigenin)

Cat. No.: HY-N0035

Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (**influenza A virus**) activities.



Purity: 99.69%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Arctigenin 4'-O-β-gentiobioside

Cat. No.: HY-N2212

Arctigenin 4'-O-β-gentiobioside is a natural compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arg-Gly-Asp-Ser

(RGDS peptide; Fibronectin tetrapeptide)

Cat. No.: HY-12290

Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits **integrin receptor** function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Arg-Gly-Asp-Ser (TFA)

(RGDS peptide (TFA); Fibronectin tetrapeptide (TFA))

Cat. No.: HY-12290A

Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits **integrin receptor** function. Arg-Gly-Asp-Ser (TFA) directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Arglabin

((+)-Arglabin)

Cat. No.: HY-16059

Arglabin ((+)-Arglabin), a natural product isolated from Artemisia glabella, is a **NLRP3 inflammasome** inhibitor. Arglabin shows anti-inflammatory and antitumor activities.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Arimoclomol

(BRX-220 free base)

Cat. No.: HY-106443

Arimoclomol (BRX-220 free base) is a co-inducer of heat shock proteins (**HSP**). Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arimoclomol citrate

(BRX-220 citrate)

Cat. No.: HY-106443B

Arimoclomol citrate (BRX-220 citrate) is a co-inducer of heat shock proteins (**HSP**). Arimoclomol citrate protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arimoclomol maleate

(BRX-220)

Cat. No.: HY-106443A

Arimoclomol maleate (BRX-220) is a co-inducer of heat shock proteins (**HSP**). Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system.



Purity: 99.96%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Aristolactam I

(Aristololactam; Aristolactam)

Cat. No.: HY-N2013

Aristololactam I (AL-I), is the main metabolite of aristolochic acid I (AA-I), participates in the processes that lead to renal damage.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Arjunolic acid

Cat. No.: HY-N2896

Arjunolic acid is a saponin isolated from Symplocos lancifolia and has various biological activities, including antioxidant, antimicrobial, antibacterial and anti-inflammory activities.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Armepavine

Cat. No.: HY-N6857

Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Armillarisin A

Cat. No.: HY-108013

Armillarisin A has the potential for the ulcerative colitis (UC) study. Armillarisin A increases IL-4 and lower IL-1β.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg

ARN 077

(URB913)

Cat. No.: HY-120813

ARN 077 is a potent and selective **N-acylethanolamine acid amidase (NAAA)** inhibitor with an IC_{50} of 7 nM for human NAAA. ARN 077 significantly increases palmitoyl ethanolamine (PEA) levels within the CNS and has broad antinociceptive activity in mice and rats.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ARN 077 (enantiomer)

(URB913 (enantiomer))

Cat. No.: HY-120813A

ARN 077 enantiomer (19) is the less active enantiomer of ARN 077, with an IC_{50} of 3.53 μM for rat NAAA.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

ARN-3236

Cat. No.: HY-120856

ARN-3236 is an oral active and selective inhibitor of **salt-inducible kinase 2 (SIK2)**, with IC_{50}**s** of <1 nM, 21.63 nM and 6.63 nM for SIK2, SIK1 and SIK3, respectively. Has anti-cancer activity.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

ARN19689

Cat. No.: HY-132882

ARN19689 is a potent, selective, orally active and non-covalent inhibitor of **NAcylethanolamine-Hydrolyzing Acid Amidase (NAAA)**, with an IC_{50} of 42 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ARN19702

Cat. No.: HY-145339

ARN19702 is a selective, orally active, reversible, and brain-penetrant **N-acylethanolamine acid amidase (NAAA)** inhibitor with an IC_{50} of 230 nM for **human NAAA**. ARN19702 has pain relief effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ARQ 531

(MK-1026)

Cat. No.: HY-112215

ARQ 531 (MK-1026) is a reversible non-covalent and orally active inhibitor of Bruton's Tyrosine Kinase (**BTK**), with IC_{50}**s** of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.



Purity: 99.24%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Artemisic acid

(Qing Hao acid; Artemisinic acid; Arteannuic acid)

Cat. No.: HY-N1984

Artemisinic acid (Qing Hao acid), an amorphane sesquiterpene isolated from Artemisia annua L.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Artemitin

Cat. No.: HY-N3017

Artemitin is a flavonol found in Laggera pterodonta (DC.) Benth., with antioxidative, anti-inflammatory, and antiviral activity.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

AS-041164

Cat. No.: HY-118521

AS-041164 is a potent, selective and orally active **PI3Kγ** isoform inhibitor with an **IC_{50}** of 70 nM. AS-041164 shows less activity against PI3Kα, PI3Kβ, and PI3Kδ (IC_{50}s of 240 nM, 1.45 μM, and 1.70 μM, respectively). AS-041164 has anti-inflammatory effects.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AS-35

Cat. No.: HY-101946

AS-35 is an orally effective, potent and selective antagonist of **leukotrienes**, antagonizes LTC4-, LTD4 and LTE4-induced contractions of the ileum with **IC_{50}** values of 8 nM, 4 nM and 3 nM, respectively, and has antiallergic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS1517499

Cat. No.: HY-100614

AS1517499 is a potent and brain-permeable **STAT6** phosphorylation inhibitor with an **IC_{50}** of 21 nM.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AS1810722

Cat. No.: HY-134772

AS1810722 is an orally active and potent **STAT6** inhibitor with an **IC_{50}** of 1.9 nM. AS1810722 shows a good profile of **CYP3A4** inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AS2444697

Cat. No.: HY-18992

AS2444697 is an orally active **IRAK-4** inhibitor with an **IC_{50}** of 21 nM. AS2444697 potently inhibits human and rat IRAK-4 activity. AS2444697 exhibits renoprotective effects through anti-inflammatory action.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS2521780

Cat. No.: HY-12663

AS2521780 is a novel **PKCθ** selective inhibitor with an **IC_{50}** of 0.48 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS2717638

Cat. No.: HY-114379

AS2717638 is an oral active and selective **lysophosphatidic acid receptor 5 (LPA5)** antagonist, with an **IC_{50}** of 38 nM for hLPA5. AS2717638 also significantly improves PGE_2-, $PGF_{2\alpha}$-, and AMPA-induced allodynia.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

AS2863619

Cat. No.: HY-126675A

AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3$^+$ regulatory T (T_{reg}) cells for the treatment of various immunological diseases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AS2863619 free base

Cat. No.: HY-126675

AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3$^+$ regulatory T (T_{reg}) cells for the treatment of various immunological diseases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AS601245

Cat. No.: HY-11010

AS601245 is an orally active, selective, ATP competitive **JNK (c-Jun NH2-terminal protein kinase)** inhibitor with **IC_{50}**s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Asapiprant

(S-555739)

Cat. No.: HY-16763

Asapiprant is a potent and selective **DP_1 receptor** antagonist with a K_i of 0.44 nM.



Purity: 99.58%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Asaraldehyde (Asaronaldehyde; Asaraldehyde; 2,4,5-trimethoxy-Benzaldehyde)

Cat. No.: HY-100580

Asarylaldehyde (Asaronaldehyde), a **COX-2** inhibitor, significantly inhibits cyclooxygenase II (COX-2) activity with an **IC_{50}** value of 100 μg/mL.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 100 mg

Asatone

Cat. No.: HY-N6826

Asatone is an active component isolated from Radix et Rhizoma Asari, with anti-inflammatory effect via activation of NF-κB and donwn regulation of p-MAPK (ERK, JNK and p38) pathways.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Ascochlorin

(Ilicicolin D)

Cat. No.: HY-101021

Ascochlorin (Ilicicolin D), an isoprenoid antibiotic, mediates its anti-tumor effects predominantly through the suppression of **STAT3** signaling cascade. Ascochlorin induces **apoptosis**. Anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

Ascomycin

(Immunomycin; FR-900520; FK520)

Cat. No.: HY-13557

Ascomycin (Immunomycin; FR-900520; FK520) is an ethyl analog of Tacrolimus (FK506) with strong immunosuppressant properties. Ascomycin is also a macrocyclic polyketide **antibiotic** with multiple biological activities such as anti-malarial, anti-fungal and anti-spasmodic.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Asiatic acid

Cat. No.: HY-N0194

Asiatic acid, a pentacyclic triterpene found in Centella asiatica, induces apoptosis in melanoma cells. Asiatic acid has the potential for skin cancer treatment. Asiatic acid also has anti-inflammatory activities.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Asiaticoside

Cat. No.: HY-N0439

Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses **TGF-β/Smad** signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Asimadoline

(EMD-61753)

Cat. No.: HY-107384

Asimadoline (EMD-61753) is an orally active, selective and peripherally active **κ-opioid** agonist with **IC_{50}**s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant).



Purity: 99.36%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Asimadoline hydrochloride

(EMD-61753 hydrochloride)

Cat. No.: HY-107384A

Asimadoline (EMD-61753) hydrochloride is an orally active, selective and peripherally active **κ-opioid** agonist with **IC_{50}**s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant).



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Asivatrep

(PAC-14028)

Cat. No.: HY-12777

Asivatrep (PAC-14028) is a potent and selective transient receptor potential vanilloid type I (**TRPV1**) antagonist.



Purity: 95.14%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

ASK1-IN-1

Cat. No.: HY-133554

ASK1-IN-1 is a CNS-penetrant **ASK1** (apoptosis signal-regulating kinase 1) inhibitor, with good potency (cell IC_{50}=138 nM; Biochemical IC_{50}=21 nM).



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ASK1-IN-2

Cat. No.: HY-131969

ASK1-IN-2 is a potent and orally active inhibitor of **apoptosis signal-regulating kinase 1 (ASK1)**, with an IC_{50} of 32.8 nM. ASK1-IN-2 can be used for the research of ulcerative colitis.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ASP-4058

Cat. No.: HY-111021

ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 **($S1P_1$ and $S1P_5$)**, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.



Purity: 99.43%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ASP-4058 hydrochloride

Cat. No.: HY-111021A

ASP-4058 hydrochloride is a next-generation, selective and orally active agonist for Sphingosine 1-Phosphate receptors 1 and 5 **($S1P_1$ and $S1P_5$)**, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ASP1126

Cat. No.: HY-125881

ASP1126 is a selective and orally active **sphingosine-1-phosphate (S1P)** agonist, with EC_{50} values of 7.12 nM, 517 nM for $hS1P_1$ and $hS1P_3$, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aspartyl-alanyl-diketopiperazine

(DA-DKP)

Cat. No.: HY-107091

Aspartyl-alanyl-diketopiperazine (DA-DKP) is an immunomodulatory molecule generated by cleavage and cyclization from the N-terminus of human albumin and can modulate the inflammatory immune response through a molecular pathway implicated in T- lymphocyte anergy.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Asperphenamate

Cat. No.: HY-129578

Asperphenamate, a fungal metabolite of Aspergillus flatiipes with anti-cancer effect, exhibits IC_{50} values of 92.3 μM, 96.5 μM and 97.9 μM in T47D, MDA-MB-231 and HL-60 cells, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Asperuloside

Cat. No.: HY-N1382

Asperuloside is an iridoid isolated from Hedyotis diffusa, with anti-inflammatory activity. Asperuloside inhibits inducible nitric oxide synthase (**iNOS**), suppresses NF-κB and MAPK signaling pathways.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Asperulosidic Acid

Cat. No.: HY-N6246

Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Aspirin

(Acetylsalicylic Acid; ASA)

Cat. No.: HY-14654

Aspirin is a non-selective and irreversible inhibitor of **COX-1** and **COX-2** with IC_{50}s of 5 and 210 μg/mL.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Aspirin Aluminum

(Aluminum diacetylsalicylate) Cat. No.: HY-B2175

Aspirin Aluminum is a novel intermolecular compound which can inhibit gastrointestinal mucosal disorders induced by NSAIDs (non-steroidal anti-inflammatory agents) extracted from patent WO 2010064441 A1.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Aspirin-d3

(Acetylsalicylic Acid-d3; ASA-d3) Cat. No.: HY-14654S

Aspirin-d3 (Acetylsalicylic Acid-d3) is the deuterium labeled Aspirin. Aspirin is a non-selective and irreversible inhibitor of **COX-1** and **COX-2** with IC_{50}s of 5 and 210 μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Astemizole

(R 43512) Cat. No.: HY-12532

Astemizole (R 43512), a second-generation antihistamine drug to diminish allergic symptoms with a long duration of action, is a **histamine H1-receptor** antagonist, with an IC_{50} of 4 nM.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Asthma relating compound 1

Cat. No.: HY-U00412

Asthma relating compound 1 is an anti-asthmatic agent candidate extracted from patent EP0295656A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Astilbin

Cat. No.: HY-N0509

Astilbin is a flavonoid compound and enhances **NRF2** activation. Astilbin also suppresses **TNF-α** expression and **NF-κB** activation.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Astragalin (Astragaline; 3-Glucosylkaempferol; Kaempferol 3-β-D-glucopyranoside)

Cat. No.: HY-N0015

Astragalin (kaempferol-3-O-glucoside) is a flavonoid with anti-inflammatory activity and newly found in persimmon leaves and green tea seeds.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Astragaloside VI

Cat. No.: HY-N6577

Astragaloside VI could activate **EGFR/ERK** signalling pathway to improve wound healing.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 5 mg

Astragenol

Cat. No.: HY-N7924

Astragenol is an intermediate used for Astragenol derivative synthesis. Astragenol derivatives are promising anti-inflammatory agents for prostate cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

AT-56

Cat. No.: HY-13988

AT-56 is a potent, selective and orally active inhibitor of **lipocalin-type prostaglandin D synthase (L-PGDS)**, with an IC_{50} of 95 μM and K_i of 75 μM. AT-56 could selectively suppress the drowsiness or pain reaction mediated by **L-PGDS**-catalyzed PGD_2.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

AT791

Cat. No.: HY-124603

AT791 is a potent and orally bioavailable **TLR7** and **TLR9** inhibitor. AT791 inhibits TLR7 and 9 signaling in a variety of human and mouse cell types and inhibits DNA-TLR9 interaction in vitro.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ATI-2341

Cat. No.: HY-P0172

ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 **(CXCR4)**, which functions as a biased ligand, favoring Gαi activation over Gα13.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ATI-2341 TFA

Cat. No.: HY-P0172A

ATI-2341 is a potent and functionally selective allosteric agonist of **C-X-C chemokine receptor type 4 (CXCR4)**, which functions as a biased ligand, favoring Gαi activation over Gα13.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Atocalcitol

Cat. No.: HY-32346

Atocalcitol, a vitamin D3 analogue, is used in the study for psoriasis.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Atorvastatin

Cat. No.: HY-B0589

Atorvastatin is an orally active **HMG-CoA** reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC_{50}s of 0.39 μM and 2.39 μM, respectively.



Purity: 99.05%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Atorvastatin 3-Deoxyhept-2E-Enoic Acid

((2E)-2,3-Dehydroxy Atorvastatin)

Cat. No.: HY-135377

Atorvastatin 3-Deoxyhept-2E-Enoic Acid ((2E)-2,3-Dehydroxy Atorvastatin) is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atorvastatin ethyl ester

Cat. No.: HY-135378

Atorvastatin ethyl ester is a derivative of Atorvastatin and displays strong inhibition of the 9-cis-RA-induced Gal4 reporter activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atorvastatin hemicalcium salt

(CI-981; Atorvastatin hemicalcium)

Cat. No.: HY-17379

Atorvastatin hemicalcium salt (CI-981) is an orally active **3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)** reductase inhibitor, has the ability to effectively decrease blood lipids.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Atorvastatin lactone

Cat. No.: HY-101873

Atorvastatin lactone is a prodrug form of atorvastatin. Atorvastatin is an orally active **3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)** reductase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Atorvastatin lactone D5

Cat. No.: HY-101873S

Atorvastatin lactone D5 is a deuterated form of Atorvastatin lactone (HY-101873). Atorvastatin lactone is a prodrug form of atorvastatin. Atorvastatin is an orally active **3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)** reductase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atorvastatin-d5 sodium

Cat. No.: HY-B0589S1



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

ATP
(Adenosine 5'-triphosphate) Cat. No.: HY-B2176

ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation.



Purity: 99.62%
Clinical Data: Launched
Size: 100 mg, 500 mg

ATP dipotassium
(Adenosine 5'-triphosphate dipotassium) Cat. No.: HY-B2176C

ATP dipotassium (Adenosine 5'-triphosphate dipotassium) is a central component of energy storage and metabolism in vivo. ATP dipotassium provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

ATP disodium salt (Adenosine 5'-triphosphate disodium salt; Disodium adenosine triphosphate)
Cat. No.: HY-B0345A

ATP disodium salt (Adenosine 5'-triphosphate disodium salt) is a central component of energy storage and metabolism in vivo, provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells.



Purity: ≥98.0%
Clinical Data: Phase 3
Size: 500 mg, 1 g, 5 g

ATP disodium salt hydrate
(Adenosine 5'-triphosphate disodium salt hydrate) Cat. No.: HY-W010735

ATP disodium salt hydrate (Adenosine 5'-triphosphatedisodium salt hydrate) is a central component of energy storage and metabolism in vivo, provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells.



Purity: ≥98.0%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g

ATP disodium trihydrate
(Adenosine-5'-triphosphate disodium trihydrate) Cat. No.: HY-B2176A

ATP disodium trihydrate (Adenosine 5'-triphosphate disodium trihydrate) is a central component of energy storage and metabolism in vivo. ATP disodium trihydrate provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells.



Purity: 98.34%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

ATP-PEG8-Biotin
Cat. No.: HY-145249

ATP-PEG8-Biotin is a PEG-based linker that incorporates ATP. ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AtPep3
Cat. No.: HY-P2194

AtPep3 is a hormone-like peptide. AtPep3 can enhance salinity tolerance of plants and inhibits the salt-induced bleaching of chlorophyll in seedlings.

EIKARGKNKTKPTPSSGKGGKHN

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AtPep3 TFA
Cat. No.: HY-P2194A

AtPep3 TFA is a hormone-like peptide. AtPep3 TFA can enhance salinity tolerance of plants and inhibits the salt-induced bleaching of chlorophyll in seedlings.

EIKARGKNKTKPTPSSGKGGKHN (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ATPγS tetralithium salt (Adenosine-5'-O-3-thiotriphosphate (tetralithium salt); ...)
Cat. No.: HY-108666

ATPγS (tetralithium salt) is a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A.



Purity: ≥93.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atuzabrutinib
Cat. No.: HY-132808

Atuzabrutinib is a potent **BTK (Bruton's tyrosine kinase)** inhibitor (patent WO2016100914A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ATX inhibitor 5

Cat. No.: HY-133019

ATX inhibitor 5 is a potent and orally active **autotaxin (ATX)** inhibitor, with an IC_{50} of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Aucubin

Cat. No.: HY-N0664

Aucubin, an iridoid glucoside, is isolated from Plantago asiatica, Eucommia ulmoides, the leaves of Aucuba japonica and more recently from butterfly larva.



Purity: 98.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

AUDA

Cat. No.: HY-108570

AUDA (compound 43) is a potent **soluble epoxide hydrolase (sEH)** inhibitor with IC_{50}s of 18 and 69 nM for the mouse and human sEH, respectively. AUDA has anti-inflammatory activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 250 mg

Auranofin

(SKF-39162)

Cat. No.: HY-B1123

Auranofin (SKF-39162) is a thioredoxin reductase (**TrxR**) inhibitor with an IC_{50} of 0.2 μM. Auranofin exhibits antiviral activity against **SARS-CoV21**, with a CC_{50} of 4.2μM for monkey kidney Vero E6 cells.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Aurantiamide

Cat. No.: HY-N2909

Aurantiamide is an orally active constituent of Portulaca oleracea L and has various biological activities, including antioxidant, antiplatelet, anti-inflammatory, and antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aurantiamide acetate

(Asperglaucide)

Cat. No.: HY-N2905

Aurantiamide acetate (TMC-58A) is a selective and orally active **cathepsin** inhibitor isolated from Portulaca oleracea L. Aurantiamide acetate has anti-inflammatory activities and can be used for the study of inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Aurantio-obtusin

Cat. No.: HY-N0261

Aurantio-obtusin is an anthraquinone isolated from Semen Cassiae, with anti-Inflammatory, anti-oxidative, anti-coagulating and anti-hypertension activities.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Auraptene

Cat. No.: HY-N2388

Auraptene is the most abundant naturally occurring geranyloxycoumarin. Auraptene decreases the secretion of matrix metalloproteinase 2 (**MMP-2**) as well as key inflammatory mediators, including IL-6, IL-8, and chemokine (C-C motif) ligand-5(CCL5).



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Aureobasidin A

(Basifungin)

Cat. No.: HY-P1975

Aureobasidin A (Basifungin), a cyclic depsipetide, is an antifungal antibiotic. Aureobasidin A (Basifungin) A is an inhibitor of the inositolphosphorylceramide synthase **AUR1**.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Aurintricarboxylic acid

Cat. No.: HY-122575

Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive **P2X1Rs** and **P2X3Rs**, with IC_{50}s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Aurothiomalate sodium

Cat. No.: HY-106381

Aurothiomalate sodium is a potent and selective oncogenic **PKC$_\iota$** signaling inhibitor.
Aurothiomalate sodium inhibits tumor cell proliferation and not cell apoptosis.
Aurothiomalate sodium is a potent **thioredoxin reductase (TrxR)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Autotaxin-IN-1

Cat. No.: HY-123637

Autotaxin-IN-1 is a potent **autotaxin** inhibitor, which has favorable potency (IC_{50}=2.2 nM), PK properties, and a robust PK/PD relationship. Autotaxin-IN-1 is used in treatment of osteoarthritis pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Autotaxin-IN-3

Cat. No.: HY-135053

Autotaxin-IN-3 is a **Autotaxin(ATX)** inhibitor with an IC_{50} of 2.4 nM, compound 33, sourced from patent WO2018212534A1.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Autotaxin-IN-4

Cat. No.: HY-135088

Autotaxin-IN-4 (compound 51), extracted from patent WO2018212534A1, is an **Autotaxin** inhibitor. Autotaxin-IN-4 has the potential to treat idiopathic pulmonary fibrosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Autotaxin-IN-5

Cat. No.: HY-135089

Autotaxin-IN-5 (compound 63), extracted from patent WO2018212534A1, is an **Autotaxin** inhibitor. Autotaxin-IN-5 has the potential to treat idiopathic pulmonary fibrosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Avadomide

(CC 122)

Cat. No.: HY-100507

Avadomide (CC 122) is an orally active **cereblon** modulator. Avadomide modulates cereblon E3 ligase activity and induces **apoptosis** of diffuse large B-cell lymphoma (DLBCL) cell lines. Avadomide exhibits potent antitumor and immunomodulatory activities.



Purity: 99.50%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Avarofloxacin

(JNJ-Q2)

Cat. No.: HY-16764

Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Avasopasem manganese

(GC-4419; M-40419)

Cat. No.: HY-109110

Avasopasem manganese (GC4419; M-40419) is a potent superoxide dismutase mimetic that rapidly and specifically converts $O_2^{\bullet-}$ to hydrogen peroxide (H_2O_2), arresting the initiation of this cascade.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Avatrombopag

(AKR-501; E5501; YM477)

Cat. No.: HY-13463

Avatrombopag (AKR-501) is an orally active, nonpeptide **thrombopoietin (TPO) receptor** agonist (EC_{50}=3.3 nM). Avatrombopag mimics the biological activities of TPO.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Avelumab (Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C)

Cat. No.: HY-108730

Avelumab is a fully human IgG1 anti-**PD-L1** monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.

Avelumab

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Avicularin

Cat. No.: HY-N0222

Avicularin is a bio-active flavonoid from plants, anti-inflammatory, anti-allergic, anti-oxidant, hepatoprotective, and anti-tumor activities.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Aviptadil (Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine))

Cat. No.: HY-P0012

Aviptadil is an analog **vasoactive intestinal polypeptide (VIP)** with potent **vasodilatory** effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation.

Purity: 97.18%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 50 mg

Aviptadil acetate (Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine))

Cat. No.: HY-P0012A

Aviptadil acetate is an analog **vasoactive intestinal polypeptide (VIP)** with potent **vasodilatory** effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation.

Purity: 99.09%
Clinical Data: Launched
Size: 5 mg, 10 mg

AX-024

Cat. No.: HY-107390

AX-024 is an orally available, first-in-class inhibitor of the **TCR-Nck** interaction that selectively inhibits TCR-triggered T cell activation with an IC_{50} ~1 nM. AX-024 modulates cell signaling by targeting **SH3** domains.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AX-024 hydrochloride

Cat. No.: HY-107390A

AX-024 hydrochloride is an orally available, first-in-class inhibitor of the **TCR-Nck** interaction that selectively inhibits TCR-triggered T cell activation with an IC_{50} ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting **SH3** domains.



Purity: 99.12%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AX-15836

Cat. No.: HY-101846

AX-15836 is a potent and selective **ERK5** inhibitor with an IC_{50} of 8 nM.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

AXC-715 hydrochloride

Cat. No.: HY-138139A

AXC-715 hydrochloride is a **TLR7/TLR8** dual agonist, extracted from patent WO2020168017 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ayanin

Cat. No.: HY-N2913

Ayanin is a bioflavonoid isolated from Croton schiedeanus Schlecht. Ayanin is a non-selective **phosphodiesterase**$_{1-4}$ inhibitor and can be used for the study of respiratory disease,such as allergic asthma et al.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 5 mg

AZ084

Cat. No.: HY-119217

AZ084 is a potent, selective, allosteric and oral active **CCR8** antagonist, with a K_i of 0.9 nM. Has potential to treat asthma.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZ2

Cat. No.: HY-111570

AZ2 is a highly selective **PI3Kγ** inhibitor (The pIC_{50} value for **PI3Kγ** is 9.3). AZ2 can be used for the research of inflammatory and immune diseases.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZ3451

Cat. No.: HY-112558

AZ3451 is a potent **protease-activated receptor-2 (PAR2)** antagonist with IC_{50} of 23 nM.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Azadirachtin B

Cat. No.: HY-133108

Azadirachtin B is an limonoid isolated from seed kernels of Azadirachta indica. Azadirachtin B increases alkaline phosphatase (ALP) activity and stimulates osteoblast differentiation. Azadirachtin B is active against the **Epstein-Barr virus early antigen (EBV-EA)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azatadine

Cat. No.: HY-B0170

Azatadine is an histamine and cholinergic inhibitor with IC50 of 6.5 nM and 10 nM, respectively. Target: Histamine Receptor Azatadine, a new antihistamine, was evaluated for its efficacy in 20 patients with chronic allergic rhinitis.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Azatadine dimaleate

(Azatadine maleate)

Cat. No.: HY-B0170A

Azatadine dimaleate is an histamine and cholinergic inhibitor with IC50 of 6.5 nM and 10 nM, respectively. Target: Histamine Receptor Azatadine, a new antihistamine, was evaluated for its efficacy in 20 patients with chronic allergic rhinitis.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Azathioprine

(BW 57-322)

Cat. No.: HY-B0256

Azathioprine(Azasan, Imuran; BW 57-322) is a drug that suppresses the immune system and is used in organ transplantation and autoimmune disease. Target: Azathioprine is an immunosuppressive antimetabolite pro-drug.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

AZD 4407

(ZD 4407)

Cat. No.: HY-U00217

AZD 4407 is a potent **5-lipoxygenase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD-0284

Cat. No.: HY-120384

AZD-0284 is a selective inverse agonist of the nuclear receptor **RORγ**. AZD-0284 has the potential for plaque psoriasis vulgaris and respiratory tract disorders treatment.



Purity: 99.92%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD-4818

Cat. No.: HY-15545

AZD-4818 is a potent antagonist of chemokine **CCR1**. AZD-4818 can be used for the treatment of chronic obstructive pulmonary disease (COPD) .



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD-5672

Cat. No.: HY-119101

AZD-5672 is an orally active, potent, and selective **CCR5** antagonist (IC_{50}=0.32 nM). AZD-5672 shows moderate activity against the **hERG** ion channel (binding IC_{50}=7.3 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD-7295

Cat. No.: HY-111087

AZD-7295 is a **HCV NS5A** protein inhibitor, with an EC_{50} of 7 nM for GT-1b replicon.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD1390

Cat. No.: HY-109566

AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant **ATM** inhibitor with an IC_{50} of 0.78 nM in cell.



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

AZD1981

Cat. No.: HY-15950

AZD1981 is a potent and selective CRTh2 antagonist; displaces radio-labelled PGD2 from human recombinant DP2 with high potency (pIC50 = 8.4).



Purity: 99.82%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

AZD2098

Cat. No.: HY-U00064

AZD2098 is a potent and selective **CC-chemokine receptor 4 (CCR4)** inhibitor with pIC_{50}s of 7.8, 8.0, 8.0 and 7.6 for human, rat, mouse and dog respectively, used for asthma research.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD3264

Cat. No.: HY-19362

AZD3264 is a selective IkB-kinase **IKK2** inhibitor.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

AZD3458

Cat. No.: HY-112443

AZD3458 is a potent and remarkably selective **PI3Kγ** inhibitor with pIC_{50}s of 9.1, 5.1, <4.5, and 6.5 for **PI3Kγ**, **PI3Kα**, **PI3Kβ**, and **PI3Kδ**, respectively.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD5423

Cat. No.: HY-108243

AZD5423 is an inhaled, potent, selective, and non-steroidal **glucocorticoid receptor (GR)** modulator (SGRM). AZD5423 effectively reduces allergen-induced responses in subjects with mild allergic asthma.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD7325

Cat. No.: HY-111052

AZD7325 is a potent and orally active partial selective PAM of **GABAAα2 and Aα3 receptor** (K_i=0.3 and 1.3 nM, respectively), and has less antagonistic efficacy at the Aα1 and Aα5 receptor subtypes.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD7624

Cat. No.: HY-103672

AZD7624 is an inhaled **p38** inhibitor, with potent anti-inflammatory activity.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

AZD8154

Cat. No.: HY-115870

AZD8154 is a novel inhaled selective **PI3Kγδ** dual inhibitor targeting airway inflammatory disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD8797

(KAND567)

Cat. No.: HY-13848

AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human **CX3CR1** receptor; antagonizes CX3CR1 and CXCR2 with K_is of 3.9 and 2800 nM, respectively.



Purity: 98.65%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD8848

Cat. No.: HY-111269

AZD8848 is a selective **toll-like receptor 7 (TLR7)** antedrug agonist which is developed for the research of asthma and allergic rhinitis.



Purity: 98.08%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD9056 hydrochloride

Cat. No.: HY-19427A

AZD9056 hydrochloride is a selective orally active inhibitor of **P2X7** which plays a significant role in inflammation and pain-causing diseases.



Purity: 98.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD9567

Cat. No.: HY-120012

AZD9567 (compound 15) is a potent, oral active, non-steroidal and **selective glucocorticoid receptor modulator (SGRM)**, with an IC_{50} of 3.8 nM. Exhibits excellent efficacy in the streptococcal cell wall (SCW) reactivation model of joint inflammation.



Purity: ≥99.0%
Clinical Data: Phase 2
Size: 5 mg, 10 mg

AZD9898

Cat. No.: HY-126329

AZD9898 is an orally active **leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II)** inhibitor, with an IC_{50} of 0.28 nM. AZD9898 mitigates the GABA binding and hepatic toxicity signal. AZD9898 has the potential to treat asthma.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Azelastine

Cat. No.: HY-B0462A

Azelastine, an antihistamine, is a potent and selective **histamine 1 (H_1)** antagonist. Azelastine can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Azelastine hydrochloride

Cat. No.: HY-B0462

Azelastine hydrochloridem, an antihistamine, is a potent and selective **histamine 1 (H_1)** antagonist. Azelastine hydrochloride can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg

Azido-PEG4-C2-acid

Cat. No.: HY-130653

Azido-PEG4-C2-acid a PEG-based **PROTAC** linker can be used in the synthesis of vRucaparib-TP4. Azido-PEG4-C2-acid is also a non-cleavable 4 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azido-PEG5-acid

Cat. No.: HY-130572

Azido-PEG5-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs, such as the conjugate CPT-APO (CPT: Camptothecin (HY-16560)). Azido-PEG5-acid is a non-cleavable 5 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azido-PEG9-acid

Cat. No.: HY-130475

Azido-PEG9-acid is a non-cleavable 9 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG9-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

B022

Cat. No.: HY-120501

B022 is a potent and selective **NF-κB-inducing kinase (NIK)** inhibitor (K_i of 4.2 nM; IC_{50}=15.1 nM). B022 protects liver from toxin-induced inflammation, oxidative stress, and injury.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

B7/CD28 interaction inhibitor 1

Cat. No.: HY-102090

B7/CD28 interaction inhibitor 1 (copmound 6b) is a potent **B7.1-CD28 interaction** inhibitor with an IC_{50} of 50 nM.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

BAA473

Cat. No.: HY-123879

BAA473 is a bile acid analog and is a potent activator of the **pyrin inflammasome** that induces the secretion of interleukin 18 (IL-18) through activation of the **inflammasome** in both myeloid and intestinal epithelial cells.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Baicalin

(Baicalein 7-O-β-D-glucuronide)

Cat. No.: HY-N0197

Baicalin, as a flavonoid glycoside, is an allosteric carnitine palmityl transferase 1 (**CPT1**) activator. Baicalin reduces the expression of **NF-κB**.



Purity: 98.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Bakkenolide B

Cat. No.: HY-N7292

Bakkenolide B is isolated from petasites japonicas leaves and has anti-allergic and anti-inflammatory effects. Bakkenolide B can be used for the study of asthma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Baldrinal

Cat. No.: HY-N2401

Baldrinal is derived from the extracts of valerian rhizomes and roots, inhibits autonomic activity, and has anti-inflammatory effects.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Balicatib

(AAE581)

Cat. No.: HY-15100

Balicatib(AAE-581) is a potent and selective inhibitor of cathepsin K; 10-100 fold more potent in cell-based enzyme occupancy assays than against cathepsin B, L, and S.



Purity: 99.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Balsalazide

Cat. No.: HY-B0667

Balsalazide could suppress colitis-associated carcinogenesis through modulation of **IL-6/STAT3** pathway.



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Balsalazide sodium hydrate

(Balsalazide disodium dihydrate)

Cat. No.: HY-B0667A

Balsalazide sodium hydrate could suppress colitis-associated carcinogenesis through modulation of **IL-6/STAT3** pathway.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

BAM(8-22)

Cat. No.: HY-P1241

BAM(8-22), a proteolytically cleaved product of proenkephalin A, is a potent activator of Mas-related G-protein-coupled receptors (Mrgprs), MrgprC11 and hMrgprX1, and induces scratching in mice in an Mrgpr-dependent manner.

VGRPEWWMDYQKRYG

Purity: 99.91%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

BAM(8-22) TFA

Cat. No.: HY-P1241A

BAM(8-22) TFA, a proteolytically cleaved product of proenkephalin A, is a potent activator of Mas-related G-protein-coupled receptors (Mrgprs), MrgprC11 and hMrgprX1, and induces scratching in mice in an Mrgpr-dependent manner.

VGRPEWWMDYQKRYG (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bamaquimast

(F 10126; L 0042)

Cat. No.: HY-101427

Bamaquimast (F 10126; L 0042) is a potent antiasthmatic drug.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAMEA-O16B

Cat. No.: HY-139306

BAMEAO16B is a lipid nanoparticle. BAMEAO16B integrated with disulfide bonds, can efficiently deliver Cas9 mRNA and sgRNA into cells while releasing RNA in response to the reductive intracellular environment for genome editing.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 50 mg

Bamirastine

(TAK-427)

Cat. No.: HY-101601

Bamirastine inhibits ligand binding to recombinant human histamine H_1 receptors (**rhH$_1$R**) with an **IC$_{50}$** value of 17.3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Baohuoside I

(Icariin-II; Icariside-II)

Cat. No.: HY-N0011

Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of **CXCR4**, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAR502

Cat. No.: HY-101273

BAR502 is a dual **FXR** and **GPBAR1** agonist with **IC$_{50}$** values of 2 μM and 0.4 μM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Baricitinib

(LY3009104; INCB028050)

Cat. No.: HY-15315

Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable **JAK1** and **JAK2** inhibitor with **IC$_{50}$**s of 5.9 nM and 5.7 nM, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Baricitinib phosphate

(LY3009104 phosphate; INCB028050 phosphate)

Cat. No.: HY-15315A

Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable **JAK1**/**JAK2** inhibitor with **IC$_{50}$** of 5.9 nM and 5.7 nM, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Barlerin

(8-O-Acetyl shanzhiside methyl ester)

Cat. No.: HY-N0758

Barlerin (8-O-Acetyl shanzhiside methyl ester) is an iridoid glucoside isolated from the leaves of Lamiophlomis rotata Kudo, a Chinese folk medicinal plant in Xi-zang. Barlerin (8-O-Acetyl shanzhiside methyl ester) could inhibt **NF-κB**.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Batatasin I

Cat. No.: HY-N0940

Batatasin I is a natural product that can be isolated from tuberous roots of Dioscorea batatas, with antifungal activity and anti-inflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Batefenterol

(GSK961081; TD-5959)

Cat. No.: HY-12980

Batefenterol (GSK961081;TD-5959) is a novel **muscarinic** receptor antagonist and **β$_2$-adrenoceptor** agonist; displays high affinity for hM2, hM3 muscarinic and hβ$_2$-adrenoceptor with **K$_i$** values of 1.4, 1.3 and 3.7 nM, respectively.



Purity: 98.17%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bavachinin

(7-O-Methylbavachin; Bavachinin A) Cat. No.: HY-N0234

Bavachinin(7-O-Methylbavachin) is a natural compound isolated from the Chinese herb Fructus Psoraleae;has potent anti-angiogenic activity.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

BAY 11-7082

(BAY 11-7821) Cat. No.: HY-13453

BAY 11-7082 is an **IκBα phosphorylation** and **NF-κB** inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAY 41-2272

Cat. No.: HY-12376

BAY 41-2272 is a soluble guanylate cyclases (sGC) activator.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY 60-6583

Cat. No.: HY-103171

BAY 60-6583 is a potent and high-affinity agonist of **adenosine A_{2B}** receptor (EC_{50} = 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with K_i values of 750 nM, 340 nM and 330 nM, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAY 61-3606

Cat. No.: HY-76474

BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective **Syk** inhibitor with a K_i of 7.5 nM and an IC_{50} of 10 nM. BAY 61-3606 reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BAY 61-3606 dihydrochloride

Cat. No.: HY-14985

BAY 61-3606 dihydrochloride is an orally available, ATP-competitive, reversible and highly selective **Syk** inhibitor with a K_i of 7.5 nM an IC_{50} of 10 nM. BAY 61-3606 dihydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Bay 65-1942 (R form)

Cat. No.: HY-50949A

Bay 65-1942 R form is the less active R-form of Bay 65-1942. Bay 65-1942 is an ATP-competitive and selective IKKβ inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Bay 65-1942 free base

Cat. No.: HY-50949

Bay 65-1942 free base is an ATP-competitive and selective **IKKβ** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bay 65-1942 hydrochloride

Cat. No.: HY-50948

Bay 65-1942 hydrochloride is an ATP-competitive and selective **IKKβ** inhibitor.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

BAY-1316957

Cat. No.: HY-111539

BAY-1316957 is a potent, selective and orally active **prostaglandin E2 receptor subtype 4 (EP4-R)** antagonist with an IC_{50} of 15.3 nM for **human EP4-R**. BAY-1316957 has excellent drug metabolism and pharmacokinetics properties, and can be used for endometriosis research.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-545

Cat. No.: HY-111767

BAY-545 is a potent and selective **A_{2B} adenosine receptor** antagonist, with an **IC_{50}** of 59 nM.



Purity: 97.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

BAY-677

Cat. No.: HY-111457

BAY-677 is an inactive control for BAY-678.
BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase **(HNE)**, with an **IC_{50}** of 20 nM.



Purity: 97.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BAY-678

Cat. No.: HY-111457A

BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase **(HNE)**, with an **IC_{50}** of 20 nM. BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC).



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY-678 racemate

Cat. No.: HY-111515

BAY-678 racemate is a racemate of BAY-678. BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase **(HNE)**, with an **IC_{50}** of 20 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BAY-7598

Cat. No.: HY-120944

BAY-7598 is a potent, orally bioavailable, and selective **MMP12** inhibitor probe with **IC_{50}**s of 0.085, 0.67 and 1.1 nM for human MMP12, murine MMP12, and rat MMP12, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bayogenin 3-O-β-D-glucopyranoside

Cat. No.: HY-N2601

Bayogenin 3-O-β-D-glucopyranoside, a triterpenoid saponin isolated from Polygala japonica, possesses anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BB-Cl-Amidine

Cat. No.: HY-111347

BB-Cl-Amidine is a peptidylarginine deminase **(PAD)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BB-Cl-Amidine hydrochloride

Cat. No.: HY-111347A

BB-Cl-Amidine hydrochloride is a peptidylarginine deminase **(PAD)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

BBIQ

Cat. No.: HY-111582

BBIQ is a imidazoquinoline compound and a potent and selectively **toll-like receptor 7 (TLR7)** agonist with an **EC_{50}** of 59.1 nM for **human TLR7**. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BC-1215

Cat. No.: HY-117937

BC-1215 is an inhibitor of **F-box protein 3 (FBXO3**, a ubiquitin E3 ligase component, **IC_{50}**=0.9 μg/mL for IL-1β release). BC-1215 decreases Fbxo3-Fbxl2 interaction and prevents SCF^{Fbxo3} catalyzed Fbxl2 ubiquitination.



Purity: 99.80%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BC-1382

Cat. No.: HY-W062696

BC-1382 is a potent ubiquitin E3 ligase **HECTD2** inhibitor that specificly disrupts the HECTD2/PIAS1 interaction (IC_{50}≈ 5 nM).Anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BC1618

Cat. No.: HY-134656

BC1618, an orally active **Fbxo48** inhibitory compound, stimulates Ampk-dependent signaling (via preventing activated pAmpkα from Fbxo48-mediated degradation). BC1618 promotes mitochondrial fission, facilitates autophagy and improves hepatic insulin sensitivity.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BCI

((E)-BCI)

Cat. No.: HY-115502

BCI is an allosteric inhibitor of dual specificity phosphatase (**DUSP**). BCI specifically inhibits **DUSP6** and **DUSP1** with EC_{50}s of 13.3 and 8.0 μM in cells, respectively. BCI does not inhibit DUSP5.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

BCI hydrochloride

((E)-BCI hydrochloride)

Cat. No.: HY-115502A

BCI hydrochloride ((E)-BCI hydrochloride) is an allosteric inhibitor of dual specificity phosphatase (**DUSP**). BCI hydrochloride specifically inhibits **DUSP6** and **DUSP1** with EC_{50}s of 13.3 and 8.0 μM in cells, respectively. BCI hydrochloride does not inhibit DUSP5.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Bcl-2-IN-2

Cat. No.: HY-131247

Bcl-2-IN-2 is a potent and selective **Bcl-2** inhibitor with an IC_{50} of 0.034 nM and also inhibits Bcl-xL with an IC_{50} of 43 nM, showing >1000-fold selectivity for Bcl-2 over Bcl-xL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCX 1470

Cat. No.: HY-50874

BCX 1470 inhibits the esterolytic activity of **factor D** (IC_{50}=96 nM) and **C1s** (IC_{50}=1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCX 1470 methanesulfonate

Cat. No.: HY-50875

BCX 1470 methanesulfonate inhibits the esterolytic activity of **factor D** (IC_{50}=96 nM) and **C1s** (IC_{50}=1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

BD750

Cat. No.: HY-131140

BD750, an effective immunosuppressant and a **JAK3/STAT5** inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC_{50} values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Beclometasone

(Beclomethasone)

Cat. No.: HY-B1540

Beclometasone (Beclomethasone) is a prototype **glucocorticoid receptor** agonist.



Purity: 95.44%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Beclometasone dipropionate

Cat. No.: HY-13571A

Betamethasone dipropionate, the prodrug of Betamethasone, is an orally active and potent **glucocorticoid** with anti-inflammatory and immunosuppressive activity. Betamethasone appears to be an effective inhibitor of LPS-induced inflammation and MMP release.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 250 mg

Beclomethasone 17-propionate

(Beclomethasone-17-monopropionate; 17-BMP)

Cat. No.: HY-136239

Beclomethasone 17-propionate (Beclomethasone-17-monopropionate), an active metabolite of Beclomethasone dipropionate (HY-13571), is a **glucocorticoid receptor (GR)** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Bellidifolin

Cat. No.: HY-N2000

Bellidifolin is a xanthone isolated from the stems of Swertia punicea, with hepatoprotective, hypoglycemic, anti-oxidation, anti-inflammatory and antitumor activities. Bellidifolin also acts as a **viral protein R (Vpr)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Belnacasan

(VX-765)

Cat. No.: HY-13205

Belnacasan (VX-765) is an orally bioactive prodrug of VRT-043198, which is a potent and selective inhibitor of **IL-converting enzyme (ICE)/caspase-1** with K_is of 0.8 nM and less than 0.6 nM for caspase-1 and caspase-4, respectively.



Purity: 99.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Belumosudil

(KD025; SLx-2119)

Cat. No.: HY-15307

Belumosudil (KD025) is a selective inhibitor of **ROCK2** with IC_{50}s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Belumosudil mesylate

(KD025 mesylate; SLx-2119 mesylate)

Cat. No.: HY-15307A

Belumosudil mesylate (KD025 mesylate) is a selective inhibitor of **ROCK2** with IC_{50}s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Bendazac

Cat. No.: HY-17480

Bendazac is an oxyacetic acid with anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties. Bendazac acts by preventing protein denaturation and delays the cataractogenic process.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Benorilate

(Salipran)

Cat. No.: HY-107795

Benorylate (Salipran) is the esterification product of paracetamol and acetylsalicylic acid. Benorylate has anti-inflammatory, analgesic and antipyretic properties. Benorylate could also inhibit **prostaglandin (PG)** synthesis.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Benproperine phosphate

Cat. No.: HY-114657A

Benproperine phosphate is an orally active, potent **actin-related protein 2/3 complex subunit 2 (ARPC2)** inhibitor. Benproperine phosphate attenuates the actin polymerization rate of action polymerization nucleation by impairing Arp2/3 function.



Purity: 99.23%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Benpyrine

Cat. No.: HY-133807

Benpyrine is a highly specific and orally active **TNF-α** inhibitor with a K_D value of 82.1 μM. Benpyrine tightly binds to **TNF-α** and blocks its interaction with TNFR1, with an IC_{50} value of 0.109 μM.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Benralizumab

(MEDI-563; BIW-8405)

Cat. No.: HY-P9923

Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity.

Benralizumab

Purity: ≥99.1%
Clinical Data: Launched
Size: 1 mg, 2 mg

Benzothiazole

Cat. No.: HY-W012634

Benzothiazole is a natural occurring heterocyclic nuclei. Benzothiazole nucleus possesses a number of biological activities such as anticancer, antimicrobial, antidiabetic, anti-inflammatory, antileishmanial, and antiviral.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Benzoylalbiflorin

(Paeonivayin)

Cat. No.: HY-N7601

Benzoylalbiflorin, a monoterpenoid, is isolated from Radix Paeoniae Alba. Radix Paeoniae Alba is a traditional Chinese medicine that has been used for the research of rheumatoid arthritis, to alleviate inflammation, amenorrhea, epistaxis, abdominal pain, and other symptoms.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Benzoylgomisin O

Cat. No.: HY-N2266

Benzoylgomisin O isolated from Schisandra rubriflora, has inhibitory activity against **15-LOX**, **COX-1** and **COX-2** enzymes and anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Benzoylgomisin P

Cat. No.: HY-N2988A

Benzoylgomisin P is an anti-inflammatory agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Benzoylmesaconine

(Mesaconine 14-benzoate)

Cat. No.: HY-N0218

Benzoylmesaconine is the most abundant component of Wutou decoction, which is widely used in China because of its therapeutic effect on rheumatoid arthritis.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Benzoyloxypaeoniflorin

Cat. No.: HY-N2101

Benzoyloxypaeoniflorin, isolated from the root of Paeonia suffruticosa, is a **tyrosinase** inhibitor against mushroom tyrosinase with IC_{50} of 0.453 mM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Benzydamine hydrochloride

Cat. No.: HY-30235A

Benzydamine hydrochloride is a locally-acting nonsteroidal anti-inflammatory drug with local anaesthetic and analgesic properties; selectively binds to prostaglandin synthetase and has notable in vitro antibacterial activity.



Purity: 98.02%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Beperidium iodide

(SX 810)

Cat. No.: HY-100152

Beperidium iodide shows a competitive antagonistic effect against **acetylcholine receptor** with a **pA2** of 7.93.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Bepotastine

Cat. No.: HY-I0021

Bepotastine is a selective and orally active second-generation **histamine H1 receptor** antagonist. Bepotastine has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research.



Purity: 98.12%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Bepotastine besilate

Cat. No.: HY-A0015

Bepotastine besilate is a selective and orally active second-generation **histamine H1 receptor** antagonist. Bepotastine besilate has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Beraprost sodium

Cat. No.: HY-13569A

Beraprost sodium, a prostacyclin analog, is a stable and orally active prodrug of **PGI2**. Beraprost sodium is a potent **vasodilator**, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation.



Purity: 99.88%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Berberine

(Natural Yellow 18)

Cat. No.: HY-N0716

Berberine (Natural Yellow 18) is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an **antibiotic**. Berberine (Natural Yellow 18) induces reactive oxygen species (**ROS**) generation and inhibits **DNA topoisomerase**.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Berberrubine chloride

Cat. No.: HY-125850

Berberrubine chloride is an active metabolite of berberine, attenuates ulcerative colitis in mice model.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Bergenin

(Cuscutin)

Cat. No.: HY-N0017

Bergenin is a cytoprotective and antioxidative polyphenol found in many medicinal plants. Bergenin has a wide spectrum activities such as hepatoprotective, antiinflammatory, immunomodulatory, antitumor, antiviral, and antifungal properties.



Purity: 99.63%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Bermoprofen

(AD-1590)

Cat. No.: HY-118561

Bermoprofen (AD-1590) is an orally active non-steroidal anti-inflammatory agent. Bermoprofen has potent antipyretic activities with a short biological half-life. Bermoprofen is a potent antagonist of LPS-induced fever in rabbits.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Beta-Acetoxyisovalerylshikonin

Cat. No.: HY-N2188

Beta-Acetoxyisovalerylshikonin is a naphthoquinone derivative isolated from Arnebia euchroma.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Beta-asarone

Cat. No.: HY-N1501

Beta-asarone is a major ingredient of Acorus tatarinowii Schott, penetrates blood brain barrier, with the properties of immunosuppression, central nervous system inhibition, sedation, and hypothermy. Beta-asarone protects against Parkinson's disease.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Beta-defensin 1, pig

Cat. No.: HY-P2290

Beta-defensin 1, pig is an antimicrobial peptide found primarily in tongue mucosa of pig.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Beta-defensin 1, pig TFA

Cat. No.: HY-P2290A

Beta-defensin 1, pig TFA is an antimicrobial peptide found primarily in tongue mucosa of pig.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Beta-defensin 103 isoform X1, pig

Cat. No.: HY-P2291

Beta-defensin 103 isoform X1, pig is an antimicrobial peptide found in different living organisms, involved in the first line of defense in their innate immune response against pathogens.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Beta-defensin 103 isoform X1, pig TFA

Cat. No.: HY-P2291A

Beta-defensin 103 isoform X1, pig TFA is an antimicrobial peptide found in different living organisms, involved in the first line of defense in their innate immune response against pathogens.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Beta-Sitosterol (purity>75%) (β-Sitosterol (purity>75%); 22,23-Dihydrostigmasterol (purity>75%))

Cat. No.: HY-N0171B

Beta-Sitosterol (purity>75%) includes 75% β-sitosterol and 10% campesterol. Beta-Sitosterol is a plant sterol.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Beta-Sitosterol (purity>80%) (β-Sitosterol (purity>80%); 22,23-Dihydrostigmasterol (purity>80%))

Cat. No.: HY-N0171

Beta-Sitosterol (purity>80%) includes β-sitosterol (≥80%), stigmasterol, campesterol and brassicasterol mainly. Beta-Sitosterol is a plant sterol.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg, 1 g, 5 g

Beta-Sitosterol (purity>98%) (β-Sitosterol (purity>98%); 22,23-Dihydrostigmasterol (purity>98%))

Cat. No.: HY-N0171A

Beta-Sitosterol (purity>98%) is a plant sterol. Beta-Sitosterol (purity>98%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Betahistine

Cat. No.: HY-B0524

Betahistine is an orally active **histamine H1 receptor** agonist and a **H3 receptor** antagonist. Betahistine is used for the study of rheumatoid arthritis (RA).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Betahistine dihydrochloride

Cat. No.: HY-B0524A

Betahistine dihydrochloride is an orally active **histamine H1 receptor** agonist and a **H3 receptor** antagonist. Betahistine dihydrochloride is used for the study of rheumatoid arthritis (RA).



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Betahistine EP Impurity C (NSC19005)

Cat. No.: HY-107495

Betahistine EP Impurity C (NSC19005) is an impurity of Betahistine. Betahistine is a potent, orally active and well-tolerated histamine H1 receptor agonist and H3 receptor antagonist used for the study of rheumatoid arthritis (RA).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Betahistine mesylate

Cat. No.: HY-D0237

Betahistine mesylate is an orally active **histamine H1 receptor** agonist and a **H3 receptor** antagonist. Betahistine mesylate is used for the study of rheumatoid arthritis (RA).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Betamethasone

Cat. No.: HY-13570

Betamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive activities. Betamethasone accelerates fetal lung maturation and induces gene expression and apoptosis.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Betamethasone 17-benzoate

Cat. No.: HY-U00161

Betamethasone 17-benzoate is a representative steroid, which can be used in the treatment of recurrent aphothous ulcers (RAU).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Betamethasone acibutate

Cat. No.: HY-121062

Betamethasone acibutate, derives from Betamethasone, is an acetate ester. Betamethasone acibutate is a glucocorticoid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Betamethasone dipropionate

(Betamethasone 17,21-dipropionate)

Cat. No.: HY-13571

Betamethasone dipropionate is a **glucocorticoid** steroid with anti-inflammatory and immunosuppressive abilities.



Purity: 98.31%
Clinical Data: Launched
Size: 10 mM × 1 mL, 250 mg, 1 g

Betamethasone hydrochloride

Cat. No.: HY-13570A

Betamethasone hydrochloride is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive activities. Betamethasone hydrochloride accelerates fetal lung maturation and induces gene expression and apoptosis.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Betamethasone valerate

(Betamethasone 17-valerate)

Cat. No.: HY-B0727

Betamethasone valerate (Betamethasone 17-valerate), the 17-valerate ester of Betamethasone, is a topical corticosteroid with anti-inflammatory activity. Betamethasone valerate is used in the treatment of recurrent aphthous stomatitis.



Purity: 99.14%
Clinical Data: Launched
Size: 25 mg, 50 mg, 100 mg

Betamethasone-17-butyrate-21-propionate

Cat. No.: HY-B0775

Betamethasone-17-butyrate-21-propionate is a topical corticosteroid with potential in the treatment of inflammatory skin diseases.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Betulin diacetate

(Betulin 3,28-diacetate)

Cat. No.: HY-N9437

Betulin diacetate, a triterpene and derivative of Betulin, is an anti-AID agent and also possesses anti-cancer activity.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Betulinic acid

(Lupatic acid; Betulic acid)

Cat. No.: HY-10529

Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic **topoisomerase I** inhibitor, with an IC_{50} of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties. Betulinic acid acts as a new activator of **NF-kB**.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Betulinic acid derivative-1

Cat. No.: HY-115720

Betulinic acid derivative-1 exhibits distinguished activities on inhibiting osteoclast (OC) differentiation with an IC_{50} value of 1.86 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Betulonic acid

(Betunolic acid; Liquidambaric acid; (+)-Betulonic acid)

Cat. No.: HY-N1451

Betulonic acid (Betunolic acid), a naturally occurring triterpene, is found in many plants. Betulonic acid has anti-tumor, anti-inflammatory, antiparasitic and anti-viral (**HSV-1**) activities.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Bevurogant

Cat. No.: HY-132810

Bevurogant is a retinoid-related **orphan receptor-gamma t (RORγt)** antagonist. Bevurogant can be used for the research of chronic inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BI 653048

Cat. No.: HY-12946

BI 653048 is a selective and orally active nonsteroidal **glucocorticoid (GC)** agonist with an IC_{50} value of 55 nM. BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms' activity and reduces affinity for the hERG ion channel (IC_{50}>30 μM).



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

BI 653048 phosphate

Cat. No.: HY-12946A

BI 653048 phosphate is a selective and orally active nonsteroidal **glucocorticoid (GC)** agonist with an IC_{50} value of 55 nM.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

BI-1950

Cat. No.: HY-124040

BI-1950 is a highly potent **lymphocyte function associated antigen-1 (LFA-1)** inhibitor. LFA-1 is an essential component in normal immune system function and a target for drug discovery.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BI-2545

Cat. No.: HY-124772

BI-2545 is a potent **autotaxin (ATX)** inhibitor that significantly reduces LPA, with IC_{50}s of 2.2 nM and 3.4 nM for human ATX and rat ATX, respectively.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BI-671800

Cat. No.: HY-114141

BI-671800 is a highly specific and potent antagonist of chemoattractant receptor-homologous molecule on Th2 cells **(DP2/CRTH2)**, with IC_{50} values of 4.5 nM and 3.7 nM for PGD2 binding to CRTH2 in hCRTH2 and mCRTH2 transfected cells, respectively.



Purity: 99.23%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BI-6901

Cat. No.: HY-116835

BI 6901 is a potent, selective **CCR10** antagonist (pIC_{50}=9.0). BI 6901 shows high selectivity over other GPCRs, including a number of other chemokine receptors. BI 6901 is efficacious in the murine DNFB model of contact hypersensitivity and can be used for inflammation research.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BIBR 1087 SE

(Desethyl Dabigatran Etexilate)

Cat. No.: HY-W004360

BIBR 1087 SE is an intermediate metabolite of dabigatran etexilate.



Purity: 96.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

BIIB068

Cat. No.: HY-131342

BIIB068 is a potent, selective, reversible and orally active **BTK** inhibitor with an IC_{50} of 1 nM and a K_d of 0.3 nM. BIIB068 shows more >400-fold selective for **BTK** than other kinases. BIIB068 has the potential for autoimmune diseases research.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BIIB091

Cat. No.: HY-139984

BIIB091 is a highly selective, reversible **BTK** inhibitor for treating autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BIIL-260 hydrochloride

Cat. No.: HY-114641A

BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor **LTB_4** antagonist, with anti-inflammatory activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Bilastine

Cat. No.: HY-14447

Bilastine is a selective histamine H1 receptor antagonist used for treatment of allergic rhinoconjunctivitis and urticaria.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Bilastine-d6

Cat. No.: HY-14447S

Bilastine-d6 is the deuterium labeled Bilastine. Bilastine is a selective histamine H1 receptor antagonist used for treatment of allergic rhinoconjunctivitis and urticaria.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Bim BH3, Peptide IV

Cat. No.: HY-P1889

Bim BH3, Peptide IV is a 26-residue peptide from BH3-only protein Bim, which belongs to the pro-apoptotic group of the Bcl-2 family of proteins.

DMRPEIWIAQELRRIGDEFNAYYARR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bim BH3, Peptide IV TFA

Cat. No.: HY-P1889A

Bim BH3, Peptide IV TFA is a 26-residue peptide from BH3-only protein Bim, which belongs to the pro-apoptotic group of the Bcl-2 family of proteins.

DMRPEIWIAQELRRIGDEFNAYYARR (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bimosiamose

(TBC-1269)

Cat. No.: HY-106139

Bimosiamose (TBC-1269) is a nonoligosaccharide pan-**selectin** antagonist with IC_{50}s of 88 μM, 20 μM, and 86 μM for **E-selectin**, **P-selectin**, and **L-selectin**, respectively. Bimosiamose has anti-inflammatory effects.



Purity: 99.33%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg

Bimosiamose disodium

(TBC-1269Z)

Cat. No.: HY-106139A

Bimosiamose disodium (TBC-1269Z) is a nonoligosaccharide pan-**selectin** inhibitor with IC_{50}s of 88 μM, 20 μM, and 86 μM for **E-selectin**, **P-selectin**, and **L-selectin**, respectively. Bimosiamose disodium has anti-inflammatory effects.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Bindarit

(AF2838)

Cat. No.: HY-B0498

Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins **MCP-1/CCL2**, **MCP-3/CCL7**, and **MCP-2/CCL8**, and no effect on other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, MIP-3/CCL23. Bindarit also has anti-inflammatory activity.



Purity: 99.68%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

BIO-11006 acetate

Cat. No.: HY-106377A

BIO-11006 acetate, an analog of the MANS peptide, is a **MARCKS** (myristoylated alanine-rich C kinase substrate) inhibitor.



Purity: >98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BIO-1211

Cat. No.: HY-14126

BIO-1211 is a highly selective and orally active **α4β1 (VLA-4)** inhibitor, with IC_{50} values of 4 nM and 2 μM for α4β1 and α4β7, respectively.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 1 mg

BIO-acetoxime

(BIA)

Cat. No.: HY-15356

BIO-acetoxime (BIA) is a potent and selective **GSK-3** inhibitor, with IC_{50}s of both 10 nM for GSK-3α/β. BIO-acetoxime has anticonvulsant and anti-infection activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BIO5192

Cat. No.: HY-107589

BIO5192 is a selective and potent integrin **α4β1** (VLA-4) inhibitor (K_d<10 pM). BIO5192 selectively binds to α4β1 (IC_{50}=1.8 nM) over a range of other integrins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BIO5192 hydrate

Cat. No.: HY-107589A

BIO5192 hydrate is a selective and potent integrin **α4β1 (VLA-4)** inhibitor (K_d<10 pM). BIO5192 hydrate selectively binds to α4β1 (IC_{50}=1.8 nM) over a range of other integrins.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Biotin-PEG2-acid

Cat. No.: HY-126958

Biotin-PEG2-acid is a non-cleavable 2 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). Biotin-PEG2-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.



Purity: 96.14%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 250 mg

Biotin-PEG7-C2-NH-Vidarabine-S-CH3

Cat. No.: HY-145248

Biotin-PEG7-C2-NH-Vidarabine-S-CH3 is a PEG-based linker that incorporates adenosine analog Vidarabine. Vidarabine is an antiviral agent which is active against herpes simplex and varicella zoster viruses.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis(dihydrochelerythrinyl)amine

Cat. No.: HY-N8089

Bis(dihydrochelerythrinyl)amine possesses anti-bacteria activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bis-PEG1-PFP ester

Cat. No.: HY-112561

Bis-PEG1-PFP ester is a non-cleavable (1 unit PEG) ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bisabolangelone

Cat. No.: HY-N4233

Bisabolangelone, a sesquiterpene derivative, is isolated from the roots of Osterici Radix.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Bisabolol oxide A

Cat. No.: HY-N8117

Bisabolol oxide A possesses antihyperalgesic and antiedematous effects with oral activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bisandrographolide C

Cat. No.: HY-N2941

Bisandrographolide C is an unusual dimer of ent-labdane diterpenoid isolated and identified from Andrographis paniculata.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bisindolylmaleimide VIII acetate

(Ro 31-7549 acetate; Bis VIII acetate)

Cat. No.: HY-129624A

Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective **protein kinase C (PKC)** inhibitor with an IC_{50} of 158 nM for rat brain PKC.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg

Bisindolylmaleimide XI hydrochloride

(Ro 32-0432; Ro 31-8830 hydrochloride)

Cat. No.: HY-117610A

Bisindolylmaleimide XI hydrochloride (Ro 32-0432) is a potent, selective and orally active **PKC** inhibitor with **IC_{50}**s of 9 nM, 28 nM, 31 nM, 37 nM, and 108 nM for **PKCα**, **PKCβI**, **PKCβII**, **PKCγ**, and **PKCε**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Bisoprolol hemifumarate

Cat. No.: HY-B0076

Bisoprolol hemifumarate is a selective **type β1 adrenergic receptor** blocker.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Bixin

Cat. No.: HY-N6884

Bixin (BX), isolated from the seeds of Bixa orellana, is a carotenoid, possessing anti-inflammatory, anti-tumor and anti-oxidant activities.



Purity: 97.50%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

BIZ 114

Cat. No.: HY-135808

BIZ 114 (Example 11) is a fatty acid derivative and potent inhibits the TNF-α activated **NF-κB** pathway. BIZ 114 has the potential to prevent and / or treat ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

BJE6-106

(B106)

Cat. No.: HY-117800

BJE6-106 (B106) is a potent, selective 3rd generation **PKCδ** inhibitor with an **IC_{50}** of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC_{50}=50 μM). BJE6-106 (B106) induces caspase-dependent **apoptosis**. BJE6-106 (B106) possesses tumor-specific effect.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BL-1249

Cat. No.: HY-108596

BL-1249 is a **nonsteroidal anti-inflammatory drug (NSAID)** and a **potassium channel** activator. BL-1249 potently activates **K_{2P}2.1 (TREK-1)** and **K_{2P}10.1 (TREK-2)** with **EC_{50}** values of 5.5 μM and 8.0 μM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

BLT-1

(Block lipid transport-1)

Cat. No.: HY-116767

BLT-1, a thiosemicarbazone copper chelator, is a selective **scavenger receptor B, type 1 (SR-BI)** inhibitor. BLT-1 inhibits the transfer of lipids between high-density lipoproteins (HDL) and cells mediated by SR-BI. BLT-1 is a potent HCV entry inhibitor.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Blumeatin

Cat. No.: HY-N2358

Blumeatin, isolated from Blumea balsamifera DC, could protect liver against injury induced by CCl4 and thioacetamide (TAA).



Purity: 98.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

BML-111

Cat. No.: HY-100450

BML-111, a lipoxin A_4 analog, is a **lipoxin A_4 receptor** agonist. BML-111 represses the activity of **angiotensin converting enzyme (ACE)** and increases the activity of **angiotensinconverting enzyme 2 (ACE2)**. BML-111 has antiangiogenic, antitumor and anti-inflammatory properties.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg

BMS 753

Cat. No.: HY-107395

BMS 753 is an isotype-selective **retinoic acid receptor α (RARα)** agonist, with a **K_i** of 2 nM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

BMS CCR2 22

Cat. No.: HY-101908

BMS CCR2 22 is a potent, specific and high affinity **CC-type chemokine receptor 2 (CCR2)** antagonist with excellent binding affinity (binding IC_{50} of 5.1 nM) and potent functional antagonism (calcium flux IC_{50} of 18 nM and chemotaxis IC_{50} of 1 nM).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

BMS-066

Cat. No.: HY-18710

BMS-066 is an **IKKβ/Tyk2** pseudokinase inhibitor, with IC_{50}**s** of 9 nM and 72 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-1

(PD-1/PD-L1 inhibitor 1)

Cat. No.: HY-19991

BMS-1 is an inhibitor of the **PD-1/PD-L1** protein/protein interaction (IC_{50} between 6 and 100 nM).



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-1001 hydrochloride

Cat. No.: HY-120635

BMS-1001 hydrochloride is an orally active human **PD-L1/PD-1** immune checkpoint inhibitor. BMS-1001 hydrochloride exhibits low-toxicity in cells.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-1166

Cat. No.: HY-102011

BMS-1166 is a potent **PD-1/PD-L1** immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC_{50} of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-1166 hydrochloride

Cat. No.: HY-102011A

BMS-1166 hydrochloride is a potent **PD-1/PD-L1** immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC_{50} of 1.4 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-470539 dihydrochloride

Cat. No.: HY-115644

BMS-470539 dihydrochloride is a highly potent and selective **melanocortin-1 receptor (MC-1R)** agonist with an IC_{50} of 120 nM, an EC_{50} of 28 nM. BMS-470539 dihydrochloride does not activate MC-3R and is a very weak partial agonist at MC-4R and MC-5R.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-509744

Cat. No.: HY-11092

BMS-509744 is a potent, selective and ATP competitive **Itk** inhibitor with an IC_{50} of 19 nM.



Purity: 97.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BMS-582949 hydrochloride

Cat. No.: HY-14305A

BMS-582949 hydrochloride is an orally active and highly selective **p38α MAPK** inhibitor, with an IC_{50} of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease.



Purity: 98.29%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-587101

Cat. No.: HY-120628

BMS-587101 is a potent and orally active antagonist of **leukocyte function associated antigen-1 (LFA-1)**. BMS-587101 has anti-inflammatory effects and can be used for rheumatoid arthritis research.



Purity: 98.67%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-688521

Cat. No.: HY-10596

BMS-688521 is a highly potent, orally active inhibitor of the **LFA-1/ICAM** interaction, with an IC_{50} of 2.5 nM in the adhesion assay and an IC_{50} of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

BMS-935177

Cat. No.: HY-101793

BMS-935177 is a potent and selective reversible inhibitor of Bruton's tyrosine kinase (**Btk**) with an IC_{50} of 3 nM.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-986020

Cat. No.: HY-100619

BMS-986020 is a high-affinity and selective **lysophosphatidic acid receptor 1 (LPA1)** antagonist. BMS-986020 inhibits bile acid and phospholipid transporters with IC_{50}s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively.



Purity: 99.53%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

BMS-986020 sodium

Cat. No.: HY-100619A

BMS-986020 sodium is a high-affinity lysophosphatidic acid receptor 1 (**LPA1**) antagonist. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC_{50}s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively.



Purity: 99.60%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

BMS-986120

Cat. No.: HY-19837

BMS-986120 is a first-in-class oral and reversible protease-activated receptor 4 (**PAR4**) antagonist, with IC_{50}s of 9.5 nM and 2.1 nM in human and monkey blood, respectively. BMS-986120 has potent and selective antiplatelet effects.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-986142

Cat. No.: HY-101856

BMS-986142 is a potent and highly selective reversible inhibitor of **Bruton's tyrosine kinase (BTK)** with an IC_{50} of 0.5 nM.



Purity: 99.92%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-986144

Cat. No.: HY-131905S

BMS-986144 is a third-generation, pan-genotype (GT) **NS3/4A protease** inhibitor. BMS-986144 inhibits HCV replicon with EC_{50}s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-986202

Cat. No.: HY-131968

BMS-986202 is a potent, selective and orally active **Tyk2** inhibitor that binds to **Tyk2 JH2** with an IC_{50} of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members.



Purity: 99.46%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-986251

Cat. No.: HY-136527

BMS-986251 is an orally active and selective **RORγt** inverse agonist with an EC_{50} of 12 nM for RORγt GAL4. BMS-986251 inhibits **IL-17** with an EC_{50} of 24 nM in human whole blood assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMY-25271

Cat. No.: HY-100191

BMY-25271 is a **histamine H2 receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BN201

Cat. No.: HY-135749

BN201 promotes neuronal differentiation, the differentiation of precursor cells to mature oligodendrocytes (EC_{50} of 6.3 μM) in vitro, and the myelination of new axons (EC_{50} of 16.6 μM).



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

BnO-PEG6-OH

Cat. No.: HY-W042654

BnO-PEG6-OH is a non-cleavable 6 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). BnO-PEG6-OH is also a PEG-based PROTAC linker can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

BNTA

Cat. No.: HY-136651

BNTA, a potent **extracellular matrix (ECM)** modulator, facilitates cartilage structural molecule synthesis on chondrocytes by activating **superoxide dismutase 3 (SOD3)**. BNTA shows a promising potential for osteoarthritis alleviation by modulating cartilage generation.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Boc-Asp(OMe)-fluoromethyl ketone

(Boc-Asp(OMe)-FMK)

Cat. No.: HY-103348

Boc-Asp(OME)-Fluoromethyl Ketone is a broad range caspase inhibitor that inhibits Fas-mediated phagocytosis and oxidative rupture inhibition, but does not affect the chemotactic activity of IL-8.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Boc-MLF TFA

(Boc-Met-Leu-Phe-OH (TFA))

Cat. No.: HY-103473A

Boc-MLF (TFA) is a peptide, used as a specific **formyl peptide receptor (FPR)** antagonist, also inhibits the signaling through **formyl peptide receptor like 1 (FPRL1)** at higher concentrations.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BODIPY 581/591 C11

Cat. No.: HY-D1301

C11-BODIPY581/591 is a fluorescent ratio-probe of **lipid oxidation**. C11-BODIPY581/591 is often used for indexing lipid peroxidation and antioxidant efficacy in model membrane systems and living cells. C11-BODIPY581/591 is applied in the quantitation of ferroptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Boeravinone B

Cat. No.: HY-N2947

Boeravinone B, a dual inhibitor of NorA bacterial efflux pump of Staphylococcus aureus and human P-Glycoprotein, reduces the biofilm formation and intracellular invasion of bacteria. Boeravinone B act as anti-aging and anti-apoptosis phyto-molecules during oxidative stress.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Boldine

Cat. No.: HY-N6973

Boldine is an aporphine isoquinoline alkaloid extracted from the root of Litsea cubeba and also possesses these properties, including antioxidant, anti-inflammatory and cytoprotective effects.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

BOP sodium

Cat. No.: HY-129453

BOP sodium is a potent and selective dual **α9β1/α4β1 integrin** inhibitor with K_d values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BPC 157

Cat. No.: HY-105174

BPC 157 is a stable gastric pentadecapeptide and a partial sequence of the human gastric juice protein BPC. BPC 157 is an anti-ulcer peptidergic agent with no reported toxicity. BPC 157 links inflammatory bowel disease and multiple sclerosis.

GEPPPGKPADDAGLV

Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BPK-21

Cat. No.: HY-141549

BPK-21, an active acrylamide, suppresses T cell activation through blockade of ERCC3 function. BPK-21 specifically targets C342 in the helicase ERCC3.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BPK-25

Cat. No.: HY-141550

BPK-25, an active acrylamide, promotes degradation of **nucleosome remodeling and deacetylation (NuRD) complex proteins** by a post-translational mechanism involving covalent protein engagement. BPK-25 inhibits TMEM173 activation by the cyclic dinucleotide ligand cGAMP.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BPO-27 racemate

Cat. No.: HY-19778A

BPO-27 racemate is a potent **CFTR** inhibitor with an IC_{50} of 8 nM.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

BPR1R024

Cat. No.: HY-132935

BPR1R024 is an orally active and selective **CSF1R** inhibitor (IC_{50} = 0.53 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

bpV(phen)

Cat. No.: HY-136065

bpV(phen), a insulin-mimetic agent, is a potent **protein tyrosine phosphatase (PTP)** and **PTEN** inhibitor with IC_{50}s of 38 nM, 343 nM and 920 nM for **PTEN**, **PTP-β** and **PTP-1B**, respectively. bpV(phen) inhibits proliferation of the protozoan **parasite Leishmania** in vitro.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

bpV(phen) trihydrate

Cat. No.: HY-122818

bpV(phen) trihydrate, a insulin-mimetic agent, is a potent **protein tyrosine phosphatase (PTP)** and **PTEN** inhibitor with IC_{50}s of 38 nM, 343 nM and 920 nM for **PTEN**, **PTP-β** and **PTP-1B**, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Brazilin

Cat. No.: HY-N0072

Brazilin is a red dye precursor obtained from the heartwood of several species of tropical hardwoods. Brazilin inhibits the cells proliferation, promotes **apoptosis**, and induces **autophagy** through the AMPK/mTOR pathway.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

BRD4-IN-2

Cat. No.: HY-141843

BRD4-IN-2 is a bromodomain **BRD4** inhibitor with an IC_{50} value of 9.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD5529

Cat. No.: HY-115497

BRD5529 is a selective **CARD9-E3 ubiquitin ligase TRIM62** protein-protein interaction inhibitor with an IC_{50} of 8.6 μM.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BRD5631

Cat. No.: HY-125197

BRD5631 is an **autophagy** enhancer, enhances **autophagy** through an mTOR-independent pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD6989

Cat. No.: HY-122586

BRD6989, an analog of the natural product cortistatin A (dCA), inhibits **CDK8** and upregulates **IL-10**. BRD6989 selectively binds a complex of CDK8 with an IC_{50} of ~200 nM. BRD6989 inhibits the kinase activity of recombinant CDK8 or CDK19 complexes.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Brensocatib

(AZD7986; INS 1007)

Cat. No.: HY-101056

Brensocatib (AZD7986) is an oral **dipeptidyl peptidase 1** (**DPP1**) inhibitor with **p**IC_{50}s of 6.85, 7.6, 7.7, 7.8, and 7.8 in human, mouse, rat, dog and rabbit, respectively.



Purity: 99.66%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Brepocitinib

(PF-06700841)

Cat. No.: HY-112708

Brepocitinib (PF-06700841) is a potent dual **Janus kinase 1 (JAK1)** and **TYK2** inhibitor with IC_{50}s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits **JAK2** and **JAK3** with IC_{50}s of 77 nM and 6.49 μM, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Brepocitinib P-Tosylate

(PF-06700841 P-Tosylate)

Cat. No.: HY-112708A

Brepocitinib (PF-06700841) P-Tosylate is a potent dual **Janus kinase 1 (JAK1)** and **TYK2** inhibitor with IC_{50}s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits **JAK2** and **JAK3** with IC_{50}s of 77 nM and 6.49 μM, respectively.



Purity: 99.69%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Brequinar

(DUP785; NSC 368390)

Cat. No.: HY-108325

Brequinar (DUP785) is a potent inhibitor of **dihydroorotate dehydrogenase (DHODH)** with an IC_{50} of 5.2 nM for **human DHODH**. Brequinar has potent activities against a broad spectrum of viruses.



Purity: 99.75%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

Brevetoxin-3

(PbTx-3)

Cat. No.: HY-12545

Brevetoxin-3 (PbTx-3) is a potent allosteric **voltage-gated Na^+ channel** activator and has multiple active centers (A-ring lactone, C-42 of R side chain).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Brevifolincarboxylic acid

Cat. No.: HY-N4095

Brevifolincarboxylic acid is extracted from Polygonum capitatum, has inhibitory effect on the aryl hydrocarbon receptor (**AhR**). Brevifolincarboxylic acid is an **α-glucosidase** inhibitor with an IC_{50} of 323.46 μM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Brilaroxazine

(RP5063)

Cat. No.: HY-109112

Brilaroxazine (RP5603) is a potent and orally active multimodal **dopamine (DA)/serotonin (5-HT)** modulator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Britannin

Cat. No.: HY-N3005

Britannin, isolated from Inula aucheriana, is a sesquiterpene lactone. Britannin induces **apoptosis** and **autophagy** by activating AMPK regulated by ROS in liver cancer cells. Britannin has anti-proliferative and anti-inflammatory activities.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Brombuterol D9

(Bromobuterol D9)

Cat. No.: HY-131104S

Brombuterol D9 (Bromobuterol D9) is a deuterium labeled Brombuterol. Brombuterol is a **β-adrenergic receptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Brombuterol D9 hydrochloride

(Bromobuterol D9 hydrochloride) Cat. No.: HY-131104AS

Brombuterol D9 hydrochloride (Bromobuterol D9 hydrochloride) is a deuterium labeled Brombuterol hydrochloride. Brombuterol hydrochloride is a **β-adrenergic receptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Brombuterol hydrochloride

(Bromobuterol hydrochloride) Cat. No.: HY-131145

Brombuterol hydrochloride (Bromobuterol hydrochloride) is a **β-adrenergic receptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bromchlorbuterol hydrochloride

Cat. No.: HY-136449

Bromchlorbuterol hydrochloride is an active β-adrenergic agonist (**β-agonist**) and can be used for the research of pulmonary disease and asthma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bromelain

Cat. No.: HY-129611

Bromelain is an anti-inflammatory drug derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of **Prostaglandin E2** expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well...

Bromelain

Purity: >98%
Clinical Data: Phase 2
Size: 100 mg

Bromfenac sodium

Cat. No.: HY-B1888A

Bromfenac sodium is a potent and orally active inhibitor of **COX**, with IC_{50}s of 5.56 and 7.45 nM for **COX-1** and **COX-2**, respectively.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Bromfenac sodium hydrate

(Bromfenac monosodium salt sesquihydrate) Cat. No.: HY-B1888B

Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) is a potent and orally active inhibitor of **COX**, with IC_{50}s of 5.56 and 7.45 nM for **COX-1** and **COX-2**, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Bromisoval

(Bromovalerylurea) Cat. No.: HY-B2113

Bromisoval has anti-inflammatory effects.



Purity: 99.48%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Bromodomain inhibitor-8

Cat. No.: HY-128703

Bromodomain inhibitor-8 (Intermediate 21) is a **BET bromodomain** inhibitor for treating autoimmune and inflammatory diseases.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bromoenol lactone

((6E)-Bromoenol lactone) Cat. No.: HY-107411

Bromoenol lactone ((6E)-Bromoenol lactone) is a suicide-based irreversible, selective, potent inhibitor of **calcium-independent phospholipase A_2 ($iPLA_2\beta$)** with an IC_{50} value of approximately 7 μM, which inhibits antigen-stimulated mast cell exocytosis without blocking Ca^{2+} influx.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Brompheniramine maleate

((±)-Brompheniramine maleate) Cat. No.: HY-B0480

Brompheniramine ((±)-Brompheniramine) maleate is a potent and orally active antihistamine of the propylamine class. Brompheniramine maleate is a selective **histamine H1 receptor** antagonist with a K_d of 6.06 nM.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Bronchospasmolytic agent 1

Cat. No.: HY-U00405

Bronchospasmolytic agent 1, a synthetic flutropium bromide compound, acts as a bronchospasmolytic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bruceine B

(Brucein B)

Cat. No.: HY-N3013

Bruceine B inhibits protein synthesis and nucleic acid synthesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bryodulcosigenin

Cat. No.: HY-N4312

Bryodulcosigenin is an extract of the roots of Bryoniadioica with anti-inflammatory effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Bryonolic acid

Cat. No.: HY-N2965

Bryonolic acid is an active triterpenoid compound with immunomodulatory, anti-inflammatory, antioxidant and anticancer activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bryostatin 1

Cat. No.: HY-105231

Bryostatin 1 is a natural macrolide isolated from the bryozoan Bugula neritina and is a potent and central nervous system (CNS)-permeable **PKC** modulator.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 μg

BTK IN-1

(SNS062 analog)

Cat. No.: HY-101941

BTK IN-1 (SNS062 analog) is a potent **BTK** inhibitor, with an IC_{50} of <100 nM.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BTK inhibitor 10

Cat. No.: HY-125997

BTK inhibitor 10 is a potent and orally active **Bruton kinase (BTK)** inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK inhibitor 13

Cat. No.: HY-130255

BTK inhibitor 13 (compound 8) is a potent and selective **Bruton's tyrosine kinase (BTK)** inhibitor with an IC_{50} of 1.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTK inhibitor 17

Cat. No.: HY-131705

BTK inhibitor 17 is a potent and orally active irreversible **BTK** inhibitor with an IC_{50} of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BTK inhibitor 18

Cat. No.: HY-132196

BTK inhibitor 18 is a potent, selective,orally active and covalent **Btk** inhibitor with a IC_{50} of 142 nM. BTK inhibitor 18 has anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Btk inhibitor 2

(BGB-3111 analog)

Cat. No.: HY-101766

Btk inhibitor 2 (BGB-3111 analog) is a **Bruton's tyrosine kinase** (**BTK**) inhibitor extracted from patent US 20170224688 A1.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BTK-IN-5

Cat. No.: HY-115876

BTK-IN-5 is a covalent **BTK** inhibitor for treating medical conditions such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BTM-1086

Cat. No.: HY-U00406

BTM-1086 is a potent anti-ulcer and gastric secretory inhibiting agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bucladesine sodium

(Dibutyryl cAMP sodium salt; DBcAMP sodium salt)

Cat. No.: HY-B0764

Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective **PKA** activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a **phosphodiesterase (PDE)** inhibitor.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Buclizine dihydrochloride

Cat. No.: HY-A0128A

Buclizine dihydrochloride is an orally active **antihistamine** antiallergic compound. Buclizine dihydrochloride is a potent teratogen in the rat.



Purity: ≥98.0%
Clinical Data: Launched
Size: 100 mg

Bucloxic acid

(804CB; Bucloxonic acid; Esfar)

Cat. No.: HY-101581

Bucloxic acid is an anti-inflammatory pyrrazole derivative. Bucloxic acid can be used in the treatment of chronic glomerular nephropathies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bucolome

(Paramidin; Paramidine)

Cat. No.: HY-U00048

Bucolome is a **CYP2C9** inhibitor, used as an uricosuric agent or anti-inflammatory agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Buddlejasaponin IV

Cat. No.: HY-125131

Buddlejasaponin IV (BSIV) exerts anti-inflammatory and cytotoxic effects against cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Buddlejasaponin IVb

Cat. No.: HY-N2138

Buddlejasaponin IVb (Compound 2), a triterpene saponin isolated from Clinopodium chinense (Benth.) O. Kuntze, Compound 2 has hemostasis efficacy, shortens thrombin time (TT) by 20.6 %.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Budesonide

Cat. No.: HY-13580

Budesonide, an inhaled glucocortical steroid, is an orally active **glucocorticoid receptor** agonist. Budesonide decreases the size of lung tumors, reverses DNA hypomethylation and modulates mRNA expression of genes. Budesonide is an anti-inflammatory agent used for asthma.



Purity: 98.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Budesonide impurity C

Cat. No.: HY-100087

Budesonide impurity C is an impurity of Budesonide. Budesonide, an inhaled glucocortical steroid, is an orally active glucocorticoid receptor agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Budesonide-d8

Cat. No.: HY-13580S

Budesonide-d8 is the deuterium labeled Budesonide. Budesonide, an inhaled glucocortical steroid, is an orally active **glucocorticoid receptor** agonist. Budesonide decreases the size of lung tumors, reverses DNA hypomethylation and modulates mRNA expression of genes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Bufexamac

(Bufexamic acid)

Cat. No.: HY-B0494

Bufexamac is a class IIB histone deacetylases (HDAC6 and HDAC10) inhibitor used as an anti-inflammatory agent.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Bullatine A

Cat. No.: HY-N5025

Bullatine A, a diterpenoid alkaloid of the genus Aconitum, possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bumadizone

Cat. No.: HY-17481

Bumadizone is a non-steroidal anti-inflammatory drug (NSAID) and can relieve pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bunaprolast

(U66858)

Cat. No.: HY-U00170

Bunaprolast (U66858) is a potent inhibitor of **LTB_4** production in human whole blood. Bunaprolast (U66858) also exhibits significant inhibition of **lipoxygenase** and **TXB_2** release.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bupranolol

Cat. No.: HY-A0252

Bupranolol is an orally active, competitive and non-selective **β-adrenoceptor** antagonist without intrinsic sympathomimetic activity.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 25 mg

Burixafor hydrobromide

(TG-0054 hydrobromide)

Cat. No.: HY-19867A

Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of **CXCR4** and a well anti-angiogenic drug that is of potential value in treating choroid neovascularization.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Butin

Cat. No.: HY-N6020B

Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera, with strong antioxidant, antiplatelet and anti-inflammatory activities.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Butylhydroxyanisole

(Butylated hydroxyanisole; BHA; E320)

Cat. No.: HY-B1066

Butylhydroxyanisole (Butylated hydroxyanisole) is an antioxidant used as a food additive preservative. Butylhydroxyanisole mediates liver toxicity, retardation in reproductive organ development and learning, and sleep deficit.



Purity: ≥99.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 500 mg, 1 g

BVT 2733

Cat. No.: HY-18054

BVT 2733 is a potent, selective, and orally active non-steroidal **11β-hydroxydehydrogenase 1 (11β-HSD1)** inhibitor. BVT 2733 is potently against the mouse enzyme (IC_{50}=96 nM) over the human enzyme (IC_{50}=3341 nM).



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BW-A 78U

Cat. No.: HY-100118

BW-A 78U is a **PDE4** inhibitor with an IC_{50} of 3 μM.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

BX471

(ZK-811752)

Cat. No.: HY-12080

BX471 (ZK-811752) is an orally active, potent and selective non-peptide **CCR1** antagonist with a K_i of 1 nM, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

BX471 hydrochloride

(ZK-811752 hydrochloride)

Cat. No.: HY-12080A

BX471 hydrochloride (ZK-811752 hydrochloride) is a potent, selective non-peptide **CCR1** antagonist with K_i of 1 nM for human CCR1, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Byakangelicol

Cat. No.: HY-N0074

Byakangelicol, isolated from Angelica dahurica, inhibits interleukin-1beta (IL-1beta) -induced prostaglandin E2 (PGE2) release in A549 cells mediated by suppression of **cyclooxygenase-2 (COX-2)** expression and the activity of COX-2 enzyme.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Bz 423

(BZ48)

Cat. No.: HY-13108

Bz 423 is a pro-apoptotic 1,4-benzodiazepine with therapeutic properties in murine models of lupus demonstrating selectivity for autoreactive lymphocytes, and activates Bax and Bak.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BzATP triethylammonium salt

Cat. No.: HY-136254

BzATP triethylammonium salt acts as a **P2X receptor** agonist with pEC_{50}s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

C 87

Cat. No.: HY-100735

C 87 is a novel small-molecule **TNFα** inhibitor; potently inhibits TNFα-induced cytotoxicity with an IC_{50} of 8.73 μM.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

C-021

Cat. No.: HY-103364

C-021 is a potent **CC chemokine receptor-4 (CCR4)** antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC_{50}s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [^{35}S]GTPγS from binding to the receptor with an IC_{50} of 18 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

C-021 dihydrochloride

Cat. No.: HY-103364A

C-021 dihydrochloride is a potent **CC chemokine receptor-4 (CCR4)** antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC_{50}s of 140 nM and 39 nM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

C-176

Cat. No.: HY-112906

C-176 is a strong and covalent mouse **STING** inhibitor.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

C-178

Cat. No.: HY-123963

C-178 is a potent and selective covalent inhibitor of **STING**. C-178 binds to Cys91 and suppresses the STING responses elicited by distinct bona fide activators in mouse but not human.</br>.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

c-di-AMP

(Cyclic diadenylate; Cyclic-di-AMP)

Cat. No.: HY-12326

c-di-AMP (Cyclic diadenylate) is a **STING** agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-di-AMP diammonium

(Cyclic diadenylate diammonium; Cyclic-di-AMP diammonium)

Cat. No.: HY-12326B

c-di-AMP diammonium is a **STING** agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg

c-di-AMP sodium

(Cyclic diadenylate sodium; Cyclic-di-AMP sodium)

Cat. No.: HY-12326A

c-di-AMP (Cyclic diadenylate) sodium is a **STING** agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg, 10 mg, 25 mg

c-Fms-IN-1

Cat. No.: HY-18791

c-Fms-IN-1 is a **FMS kinase** inhibitor with an IC_{50} of 0.0008 µM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

c-Fms-IN-10

Cat. No.: HY-126297

c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of **FMS** (Colony stimulating factor-1 receptor, CSF-1R) with IC_{50} of 2 nM. c-Fms-IN-10 has anti-tumor activity.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

c-Fms-IN-2

Cat. No.: HY-18787

c-Fms-IN-2 is a **FMS kinase** inhibitor with an IC_{50} of 0.024 µM.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

c-Fms-IN-3

Cat. No.: HY-13075

c-Fms-IN-3 is a novel c-Fms kinase inhibitor with a potential as anti-inflammatory agent and antirheumatic agent.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

c-Fms-IN-6

Cat. No.: HY-111947

c-Fms-IN-6 is a potent inhibitor of **c-FMS**, with an IC_{50} of ≤10 nM for unphosphorylated c-FMS, also weakly inhibits unphosphorylated c-KIT and PDGFR (IC_{50}, > 1 µM). Used in the research of autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

c-Fms-IN-7

Cat. No.: HY-111948

c-Fms-IN-7 is a **cFMS** inhibitor extracted from patent WO2011079076A1, example159, has an IC_{50} of 18.5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C-Reactive Protein (CRP) (174-185)

Cat. No.: HY-P1823

C-Reactive Protein (CRP) 174-185 is the 174-185 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C-Reactive Protein (CRP) (201-206)

Cat. No.: HY-P1824

C-Reactive Protein (CRP) 201-206 is the 201-206 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C-Reactive Protein (CRP) (77-82)

Cat. No.: HY-P1836

C-Reactive Protein (CRP) 77-82 is the 77-82 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C-telopeptide

Cat. No.: HY-P0284

C-telopeptide, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD).

EKAHDGGR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

C/EBPα inducer 1

Cat. No.: HY-134334

C/EBPα inducer 1 (compound 78) is a potent inducer of **C/EBPα** and myeloid differentiation.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

C16-PAF

(PAF (C16))

Cat. No.: HY-108635

C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (**PAFR**). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

C25-140

Cat. No.: HY-120934

C25-140, a first-in-class, orally active, and fairly selective **TRAF6-Ubc13** inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces **NF-κB** activation, and combats autoimmunity.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

C29

Cat. No.: HY-100461

C29 is a **Toll-like receptor 2 (TLR2)** inhibitor. C29 blocks hTLR2/1 and hTLR2/6 signaling with IC_{50}s of 19.7 and 37.6 μM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

C3a (70-77)

(Complement 3a (70-77))

Cat. No.: HY-P1505

C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C3a (70-77) (TFA)

(Complement 3a (70-77) (TFA)) Cat. No.: HY-P1505A

C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.



Purity: 95.02%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

C8-Ceramide

(N-Octanoyl-D-erythro-sphingosine) Cat. No.: HY-108391

C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

CA-170

Cat. No.: HY-101093

CA-170 is an orally delivered dual inhibitor of **VISTA** and **PD-L1**. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CA-4948

Cat. No.: HY-135317

CA-4948 is a potent **IRAK4/FLT3** inhibtor with anti-tumor activity.



Purity: 99.92%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CaCCinh-A01

Cat. No.: HY-100611

CaCCinh-A01 is an inhibitor of both **TMEM16A** and **calcium-activated chloride channel** (**CaCC**) with IC_{50}s of 2.1 and 10 μM, respectively.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Caerulomycin A

(Cerulomycin; Caerulomycin) Cat. No.: HY-114495

Caerulomycin A (Cerulomycin; Caerulomycin), an **antifungal** compound, induces generation of T cells, enhances TGF-β-Smad3 protein signaling via suppressing interferon-γ-induced STAT1 signaling. Antifungal and antibiotic activity, and used in autoimmune diseases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cafestol

Cat. No.: HY-N6257

Cafestol, one of the major components of coffee, is a coffee-specific diterpene from. Cafestol is a **ERK** inhibitor for AP-1-targeted activity against PGE_2 production and the mRNA expression of **cyclooxygenase (COX)-2** in LPS-activated RAW264.7 cells.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Caffeic acid

Cat. No.: HY-N0172

Caffeic acid is an inhibitor of both **TRPV1** ion channel and **5-Lipoxygenase** (**5-LO**).



Purity: 98.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 5 g

Caffeic acid phenethyl ester

Cat. No.: HY-N0274

Caffeic acid phenethyl ester is a **NF-κB** inhibitor.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 100 mg

Caffeic acid-pYEEIE

Cat. No.: HY-P1377

Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Caffeic acid-pYEEIE TFA

Cat. No.: HY-P1377A

Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Calcipotriol

(MC 903; Calcipotriene)

Cat. No.: HY-10001

Calcipotriol is a synthetic $VitD_3$ analogue with a high affinity for the **vitamin D** receptor.



Purity: 99.77%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Calcipotriol Impurity C

Cat. No.: HY-75035

Calcipotriol Impurity C is the impurity of Calcipotriol, Calcipotriol is a ligand of VDR-like receptors. Target: VDR.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

Calcipotriol monohydrate

Cat. No.: HY-10001A

Calcipotriol monohydrate is a synthetic VitD3 analogue with a high affinity for the **vitamin D** receptor.



Purity: 99.75%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Calf thymus DNA

(DNA from calf thymus, Thymonucleic acid)

Cat. No.: HY-109517

Calf thymus DNA (DNA from calf thymus) is high quality double-stranded template DNA isolated from the thymus of male and female calves.

Calf thymus DNA

Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CALP1

Cat. No.: HY-P1077

CALP1 is a **calmodulin (CaM)** agonist (K_d of 88 μM) with binding to the **CaM** EF-hand/Ca^{2+}-binding site. CALP1 blocks calcium influx and apoptosis (IC_{50} of 44.78 μM) through inhibition of **calcium channel** opening.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CALP1 TFA

Cat. No.: HY-P1077A

CALP1 TFA is a **calmodulin (CaM)** agonist (K_d of 88 μM) with binding to the **CaM** EF-hand/Ca^{2+}-binding site. CALP1 TFA blocks calcium influx and apoptosis (IC_{50} of 44.78 μM) through inhibition of **calcium channel** opening.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CALP2

Cat. No.: HY-P1076

CALP2 is a **calmodulin (CaM)** antagonist ((K_d of 7.9 μM)) with high affinity for binding to the **CaM** EF-hand/Ca^{2+}-binding site. CALP2 inhibits **CaM**-dependent **phosphodiesterase** activity and increases intracellular Ca^{2+} concentrations.

VKFGVGFKVMVF

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CALP2 TFA

Cat. No.: HY-P1076A

CALP2 TFA is a **calmodulin (CaM)** antagonist (K_d of 7.9 μM) with high affinity for binding to the **CaM** EF-hand/Ca^{2+}-binding site. CALP2 TFA inhibits **CaM**-dependent **phosphodiesterase** activity and increases intracellular Ca^{2+} concentrations.

VKFGVGFKVMVF (TFA salt)

Purity: 98.48%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Calpeptin

Cat. No.: HY-100223

Calpeptin is a potent, cell penetrating **calpain** inhibitor, with an ID_{50} of 40 nM for Calpain I in human platelets. Calpeptin is also an inhibitor of **cathepsin K**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Calycanthoside

Cat. No.: HY-N3524

Calycanthoside is a natural compound isolated from Angelica tenuissima.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Camelliaside A

Cat. No.: HY-N2524

Camelliaside A is a flavonoid from the methanol extract of tea (Camella oleifera) seed pomace.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Camelliaside B

Cat. No.: HY-N2605

Camelliaside B is a flavonoid from the methanol extract of tea (Camella oleifera) seed pomace.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CaMKII-IN-1

Cat. No.: HY-18271

CaMKII-IN-1 is a potent and highly selective CaMKII inhibitor with IC50 of 63 nM; significantly high selectivity against CaMKIV, MLCK, p38a, Akt1, and PKC. IC50 value: 63 nM Target: CaMKII.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Camobucol

(AGIX 4207)

Cat. No.: HY-14916

Camobucol (AGIX 4207) is an orally active, phenolic antioxidant and anti-inflammatory compound with antirheumatic properties.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Camostat mesylate

(Camostat mesilate; FOY305; FOY-S980)

Cat. No.: HY-13512

Camostat mesylate (Camostat mesilate) is an orally active, synthetic **serine protease** inhibitor for chronic pancreatitis. Camostat mesylate, an inhibitor of **TMPRSS2**, shows antiviral activity against **SARS-CoV-2**.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Camphor

((±)-Camphor)

Cat. No.: HY-N0808

Camphor ((±)-Camphor) is a topical anti-infective and anti-pruritic and internally as a stimulant and carminative. However, Camphor is poisonous when ingested. Antiviral, antitussive, and anticancer activities. Camphor is a **TRPV3** agonist.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Cangrelor tetrasodium

Cat. No.: HY-19638A

Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet **P2Y12** antagonist, with prompt and potent antiplatelet effects.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Canthaxanthin

(E 161g; all-trans-Canthaxanthin)

Cat. No.: HY-B1960

Canthaxanthin is a red-orange carotenoid with various biological activities, such as antioxidant, antitumor properties.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Canthin-6-one

Cat. No.: HY-N3536

Canthin-6-one displays a wide range of biological activities, such as antimycobacterial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Capillarisin

Cat. No.: HY-121192

Capillarisin, as a constituent from Artemisiae Capillaris herba, is found to exert anti-inflammatory and antioxidant properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Capsaicinoid

Cat. No.: HY-10448A

Capsaicinoid is a mixture of Capsaicin and Dihydrocapsaicin. Capsaicinoid is an **capsaicin receptor (TRPV1)** agonist.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Capsiate

Cat. No.: HY-N8377

Capsiate, as a capsaicin analogue extracted from a non-pungent cultivar of CH-19 sweet red pepper, is an orally active agonist of **TRPV1**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Carbasalate calcium

Cat. No.: HY-17476

Carbasalate calcium is an anti-inflammatory, antipyretic, and analgesic agent.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Carbenoxolone disodium

Cat. No.: HY-B1367

Carbenoxolone disodium is the active **metabolite** of Glycyrrhizic acid (HY-N0184) and the inhibitor of human **11β-HSD** and bacterial **3α, 20β-HSD**. Carbenoxolone disodium is an uncoupling agent for **gap junctions** and a potent inhibitor of Vaccinia virus replication.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Carbetapentane citrate

(Pentoxyverine citrate)

Cat. No.: HY-B1055

Carbetapentane citrate is a selective inhibitor of the cough, with mild atropine-like effect and local anesthesia effect.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Carbocisteine

(S-(Carboxymethyl)-L-cysteine)

Cat. No.: HY-D0205A

Carbocisteine, a mucolytic agent, can be used for the research of chronic obstructive pulmonary disease (COPD).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Carboxy-PTIO

Cat. No.: HY-18734

Carboxy-PTIO is a potent **nitric oxide (NO)** scavenger that can make a quick reaction with NO to produce NO_2. Carboxy-PTIO can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Carboxy-PTIO potassium

Cat. No.: HY-18734A

Carboxy-PTIO potassium is a potent **nitric oxide (NO)** scavenger that can make a quick reaction with NO to produce NO_2. Carboxy-PTIO potassium can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Carboxyamidotriazole

(L-651582; CAI)

Cat. No.: HY-16126

Carboxyamidotriazole (L-651582) is a cytostatic inhibitor of **nonvoltage-operated calcium channels** and **calcium channel-mediated signaling pathways**. Carboxyamidotriazole shows anti-tumor, anti-inflammatory and antiangiogenic effects.



Purity: ≥99.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg

Carboxyamidotriazole Orotate

(L-651582 Orotate; CAI Orotate) Cat. No.: HY-16125

Carboxyamidotriazole Orotate (L-651582 Orotate) is the orotate salt form of Carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Carcainium chloride

(QX 572; RSD 931) Cat. No.: HY-106372A

Carcainium chloride (QX 572) is a quaternary derivative of Lidocaine. Antitussive effect.



Purity: 99.02%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Cardamonin

(Cardamomin; Alpinetin chalcone) Cat. No.: HY-N0279

Cardamonin (Cardamomin) acts as an **aryl hydrocarbon receptor** (**AhR**) activator. Cardamonin alleviates inflammatory bowel disease by the inhibition of **NLRP3 inflammasome** activation via an AhR/Nrf2/NQO1 pathway.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Cariporide

(HOE-642) Cat. No.: HY-19693

Cariporide (HOE-642) is a selective Na^+/H^+ exchange inhibitor.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Carmine

(Carmine red) Cat. No.: HY-N1389

Carmine (Carmine red), a natural red dye extracted from the dried females of the insect Dactylopius coccus var. Costa (cochineal). Carmine is a widely used food additive. Carmine provokes both an immediate hypersensitivity and a delayed systemic response with cutaneous expression.

Carmine

Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Carmoisine

(Azorubine; Acid Red 14; E122) Cat. No.: HY-128448

Carmoisine (Azorubine) is an azo dye that can be used as a food additive.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Carnosic acid

Cat. No.: HY-N0644

Carnosic acid has demonstrated inhibition of oxidative stress and inflammation, suppression of cell proliferation, and antibacterial activity.



Purity: 97.71%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

Carotegrast

Cat. No.: HY-14857

Carotegrast is an orally available **α4 integrin receptor** inhibitor with anti-inflammatories activities.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Carotegrast methyl

(AJM300) Cat. No.: HY-124290

Carotegrast methyl (AJM300) is an orally active and selective **α4 integrin** antagonist. HCA2969, an active metabolite of Carotegrast methyl, is a specific and dual α4β1/α4β7 integrin antagonist. Carotegrast methyl prevents the development of colitis in mice.
.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Carpaine

Cat. No.: HY-N7016

Carpaine is an alkaloid isolated from Carica papaya Linn with **anti-thrombocytopenic** activity, exhibits potent activity in sustaining platelet counts with no acute toxicity. Carpaine has **anti-plasmodial** activity to prevent malaria.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Carpaine hydrochloride

Cat. No.: HY-N7016A

Carpaine hydrochloride is an alkaloid isolated from Carica papaya Linn anti-thrombocytopenic activity, exhibits potent activity in sustaining platelet counts with no acute toxicity. Carpaine hydrochloride has anti-plasmodial activity to prevent malaria.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Carprofen

Cat. No.: HY-B1227

Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target **FAAH/COX** inhibitor, with IC_{50}s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Carsalam

(Carbonylsalicylamide)

Cat. No.: HY-B1047

Carsalam (Carbonylsalicylamide) is a nonsteroidal anti-inflammatory drug.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Carvacrol

Cat. No.: HY-N0711

Carvacrol is a monoterpenoid phenol isolated from Lamiaceae family plants, with antioxidant, anti-inflammatory and anticancer properties. Carvacrol causes cell cycle arrest in G0/G1, downregulates **Notch-1**, and Jagged-1, and induces **apoptosis**.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Carvedilol

(BM 14190)

Cat. No.: HY-B0006

Carvedilol (BM 14190) is a non-selective **β/α-1** blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC_{50} of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Carvedilol metabolite 4-Hydroxyphenyl Carvedilol

(4-Hydroxyphenyl Carvedilol; 4-Hydroxycarvedilol)

Cat. No.: HY-12767

4-Hydroxyphenyl Carvedilol is a metabolite of Carvedilol, which is a nonselective beta blocker/alpha-1 blocker.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Carvedilol phosphate hemihydrate

(BM 14190 phosphate hemihydrate)

Cat. No.: HY-B0006A

Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is a non-selective **β/α-1** blocker. Carvedilol phosphate hemihydrate inhibits **lipid peroxidation** with an IC_{50} of 5 μM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Caryophyllene oxide

((-)-Caryophyllene oxide)

Cat. No.: HY-N3544

Caryophyllene oxide, isolated from from Annona squamosa L. bark., possesses analgesic and anti-inflammatory activity.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Cassiaside

Cat. No.: HY-N7887

Cassiaside is a naphthopyrone glucoside, shows mixed-type inhibition against **BACE1** (IC_{50}=4.45 μM; K_i=9.85 μM). Cassiaside possesses potential anti- Alzheimer's disease (AD) activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cassiaside B2

Cat. No.: HY-N8200

Cassiaside B2 is a protein tyrosine phosphatase 1B **(PTP1B)** and **human monoamine oxidase A (hMAO-A)** inhibitor. Cassiaside B2 possesses antiallergic and is a **5-HT2C** receptor agonist..



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Casticin

(Vitexicarpin)

Cat. No.: HY-N0516

Casticin is a methyoxylated flavonol isolated from Viticis Fructus, with antimitotic and anti-inflammatory effect. Casticin inhibits the activation of **STAT3**.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Catalpol

(Catalpinoside)

Cat. No.: HY-N0820

Catalpol (Catalpinoside), an iridoid glycoside found in Rehmannia glutinosa. Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-**HBV** effects.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Catalposide

Cat. No.: HY-N3552

Catalposide, an iridoid glycoside that could be isolated from Catalpa ovate G. Don (Bignoniaceae), inhibits TNF-α, IL-1β, and IL-6 productions and NF-κB (p65) activation in lipopolysaccharide-activated RAW 264.7 macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cathepsin Inhibitor 2

Cat. No.: HY-U00377

Cathepsin Inhibitor 2 is a potent **Cathepsin S** inhibitor extracted from patent WO2009123623A1, has a K_i of <20 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Caulophylline B

Cat. No.: HY-N6672

Caulophylline B is a fluorenone alkaloid isolated from the roots of Caulophyllum robustum Maxim, affords a low scavenging effect against DPPH radical.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Caulophyllogenin

Cat. No.: HY-N7687

Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial **PPARγ** agonist, with an EC_{50}of12.6μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Cauloside C

Cat. No.: HY-N6919

Cauloside C is a triterpene glycoside isolated from Caulophyllum robustum Max. Cauloside C exerts anti-inflammatory effects through the inhibition of expression of iNOS and proinflammatory cytokines.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Cauloside D

Cat. No.: HY-N6878

Cauloside D is a triterpene glycoside isolated from Caulophyllum robustum Max. Cauloside D exerts anti-inflammatory effects through the inhibition of expression of iNOS and proinflammatory cytokines.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CAY10404

Cat. No.: HY-121537

CAY10404 is a potent and selective **cyclooxygenase-2 (COX-2)** inhibitor with an IC_{50} of 1 nM and a selectivity index (SI; COX-1 IC_{50}/COX-2 IC_{50}) of >500000.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CAY10471

(TM30089)

Cat. No.: HY-13706A

CAY10471 (TM30089) is a potent, selective, and orally active **prostaglandin D2 receptor CRTH2** antagonist. CAY10471 attenuates the progression of tubulointerstitial fibrosis and chronic contact hypersensitivity (CHS) in animal model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CAY10583

Cat. No.: HY-122124

CAY10583 is a potent and selective full Leukotriene B4 receptor type 2 (BLT2) agonist. CAY10583 directly promotes keratinocyte migration in vitro and accelerates wound closure in vivo. CAY10583 is a promising pharmaceutical agent for diabetic wounds.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CAY10595

Cat. No.: HY-118180

CAY10595 is a potent **CRTH2/DP2** receptor antagonist that binds to the human receptor with a K_i of 10 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CAY10602

Cat. No.: HY-104073

CAY10602 is a **SIRT1** activator. CAY10602 dose-dependently suppresses the NF-κB-dependent induction of TNF-α by lipopolysaccharide in THP-1 cells.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CAY10650

Cat. No.: HY-10801

CAY10650 is a highly potent cytosolic phospholipase A2α **(cPLA2α)** inhibitor with an IC_{50} value of 12 nM. CAY10650 suppresses lipid droplets formation and PGE2 secretion.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

CAY10698

Cat. No.: HY-121585

CAY10698 (compound 1) is a potent and selective inhibitor of **12-Lipoxygenase (12-LOX)** with an IC_{50} of 5.1 μM. CAY10698 is inactive against 5-LOX, 15-LOX-1, 15-LOX-2 and COX-1/2.



Purity: 98.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CB1 antagonist 1

Cat. No.: HY-U00397

CB1 antagonist 1 is an antagonist of **CB1 receptor**, used in the research of metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, gastrointestinal disorders, and cardiovascular conditions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CB2 modulator 1

Cat. No.: HY-135419

CB2 modulator 1 (compound 130) is a potent **CB2** modulator. CB2 modulator 1 has the potential for immunedisorders, inflammation, osteoporosis, renal ischemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cbl-b-IN-1

Cat. No.: HY-136339

Cbl-b-IN-1 (example 519) is a **Cbl-b** inhibitor, extracted from patent WO2019148005A1, with an IC_{50} <100 nM.



Purity: 99.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CC-90001

Cat. No.: HY-138304

CC-90001 is a potent, selective and orally active inhibitor of **c-Jun N-terminal kinase (JNK)**. CC-90001 shows 12.9-fold selectivity for **JNK1** over **JNK2** in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CC-90005

Cat. No.: HY-132304

CC-90005 is a potent, selective and orally active inhibitor of **protein kinase C-θ (PKC-θ)**, with an IC_{50} of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC_{50}=4440 nM). CC-90005 can inhibit T cell activation by IL-2 expression.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CC-99677

Cat. No.: HY-139504

CC-99677 is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (**MK2**) pathway in both biochemical (IC_{50}=156.3 nM) and cell based assays (EC_{50}=89 nM). CC-99677 is extracted from patent WO2020236636, compound 1.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCCP (Carbonyl cyanide 3-chlorophenylhydrazone; Carbonyl Cyanide m-Chlorophenylhydrazone)

Cat. No.: HY-100941

CCCP is an oxidative phosphorylation (**OXPHOS**) uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

CCG-203971

Cat. No.: HY-108361

CCG-203971 is a second-generation **Rho/MRTF/SRF** pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC_{50} =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC_{50} of 4.2 μM. Potential anti-metastasis Agent.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

CCG-50014

Cat. No.: HY-13509

CCG-50014 is the most potent against **the regulator of G-protein signaling protein type 4 (RGS4)** (IC_{50} =30 nM) and is >20-fold selective for RGS4 over other RGS proteins.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

CCG-63802

Cat. No.: HY-70074

CCG-63802 is a selective, reversible and allosteric **RGS4** inhibitor. CCG-63802 specifically binds to **RGS4** and blocks the RGS4-$G\alpha_o$ interaction, with an IC_{50} value of 1.9 μM.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CCP peptide

Cat. No.: HY-P2171

CCP peptide is a synthetic cyclic citrullinated peptide (CCP) and used as the substrate for detecting anti-CCP antibodies serologically. CCP peptide functions as a target for autoantibodies with a very high specificity for rheumatoid arthritis (RA).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCP peptide TFA

Cat. No.: HY-P2171A

CCP peptide TFA is a synthetic cyclic citrullinated peptide (CCP) and used as the substrate for detecting anti-CCP antibodies serologically. CCP peptide TFA functions as a target for autoantibodies with a very high specificity for rheumatoid arthritis (RA).

Purity: 98.94%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CCR1 antagonist 6

Cat. No.: HY-114193

CCR1 antagonist 6 (compound 16q) is a **chemokine receptor 1 (CCR1)** antagonist, with an IC_{50} of 3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCR1 antagonist 7

Cat. No.: HY-114194

CCR1 antagonist 7 (compound 16r) is a **chemokine receptor 1 (CCR1)** antagonist, with an IC_{50} of 4 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCR1 antagonist 8

Cat. No.: HY-120588

CCR1 antagonist 8 (compound 19n), a third azaindazole series compound, is a **CCR1** antagonist, with an IC_{50} of 1.8 nM in Ca^{2+} flux assay.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CCR1 antagonist 9

Cat. No.: HY-124759

CCR1 antagonist 9 is a potent and selective **CCR1** antagonist with an **IC_{50}** of 6.8 nM in calcium flux assay.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CCR2 antagonist 3

Cat. No.: HY-101264

CCR2 antagonist 3 is a chemokine receptor 2 **(CCR2)** antagonist.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCR2 antagonist 4

(Teijin compound 1)

Cat. No.: HY-108323

CCR2 antagonist 4 (Teijin compound 1) is a potent and specific **CCR2** antagonist, with **IC_{50}**s of 180 nM for CCR2b. CCR2 antagonist 4 potently inhibits MCP-1-induced chemotaxis with an IC_{50} of 24 nM.



Purity: 100.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

CCR2 antagonist 4 hydrochloride

(Teijin compound 1 hydrochloride)

Cat. No.: HY-103362

CCR2 antagonist 4 hydrochloride (Teijin compound 1 hydrochloride) is a potent and specific **CCR2** antagonist, with **IC_{50}**s of 180 nM for CCR2b. CCR2 antagonist 4 hydrochloride potently inhibits MCP-1-induced chemotaxis with an IC_{50} of 24 nM.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCR2-RA-[R]

Cat. No.: HY-50081

CCR2-RA-[R] is an allosteric antagonist of the **C-C chemokine receptor type 2 (CCR2)** with an **IC_{50}** of 103 nM.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCR3 antagonist 1

Cat. No.: HY-U00331

CCR3 antagonist 1 is a potent antagonist of **CCR3**, used for the research of immunologic and inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CCR6 inhibitor 1

Cat. No.: HY-112701

CCR6 inhibitor 1 is a potent and selective **CCR6** inhibitor, with **IC_{50}**s of 0.45 and 6 nM for monkey and human CCR6, much more selective at CCR6 over human CCR1 (IC_{50}, > 30000 nM), and CCR7 (IC_{50}, 9400 nM). CCR6 inhibitor 1 markedly blocks ERK phosphorylation.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CCX354

Cat. No.: HY-U00350

CCX354 is an antagonist of **CCR1**, with anti-inflammatory activity.



Purity: ≥99.0%
Clinical Data: Phase 2
Size: 5 mg, 10 mg

CD73-IN-4

Cat. No.: HY-131967

CD73-IN-4 is a potent and selective methylenephosphonic acid **CD73** inhibitor, with an **IC_{50}** of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CD80-IN-3

Cat. No.: HY-100891

CD80-IN-3, a potent **CD80** inhibitor, inhibits CD80/CD28 interaction with an **EC_{50}** of 630 nM and a **K_d** of 125 nM.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CDDO-dhTFEA

(RTA dh404)

Cat. No.: HY-112671

CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates **Nrf2** and inhibits the pro-inflammatory transcription factor **NF-κB**.



Purity: 99.71%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CDK8-IN-3

Cat. No.: HY-111463

CDK8-IN-3 is an inhibitor of **CDK8** extracted from patent WO2016041618A1, compound example 1.7.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDKI-73

(LS-007)

Cat. No.: HY-12445

CDKI-73 (LS-007) is an orally active and highly efficacious **CDK9** inhibitor, with K_i values of 4 nM, 4 nM and 3 nM for CDK9, CDK1 and CDK2, respectively. CDKI-73 down-regulates the RNAPII phosphorylation.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cecropin A

Cat. No.: HY-P1539

Cecropin A is a linear 37-residue antimicrobial polypeptide, with anticancer and anti-inflammatory activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cecropin A TFA

Cat. No.: HY-P1539A

Cecropin A TFA is a linear 37-residue antimicrobial polypeptide isolated from Hyalaphora cecropia pupae. Cecropin A TFA exhibits anti-bacterial, anti-inflammatory and anti-cancer activity.

Purity: 98.96%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cedirogant

(ABBV-157)

Cat. No.: HY-137434

Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant can be used for psoriasis research.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cedrol

((+)-Cedrol; α-Cedrol)

Cat. No.: HY-N2071

Cedrol is a bioactive sesquiterpene, a potent competitive inhibitor of **cytochrome P-450** (CYP) enzymes. Cedrol inhibits CYP2B6-mediated bupropion hydroxylase and CYP3A4-mediated midazolam hydroxylation with K_i of 0.9 μM and 3.4 μM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

CEF19, Epstein-Barr Virus latent NA-3A (458-466)

Cat. No.: HY-P1920

CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CEF8, Influenza Virus NP (383-391)

Cat. No.: HY-P1835

CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B*2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic T lymphocytes-mediated immunity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cefalonium hydrate

Cat. No.: HY-B1252A

Cefalonium hydrate is the first-generation β-lactam cephalosporin antibiotic that is widely used to research bovine mastitis caused by Gram-positive bacteria including staphylococci.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cefamandole nafate

(Cefamandole formate sodium)

Cat. No.: HY-B1166

Cefamandole nafate (Cefamandole formate sodium) is a second-generation broad-spectrum cephalosporin antibiotic.



Purity: ≥98.0%
Clinical Data: Launched
Size: 100 mg, 500 mg

Cefazolin

Cat. No.: HY-B1892

Cefazolin is an **antibiotic** used for the research of a number of anti-bacterial infections. Cefazolin can be used for the prophylaxis of surgical antimicrobial. Cefazolin has anti-inflammatory effect and can attenuate post-operative cognitive dysfunction (POCD).



Purity: 98.28%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Cefixime trihydrate **(FR-17027 trihydrate; FK-027 trihydrate; CL-284635 trihydrate)**

Cat. No.: HY-B1381A

Cefixime trihydrate (FR-17027 trihydrate) is an antibiotic and a third generation cephalosporin antibiotic, useful for the treatment of a number of bacterial infections.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cefoperazone dihydrate

Cat. No.: HY-B0210C

Cefoperazone dihydrate, a semisynthetic cephalosporin, has a broad spectrum of antibacterial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cefotaxime

(Cefotaxim; HR-756)

Cat. No.: HY-A0088A

Cefotaxime, a β-lactamase stable cephalosporin and a third-generation cephalosporin antibiotic, possesses broad-spectrum antibiotic activity against numerous Gram-positive and Gram-negative bacteria.



Purity: 99.55%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg

Celecoxib

(SC 58635)

Cat. No.: HY-14398

Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective **COX-2** inhibitor with an **IC_{50}** of 40 nM.



Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g

Cenerimod

(ACT-334441)

Cat. No.: HY-17606

Cenerimod (ACT-334441) is a potent, selective and orally active **S1P1 receptor** modulator, with an **EC_{50}** of 1 nM. Cenerimod shows more than 36fold selctivity for hS1P1 over hS1P2, hS1P3, hS1P4, and hS1P5 receptor subtypes (EC_{50}s=>10000, 228, 2134, and 36 nM, respectively).



Purity: 98.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cenicriviroc Mesylate

(TAK-652 Mesylate; TBR-652 Mesylate)

Cat. No.: HY-14882A

Cenicriviroc Mesylate (TAK-652 Mesylate) is a dual **CCR2/CCR5** antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.



Purity: 98.84%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Centhaquin

(Centhaquine; PMZ-2010)

Cat. No.: HY-106690

Centhaquine (Centhaquin; PMZ-2010) is a novel agent has the potential for treatment of **haemorrhagic shock**. Centhaquine (Centhaquin; PMZ-2010) can augment cardiac output, reduce systemic vascular resistance in haemorrhagic models.



Purity: 99.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cephalosporin C zinc salt

Cat. No.: HY-B1299A

Cephalosporin C zinc salt is a potent inhibitor of **SAMHD1** with an **IC_{50}** of 1.1 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

Cepharanthine

Cat. No.: HY-N6972

Cepharanthine is an alkaloid derived from Stephania cepharantha Hayata, with possesses anti-inflammatory and antioxidative activities. Cepharanthine attenuates muscle and kidney injuries induced by limb ischemia/reperfusion (I/R).



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Cephradine

(Cefradine; SQ-11436)

Cat. No.: HY-B1156

Cephradine (Cefradine) is a broad-spectrum and orally active cephalosporin. Cephradine is active against both gram-positive and gram-negative pathogens. Cephradine is effective in eradicating most penicillinase-producing organisms.



Purity: 95.11%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Cephradine monohydrate

(Cefradine monohydrate)

Cat. No.: HY-128449

Cephradine (Cefradine) monohydrate is a broad-spectrum and orally active cephalosporin.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Cetalkonium chloride

(Benzyldimethylhexadecylammonium chloride)

Cat. No.: HY-B1597

Cetalkonium chloride is an ammonium antiseptic agent used in many topical drugs for infections of mouth, throat and eye. Cetalkonium chloride acts as anti-inflammatory amphiphilic agent.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Cethromycin

(ABT-773; Abbott-195773; A-195773)

Cat. No.: HY-19655

Cethromycin (ABT-773) is a ketolide antibiotic.



Purity: 91.80%
Clinical Data: Phase 3
Size: 5 mg

Cetirizine

Cat. No.: HY-17042

Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine **H1-receptor** antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Cetirizine D4

Cat. No.: HY-17042S

Cetirizine D4 is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine **H1-receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cetirizine D4 dihydrochloride

Cat. No.: HY-17042AS

Cetirizine D4 dihydrochloride is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine **H1-receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cetirizine D8

Cat. No.: HY-17042S1

Cetirizine D8 is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine **H1-receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cetirizine D8 dihydrochloride

Cat. No.: HY-17042AS1

Cetirizine D8 dihydrochloride is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine **H1-receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cetirizine dihydrochloride

(P071) Cat. No.: HY-17042A

Cetirizine dihydrochloride, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine **H1-receptor** antagonist.



Purity: 99.17%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Cetirizine Impurity C

Cat. No.: HY-131256

Cetirizine Impurity C is an impurity of Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting **histamine H1-receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Cetirizine Impurity D

Cat. No.: HY-100661

Cetirizine Impurity D is an impurity of Cetirizine. Cetirizine, a second-generation antihistamine, is a specific, orally active and long-acting histamine **H1-receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cetraxate hydrochloride

(DV-1006) Cat. No.: HY-122762

Cetraxate hydrochloride (DV-1006), an orally active **anti-ulcer** agent with mucosal protective effects, can be used for gastric ulcers research. Cetraxate hydrochloride is a potent **acrosomal proteinase acrosin** inhibitor with a K_i and an IC_{50} of 0.94 μM and 3.3 μM, respectively.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cetylpyridinium chloride

Cat. No.: HY-B1464

Cetylpyridinium chloride, a cationic quaternary ammonium compound, is an anti-bacterial agent with broad-spectrum activity. Cetylpyridinium chloride is an effective anti-**HBV capsid assembly** inhibitor with an **IC_{50}** of 2.5 μM.



Purity: 99.44%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Cevidoplenib

Cat. No.: HY-109082

Cevidoplenib is an orally available inhibitor of **spleen tyrosine kinase (Syk)**, with potential anti-inflammatory and immunomodulating activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

cFMS Receptor Inhibitor II

Cat. No.: HY-112451

cFMS Receptor Inhibitor II is a **CSF1R** kinase inhibitor. CSF-1 is a cytokine.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CFTR corrector 2

Cat. No.: HY-125381

CFTR corrector 2 is a **cystic fibrosis transmembrane conductance corrector (CFTR)**, extracted from patent US20140274933.



Purity: 99.85%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

CFTR corrector 4

Cat. No.: HY-135279

CFTR corrector 4 (Compound 13), an active (R,R)-form enantiomer, is a highly potent and orally active **cystic fibrosis transmembrane conductance regulator (CFTR)** corrector.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CFTR corrector 6

Cat. No.: HY-136939

CFTR corrector 6 is a potent potentiator of **Cystic Fibrosis Transmembrane conductance Regulator (CFTR)**. CFTR corrector 6 has the potential for cystic fibrosis (CF) and other CFTR associated disorders research.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

cGAMP

(Cyclic GMP-AMP; 3',3'-cGAMP) Cat. No.: HY-12512

cGAMP (Cyclic GMP-AMPP) functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

cGAMP diammonium

(Cyclic GMP-AMP diammonium; 3',3'-cGAMP diammonium) Cat. No.: HY-110385A

cGAMP (Cyclic GMP-AMPP) diammonium functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg, 10 mg, 25 mg

cGAMP disodium

(Cyclic GMP-AMP disodium; 3',3'-cGAMP disodium) Cat. No.: HY-110385

cGAMP (Cyclic GMP-AMPP) disodium functions as an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg, 10 mg, 25 mg

CGI-1746

Cat. No.: HY-11999

CGI-1746 is a potent and highly selective inhibitor of the **Btk** with IC_{50} of 1.9 nM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CGS 15435

Cat. No.: HY-100283

CGS 15435, a potent thromboxane (TxA_2) synthetase inhibitor with an IC_{50} of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI_2 synthetase and lipoxygenase enzymes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CGS 15943

Cat. No.: HY-100678

CGS 15943 is an orally bioavailable non-xanthine **Adenosine Receptor** antagonist. Its K_i for human A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2, 16, and 50 nM in transfected CHO cells, respectively.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

CH 5450

(Z-Ile-Glu-Pro-Phe-Ome) Cat. No.: HY-16707

CH 5450 (Z-Ile-Glu-Pro-Phe-Ome) is a human chymase inhibitor.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Chalcone

Cat. No.: HY-121054

Chalcone is isolated from Glycyrrhizae inflata and used to synthesize chalcone derivatives. Chalcone derivatives possess varied biological and pharmacological activity, including anti-inflammatory, antioxidative, antibacterial, anticancer, and anti-parasitic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chamaechromone

Cat. No.: HY-133721

Chamaechromone is a biflavonoid ingredient isolated from the roots of Stellera chamaejasme L. (Thymelaeaceae). Chamaechromone possesses **anti-hepatitis B virus (HBV)** effects against the surface antigen of HBV (HBsAg) secretion and has insecticidal activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Charybdotoxin

Cat. No.: HY-P0191

Charybdotoxin, a 37-amino acid peptide, is a K^+ channel blocker.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Charybdotoxin TFA

Cat. No.: HY-P0191A

Charybdotoxin TFA, a 37-amino acid peptide, is a K^+ channel blocker.

Purity: 96.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Chebulagic acid

Cat. No.: HY-N1996

Chebulagic acid is a **COX-LOX** dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a **M2 serine to asparagine 31 mutation (S31N)** inhibitor and influenza antiviral.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Chelerythrine

Cat. No.: HY-N2359

Chelerythrine is a natural alkaloid, acts as a potent and selective Ca^{2+}/phospholipid-dependent **PKC** antagonist, with an **IC_{50}** of 0.7 μM. Chelerythrine has antitumor, antidiabetic and anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Chelerythrine chloride

Cat. No.: HY-12048

Chelerythrine chloride is a potent, cell-permeable inhibitor of **protein kinase C**, with an **IC_{50}** of 660 nM. Chelerythrine chloride inhibits the **Bcl-XL-Bak BH3** peptide binding with **IC_{50}** of 1.5 μM and displaces Bax from Bcl-XL. Chelerythrine chloride induces **apoptosis** and **autophagy**.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Chelidonic acid

Cat. No.: HY-W041489

Chelidonic acid is a component of Chelidonium majus L., used as a mild analgesic, an antimicrobial, an acentral nervous system sedative. Chelidonic acid also shows anti-inflammatory activity.



Purity: 95.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Chemerin-9 (149-157)

Cat. No.: HY-P1844

Chemerin-9 (149-157), the nonapeptide (149)YFPGQFAFS(157) (chemerin-9), corresponding to the C terminus of processed chemerin, retains most of the activity of the full-size protein, with regard to agonism toward the chemerinR.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CHF5407

Cat. No.: HY-U00302

CHF5407 is a selective, long-acting and competitive **muscarinic M3 receptor** antagonist. CHF5407 shows subnanomolar affinities for human muscarinic M1 (hM1), M2 (hM2) and M3 (hM3) receptors. CHF5407 shows a prolonged antibronchospastic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CHIC35

Cat. No.: HY-111303

CHIC35, an analog of EX-527, is a potent and selective inhibitor of **SIRT1** (IC_{50}=0.124 μM). CHIC35 shows potential selective inhibition against SIRT1 over SIRT2 (IC_{50}=2.8 μM) or SIRT3 (IC_{50}>100 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chicanine

Cat. No.: HY-N2270

Chicanine is a lignan compound of Schisandra chinesis, inhibits LPS-induced phosphorylation of **p38 MAPK**, **ERK 1/2** and **IκB-α**, with anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Chitoheptaose heptahydrochloride

Cat. No.: HY-N7697D

Chitoheptaose heptahydrochloride is a chitosan oligosaccharide with antioxidant, anti-inflammatory, antiapoptotic and cardioprotective activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Chitohexaose hexahydrochloride

Cat. No.: HY-N7697C

Chitohexaose hexahydrochloride is a chitosan oligosaccharide with anti-inflammatory effect. Chitohexaose hexahydrochloride binds to the active sites of **TLR4** and inhibits LPS induced inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Chitopentaose pentahydrochloride

Cat. No.: HY-N7697A

Chitopentaose pentahydrochloride is a chitosan oligosaccharide with anti-inflammatory effect. Chitopentaose pentahydrochloride is a substrate of gene encoding chitinase B (FjchiB).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Chloraholide C

Cat. No.: HY-N8404

Chloraholide C, a lindenane sesquiterpenoid dimer, is isolated from Chloranthus holostegius. Chloraholide C is a potent and selective potassium channel blocker, with an IC_{50} of 3.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chlorogenic acid

(3-O-Caffeoylquinic acid; Heriguard; NSC-407296)

Cat. No.: HY-N0055

Chlorogenic acid is a major phenolic compound in coffee and tea.



Purity: 99.43%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 500 mg

Chloroquine

Cat. No.: HY-17589A

Chloroquine is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.



Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Chloroquine dihydrochloride

Cat. No.: HY-17589B

Chloroquine dihydrochloride is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine dihydrochloride is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Chloroquine phosphate

Cat. No.: HY-17589

Chloroquine phosphate is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Chloroquine-d5

Cat. No.: HY-17589AS

Chloroquine D5 is deuterium labeled Chloroquine. Chloroquine is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chlorphenesin

Cat. No.: HY-A0133

Chlorphenesin is a reversible antigen-associated immunosuppressant. Chlorphenesin is an **antibacterial** and **antifungal** agent used in numerous eye care cosmetics.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg

Chlorpheniramine maleate

(Chlorphenamine maleate)

Cat. No.: HY-B0286A

Chlorpheniramine maleate is an histamine H1 receptor antagonist with IC50 of 12 nM.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g

Chlorthenoxazine
(Chlorethylbenzmethoxazone)

Cat. No.: HY-101751

Chlorthenoxazine is a nonsteroidal anti-inflammatory drug.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Chlorzoxazone

Cat. No.: HY-B1462

Chlorzoxazone is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort. It acts on the spinal cord by depressing reflexes.



Purity: 99.60%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g

Chlorzoxazone-d3

Cat. No.: HY-B1462S

Chlorzoxazone-d3 is the deuterium labeled Chlorzoxazone. Chlorzoxazone is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort. It acts on the spinal cord by depressing reflexes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cholesteryl palmitate

Cat. No.: HY-W010708

Cholesteryl palmitate is a useful prognostic biomarker for chronic interstitial pneumonia (CIP).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg

Choline theophyllinate
(Oxtriphylline)

Cat. No.: HY-B1718

Choline theophyllinate (Oxtriphylline) is a choline salt of theophylline with anti-asthmatic activity.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Chondroitin sulfate
(Chondroitin polysulfate)

Cat. No.: HY-B2162

Chondroitin sulfate, one of five classes of glycosaminoglycans, has been widely used in the treatment of osteoarthritis. Chondroitin sulfate reduces inflammation mediators and the apoptotic process and is able to reduce protein production of inflammatory cytokines, **iNOS** and **MMPs**.



Purity: >98%
Clinical Data: Launched
Size: 250 mg, 1 g

CHPG

Cat. No.: HY-101364

CHPG is a selective **mGluR5** agonist, and attenuates SO_2-induced oxidative stress and inflammation through **TSG-6/NF-κB** pathway in BV2 microglial cells.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

CHPG sodium salt

Cat. No.: HY-101364A

CHPG sodium salt is a selective **mGluR5** agonist, and attenuates SO_2-induced oxidative stress and inflammation through **TSG-6/NF-κB** pathway in BV2 microglial cells.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 5 mg

Chrysophanol tetraglucoside

Cat. No.: HY-N8206

Chrysophanol tetraglucoside possesses anti-hypolipidemic and antibacterial activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chrysosplenol D

Cat. No.: HY-N6007

Chrysosplenol D is a methoxy flavonoid that induces ERK1/2-mediated apoptosis in triple negative human breast cancer cells. Chrysosplenol D also exhibits anti-inflammatory and moderate antitrypanosomal activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chymase-IN-1

Cat. No.: HY-100269

Chymase-IN-1 is a potent, selective, orally active, nonpeptide inhibitor of human mast cell **chymase** with an IC_{50} of 29 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chymase-IN-2

Cat. No.: HY-U00282

Chymase-IN-2 is a chymase modulator which is useful in the treatment of inflammatory and serine protease mediated disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CI 972 anhydrous

Cat. No.: HY-118047

CI 972 anhydrous is a potent, orally active, and competitive inhibitor of **purine nucleoside phosphorylase (PNP)** (K_i=0.83 μM) under development as a T cell-selective immunosuppressive agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CI-1044

(PD-189659)

Cat. No.: HY-100246

CI-1044 is an orally active **PDE4** inhibitor with IC_{50}s of 0.29, 0.08, 0.56, 0.09 μM for **PDE4A5**, **PDE4B2**, **PDE4C2** and **PDE4D3**, respectively.



Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CI-949

Cat. No.: HY-U00364

CI-949 is an allergic mediator release inhibitor, which inhibits **histamine**, **leukotriene C_4/D_4 (LTC_4/LTD_4)**, and **thromboxane B_2 (TXB_2)** release with IC_{50}s of 11.4 μM, 0.5 μM and 0.1 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ciclesonide

(RPR251526)

Cat. No.: HY-B0625

Ciclesonide (RPR251526) is a glucocorticoid with an potent anti-inflammatory activity. Ciclesonide can be used for asthma research.



Purity: 99.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Cicloxilic acid

(Cycloxilic acid)

Cat. No.: HY-U00305

Cicloxilic acid is a biologically active agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CID-1067700

(ML282)

Cat. No.: HY-13452

CID-1067700 (ML282) is a pan **GTPase** inhibitor, and competitively inhibits Ras-related in brain 7 (**Rab7**) with a K_i of 13 nM.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

CID-2858522

Cat. No.: HY-15530

CID-2858522 is a highly potent and selective antigen receptor-mediated **NF-κB** activation inhibitor with an IC_{50} of 70 nM.



Purity: 96.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

CID1231538

Cat. No.: HY-134801

CID1231538, a benzothiazole analogue, is a potent **GPR35** antagonist (IC_{50}=0.55 μM). GPR35 is a G protein-coupled receptor (GPCR).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cilofexor

(GS-9674)

Cat. No.: HY-109083

Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal **FXR** agonist with an EC_{50} of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research.



Purity: 99.82%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cilomilast

(SB-207499)

Cat. No.: HY-10790

Cilomilast (SB-207499) is a potent, selective and orally active inhibitor of **Phosphodiesterase 4 (PDE4)**, with IC_{50}s of ~100 and 120 nM for LPDE4 and HPDE4, respectively.



Purity: 99.11%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cilomilast-d9

Cat. No.: HY-10790S

Cilomilast-d9 (SB-207499-d9) is the deuterium labeled Cilomilast. Cilomilast (SB-207499) is a potent, selective and orally active inhibitor of **Phosphodiesterase 4 (PDE4)**, with IC_{50}s of ~100 and 120 nM for LPDE4 and HPDE4, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Cimetidine sulfoxide

(Cimetidine sulphoxide)

Cat. No.: HY-136338

Cimetidine sulfoxide (Cimetidine sulphoxide) is a sulfoxide metabolite of Cimetidine. Cimetidine is a **histamine H_2-receptor** antagonist. Cimetidine has the potential for peptic ulcer disease and upper gastrointestinal haemorrhage treatment.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

Cimetropium Bromide

(DA-3177)

Cat. No.: HY-U00106

Cimetropium Bromide (DA-3177) is a **mAChR** antagonist for long-term treatment of irritable bowel syndrome.



Purity: 96.19%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Cimicifugoside

Cat. No.: HY-N7119

Cimicifugoside, a triterpenoid isolated from Cimicifuga simplex, is a novel specific **nucleoside transport** inhibitor that displays synergistic potentiation of methotrexate cytotoxicity.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Cimifugin

(Cimitin)

Cat. No.: HY-N0634

Cimifugin (Cimitin) is a bioactive component of Saposhnikovia divaricata, a Chinese herb. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Cimifugin 4'-O-β-D-glucopyranoside

Cat. No.: HY-N2287

Cimifugin 4'-O-β-D-glucopyranoside is a derivative of cimifugin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cimiside B

Cat. No.: HY-N3587

Cimiside B is a glycoside alkaloid with anti-inflammatory activity.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 mg

Cimpuciclib

Cat. No.: HY-112243

Cimpuciclib is a **cyclin-dependent kinase(CDK)** inhibitor and antineoplastic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cinanserin hydrochloride

(SQ 10643)

Cat. No.: HY-100943

Cinanserin hydrochloride (SQ 10643) is a potent, selective and highly affinity **5-HT$_2$ receptor** antagonist with a K_i of 41 nM. Cinanserin hydrochloride has a much higher binding affinity for the **5-HT$_2$** than for the 5-HT$_1$ receptor (K_i of 3500 nM).



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Cinchophen

Cat. No.: HY-B0972

Cinchophen is a potent and orally active non-steroidal **anti-inflammatory agent**, has analgesic and antimicrobial effects. Cinchophen can be used for the research of arthritis and some liver diseases.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 5 g

Cirsilineol

Cat. No.: HY-119347

Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4$^+$ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

cis-Clovamide

Cat. No.: HY-122267A

cis-Clovamide, a natural phenolic compound with antioxidant, anti-inflammatory and antiapoptotic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

cis-Mulberroside A

(Mulberroside D)

Cat. No.: HY-N0619A

cis-Mulberroside A (Mulberroside D) is the cis-isomer of Mulberroside A. Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

cis-Urocanic acid

((Z)-Urocanic acid; cis-UCA)

Cat. No.: HY-113008A

cis-Urocanic acid is a **5-HT2A receptor** agonist. cis-Urocanic acid binds to **5-HT receptor** with relatively high affinity (K_d=4.6 nM). cis-Urocanic acid is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor.



Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

Cistanoside A

Cat. No.: HY-N0023

Cistanoside A is a phenylethanoid isolated from Cistanche deserticola, reduces NO accumulation, but shows no effect on iNOS mRNA, iNOS protein levels or iNOS activity. Anti-inflammatory effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Citral

Cat. No.: HY-N7083

Citral is a monoterpene found in Cymbopogon citratus essential oil, with antihyperalgesic, anti-nociceptive and anti-inflammatory effects.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Citric acid

Cat. No.: HY-N1428

Citric acid is a weak organic tricarboxylic acid found in citrus fruits. Citric acid is a natural preservative and food tartness enhancer.



Purity: ≥97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Ciwujianoside C3

Cat. No.: HY-N4134

Ciwujianoside C3, an orally active and brain penetrated compound, is isolated the leaves of Acanthopanax henryi Harms. Ciwujianoside C3 has anti-inflammatory effect and can reinforces object recognition memory.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

CJ-42794

(CJ-042794)

Cat. No.: HY-10797

CJ-42794 is a selective prostaglandin E receptor subtype 4 (EP4) antagonist, inhibits [3H]-PGE2 binding to the human EP4 receptor with a mean pKi of 8.5, a binding affinity that was at least 200-fold more selective for the human EP4 receptor than other human EP receptor subtypes (EP1,...



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

CK-636

(CK-0944636)

Cat. No.: HY-15892

CK-636 is a cell permeable inhibitor of **Arp2/3 complex**, that could inhibit actin polymerization, with IC_{50} values of 4 μM, 24 μM and 32 μM for human, fission yeast and bovine, respectively.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

CK1-IN-1

Cat. No.: HY-111820

CK1-IN-1 is a **casein kinase 1 (CK1)** inhibitor extracted from patent WO2015119579A1, compound 1c, has IC_{50}s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively.



Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CK2/PIM1-IN-1

Cat. No.: HY-135816

CK2/PIM1-IN-1 is an inhibitor of **CK2** and **PIM1**, with IC_{50}s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CL-82198

Cat. No.: HY-100359

CL-82198 is a selective inhibitor of **MMP-13**. CL-82198 binds to the entire S1' pocket of MMP-13, which is the basis for its selectivity towards MMP-13 and the lack of inhibitory activities against other MMPs.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cl-amidine

Cat. No.: HY-100574

Cl-amidine is an orally active **peptidylarginine deminase (PAD)** inhibitor, with IC_{50} values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine induces apoptosis in cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cl-amidine hydrochloride

Cat. No.: HY-100574A

Cl-amidine hydrochloride is an orally active **peptidylarginine deminase (PAD)** inhibitor, with IC_{50} values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride induces apoptosis in cancer cells.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Cl-amidine TFA

Cat. No.: HY-100574B

Cl-amidine TFA is an orally active **peptidylarginine deminase (PAD)** inhibitor, with IC_{50} values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine TFA induces apoptosis in cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CL075

(3M002)

Cat. No.: HY-117066

CL075 (3M002) is a selective **TLR8** agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

CL097

Cat. No.: HY-128799

CL097, a potent **TLR7/8** agonist, induces pro-inflammatory cytokines in macrophages. CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CL264

Cat. No.: HY-135905

CL264 is a **TLR7**-specific agonist for innate immune signals research.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CL2A

Cat. No.: HY-128945

CL2A is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CL2A-SN-38

Cat. No.: HY-128946

CL2A-SN-38 is a **drug-linker conjugate** composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CL656

(c-[2'FdAMP(S)-2'FdIMP(S)])

Cat. No.: HY-112878

CL656 is an activator of stimulator of interferon genes (**STING**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clemastanin B

Cat. No.: HY-N6025

Clemastanin B, a lignin, has potent **anti-influenza** activities by inhibiting the virus multiplication, prophylaxis and blocking the virus attachment. Clemastanin B targets viral endocytosis, uncoating or ribonucleoprotein (RNP) export from the nucleus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clematichinenoside AR

Cat. No.: HY-N4232

Clematichinenoside AR is a major active ingredient that could be extracted from the traditional Chinese herb **Clematis chinensis** and has potent pharmacological effects on various diseases, including atherosclerosis (AS).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Clematomandshurica saponin B

Cat. No.: HY-N4230

Clematomandshurica saponins B shows significant inhibitory activity on cyclooxygenase-2 (IC_{50}=2.58 mM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clemizole

Cat. No.: HY-30234

Clemizole is an **H1 histamine receptor** antagonist, is found to substantially inhibit **HCV** replication. Clemizole is an inhibitor of **TRPC5 channel**. The IC_{50} of Clemizole for RNA binding by **NS4B** is 24±1 nM, whereas its EC_{50} for viral replication is 8 μM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Clemizole hydrochloride

Cat. No.: HY-30234A

Clemizole hydrochloride is an **H1 histamine receptor** antagonist, is found to substantially inhibit **HCV** replication. Clemizole hydrochloride is an inhibitor of **TRPC5 channel**.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cleomiscosin A

Cat. No.: HY-N3595

Cleomiscosin A is a coumarino-lignoid from branch of Macaranga adenantha. Cleomiscosin A is active against **TNF-alpha** secretion of the mouse peritoneal macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cletoquine
(Desethylhydroxychloroquine) Cat. No.: HY-135810

Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cletoquine oxalate
(Desethylhydroxychloroquine oxalate) Cat. No.: HY-135810A

Cletoquine oxalate (Desethylhydroxychloroquine oxalate) is a major active metabolite of Hydroxychloroquine. Cletoquine oxalate is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CLIP (86-100)
Cat. No.: HY-P1826

CLIP (86-100) is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP).

PVSKMRMATPLLMQA

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CLIP (86-100) (TFA)
Cat. No.: HY-P1826A

CLIP (86-100) TFA is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP).

PVSKMRMATPLLMQA (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clobetasol propionate
Cat. No.: HY-13600

Clobetasol propionate is a potent and selective **CYP3A5** inhibitor with an IC_{50} of 0.206 μM. Clobetasol propionate has no inhibiting on CYP4A4 or other major CYPs. Clobetasol propionate is a corticosteroid and has the potential for psoriasis and other dermatoses research.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Clobetasone butyrate
Cat. No.: HY-B1616

Clobetasone butyrate is a synthetic **glucocorticoid** and has topical anti-inflammatory activity especially in skin. Clobetasone butyrate can be used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Clodronate disodium tetrahydrate
(Disodium clodronate tetrahydrate) Cat. No.: HY-107794

Clodronate disodium tetrahydrate (Disodium clodronate tetrahydrate) is first-generation bisphosphonate, with anti-osteoporotic, anti-inflammatory and analgesic effects.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 250 mg

Clodronic acid disodium salt
(Clodronate disodium salt) Cat. No.: HY-B0657A

Clodronic acid (Clodronate) disodium salt, a first-generation bisphosphonate, is orally active **osteoclastic bone resorption** inhibitor. Clodronic acid disodium salt can be used in high bone turnover states, Paget's disease and osteolytic bone metastases.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

Clofazimine
Cat. No.: HY-B1046

Clofazimine is an iminophenazine dye, has a marked anti-inflammatory effect, has been used in combination with other antimycobacterial drugs to treat AIDS and Crohn's disease.



Purity: 99.23%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Clonixin
(SCH-10304) Cat. No.: HY-121235

Clonixin (SCH-10304) is an orally active non-steroidal anti-inflammatory agent in rodents.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg, 500 mg

Cloperastine fendizoate

Cat. No.: HY-B2179

Cloperastine fendizoate inhibits the **hERG K⁺ currents** in a concentration-dependent manner with an IC_{50} value of 27 nM.



Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Cloperastine hydrochloride

Cat. No.: HY-B2133

Cloperastine hydrochloride inhibits the **hERG K⁺ currents** in a concentration-dependent manner with an IC_{50} value of 27 nM.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Clorprenaline D7

Cat. No.: HY-131106S

Clorprenaline D7 is a deuterium labeled Clorprenaline. Clorprenaline is a **β2-adrenergic receptor** agonist that is implicated in bronchial expansion. Clorprenaline has the potential for asthma research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clorprenaline hydrochloride

Cat. No.: HY-B1347

Clorprenaline hydrochloride is a **β_2-adrenergic receptor** agonist that is implicated in bronchial expansion. Clorprenaline has the potential for asthma research.



Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Clorprenaline-d6

Cat. No.: HY-134577S



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Clovamide

(trans-Clovamide)

Cat. No.: HY-122267

Clovamide (trans-Clovamide), a natural phenolic compound, is a potent antioxidant. Clovamide is an excellent **ROS** and oxygen radical scavenger. Clovamide also has anti-inflammatory and neuroprotective effects.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cloxacillin sodium

Cat. No.: HY-B0466B

Cloxacillin sodium exhibits antibiotic efficacy, with a MIC of 256 mg/L for Staphylococcus aureus 25923.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Cloxacillin sodium monohydrate

Cat. No.: HY-B0466

Cloxacillin sodium monohydrate exhibits antibiotic efficacy, with a MIC of 256 mg/L for Staphylococcus aureus 25923.



Purity: 98.57%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Clozic

(ICI 55897; Clobuzarit)

Cat. No.: HY-100142

Clozic is a potential anti-arthritic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CLP-3094

Cat. No.: HY-141487

CLP-3094 is a potent **BF3** (binding function 3)-directed inhibitor of the **androgen receptor (AR)**. CLP-3094 inhibits AR transcriptional activity (IC_{50}=4 μM). CLP-3094 is a selective, potent **GPR142** antagonist.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

CMC2.24

(TRB-N0224)

Cat. No.: HY-120793

CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting **Ras** activation and its downstream effector ERK1/2 pathway.



Purity: 96.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CMD178 TFA

Cat. No.: HY-P1453A

CMD178 (TFA) is a lead peptide that consistently reduces the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling. CMD178 (TFA) also is an inhibitor of **STAT5** and inhibits T_{reg}cells development.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

CMI-392

Cat. No.: HY-19205A

CMI-392 is a dual **5-lipoxygenese** inhibitor and platelet-activating factor (**PAF**) receptor antagonist with **IC_{50}**s of 100 and 10 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CMI977

(LDP977)

Cat. No.: HY-U00260

CMI977 is a potent **5-Lipoxygenase** (**5-LO**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CMS-121

Cat. No.: HY-135981

CMS-121 is a quinolone derivative and an orally active **acetyl-CoA carboxylase 1 (ACC1)** inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage with **EC_{50}** values of 7 nM and 200 nM, respectively.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Coenzyme Q10

(CoQ10; Ubiquinone-10)

Cat. No.: HY-N0111

Coenzyme Q10 is an essential cofactor of the electron transport chain and a potent antioxidant agent.

Purity: ≥98.0%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg, 1 g, 5 g

COG 133

Cat. No.: HY-P1050

COG 133 is a fragment of Apolipoprotein E (APOE) peptide. COG 133 competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 is also a **nAChR** antagonist with an **IC_{50}** of 445 nM.

Ac-LRVRLASHLRKLRKRLL-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COG 133 TFA

Cat. No.: HY-P1050A

COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a **nAChR** antagonist with an **IC_{50}** of 445 nM.

Ac-LRVRLASHLRKLRKRLL-NH_2 (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COG1410

Cat. No.: HY-P2136

COG1410 is an apolipoprotein E-derived peptide. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease.

Ac-AS-{Aib}-LRKL-{Aib}-KRLL-NH_2

Purity: 99.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Col003

Cat. No.: HY-124817

Col003 is a selective and potent inhibitor of **Hsp47** and competitively binds to the collagen binding site on Hsp47 (**IC_{50}**=1.8 μM). Col003 discourages the interaction of Hsp47 with collagen and inhibits collagen secretion by destabilizing the collagen triple helix.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Colcemid

(Demecolcine)

Cat. No.: HY-N0282

Colcemid (Demecolcine), a derivative of colchicine, is a potent **mitotic** inhibitor. Colcemid binds to the protein tubulin and arrest cells in metaphase for karyotyping assays. Colcemid incuces cell apoptosis and can be used for cancer research.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Colominic acid sodium salt

(Polysialic acid sodium salt)

Cat. No.: HY-N7476

Colominic acid sodium salt (Polysialic acid sodium salt) could be naturally isolated from the cell wall of Escherichia coli and animals, gives a red color which has an absorption maximum at 530 nm. Colominic acid sodium salt (Polysialic acid sodium salt) possesses anti-bacterial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Columbianadin

Cat. No.: HY-N0362

Columbianadin, a natural coumarin from, is known to have various biological activities including anti-inflammatory and anti-cancer effects.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Columbianetin

Cat. No.: HY-N5003

Columbianetin is a phytoalexin associated with celery (Apium graveolens) resistance to pathogens during storage. Columbianetin exhibits excellent anti-fungal and anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Columbin

Cat. No.: HY-N0389

Columbin is an orally active diterpenoid furanolactone from Calumbae radix, has anti-inflammatory and anti-trypanosomal effects. Columbin selectively inhibits **COX-2** (EC_{50}=53.1 μM) over COX-1 (EC_{50}=327 μM).



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Comanthoside B

Cat. No.: HY-N7643

Comanthoside B is a flavonoid glycoside isolated from the aerial portions of Ruellia tuberosa L. Comanthoside B has anti-inflammatory and antiseptic activities.</br>.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Complanatoside B

Cat. No.: HY-N7903

Complanatoside B is a P. chinense Fisch flavonoid with potential anti-inflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Complanatuside

Cat. No.: HY-N1444

Complanatuside is a flavonoid found in the traditional Chinese medicine Semen Astragali Complanati.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Complement C5-IN-1

Cat. No.: HY-128342

Complement C5-IN-1 (Compound 7) is a small-molecule inhibitor of complement component 5 protein (**C5**).



Purity: 98.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

Complement factor D-IN-1

Cat. No.: HY-102034

Complement factor D-IN-1 is a potent and selective **small-molecule reversible factor d** inhibitor, with IC_{50}s of 0.006 and 0.05 μM in FD Thioesterolytic Fluorescent Assay and a MAC Deposition Assay, respectively.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Complement factor D-IN-2

Cat. No.: HY-138281

Complement factor D-IN-2 is an inhibitor of **complement factor D** extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Compstatin control peptide

Cat. No.: HY-P1398

Compstatin control peptide is a **complement protein C3** inhibitor that binds and inhibits cleavage of complement C3.

IAVVQDWGHHRAT-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Compstatin control peptide TFA

Cat. No.: HY-P1398A

Compstatin control peptide TFA is a **complement** inhibitor that binds and inhibits cleavage of complement C3.

IAVVQDWGHHRAT-NH_2 (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Coniferaldehyde

(Ferulaldehyde)

Cat. No.: HY-N2535

Coniferaldehyde (Ferulaldehyde) is an effective inducer of **heme oxygenase-1** (**HO-1**). Coniferaldehyde exerts anti-inflammatory properties in response to LPS.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Contezolid

(MRX-I)

Cat. No.: HY-19915

Contezolid (MRX-I), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria.



Purity: 99.37%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg

Contezolid acefosamil

(MRX-4)

Cat. No.: HY-19915A

Contezolid acefosamil (MRX-4) is the orally active prodrug of the active antimicrobial metabolite Contezolid (MRX-I), an oxazolidinone which shows potent in vitro activity against various multidrug-resistant Gram-positive bacteria, including MRSA.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Contezolid acefosamil sodium

(MRX-4 sodium)

Cat. No.: HY-19915B

Contezolid acefosamil sodium (MRX-4), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Continentalic acid

Cat. No.: HY-N6908

Continentalic acid from Aralia continentalis has minimum inhibitory concentrations (MICs) of approximately 8-16 μg/mL against S. aureus, including the Methicillin susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus...



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Convallatoxin

Cat. No.: HY-N2453

Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of **PPARγ** and suppression of **NF-κB**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 25 mg, 50 mg

Copper tripeptide

(GHK-Cu)

Cat. No.: HY-P0063

Copper tripeptide (GHK-Cu), a naturally occurring tripeptide, is first isolated from human plasma, but can be found in saliva and urine.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Cordycepin
(3'-Deoxyadenosine)

Cat. No.: HY-N0262

Cordycepin (3'-Deoxyadenosine) is a nucleoside derivative and inhibits IL-1β-induced **MMP-1** and **MMP-3** expression in rheumatoid arthritis synovial fibroblasts (RASFs) in a dose-dependent manner.



Purity: 98.64%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Corilagin

Cat. No.: HY-N0462

Corilagin, a gallotannin, inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows good anti-tumor activity on hepatocellular carcinoma and ovarian cancer.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

CORM-3

Cat. No.: HY-100581

CORM-3, a carbon monoxide-releasing molecule, attenuates **NF-κB p65** nuclear translocation, reduces ROS generation and enhances intracellular glutathione and superoxide dismutase levels. CORM-3 reduces **NLRP3** inflammasome activation.



Purity: ≥92.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

CORM-401

Cat. No.: HY-109804

CORM-401 is an oxidant-sensitive CO-releasing molecule, can be used in the research of inflammatory and oxidative stress-mediated pathologies.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Cornuside

Cat. No.: HY-N0631

Cornuside is a secoiridoid glucoside isolated from the fruit of Cornus officinalis Sieb. et Zucc., which is a traditional oriental medicine for treating inflammatory diseases and invigorating blood circulation.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Coronalolic acid
(Coronalonic acid)

Cat. No.: HY-N3625

Coronalolic acid, extract from the apical bud of Gardenia sootepenesis Hutch, inhibits TNF-α-induced **NF-κB** activity and **NO** production.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cortisone (17-Hydroxy-11-dehydrocorticosterone; Kendall's compound E)

Cat. No.: HY-17461

Cortisone (17-Hydroxy-11-dehydrocorticosterone), an oxidized metabolite of Cortisol (a Glucocorticoid). Cortisone acts as an immunosuppressant and anti-inflammatory agent.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Cortisone acetate
(Cortisone 21-acetate)

Cat. No.: HY-17461A

Cortisone acetate (Cortisone 21-acetate), an oxidized metabolite of Cortisol (a Glucocorticoid). Cortisone acetate acts as an immunosuppressant and anti-inflammatory agent.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Cortistatin-14

Cat. No.: HY-P1932

Cortistatin-14, a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties.

Purity: 99.93%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

Cortistatin-14 TFA

Cat. No.: HY-P1932A

Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties.

Purity: 99.88%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

Cortodoxone

(11-Deoxycortisol; cortexolone; Reichstein's substance S)

Cat. No.: HY-77839

Cortodoxone is a glucocorticoid steroid hormone that can be oxygenated to cortisol (Hydrocortisone).



Purity: 98.74%
Clinical Data: No Development Reported
Size: 100 mg

Corynoline

Cat. No.: HY-N0826

Corynoline is a reversible and noncompetitive acetylcholinesterase (**AChE**) inhibitor with an IC_{50} of 30.6 μM. Corynoline exhibits anti-inflammatory activity by activating **Nrf2**.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Cot inhibitor-1

Cat. No.: HY-32015

Cot inhibitor-1 (compound 28) is a selective **tumor progression loci-2 (Tpl2) kinase** inhibitor with an IC_{50} of 28 nM. Cot inhibitor-1 shows an inhibition of TNF-alpha production in human whole blood with an IC_{50} of 5.7 nM.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Coumarin

Cat. No.: HY-N0709

Coumarin is the primary bioactive ingredient in Radix Glehniae, named Beishashen in China, which possesses many pharmacological activities, including anticancer, anti-inflammation and antivirus activities.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

COX-2-IN-1

Cat. No.: HY-U00275

COX-2-IN-1 is potent and slective **COX-2** inhibitor with an IC_{50} of 3.9 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX-2-IN-2

Cat. No.: HY-101655

COX-2-IN-2 is a selective and inducible **COX2** inhibitor with an IC_{50} of 0.24 μM. COX-2-IN-1 is an anti-inflammatory compound with anti-inflammatory and analgesic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

COX/5-LO-IN-1

(Atreleuton analog)

Cat. No.: HY-U00347

COX/5-LO-IN-1 (Atreleuton analog) is an inhibitor of **cylooxygenase** and **5-lipoxygenase (5-LO)**, used for the research of inflammatory and allergic disease states.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CP-105696

(Pfizer 105696)

Cat. No.: HY-19193

CP-105696 is a potent and selective **Leukotriene B_4** Receptor antagonist, with an IC_{50} of 8.42 nM.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 5 mg

CP-20961

(Avridine)

Cat. No.: HY-107634

CP-20961 is a potent synthetic non-immunogenic adjuvant that induces arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CP-471474

Cat. No.: HY-W011085

CP-471474 is an orally active and pan **MMP** inhibitor, with IC_{50} values of 1170 nM (MMP-1), 0.7 nM (MMP-2), 16 nM (MMP-3), 13 nM (MMP-9) and 0.9 nM (MMP-13), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CP-544439

Cat. No.: HY-107013

CP-544439 is a potent and orally active matrix metalloproteinase-13 **(MMP-13)** inhibitor with an IC_{50} of 0.75 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CP-868388 free base

Cat. No.: HY-116699

CP-868388 free base is a potent, selective and orally active **PPARα** agonist with a K_i value of 10.8 nM. CP-868388 free base has little or no affinity for PPARβ (K_i of 3.47 μM) and PPARγ. CP-868388 free base has hypolipidemic and anti-inflammatory actions.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CP-96021 hydrochloride

Cat. No.: HY-101731

CP-96021 hydrochloride is a balanced, combined, potent and orally active **leukotriene D4 (LTD4)/platelet activating factor (PAF)** receptor antagonist with K_i values of 34 nM and 37 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CP-96486

Cat. No.: HY-100316

CP-96486 is a potent and orally active leukotriene D_4 (LTD_4)/platelet activating factor (**PAF**) receptor antagonist with K_is of 20 and 24 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CPYPP

Cat. No.: HY-110100

CPYPP is a **DOCK2-Rac1 interaction** inhibitor. CPYPP binds to **DOCK2 DHR-2 domain** and inhibits the guanine nucleotide exchange factor (GEF) activity of $DOCK2^{DHR-2}$ for Rac1 in a dose-dependent manner with an IC_{50} of 22.8 μM.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CRA-2059

Cat. No.: HY-19303

CRA-2059 is a highly specific and selective **tryptase** inhibitor, with a K_i of 620 pM for recombinant human tryptase-β (rHTβ).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CRA-2059 hydrochloride

Cat. No.: HY-19303A

CRA-2059 hydrochloride is a highly specific and selective **tryptase** inhibitor, with a K_i of 620 pM for recombinant human tryptase-β (rHTβ).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CRA-2059 TFA

Cat. No.: HY-19303B

CRA-2059 is a highly specific and selective **tryptase** inhibitor, with a K_i of 620 pM for recombinant human tryptase-β (rHTβ).



Purity: 99.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

CRAC intermediate 1

Cat. No.: HY-20587

CRAC intermediate 1 is a key intermediate in the chemical synthesis of a series of CRAC channel inhibitors, detailed information can be found in Patent WO 2010122089 A1, intermediate 9.



Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Crebanine

Cat. No.: HY-N2255

Crebanine, an alkaloid from Stephania venosa, induces G1 arrest and apoptosis in human cancer cells. Crebanine exhibits anti-inflammatory activity via suppressing MAPKs and Akt signaling. Crebanine also possesses antiarrhythmic effect.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

CRF, bovine

(Corticotropin Releasing Factor bovine)

Cat. No.: HY-P1533

CRF, bovine is a potent agonist of **CRF receptor**, and displaces [^{125}I-Tyr]ovine CRF with a K_i of 3.52 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CRF, bovine TFA

(Corticotropin Releasing Factor bovine TFA)

Cat. No.: HY-P1533A

CRF, bovine (TFA) is a potent agonist of **CRF receptor**, and displaces [^{125}I-Tyr]ovine CRF with a K_i of 3.52 nM.

Purity: 96.50%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg

Cridanimod

Cat. No.: HY-W011890

Cridanimod is a potent **progesterone receptor (PR)** activator mediated through induction of **IFNα** and **IFNβ** expression. Cridanimod is a small-molecule immunomodulator and interferon inducer.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Crisaborole

(AN-2728; PF-06930164)

Cat. No.: HY-10978

Crisaborole (AN-2728) is a potent inhibitor of **PDE4** and **cytokine** release; inhibit PDE4 with an IC_{50} of 0.49 µM.



Purity: 96.55%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Crocetin

(β-Crocetin)

Cat. No.: HY-N6904

Crocetin (β-Crocetin), isolated from Crocus sativus, possesses anti-inflammatory, neuroprotective and antioxidant activity.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Crocin

(Crocin I)

Cat. No.: HY-N0697

Crocin (Crocin I) is a nutraceutical and the main constituent isolated from the stigmas of Crocus sativus with immense pharmacological properties as anti-inflammatory, anticancer, antidepressant and anticonvulsant.



Purity: 99.41%
Clinical Data: Launched
Size: 5 mg, 10 mg, 20 mg

Crocin II

Cat. No.: HY-N0698

Crocin II is isolated from the fruit of Gardenia jasminoides with antioxidant, anticancer, and antidepressant activity. Crocin II inhibits NO production with an IC_{50} value of 31.1 µM. Crocin II suppresses the expressions of protein and m-RNA of **iNOS** and **COX-2**.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Crocin III

Cat. No.: HY-N6644

Crocin III is a crocetin from saffron (Crocus sutivus L.). Crocetins inhibit cell growth of tumor cells and has anti-inflammatory activity. Crocins serve as spices and coloring agents.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Cromolyn sodium

(Disodium Cromoglycate; FPL-670)

Cat. No.: HY-B0320A

Cromolyn sodium (Disodium Cromoglycate; FPL-670) is an antiallergic drug. Cromolyn sodium is a **GSK-3β** inhibitor with an IC_{50} of 2.0 µM.



Purity: 99.10%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

CRT0066854

Cat. No.: HY-18713

CRT0066854 is a potent and selective atypical **PKC isoenzymes** inhibitor. CRT0066854 is against full-length (FL) **PKCι**, **PKCζ**, and **ROCK-II** kinases with IC_{50} values of 132 nM, 639 nM, and 620 nM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

CRTh2 antagonist 1

Cat. No.: HY-112265

CRTh2 antagonist 1 is a **CRTh2** antagonist with an **IC_{50}** of 89 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CRTh2 antagonist 3

Cat. No.: HY-135773

CRTh2 antagonist 3 is a potent **chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2)** antagonist. CRTh2 antagonist 3 enhances the activity of PDK1 toward a short peptide substrate, with an **EC_{50}** of 2 μM and a **K_d** of 8.4 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CRTH2-IN-1

(Ramatroban analog)

Cat. No.: HY-U00423

CRTH2-IN-1 (Ramatroban analog) is a selective **prostaglandin D2 receptor DP2** (**CRTH2**) antagonist with an IC_{50} of 6 nM in a human DP2 binding assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CTPI-2

Cat. No.: HY-123986

CTPI-2 is a third-generation mitochondrial citrate carrier **SLC25A1** inhibitor with a **K_D** of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

CTTHWGFTLC, CYCLIC

Cat. No.: HY-P1789

CTTHWGFTLC, CYCLIC is a cyclic peptide inhibitor for **matrix metalloproteinases MMP-2** and **MMP-9**. The **IC_{50}** value for MMP-9 is ~8 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CTTHWGFTLC, CYCLIC TFA

Cat. No.: HY-P1789A

CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for **matrix metalloproteinases MMP-2** and **MMP-9**. The **IC_{50}** value for MMP-9 is ~8 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cu(II) protoporphyrin IX

Cat. No.: HY-136476B

Cu (II) Protoporphyrin IX is used as a negative control for Zn (II) Protoporphyrin (an inihibitor of heme oxygenase).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CU-115

Cat. No.: HY-131945

CU-115 is a potent TLR8 antagonist (**IC_{50}=1.04 μM**), and shows selective for TLR8 over TLR7 (IC_{50}=>50 μM). CU-115 decreases TNF-α and IL-1β production activated by R-848 in THP-1 cells.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CU-3

Cat. No.: HY-121638

CU-3 is the racemate of (5Z,2E)-CU-3. (5Z,2E)-CU-3 is a potent and selective inhibitor against the α-isozyme of **DGK** with an **IC_{50}** value of 0.6 μM, competitively inhibits the affinity of DGKα for ATP with a **K_m** value of 0.48 mM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CU-CPT-8m

(TLR8-specific antagonist)

Cat. No.: HY-112050

CU-CPT-8m is a specific **TLR8** antagonist, with an **IC_{50}** of 67 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CU-CPT-9a

Cat. No.: HY-112667

CU-CPT-9a is a specific **TLR8** antagonist, with an IC_{50} of 0.5 nM.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CU-CPT17e

Cat. No.: HY-101929

CU-CPT17e is a potent multi-**Toll-like receptor** (**TLR**) agonist that activates **TLR3**, **TLR8**, and **TLR9**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CU-CPT9b

Cat. No.: HY-112051

CU-CPT9b is a specific **TLR8** antagonist, with an IC_{50} of 0.7 nM. CU-CPT9b shows high binding affinity towards TLR8 with a K_d of 21 nM.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CU-T12-9

Cat. No.: HY-110353

CU-T12-9 is a specific **TLR1/2** agonist with EC_{50} of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Cucurbitacin IIb

Cat. No.: HY-N1987

Cucurbitacin IIb is an active component isolated from **Hemsleya amabilis**, induces **apoptosis** with anti-inflammatory activity.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Cucurbitacin S

Cat. No.: HY-N0725

Cucurbitacin S is isolated from cucurbitaceae with anticancer and anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CUR61414

Cat. No.: HY-113965

CUR61414 is a novel, potent and cell permeable **Hedgehog signaling pathway inhibitor** (IC_{50} =100-200 nM). CUR61414 is a small-molecule aminoproline class compound and selectively binds to **smoothened (Smo)** with a K_i value of 44 nM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mg

Curculigoside

Cat. No.: HY-N0705

Curculigoside is the main saponin in C. orchioide, exerts significant antioxidant, anti-osteoporosis, antidepressant and neuroprotection effects. Curculigoside possesses significant anti-arthritic effects in vivo and in vitro via regulation of the **JAK/STAT/NF-κB** signaling pathway.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Curcumenol

((+)-Curcumenol)

Cat. No.: HY-N2259

Curcumenol ((+)-Curcumenol) is a potent **CYP3A4** inhibitor with an IC_{50} of 12.6 μM, which is one of constituents in the plants of medicinally important genus of Curcuma zedoaria, with neuroprotection, anti-inflammatory, anti-tumor and hepatoprotective activities.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 100 mg

Curcumin-d6 (Diferuloylmethane-d6; Natural Yellow 3-d6; Turmeric yellow-d6)

Cat. No.: HY-N0005S

Curcumin D6 (Diferuloylmethane D6) is a deuterium labeled Curcumin (Turmeric yellow). Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Curvularin

((S)-Curvularin)

Cat. No.: HY-N6770

Curvularin, a fungal metabolite and a potent mycotoxin naturally isolated from Curvularia lunata, inhibits cytokine-induced **nitric oxide synthase (iNOS)**, with an IC_{50} of 9.5 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CV-159

Cat. No.: HY-19025

CV-159 is a unique dihydropyridine Ca^{2+} antagonist with an anti-calmodulin (CaM) action, and has antiinflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CV1808

(2-Phenylaminoadenosine)

Cat. No.: HY-103183

CV1808 (2-Phenylaminoadenosine) is a non-selective **A2 adenosine receptor** (**A2 AR**) agonist with K_is of 76 and 1450 nM for A2A and A3 adenosine receptor subtypes, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

CXCL12 ligand 1

Cat. No.: HY-139906

CXCL12 ligand 1 is the first ligand of the sY12-binding pocket on chemokine **CXCL12**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CXCR2-IN-1

Cat. No.: HY-101022

CXCR2-IN-1 is a central nervous system penetrant **CXCR2** antagonists with a pIC_{50} of 9.3.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CXCR2-IN-2

Cat. No.: HY-120878

CXCR2-IN-2 is a selective, brain penetrant, and orally bioavailable **CXCR2** antagonist (IC_{50}=5.2 nM/1 nM in β-arrestin assay/CXCR2 Tango assay, respectively).



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CXCR7 antagonist-1

Cat. No.: HY-139643

CXCR7 antagonist-1 is an inhibitor of the binding of the **SDF-1** chemokine (also known as the **CXCL12** chemokine) or **I-TAC** (also known as **CXCL11**) to the chemokine receptor **CXCR**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CY-09

Cat. No.: HY-103666

CY-09 is a selective and direct **NLRP3** inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of **NLRP3 inflammasome** assembly and activation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Cy5.5

(Sulfo-Cyanine5.5)

Cat. No.: HY-D0924

Cy5.5 (Sulfo-Cyanine5.5) is a near-infrared fluorescent dye (Ex=673 nm, Em=707 nm) used to label biological molecules, such as peptides, proteins, and oligonucleotides.



Purity: 95.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Cyanidin 3-sambubioside chloride

(Cyanidin-3-O-sambubioside chloride)

Cat. No.: HY-N2533

Cyanidin 3-sambubioside chloride (Cyanidin-3-O-sambubioside chloride), a major anthocyanin, a natural colorant, and is a potent **NO** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyanuric acid-13C3

Cat. No.: HY-W010407S



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cycleanine

Cat. No.: HY-N2005

Cycleanine is a potent vascular selective **Calcium** antagonist. Cycleanine has analgesic, muscle relaxant and anti-inflammatory activities. Cycleanine has potential for anti-ovarian cancer acting through the **apoptosis** pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclic ADP-ribose

(cADPR)

Cat. No.: HY-N7395

Cyclic ADP-ribose (cADPR) is a potent second messenger for **calcium mobilization** that is synthesized from NAD^+ by an ADP-ribosyl cyclase.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 500 μg

Cyclic ADP-ribose ammonium

(cADPR ammonium)

Cat. No.: HY-N7395A

Cyclic ADP-ribose ammonium (cADPR ammonium) is a potent second messenger for **calcium mobilization** that is synthesized from NAD^+ by an ADP-ribosyl cyclase.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 500 μg

Cyclo(his-pro) (Cyclo(histidyl-proline); Histidylproline diketopiperazine)

Cat. No.: HY-101402

Cyclo(his-pro) (Cyclo(histidyl-proline)) is an orally active cyclic dipeptide structurally related to tyreotropin-releasing hormone. Cyclo(his-pro) could inhibit **NF-κB** nuclear accumulation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cyclo(his-pro) TFA (Cyclo(histidyl-proline) TFA; Histidylproline diketopiperazine TFA)

Cat. No.: HY-101402A

Cyclo(his-pro) TFA (Cyclo(histidyl-proline) TFA) is an orally active cyclic dipeptide structurally related to tyreotropin-releasing hormone. Cyclo(his-pro) TFA could inhibit **NF-κB** nuclear accumulation.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Cycloartenyl ferulate

(Cycloartenol ferulate; Cycloartenol ferulic acid ester)

Cat. No.: HY-125938

Cycloartenyl ferulate (Cycloartenol ferulate) is one of the typical triterpene alcohols and possesses several biological activities including anti-oxidative activity, antiallergic activity, anti-inflammatory and anticancer activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cycloastragenol

(Astramembrangenin; Cyclosieversigenin)

Cat. No.: HY-N1485

Cycloastragenol (Astramembrangenin), the active form of astragaloside IV, has anti-oxidant, anti-inflammatory, anti-aging, anti-apoptotic, and cardiovascular protective effects. Cycloastragenol is a potent **telomerase** activator and can lengthen telomeres.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Cyclobuxine D

Cat. No.: HY-N4080

Cyclobuxine D is a steroidal alkaloid extracted from Buxus microphylla. Cyclobuxine D has a significant bradycardic effect in the rat heart and an inhibitory action on **acetylcholine** and Ba^{++}-induced contraction of the longitudinal muscle isolated from the rabbit jejunum.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclosporin A

(Cyclosporine A; Ciclosporin A; CsA)

Cat. No.: HY-B0579

Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of **calcineurin** with an IC_{50} of 5 nM. Cyclosporin A also inhibits **CD11a/CD18** adhesion.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Cyclosporin A-Derivative 1

Cat. No.: HY-P1355

Cyclosporin A-Derivative 1 is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1. Cyclosporin A is an immunosuppressive agent which can bind to the cyclophilin and inhibit calcineurin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclosporin D

Cat. No.: HY-W019721

Cyclosporin D, a metabolite of Cyclosporin A, is a weak immunosuppressant. Cyclosporin D is used as internal standard for quantification of Cyclosporin A.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclosporin H

Cat. No.: HY-P1122

Cyclosporin H is a selective and potent inhibitor of **FPR-1 (formyl peptide receptor 1)**. Cyclosporin H, a **viral transduction** enhancer, increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs).



Purity: 99.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Cyclotriazadisulfonamide

(CADA)

Cat. No.: HY-134809

Cyclotriazadisulfonamide (CADA) is a specific **CD4**-targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP)-dependent way.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cynarin

(Cynarine)

Cat. No.: HY-N0359

Cynarin is an antichoke agent with a variety of biological activities including antioxidant, antihistamic and antiviral activities.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Cyperotundone

Cat. No.: HY-N3004

Cyperotundone is a sesquiterpene isolated from Nagarmotha (Cyperus rotundus).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Cystathionine-γ-lyase-IN-1

Cat. No.: HY-136211

Cystathionine-γ-lyase-IN-1 is a selective **cystathionine γ-lyase (CSE)** enzyme inhibitor with an IC_{50} of 6.3 μM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Cytochrome c-pigeon (88-104)

(PCC 88-104)

Cat. No.: HY-P1089

Cytochrome c-pigeon (88-104) (PCC 88-104) has full stimulatory activity for pigeon cytochrome c-primed T cells from B10.A mice. The I-E^k-restricted T cell response to Cytochrome c pigeon (pcyt c) is specific for the COOH-terminal sequence 88-104.

KAERADLIAYLKQATAK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CZC24832

Cat. No.: HY-15294

CZC24832 is a highly selective and potent **PI3Kγ** inhibitor (IC_{50}=27 nM) with apparent dissociation constants (K_d^{app}) of 19 nM.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

D(+)-Galactosamine hydrochloride

(D-Galactosamine hydrochloride)

Cat. No.: HY-42682

D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 50 mg

D-(-)-Quinic acid

Cat. No.: HY-N0464

D-(-)-Quinic acid is a cyclohexanecarboxylic acid and is implicated in the perceived acidity of coffee.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

D-Cl-amidine

Cat. No.: HY-100574C

D-Cl-amidine is a potent and highly selective **PAD1** inhibitor. D-Cl-amidine is well-torelated with no significant toxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

D-Glucuronic acid

Cat. No.: HY-N6612

D-Glucuronic acid is an important intermediate isolated from many gums. D-Glucuronic acid and its derivative glucuronolactone are as a liver antidote in the prophylaxis of human health. D-Glucuronic acid has an anti-inflammatory effect for the skin.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

D-Mannuronic acid sodium

Cat. No.: HY-N7703

D-Mannuronic acid sodium, isolated from Macrocystis pyrifera, has the potential in autoimmune encephalomyelitis (EAE), adjuvant induced arthritis (AIA), nephrotic syndrome, and acute glomerulonephritis studies.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

D-Melibiose

Cat. No.: HY-107824

D-Melibiose is a disaccharide which is composed of one galactose and one glucose moiety in an alpha (1-6) glycosidic linkage.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

D-Panthenol

(Dexpanthenol)

Cat. No.: HY-B1391

D-Panthenol is the biologically-active alcohol of pantothenic acid, which leads to an elevation in the amount of coenzyme A in the cell.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

D-Pinitol

(3-O-Methyl-D-chiro-inositol)

Cat. No.: HY-N0655

D-pinitol (3-O-Methyl-D-chiro-inositol) is a natural compound presented in several plants, like Pinaceae and Leguminosae plants. D-pinitol exerts hypoglycemic activity and protective effects in the cardiovascular system. D-pinitol has antiviral and larvicidal activities.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

D-Ribose(mixture of isomers)

Cat. No.: HY-W018772

D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

D-Trimannuronic acid

Cat. No.: HY-N7699A

D-Trimannuronic acid, an alginate oligomer is extracted from seaweed. D-Trimannuronic acid can induce TNFα secretion by mouse macrophage cell lines. D-Trimannuronic acid can be used for the research of pain and vascular dementia.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate; (R)-2-Hydroxyglutaric acid; ...)

Cat. No.: HY-113038

D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

D-α-Hydroxyglutaric acid disodium

(Disodium (R)-2-hydroxyglutarate)

Cat. No.: HY-100542

D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

D18024

Cat. No.: HY-U00210

D18024 is a phthalazinonderivat antiallergic and antihistaminic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

D75-4590

Cat. No.: HY-134655

D75-4590, a pyridobenzimidazole derivative and a **β-1,6-glucan** synthesis inhibitor, possesses antifungal activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DA-JC4

Cat. No.: HY-P3255

DA-JC4 is a dual **GLP-1/GIP receptor** agonist and can be used for the research of neurological disease and insulin signaling pathways.

Purity: 96.57%
Clinical Data: No Development Reported
Size: 5 mg

DAGLβ-IN-1

Cat. No.: HY-18551

DAGLβ-IN-1 is an inhibitor of **diacylglycerol lipase-β (DAGLβ)**, serves as a versatile intermediate for the design of DAGL-tailored activity-based probes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dagrocorat

(PF-00251802)

Cat. No.: HY-16718

Dagrocorat (PF-00251802) is an orally active and selective high-affinity partial agonist of the **glucocorticoid receptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dagrocorat hydrochloride

(PF-00251802 hydrochloride)

Cat. No.: HY-16718A

Dagrocorat (PF-00251802) hydrochloride is an orally active and selective high-affinity partial agonist of the **glucocorticoid receptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dahurinol

Cat. No.: HY-N6907

Dahurinol is a natural compound isolated from Cimicifuga acerina.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Damascenone

((E/Z)-Damascenone)

Cat. No.: HY-N2543

Damascenone ((E/Z)-Damascenone) is an active compound of Epipremnum pinnatum with anti-inflammatory activity. Damascenone is a mixture complex of E-isomer-Damascenone and Z-isomer Damascenone.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Damnacanthal

Cat. No.: HY-108485

Damnacanthal is an anthraquinone isolated from the root of Morinda citrifolia. Damnacanthal is a highly potent, selective inhibitor of **p56^{lck} tyrosine kinase** activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Danicopan

(ACH-4471)

Cat. No.: HY-117930

Danicopan (ACH-4471), a selective and orally active small-molecule **factor D** inhibitor, shows high binding affinity to human Factor D with K_d value of 0.54 nM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 90 mg, 100 mg

Danirixin

(GSK1325756)

Cat. No.: HY-19768

Danirixin is a selective, and reversible **CXCR2** antagonist, with IC_{50}of12.5 nM for CXCL8.



Purity: 98.21%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Dapansutrile

Cat. No.: HY-17629

Dapansutrile is a potent, selective and orally active inhibitor of **NLRP3 inflammasome**. Anti-inflammatory, analgesic activity.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg

Daphnetin

(7,8-Dihydroxycoumarin)

Cat. No.: HY-N0281

Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative isolated from plants of the Genus Daphne, is a **protein kinase** inhibitor, with IC_{50}s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively.



Purity: 99.21%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Daphylloside

Cat. No.: HY-N6245

Daphylloside is an iridoid isolated from the aerial parts of Galium verum.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dapsone

(4,4′-Diaminodiphenyl sulfone; DDS)

Cat. No.: HY-B0688

Dapsone (4,4′-Diaminodiphenyl sulfone) is an orally active and blood-brain penetrant sulfonamide **antibiotic** with bacteriostatic, antimycobacterial and antiprotozoal activities.



Purity: 99.22%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Dapsone-d8

(4,4′-Diaminodiphenyl sulfone-d8; DDS-d8)

Cat. No.: HY-B0688S

Dapsone D8 (4,4′-Diaminodiphenyl sulfone D8) is a deuterium labeled Dapsone. Dapsone is an orally active and blood-brain penetrant sulfonamide **antibiotic** with bacteriostatic, antimycobacterial and antiprotozoal activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

DAPT

(GSI-IX)

Cat. No.: HY-13027

DAPT (GSI-IX) is a potent and orally active **γ-secretase** inhibitor with IC_{50}s of 115 nM and 200 nM for total **amyloid-β (Aβ)** and $Aβ_{42}$, respectively. DAPT inhibits the activation of **Notch 1** signaling and induces cell differentiation.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Daratumumab

(Anti-Human CD38, Human Antibody)

Cat. No.: HY-P9915

Daratumumab (Anti-Human CD38) is the first-in-class human-specific **anti-CD38** monoclonal antibody. Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

Daratumumab

Purity: 98.70%
Clinical Data: Launched
Size: 1 mg, 5 mg

Darbufelone

(CI-1004)

Cat. No.: HY-101438

Darbufelone is a dual inhibitor of cellular $PGF_{2α}$ and LTB_4 production. Darbufelone potently inhibits **PGHS-2** (IC_{50}= 0.19 μM) but is much less potent with **PGHS-1** (IC_{50}=20 μM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Darbufelone mesylate

(CI-1004 mesylate) Cat. No.: HY-101438A

Darbufelone mesylate (CI-1004 mesylate) is a dual inhibitor of cellular $PGF_{2\alpha}$ and LTB_4 production. Darbufelone potently inhibits **PGHS-2** (IC_{50} = 0.19 μM) but is much less potent with **PGHS-1** (IC_{50}= 20 μM).



Purity: 98.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Darunavir

(TMC114; UIC-94017) Cat. No.: HY-17040

Darunavir (TMC114), an orally active next generation **HIV protease** inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Darunavir-d9

(TMC114-d9; UIC-94017-d9) Cat. No.: HY-112585

Darunavir-d9 (TMC114-d9) is the deuterium labeled Darunavir. Darunavir (TMC114), an orally active next generation **HIV protease** inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Darutigenol

Cat. No.: HY-N3003

Darutigenol is an ent-pimarane-type diterpenoid isolated from Siegesbecikia orientalis L..



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Darutoside

Cat. No.: HY-N6028

Darutoside is a diterpenoid isolated from Siegesbeckia.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Dauricine

Cat. No.: HY-N0220

Dauricine, a bisbenzylisoquinoline alkaloid in Asiatic Moonseed Rhizome, possesses anti-inflammatory activity. Dauricine inhibits cell proliferation and invasion, and induces apoptosis by suppressing **NF-κB** activation in a dose- and time-dependent manner in colon cancer.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Dazcapistat

Cat. No.: HY-132850

Dazcapistat is a potent **calpain** inhibitor, with IC_{50}s of <3 μM for calpain 1, calpain 2 and calpain 9, respectively (patent WO2018064119A1, compound 405).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dazoxiben

Cat. No.: HY-106067A

Dazoxiben is a potent and orally active **thromboxane (TX) synthase** inhibitor.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dazucorilant

(CORT113176) Cat. No.: HY-132811

Dazucorilant (CORT113176) is a selective and high affinity non-steroidal glucocorticoid receptor (**GR**) modulator with a K_i value 1 nM in vitro. Dazucorilant can be used for the research of neurological disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DCEBIO

Cat. No.: HY-102052

DCEBIO, a derivative of 1-EBIO, is an extremely potent activator of **Cl^- secretion** in T84 colonic cells. DCEBIO stimulates Cl^- secretion via the activation of hIK1 K^+ channels and the activation of an apical membrane Cl^- conductance.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg

DCVC

(S-[(1E)-1,2-dichloroethenyl]--L-cysteine)

Cat. No.: HY-19717

DCVC (S-[(1E)-1,2-dichloroethenyl]--L-cysteine) is a bioactive metabolite of trichloroethylene (TCE). DCVC inhibits pathogen-stimulated pro-inflammatory cytokines IL-1β, IL-8, and **TNF-α** release from tissue cultures.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DDR1-IN-2

Cat. No.: HY-U00444

DDR1-IN-2 is a potent inhibitor of **discoidin domain receptor 1** (**DDR1**), with an IC_{50} of 13.1 nM, and also less potently inhibits DDR2, with an IC_{50} of 203 nM.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

DDR1-IN-4

Cat. No.: HY-114173

DDR1-IN-4 (Compound 2.45) is a selective and potent **Discoidin Domain Receptor 1 (DDR1)** autophosphorylation inhibitor, with IC_{50} values of 29 nM and 1.9 μM for DDR1 and DDR2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Deacetylasperulosidic Acid

Cat. No.: HY-N0594

Deacetylasperulosidic acid (DAA) is a major phytochemical constituent of Morinda citrifolia fruit. Deacetylasperulosidic acidhas antioxidant activity by increasing superoxide dismutase activity.



Purity: 98.33%
Clinical Data: Phase 4
Size: 5 mg, 10 mg, 20 mg

Deapi-platycodin D3

Cat. No.: HY-N3520

Deapi-platycodin D3 is a triterpenoid saponin from the roots of Platycodon grandiflorum.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Decanoyl-RVKR-CMK

(DecRVKRcmk)

Cat. No.: HY-107760

Decanoyl-RVKR-CMK (DecRVKRcmk) inhibits over-expressed gp160 processing and HIV-1 replication.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Decarboxy Moxifloxacin

Cat. No.: HY-135398

Decarboxy Moxifloxacin (compound 8) is a decarboxylated compound of Moxifloxacin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Decernotinib

(VX-509; VRT-831509)

Cat. No.: HY-12469

Decernotinib is a potent, orally active **JAK3** inhibitor, with K_is of 2.5, 11, 13 and 11 nM for **JAK3**, JAK1, JAK2, and TYK2, respectively.



Purity: 99.45%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Decloxizine

(UCB-1402; NSC289116)

Cat. No.: HY-17582

Decloxizine(UCB-1402; NSC289116) is a histamine 1 receptor antagonist.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Decloxizine dihydrochloride

(UCB 1402 dihydrochloride)

Cat. No.: HY-A0075

Decloxizine dihydrochloride(UCB-1402; NSC289116) is a histamine 1 receptor antagonist.



Purity: 98.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Decursin

((+)-Decursin)

Cat. No.: HY-18981

Decursin ((+)-Decursin) is a cytotoxic agent and a potent **protein kinase C** activator from the Root of Angelica gigas. Decursin inhibits tumor growth, migration, and invasion in gastric cancer by down-regulating CXCR7 expression.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Decursinol

Cat. No.: HY-N4109

Decursinol, isolated from the roots of Angelica gigas, possesses antinociceptive effect with orally bioavailability. Decursinol possesses anti-tumor and anti-metastasis activity.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Decursinol angelate

Cat. No.: HY-N4322

Decursinol angelate, a cytotoxic and **protein kinase C (PKC)** activating agent from the root of Angelica gigas, possesses anti-tumor and anti-inflammatory activities.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Defibrotide sodium

Cat. No.: HY-108746

Defibrotide sodium is a complex mixture of single stranded polydeoxyribonucleotides. Defibrotide sodium has liver protection, anti-inflammatory, antithrombotic, profibrinolytic, and anti-ischemic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Deflazacort

Cat. No.: HY-13609

Deflazacort, a glucocorticoid, is an inactive prodrug and is converted rapidly to the active metabolite 21-desacetyldeflazacort. Deflazacort is used as an anti-inflammatory and immunosuppressant.



Purity: 99.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Deflazacort-D5

Cat. No.: HY-13609S

Deflazacort-D5 is the deuterium labeled Deflazacort. Deflazacort, a glucocorticoid, is an inactive prodrug and is converted rapidly to the active metabolite 21-desacetyldeflazacort. Deflazacort is used as an anti-inflammatory and immunosuppressant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Deflazacort-D7

Cat. No.: HY-13609S1

Deflazacort-D7 is the deuterium labeled Deflazacort. Deflazacort, a glucocorticoid, is an inactive prodrug and is converted rapidly to the active metabolite 21-desacetyldeflazacort. Deflazacort is used as an anti-inflammatory and immunosuppressant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Dehydroabietic acid

Cat. No.: HY-N6869

Dehydroabietic acid possesses antiviral activity.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Dehydroandrographolide succinate

Cat. No.: HY-N0677

Dehydroandrographolide succinate, extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used for the treatment of viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Dehydroandrographolide succinate potassium sodium salt

Cat. No.: HY-N0677B

Dehydroandrographolide succinate (potassium sodium salt), extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used for the treatment of viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective...



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 20 mg

Dehydrobruceine A

Cat. No.: HY-N8257

Dehydrobruceine A is a low potent antitrypanosomal agent, with an IC_{50} of 88.5 nM for Plasmodium falciparum.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dehydrocurdione

Cat. No.: HY-N8160

Dehydrocurdione, a zedoary-derived sesquiterpene, induces heme oxygenase (**HO**)-**1**, an antioxidative enzyme, in RAW 264.7 macrophages. Dehydrocurdione interacts with **Keap1**, resulting in Nrf2 translocation followed by activation of the HO-1 E2 enhancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dehydrodiisoeugenol

Cat. No.: HY-N0589

Dehydrodiisoeugenol is isolated from Myristica fragrans Houtt, shows anti-inflammatory and anti-bacterial actions. Dehydrodiisoeugenol inhibits LPS- stimulated **NF-κB** activation and cyclooxygenase (**COX**)-2 gene expression in murine macrophages.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Dehydroeburicoic acid monoacetate

(3-O-Acetyldehydroeburicoic acid)

Cat. No.: HY-N4125

Dehydroeburicoic acid monoacetate (Compound 18) is a lanostane triterpenoid isolated from Wolfiporia cocos.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Dehydroevodiamine

Cat. No.: HY-N2106

Dehydroevodiamine is a major bioactive quinazoline alkaloid isolated from Evodiae Fructus, has an antiarrhythmic effect in guinea-pig ventricular myocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Dehydroevodiamine hydrochloride

Cat. No.: HY-N6029

Dehydroevodiamine hydrochloride is isolated from the leaves of Evodia rutaecarpa.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Dehydroglyasperin C

Cat. No.: HY-N7335

Dehydroglyasperin C, a isoflavone, is a potent **NAD(P)H:oxidoquinone reductase (NQO1)** and **phase 2 enzyme** inducer. Dehydroglyasperin C has antioxidant, neuroprotective, cancer chemopreventive, and anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dehydroleucodine

Cat. No.: HY-122295

Dehydroleucodine is a sesquiterpene lactone isolated from Gynoxys verrucosa. Dehydroleucodine is a mast cell stabilizer that inhibits tmast cell degranulation induced by compound 48/80. Dehydroleucodine inudces cells **apoptosis**, and has gastric ulcer inhibition and antileukemic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dehydrotrametenolic acid

Cat. No.: HY-N2490

Dehydrotrametenolic acid is a sterol isolated from the sclerotium of Poria cocos. Dehydrotrametenolic acid induces **apoptosis** through **caspase-3** pathway. Dehydrotrametenolic acid has anti-tumor activity, anti-inflammatory, anti-diabetic effects.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Delavinone

(Sinpeinine A)

Cat. No.: HY-107273

Delavinone (Sinpeinine A) is an alkaloid. Delavinone is suitable for electrospray ionization (ESI) positive electrode detection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Delcasertib

(KAI-9803; BMS-875944) Cat. No.: HY-106262

Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (**δPKC**) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).



Purity: 98.21%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg

Delcasertib hydrochloride

(KAI-9803 hydrochloride; BMS-875944 hydrochloride) Cat. No.: HY-106262B

Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (**δPKC**) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).



Purity: 98.11%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Delgocitinib

(JTE-052) Cat. No.: HY-109053

Delgocitinib (JTE-052) is a specific **JAK** inhibitor with **IC_{50}**s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Deloxolone

Cat. No.: HY-U00278

Deloxolone has the potential for inflammatory, ischemic and proliferative diseases treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Demethoxycurcumin

(Curcumin II; Desmethoxycurcumin; Monodemethoxycurcumin) Cat. No.: HY-N0006

Demethoxycurcumin(Curcumin II) is a major active curcuminoid; possess anti-inflammatory properties; also exert cytotoxic effects in human cancer cells via induction of apoptosis. IC50 value: Target: in vitro: DMC significantly decreased NO secretion by 35-41% in our inflamed cell model.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Demethyleneberberine

Cat. No.: HY-N0592

Demethyleneberberine is a natural mitochondria-targeted antioxidant. Demethyleneberberine alleviates mice colitis and inhibits the inflammatory responses by inhibiting **NF-κB** pathway and regulating the balance of Th cells.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Demethylsuberosin

(7-Demethylsuberosin) Cat. No.: HY-N2488

Demethylsuberosin (7-Demethylsuberosin) is a coumarin compound isolated from Angelica gigas Nakai, and has anti-inflammatory activity.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Demethylzeylasteral

Cat. No.: HY-N0587

Demethylzeylasteral is a triterpene compound isolated from Tripterygium wilfordii Hook F, with anti-inflammatory, immunosuppressive and anti-tumor activities. Demethylzeylasteral can significantly alleviates atherosclerosis (AS).



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Deoxyandrographolide

Cat. No.: HY-N0857

Deoxyandrographolide suppresses LPS induced increase in mRNA levels of iNOS as well as production of proinflammatory mediators TNF-α and IL-6. Deoxyandrographolide potentiates NGF-induced neurite outgrowth.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Deoxylimonin

Cat. No.: HY-N7640

Desoxylimonin is a triterpenoid compound isolated from grapefruit seed. Desoxylimonin derivatives has better anticancer, analgesic and anti-inflammatory activitythan the lead compound.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 1 mg

Deprodone propionate

(RD20000) Cat. No.: HY-U00190

Deprodone propionate (RD20000) is a corticosteroid which is obtained by esterifying with propionic acid the 17-position of the prednisolone skeleton and deoxidating its 21-position.



Purity: 99.18%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Deracoxib

(SC 046; SC 46; SC 59046) Cat. No.: HY-17509

Deracoxib, a selective cyclooxygenase-2 inhibitor, is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID).



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Dermorphin Analog

Cat. No.: HY-P1577

Dermorphin Analog is an analog of Dermorphin. Dermorphin is a natural heptapeptide **μ-opioid receptor** agonist found in amphibian skin.

Y-d-RF-Sar-YPS-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Desfluoro-atorvastatin

Cat. No.: HY-135373

Desfluoro-atorvastatin is an impurity of Atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Desisobutyryl-ciclesonide

(CIC-AP; Ciclesonide active principle) Cat. No.: HY-111490

Desisobutyryl-ciclesonide is the active metabolite of Ciclesonide. Desisobutyryl-ciclesonide has affinity for the **glucocorticoid receptor**.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Desloratadine

(Sch34117) Cat. No.: HY-B0539

Desloratadine (Sch34117) is the orally active major metabolite of the nonsedating **H1-antihistamine** Loratadine. Desloratadine is a selective **H1-receptor** antagonist that has anti-allergic and anti-inflammatory activities.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Desmethyl Celecoxib

Cat. No.: HY-118139

Desmethyl Celecoxib (compound 3b) is a selective cyclooxygenase-2 (**COX-2**) inhibitor (IC_{50}=32 nM) with anti-inflammatory activities. Desmethyl Celecoxib is an analog of Celecoxib and with the optimal yield of 75%.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Desmethyl Ketoprofen

Cat. No.: HY-131118

Desmethyl Ketoprofen has anti-inflammatory activities. Desmethyl Ketoprofen can be used for the study of angiogenesis-related disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Desonide

Cat. No.: HY-B0248

Desonide is a nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses. Target: Glucocorticoid Receptor Desonide is a low-potency topical corticosteroid that has been used for decades in the treatment of steroid-responsive dermatoses .



Purity: 99.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Desoximetasone

Cat. No.: HY-17570

Desoximetasone(Topicort) is a medication belonging to the family of medications known as topical corticosteroids; is used for the relief of various skin conditions, including rashes.



Purity: 99.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Deucravacitinib

(BMS-986165) Cat. No.: HY-117287

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric **TYK2** inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC_{50}=1.0 nM) and blocks receptor-mediated Tyk2 activation by...



Purity: 99.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Deuruxolitinib

(CTP-543; Ruxolitinib D8; Deuterated Ruxolitinib) Cat. No.: HY-50856S

Deuruxolitinib (CTP-543), a deuterated Ruxolitinib, modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dexamethasone

(Hexadecadrol; Prednisolone F) Cat. No.: HY-14648

Dexamethasone (Hexadecadrol) is a **glucocorticoid receptor** agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Dexamethasone 9,11-epoxide

Cat. No.: HY-N0348

Dexamethasone 9,11-epoxide, a compound extracted from patent CN 106520896 A and RU 2532902 C1, is an intermediate in the preparation of dexamethasone.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Dexamethasone acetate

(Dexamethasone 21-acetate; Hexadecadrol acetate) Cat. No.: HY-14648A

Dexamethasone acetate (Dexamethasone 21-acetate) is a **glucocorticoid receptor** agonist. Dexamethasone acetate has the potential for ophthalmic infections treatment.



Purity: 98.24%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Dexamethasone palmitate

(DXP) Cat. No.: HY-128922

Dexamethasone palmitate (DXP) is a prodrug of Dexamethasone, which is a glucocorticoid receptor agonist. Dexamethasone palmitate (DXP) has a 47-fold lower affinity for the glucocorticoid receptor than Dexamethasone. Anti-inflammatory agent.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dexamethasone phosphate disodium

(Dexamethasone 21-phosphate disodium salt) Cat. No.: HY-B1829A

Dexamethasone phosphate disodium is a **glucocorticoid receptor** agonist.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Dexchlorpheniramine maleate

(S-(+)-Chlorpheniramine maleate salt) Cat. No.: HY-B1062

Dexchlorpheniramine maleate is an antihistamine, with anticholinergic properties, used to treat allergic conditions.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg

Dextran sulfate sodium salt (MW 16000-24000)

Cat. No.: HY-116282B

Dextran sulfate sodium salt (MW 16000-24000) is a is a polymer of anhydroglucose with the molecular weight range of 16000-24000. Dextran sulfate sodium salt inhibits the replication of the human immunodeficiency virus by preventing the adsorption of the virus into host cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Dextran sulfate sodium salt (MW 35000-45000)

Cat. No.: HY-116282C

Dextran sulfate sodium salt (MW 35000-45000) is a is a polymer of anhydroglucose with the molecular weight range of 35000-45000. Dextran sulfate sodium salt inhibits the replication of the human immunodeficiency virus by preventing the adsorption of the virus into host cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Dextran sulfate sodium salt (MW 4500-5500)

Cat. No.: HY-116282A

Dextran sulfate sodium salt (MW 4500-5500) is a is a polymer of anhydroglucose with the molecular weight range of 4500-5500. Dextran sulfate sodium salt inhibits the replication of the human immunodeficiency virus by preventing the adsorption of the virus into host cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Dextran sulfate sodium salt (MW 450000-550000)

Cat. No.: HY-116282D

Dextran sulfate sodium salt (MW 450000-550000) is a is a polymer of anhydroglucose with the molecular weight range of 450000-550000. Dextran sulfate sodium salt inhibits the replication of the human immunodeficiency virus by preventing the adsorption of the virus into host cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

DFP00173

Cat. No.: HY-126073

DFP00173 is a potent and selective **aquaporin-3 (AQP3)** inhibitor. DFP00173 inhibits mouse and human AQP3 with an IC_{50} of 0.1-0.4 μM. DFP00173 is selective for AQP3 over the homologous AQP isoforms AQP7 and AQP9.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DGK-IN-1

Cat. No.: HY-135898

DGK-IN-1 is a T cell activator extracted from patent WO2020006018A1, example 25. DGK-IN-1 can be used for tumor immunity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DHODH-IN-11

Cat. No.: HY-135675

DHODH-IN-11 (Compound 14b) is a Leflunomide derivative and a weak **dihydroorotate dehydrogenase (DHODH)** inhibitor with a pK_a of 5.03.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DHODH-IN-12

Cat. No.: HY-135676

DHODH-IN-12 (Compound 12b) is a Leflunomide derivative and a weak **dihydroorotate dehydrogenase (DHODH)** inhibitor with a pK_a of 5.07.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DHODH-IN-13

Cat. No.: HY-135677

DHODH-IN-13 (Compound 7a) is a hydroxyfurazan analog of A771726. DHODH-IN-13 is a **dihydroorotate dehydrogenase (DHODH)** inhibitor with an IC_{50} of 4.3 μM for **rat liver DHODH**. DHODH-IN-13 can be used for rheumatoid arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DHODH-IN-14

Cat. No.: HY-135678

DHODH-IN-14 (Compound 7l) is a hydroxyfurazan analog of A771726. DHODH-IN-14 is a **dihydroorotate dehydrogenase (DHODH)** inhibitor with an IC_{50} of 0.49 μM for **rat liver DHODH**. DHODH-IN-14 can be used for rheumatoid arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DHODH-IN-15

Cat. No.: HY-135679

DHODH-IN-15 (Compound 7b) is a hydroxyfurazan analog of A771726. DHODH-IN-15 is a **dihydroorotate dehydrogenase (DHODH)** inhibitor with an IC_{50} of 11 μM for **rat liver DHODH**. DHODH-IN-15 can be used for rheumatoid arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DHODH-IN-4

Cat. No.: HY-135619

DHODH-IN-4 (compound 17) is a human and Plasmodium falciparum **dihydroorotate dehydrogenase (DHODH)** inhibitor, with IC_{50} values of 4 μM and 0.18 μM for PfDHODH and HsDHODH, respectively. DHODH-IN-4 (compound 17) possess antimalarial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Di((Z)-Non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate

Cat. No.: HY-139298

Di((Z)-Non-2-en-1-yl)9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate can be used for synthetic liposomes, from the patent WO-2011153493-A2, compound 1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Di-O-methyldemethoxycurcumin

Cat. No.: HY-N7275

Di-O-methyldemethoxycurcumin, a curcuminoid analog, inhibits **IL-6** production with an EC_{50} of 16.20 μg/mL. Anti-inflammatory and antioxidant properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

diABZI STING agonist-1

Cat. No.: HY-112921A

diABZI STING agonist-1 is a selective stimulator of interferon genes **(STING)** receptor agonist, with EC_{50}s of 130, 186 nM for human and mouse, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

diABZI STING agonist-1 (Tautomerism)

Cat. No.: HY-112921

diABZI STING agonist-1 Tautomerism (compound 3) is a selective stimulator of interferon genes **(STING)** receptor agonist, with EC_{50}s of 130, 186 nM for human and mouse, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

diABZI STING agonist-1 trihydrochloride

Cat. No.: HY-112921B

diABZI STING agonist-1 (trihydrochloride) is a selective stimulator of interferon genes **(STING)** receptor agonist, with EC_{50}s of 130, 186 nM for human and mouse, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Diacerein

(Diacerhein; Diacetylrhein)

Cat. No.: HY-N0283

Diacerein (Diacerhein), a interleukin-1 beta inhibitor, is a slow-acting medicine of the class anthraquinone used to treat joint diseases.



Purity: 98.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Diacetoxyscirpenol

Cat. No.: HY-N6692

Diacetoxyscirpenol (DAS) is a trichothecene mycotoxin, a secondary metabolite product of fungi. Diacetoxyscirpenol (DAS) consumption induces haematological disorders (neutropenia, aplastic anemia) in human and animals.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Diammonium Glycyrrhizinate

Cat. No.: HY-N6804

Diammonium Glycyrrhizinate, isolated from the licorice root, is a widely used anti-inflammatory agent.



Purity: 99.04%
Clinical Data: Launched
Size: 5 mg, 10 mg, 20 mg

Diarylalkane derivative 1

Cat. No.: HY-U00384

Diarylalkane derivative 1 is used for the research of pancreatitis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Diatrizoic acid

(Diatrizoate; Amidotrizoic acid)

Cat. No.: HY-B0926

Diatrizoic acid (Diatrizoate) is an iodinated radiocontrast agent and has the potential for radiographic imaging of the airways. Diatrizoic acid induces mitochondrial turnover and oxidative stress, and activating apoptosis by dysregulating calcium.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Dichlorisone acetate

Cat. No.: HY-B1383

Dichlorisone acetate is a synthetic glucocorticoid corticosteroid used as an anti-inflammatory agent.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mg, 50 mg

Diclofenac

Cat. No.: HY-15036

Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a **COX** inhibitor, with IC_{50}s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Diclofenac diethylamine

Cat. No.: HY-15036A

Diclofenac diethylamine is a potent and nonselective anti-inflammatory agent, acts as a **COX** inhibitor, with IC_{50}s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Diclofenac potassium

Cat. No.: HY-15038

Diclofenac potassium is a potent and nonselective anti-inflammatory agent, acts as a **COX** inhibitor, with IC_{50}s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

Diclofenac Sodium

(GP 45840)

Cat. No.: HY-15037

Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a **COX** inhibitor, with IC_{50}s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g

Dicloxacillin Sodium hydrate

(Dicloxacillin sodium salt monohydrate)

Cat. No.: HY-B0977

Dicloxacillin Sodium hydrate (Dicloxacillin sodium salt monohydrate) is a narrow-spectrum β-Lactam antibiotic of the penicillin class, is used to treat infections caused by susceptible Gram-positive bacteria, active against beta-lactamase-producing organisms such...



Purity: 98.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Diethyl fumarate

Cat. No.: HY-W010056

Diethyl fumarate is a decomposition product of Malathion (an insecticide). Diethyl fumarate is a reputed skin irritant. Diethyl fumarate can causes non-immunologic contact urticaria on skin.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Difamilast

(OPA-15406)

Cat. No.: HY-109085

Difamilast (OPA-15406) is a topical, selective and nonsteroidal **phosphodiesterase-4 (PDE4)** inhibitor with particularly efficient inhibition of **subtype B** (IC_{50}=11.2 nM). Difamilast can be used for the research of mild to moderate atopic dermatitis (AD).



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Diffractaic acid

Cat. No.: HY-N2399

Diffractaic acid, a major constituent of U. longissimi, acts as an effective proapoptotic agent in various disorders research. Diffractaic acid is the analgesic and antipyretic component of Usnea diffracta.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Diflapolin

Cat. No.: HY-128171

Diflapolin is a highly active dual 5-lipoxygenase-activating protein **(FLAP)**/soluble epoxide hydrolase **(sEH)** inhibitor with marked anti-inflammatory efficacy and high target selectivity.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Diflorasone

Cat. No.: HY-A0158

Diflorasone act as a **corticosteroid hormone receptor** agonist with anti-inflammatory and immunosuppressive properties. Diflorasone enters the cell by diffusion across the cell membrane and binds to the glucocorticoid receptor (GR) in the cytoplasm.



Purity: 99.62%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Diflorasone diacetate

Cat. No.: HY-107961

Diflorasone diacetate is an anti-inflammatory steroid compound used as locally or topically agent. Diflorasone diacetate is being used for skin disorders to control corticosteroid-responsive dermatoses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Difloxacin

Cat. No.: HY-121272

Difloxacin is an antimicrobial agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Difloxacin-d3 hydrochloride trihydrate

Cat. No.: HY-121272AS

Difloxacin D3 hydrochloride trihydrate is a deuterium labeled Difloxacin. Difloxacin is an antimicrobial agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Diflucortolone valerate

Cat. No.: HY-U00058

Diflucortolone valerate is a powerful corticosteroid used topically for the research of various skin diseases.



Purity: 99.48%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg

Diflumidone

(R807)

Cat. No.: HY-100139

Diflumidone is a non-steroidal antiinflammatory drug.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Diflunisal

(MK-647)

Cat. No.: HY-18342

Diflunisal (MK-647) is a salicylate derivative with nonsteroidal anti-inflammatory and uricosuric properties, which is used alone as an analgesic and in rheumatoid arthritis patients. The mechanism of action of diflunisal is as a Cyclooxygenase (**COX**) Inhibitor.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Difluprednate

Cat. No.: HY-17569

Difluprednate(Durezol) is a corticosteroid, approved difluprednate for the treatment of post-operative ocular inflammation and pain. IC50 value: Target: Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a U.S.



Purity: 99.53%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Digeranyl bisphosphonate

(DGBP)

Cat. No.: HY-U00145

Digeranyl bisphosphonate (DGBP) is a potent geranylgeranylpyrophosphate (GGPP) synthase inhibitor, which inhibits geranylgeranylation of Rac1.



Purity: 81.48%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

Digoxigenin

(Lanadigenin)

Cat. No.: HY-B1025

Digoxigenin is a hapten, a small molecule with high antigenicity, that is used in many molecular biology applications, as an alternative probe labeling for in situ hybridization.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Dihomo-γ-linolenic acid

(all-cis-8,11,14-Eicosatrienoic acid)

Cat. No.: HY-A0143

Dihomo-γ-linolenic acid (all-cis-8,11,14-Eicosatrienoic acid) is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dihydro Dutasteride

Cat. No.: HY-135385

Dihydro Dutasteride is a metabolite of Dutasteride. Dutasteride is a potent inhibitor of both 5 alpha-reductase isozymes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dihydroberberine

Cat. No.: HY-N1934

Dihydroberberine inhibits **human ether-a-go-go-related gene (hERG)** channels and remarkably reduces **heat shock protein 90 (Hsp90)** expression and its interaction with hERG.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Dihydrocaffeic acid

(3,4-Dihydroxy-benzenepropanoic acid)

Cat. No.: HY-N2406

Dihydrocaffeic acid is a phenolic acid found in Gynura bicolor, reduces phosphorylation of **MAPK p38** and prevent UVB-induced skin damage. Antioxidant potential and anti-inflammatory activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Dihydrocucurbitacin B

Cat. No.: HY-N4171

Dihydrocucurbitacin B, a triterpene isolated from Cayaponia tayuya roots, inhibits nuclear factor of activated T cells (**NFAT**), induces cell cycle arrested in the G0 phase, and inhibits delayed type hypersensitivity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dihydrokaempferol

Cat. No.: HY-N2897

Dihydrokaempferol is isolated from Bauhinia championii (Benth). Dihydrokaempferol induces **apoptosis** and inhibits Bcl-2 and Bcl-xL expression. Dihydrokaempferol is a good candidate for new antiarthritic drugs.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Dihydrolipoic Acid

(DHLA)

Cat. No.: HY-116807

Dihydrolipoic Acid (DHLA) is an excellent antioxidant capable of scavenging almost any oxygen-centered radical. Dihydrolipoic acid exhibits anti-inflammatory properties in various diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Dihydromethysticin

((+)-Dihydromethysticin)

Cat. No.: HY-N0921

Dihydromethysticin is one of the six major kavalactones found in the kava plant; has marked activity on the induction of CYP3A23.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Dihydropalmatine

Cat. No.: HY-N4240

Dihydropalmatine is a alkaloid isolated from Berberis aristata.



Purity: 91.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Dilmapimod

(SB-681323; GW 681323)

Cat. No.: HY-10404

Dilmapimod (SB-681323) is a potent **p38 MAPK** inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.



Purity: 99.56%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dimemorfan phosphate

Cat. No.: HY-B2215

Dimemorfan phosphate is a **sigma 1 receptor** agonist, used as a potent antitussive.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Dimethyl fumarate

(DMF)

Cat. No.: HY-17363

Dimethyl fumarate (DMF) is an orally active and brain-penetrant **Nrf2** activator and induces upregulation of antioxidant gene expression.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g

Dimethyl fumarate-d6

(DMF-d6)

Cat. No.: HY-17363S

Dimethyl fumarate D6 is a deuterium labeled Dimethyl fumarate. Dimethyl fumarate is a nuclear factor (erythroid-derived)-like 2 (**Nrf2**) pathway activator and induces upregulation of antioxidant gene expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

Dimethyl sulfoxide

(DMSO)

Cat. No.: HY-Y0320

Dimethyl sulfoxide (DMSO) is an aprotic solvent that dissolves both polar and nonpolar compounds. Dimethyl sulfoxide has anti-freezing and bacteriostatic properties.



Purity: ≥99.0%
Clinical Data: Launched
Size: 100 mL, 200 mL, 500 mL

Diminazene aceturate

(Diminazene diaceturate)

Cat. No.: HY-12404

Diminazene aceturate (Diminazene diaceturate) is an anti-trypanosome agent for livestock.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Diosgenin glucoside

Cat. No.: HY-N0730

Diosgenin glucoside, a saponin compound extracted from Tritulus terrestris L., provides neuroprotection by regulating microglial M1 polarization. Diosgenin glucoside protects against spinal cord injury by regulating autophagy and alleviating apoptosis .



Purity: 99.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Diphenhydramine hydrochloride

Cat. No.: HY-B0303A

Diphenhydramine hydrochloride is a first-generation histamine H1-receptor antagonist with anti-cholinergic effect. Diphenhydramine hydrochloride can across the ovine blood-brain barrier (BBB).



Purity: 99.04%
Clinical Data: Launched
Size: 10 mM × 1 mL, 250 mg, 500 mg, 5 g

Diphenylcyclopropenone

(Diphencyprone)

Cat. No.: HY-W014605

Diphenylcyclopropenone (Diphencyprone) is a topical immunomodulatory agent that can be used for alopecia areata research.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Diphenyleneiodonium chloride

(DPI)

Cat. No.: HY-100965

Diphenyleneiodonium chloride is a **NADPH oxidase** (**NOX**) inhibitor and also functions as a **TRPA1** activator with an EC_{50} of 1 to 3 μM. Diphenyleneiodonium chloride selectively inhibits intracellular **reactive oxygen species**.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Diphenylpyraline

Cat. No.: HY-107431

Diphenylpyraline is a potent **histamine H_1 receptor** antagonist. Diphenylpyraline acts as an orally active antihistamine agent with antimuscarinic and antiallergic effects.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Diphyllin

Cat. No.: HY-N2532

Diphyllin is an arylnaphthalene lignan isolated from Justicia procumbens and is a potent **HIV-1** inhibitor with an IC50 of 0.38 μM. Diphyllin is active against **vesicular stomatitis virus (VSV)** and **influenza virus**.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

Diphylline

(Diprophylline)

Cat. No.: HY-B0128

Diphylline (Diprophylline) is a potent **A1/A2 adenosine receptor** antagonist and cyclic nucleotide **phosphodiesterase** inhibitor. Diphylline, a xanthine derivative, is a bronchodilator and vasodilator drug and has the potential for chronic bronchitis and emphysema.



Purity: 99.07%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Dipotassium glycyrrhizinate

(Glycyrrhizic acid dipotassium; Dipotassium glycyrrhizate)

Cat. No.: HY-N0184A

Dipotassium glycyrrhizinate is a natural compound, inhibits atopic dermatitis-related gene expression with anti-anti-inflammatory activity.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Dipsacoside B

Cat. No.: HY-N0266

Dipsacoside B is a major bioactive saponin, which can be used as a marker.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Dipyrocetyl

Cat. No.: HY-B1179

Dipyrocetyl is an anti-inflammatory and analgesic agent extracted from patent WO 2011132171 A1.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Diquafosol tetrasodium

(INS365)

Cat. No.: HY-B0606

Diquafosol tetrasodium is a **P2Y2** receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.



Purity: 98.49%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Direct Black 38 free acid

(Chlorazol Black E free acid; Ferristatin II; C.I. 30235 free acid)

Cat. No.: HY-D0256A

Direct Black 38 free acid is a polysulphonated dye. Direct Black 38 free acid promotes degradation of transferrin receptor-1 in vitro and in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dirocaftor

(PTI-808)

Cat. No.: HY-137437

Dirocaftor (PTI-808) is a **CFTR** potentiator that enhances the function of **CFTR** protein by opening chloride channels. Dirocaftor can be used for cystic fibrosis (CF) research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dithranol

(Anthralin)

Cat. No.: HY-B0738

Dithranol (Anthralin) is an anthraquinone derivative, with potent anti-psoriatic effects. Dithranol can inhibit DNA replication and repair.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

DJ001

Cat. No.: HY-133146

DJ001 is a highly specific, selective and non-competitive **protein tyrosine phosphatase-σ (PTPσ)** inhibitor with an IC_{50} of 1.43 μM. DJ001 displays no inhibitory activity against other phosphatases, with only modest inhibitory activity against Protein Phosphatase 5.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DL-Methionine

Cat. No.: HY-N0325

DL-Methionine is an essential amino acid containing sulfur with oxidative stress defense effects. DL-Methionine can be used for animal natural feed. DL-Methionine also kills **H. rostochiensis** on potato plants.



Purity: ≥97.0%
Clinical Data: Launched
Size: 500 mg

DL-Methionine methylsulfonium chloride

Cat. No.: HY-N6655

DL-methionine methylsulfonium chloride is a naturally occurring methionine derivative. DL-methionine methylsulfonium chloride protects gastric mucosal from ethanol-induced damage.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

DL-Threonine

Cat. No.: HY-N0658A

DL-Threonine, an essential amino acid, has the potential to treat hypostatic leg ulceration.



Relative stereochemistry

Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 500 mg

DL-α-Tocopherol acetate

(Vitamin E acetate)

Cat. No.: HY-B1278A

DL-α-Tocopherol acetate is a vitamin E derivative which is often included in the formulations of enteral nutrition.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

DMP 777

(L-694458)

Cat. No.: HY-75957

DMP 777 is a potent, selective, and orally active **human leukocyte elastase (HLE)** inhibitor.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DMT1 blocker 1

Cat. No.: HY-126301

DMT1 blocker 1 is a blocker of divalent metal transporter 1 (**DMT1**) with an IC_{50} of 0.64 μM, is expected to block iron uptake by enterocytes in vivo.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Docebenone

(AA 861)

Cat. No.: HY-12886

Docebenone (AA 861) is a potent, selective and orally active **5-LO (5-lipoxygenase)** inhibitor.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DODAP

Cat. No.: HY-130751

DODAP is a cationic lipid. The ionizable lipid DODAP is a lipid component of the liposome. DODAP can be used to encapsulate siRNA, immunostimulatory chemotherapeutic agents for in vitro and in vivo delivery and so on.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Doramapimod

(BIRB 796)

Cat. No.: HY-10320

Doramapimod (BIRB 796) is an orally active, highly potent **p38 MAPK** inhibitor, which has an IC_{50} for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (K_d=0.1 nM). Doramapimod also inhibits **B-Raf** with an IC_{50} of 83 nM.



Purity: 99.88%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Doxofylline

Cat. No.: HY-B0004

Doxofylline is an antagonist of **adenosine A1 receptor** which also inhibits **phosphodiesterase IV**.



Purity: 99.32%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Doxofylline-d4

Cat. No.: HY-B0004S1

Doxofylline-d4 is the deuterium labeled Doxofylline. Doxofylline is an antagonist of **adenosine A1 receptor** which also inhibits **phosphodiesterase IV**.



Purity: >98%
Clinical Data:
Size: 5 mg, 50 mg

Doxylamine D5 succinate

Cat. No.: HY-A0069S

Doxylamine D5 succinate is deuterium labeled Doxylamine, which is a first generation antihistamine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Doxylamine succinate

Cat. No.: HY-A0069

Doxylamine (succinate) is a first generation antihistamine; can be used by itself as a short-term sedative and in combination with other drugs to provide night-time allergy and cold relief.



Purity: 99.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Doxylamine-d5

Cat. No.: HY-A0069AS

Doxylamine D5 is deuterium labeled Doxylamine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DPA-714

Cat. No.: HY-122607

DPA-714 is a high affinity translocator protein **(TSPO)** ligand (K_i=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography.



Purity: 99.70%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DPP-IV-IN-2

Cat. No.: HY-108319

DPP-IV-IN-2 is an inhibitor of both **dipeptidyl peptidase IV** (**DPIV**) and **DP8/9** with IC_{50}s of 0.1 and 0.95 μM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

DPTIP

Cat. No.: HY-131002

DPTIP is a potent brain penetrant **neutral sphingomyelinase 2 (N-SMase 2)** inhibitor (exosome inhibitor), with an IC_{50} of 30 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Draflazine

(R-75231; R88021)

Cat. No.: HY-106841

Draflazine (R-75231) is a **ENT1** inhibitor. Draflazine (R-75231) completely reverses the hypersensitivity in the complete Freund's adjuvant (CFA) model of mechanical hyperalgesia and the carrageenan inflammation model of thermal and mechanical hyperalgesia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DRI-C21045

Cat. No.: HY-120323

DRI-C21045 (compound 10) is a potent and selective inhibitor of the **CD40-CD40L** costimulatory protein-protein interaction (PPI) with an IC_{50} of 0.17 μM.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

DS-437

Cat. No.: HY-124131

DS-437 is a dual **PRMT5/7** inhibitor (IC_{50}s of PRMT5/7=6 μM). DS-437 is selective for PRMT5 and PRMT7 over 29 other human protein-, DNA-, and RNA-methyltransferases. DS-437 is a S-adenosylmethionine (SAM)-competitive inhibitor of PRMT5.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DS28120313

Cat. No.: HY-107980

DS28120313 (compound 32) is an orally **hepcidin production** inhibitor with an IC_{50} of 0.093 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DSG Crosslinker

Cat. No.: HY-114697

DSG Crosslinker is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

DSP Crosslinker

Cat. No.: HY-118759

DSP Crosslinker is a cleavable **ADC linker**, used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 98.73%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

DSTYSLSSTLTLSK

Cat. No.: HY-P3203

DSTYSLSSTLTLSK is a generic human peptide and can be used for infliximab quantitative detection. Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.

DSTYSLSSTLTLSK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DSTYSLSSTLTLSK TFA

Cat. No.: HY-P3203A

DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection. Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.

DSTYSLSSTLTLSK (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

DuP-697

Cat. No.: HY-103387

DuP-697 is a member of the vicinal diaryl heterocycles and a potent, irreversible, selective and orally active **COX-2** inhibitor (IC_{50} of 10 nM and 800 nM for human **COX-2** and **COX-1**, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dupilumab

(REGN-668; SAR-231893)

Cat. No.: HY-P9926

Dupilumab (REGN-668) is a fully human mAb to **IL-4 receptor α (IL-4Rα)** that inhibits both **IL-4** and **IL-13** signaling, markedly improved moderate-to-severe atopic dermatitis.

Dupilumab

Purity: ≥99.20%
Clinical Data: Launched
Size: 1 mg, 5 mg

DW-1350

Cat. No.: HY-100173

DW-1350 is a **LTB_4 receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dyclonine hydrochloride

(Dyclocaine hydrochloride)

Cat. No.: HY-B0364A

Dyclonine hydrochloride (Dyclocaine hydrochloride) is an effective component of Runhou tablets. Dyclonine hydrochloride has significant bactericidal and fungicidal activity.



Purity: 98.39%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

DZ2002

Cat. No.: HY-18620

DZ2002 is a potent and reversible S-Adenosyl-L-homocysteine Hydrolase(SAHH; AdoHcy Hydrolase) inhibitor with Ki of 17.9 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

E-64

(Proteinase inhibitor E 64)

Cat. No.: HY-15282

E-64 (Proteinase inhibitor E 64) is a potent irreversible inhibitor against general **cysteine proteases** with IC_{50} of 9 nM for **papain**.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

E-6123

Cat. No.: HY-10164

E-6123 is a platelet-activating factor (**PAF**) receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E6130

Cat. No.: HY-107456

E6130 is an orally active and highly selective **CX3CR1** modulator, that may be effective for treatment of inflammatory bowel disease.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EB-47

Cat. No.: HY-15046

EB-47, a potent and selective **PARP-1/ARTD-1** inhibitor with an IC_{50} value of 45 nM, shows modest potency against ARTD5 with an IC_{50} value of 410 nM. EB-47 mimics the substrate NAD^+ and extends from the nicotinamide to the adenosine subsite.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

EB-47 dihydrochloride

Cat. No.: HY-108631

EB-47 dihydrochloride, a potent and selective **PARP-1/ARTD-1** inhibitor with an IC_{50} value of 45 nM, shows modest potency against ARTD5 with an IC_{50} value of 410 nM. EB-47 mimics the substrate NAD^+ and extends from the nicotinamide to the adenosine subsite.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ebastine

(LAS-W 090; RP64305)

Cat. No.: HY-B0674

Ebastine (LAS-W 090) is an orally active, second-generation **histamine H1 receptor** antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Ebastine-d5

Cat. No.: HY-B0674S

Ebastine-d5 (LAS-W 090-d5) is the deuterium labeled Ebastine. Ebastine (LAS-W 090) is an orally active, second-generation **histamine H1 receptor** antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Ebrotidine

(FI3542)

Cat. No.: HY-15538

Ebrotidine(FI 3542) is a competitive H2-receptor antagonist (Ki= 127.5 nM) with a potent antisecretory activity and evidenced gastroprotection.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ebselen

(SPI-1005; PZ-51; CCG-39161)

Cat. No.: HY-13750

Ebselen (SPI-1005), a glutathione peroxidase mimetic, is a potent **voltage-dependent calcium channel (VDCC)** blocker. Ebselen potently inhibits M^{pro} (IC_{50}=0.67 μM) and **COVID-19** virus (EC_{50}=4.67 μM).Ebselen is an inhibitor of **HIV-1** capsid CTD dimerization.



Purity: 99.58%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Echinatin

Cat. No.: HY-N0269

Echinatin is a chalcone isolated from the Chinese herbal medicine Gancao with hepatoprotective and anti-inflammatory effects. Echinatin can be quickly absorbed and eliminated and extensively distributed with an absolute bioavailability of approximately 6.81% in Rat.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Echinocystic acid

Cat. No.: HY-N0271

Echinocystic acid a pentacyclic triterpene isolated from the fruits of Gleditsia sinensis Lam, has potent antioxidant, anti-inflammatory and anti-tumor properties. In vitro: Echinocystic acid (EA) inhibit the formation of osteoclast.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Echistatin

Cat. No.: HY-P1189

Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of **platelet aggregation**. Echistatin is a potent inhibitor of **bone resorption** in culture.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Echistatin TFA

Cat. No.: HY-P1189A

Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of **platelet aggregation**. Echistatin is a potent inhibitor of **bone resorption** in culture.

Purity: 95.13%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ecliptasaponin A

Cat. No.: HY-N1508

Ecliptasaponin A , a pentacyclic triterpenoid saponin, is one of major compounds separated from Eclipta prostrate.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Ecliptasaponin D

Cat. No.: HY-N2191

Ecliptasaponin D is a triterpenoid glucoside isolated from Eclipta alba (L.) Hassk which is the aerial part of Eclipta prostrate.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Eclitasertib

(DNL-758; SAR-443122)

Cat. No.: HY-114371

Eclitasertib (DNL-758) is a potent **receptor-interacting protein kinase 1 (RIPK1)** inhibitor with an IC_{50} of <1 μM (From patent WO2017136727A2, example 42).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ecopladib

(PLA 725)

Cat. No.: HY-U00037

Ecopladib is a sub-micromolar inhibitor of cytosolic **phospholipase A2α (cPLA2α)**, with IC_{50}s of 0.15 μM and 0.11 μM in the GLU micelle and rat whole blood assays, respectively.



Purity: 95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

Ectoine

Cat. No.: HY-107784

Ectoine is a natural cell protectant, an amino acid derivate produced by bacteria living under extremely harsh environmental conditions.



Purity: 99.67%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg

Ecubectedin

Cat. No.: HY-139570

Ecubectedin is a derivative. Ecteinascidins is a family of tetrahydroisoquinoline alkaloids with wide range of antitumor and antimicrobial activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Edicotinib

(JNJ-40346527; JNJ-527)

Cat. No.: HY-109086

Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active **colony-stimulating factor-1 receptor (CSF-1R)** inhibitor with an IC_{50} of 3.2 nM.



Purity: 99.56%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Edpetiline

Cat. No.: HY-N1921

Edpetiline is a principal alkaloid from P. eduardi. Edpetiline has significant antiinflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

EGF Receptor Substrate 2 Phospho-Tyr5

Cat. No.: HY-P0320

EGF Receptor Substrate 2 (Phospho-Tyr5) is a biologically active peptide derived from an autophosphorylation site (Tyr^{992}) of epidermal growth factor receptor (EGFR).

DADE-pY-LIPQQG

Purity: 98.70%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

EGTA

Cat. No.: HY-D0861

EGTA is a specific calcium ion chelator. EGTA has an apparent calcium dissociation constant (K_d) of 60.5 nM at physiological pH (7.4) and has very high specificity for Ca^{2+} over Mg^{2+} (Mg^{2+} K_d 1-10 mM).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 500 mg

EHP-101

(VCE-004.8)

Cat. No.: HY-128872

EHP-101 (VCE-004.8) is an orally active, specific **PPARγ** and **CB_2** receptor dual agonist. EHP-101 inhibits **prolyl-hydroxylases (PHDs)** and activates the **HIF** pathway. EHP-101, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

EIPA

(L593754; MH 12-43)

Cat. No.: HY-101840

EIPA (L593754) is a **TRPP3 channel** inhibitor with an **IC_{50}** of 10.5 μM. EIPA also inhibits **Na^+/H^+-exchanger** (**NHE**) and **macropinocytosis**.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

EIPA hydrochloride

(L593754 hydrochloride; MH 12-43 hydrochloride)

Cat. No.: HY-101840A

EIPA hydrochloride (L593754 hydrochloride) is a **TRPP3 channel** inhibitor with an **IC_{50}** of 10.5 μM. EIPA hydrochloride also inhibits **Na^+/H^+-exchanger** (**NHE**) and **macropinocytosis**.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

ELA-11(human)

Cat. No.: HY-P2197

ELA-11(human), a peptide, is a full agonist of **human apelin receptor**, with a **pK_i** of 7.85. ELA-11(human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment.

CMPLHSRVPFP

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Elastatinal

Cat. No.: HY-100397

Elastatinal is a potent and competitive inhibitor of **elastase**, with a **K_i** of 0.21 μM. Elastatinal more potently inhibits pancreatic elastase versus leucocyte elastase. Elastatinal shows no activity on human leucocyte chymotrypsin-like protease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eleutheroside B1

Cat. No.: HY-135646

Eleutheroside B1, a coumarin compound, has a wide spectrum of anti-human **influenza virus** efficacy, with an **IC_{50}** value of 64-125 μg/ml. Eleutheroside B1 mediates its anti-influenza activity through POLR2A and N-glycosylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eleutheroside D

Cat. No.: HY-N4147

Eleutheroside D is an active lignan isolated from the root of Eleutherococcus senticosus, has anti-inflammatory and hypoglycemic activities. Eleutheroside D is an optical isomer of Eleutheroside E (HY-N0272).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eleutheroside E

Cat. No.: HY-N0272

Eleutheroside E, a principal component of Eleutherococcus enticosus, has anti-inflammatory and protective effects in ischemia heart.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Eliapixant

(BAY 1817080)

Cat. No.: HY-109170

Eliapixant (BAY 1817080) is a potent and selective antagonist of **P2X3 receptor**, with an IC_{50} of 8 nM. Eliapixant can be used for the research of refractory chronic cough.



Purity: 99.69%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Elsubrutinib

(ABBV-105)

Cat. No.: HY-109143

Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (**BTK**) inhibitorThe IC_{50} of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eltenac

Cat. No.: HY-106093

Eltenac, a non-steroidal anti-inflammatory drug (NSAID), is a COX inhibitor. Eltenac shows IC50 of 0.03 μM for both COX-1 and COX-2 in isolated human whole blood.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Elubrixin

(SB-656933)

Cat. No.: HY-18263A

Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active **CXCR2** antagonist and an **IL-8 receptor** antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC_{50} of 260.7 nM) and shape change (IC_{50} of 310.5 nM).



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Elubrixin tosylate

(SB-656933 tosylate)

Cat. No.: HY-18263C

Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active **CXCR2** antagonist and an **IL-8 receptor** antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC_{50} of 260.7 nM) and shape change (IC_{50} of 310.5 nM).



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Elucaine

Cat. No.: HY-101743

Elucaine is a **muscarinic acetylcholine receptor** antagonist with anti-ulcerative activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Embramine

Cat. No.: HY-U00132

Embramine is a monoethanolamine used as an antihistamine and anticholinergic.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

EMD527040

Cat. No.: HY-101473

EMD527040 is a potent and highly selective **αvβ6** antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Emedastine

Cat. No.: HY-108411

Emedastine is an orally active, selective and high affinity **histamine H_1 receptor** antagonist with a K_i value of 1.3 nM.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Emedastine difumarate

Cat. No.: HY-B2178

Emedastine difumarate is an orally active, selective and high affinity **histamine H_1 receptor** antagonist with a K_i value of 1.3 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Emeramide

(BDTH2)

Cat. No.: HY-16739

Emeramide is a thiol-redox antioxidant and heavy metal chelator.



Purity: 99.56%
Clinical Data: Phase 2
Size: 100 mg, 500 mg

Emivirine

(MKC-442)

Cat. No.: HY-15353

Emivirine (MKC-442) is a **non-nucleoside reverse transcriptase** inhibitors (NNRTIs) with K_i values of 0.20 and 0.01 μM for dTTP- and dGTP-dependent DNA or RNA polymerase activity, respectively. Emivirine displays potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Emlenoflast

(MCC7840)

Cat. No.: HY-137245

Emlenoflast (MCC7840), a sulfonylurea, is a potent and selective inhibitor of **NLRP3 inflammasome**, with an IC_{50} of <100 nM. Emlenoflast can be used for the research of inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Emlenoflast sodium

(MCC7840 sodium)

Cat. No.: HY-137245A

Emlenoflast (MCC7840) sodium, a sulfonylurea, is a potent and selective inhibitor of **NLRP3 inflammasome**, with an IC_{50} of <100 nM. Emlenoflast sodium can be used for the research of inflammatory diseases.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Emodin 6-O-β-D-glucoside

(Glucoemodin)

Cat. No.: HY-N8126

Emodin-6-O-β-D-glucoside (Glucoemodin) is an active compound from Reynoutria japonica. Emodin-6-O-β-D-glucoside shows potent anti-inflammatory and barrier protective effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Emodin-1-O-β-D-glucopyranoside

Cat. No.: HY-N2394

Emodin-1-O-β-D-glucopyranoside, isolated from medicinal plant Polygonum cuspidatum Sieb. & Zucc, is a potent and noncompetitive **bacterial neuraminidase (BNA)** inhibitor with an IC_{50} of 0.85 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Enazadrem

Cat. No.: HY-U00024

Enazadrem is a **5-lipoxygenase** inhibitor with antiinflammatory activities.



Purity: 97.26%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Enclomiphene citrate ((E)-Clomiphene citrate; trans-Clomiphene citrate; Enclomifene citrate)

Cat. No.: HY-118861A

Enclomiphene citrate is a potent and orally active **oestrogen receptor** antagonist, with antioestrogenic property.



Purity: 98.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Enclomiphene D4 hydrochloride ((E)-Clomiphene D4 hydrochloride; trans-Clomiphene D4 hydrochloride; ...)

Cat. No.: HY-118861S

Enclomiphene D4 hydrochloride ((E)-Clomiphene D4 hydrochloride; trans-Clomiphene D4 hydrochloride; Enclomifene D4 hydrochloride) is a deuterium labeled Enclomiphene.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Endothelin 1 (swine, human)

Cat. No.: HY-P0202

Endothelin 1 (swine, human) is a synthetic peptide with the sequence of human and swine Endothelin 1, which is a potent endogenous vasoconstrictor. Endothelin 1 acts through two types of receptors ET_A and ET_B.



Purity: 96.35%
Clinical Data: No Development Reported
Size: 500 µg, 1 mg, 5 mg, 10 mg

Enflicoxib

(E 6087)

Cat. No.: HY-19384

Enflicoxib (E 6087) is a nonsteroidal anti-inflammatory compound that selectively inhibits **cyclooxygenase-2** (**COX-2**). Enflicoxib does not inhibit cyclooxygenase-1 (COX-1). E-6087 shows anti-inflammatory, analgesic and antipyretic activities in animal models.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Engeletin

Cat. No.: HY-N0436

Engeletin is a flavanonol glycoside isolated from hymenaea martiana, inhibits **NF-κB** signaling-pathway activation, and possesses anti-inflammatory, analgesic, diuresis, detumescence, and antibiosis effects.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ENMD-1068 hydrochloride

Cat. No.: HY-124748A

ENMD-1068 hydrochloride is a selective **protease-activated receptor 2 (PAR2)** antagonist with antiangiogenic and anti-inflammatory activities.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Enmein

Cat. No.: HY-N5028

Enmein is isolated from I. serra with immunosuppressive effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Enocyanin

Cat. No.: HY-114336

Enocyanin is an anthocyanin extracted from grapes. Enocyanin shows inhibitory effect on the leucine aminopeptidase, acid phosphatase, γ-glutamyl transpeptidase and esterase activity.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mg(10 mg × mL in DMSO), 100 mg

Enoximone

Cat. No.: HY-B1639

Enoximone is an inotropic vasodilating agent and a selective and orally active **phosphodiesterase III (PDE3)** inhibitor with an IC_{50} of 5.9 µM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Enpatoran

(M5049)

Cat. No.: HY-134581

Enpatoran (M5049) is a potent, orally active and dual **TLR7/8** inhibitor with IC_{50}s of 11.1 nM and 24.1 nM in HEK293 cells, respectively. Enpatoran is inactive against TLR3, TLR4 and TLR9. Enpatoran can block molecule synthetic ligands and natural endogenous RNA ligands.



Purity: 99.77%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Enpatoran hydrochloride

(M5049 hydrochloride)

Cat. No.: HY-134581A

Enpatoran (M5049) hydrochloride is a potent, orally active and dual **TLR7/8** inhibitor with IC_{50}s of 11.1 nM and 24.1 nM in HEK293 cells, respectively. Enpatoran hydrochloride is inactive against TLR3, TLR4 and TLR9.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Ensifentrine

(RPL-554)

Cat. No.: HY-119708

Ensifentrine (RPL-554) is an inhaled first-in-class dual inhibitor of **phosphodiesterase 3 (PDE3)** and **PDE4** with IC_{50}s of 0.4 nM and 1479 nM, respectively. Ensifentrine has bronchoprotective and anti-inflammatory activities.



Purity: 99.47%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EP4 receptor antagonist 1

Cat. No.: HY-133123

EP4 receptor antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist for cancer immunotherapy. EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC_{50}s of 6.1 nM and 16.2 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EP4 receptor antagonist 3

Cat. No.: HY-138761

EP4 receptor antagonist 3 is a potent **EP4 receptor** antagonist, example 3,extracted from patent WO2010019796 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Epacadostat

(INCB 024360)

Cat. No.: HY-15689

Epacadostat (INCB 024360) is a potent and selective **indoleamine 2,3-dioxigenase 1 (IDO1)** inhibitor with an **IC_{50}** of 71.8 nM.



Purity: 99.66%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Epibetulinic acid

Cat. No.: HY-N0223

Epibetulinic acid exhibits potent inhibitory effects on **NO** and prostaglandin E2 (**PGE2**) production in mouse macrophages (RAW 264.7) stimulated with bacterial endotoxin with **IC_{50}**s of 0.7 and 0.6 μM, respectively. Anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Epicorynoxidine

Cat. No.: HY-N7011

Epicorynoxidine, a natural alkaloid, shows cytotoxic effects P-388 cell line with an ED_{50} of 25.53 μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Epigomisin O

Cat. No.: HY-N2222

Epigomisin O is isolate from the fruits of Schisandra plants.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Epimagnolin B

Cat. No.: HY-N6261

Epimagnolin B is a bisepoxylignan isolated from Magnolia fargesii, with anti-inflammatory activity and antiallergic effects. Epimagnolin B inhibits NO production in LPS-activated microglia. Epimagnolin B exhibited antiallergic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Epimedin K

(Korepimedoside B)

Cat. No.: HY-N8087

Epimedin K (Korepimedoside B), a flavonol glycoside, is isolated from the aerial parts of Epimedium koreanum Nakai.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Epinastine

(WAL801)

Cat. No.: HY-B0640

Epinastine (WAL801) is an antihistamine and mast cell stabilizer. Epinastine is a potent, selective and orally-active **histamine H1 receptor** antagonist. Epinastine also inhibits IL-8 release and has an antiallergic action.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Epinastine hydrochloride

(WAL801 hydrochloride)

Cat. No.: HY-B0640A

Epinastine hydrochloride (WAL801 hydrochloride) is an antihistamine and mast cell stabilizer. Epinastine hydrochloride is a potent, selective and orally-active **histamine H1 receptor** antagonist. Epinastine hydrochloride also inhibits IL-8 release and has an antiallergic action.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Episappanol

Cat. No.: HY-N9315

Episappanol is a natural compound isolated from Caesalpinia sappan heartwood with anti-inflammatory activity. Episappanol significantly inhibits the **IL-6** and **TNF-α** secretion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Episyringaresinol 4'-O-β-D-glncopyranoside

Cat. No.: HY-N2182

Episyringaresinol 4'-O-β-D-glncopyranoside (compound 22), isolated from Alhagi sparsifolia Shap, is a natural potential neuroinflammatory inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Epitheaflagallin 3-O-gallate

Cat. No.: HY-N4298

Epitheaflagallin 3-O-gallate is a minor polyphenol in black tea.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Epmedin C

(Epimedin-C; Baohuoside-VI)

Cat. No.: HY-N0260

Epmedin C, a natural product, has estrogen-like effects for ovariectomized mice.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Epoxomicin

(BU-4061T)

Cat. No.: HY-13821

Epoxomicin (BU-4061T) is an epoxyketone-containing natural product and a potent, selective and irreversible **proteasome** inhibitor.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 μg, 1 mg, 5 mg, 10 mg, 20 mg

Epoxymicheliolide

(1β,10β-Epoxymicheliolide)

Cat. No.: HY-N0845

Epoxymicheliolide is a micheliolide derivative.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eprazinone dihydrochloride

Cat. No.: HY-B2078A

Eprazinone dihydrochloride is a gent with mucolytic, secretolytic, antitussive, and bronchial antispasmodic properties. Eprazinone dihydrochloride is a **neurokinin 1 receptor (NK1R)** ligand.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg, 500 mg

Eprodisate

Cat. No.: HY-128849

Eprodisate is a new compound designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Epsilon-V1-2

(ε-V1-2; EAVSLKPT)

Cat. No.: HY-P0154

Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide, is a selective **PKCε** inhibitor. Epsilon-V1-2 inhibits the translocationof PKCε, but not α-, β-, and δPKC.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Eragidomide

(CC-90009)

Cat. No.: HY-130800

Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the $CRL4^{CRBN}$ to selectively target GSPT1 for ubiquitination and proteasomal degradation.



Purity: 99.51%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ERAP1-IN-1

Cat. No.: HY-133125

ERAP1-IN-1 is an **endoplasmic reticulum aminopeptidase 1 (ERAP1)** inhibitor. ERAP1-IN-1 competitively inhibits ERAP1 activity towards a nonamer peptide representative of physiological substrates.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ERB-196

(WAY-202196)

Cat. No.: HY-19468

ERB-196 is a nonsteroidal selective **estrogen receptor-β (ERβ)** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Erdosteine

(RV 144)

Cat. No.: HY-B0289

Erdosteine inhibits lipopolysaccharide (LPS)-induced **NF-κB** activation. Erdosteine has muco-modulatory, anti-bacterial, anti-inflammatory and anti-oxidant effects.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Erdosteine-13C4

(RV 144-13C4)

Cat. No.: HY-B0289S

Erdosteine-13C4 (RV 144-13C4) is a 13C-labeled Erdosteine. Erdosteine inhibits lipopolysaccharide (LPS)-induced **NF-κB** activation. Erdosteine has muco-modulatory, anti-bacterial, anti-inflammatory and anti-oxidant effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Ergolide

Cat. No.: HY-N6893

Ergolide is a sesquiterpene lactone isolated from the dried flowers of Inula Britannica. Ergolide inhibits inducible nitric oxide synthase and cyclo-oxygenase-2 expression in RAW 264.7 macrophages through the inactivation of **NF-κB**.



Purity: 99.42%
Clinical Data:
Size: 5 mg, 10 mg

Ergosterol

(Ergosterin; Provitamin D; Provitamin D2)

Cat. No.: HY-N0181

Ergosterol is the primary sterol found in fungi, with antioxidative, anti-proliferative, and anti-inflammatory effects.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 100 mg

Ergosterol peroxide

Cat. No.: HY-N3845

Ergosterol peroxide is a steroid derivative and can be isolated from a variety of fungi, yeast, lichens or sponges. Ergosterol peroxide has anti-tumour, proapoptotic, anti-inflammatory, anti-mycobacterial, and anti-proliferative activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Eriocalyxin B

Cat. No.: HY-N2303

Eriocalyxin B is an ent-Kaurene diterpenoid isolated from Chinese herb Isodon eriocalyx. Eriocalyxin B has anti-cancer and anti-infammatory activities. Eriocalyxin B induces cell **apoptosis**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Eriodictyol

(Huazhongilexone)

Cat. No.: HY-N0637

Eriodictyol is a flavonoid isolated from the Chinese herb, with antioxidant and anti-inflammatory activity. Eriodictyol induces **Nrf2** signaling pathway. Eriodictyol is also a potent **influenza RNA-dependent RNA polymerase** inhibitor with an IC_{50} of 18 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Ermanin

Cat. No.: HY-N3848

Ermanin is a flavonoid isolated from Tanacetum microphyllum. Ermanin potently inhibits **iNOS**, **COX-2** activities, and inhibits platelet aggregation. Ermanin has anti-inflammatory, anti-tuberculous and anti-viral/bacterial properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Escin

Cat. No.: HY-B2114

Escin, a natural compound of triterpenoid saponins isolated from horse chestnut (Aesculus hippocastanum) seeds, can be used as a vasoprotective anti-inflammatory, anti-edematous and anti-nociceptive agent.



Purity: ≥95.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg

Escin IIa

Cat. No.: HY-107248

Escin IIa, isolated from horse chestnut, the seeds of Aesculus hippocastanum L., has positive effects on acute inflammation in animals. Escin IIa has gastroprotections on ethanol-induced gastric mucosal lesions in rats.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Escin IIb

Cat. No.: HY-107247

Escin IIb, isolated from horse chestnut, the seeds of Aesculus hippocastanum L., has positive effects on acute inflammation in animals. Escin IIb showed potent protective effects against ethanol-induced gastric mucosal lesions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Esculentoside A

Cat. No.: HY-N0632

Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta. Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models, has selective inhibitory activity towards cyclooxygenase-2 (**COX-2**).



Purity: 98.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Esculetin

Cat. No.: HY-N0284

Esculetin is an active ingredient extracted mainly from the bark of Fraxinus rhynchophylla. Esculetin inhibits platelet-derived growth factor (PDGF)-induced airway smooth muscle cells (ASMCs) phenotype switching through inhibition of **PI3K/Akt** pathway.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Esculin

Cat. No.: HY-N0188

Esculin, a fluorescent coumarin glucoside, is an active ingredient of ash bark. Esculin ameliorates cognitive impairment in experimental diabetic nephropathy (DN), and exerts antioxidative stress and antiinflammatory effects, via the **MAPK** signaling pathway.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt)

Cat. No.: HY-17021A

Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the **H⁺, K⁺-ATPase** in gastric parietal cells.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Esomeprazole potassium salt ((S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt)

Cat. No.: HY-17021B

Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the **H⁺, K⁺-ATPase** in gastric parietal cells.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Esonarimod (KE-298)

Cat. No.: HY-19440

Esonarimod (KE-298) is an antirheumatic agent.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Etalocib (LY293111; VML 295)

Cat. No.: HY-13628

Etalocib (LY293111), an orally active **leukotriene B_4 receptor** antagonist, inhibits the binding of **[^{3}H]LTB$_4$**, with a **K_i** of 25 nM. Etalocib (LY293111) prevents LTB_4-induced calcium mobilization with an **IC_{50}** of 20 nM. Etalocib (LY293111) induces apoptosis.



Purity: 98.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Etanercept

Cat. No.: HY-108847

Etanercept, a dimeric fusion protein that binds TNF, acts as a **TNF** inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive.

Etanercept

Purity: ≥96.0%
Clinical Data: Launched
Size: 1 mg, 5 mg

Etavopivat

(FT-4202)

Cat. No.: HY-139573

Etavopivat is a potent, selective, orally bioavailable red blood cell (RBC) **pyruvate kinase (PKR)** activator. Etavopivat has potent antisickling effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ethacrynic acid

Cat. No.: HY-B1640

Ethacrynic acid is a diuretic. Ethacrynic acid is an inhibitor of **glutathione S-transferases (GSTs)**. Ethacrynic acid is a potent inhibitor of **NF-kB-signaling** pathway, and also modulates leukotriene formation.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Ethacrynic acid D5

Cat. No.: HY-108538

Ethacrynic acid D5 is a deuterium labeled Ethacrynic acid. Ethacrynic acid is a diuretic. Ethacrynic acid is an inhibitor of **glutathione S-transferases (GSTs)**. Ethacrynic acid is a potent inhibitor of **NF-kB-signaling** pathway, and also modulates leukotriene formation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ethoxzolamide

(Redupresin; L-643786; PNU-4191)

Cat. No.: HY-B1480

Ethoxzolamide is a **carbonic anhydrase** inhibitor with K_i of 1 nM.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Ethyl Caffeate

Cat. No.: HY-N6966

Ethyl Caffeate is a natural phenolic compound isolated from Bidens pilosa.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Ethyl pyruvate

Cat. No.: HY-Y1362

Ethyl pyruvate is a simple derivative of the endogenous metabolite, pyruvic acid. Ethyl pyruvate is an anti-inflammatory agent.



Purity: 99.29%
Clinical Data: Phase 4
Size: 100 mg

Ethylene dimethanesulfonate

Cat. No.: HY-129524

Ethylene dimethane sulfonate is a mild alkylating, non-volatile methanesulfonic diester of ethylene glycol. Ethylene dimethanesulfonate has selective pro-apoptotic effects on LCs.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Etodolac

(AY-24236)

Cat. No.: HY-76251

Etodolac (AY-24236) is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC_{50}=53.5 nM).



Purity: 99.11%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Etofenamate

Cat. No.: HY-17361

Etofenamate, a non-steroid anti-inflammatory drug (**NSAID**) and a non-selective **COX** inhibitor, possesses analgesic, anti-rheumatic, antipyretic and anti-inflammatory properties. Etofenamate is used in the research for osteoarthritis, arthritis and other inflammatory diseases.



Purity: 98.14%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Etofenamate-d4

Cat. No.: HY-17361S

Etofenamate-d4 is the deuterium labeled Etofenamate. Etofenamate, a non-steroid anti-inflammatory drug (**NSAID**) and a non-selective **COX** inhibitor, possesses analgesic, anti-rheumatic, antipyretic and anti-inflammatory properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Etoricoxib

(MK-0663; L-791456)

Cat. No.: HY-15321

Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active **COX-2** inhibitor, with IC_{50}s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.



Purity: 99.10%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Etosalamide

(Ethosalamide)

Cat. No.: HY-B1015

Etosalamide (Ethosalamide) is an **antipyretic** and analgesic agent. Etosalamide has anti-inflammatory activity and can be used for allergic disease research.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Etrasimod

(APD334)

Cat. No.: HY-12789

Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 ($S1P_1$) receptor with an IC_{50} value of 1.88 nM in CHO cells.



Purity: 99.57%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

Eudesmin

((-)-Eudesmin; Eudesmine; (-)-Eudesmine)

Cat. No.: HY-N2357

Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of **S6K1** signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 5 mg

Eugenol

Cat. No.: HY-N0337

Eugenol is an essential oil found in cloves with antibacterial, anthelmintic and antioxidant activity. Eugenol is shown to inhibit lipid peroxidation.



Purity: 98.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Eulophiol

Cat. No.: HY-N7518

Eulophiol shows the 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical scavenging activity with an EC_{50} of 27.7μM. Antioxidant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Eupalinolide A

Cat. No.: HY-N0754

Eupalinolide A, isolated from Eupatorium lindleyanum, induces the expression of HSP70 via the activation of **HSF1** by inhibiting the interaction between HSF1 and HSP90.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

Eupalinolide H

Cat. No.: HY-N8149

Eupalinolide H, a sesquiterpene lactone, has the potential to be used as natural anti-inflammatory agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eupatilin

Cat. No.: HY-N0783

Eupatilin, a lipophilic flavonoid isolated from Artemisia species, is a **PPARα** agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.



Purity: 99.01%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Euphol

Cat. No.: HY-N0313

Euphol is a tetracyclic triterpene alcohol isolated from the sap of Euphorbia tirucalli with anti-mutagenic, anti-inflammatory and immunomodulatory effects, orally active.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Eurycomalactone

Cat. No.: HY-N4327

Eurycomalactone is a natural product found in Eurycoma longifolia Jack., acts as a potent **NF-κB** inhibitor, with an IC_{50} of 0.5 μM.



Purity: 93.09%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Evocarpine

Cat. No.: HY-N2060

Evocarpine, a quinolone alkaloid that could be isolated from Evodiae fructus, inhibitss Ca^{2+} influx through voltage-dependent calcium channels. Antimycobacterial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Evodol

Cat. No.: HY-N2621

Evodol is a natural product isolated from the dried and nearly ripe fruits of Euodia rutaecarpa. Evodol shows inhibitory activity against NO production. Evodol possesses larvicidal activity against the Asian tiger mosquitoes with a LC_{50} value of 32.43 μg/ml.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Evogliptin tartrate

(DA-1229 tartrate)

Cat. No.: HY-117985B

Evogliptin tartrate is a potent, orally bioavailable and selective **dipeptidyl peptidase-4 (DPP-4)** inhibitor, with antidiabetic activity. Evogliptin tartrate has potential for anti-atherosclerosis therapy that targets arterial inflammation.



Purity: 99.96%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Evolitrine

(7-Methoxydictamnine; Evolitrin)

Cat. No.: HY-N5022

Evolitrine (7-Methoxydictamnine; Evolitrin) is isolated from Acronychia pedunculata and show anti-inflammatory and antifeedant activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Ezurpimtrostat

Cat. No.: HY-137978

Ezurpimtrostat (compound 2-2) is used for the study of fibrosis, cancer, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases (extracted from patent WO2020048694 A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fabiatrin

Cat. No.: HY-N2285

Fabiatrin is a natural product isolated from Przewalskia tangutica.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

FABP-IN-1

Cat. No.: HY-129911

FABP-IN-1 (Compounds 4b) is a high affinity **fatty acid binding protein (FABP)** inhibitor. FABP-IN-1 inhibits **FABP3**, **FABP5**, and **FABP7** with K_i values of 0.69 μM, 0.55 μM and 0.67 μM, respectively. FABP-IN-1 displays potent antinociceptive effects.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FABP5-IN-1

Cat. No.: HY-129910

FABP5-IN-1 is a selective and high affinity **fatty acid binding protein 5 (FABP5)** inhibitor with a K_i value of 1.7 μM, and does not bind to both FABP3 and FABP7. FABP5-IN-1 shows potent antinociceptive effects.



Purity: 98.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Factor B-IN-1

Cat. No.: HY-136556

Factor B-IN-1 is a **Factor B** inhibitor extracted from patent WO2013164802A1, Example 24.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Factor D inhibitor 6

Cat. No.: HY-122700

Factor D inhibitor 6 is a potent, highly selective and orally active **factor D (FD)** inhibitor with an IC_{50} of 30 nM and a K_d of 6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Falcarindiol

Cat. No.: HY-N0364

Falcarindiol, an orally active polyacetylenic oxylipin, activates PPARγ and increases the expression of the cholesterol transporter ABCA1 in cells. Falcarindiol induces **apoptosis** and **autophagy**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Fargesin

Cat. No.: HY-N0719

Fargesin is a bioactive neolignan isolated from magnolia plants, with antihypertensive and anti-inflammatory effects.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Farrerol

Cat. No.: HY-N0344

Farrerol is a bioactive constituent of Rhododendron, with broad activities such as anti-oxidative, anti-inflammatory, anti-tumor, neuroprotective and hepatoprotective effects.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

FCPR03

Cat. No.: HY-117977

FCPR03 is a potent and selective **phosphodiesterase 4 (PDE4)** inhibitor with IC_{50} values of 60 nM, 31 nM and 47 nM for **PDE4 catalytic domain**, **PDE4B1** and **PDE4D7**, respectively. FCPR03 displays at least 2100-fold selectivity over other PDEs (PDE1-3 and PDE5-11).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FD-IN-1

Cat. No.: HY-128570

FD-IN-1 (Compound 12) is an orally bioavailable and selective **factor D** (**FD**) inhibitor with an IC_{50} of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Felbinac

(4-Biphenylacetic acid)

Cat. No.: HY-B0641

Felbinac is a potent non-steroidal anti-inflammatory agent, used to treat muscle inflammation and arthritis.



Purity: 98.07%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Fenamic acid

(N-Phenylanthranilic acid)

Cat. No.: HY-W040265

Fenamic acid is a **chloride channel** blocker.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Fenbufen

(CL-82204)

Cat. No.: HY-B1138

Fenbufen (CL-82204) is an orally active **non-steroidal anti-inflammatory drug (NSAID)**, with analgetic and antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis.



Purity: 98.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Fenbufen-d9

Cat. No.: HY-B1138S

Fenbufen-d9 (CL-82204-d9) is the deuterium labeled Fenbufen. Fenbufen (CL-82204) is an orally active **non-steroidal anti-inflammatory drug (NSAID)**, with antipyretic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Fenclozine

Cat. No.: HY-19017

Fenclozine is a non-steroidal antiinflammatory drug extracted from patent WO 2012112690 A2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fenoprofen Calcium

Cat. No.: HY-B0288A

Fenoprofen Calcium is a nonsteroidal, anti-inflammatory antiarthritic agent.



Purity: >98%
Clinical Data: Launched
Size: 500 mg

Fenoprofen Calcium hydrate

(Fenoprofen calcium salt dihydrate)

Cat. No.: HY-B0288B

Fenoprofen Calcium hydrate is a nonsteroidal, anti-inflammatory antiarthritic agent.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Fenoterol

(Th-1165; Phenoterol)

Cat. No.: HY-B0976

Fenoterol (Th-1165), a sympathomimetic agent, is a selective and orally active **β2-adrenoceptor** agonist. Fenoterol is an effective bronchodilator and can be used for bronchospasm associated with asthma, bronchitis and other obstructive airway diseases research.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Fenoterol hydrobromide

(Th-1165a; Phenoterol hydrobromide)

Cat. No.: HY-B0976A

Fenoterol hydrobromide (Th-1165a), a sympathomimetic agent, is a selective and orally active **β2-adrenoceptor** agonist.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Fenoterol-d6 hydrobromide

Cat. No.: HY-B0976AS

Fenoterol-d6 hydrobromide (Th-1165a-d6) is the deuterium labeled Fenoterol hydrobromide. Fenoterol hydrobromide (Th-1165a), a sympathomimetic agent, is a selective and orally active **β2-adrenoceptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Fenspiride hydrochloride

Cat. No.: HY-A0027

Fenspiride hydrochloride is an α adrenergic and H1 histamine receptor antagonist. IC50 value: Target: Adrenergic receptor; H1 receptor Fenspiride hydrochloride is a bronchodilator with anti-inflammatory properties.



Purity: 99.11%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Fenspiride-d5 hydrochloride

Cat. No.: HY-A0027S

Fenspiride-d5 hydrochloride is the deuterium labeled Fenspiride hydrochloride. Fenspiride hydrochloride is an α adrenergic and H1 histamine receptor antagonist.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Feretoside

Cat. No.: HY-N6249

Feretoside, a phenolic compound extracted from the barks of E. ulmoides, is a **HSP inducer** which act as cytoprotective agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ferrous bisglycinate

Cat. No.: HY-130078

Ferrous bisglycinate is an orally active iron fortificants and therapeutic iron supplements. Ferrous bisglycinate can be used for the research of iron deficiency anemia.



Purity: ≥98.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 250 mg

Ferulic acid methyl ester

(Methyl ferulate)

Cat. No.: HY-W018643

Ferulic acid methyl ester (Methyl ferulate) is a derivative of ferulic acid, isolated from Stemona tuberosa, with anti-inflammatory and antioxidant properties.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

FeTPPS

Cat. No.: HY-131697

FeTPPS, a 5,10,15,20-tetrakis (4-sulfonatophenyl) porphyrin iron III chloride peroxynitrite decomposition catalyst, possesses evident neuroprotective effects in a experimental model of spinal cord damage. FeTPPS acts as a.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fexofenadine hydrochloride (MDL-16455 hydrochloride; Terfenadine carboxylate hydrochloride)

Cat. No.: HY-B0801A

Fexofenadine hydrochloride (MDL-16455 hydrochloride), a **H1R** antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial (person aged ≥16 years).



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Fexofenadine-d6

(MDL-16455-d6; Terfenadine carboxylate-d6)

Cat. No.: HY-B0801S

Fexofenadine D6 (MDL-16455 D6) is deuterium labeled is Fexofenadine, which is an antihistamine pharmaceutical agent.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fezagepras

(Setogepram; PBI-4050)

Cat. No.: HY-100775A

Fezagepras (Setogepram) acts as an orally active agonist for **GPR40** and as an antagonist or inverse agonist for **GPR84**. Fezagepras decreases renal, liver and pancreatic fibrosis. Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Fezagepras sodium

(Setogepram sodium; PBI-4050 sodium)

Cat. No.: HY-100775

Fezagepras (Setogepram) sodium acts as an orally active agonist for **GPR40** and as an antagonist or inverse agonist for **GPR84**. Fezagepras sodium decreases renal, liver and pancreatic fibrosis. Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions.



Purity: 99.65%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fiboflapon

(GSK2190915; AM-803)

Cat. No.: HY-15874

Fiboflapon (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (**FLAP**) inhibitor with a potency of 2.9 nM in FLAP binding, an IC_{50} of 76 nM for inhibition of **LTB4** in human blood.



Purity: 98.54%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Fiboflapon sodium

(GSK2190915 sodium salt; AM-803 sodium)

Cat. No.: HY-15874A

Fiboflapon sodium (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (**FLAP**) inhibitor with a potency of 2.9 nM in FLAP binding, an IC_{50} of 76 nM for inhibition of **LTB4** in human blood.



Purity: 99.08%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Fibrinopeptide B, human

(FPB,human)

Cat. No.: HY-P1493

Fibrinopeptide B, human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin.

{Glp}GVNDNEEGFFSAR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fibrinopeptide B, human TFA

(FPB,human TFA)

Cat. No.: HY-P1493A

Fibrinopeptide B, human TFA (FPB,human TFA), human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin.

{Glp}GVNDNEEGFFSAR (TFA salt)

Purity: 99.81%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Fibronectin

Cat. No.: HY-P3160

Fibronectin, a glycoprotein (~500 kDa) present in blood as well as in cells, is a biomarker of tissue injury. Fibronectin binds to membrane-spanning receptor proteins called integrins.

Fibronectins

Purity: 97.40%
Clinical Data: No Development Reported
Size: 1 mg

Fibronectin Active Fragment Control

Cat. No.: HY-P1897

Fibronectin Active Fragment Control is an active peptide fragment of fibronectin. Fibronectin is a glycoprotein interacting with integrins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Filipin III

Cat. No.: HY-N6718

Filipin III is the major component of Filipin, a 28-membered ring pentaene macrolide **antifungal antibiotic** produced by S. filipinensis, S. avermitilis and S. miharaensis. Filipin interacts with membrane sterols causing the alteration of membrane structure.



Purity: 99.0%
Clinical Data: No Development Reported
Size: 1 mg

Fingolimod

(FTY720 free base)

Cat. No.: HY-11063

Fingolimod (FTY720 free base) is a **sphingosine 1-phosphate** (**S1P**) antagonist with an IC_{50} of 0.033 nM in K562 and NK cells. Fingolimod also is a **pak1** activator, a immunosuppressant.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g, 5 g

Fingolimod hydrochloride

(FTY720)

Cat. No.: HY-12005

Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent **sphingosine 1-phosphate** (**S1P**) receptors modulator. Fingolimod hydrochloride is phosphorylated by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g, 5 g

FIPI

(5-Fluoro-2-indolyl deschlorohalopemide)

Cat. No.: HY-12807

FIPI is a derivative of halopemide which potently inhibits both **PLD1** and **PLD2** with IC_{50}s of 25 nM and 20 nM, respectively.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Firocoxib

(ML 1785713)

Cat. No.: HY-14670

Firocoxib (ML 1785713) is a potent, selective and orally active **COX-2** inhibitor with an IC_{50} of 0.13 μM. Firocoxib shows 58-fold more selective for **COX-2** than COX-1 (IC_{50} of 7.5 μM). Firocoxib has anti-inflammatory effects.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Firocoxib-d4

Cat. No.: HY-14670S

Firocoxib-d4 (ML 1785713-d4) is the deuterium labeled Firocoxib. Firocoxib (ML 1785713) is a potent, selective and orally active **COX-2** inhibitor with an IC_{50} of 0.13 μM. Firocoxib shows 58-fold more selective for **COX-2** than COX-1 (IC_{50} of 7.5 μM).



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Firzacorvir

Cat. No.: HY-139574

Firzacorvir is a cyclic sulfamide compound and modulates **HBV** core protein. Firzacorvir has anti-HBV activity with EC_{50} < 1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fisetin

Cat. No.: HY-N0182

Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.



Purity: 98.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

FK 3311

(COX-2 Inhibitor V)

Cat. No.: HY-14445

FK 3311 (COX-2 Inhibitor V) is a selective inhibitor of **COX-2** with antiinflammatory agent.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

FK706

Cat. No.: HY-19269

FK706 is a potent, slow-binding and competitive inhibitor of **human neutrophil elastase** with an IC_{50} of 83 nM and a K_i of 4.2 nM.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

FKK

Cat. No.: HY-100194

FKK is an indazole derivative and also a novel bronchodilator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLAG peptide

Cat. No.: HY-P0223

FLAG peptide is an eight amino acids peptide (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) with an enterokinase-cleavage site; designed for antibody-mediated identification and purification of recombinant proteins.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Flavanone hydrazone

Cat. No.: HY-135301

Flavanone hydrazine is a potent non-steroidal anti-inflammatory agent. Flavanone hydrazine effectively inhibits lens protein-induced ocular inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FliC, Serotype a (427-441), S.paratyphi A

Cat. No.: HY-P1916

FliC, Serotype a (427-441), S.paratyphi A is amino acids 427 to 441 fragment belongs to the FliC, serotype a of the S. FliC epitope.

VQNRFNSAITNLGNT

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Floctafenine

Cat. No.: HY-A0259

Floctafenine, a nonsteroidal anti-inflammatory agent (NSAID), acts as an effective analgesic agent. Floctafenine is an inhibitor of **COX-1 and COX-2 activities in vitro,showing a slightly higher potency towards COX-I. Floctafenine is used for the research of short term pain treatment.**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flosulide

(ZK 38997; CGP 28238)

Cat. No.: HY-U00083

Flosulide is a potent and selective **COX-2** inhibitor, used for the treatment for inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fludrocortisone

(9α-Fludrocortisone; 9α-Fluorcortisol)

Cat. No.: HY-B1203

Fludrocortisone, a synthetic mineralocorticoid with anti-inflammatory activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Fludrocortisone acetate

(9α-Fludrocortisone acetate; 9α-Fluorcortisol acetate)

Cat. No.: HY-B1203A

Fludrocortisone acetate (9α-Fludrocortisone acetate) is a synthetic mineralocorticoid, used to control the amount of sodium and fluids in your body.



Purity: 99.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Flufenamic acid

Cat. No.: HY-B1221

Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (**COX**), activates **AMPK**, and also modulates ion channels, blocking **chloride channels** and **L-type Ca^{2+} channels**, modulating non-selective cation channels (**NSC**), activating...



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Flumethasone

(Flumetasone)

Cat. No.: HY-B1051

Flumethasone is a corticosteroid for topical use, in combination with Clioquinol for the treatment of otitis externa and otomycosis. Flumethasone shows fully 420 times the potency of cortisone in an animal model for anti-inflammatory activity.



Purity: 99.63%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

Flunisolide

Cat. No.: HY-B1121

Flunisolide is a corticosteroid often used to treat allergic rhinitis.The principal mechanism of action of Flunisolide is to activate glucocorticoid receptors, meaning it has an anti-inflammatory action.



Purity: 99.92%
Clinical Data: Launched
Size: 100 mg

Flunixin meglumine

Cat. No.: HY-B0386

Flunixin Meglumine is a potent inhibitor of COX used as analgesic agent with anti-inflammatory and antipyretic activity. Target: COX Flunixin meglumine is a potent, non-narcotic, non-steroidal analgesic agent with anti-inflammatory and antipyretic activity.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Flunixin-d3

Cat. No.: HY-121046S

Flunixin-d3 is the deuterium labeled Flunixin. Flunixin Meglumine is a potent inhibitor of COX used as analgesic agent with anti-inflammatory and antipyretic activity.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Fluocinolone (Acetonide)

Cat. No.: HY-B0415

Fluocinolone Acetonide is a glucocorticoid derivative used topically in the treatment of various skin disorders. Target: Glucocorticoid Receptor Fluocinolone acetonide is a corticosteroid primarily used in dermatology to reduce skin inflammation and relieve itching.



Purity: 99.11%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Fluocinonide

Cat. No.: HY-B0485

Fluocinonide (Vanos) is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Fluorescein Biotin

Cat. No.: HY-D1030

Fluorescein Biotin is used as an alternative to radioactive biotin for detecting and quantitating biotin-binding sites by either fluorescence or absorbance; the the fluorescence or absorbance of Fluorescein Biotin is quenched, upon binding to avidin or streptavidin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Fluorofenidone

(AKF-PD)

Cat. No.: HY-121246

Fluorofenidone (AKF-PD), an analogue of AMR69, shows equivalent antifibrotic activity, lower toxicity and longer half-life.



Purity: 98.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fluorometholone

Cat. No.: HY-B1893

Fluorometholone, a synthetic glucocorticoid, is a **glucocorticoid receptor** agonist with anti-inflammatory and anti-allergic properties. Fluorometholone can be used for the research of dry eye.



Purity: 99.49%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Fluorometholone acetate

Cat. No.: HY-B1471

Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits **carbonic anhydrase (CA)** with IC_{50}s of 2.18 μM and 17.5 μM for **hCA-I** and **hCA-II**, respectively.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Flurandrenolide

(Fludroxycortide; Flurandrenolone)

Cat. No.: HY-B1013

Fludroxycortide is a synthetic topical steroid and is used as an anti-inflammatory treatment for use on skin irritations.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Flurbiprofen

(dl-Flurbiprofen)

Cat. No.: HY-10582

Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Flurbiprofen axetil

Cat. No.: HY-101481

Flurbiprofen axetil is a non-selective **cyclooxygenase (COX)** inhibitor. Flurbiprofen axetil has anti-inflammatory effect.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Fluticasone (propionate)

Cat. No.: HY-B0154

Fluticasone propionate, a potent topical anti-inflammatory corticosteroid, is a selective **glucocorticoid receptor** agonist, with an absolute affinity (K_D) of 0.5 nM. Fluticasone propionate shows little or no activity at other steroid receptors. Anti-viral activity.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Fluticasone furoate

Cat. No.: HY-15234

Fluticasone furoate is a topical, intranasal, enhanced-affinity synthetic trifluorinated **corticosteroid** with a K_d of 0.3 nM. Fluticasone furoate has potent anti-inflamatory and anti-asthmatic activity, and low systemic exposure.



Purity: 99.06%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg

FM-381

Cat. No.: HY-102046

FM-381 is a potent covalent reversible inhibitor of **JAK3** targeting the unique Cys909. FM-381 has an IC_{50} of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FM-479

Cat. No.: HY-131014

FM-479 is the **negative control** of FM-381 (HY-102046) and has no activity on JAK3 or other kinases. FM-381 is a potent covalent reversible inhibitor of **JAK3** targeting the unique Cys909.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fmoc-Thr[GalNAc(Ac)3-α-D]-OH

(Fmoc-Thr(Ac_3AcNH-α-Gal)-OH)

Cat. No.: HY-P0232

AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight.



Purity: 98.36%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Fodipir

(DPDP)

Cat. No.: HY-108869

Fodipir is an active metabolite of mangafodipir, involved in mangafodipir-mediated cytoprotection against 7β-hydroxycholesterol-induced cell death.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Forskolin

(Coleonol; Colforsin)

Cat. No.: HY-15371

Forskolin (Coleonol) is a potent **adenylate cyclase** activator with an IC_{50} of 41 nM and an EC_{50} of 0.5 μM for **type I adenylyl cyclase**. Forskolin is also an inducer of intracellular **cAMP** formation.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Forsythiaside A

Cat. No.: HY-N0028

Forsythiaside A, a phenylethanoside product isolated from air-dried fruits of Forsythia suspense, has anti-inflammatory and antioxidant effects.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Forsythoside B

Cat. No.: HY-N0029

Forsythoside B is a phenylethanoid glycoside isolated from the leaves of Lamiophlomis rotata Kudo, a Chinese folk medicinal plant for treating inflammatory diseases and promoting blood circulation. Forsythoside B could inhibit **TNF-alpha**, **IL-6**, **IκB** and modulate **NF-κB**.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Forsythoside E

Cat. No.: HY-N2173

Forsythoside E is a phenylethanoid glycoside isolated from the fruits of forsythia suspense (thunb.) vahl.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Forsythoside H

Cat. No.: HY-N5043

Forsythoside H, a caffeoyl phenylethanoid glycoside (CPG) isolated from the fruits of Forsythia suspense (Thunb.) Vahl, may possesses anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Forsythoside I

Cat. No.: HY-N5042

Forsythoside I, a caffeoyl phenylethanoid glycoside (CPG) isolated from the fruits of Forsythia suspense (Thunb.) Vahl, may possesses anti-inflammatory activities.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Fosdagrocorat

(PF-04171327)

Cat. No.: HY-16722

Fosdagrocorat (PF-04171327) is a dissociated **glucocorticoid receptor** agonist.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fosifidancitinib

Cat. No.: HY-109175

Fosifidancitinib is a potent and selective inhibitor of **JAK kinases 1/3**. Fociatinib is used in studies of allergies, asthma and autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fostamatinib

(R788)

Cat. No.: HY-13038A

Fostamatinib (R788) is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM. R406 also inhibits Lyn (IC_{50}=63 nM) and Lck (IC_{50}=37 nM).



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fostamatinib Disodium

(R788(Disodium)) Cat. No.: HY-13038

Fostamatinib Disodium (R788 Disodium) is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM. R406 also inhibits Lyn (IC_{50}=63 nM) and Lck (IC_{50}=37 nM).



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fostamatinib disodium hexahydrate

(R788 disodium hexahydrate) Cat. No.: HY-13038B

Fostamatinib (R788) disodium hexahydrate is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM. R406 also inhibits Lyn (IC_{50}=63 nM) and Lck (IC_{50}=37 nM).



Purity: 98.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FPFT-2216

Cat. No.: HY-145319

FPFT-2216, a "molecular glue" compound, degrades phosphodiesterase 6D (**PDE6D**), zinc finger transcription factors Ikaros (**IKZF1**), Aiolos (**IKZF3**), and casein kinase 1α (**CK1α**). FPFT-2216 can be used for the research of cancer and inflammatory disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FPL 62064

Cat. No.: HY-105024

FPL 62064 is a potent **5-lipoxygenase (5-LOX)** and **COX** dual inhibitor, with IC_{50} values of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and prostaglandin synthetase (cyclooxygenase), respectively. FPL 62064 has potent anti-inflammatory activity.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

FPR Agonist 43

Cat. No.: HY-19574

FPR Agonist 43 (compound 43) is a dual **formyl peptide receptor 1 (FPR1)** and **formyl peptide receptor 2 (FPR2)/ALX** agonist.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

FR-188582

Cat. No.: HY-U00146

FR-188582 is a highly selective inhibitor of **cyclooxygenase** (**COX**)-2, with an IC_{50} value of 17 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

FR167344 free base

Cat. No.: HY-100301

FR167344 free base is an orally active, nonpeptide **bradykinin receptor B2** antagonist. FR167344 free base shows a high affinity binding to the B2 receptor with an IC_{50} value of 65 nM and no binding affinity for the B1 receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FR183998 free base

Cat. No.: HY-100302

FR183998 free base is a potent **Na^+/H^+-exchange** inhibitor, with IC_{50}s of 0.3 nM, 3.1 nM and 6.5 nM by measurement of pH_i change in rat lymphocytes, rat and human platelets, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fraxetin

Cat. No.: HY-N0580

Fraxetin is isolated from Cortex Fraxini. Fraxetin has antitumor, anti-oxidation effects and anti-inflammory effects. Fraxetin induces **apoptosis**.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Fraxin

(Fraxoside) Cat. No.: HY-N0579

Fraxin isolated from Acer tegmentosum, F. ornus or A. hippocastanum, is a glucoside of fraxetin and reported to exert potent anti-oxidative stress action, anti-inflammatory and antimetastatic properties.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Fraxinellone

Cat. No.: HY-N0242

Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a **PD-L1** inhibitor and inhibits **HIF-1α** protein synthesis without affecting HIF-1α protein degradation.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Frentizole

Cat. No.: HY-15374

Frentizole, an FDA-approved immunosuppressive drug, is a novel inhibitor of the Aβ-ABAD interaction.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Freselestat

(ONO-6818; ONO-PO-736)

Cat. No.: HY-15652

Freselestat (ONO-6818) is a potent and orally active **neutrophil elastase** inhibitor with a K_i of 12.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

Freselestat quarterhydrate

(ONO-6818 quarterhydrate; ONO-PO-736 quarterhydrate)

Cat. No.: HY-15652A

Freselestat quarterhydrate (ONO-6818 quarterhydrate) is a potent and orally active **neutrophil elastase** inhibitor with a K_i of 12.2 nM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

FRG8701

Cat. No.: HY-U00238

FRG-8701 is a new **Histamine H_2-receptor** antagonist with an **IC_{50}** of ranging from 0.25 to 0.43 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FT011

Cat. No.: HY-100495

FT011 is an anti-fibrotic agent, reduces mRNA expression of collagens I and III and inhibits collagen synthesis.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FT895

Cat. No.: HY-112285

FT895 is a potent and selective **HDAC11** inhibitor with an **IC_{50}** of 3 nM.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

FTY720 (S)-Phosphate

((S)-FTY720P; (S)-FTY720 phosphate)

Cat. No.: HY-15382

FTY720 (S)-Phosphate is an agonist of **S1P receptor 1 (S1PR1)**, used in the research of acute inflammatory diseases such as acute lung injury.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Fucoxanthin

(all-trans-Fucoxanthin)

Cat. No.: HY-N2302

Fucoxanthin is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.

Purity: 98.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fudosteine

Cat. No.: HY-B0393

Fudosteine is a cysteine derivative and a mucoactive agent. Fudosteine inhibits MUC5AC mucin hypersecretion by reducing MUC5AC gene expression.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Fulvic Acid

Cat. No.: HY-122515

Fulvic Acid is a natural healthy product, which comes from humic substances produced by microorganisms in soil. Fulvic Acid can modulate the immune system, influence the oxidative state of cells, and improve gastrointestinal function.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Funapide

(TV 45070; XEN402)

Cat. No.: HY-16723

Funapide (TV 45070; XEN402) is a potent **Sodium Channel Nav1.7** inhibitor.



Purity: 99.72%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Furaltadone hydrochloride

(Altafur hydrochloride)

Cat. No.: HY-B1148

Furaltadone hydrochloride, a nitrofuran drug, has the potential for the study in infections of chickens with salmonella enteritidis. Furaltadone is inhibitory and bactericidal in vitro for staphylococci .



Purity: 98.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Furaltadone L-tartrate

(Altafur L-tartrate)

Cat. No.: HY-B1148B

Furaltadone L-tartrate (Altafur L-tartrate), a nitrofuran drug, has the potential for the study in infections of chickens with salmonella enteritidis. Furaltadone is inhibitory and bactericidal in vitro for staphylococci .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Furamidine

(DB75; NSC 305831)

Cat. No.: HY-110137A

Furamidine (DB75) is a selective **protein arginine methyltransferase 1 (PRMT1)** inhibitor with an **IC_{50}** of 9.4 μM. Furamidine is selective for **PRMT1** over PRMT5, PRMT6, and PRMT4 (CARM1) (IC_{50}s of 166 μM, 283 μM, and >400 μM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Furamidine dihydrochloride

(DB75 dihydrochloride; NSC 305831 dihydrochloride)

Cat. No.: HY-110137

Furamidine dihydrochloride (DB75 dihydrochloride) is a selective **protein arginine methyltransferase 1 (PRMT1)** inhibitor with an **IC_{50}** of 9.4 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Furamidine-d8

Cat. No.: HY-110137AS

Furamidine-d8 (DB75-d8) is the deuterium labeled Furamidine. Furamidine (DB75) is a selective **protein arginine methyltransferase 1 (PRMT1)** inhibitor with an **IC_{50}** of 9.4 μM.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Furobufen

Cat. No.: HY-105808

Furobufen, an anti-inflammatory agent, produces antiarthritic, antipyretic effects. Furobufen has an analgesic effect in inflamed tissue.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Furprofen

Cat. No.: HY-106907

Furprofen is an non-steroidal anti-inflammatory drug (NSAID) with analgesic properties. Furprofen acts via the inhibition of **prostaglandin (PGE) synthesis**. Furprofen can be treated orally for the relief of pain.



Purity: 99.85%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fursultiamine

Cat. No.: HY-B2082

Fursultiamine is a **vitamin B_1 derivative**, has anti-nociceptive and antineoplastic activity. Fursultiamine can be used for vitamin B_1 deficiency, osteoarthritis (OA) and cancer research.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Futoquinol

Cat. No.: HY-N3915

Futoquinol is a neolignan isolated from the dried aerial parts of Piper kadsura (Piperaceae). Futoquinol potently inhibits NO production in microglia cells. Futoquinol has anti-neuroinflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FW1256

Cat. No.: HY-121955

FW1256 is a phenyl analogue and a slow-releasing hydrogen sulfide (H_2S) donor. FW1256 inhibits **NF-κB** activity and induces cell **apoptosis**. FW1256 exerts potent anti-inflammatory effects and has the potential for cancer and cardiovascular disease treatment.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

G-744

Cat. No.: HY-102036

G-744 is a highly potent, selective and orally active **Btk** inhibitor with an **IC_{50}** of 2 nM. G-744 is metabolically stable, well tolerated and efficacious to treat arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

G140

Cat. No.: HY-133916

G140 is a potent and selective inhibitor of **cyclic GMP-AMP synthase (cGAS)**, with **IC_{50}**s of 14.0nM and 442nM for h-cGAS and m-cGAS, respectively. G140 has anti-inflammatory activity.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

G150

Cat. No.: HY-128583

G150 is a potent and highly selective **human cyclic GMP-AMP synthase (h-cGAS)** inhibitor for repression of dsDNA-triggered interferon expression, with an **IC_{50}** of 10.2 nM.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Gabexate mesylate

(FOY)

Cat. No.: HY-B0385

Gabexate mesylate is a Factor X inhibitor; serine protease inhibitor .



Purity: 98.12%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 100 mg

GAD65 (206-220)

Cat. No.: HY-P2525

GAD65 (206-220) is glutamic acid decarboxylase (GAD) 65-derived peptide, corresponding to residues 180-188. GAD65 is presented to T cells in association with I-Ag7 MHC class II molecules and a major pancreatic antigens targeted by self-reactive T cells in type I diabetes mellitus.

TYEIAPVFVLLEYVT

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GAL-021

Cat. No.: HY-101422

GAL-021 a new intravenous **BKCa-channel** blocker.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Galantide

Cat. No.: HY-P0262

Galantide, a non-specific **galanin receptor** antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (K_D<0.1 nM and ~6 nM) in the rat hypothalamus.

GWTLNSAGYLLGPQQFFGLM-NH_2

Purity: 99.27%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Galicaftor

(ABBV-2222; GLPG-2222)

Cat. No.: HY-111111

Galicaftor (ABBV-2222; GLPG-2222) is a potent and orally active **cystic fibrosis transmembrane conductance regulator (CFTR)** corrector. Galicaftor can be used for cystic fibrosis research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gallic acid hydrate

(3,4,5-Trihydroxybenzoic acid hydrate) Cat. No.: HY-N0523A

Gallic acid (3,4,5-Trihydroxybenzoic acid) hydrate is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit **cyclooxygenase-2 (COX-2)**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Gamma-glutamylcysteine

(γ-Glutamylcysteine) Cat. No.: HY-113402

Gamma-glutamylcysteine (γ-Glutamylcysteine), a dipeptide containing cysteine and glutamic acid, is a precursor to glutathione (GSH). Gamma-glutamylcysteine is a cofactor for glutathione peroxidase (GPx) to increase GSH levels.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg

Gamma-glutamylcysteine TFA

(γ-Glutamylcysteine TFA) Cat. No.: HY-113402A

Gamma-glutamylcysteine (γ-Glutamylcysteine) TFA, an intermediate in glutathione (GSH) synthesis, is a dipeptide served as an essential cofactor for the antioxidant enzyme glutathione peroxidase (GPx).



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Ganoderic acid C1

Cat. No.: HY-129151

Ganoderic acid C1, a natural compound that could be isolated from G. lucidum, suppresses TNF-α production by murine macrophages (RAW 264.7 cells).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ganoderic acid D2

Cat. No.: HY-N3500

Ganoderic acid D2 (compound 27) is a triterpenoid isolated from Ganoderma lucidum. Ganoderic acid D2 has anticancer, anti-inflammatory and antioxidative activity.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Ganoderic acid DM

Cat. No.: HY-120140

Ganoderic acid DM, a natural triterpenoid isolated from Ganoderma lucidum, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Ganoderic acid DM as a specific inhibitor of osteoclastogenesis.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ganoderic acid J

Cat. No.: HY-N9312

Ganoderic acid J is a natural terpenoid isolated from the Fungus Ganoderma lucidum. Ganoderic acid J possesses anti-inflammatory anti-inflammatory activity.



Purity: 98.27%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Ganoderol A

Cat. No.: HY-N3925

Ganoderol A is a terpenoid extracted from Ganoderma lucidum with antimicrobial activities. Ganoderol A inhibits cholesterol synthesis pathway and has significant anti-inflammatory activity and protection against ultraviolet A (UVA) damage.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Garcinol

Cat. No.: HY-107569

Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards **acetyl cholinesterase (AChE)** and **butyrylcholinesterase (BChE)** with **IC_{50}**s of 0.66 μM and 7.39 μM, respectively.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Gastrodin

(Gastrodine) Cat. No.: HY-N0115

Gastrodin, a main constituent of a Chinese herbal medicine Tianma, has been known to display anti-inflammatory effects. Gastrodin, has long been used for treating dizziness, epilepsy, stroke and dementia.



Purity: 99.14%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Gastrofensin AN 5 free base

Cat. No.: HY-100296

Gastrofensin AN 5 free base, a 4-phenyl-tetrahydroisoquinoline derivative, is an antiulcer agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gatifloxacin sesquihydrate (AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate)

Cat. No.: HY-10581C

Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone **antibiotic** with broad-spectrum antibacterial activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Gaultherin

Cat. No.: HY-N1965

Gaultherin, a natural salicylate derivative, is isolated from Gaultheria yunnanensis. Gaultherin is a non-steroidal anti-inflammatory drug (NSAID). Gaultherin has analgesic and anti-inflammatory effects and lack gastric ulcerogenic effect compared to Aspirin.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

GB-110

Cat. No.: HY-120528

GB-110 is a potent, orally active, and nonpeptidic **protease activated receptor 2 (PAR2)** agonist. GB-110 selectively induces PAR2-mediated intracellular Ca^{2+} release in HT29 cells with an EC_{50} of 0.28 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GB-110 hydrochloride

Cat. No.: HY-120528A

GB-110 hydrochloride is a potent, orally active, and nonpeptidic **protease activated receptor 2 (PAR2)** agonist. GB-110 hydrochloride selectively induces PAR2-mediated intracellular Ca^{2+} release in HT29 cells with an EC_{50} of 0.28 μM.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GB-88

Cat. No.: HY-120261

GB-88 is an oral, selective non-peptide antagonist of **PAR2**, inhibits **PAR2** activated Ca^{2+} release with an IC_{50} of 2 μM.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GDC-0834

Cat. No.: HY-15427

GDC-0834 is a potent and selective **BTK** inhibitor. GDC-0834 inhibits BTK with an in vitro IC_{50} of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC_{50} of 1.1 and 5.6 μM in mouse and rat, respectively.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GDC-0834 Racemate

Cat. No.: HY-15427A

GDC-0834 Racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Gedunin

Cat. No.: HY-107577

Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent **Hsp90** inhibitor and induces the degradation of Hsp90-dependent client proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gefapixant (MK-7264; AF-219)

Cat. No.: HY-101588

Gefapixant (MK-7264) is an orally active P2X3 receptor (**P2X3R**) antagonist with IC_{50}s of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors.



Purity: 99.32%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gefarnate

Cat. No.: HY-B2206

Gefarnate is a drug used for the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of dry eye syndrome.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Geldanamycin

Cat. No.: HY-15230

Geldanamycin is a **Hsp90** inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus **H5N1** activities.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Gemcabene

(PD-72953)

Cat. No.: HY-109567

Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein...



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Gemcabene calcium

(PD-72953 calcium)

Cat. No.: HY-109567A

Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein,...



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Gemilukast

(ONO-6950)

Cat. No.: HY-16780

Gemilukast is an orally active and potent dual cysteinyl leukotriene 1 and 2 receptors **($CysLT_1$ and $CysLT_2$)** antagonist, with **IC_{50}s** of 1.7, 25 nM for human $CysLT_1$ and $CysLT_2$, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Genipin

((+)-Genipin)

Cat. No.: HY-17389

Genipin ((+)-Genipin) is a natural crosslinking reagent derived from Gardenia jasminoides Ellis fruits. Genipin inhibits UCP2 (uncoupling protein 2) in cells.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Genipin 1-β-D-gentiobioside (Genipin 1-gentiobioside; Genipin 1-β-gentiobioside; Genipin gentiobioside)

Cat. No.: HY-N2094

Genipin 1-β-D-gentiobioside (Genipin 1-gentiobioside) is one of the most abundant and bioactive iridoid glycosides in Gardenia jasminoides Ellis, which possesses hepatoprotective, anti-inflammatory, antioxidant, and antithrombotic activities.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Genkwanin

(Puddumetin)

Cat. No.: HY-N0731

Genkwanin is a major non-glycosylated flavonoid with anti-flammatory activities.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Gentianine

Cat. No.: HY-N6039

Gentianine, an active metabolite of Swertiamarin, has anti-diabetic effect and anti-inflammatory property.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gentiopicroside

(Gentiopicrin)

Cat. No.: HY-N0494

Gentiopicroside, a naturally occurring iridoid glycoside, inhibits **P450** activity, with an IC_{50} and a K_i of 61 μM and 22.8 μM for CYP2A6; Gentiopicroside has antianti-inflammatoryand antioxidative effects.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

GENZ-882706

(RA03546849)

Cat. No.: HY-101526

GENZ-882706 is a potent colony stimulating factor-1 receptor (**CSF-1R**) Inhibitor extracted from patent WO 2017015267A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Geraniin

Cat. No.: HY-N0472

Geraniin is a **TNF-α** releasing inhibitor with numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities, with an IC_{50} of 43 μM.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginger extract

Cat. No.: HY-N9451

Ginger extract exhibits anti-cancer, anti-inflammatory and chemotherapeutic effects in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg

Ginkgetin

Cat. No.: HY-N0889

Ginkgetin, a biflavone, is isolated from Ginkgo biloba leaves. Ginkgetin exhibit anti-tumor, anti-inflammatory, neuroprotective, anti-fungal activities. Ginkgetin is also a potent inhibitor of **Wnt signaling**, with an IC_{50} of 5.92 μM.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginkgolide A

(BN-52020)

Cat. No.: HY-B0355

Ginkgolide A (BN-52020) is an extract from in Ginkgo biloba and a g-aminobutyric acid (GABA) antagonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ginsenoside C-K

(Ginsenoside compound K; Ginsenoside K)

Cat. No.: HY-N0904

Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing **iNOS** and **COX-2**. Ginsenoside C-K exhibits an inhibition against the activity of **CYP2C9** and **CYP2A6** in human liver microsomes with IC_{50}s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside F3

Cat. No.: HY-N0600

Ginsenoside F3, a component of PPTGs (an minor saponin in the leaves of Panax ginseng), has immunoenhancing activity by regulating production and gene expression of type 1 cytokines (IL-2, IFN-gamma) and type 2 cytokines (IL-4 and IL-10).



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

Ginsenoside F4

Cat. No.: HY-N2503

Ginsenoside F4 (GF4), ginseng saponinis, isolated from notoginseng or red ginseng. Ginsenoside F4 (GF4) has inhibitory effect on human lymphocytoma JK cell by inducing its **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ginsenoside Ra2

Cat. No.: HY-N4260

Ginsenoside Ra2 is a component from Panax ginseng.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ginsenoside Rb1

(Gypenoside III)

Cat. No.: HY-N0039

Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits **Na^+, K^+-ATPase** activity with an IC_{50} of 6.3±1.0 μM. Ginsenoside also inhibits **IRAK-1** activation and phosphorylation of **NF-κB p65** .



Purity: 98.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ginsenoside Rb2

(Ginsenoside C)

Cat. No.: HY-N0040

Ginsenoside Rb2 is one of the main bioactive components of ginseng extracts. Rb2 can upregulate **GPR120** gene expression. Ginsenoside Rb2 has antiviral effects.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rb3

(Gypenoside IV)

Cat. No.: HY-N0041

Ginsenoside Rb3 is extracted from steamed Panax notoginseng. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced **NF-κB** transcriptional activity with an IC_{50} of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of **COX-2** and **iNOS** mRNA.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rc

(Panaxoside Rc)

Cat. No.: HY-N0042

Ginsenoside Rc, one of major Ginsenosides from Panax ginseng, enhances GABA receptor$_A$ (**GABA$_A$**)-mediated ion channel currents (I_{GABA}). Ginsenoside Rc inhibits the expression of **TNF-α** and **IL-1β**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rd

(Gypenoside VIII)

Cat. No.: HY-N0043

Ginsenoside Rd inhibits TNFα-induced **NF-κB** transcriptional activity with an IC_{50} of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of **COX-2** and **iNOS** mRNA. Ginsenoside Rd also inhibits **Ca^{2+}** influx.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rd2

Cat. No.: HY-N2516

Ginsenoside Rd2 is a saponin found in Panax japonicus with anti-inflammatory actions.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 1 mg

Ginsenoside Re

(Ginsenoside B2; Panaxoside Re; Sanchinoside Re)

Cat. No.: HY-N0044

Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the **β-amyloid** protein (**Aβ**). Ginsenoside Re plays a role in antiinflammation through inhibition of **JNK** and **NF-κB**.



Purity: 98.15%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rg1

(Panaxoside A; Panaxoside Rg1)

Cat. No.: HY-N0045

Ginsenoside Rg1 is one of the major active components of ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function, displays promising effects by reducing cerebral **Aβ** levels. Ginsenoside Rg1 also reduces **NF-κB** nuclear translocation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rg4

Cat. No.: HY-N6580

Ginsenoside Rg4 is a major protopanaxatriol type ginsenoside isolated from the leaves of Panax ginseng C. A. Meyer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ginsenoside Rg5

Cat. No.: HY-N0908

Ginsenoside Rg5 is the main component of Red ginseng. Ginsenoside blocks binding of **IGF-1** to its receptor with an IC_{50} of ~90 nM. Ginsenoside Rg5 also inhibits the mRNA expression of **COX-2** via suppression of the DNA binding activities of **NF-κB p65**.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rg6

Cat. No.: HY-N0907

Ginsenoside Rg6 inhibits TNF-α-induced **NF-κB** transcriptional activity with an IC_{50} of 29.34 μM in HepG2 cells. Ginsenoside Rg6 also exhibits **apoptosis**-inducing effect.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ginsenoside Rh1

(Prosapogenin A2; Sanchinoside B2; Sanchinoside Rh1)

Cat. No.: HY-N0604

Ginsenoside Rh1 (Prosapogenin A2) inhibits the expression of **PPAR-γ**, **TNF-α**, **IL-6**, and **IL-1β**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rh3

Cat. No.: HY-N0606

Ginsenoside Rh3 is a bacterial metabolite of Ginsenoside Rg5. Ginsenoside Rh3 treatment in human retinal cells induces **Nrf2** activation.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 5 mg

Ginsenoside Rk1

Cat. No.: HY-N2515

Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of **Jak2/Stat3** signaling pathway and **NF-κB**.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Ginsenoside Rk2

Cat. No.: HY-N2504

Ginsenoside Rk2 is a dammarane glycoside isolated from the processed ginseng (SG; Sun Ginseng).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ginsenoside Rk3

Cat. No.: HY-N0906

Ginsenoside Rk3 is present in the roots Panax notoginseng herbs. Ginsenoside Rk3 significantly inhibits TNF-α-induced **NF-κB** transcriptional activity, with an IC_{50} of 14.24±1.30 μM in HepG2 cells.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Girinimbine

(Girinimbin)

Cat. No.: HY-N9488

Girinimbine (Girinimbin) is a carbazole alkaloid with a variety of biological effects. Girinimbine can induce **apoptosis**, and has antitrypanosomal, antiplatelet activity, antibacterial activity, anti-inflammatory, antioxidant and antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GKT136901

Cat. No.: HY-101499

GKT136901 is a potent, selective and orally active inhibitor of **NADPH oxidase (NOX1/4)**, with K_is of 160 and 165 nM, respectively. GKT136901 is also a selective and direct scavenger of peroxynitrite.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Glabrescone C

Cat. No.: HY-N10112

Glabrescone C possesses potent anti-inflammatory activity by directly bnding to **IKKα/β**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glabridin

Cat. No.: HY-N0393

Glabridin is a natural isoflavan from Glycyrrhiza glabra, binds to and activates **PPARγ**, with an EC_{50} of 6115 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Glafenine

(Glafenin)

Cat. No.: HY-B1153

Glafenine is a non-steroidal anti-inflammatory drug (NSAID), is a non-narcotic analgesic agent, widely used for the treatment of pains of various origins.



Purity: ≥95.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg

Glafenine hydrochloride

(Glafenin hydrochloride)

Cat. No.: HY-B1153A

Glafenine hydrochloride is a non-narcotic analgesic and non-steroidal anti-inflammatory drug. It is an **ABCG2** inhibitor with an **IC_{50}** of 3.2 μM.



Purity: 99.26%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Glafenine-d4

Cat. No.: HY-B1153S

Glafenine-d4 (Glafenin-d4) is the deuterium labeled Glafenine. Glafenine is a non-steroidal anti-inflammatory drug (NSAID), is a non-narcotic analgesic agent, widely used for the treatment of pains of various origins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Glatiramer acetate

Cat. No.: HY-109520

Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg

Glaucine

(O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396)

Cat. No.: HY-N3945

Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum Crantz with antitussive, bronchodilation and anti-inflammatory properties.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Gliadin p31-43

Cat. No.: HY-P3151

Gliadin p31-43 is an undigested gliadin peptide. Gliadin p31-43 induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 can be used for celiac disease research.

LGQQQPFPPQQPY

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gliadin p31-43 TFA

Cat. No.: HY-P3151A

Gliadin p31-43 TFA is an undigested gliadin peptide. Gliadin p31-43 TFA induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 TFA can be used for celiac disease research.

LGQQQPFPPQQPY (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gliotoxin

(Aspergillin)

Cat. No.: HY-N6727

Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells .



Purity: 99.51%
Clinical Data: No Development Reported
Size: 5 mg

GLPG-3221

Cat. No.: HY-133013

GLPG-3221 is a potent, orally active corrector of **CFTR** (cystic fibrosis transmembrane conductance regulator), with an **EC_{50}** of 105 nM. GLPG-3221 can be uesd for the treatment of cystic fibrosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLPG1205

Cat. No.: HY-135303

GLPG1205 is potent, selective and orally active **GPR84** (a G-protein-coupled receptor) antagonist with a favorable PK/PD profile. GLPG1205 has anti-inflammatory activity and is used for the treatment of pulmonary fibrosis.



Purity: 99.66%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GLPG2451

Cat. No.: HY-119936

GLPG2451 is a **cystic fibrosis transmembrane conductance regulator (CFTR)** potentiator, which effectively potentiates low temperature rescued F508del CFTR with an **EC_{50}** of 11.1 nM.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Glucocorticoid receptor agonist-1

Cat. No.: HY-131974

Glucocorticoid receptor agonist-1 is a potent **glucocorticoid receptor** agonist with an IC_{50} of 2.8 nM extracted from patent WO2017210471A1, compound 41.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Glucocorticoids receptor agonist 1

Cat. No.: HY-139709

Glucocorticoids receptor agonist 1 is a potent anti-inflammatory, arylpyrazole-based **glucocorticoid receptor** agonist that does not impair insulin secretion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glucocorticoids receptor agonist 2

Cat. No.: HY-139710

Glucocorticoids receptor agonist 2 is a potent anti-inflammatory, arylpyrazole-based **glucocorticoid receptor** agonist that does not impair insulin secretion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glucosamine

(D-Glucosamine; Chitosamine)

Cat. No.: HY-B1125

Glucosamine (D-Glucosamine) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as a dietary supplement.



Purity: ≥98.0%
Clinical Data: Launched
Size: 100 mg

Glucosamine hydrochloride (D-(+)-Glucosamine hydrochloride; Chitosamine hydrochloride)

Cat. No.: HY-N0733

Glucosamine hydrochloride (D-Glucosamine hydrochloride) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as a dietary supplement.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Glucosamine sulfate

(D-Glucosamine sulfate)

Cat. No.: HY-N0487

Glucosamine sulfate (D-Glucosamine sulfate) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as a dietary supplement.



Purity: ≥98.0%
Clinical Data: Launched
Size: 500 mg

GLUT inhibitor-1

Cat. No.: HY-139605

GLUT inhibitor-1 is a potent and orally active inhibitor of glucose transporters, targeting both **GLUT1** and **GLUT3**, with IC_{50}s of 242 nM and 179 nM, respectively. GLUT inhibitor-1 has the potential for the reaesrch of cancers and autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gly-Arg-Gly-Asp-Ser TFA

Cat. No.: HY-P0295A

Gly-Arg-Gly-Asp-Ser (TFA) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to **integrin receptors** αvβ3 and αvβ5 with estimated IC_{50} of 5 and 6.5 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glycerol

(Glycerin)

Cat. No.: HY-B1659

Glycerol is used in sample preparation and gel formation for polyacrylamide gel electrophoresis.



Purity: ≥98.0%
Clinical Data: Launched
Size: 100 mL

Glyco-Obeticholic acid

Cat. No.: HY-135400

Glyco-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is a farnesoid X receptor (FXR) agonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Glycolithocholic acid

Cat. No.: HY-116374

Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Glycolithocholic acid-d4

Cat. No.: HY-116374S

Glycolithocholic acid-d4 is the deuterium labeled Glycolithocholic acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glycosmisic acid

Cat. No.: HY-N8153

Glycosmisic acid, a natural compound, possesses **anti-HBV** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glycyrrhetic acid 3-O-β-D-glucuronide

Cat. No.: HY-N6851

Glycyrrhetic acid 3-O-β-D-glucuronide, isolated from glycyrrhiza, is an important derivative of glycyrrhizin (GL) with an anti -allergic activity.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

GNE-0946

Cat. No.: HY-19774

GNE-0946 is a potent and selective **RORγ(RORc)** agonist with an EC_{50} value of 4 nM for HEK-293 cell.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GNE-1858

Cat. No.: HY-135892

GNE-1858 is a potent and ATP-competitive **hematopoietic progenitor kinase-1 (HPK1)** inhibitor, with IC_{50}s of 1.9 nM, 1.9 nM, and 4.5 nM for wild-type and the active mimetic mutants HPK1-TSEE and HPK1-SA, respectively.



Purity: 99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNE-4997

Cat. No.: HY-16984

GNE-4997 is a potent and selective **interleukin-2-inducible T-cell kinase (ITK)** inhibitor with a K_i of 0.09 nM, and the correlation between the basicity of solubilizing elements in GNE-4997 and off-target antiproliferative effects reduces cytotoxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GNE-6468

Cat. No.: HY-19775

GNE-6468 is a highly potent and selective **RORγ (RORc)** inverse agonist with an EC_{50} value of 13 nM for HEK-293 cell. GNE-6468 exhibits an EC_{50} of 30 nM for IL-17 PBMC.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg

GNE684

Cat. No.: HY-128585

GNE684 is a potent inhibitor of **potent receptor interacting protein 1 (RIP1)**, with mean K_i^{app} values of 21 nM, 189 nM and 691 nM for human mouse and rat RIP1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GNF362

Cat. No.: HY-126750

GNF362 is a selective, potent, and orally bioavailable inhibitor of **inositol trisphosphate 3' kinase B (Itpkb)** with an IC_{50} of 9 nM. GNF362 also inhibits Itpka and Itpkc with IC_{50} values of 20 nM and 19 nM, respectively.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Golotimod

(SCV 07; Gamma-D-glutamyl-L-tryptophan) Cat. No.: HY-14743

Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Golotimod hydrochloride (SCV 07 hydrochloride; Gamma-D-glutamyl-L-tryptophan hydrochloride)

Cat. No.: HY-14743B

Golotimod hydrochloride (SCV 07 hydrochloride), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function.



Purity: 98.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Golotimod TFA

(SCV 07 TFA; Gamma-D-glutamyl-L-tryptophan TFA) Cat. No.: HY-14743A

Golotimod TFA (SCV 07 TFA), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gomisin H

Cat. No.: HY-N2246

Gomisin H is a dibenzocyclooctadiene lignan isolated from the fruits of Schizandra chinensis BAILL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gomisin M2

((+)-Gomisin M2) Cat. No.: HY-N3963

Gomisin M2 ((+)-Gomisin M2) is a lignan isolated from the fruits of Schisandra rubriflora with anti-**HIV** activity (EC_{50} of 2.4 μM). Gomisin M2 exhibits anti-cancer and anti-allergic activities and has the potential for Alzheimer's disease research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gomisin N

Cat. No.: HY-N6866

Gomisin N, isolated from Schisandra chinensis, produces beneficial sedative and hypnotic bioactivity. Gomisin N has the potential for use in the treatment of allergy.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Gomisin O

Cat. No.: HY-N2235

Gomisin O is isolated from the fruits of Schizandra chinensis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gossypin

Cat. No.: HY-125911

Gossypin is a flavone isolated from Hibiscus vitifolius and has antioxidant, antiinflammatory, anticancer, anticataract, antidiabetic, and hepatoprotective activities. Gossypin inhibits **NF-κB** and NF-κB-regulated gene expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Gp100 (25-33), human

(Hgp100 (25-33)) Cat. No.: HY-P1585

Gp100 (25-33), human (Hgp100 (25-33)) is the amino acids 25-33 fragment of the human melanoma antigen. It is a 9-amino acid (AA) epitope restricted by H-2D^b and recognized by the T cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GPP78

(CAY10618) Cat. No.: HY-14374

GPP78 (CAY10618) is a potent **Nampt** inhibitor with an IC_{50} of 3.0 nM for **nicotinamide adenine dinucleotide (NAD) depletion**. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells with an IC_{50} of 3.8 nM by inducing **autophagy**. GPP78 has anti-cancer and anti-inflammatory effects.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg (11.38 mM * 1 mL in Methanol),

GPR34 receptor antagonist 2

Cat. No.: HY-138501

GPR34 receptor antagonist 2 (Compound D2) is a **GPR34 receptor** antagonist. GPR34 receptor antagonist 2 can be used for immune diseases, inflammatory diseases research.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

GPR35 agonist 2

Cat. No.: HY-15705

GPR35 agonist 2 (compound 11) is a potent agonist of **GPR35**, with **EC_{50}**s of 26 and 3.2 nM in the β-arrestin and Ca^{2+} release assay, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GPR4 antagonist 1

Cat. No.: HY-101536

GPR4 antagonist 1 is a **GPR4** antagonist, with an IC_{50} of 189 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GPR84 antagonist 1

Cat. No.: HY-139675

GPR84 antagonist 1 is a high affinity and highly selective competitive antagonist of human **GPR84**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

GPR84 antagonist 8

Cat. No.: HY-112562

GPR84 antagonist 8 is a selective **GPR84** antagonist.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GR 113808

Cat. No.: HY-103152

GR 113808 is a potent and highly selective **$5\text{-}HT_4$ receptor** antagonist (**pK_b**= 8.8). GR 113808 shows 300-fold selectivity over $5\text{-}HT_{1A}$, $5\text{-}HT_{1B}$, $5\text{-}HT_{2A}$, $5\text{-}HT_{2C}$ and $5\text{-}HT_3$ receptors.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

GR79236

Cat. No.: HY-18978

GR79236 is a highly potent, selective and orally active **adenosine A1 receptor** agonist with a **K_i**s of 3.1 nM and 1300 nM for **A1** and A2 receptors, respectively. GR79236 has anti-nociceptive and anti-inflammatory actions.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Gramicidin C

Cat. No.: HY-P2328

Gramicidin C is a naturally occuring polypeptide antibiotic isolated from B. brevis var. G.B.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Grape seed extract

Cat. No.: HY-N7072

Grape seed extract is a natural product, with anti-inflammatory and anti-proliferative effects. Grape seed extract shows inhibitory activity on the fat-metabolizing enzymes pancreatic lipase and lipoprotein lipase. Grape seed extract induces **apoptotic** in human colorectal cancer cells.



Purity: >98%
Clinical Data: Phase 3
Size: 100 mg, 250 mg, 500 mg

GRI977143

Cat. No.: HY-100676

GRI977143 is a specific **LPA_2 receptor** agonist, with an **EC_{50}** of 3.3 μM .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Grifolic acid

Cat. No.: HY-N3977

Grifolic acid is a phenolic compound that is first extracted from the mushroom Albatrellus confluens. Grifolic acid acts as an agonist of the free fatty acid receptor **(FFAR4/GPR120)**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Grp94 Inhibitor-1

Cat. No.: HY-112910

Grp94 Inhibitor-1 is a potent, selective **Grp94** inhibitor with an **IC_{50}** value of 2 nM, and over 1000-fold selectivity to Grp94 against Hsp90α.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GS-6201

(CVT-6883)

Cat. No.: HY-10081

GS-6201 (CVT-6883) is a selective **adenosine A2B receptor** antagonist. GS-6201 displays high affinity and selectivity for the human adenosine A2B receptors (**K_i**=22 nM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GS-9901

Cat. No.: HY-100694

GS-9901 is a highly selective and orally active **PI3Kδ** inhibitor, with an **IC_{50}** of 1 nM. Has potential to treat rheumatoid arthritis.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

GS143

Cat. No.: HY-110261

GS143 is a selec-tive **IκBα ubiquitination** inhibitor with an **IC_{50}** of 5.2 μM for $SCF^{\beta TrCP1}$-mediated **IκBα ubiquitylation**. GS143 sup-presses **NF-κB** acti-va-tion and tran-scrip-tion of tar-get genes and does not inhibit proteasome activity. GS143 has anti-asthma effect.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK 366

Cat. No.: HY-119171

GSK 366 is a potent **kynurenine-3-monooxygenase (KMO)** inhibitor with **IC_{50}**s of 2.3 nM and 0.7 nM for human KMO and P. fluorescens-KMO (Pf-KMO), respectively.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GSK 4027

Cat. No.: HY-101027

GSK 4027 is a chemical probe for the **PCAF/GCN5 bromodomain** with an **pIC_{50}** of 7.4±0.11 for PCAF in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK-2793660

Cat. No.: HY-112318

GSK-2793660 is an oral, irreversible inhibitor of **Cathepsin C** (**CTSC**). GSK-2793660 can be used for the research of bronchiectasis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

GSK-5498A

Cat. No.: HY-12521

GSK-5498A is a selective small molecule blocker of **CARC** (**IC_{50}**, 1 μM); inhibits mediator release from mast cells, and pro-inflammatory cytokine release from T-cells in a variety of species.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GSK-7975A

Cat. No.: HY-12507

GSK-7975A is a potent and orally available **CRAC** channel inhibitor.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK-843

(GSK'843)

Cat. No.: HY-125402

GSK-843 (GSK'843) is a **receptor-interacting protein kinase 3 (RIP3 or RIPK3)** inhibitor, which binds RIP3 kinase domain with an IC_{50} of 8.6 nM, and inhibits kinase activity with an IC_{50} of 6.5 nM.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GSK-872

Cat. No.: HY-101872

GSK-872 is a **RIPK3** inhibitor, which binds RIP3 kinase domain with an IC_{50} of 1.8 nM, and inhibits kinase activity with an IC_{50} of 1.3 nM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK-872 hydrochloride

Cat. No.: HY-101872A

GSK-872 hydrochloride is a **RIPK3** inhibitor, which binds RIP3 kinase domain with an IC_{50} of 1.8 nM, and inhibits kinase activity with an IC_{50} of 1.3 nM.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK040

Cat. No.: HY-132230

GSK040 is a potent and highly selective **BET BD2** inhibitor, with a pIC_{50} of 8.3. GSK040 shows more than 5000-fold selectivity for BET BD2 over BET BD1 (pIC_{50}=4.6). GSK040 can be used for the research of oncology and immunology diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK046

(iBET-BD2)

Cat. No.: HY-136571

GSK046 (iBET-BD2) is a potent, selective and orally active **BD2 bromodomain** inhibitor of the **BET** proteins, with IC_{50}s of 264 nM (**BRD2 BD2**), 98 nM (**BRD3 BD2**), 49 nM (**BRD4 BD2**) and 214 nM (**BRDT BD2**), respectively. GSK046 has immunomodulatory activity.



Purity: 98.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK1292263

Cat. No.: HY-12066

GSK-1292263 is an orally available **GPR119** agonist with pEC_{50}s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM).



Purity: 99.71%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK143

Cat. No.: HY-12736

GSK143 is an orally active and highly selective **spleen tyrosine kinase (SYK)** inhibitor with a pIC_{50} of 7.5. GSK143 inhibits phosphorylated Erk (pErk: pIC_{50}=7.1). GSK143 reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK143 dihydrochloride

Cat. No.: HY-12736A

GSK143 dihydrochloride is an orally active and highly selective **spleen tyrosine kinase (SYK)** inhibitor with a pIC_{50} of 7.5. GSK143 dihydrochloride inhibits phosphorylated Erk (pErk: pIC_{50}=7.1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK180

Cat. No.: HY-112179

GSK180 is a selective, competitive, and potent inhibitor of kynurenine-3-monooxygenase **(KMO)**, a key enzyme of tryptophan metabolism (IC_{50}, ~6 nM), but shows negligible activity against other enzymes on the tryptophan pathway.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK2018682

Cat. No.: HY-19511

GSK2018682 is an agonist for **S1P1** and **S1P5 receptor** with pEC_{50}s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 is used in the research of multiple sclerosis.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK205

Cat. No.: HY-120691A

GSK205 is a potent, selective **TRPV4** antagonist with an IC_{50} of 4.19 μM for inhibiting **TRPV4**-mediated Ca^{2+} influx.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK2239633A

Cat. No.: HY-100183

GSK2239633A is a CC-chemokine receptor 4 (**CCR4**) antagonist, which inhibits the binding of [^{125}I]-TARC to human CCR4 with a pIC_{50} of 7.96±0.11.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

GSK2245035

Cat. No.: HY-118250

GSK2245035 is a highly potent and selective intranasal **Toll-Like receptor 7 (TLR7)** agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has pEC_{50}s of 9.3 and 6.5 for IFNα and TFNα.



Purity: 99.79%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK2292767

Cat. No.: HY-15280

GSK2292767 is a potent and selective inhibitor of **PI3Kδ**, with a pIC_{50} of 10.1. GSK2292767 showing greater than 500-fold selective over the other PI3K isoforms. GSK2292767 can be used for the research of respiratory disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

GSK256066

Cat. No.: HY-10469

GSK256066 is a selective and high-affinity **phosphodiesterase 4 (PDE4)** inhibitor, with an IC_{50} of 3.2 pM for PDE4B. GSK256066 is developed for the research of chronic obstructive pulmonary disease.



Purity: 98.83%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

GSK256066 Trifluoroacetate

Cat. No.: HY-70069

GSK256066 Trifluoroacetate is a selective and high-affinity **phosphodiesterase 4 (PDE)** inhibitor, with an IC_{50} of 3.2 pM for PDE4B. GSK256066 Trifluoroacetate is developed for the research of chronic obstructive pulmonary disease.



Purity: 99.54%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GSK2593074A

(GSK'074)

Cat. No.: HY-122909

GSK2593074A (GSK'074) is a **necroptosis** inhibitor with dual targeting ability to both **RIP1** and **RIP3**.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK269962A

(GSK 269962)

Cat. No.: HY-15556

GSK269962A (GSK 269962) is a potent **ROCK** inhibitor with IC_{50}s of 1.6 and 4 nM for recombinant human **ROCK1** and **ROCK2** respectively. GSK269962A has anti-inflammatory and vasodilatory activities.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GSK269962A hydrochloride

(GSK 269962 hydrochloride)

Cat. No.: HY-15556A

GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent **ROCK** inhibitor with IC_{50}s of 1.6 and 4 nM for recombinant human **ROCK1** and **ROCK2** respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK2981278

Cat. No.: HY-19770

GSK2981278 is a potent and selective **RORγ** inverse agonist. GSK2981278 inhibits activation of the il17 promoter and interferes RORγ-DNA binding.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK2982772

Cat. No.: HY-101760

GSK2982772 is a potent, orally active and ATP competitive **RIP1** kinase inhibitor with IC_{50} values of 16 nM and 20 nM for human and monkey RIP1, respectively.



Purity: 98.98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK2983559

Cat. No.: HY-112038A

GSK2983559 (compound 3) is a potent, specific and oral active **receptor interacting protein 2 (RIP2) kinase** inhibitor, which has excellent activity in blocking many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples.



Purity: 99.24%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK2983559 free acid

Cat. No.: HY-112038

GSK2983559 free acid (compound 3) is a potent, specific and oral active **receptor interacting protein 2 (RIP2) kinase** inhibitor. GSK2983559 free acid has excellent activity in blocking many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples.



Purity: 99.51%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK3179106

Cat. No.: HY-100459

GSK3179106 is an orally active and selective **RET** kinase inhibitor with IC_{50}s of 0.4 nM, 0.2 nM for human RET and rat RET, respectively. GSK3179106 has the potential for irritable bowel syndrome (IBS) through the attenuation of post-inflammatory and stress-induced visceral hypersensitivity.



Purity: 99.40%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK319347A

Cat. No.: HY-14682

GSK319347A is a dual inhibitor of **TBK1** and **IKKε** with IC_{50}s of 93 nM and 469 nM, respectively. GSK319347A also inhibits **IKK2** with an IC_{50} of 790 nM.



Purity: 98.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

GSK356278

Cat. No.: HY-106003

GSK356278 is a potent, selective, orally bioavailable and brain-penetrant inhibitor of **phosphodiesterase 4 (PDE4)**, with pIC_{50}s of 8.6, 8.8, and 8.7 for human PDE4A, PDE4B, and PDE4D, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

GSK4028

Cat. No.: HY-101027A

GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC_{50} of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK481

Cat. No.: HY-100131

GSK481 is a highly potent, selective, and specific **receptor interacting protein 1 (RIP1) kinase** inhibitor with an IC_{50} of 1.3 nM, which inhibits Ser^{166} phosphorylation in wild-type human RIP1 (IC_{50}=2.8 nM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

GSK484 hydrochloride

Cat. No.: HY-100514

GSK484 hydrochloride is a selective and reversible peptidylarginine deiminase 4 (**PAD4**) inhibitor. GSK484 hydrochloride demonstrates high affinity binding to PAD4 with IC_{50}s of 50 nM in the absence of Calcium. In the presence of 2 mM Calcium, notably lower potency (250 nM) is observed.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK620

Cat. No.: HY-137892

GSK620 is a potent and orally active **pan-BD2** inhibitor with excellent broad selectivity, developability and in vivo oral pharmacokinetics. GSK620 is highly selective for the BET-BD2 family of proteins, with >200-fold selectivity over all other bromodomains.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK682753A

Cat. No.: HY-101192

GSK682753A is a selective and highly potent inverse agonist of the epstein-barr virus-induced receptor 2 (**EBI2**) with an **IC_{50}** of 53.6 nM.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK717

Cat. No.: HY-136555

GSK717 is a potent, selective **NOD2** (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an **IC_{50}** of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK726701A

Cat. No.: HY-112152

GSK726701A is a novel **prostaglandin E2 receptor 4 (EP4)** partial agonist with a **pEC_{50}** of 7.4.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GSK778

(iBET-BD1)

Cat. No.: HY-136570

GSK778 (iBET-BD1) is a potent and selective **BD1 bromodomain** inhibitor of the BET proteins, with **IC_{50}**s of 75 nM (**BRD2 BD1**), 41 nM (**BRD3 BD1**), 41 nM (**BRD4 BD1**), and 143 nM (**BRDT BD1**), respectively. GSK778 phenocopies the effects of pan-**BET** inhibitors in cancer models.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK805

Cat. No.: HY-12776

GSK805 is a potent, orally bioavailable, and CNS penetrant **RORγt** inhibitor with **pIC_{50}** of 8.4 and >8.2 for RORγ FRET assay and Th17 assay.



Purity: 97.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK840

(GSK'840)

Cat. No.: HY-104021

GSK840 (GSK'840) is a **receptor-interacting protein kinase 3 (RIP3 or RIPK3)** inhibitor, which binds RIP3 kinase domain with an **IC_{50}** of 0.9 nM, and inhibits kinase activity with an **IC_{50}** of 0.3 nM.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GSK8612

Cat. No.: HY-111941

GSK8612 is a highly selective and potent **Tank-binding Kinase-1 (TBK1)** inhibitor, with a **pIC_{50}** of 6.8 for recombinant TBK1.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GsMTx4

Cat. No.: HY-P1410

GsMTx4 is a spider venom peptide that selectively inhibits cation-permeable **mechanosensitive channels (MSCs)** belonging to the Piezo and TRP channel families.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

GsMTx4 TFA

Cat. No.: HY-P1410A

GsMTx4 TFA is a spider venom peptide that selectively inhibits cation-permeable **mechanosensitive channels (MSCs)** belonging to the Piezo and TRP channel families.

Purity: 98.29%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

GTS-21 dihydrochloride

(DMXB-A; DMBX-anabaseine)

Cat. No.: HY-14564A

GTS-21 dihydrochloride is a selective alpha7 nicotinic acetylcholine receptor **(α7-nAChR)** agonist with antiinflammatory and cognitionenhancing activities.



Purity: 99.78%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Guacetisal

Cat. No.: HY-17477

Guacetisal is obtained from the esterification of acetylsalicylic acid with guaiacol which has the potential for chronic bronchitis treatment extracted from patent CN 106866420 A.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Guaiacol

(2-Methoxyphenol)

Cat. No.: HY-N1380

Guaiacol, a phenolic compound, inhibits LPS-stimulated **COX-2** expression and **NF-κB** activation. Anti-inflammatory activity.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Guaiapate

(Klamar; Mg 5454)

Cat. No.: HY-101828

Guaiapate is an antitussive drug.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Guaifenesin (Guaiacol glyceryl ether; Guaiphenesin; Glycerol guaiacolate)

Cat. No.: HY-B0264

Guaifenesin (Guaiacol glyceryl ether), a constituent of guaiac resin from the wood of Guajacum officinale Linné, is an expectorant. Guaifenesin can alleviate cough discomfortby increasing sputum volume and decreasing its viscosity, thereby promoting effective cough.



Purity: 97.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Guaifenesin-d5

Cat. No.: HY-B0264S1

Guaifenesin-d5 (Guaiacol glyceryl ether-d5) is the deuterium labeled Guaifenesin. Guaifenesin (Guaiacol glyceryl ether), a constituent of guaiac resin from the wood of Guajacum officinale Linné, is an expectorant.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 5 mg, 25 mg, 50 mg

Guanosine 5'-diphosphate

Cat. No.: HY-113066

Guanosine 5'-diphosphate is a nucleoside diphosphate. Guanosine 5'-diphosphate is a potential iron mobilizer, which prevents the hepcidin-ferroportin interaction and modulating the interleukin-6 (IL-6)/stat-3 pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Guanosine 5'-diphosphate disodium salt

Cat. No.: HY-113066A

Guanosine 5'-diphosphate disodium salt is a nucleoside diphosphate. Guanosine 5'-diphosphate is a potential iron mobilizer, which prevents the hepcidin-ferroportin interaction and modulating the interleukin-6 (IL-6)/stat-3 pathway.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Guluronic acid

(G2013)

Cat. No.: HY-N7700

Guluronic acid (G2013), one of the organic building blocks of hyaluronic acid, is a nonsteroidal anti-inflammatory agent has favorable anti-inflammatory effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Guretolimod

Cat. No.: HY-139575

Guretolimod is a **Toll-like receptor 7 (TLR7)** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Guselkumab

(CNTO 1959)

Cat. No.: HY-P9931

Guselkumab is a recombinant human IgG1 monoclonal antibody against the **IL-23p19 subunit**. Guselkumab binds to human and cynomolgus monkey IL-23 with K_d values of 3.3 and 1.9 pmol/L, respectively.

Guselkumab

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Gusperimus trihydrochloride

(Spanidin; NKT-01; BMS181173) Cat. No.: HY-13644A

Gusperimus trihydrochloride (Spanidin) is a derivative of the antitumor antibiotic spergualin with immunosuppressant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW 766994

(GW 994) Cat. No.: HY-107051

GW 766994 (GW 994) is an orally active and specific **chemokine receptor-3 (CCR3)** antagonist. GW 766994 has the potential for asthma and eosinophilic bronchitis research.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GW-406381

Cat. No.: HY-119304

GW406381, a highly selective **cyclooxygenase-2 (COX-2)** inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury.



Purity: 99.69%
Clinical Data:
Size: 10 mM × 1 mL, 1 mg

GW-870086

Cat. No.: HY-103662

GW-870086 is a potent anti-inflammatory agent, acting as a **glucocorticoid receptor** agonist, with a **pIC$_{50}$** of 10.1 in A549 cells expressing NF-κB.



Purity: 98.00%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GW0742

(GW610742) Cat. No.: HY-13928

GW0742 is a potent **PPARβ** and **PPARδ** agonist, with an **IC$_{50}$** of 1 nM for human **PPARδ** in binding assay, and **EC$_{50}$**s of 1 nM, 1.1 μM and 2 μM for human **PPARδ**, PPARα, and PPARγ, respectively.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GW2580

Cat. No.: HY-10917

GW2580 is an orally bioavailable and selective inhibitor of **c-Fms kinase** which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

GW274150

Cat. No.: HY-12119

GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human **inducible nitric oxide synthase (iNOS)** (**IC$_{50}$**=2.19 μM; **K$_d$**=40 nM) and rat **iNOS** (**ED$_{50}$**=1.15 μM).



Purity: >98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GW274150 phosphate

Cat. No.: HY-12119A

GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human **inducible nitric oxide synthase (iNOS)** (**IC$_{50}$**=2.19 μM; **K$_d$**=40 nM) and rat **iNOS** (**ED$_{50}$**=1.15 μM).



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GW280264X

Cat. No.: HY-115670

GW280264X is the mixed **ADAM10/TACE (ADAM17) metalloproteinases** inhibitor. GW280264X potently blocks **TACE (ADAM17)** and **ADAM10** with **IC$_{50}$**s of 8.0 nM and 11.5 nM, respectively. ADAM10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW311616

Cat. No.: HY-15891

GW-311616 is a potent, orally bioavailable, long duration and selective human neutrophil elastase (**HNE**) inhibitor with **IC$_{50}$** value of 22 nM and **K$_i$** value of 0.31 nM.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GW311616 hydrochloride

(GW311616A)

Cat. No.: HY-15891A

GW-311616 is a potent, orally bioavailable, long duration and selective human neutrophil elastase (**HNE**) inhibitor with **IC_{50}** value of 22 nM and **K_i** value of 0.31 nM.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 5 mg

GW4869

Cat. No.: HY-19363

GW4869 is a noncompetitive **neutral sphingomyelinase (N-SMase)** inhibitor with an **IC_{50}** of 1 μM. GW4869 is an inhibitor of **exosome** biogenesis/release.



Purity: 95.57%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GW627368

Cat. No.: HY-16963

GW627368 (GW627368X) is a novel, potent and selective competitive antagonist of prostanoid **EP4** receptor with additional human **TP** receptor affinity, with **pK_i** values of 7.0 and 6.8 for human prostanoid EP4 and TP receptors respectively.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GW842166X

Cat. No.: HY-14167

GW842166X is a potent and selective **cannabinoid receptor 2** (CB2) agonist with **IC_{50}** values of 63 and 91 nM for human and rat CB2, respectively.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

GW9508

Cat. No.: HY-15589

GW9508 is a potent and selective **G protein-coupled receptors FFA1 (GPR40)** and **GPR120** agonist with **pEC_{50}**s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for **GPR40** over **GPR120**.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

GX-201

Cat. No.: HY-131870

GX-201 is a selective **$Na_V1.7$** inhibitor, with an **IC_{50}** of <3.2 nM for **$hNa_V1.7$**.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gypenoside L

Cat. No.: HY-N8211

Gypenoside L is a saponin that can be found in Gynostemma pentaphyllum. Gypenoside L increases the SA-β-galactosidase activity, promotes the production of senescence-associated secretory cytokines.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 5 mg

Gypenoside XLIX

Cat. No.: HY-N1990

Gypenoside XLIX, a dammarane-type glycoside, is a prominent component of G. pentaphyllum.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Gypsogenin-3-O-glucuronide

Cat. No.: HY-N1439

Gypsogenin-3-O-glucuronide is a ubiquitous saponin precursor in plants of the genus Gypsophila.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

GYY4137

Cat. No.: HY-107632

GYY4137 is a slow releasing **H_2S donor** with vasodilator and antihypertensive activity. GYY4137 also exhibits anti-inflammatory and anticancer activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg

H-151

Cat. No.: HY-112693

H-151 is a potent, selective and covalent antagonist of **STING** that has noteworthy inhibitory activity both in cells and in vivo. H-151 reduces TBK1 phosphorylation and suppresses STING palmitoylation. H-151 can be used for the research of autoinflammatory disease.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

H-Val-Pro-Pro-OH

Cat. No.: HY-114161

H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme **(ACE)**, with an IC_{50} of 9 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

H-Val-Pro-Pro-OH TFA

Cat. No.: HY-114161A

H-Val-Pro-Pro-OH (TFA), a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme **(ACE)**, with an IC_{50} of 9 μM.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

H3R-IN-1 Hydrochloride

Cat. No.: HY-112219A

H3R-IN-1 Hydrochloride is a **histamine receptor 3** (**H3R**) inverse agonist extracted from patent WO2013107336A1, compound example 2.



Purity: 95.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

H4R antagonist 1

Cat. No.: HY-111501

H4R antagonist 1 is a potent and highly selective **histamine H4 receptor** (**H4R**) antagonist with an IC_{50} of 27 nM. H4R antagonist 1 does not show any noticeable binding affinity to other subtypes of histamine receptors, H1R, H2R, and H3R.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HA Peptide

Cat. No.: HY-P0239

HA Peptide (HA tag) is a nine amino acids peptide derived from the human influenza hemagglutinin (HA). HA Peptide is extensively used to isolate, purify, detect, and track the protein of interest in cell biology and biochemistry.

YPYDVPDYA

Purity: 99.23%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

HA Peptide TFA

Cat. No.: HY-P0239A

HA Peptide (TFA) is a nine amino acids peptide derived from the human influenza hemagglutinin (HA). HA Peptide (TFA) is extensively used to isolate, purify, detect, and track the protein of interest in cell biology and biochemistry.

YPYDVPDYA (TFA salt)

Purity: 99.21%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

HA155

Cat. No.: HY-116100A

HA-155 is a potent and selective **autotaxin (ATX)** inhibitor with an IC_{50} of 5.7 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Halofuginone

(RU-19110)

Cat. No.: HY-N1584

Halofuginone (RU-19110), a Febrifugine derivative, is a competitive **prolyl-tRNA synthetase** inhibitor with a K_i of 18.3 nM. Halofuginone is a specific inhibitor of **type-I collagen** synthesis and attenuates osteoarthritis (OA) by inhibition of **TGF-β** activity.



Purity: 98.32%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Halofuginone hydrobromide

(RU-19110 hydrobromide)

Cat. No.: HY-N1584A

Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive **prolyl-tRNA synthetase** inhibitor with a K_i of 18.3 nM.



Purity: 99.55%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Hamaudol

Cat. No.: HY-N6891

Hamaudol is a chromone isolated from Saposhnikovia divaricata. Hamaudol shows significant inhibitory activity on **cyclooxygenase (COX)-1** and **COX-2** activities with IC_{50} values of 0.30, 0.57 mM, respectively, and has potent analgesia and anti-inflammary effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

HAMI 3379

Cat. No.: HY-112248A

HAMI 3379 is a potent and selective **CysLT$_2$** receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Handelin

Cat. No.: HY-N2083

Handelin is a guaianolide dimer from Chrysanthemum boreale that has potent anti-inflammatory activity by down-regulating **NF-κB** signaling and pro-inflammatory cytokine production.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Handle region peptide, rat

Cat. No.: HY-P1572

Handle region peptide, rat is a **prorenin receptor** antagonist, suppresses the progression of diabetic nephropathy and has anti-inflammatory in the eye.

RILLKKMPSV

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Harpagide

Cat. No.: HY-N0397

Harpagide is a class of iridoid glycoside isolated from Scrophularia cryptophila and has antiparasitic activity, which exhibits good in vitro trypanocidal activities against **African trypanosomes** (**T.b. rhodesiense**) with an IC_{50} of 21 μg/mL.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Harpagoside

Cat. No.: HY-N0396

Harpagoside is isolated from Harpagophytum procumbens (Hp). Harpagoside has inhibitory effects on **COX-1** and **COX-2** activity and inhibits NO production.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

HCH6-1

Cat. No.: HY-101283

HCH6-1 is a potent and competitive dipeptide antagonist of **Formyl peptide receptor 1 (FPR1)**. HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist).



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HCV-IN-31

Cat. No.: HY-138305

HCV-IN-31 (compound 4) is a **HCV** inhibitor, with an EC_{50}/EC_{95} of 15.7 μM for HCV replicon.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

hDDAH-1-IN-1

Cat. No.: HY-133126

hDDAH-1-IN-1 (compound 8a) is a potent and selective non-amino acid catalytic site inhibitor of **human dimethylarginine dimethylaminohydrolase-1 (hDDAH-1)**, with a K_i of 18 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

hDDAH-1-IN-1 TFA

Cat. No.: HY-133126A

hDDAH-1-IN-1 TFA (compound 8a) is a potent and selective non-amino acid catalytic site inhibitor of **human dimethylarginine dimethylaminohydrolase-1 (hDDAH-1)**, with a K_i of 18 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

hDDAH-1-IN-2

Cat. No.: HY-133145

hDDAH-1-IN-2 is a selective, orally active human dimethylarginine dimethylaminohydrolase-1 **(hDDAH-1)** inhibitor. hDDAH-1-IN-2 reveals an excellent profile regarding cell toxicity/viability.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

hDDAH-1-IN-2 sulfate

Cat. No.: HY-133145A

hDDAH-1-IN-2 is a selective, orally active human dimethylarginine dimethylaminohydrolase-1 **(hDDAH-1)** inhibitor. hDDAH-1-IN-2 reveals an excellent profile regarding cell toxicity/viability.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

hDHODH-IN-1

Cat. No.: HY-135658

hDHODH-IN-1 is a **human dihydroorotate dehydrogenase (hDHODH)** inhibitor. hDHODH-IN-1 has anti-inflammatory effect.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

hDHODH-IN-2

Cat. No.: HY-135654

hDHODH-IN-2 is an analogue of the active metabolite of Leflunomide. hDHODH-IN-2 is a **human dihydroorotate dehydrogenase (hDHODH)** inhibitor. hDHODH-IN-1 has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HE 3286

Cat. No.: HY-108039

HE 3286 is a synthetic derivative of a natural anti-inflammatory steroid, β-AET. HE 3286 is an orally active partial **NF-κB** inhibitor. HE3286 reduces proinflammatory signals, including IL-6 and matrix metallopeptidase 3. HE 3286 freely penetrates the blood brain barrier in mice.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Hecogenin

Cat. No.: HY-N1422

Hecogenin is a steroid saponin isolated from Agave sisalana and is a selective inhibitor of **human UDP-glucuronosyltransferases**. Hecogenin has a wide spectrum of pharmacological activities, including anti-inflammatory, antifungal and gastroprotective effects.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Hederacoside D

Cat. No.: HY-N0254

Hederacoside D is one of the bioactive saponins from Hedera helix, and plays pivotal roles in the overall biological activity.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Hederagenin 28-O-beta-D-glucopyranosyl ester

Cat. No.: HY-N2190

Hederagenin 28-O-beta-D-glucopyranosyl ester, a triterpenoid saponin isolated from Ilex cornuta, exhibits protective effects against H_2O_2-induced myocardial cell injury.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Helenalin

Cat. No.: HY-119970

Helenalin is an anti-inflammatory sesquiterpene lactone. Helenalin selectively inhibits transcription factor **NF-κB** by directly targeting p65. Helenalin has alkylating activity, targets the cysteine sulfhydryl groups in the p65 subunit of NF-κB, thereby inhibits its DNA binding.



Purity: 98.29%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

HEMADO

Cat. No.: HY-103187

HEMADO is a potent and selective **adenosine A_3 receptor** agonist with a K_i of 1.1 nM at the human A_3 subtype.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Heparan Sulfate

Cat. No.: HY-101916

Heparan sulfate, a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on the cell surface and in the extracellular matrix.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Heptamidine

(SBi4211)

Cat. No.: HY-16918

Heptamidine (SBi4211) is a potent Pentamidine-related inhibitor of the **calcium-binding protein S100B** (K_d=6.9 μM), selectively kills melanoma cells with S100B over those without S100B. Heptamidine is a useful tool for the investigation of Myotonic dystrophy (DM).

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Heptamidine dimethanesulfonate

(SBi4211 dimethanesulfonate)

Cat. No.: HY-16918A

Heptamidine dimethanesulfonate (SBi4211 dimethanesulfonate) is a potent Pentamidine-related inhibitor of the **calcium-binding protein S100B** (K_d=6.9 μM), selectively kills melanoma cells with S100B over those without S100B.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Heraclenin

Cat. No.: HY-N4053

Heraclenin, a natural furanocoumarin, significantly inhibits T cell receptor-mediated proliferation in human primary T cells in a concentration-dependent manner by targeting nuclear factor of activated T-cells (NFAT).



Purity: 99.59%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hesperidin methylchalcone

Cat. No.: HY-126382

Hesperidin methylchalcone (Hesperidin methyl chalcone) inhibits oxidative stress, cytokine production and **NF-κB** activation. Hesperidin methylchalcone inhibits inflammation and pain. Hesperidin methylchalcone exhibits vasoprotective activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Heterocyclyl carbamate derivative 1

Cat. No.: HY-101831

Heterocyclyl carbamate derivative 1 is a heterocyclyl carbamate derivative that may be used for the research of inflammatory and neurological diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hexa-N-acetylchitohexaose

Cat. No.: HY-N7698B

Hexa-N-acetylchitohexaose is an inducer of disease resistance in crop plants, which could elicit an increase of lignification-related and antioxidative enzymes in soybean plants. Hexa-N-acetylchitohexaose is a substrate of lysozyme.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Hexahydrofarnesyl acetone

(6,10,14-Trimethyl-2-pentadecanone)

Cat. No.: HY-N3074

Hexahydrofarnesyl acetone (6,10,14-Trimethyl-2-pentadecanone), a sesquiterpene isolated from Launaea mucronata, is the major constituents of the essential oil. Hexahydrofarnesyl acetone has antibacterial, anti-nociceptive and anti-inflammation activities.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg

Hexasodium phytate

(Phytic acid hexasodium; SNF-472; Hexasodium fytate)

Cat. No.: HY-N0814B

Hexasodium phytate (Phytic acid hexasodium) is a phosphorus storage compound of seeds and cereal grains. Hexasodium phytate has a strong ability to chelate multivalent metal ions, specially zinc, calcium, iron and as with protein residue.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hexidium iodide

Cat. No.: HY-114227

Hexidium iodide, a fluorescent nucleic binding acid stain (excitation/emission ~ 518/600 nm), permeants to mammalian cells and selectively stains almost all gram-positive bacteria. Hexidium iodide can bind to the DNA of all bacteria after permeabilization by EDTA.



Purity: 98.92%
Clinical Data: No Development Reported
Size: 5 mg

HG-12-6

Cat. No.: HY-123956

HG-12-6 is a type Ⅱ inhibitor of **IRAK4**. HG-12-6 shows preferential binding to unphosphorylated inactive **IRAK4** with an IC_{50} of 165 nM. HG-12-6 can modulate **IRAK4** activity in autoimmunity and inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HG-9-91-01

(SIK inhibitor 1)

Cat. No.: HY-15776

HG-9-91-01 is a potent and highly selective salt-inducible kinase (**SIK**) inhibitor with IC_{50}s of 0.92 nM, 6.6 nM and 9.6 nM for **SIK1**, **SIK2** and **SIK3** respectively.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hibifolin

Cat. No.: HY-N7368

Hibifolin, a flavonol glycoside, is a potential inhibitor of **adenosine deaminase (ADA)**, with a K_i of 49.92 μM. Hibifolin protects neurons against beta-amyloid-induced neurotoxicity.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg

Hirsutenone

Cat. No.: HY-N4042

Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hispidol

((Z)-Hispidol)

Cat. No.: HY-102040

Hispidol ((Z)-Hispidol) is a potential therapeutic for inflammatory bowel disease; inhibits **TNF-α** induced adhesion of monocytes to colon epithelial cells with an IC_{50} of 0.50 μM.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Hispidulin 4'-O-β-D-glucopyranoside

Cat. No.: HY-N8205

Hispidulin 4'-O-β-D-glucopyranosid, a natural compound, may serve as a potential COVID-19 main protease inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Histamine H4 receptor antagonist-1

Cat. No.: HY-145106

Histamine H4 receptor antagonist-1 is an antagonist of **histamine H4 receptor** extracted from patent WO2010108059A1 compound 60.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Histatin 5

Cat. No.: HY-P0273

Histatin 5 inhibits the activity of the host matrix metalloproteinases **MMP-2** and **MMP-9** with IC_{50}s of 0.57 and 0.25 μM, respectively.

DSHAKRHHGYKRKFHEKHHSHRGY

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Histatin 5 TFA

Cat. No.: HY-P0273A

Histatin 5 TFA inhibits the activity of the host matrix metalloproteinases **MMP-2** and **MMP-9** with IC_{50}s of 0.57 and 0.25 μM, respectively.

DSHAKRHHGYKRKFHEKHHSHRGY (TFA salt)

Purity: 97.17%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

HKOCl-4m

Cat. No.: HY-D1158

HKOCl-4m is a selective and mitochondria-targeting rhodol-based fluorescent probe for monitoring mitochondrial hypochlorous acid (HOCl).



Purity: 98.50%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

HOIPIN-8

Cat. No.: HY-122882

HOIPIN-8 is a potent inhibitor of **linear ubiquitin chain assembly complex (LUBAC)** with an IC_{50} of 11 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Homocarnosine

(L-Homocarnosine; γ-Aminobutyryl-L-histidine)

Cat. No.: HY-114883

Homocarnosine is a dipeptide of γ-aminobutyric acid (**GABA**) and histidine unique to brain. Homocarnosine is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Homomangiferin

Cat. No.: HY-111811

Homomangiferin is mangiferin monomethyl ether. Homomangiferin has important medicinal properties and is widely used to relieve many symptoms, for example coughing and asthma.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Homoplantaginin

Cat. No.: HY-N1949

Homoplantaginin is a flavonoid from a traditional Chinese medicine Salvia plebeia with antiinflammatory and antioxidant properties. Homoplantaginin could inhibit **TNF-α** and **IL-6** mRNA expression, **IKKβ** and **NF-κB** phosphorylation.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Hosenkoside A

Cat. No.: HY-N2249

Hosenkoside A is a baccharane glycoside isolated from the seeds of impatiens balsamina.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 5 mg

Hosenkoside B

Cat. No.: HY-N2250

Hosenkoside B is a baccharane glycoside isolated from the seeds of impatiens balsamina.



Purity: 96.23%
Clinical Data: No Development Reported
Size: 5 mg

Hosenkoside F

((+)-Hosenkoside F)

Cat. No.: HY-N2241

Hosenkoside F is a baccharane glycoside isolated from the seeds of impatiens balsamina.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 5 mg

Hosenkoside K

Cat. No.: HY-N2243

Hosenkoside K is a baccharane glycoside isolated from the seeds of impatiens balsamina.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 5 mg

Hosenkoside M

((+)-Hosenkoside M)

Cat. No.: HY-N2244

Hosenkoside M is a baccharane glycoside isolated from the seeds of impatiens balsamina.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg

HPGDS inhibitor 1

Cat. No.: HY-10439

HPGDS inhibitor 1 is a potent, selective and orally active **Hematopoietic Prostaglandin D Synthase (HPGDS)** inhibitor with an IC_{50}s of 0.6 nM and 32 nM in enzyme and cellular assays, respectively. HPGDS inhibitor 1 does not inhibit human L-PGDS, mPGES, COX-1, COX-2, or 5-LOX.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HPGDS inhibitor 2

Cat. No.: HY-126134

HPGDS inhibitor 2 is a highly potent and selective **hematopoietic prostaglandin D synthase (H-PGDS)** inhibitor with an IC_{50} of 9.9 nM.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

hPGDS-IN-1

Cat. No.: HY-12791

hPGDS-IN-1 is a hPGDS inhibitor ,with IC50 of 12 nM in the Fluorescence Polarization Assay or the EIA assay. IC50 value: 12 nM Target: hPGDS The detailed information please refer to WO2011044307A1 and WO2010080563A2.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

HPK1-IN-19

Cat. No.: HY-145107

HPK1-IN-19 is a **hematopoietic progenitor kinase 1 (HPK1)** inhibitor extracted from patent WO2018102366A1 compound I-47.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-20

Cat. No.: HY-145109

HPK1-IN-19 is a **hematopoietic progenitor kinase 1 (HPK1)** inhibitor extracted from patent WO2020235902A1 compound 106.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HPK1-IN-3

Cat. No.: HY-138568

HPK1-IN-3 is a potent and selective ATP-competitive **hematopoietic progenitor kinase 1 (HPK1; MAP4K1)** inhibitor with an IC_{50} of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC_{50} of 108 nM in human peripheral blood mononuclear cells (PBMCs).



Purity: 98.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HPN-01

Cat. No.: HY-135366

HPN-01 is a potent and selective **IKK** inhibitor, with pIC_{50} values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HQL-79

Cat. No.: HY-108259

HQL-79, a potent, selective and orally active human **hematopoietic prostaglandin D synthase (H-PGDS)** inhibitor, highly selectively inhibits the synthesis of PGD_2, and acts as an anti-allergic agent, with a K_d of 0.8 μM and an IC_{50} of 6 μM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

HS271

Cat. No.: HY-131903

HS271 is a highly potent, orally active and selective **IRAK4** inhibitor, with an IC_{50} of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic properties.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HSR6071

Cat. No.: HY-U00133

HSR6071, a pyrazinecarboxamide derivative, is an orally active and potent antiallergic agent. HSR6071 potently inhibits the experimental asthma in rat models.



Purity: 98.51%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

hTrkA-IN-1

Cat. No.: HY-136535

hTrkA-IN-1 is a potent and orally active inhibitor of **TrkA kinase** with an IC_{50} of 1.3 nM, compound 2. extracted from patent WO2015175788. hTrkA-IN-1 can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Huangjiangsu A

Cat. No.: HY-N4278

Huangjiangsu A, pseudoprotodioscin, methyl protobioside, protodioscin, and protodeltonin, isolated from D. villosa.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Human IgG1 kappa, Isotype Control

Cat. No.: HY-P99001

Human IgG1 kappa, Isotype Control, a humanized monoclonal antibody, is an isotype control for human IgG1κ antibody.

Human IgG_1 kappa, Isotype Control

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Human PD-L1 inhibitor III

Cat. No.: HY-P2564

Human PD-L1 inhibitor III is a human PD-L1 inhibitor.

TEKDYRHGNIRMKLAYDL

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Human PD-L1 inhibitor IV

Cat. No.: HY-P2477

Human PD-L1 inhibitor IV, a polypeptide, is a competitive **human PD-1 protein** inhibitor with a K_d value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1.

GNWDYNSQRAQLYNQ

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Human PD-L1 inhibitor V

Cat. No.: HY-P2478

Human PD-L1 inhibitor V, a **human PD-1 protein** binding peptide with a K_d value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1.

LDYVNRRKMYQ

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Human PD-L1 inhibitor V TFA

Cat. No.: HY-P2478A

Human PD-L1 inhibitor V TFA, a **human PD-1 protein** binding peptide with a K_d value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1.

LDYVNRRKMYQ (TFA salt)

Purity: 96.63%
Clinical Data: No Development Reported
Size: 10 mg

Humantenirine

Cat. No.: HY-N7508

Humantenirine is an indole alkaloid isolated from Gelsemium sempervirens.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Humantenmine

(Gelsenicine)

Cat. No.: HY-N4030

Humantenmine, a newalkaloid isolated from Gelsemium elegan Banth in China, has the potential for pain and rheumatic arthritis treatment.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Hupehenine

Cat. No.: HY-N0413

Hupehenine, a bioactive isosteroidal alkaloid, is a main antitussive components present in most of Fritillariae Bulbus.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Hydrocortisone

(Cortisol)

Cat. No.: HY-N0583

Hydrocortisone (Cortisol) is a steroid hormone or glucocorticoid secreted by the adrenal cortex.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Hydrocortisone 17-butyrate

(Cortisol 17-butyrate; Hydrocortisone butyrate)

Cat. No.: HY-B0983

Hydrocortisone 17-butyrate is an adrenocortico hormone.



Purity: 99.93%
Clinical Data: Launched
Size: 100 mg

Hydrocortisone acetate

(Hydrocortisone 21-acetate; Cortisol 21-acetate)

Cat. No.: HY-B1183

Hydrocortisone acetate is a corticosteroid, used to decrease swelling, itching, and pain that is caused by minor skin irritations or by hemorrhoids.



Purity: 99.17%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Hydrocortisone buteprate

(Hydrocortisone probutate; HBP)

Cat. No.: HY-106673

Hydrocortisone buteprate (Hydrocortisone probutate) is a medium potent, non-halogenated double-ester of hydrocortisone with a favorable benefit/risk ratio for the treatment of inflammatory skin disorders.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Hydrocortisone cypionate

Cat. No.: HY-U00089

Hydrocortisone cypionate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Hydrocortisone hemisuccinate

(Hydrocortisone 21-hemisuccinate)

Cat. No.: HY-B1402

Hydrocortisone hemisuccinate (Hydrocortisone 21-hemisuccinate), a physiological glucocorticoid, is an orally active steroidal anti-inflammatory drug (SAID).



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Hydrocortisone phosphate

(Hydrocortisone 21-phosphate; Cortisol 21-phosphate)

Cat. No.: HY-B1155

Hydrocortisone phosphate (Hydrocortisone 21-phosphate), a physiological glucocorticoid, and is an orally active steroidal anti-inflammatory drug (SAID).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Hydronidone

Cat. No.: HY-100438

Hydronidone is a **pyridine** derivative and an antifibrotic agent for hepatic fibrosis.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Hydroquinine

Cat. No.: HY-42034

Hydroquinine is a cinchona alkaloid, can be used in the preparation of its derivatives such as C9 epihydroquinine, 9-acetoxy-10,11-dihydroquinine and 10,11-dihydroquinine monohydrochloride.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Hydroxycitric acid tripotassium hydrate

(Potassium citrate monohydrate)

Cat. No.: HY-W009156

Hydroxycitric acid tripotassium hydrate (Potassium citrate monohydrate) is the major active ingredient of Garcinia cambogia and a derivative of citric acid. Hydroxycitric acid tripotassium hydrate competitively inhibits **ATP citrate lyase** with weight loss benefits.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Hydroxyfasudil

(HA-1100)

Cat. No.: HY-13911

Hydroxyfasudil is a **ROCK** inhibitor, with IC_{50}s of 0.73 and 0.72 μM for **ROCK1** and **ROCK2**, respectively.



Purity: 98.42%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Hydroxyfasudil hydrochloride (HA-1100 hydrochloride; HA 1100 hydrochloride; HA1100 hydrochloride)

Cat. No.: HY-13911A

Hydroxyfasudil hydrochloride is a **ROCK** inhibitor, with IC_{50}s of 0.73 and 0.72 μM for **ROCK1** and **ROCK2**, respectively.



Purity: 98.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hydroxytyrosol (DOPET; 3,4-Dihydroxyphenethyl alcohol; 3-Hydroxytyrosol)

Cat. No.: HY-N0570

Hydroxytyrosol (DOPET) is a phenolic compound drawn from the olive tree and its leaves with anti-oxidant, anti-atherogenic, anti-thrombotic, antimicrobial, anti-inflammatory and anti-tumour effects.



Purity: 99.82%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Hydroxytyrosol acetate

Cat. No.: HY-N6043

Hydroxytyrosol acetate is found in the olive oil with an antioxidant activity. Hydroxytyrosol acetate had a weaker DPPH radical scavenging activity than hydroxytyrosol.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Hydroxytyrosol-d5 (DOPET-d5; 3,4-Dihydroxyphenethyl alcohol-d5; 3-Hydroxytyrosol-d5)

Cat. No.: HY-N0570S1

Hydroxytyrosol-d5 (DOPET-d5) is the deuterium labeled Hydroxytyrosol. Hydroxytyrosol (DOPET) is a phenolic compound drawn from the olive tree and its leaves with anti-oxidant, anti-atherogenic, anti-thrombotic, antimicrobial, anti-inflammatory and anti-tumour effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Hydroxyzine

Cat. No.: HY-B0548

Hydroxyzine, a benzodiazepine **antihistamine** agent, acts as an orally active **histamine H1-receptor** and serotonin antagonist. Hydroxyzine has anxiolytic effect and can be used for the research of generalised anxiety disorder.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Hydroxyzine D4

Cat. No.: HY-B0548S

Hydroxyzine D4 is deuterium labeled Hydroxyzine. Hydroxyzine is a heterocyclic **histamine H1-receptor** antagonist. Hydroxyzine has anticholinergic, anxiolytic and analgesic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hydroxyzine D4 dihydrochloride

Cat. No.: HY-B0548AS

Hydroxyzine D4 dihydrochloride is deuterium labeled Hydroxyzine. Hydroxyzine is a heterocyclic **histamine H1-receptor** antagonist. Hydroxyzine has anticholinergic, anxiolytic and analgesic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hydroxyzine D8

Cat. No.: HY-B0548S1

Hydroxyzine D8 is deuterium labeled Hydroxyzine. Hydroxyzine is a **histamine H1-receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Hydroxyzine dihydrochloride

Cat. No.: HY-B0548A

Hydroxyzine dihydrochloride, a benzodiazepine **antihistamine** agent, acts as a orally active **histamine H1-receptor** and serotonin antagonist. Hydroxyzine dihydrochloride has anxiolytic effect and can be used forthe research of generalised anxiety disorder.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Hydroxyzine pamoate

Cat. No.: HY-B0895

Hydroxyzine pamoate is a histamine H1-receptor antagonist. Target: Histamine H1-Receptor Hydroxyzine inhibits carbachol (10 μM)-induced serotonin release by 34% at 10 μM, by 25% 1 μM and by 17% 0.1 μM in pretreated bladder slices for 60 min .



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Hydroxyzine-d8 Dihydrochloride

Cat. No.: HY-B0548AS2

Hydroxyzine-d8 Dihydrochloride is the deuterium labeled Hydroxyzine dihydrochloride. Hydroxyzine dihydrochloride, a benzodiazepine **antihistamine** agent, acts as a orally active **histamine H1-receptor** and serotonin antagonist.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Hypaconitine

Cat. No.: HY-N0267

Hypaconitine, an active and highly toxic constituent derived from Aconitum species, is widely used to treat rheumatism. IC50 value: Target: In vitro: The present study investigated the metabolism of hypaconitine in vitro using male human liver microsomes.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Hyperectumine

Cat. No.: HY-N10114

Hyperectumine exhibits moderate **anti-inflammatory** activity via suppression of LPS-activated inflammatory mediators in RAW 264.7 macrophage cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hyperoside

Cat. No.: HY-N0452

Hyperoside, a natural flavonoid, isolated from Camptotheca acuminate, possesses antifungal, anti-inflammatory, anti-viral, anti-oxidative and anti-apoptotic activities.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Hyponine D

((+)-Hyponine D)

Cat. No.: HY-N3508

Hyponine D is an immunosuppressive sesquiterpene alkaloid that could be isolated from Tripterygium wilfordii.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hyponine E

((-)-Hyponine E)

Cat. No.: HY-N3509

Hyponine E, a macrocyclic sesquiterpene pyridine alkaloid that could be isolated from from Tripterygium hypoglaucum, possesses anti-inflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hypophyllanthin

Cat. No.: HY-N4108

Hypophyllanthin is a major lignan in Phyllanthus spp, with strong anti-inflammatory activity. Hypophyllanthin directly inhibits **P-glycoprotein (P-gp)** activity and did not interfere with multidrug resistance protein 2 (MRP2) activity.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HZ-1157

Cat. No.: HY-109571

HZ-1157 inhibits **HCV NS3/4A protease** with an **IC_{50}** of 1.0 μmol/L. HZ-1157 (4a) has a high dengue virus inhibitory activity (EC_{50} = 0.15 μM) and is a relatively nontoxic (CC_{50} > 10 μM) dengue antiviral agent.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

I-BET282

Cat. No.: HY-19760

I-BET282 is a pan-inhibitor of all eight **BET bromodomains**, and selectivity over other representative bromodomain-containing proteins. I-BET282 shows pIC_{50}s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD).



Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

I-BET282E

Cat. No.: HY-19760B

I-BET282E is a pan-inhibitor of all eight **BET bromodomains**, and selectivity over other representative bromodomain-containing proteins. I-BET282E shows pIC_{50}s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

I-BET567

Cat. No.: HY-142520

I-BET567 is a potent and oral active inhibitor of **pan-BET** candidate with pIC_{50}s of 6.9 and 7.2 for BRD4 BD1 and BD2, respectively. I-BET567 has been demonstrated efficacy in mouse models of oncology and inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IA-Alkyne

(Iodoacetamide-alkyne; N-Hex-5-ynyl-2-iodo-acetamide) Cat. No.: HY-136205

IA-Alkyne (Iodoacetamide-alkyne; N-Hex-5-ynyl-2-iodo-acetamide) is a **TRP channel (TRPC)** agonist and has the potential for the study of respiratory infection. IA-Alkyne can be used to develop an isotopically tagged **probe** for quantitative **cysteine-reactivity** profiling.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

IAXO-102

Cat. No.: HY-125171

IAXO-102 is a **TLR4** antagonist which negatively regulates TLR4 signalling. IAXO-102 inhibits MAPK and p65 NF-κB phosphorylation and expression of TLR4 dependent proinflammatory protein. IAXO-102 also prevents experimental abdominal aortic aneurysm development.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Iberdomide

(CC-220) Cat. No.: HY-101291

Iberdomide (CC-220) is an orally active and potent **cereblon (CRBN) E3 ligase modulator (CELMoD)** with an IC_{50} of ~150nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities.



Purity: 98.84%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IBMX

(3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine) Cat. No.: HY-12318

IBMX is a broad-spectrum phosphodiesterase (**PDE**) inhibitor, with IC_{50}s of 6.5, 26.3 and 31.7 μM for **PDE3**, **PDE4** and **PDE5**, respectively.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

IBS008738

Cat. No.: HY-112821

IBS008738 is a potent **TAZ** activator. IBS008738 stabilizes TAZ, increases the unphosphorylated TAZ level, enhances the association of MyoD with the myogenin promoter, upregulates MyoD-dependent gene transcription, and competes with myostatin in C2C12 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ibudilast

(KC-404; AV-411; MN-166) Cat. No.: HY-B0763

Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (**PDE**) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ibudilast-d3

Cat. No.: HY-B0763S

Ibudilast-d3 (KC-404-d3) is the deuterium labeled Ibudilast. Ibudilast (KC-404) is a cyclic AMP phosphodiesterase (**PDE**) inhibitor. Ibudilast has platelet anti-aggregatory effects.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Ibuprofen

((±)-Ibuprofen) Cat. No.: HY-78131

Ibuprofen is an anti-inflammatory agent targeting **COX-1** and **COX-2** with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Ibuprofen alcohol

Cat. No.: HY-131261

Ibuprofen alcohol, a nonsteroidal antiinflammatory drug (NSAID), exhibits very little activity for acid-sensing ion channels (ASICs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ibuprofen impurity 1

Cat. No.: HY-131258

Ibuprofen impurity 1 is an Ibuprofen impurity. Ibuprofen is an anti-inflammatory inhibitor targeting **COX-1** and **COX-2** with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Ibuprofen Impurity F

Cat. No.: HY-131259

Ibuprofen Impurity F is an Ibuprofen impurity. Ibuprofen is an anti-inflammatory inhibitor targeting **COX-1** and **COX-2** with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ibuprofen Impurity K

Cat. No.: HY-131260

Ibuprofen Impurity K is an Ibuprofen impurity. Ibuprofen is an anti-inflammatory inhibitor targeting **COX-1** and **COX-2** with IC_{50}s of 13 μM and 370 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ibuprofen piconol

(U75630)

Cat. No.: HY-101482

Ibuprofen piconol is a non-steroidal, anti-inflammatory (NSAID) agent for the topical relief of primary thermal burns and sunburns.



Purity: 98.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Ibuprofen-d3

((±)-Ibuprofen-d3)

Cat. No.: HY-78131S

Ibuprofen D3 is a deuterium labeled Ibuprofen. Ibuprofen is a COX-1 and COX-2 inhibitor with IC_{50}s of 13 μM and 370 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ICAM-1-IN-1

Cat. No.: HY-U00003

ICAM-1-IN-1 is a potent and selective inhibitor of **E-selectin** and **ICAM-1** with IC_{50} values of 7 and 5 nM, respectively.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Icariin

(Ieariline)

Cat. No.: HY-N0014

Icariin is a flavonol glycoside. Icariin inhibits **PDE5** and **PDE4** activities with IC_{50}s of 432 nM and 73.50 μM, respectively. Icariin also is a **PPARα** activator.



Purity: 98.75%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Icariside D2

Cat. No.: HY-N7450

Icariside D2, isolated from Annona glabra fruit, inhibits **angiotensin-converting enzyme**. Icariside D2 shows significant cytotoxic activity on the HL-60 cell line with the IC_{50} value of 9.0 ± 1.0 μM. Icariside D2 induces apoptosis .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Icariside F2

Cat. No.: HY-N8085

Icariside F2 is a potent **NF-κB** inhibitor with an IC_{50} value of 16.25 μM. Icariside F2 is an aromatic glycoside isolated from the leaves of E. ulmoides Oliver. Icariside F2 has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Icatibant acetate

(HOE 140 acetate)

Cat. No.: HY-108896

Icatibant acetate (HOE-140 acetate) is a potent and specific peptide antagonist of **bradykinin B2 receptor** with an IC_{50} and K_i of 1.07 nM and 0.798 nM respectively.



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg

ICCB-19 hydrochloride

Cat. No.: HY-138779

ICCB-19 hydrochloride is a **TRADD (TNFRSF1A associated via death domain)** inhibitor. ICCB-19 hydrochloride binds with N-terminal domain of TRADD (TRADD-N), disrupting its binding to both TRADD-C and TRAF2. ICCB-19 hydrochloride is indirect inhibitor of **RIPK1 kinase** activity.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Icenticaftor

(QBW251)

Cat. No.: HY-109177

Icenticaftor (QBW251) is an orally active **CFTR** channel potentiator, with **EC_{50}**s of 79 nM and 497 nM for **F508del** and **G551D CFTR**, respectively. Icenticaftor can be used for chronic obstructive pulmonary disease (COPD) and cystic fibrosis research.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Icerguastat

(Sephin1; IFB-088)

Cat. No.: HY-111022

Icerguastat (Sephin1), a derivative of Guanabenz lacking the α2-adrenergic activity, is a selective inhibitor of the phosphatase regulatory subunit **PPP1R15A (R15A)**. Icerguastat inhibits eIF2α dephosphorylation, thereby prolonging the protective response. Anti-prion effect.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ICI 211965

(ZM-211965)

Cat. No.: HY-100148

ICI 211965 (ZM-211965) is a selective and orally potent **5-Lipoxygenase (5-LPO)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Icilin

(AG-3-5)

Cat. No.: HY-11062

Icilin (AG-3-5) is a super-agonist of the transient receptor potential M8 (**TRPM8**) ion channel. Icilin activates TRPM8 in EGTA in a dose-dependent manner (EC_{50}=1.4 μM). Icilin is a "super-cooling agent".



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Icosabutate

Cat. No.: HY-121212

Icosabutate, an orally active ω-3 polyunsaturated fatty acid, is an **aeicosapentaenoic acid (EPA) derivative**. Icosabutate overcomes the drawbacks of unmodified EPA for liver targeting and improves insulin sensitivity, hepatic inflammation and fibrosis.

Purity: 95.30%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IDE1

Cat. No.: HY-100533

IDE1 is an inducer of definitive endoderm 1.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

IDO-IN-13

Cat. No.: HY-129749

IDO-IN-13 is a potent **indoleamine 2,3-dioxygenase 1 (IDO1)** inhibitor with an **EC_{50}** of 17 nM, extracted from patent WO2019040102A1, example 43.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1-IN-2

Cat. No.: HY-130607

IDO1-IN-2 (compound 16) is a potent and selective **IDO1** inhibitor with **IC_{50}**s of 81 nM, 59 nM (mouse) and 28 nM (rat), respectively. IDO1-IN-2 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDR-1

Cat. No.: HY-P2320

IDR-1 is an antimicrobial peptide that is active against **Gram-positive** and **Gram-negative bacteria**. IDR-1 counters infection by selective modulation of innate immunity without obvious toxicities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Iferanserin

(S-MPEC)

Cat. No.: HY-118557

Iferanserin (S-MPEC) is a selective **5-HT receptor** (**serotonin receptor**) antagonist with an affinity for **5-HT$_{2A}$ receptor**. Iferanserin has the potential for internal hemorrhoid disease treatment.



Purity: 99.74%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IFN alpha-IFNAR-IN-1

Cat. No.: HY-12836

IFN alpha-IFNAR-IN-1 is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR; inhibit MVA-induced IFN-α responses by BM-pDCs (IC50=2-8 uM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IFN alpha-IFNAR-IN-1 hydrochloride

Cat. No.: HY-12836A

IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR; inhibit MVA-induced IFN-α responses by BM-pDCs (IC50=2-8 uM).



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IGF-I (24-41)

(Insulin-like Growth Factor I (24-41))

Cat. No.: HY-P1777

IGF-I (24-41) is amino acids 24 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).

YFNKPTGYGSSSRRAPQT

Purity: 99.79%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

IGF-I (24-41) (TFA)

(Insulin-like Growth Factor I (24-41) (TFA))

Cat. No.: HY-P1777A

IGF-I (24-41) (TFA) is amino acids 24 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).

YFNKPTGYGSSSRRAPQT (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IGF-I (30-41)

(Insulin-like Growth Factor I (30-41))

Cat. No.: HY-P1773

IGF-I (30-41) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).

GYGSSSRRAPQT

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IGF-I (30-41) (TFA)

(Insulin-like Growth Factor I (30-41) (TFA))

Cat. No.: HY-P1773A

IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).

GYGSSSRRAPQT (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Iguratimod

(T614)

Cat. No.: HY-17009

Iguratimod is an antirheumatic agent, acts as an inhibitor of **COX-2**, with an **IC$_{50}$** of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod also inhibits macrophage migration inhibitory factor (**MIF**) with an **IC$_{50}$** of 6.81 μM.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

IHMT-PI3Kδ-372

Cat. No.: HY-131910

IHMT-PI3Kδ-372 is a potent and selective **PI3Kδ** inhibitor with an **IC$_{50}$** of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (5683 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IHVR-11029

Cat. No.: HY-117721

IHVR-11029 is a small molecule inhibitor of **ER α-glucosidases**, with an **EC$_{50}$** of 0.09 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IKarisoside A

(Icarisoside-A; Baohuoside II)

Cat. No.: HY-N0875

IKarisoside A (Icarisoside-A) is a natural flavonol glycoside and has anti-inflammatory properties.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 5 mg

IKK 16

Cat. No.: HY-13687

IKK 16 is a selective IκB kinase (**IKK**) inhibitor for **IKK2**, **IKK complex** and **IKK1** with IC_{50}s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (**LRRK2**) with an IC_{50} of 50 nM.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

IKK 16 hydrochloride

Cat. No.: HY-13687A

IKK 16 hydrochloride is a selective IκB kinase (**IKK**) inhibitor for **IKK2**, **IKK complex** and **IKK1** with IC_{50}s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (**LRRK2**) with an IC_{50} of 50 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IKK-IN-1

Cat. No.: HY-13873

IKK-IN-1 is an inhibitor of **IKK** extracted from patent WO2002024679A1, compound example 18-13.



Purity: 95.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

IKK-IN-3

Cat. No.: HY-136392

IKK-IN-3 is a potent and selective **IkappaB kinase 2** (**IKK2** or **IKKβ**) inhibitor, with IC_{50}s of 19 and 400 nM for IKK2 and IKK1 (or IKKα), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IKK-IN-4

Cat. No.: HY-136393

IKK-IN-4 is a potent and selective **IkappaB kinase 2** (**IKKβ** or**IKK2**) inhibitor, with IC_{50}s of 45 and 650 nM for IKKβ and IKKα, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IKKγ NBD Inhibitory Peptide TFA

Cat. No.: HY-P1847A

IKKγ NBD Inhibitory Peptide TFA is a NEMO-binding domain peptide (NBD peptide) corresponding to the NEMO amino-terminal alpha-helical region, which is shown to block TNF-alpha-induced NF-kB activation.

Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

IL-15-IN-1

Cat. No.: HY-102049

IL-15-IN-1 is a potent and selective **Interleukin 15 (IL-15)** inhibitor, inhibiting the proliferation of IL-15-dependent cells with an IC_{50} of 0.8 μM.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IL-17 modulator 1

Cat. No.: HY-141535

IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulators extracted from patent WO 2020127685.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IL-17 modulator 1 disodium

Cat. No.: HY-141535A

IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IL-17 modulator 3

Cat. No.: HY-139203

IL-17 modulator 3 is an IL-17 modulator (US20200247785A1). IL-17 modulator 3 can be used for the research of inflammation, cancer and autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IL-17 modulator 4

Cat. No.: HY-141692

IL-17 modulator 4 is a prodrug of IL-17 modulator 1 (HY-141535). IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IL-17 modulator 4 sulfate

Cat. No.: HY-141692A

IL-17 modulator 4 sulfate is a prodrug of IL-17 modulator 1 (HY-141535). IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IL-17A antagonist 1

Cat. No.: HY-101913

IL-17A antagonist 1 (compound 1) is an **IL-17A** antagonist, with a K_d of 0.66 μM and an IC_{50} of 1.14 μM.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

IL-17A antagonist 3

Cat. No.: HY-101915

IL-17A antagonist 3 is an **IL-17A** antagonist, compound 3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IL-17A inhibitor 1

Cat. No.: HY-139206

IL-17A inhibitor 1 (example 24) is a **IL-17A** inhibitor, with IC_{50} values of <9.45 nM and 9.3 nM in alphalisa assay and HT-29 cells.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Ilaprazole

(IY-81149)

Cat. No.: HY-101664

Ilaprazole (IY-81149) is an orally active **proton pump** inhibitor. Ilaprazole irreversibly inhibits **H^+/K^+-ATPase** in a dose-dependent manner with an IC_{50} of pump inhibitory activity of 6 μM in rabbit parietal cell preparation.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Ilaprazole sodium

(IY-81149 sodium)

Cat. No.: HY-B2145

Ilaprazole (IY-81149) sodium is an orally active **proton pump** inhibitor. Ilaprazole sodium irreversibly inhibits **H^+/K^+-ATPase** in a dose-dependent manner with an IC_{50} of 6 μM in rabbit parietal cell preparation.



Purity: 98.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ilexgenin A

Cat. No.: HY-N6255

Ilexgenin A is a pentacyclic triterpenoid, which extracted from Ilex hainanensis Merr. Ilexgenin A can be used for the research of inflammation and cancer.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Ilexhainanoside D

Cat. No.: HY-N5040

Ilexhainanoside D is the main triterpenoid saponin extracted from Ilex hainanensis Merr., and the combination of Ilexhainanoside D and ilexsaponin A1 has anti-inflammation effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ilexoside O

Cat. No.: HY-N9324

Ilexoside O is a triterpene saponin isolated from the roots of Ilex pubescens. Ilexoside O exhibits weak **xanthine oxidase (XOD)** inhibitory activity (IC_{50}=53.05 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ilimaquinone

Cat. No.: HY-119500

Ilimaquinone, a marine sponge metabolite, displays anticancer activity via GADD153-mediated pathway. Ilimaquinone can induce vesiculation of the Golgi apparatus. Ilimaquinone exerts anti-HIV, anti-microbial, anti-inflammatory, and effects.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 100 μg

ILS-920

Cat. No.: HY-106345

ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin **FKBP52** and to the β1-subunit of **L-type voltage-gated calcium channels (VGCC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IMD-biphenylC

Cat. No.: HY-139719

IMD-biphenylC is a novel imidazoquinolinone-**NF-κB** immunomodulator dimer that inhibits tumor proliferation while induces low systemic inflammation and reduces adjuvant toxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IMD-catechol

Cat. No.: HY-139716

IMD-catechol is a novel imidazoquinolinone-**NF-κB** immunomodulator dimer that improves efficacy in a CT26 mouse colon carcinoma tumor model while eliciting minimal adjuvant toxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imiquimod

(R 837)

Cat. No.: HY-B0180

Imiquimod (R 837), an immune response modifier, is a selective **toll like receptor 7 (TLR7)** agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19.



Purity: 99.96%
Clinical Data: Launched
Size: 100 mg, 200 mg, 500 mg

Imiquimod hydrochloride

(R 837 hydrochloride)

Cat. No.: HY-B0180A

Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective **toll like receptor 7 (TLR7)** agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Imiquimod maleate

(R 837 maleate)

Cat. No.: HY-B0180B

Imiquimod maleate (R 837 maleate), an immune response modifier, is a selective **toll like receptor 7 (TLR7)** agonist. Imiquimod maleate exhibits antiviral and antitumor effects in vivo.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Imrecoxib

(BAP-909)

Cat. No.: HY-114200

Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (**COX-2**) inhibitor with an IC_{50} value of 18 nM, it also inhibits COX1- activity with an IC_{50} value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

IN-1130

Cat. No.: HY-18758

IN-1130 is a highly selective **transforming growth factor-β type I receptor kinase (ALK5)** inhibitor with an IC_{50} of 5.3 nM for ALK5-mediated Smad3 phosphorylation.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Inarigivir ammonium

(ORI-9020 ammonium; SB-9000 ammonium)

Cat. No.: HY-101954A

Inarigivir (ORI-9020) ammonium is a dinucleotide antiviral drug that can significantly reduce liver **HBV** DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) ammonium acts as a **RIG-I (Retinoic acid-inducible gene-I)** agonist to activate cellular innate immune responses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

INCB3344

Cat. No.: HY-50674

INCB3344 is a potent, selective and orally bioavailable **CCR2** antagonist with IC_{50} values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

INCB3344 R-isomer

Cat. No.: HY-50674A

INCB3344 R-isomer is the R-isomer of INCB3344. INCB3344 is a potent, selective and orally bioavailable **CCR2** antagonist with IC_{50} values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.



Purity: 96.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Indinavir

(MK-639; L-735524)

Cat. No.: HY-B0689

Indinavir(MK-639; L735524) is a potent and specific HIV protease inhibitor that appears to have good oral bioavailability.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Indolmycin

(TAK-083; PA-155A)

Cat. No.: HY-117319

Indolmycin (TAK-083), an antibiotic, is a competitive inhibitor of prokaryotic **tryptophanyl-tRNA ligase (TrpS)**. Indolmycin (TAK-083) possesses both anti-viral and anti-bacterial activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Indomethacin

(Indometacin)

Cat. No.: HY-14397

Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of **COX1** and **COX2**, with IC_{50}s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells. Indomethacin disrupts **autophagic flux** by disturbing the normal functioning of lysosomes.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Indomethacin farnesil

(Indometacin farnesil)

Cat. No.: HY-111274

Indomethacin farnesil is an orally active prodrug of Indomethacin. Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of **COX1** and **COX2**, with IC_{50}**s** of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Indomethacin sodium hydrate

(Indometacin sodium hydrate)

Cat. No.: HY-14397A

Indomethacin sodium hydrate (Indometacin sodium hydrate) is a potent, blood-brain permeable and nonselective inhibitor of **COX1** and **COX2**, with IC_{50}s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells.



Purity: 96.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Indomethacin-d4

(Indometacin-d4)

Cat. No.: HY-14397S

Indomethacin-D4 (Indometacin-D4) is a deuterium labeled Indomethacin. Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of **COX1** and **COX2**, with IC_{50}s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Indoprofen

((±)-Indoprofe)

Cat. No.: HY-B1104

Indoprofen is a non-steroidal anti-inflammatory drug, provide insight into treatments for spinal muscular atrophies.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Indoprofen-d3

Cat. No.: HY-B1104S

Indoprofen-d3 ((±)-Indoprofe-d3) is the deuterium labeled Indoprofen. Indoprofen is a non-steroidal anti-inflammatory drug, provide insight into treatments for spinal muscular atrophies.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

INF39

Cat. No.: HY-101868

INF39 is an irreversible and noncytotoxic **NLRP3** inhibitor.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Inflachromene

Cat. No.: HY-113772

Inflachromene, a microglial inhibitor, binds to **HMGB1** and **HMGB2** and exerts anti-inflammatory effects. Inflachromene effectively downregulates proinflammatory functions of **HMGB** and reduces neuronal damage. Inflachromene can be used for the research of neuroinflammatory disorders.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Infliximab

(Avakine; CT-P13)

Cat. No.: HY-P9970

Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to **TNF-α**. Infliximab prevents the interaction of **TNF-α** with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.

Avakine

Purity: 90.30%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg

Influenza HA (110-119)

Cat. No.: HY-P2520

Influenza HA (110-119) is the 110-119 fragment of influenza virus hemagglutinin that can stimulate Treg cells proliferation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Influenza Matrix Protein (61-72)

Cat. No.: HY-P2561

Influenza Matrix Protein (61-72) is a peptide fragment derived from matrix protein of influenza viruses, corresponds to amino acids 61-72. Influenza Matrix Protein (61-72) is a specific epitope which can induce $CD4^+$ T-cell response.

GFVFTLTVPSER

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ingenol 3,20-dibenzoate

Cat. No.: HY-137295

Ingenol 3,20-dibenzoate is a potent **protein kinase C (PKC)** isoform-selective agonist.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Ingenol Mebutate

(Ingenol 3-angelate; PEP005)

Cat. No.: HY-B0719

Ingenol Mebutate is an active ingredient in Euphorbia peplus, acts as a potent **PKC** modulator, with K_is of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively, and has antiinflammatory and antitumor activity.



Purity: 99.07%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

INH14

Cat. No.: HY-114454

INH14 is a cell permeable inhibitor of **IKKα/IKKβ**, with IC_{50}s of 8.97 and 3.59 μM, respectively. INH14 inhibits the IKKα/β-dependent **TLR** inflammatory response. INH14 also inhibits downstream of TAK1/TAB1 and NF-kB pathways. Anti-inflammatory and anti-cancer activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

INO5042

Cat. No.: HY-U00094

INO5042, a thiazole fused 1,4-naphthoquinone compound, and exhibits anti-inflammation activity.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 1 mg

Inokosterone

Cat. No.: HY-121351

Inokosterone is a potential drug target of **estrogen receptor 1** in rheumatoid arthritis patients.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Inosine

Cat. No.: HY-N0092

Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A_1 (A_1R) and A_{2A} ($A_{2A}R$) receptors.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 10 g, 25 g, 100 g

InsB (9-23)

(Insulin B chain (9-23))

Cat. No.: HY-P1745

InsB (9-23) is an insulin B-chain peptide that binds to a class II histocompatibility complex (MHC) allele called I-Ag7. InsB (9-23) can be used to treat a number of autoimmune related diseases like Type 1 diabetes.

SHLVEALYLVCGERG

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Integrin modulator 1

Cat. No.: HY-134130

Integrin modulator 1 is a potent and selective **α4β1 integrin** agonist, with an **IC_{50}** of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an **EC_{50}** of 12.9 nM.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Interferon receptor inducer-1

Cat. No.: HY-112189

Interferon receptor inducer-1 (compound 6) is an interferon **(IFN)** receptor inducer. Used accordingly in the treatment of a disorder in which the induction of interferon is involved.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Interphotoreceptor Retinoid Binding Protein Fragment (IRBP)

Cat. No.: HY-P1861

Interphotoreceptor Retinoid Binding Protein Fragment (IRBP), a 20-residue peptide and a major pathogenic epitope, is present in the first homologous repeat of the interphotoreceptor retinoid binding protein peptide (IRBP 161–180), which can induce posterior uveitis (EAU).

SGIPYIISYLHPGNTILHVD

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Interphotoreceptor retinoid-binding protein(668-687)

(IRBP(668-687))

Cat. No.: HY-P1924

Interphotoreceptor retinoid-binding protein(668-687), the amino acid residues 668 to 687 of human interphotoreceptor retinoid binding protein (IRBP), induces uveitis.

LAQGAYRTAVDLESLASQLT

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Interphotoreceptor retinoid-binding protein(668-687) TFA

(IRBP(668-687) TFA)

Cat. No.: HY-P1924A

Interphotoreceptor retinoid-binding protein(668-687) TFA, the amino acid residues 668 to 687 of human interphotoreceptor retinoid binding protein (IRBP), induces uveitis.

LAQGAYRTAVDLESLASQLT (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Inulicin

(1-O-Acetylbritannilactone)

Cat. No.: HY-N0896

Inulicin (1-O-Acetylbritannilactone) is an active compound that inhibits VEGF-mediated activation of **Src** and **FAK**. Inulicin (1-O-Acetylbritannilactone) inhibits LPS-induced **PGE_2** production and **COX-2** expression, and **NF-κB** activation and translocation.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Iodophenpropit dihydrobromide

Cat. No.: HY-107568

Iodophenpropit dihydrobromide is a potent and selective **histamine H3 receptor** antagonist. The binding of [^{125}I]Iodophenpropit is selective, saturable, readily reversible, and of high affinity (K_D 0.32 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Iotalamic acid
(Iothalamic acid)

Cat. No.: HY-B1053

Lotalamic acid (Iothalamic acid) is a molecule used as a contrast medium.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

IOX4

Cat. No.: HY-120110

IOX4 is a selective HIF prolyl-hydroxylase 2 (**PHD2**) inhibitor with an IC_{50} value of 1.6 nM, induces **HIFα** in cells and in wildtype mice with marked induction in the brain tissue. IOX4 competes with and displaces 2-oxoglutarate (2OG) at the active site of PHD2.



Purity: 99.78%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IP7e

Cat. No.: HY-110274

IP7e is a potent, brain-penetrant and orally active **Nurr1** activator with an EC_{50} value of 3.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ipecoside

Cat. No.: HY-N2261

Ipecoside is an alkaloid isolated from Psychotria.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

IPI-3063

Cat. No.: HY-111510

IPI-3063 is a potent and selective **PI3K p110δ** inhibitor with an IC_{50} of 2.5±1.2 nM.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

IPN60090

Cat. No.: HY-103671

IPN-60090 is an orally active and highly selective inhibitor of **glutaminase 1** (**GLS1**; IC_{50}=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IPN60090 dihydrochloride

Cat. No.: HY-103671A

IPN-60090 dihydrochloride is an orally active and highly selective inhibitor of **glutaminase 1** (**GLS1**; IC_{50}=31 nM), with no activity observed against GLS-2. IPN-60090 dihydrochloride exhibits excellent physicochemical and pharmacokinetic properties in vivo.



Purity: 99.05%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ipratropium bromide
(Sch 1000)

Cat. No.: HY-B0241

Ipratropium bromide (Sch 1000) is a **muscarinic receptor** antagonist, with binding IC_{50} values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Ipsalazide

Cat. No.: HY-101744

Ipsalazide is a novel sulfasalazine analog designed to release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Iptacopan
(LNP023)

Cat. No.: HY-127105

Iptacopan (LNP023) is a first-in-class, orally bioavailable, highly potent and highly selective **factor B** inhibitor with an IC_{50} value of 10 nM. Iptacopan shows direct, reversible, and high-affinity binding to human factor B with a K_D of 7.9 nM.



Purity: 99.86%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Iptacopan hydrochloride

(LNP023 hydrochloride) Cat. No.: HY-127105A

LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective **factor B** inhibitor. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a K_D of 7.9 nM. LNP023 inhibits factor B with an IC_{50} value of 10 nM.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IQ-1S free acid

Cat. No.: HY-100233

IQ-1S free acid is a prospective inhibitor of **NF-κB**/activating protein 1 (**AP-1**) activity with an IC_{50} of 2.3±0.41 μM. IQ-1S free acid has binding affinity (K_d values) in the nanomolar range for all three **JNK**s with K_ds of 100 nM, 240 nM, and 360 nM for **JNK3**, **JNK1**, and **JNK2**, respectively.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IQ-3

Cat. No.: HY-107600

IQ-3 is a specific inhibitor of the **c-Jun N-terminal kinase (JNK)** family, with preference for JNK3. IQ-3 exhibits K_d values of 0.24 μM, 0.29 μM and 0.066 μM for JNK1, JNK2 and JNK3, respectively.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IRAK inhibitor 1

Cat. No.: HY-13275

IRAK inhibitor 1 is a potent **IRAK-4** inhibitor with IC_{50} of 216 nM, is poorly active against JNK-1 and JNK-2 with IC_{50} of 3.801 μM, and >10 μM, respectively.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

IRAK inhibitor 2

Cat. No.: HY-13276

IRAK inhibitor 2 is interleukin-1 receptor associated kinase inhibitor .



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

IRAK inhibitor 3

Cat. No.: HY-13277

IRAK inhibitor 3 is an interleukin-1 (IL-I) receptor-associated kinase (**IRAK**) kinase modulator extracted from patent WO2008030579 A2.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

IRAK inhibitor 4

Cat. No.: HY-13278

IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(**IRAK4**) inhibitor.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg

IRAK inhibitor 4 trans

Cat. No.: HY-13278A

IRAK inhibitor 4 (trans) is the trans form of IRAK inhibitor 4. IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4 (**IRAK4**) inhibitor.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 5 mg

IRAK inhibitor 6

Cat. No.: HY-13280

IRAK inhibitor 6 is an inhibitor of **interleukin-1 receptor associated kinase 4 (IRAK-4)** with IC_{50} of 160 nM.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

IRAK-1-4 Inhibitor I

(IRAK-1/4 Inhibitor I) Cat. No.: HY-13329

IRAK-1-4 Inhibitor I is an inhibitor of interleukin-1 receptor-associated kinase 1/4 (**IRAK 1/4**) with IC_{50}s of 0.2 μM and 0.3 μM, respectively.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

IRAK-4 protein kinase inhibitor 2

Cat. No.: HY-77048

IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of **interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4)**, with an IC_{50} of 4 μM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disorders.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

IRAK4-IN-1

Cat. No.: HY-101922

IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (**IRAK4**) inhibitor with an IC_{50} of 7 nM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IRAK4-IN-4

Cat. No.: HY-114181

IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (**IRAK4**) inhibitor extracted from patent CN107163044A, Compound15, has an IC_{50} of 2.8 nM. IRAK4-IN-4 also inhibits **cyclic GMP-AMP synthase** (**cGAS**) with an IC_{50} of 2.1 nM.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IRAK4-IN-7

Cat. No.: HY-109585

IRAK4-IN-7 is a selective, potent and orally active **interleukin-1 receptor-associated kinase 4 (IRAK4)** inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment.



Purity: 99.86%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

IRBP (1-20), human

Cat. No.: HY-P1587

IRBP (1-20), human contains a major epitope for the H-2^b haplotype. IRBP (1-20), human induces experimental autoimmune uveoretinitis (EAU) in H-2^b mice.

GPTHLFQPSLVLDMAKVLLD

Purity: 99.16%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

IRBP (1-20), human TFA

Cat. No.: HY-P1587A

IRBP (1-20), human TFA contains a major epitope for the H-2^b haplotype. IRBP (1-20), human TFA induces experimental autoimmune uveoretinitis (EAU) in H-2^b mice.

GPTHLFQPSLVLDMAKVLLD (TFA salt)

Purity: 99.63%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Iridin

Cat. No.: HY-N3011

Iridin is an isoflavone isolated from Iris milesii.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Irisflorentin

Cat. No.: HY-N0268

Irisflorentin, a naturally occurring isoflavone, is an abundant active constituent in Rhizoma Belamcandae. Irisflorentin markedly reduces the transcriptional and translational levels of inducible nitric oxide synthase (iNOS) as well as the production of NO. Anti-inflammatory activity.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Iristectorigenin A

Cat. No.: HY-N2505

Iristectorigenin A is a natural isoflavone isolated from B. chinensis rhizomes. Iristectorigenin A shows antioxidant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Irsogladine

(Dicloguamine)

Cat. No.: HY-B0327

Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Irsogladine maleate

(Dicloguamine maleate; MN1695)

Cat. No.: HY-B0327A

Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

ISCK03

Cat. No.: HY-101443

ISCK03 is a specific **SCF/c-Kit** inhibitor.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ISO-1

(MIF Antagonist)

Cat. No.: HY-16692

ISO-1 is a macrophage migration inhibitory factor (**MIF**) antagonist with an IC_{50} of 7 μM.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Isobergapten

Cat. No.: HY-N0764

Isobergapten is an allelopathic inhibitor isolated from seeds of Hevacleum laciniatum.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Isobutylparaben

(Isobutyl 4-hydroxybenzoate)

Cat. No.: HY-W015026

Isobutylparaben (Isobutyl 4-hydroxybenzoate) is a constitutive **androstane receptor (CAR)** activator. Isobutylparaben has a broad-spectrum **antimicrobial** activity and widely used in personal care products and cosmetics.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

Isobutylshikonin

Cat. No.: HY-N2592

Isobutylshikonin is a kind of shikonin pigments from hairy root culture of Lithospermum canescens.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Isochlorogenic acid A

(3,5-Dicaffeoylquinic acid; 3,5-CQA)

Cat. No.: HY-N0056

Isochlorogenic acid A (3,5-Dicaffeoylquinic acid) is a natural phenolic acid with antioxidant and anti-inflammatory activities .



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Isoeleutherin

Cat. No.: HY-129055

Isoeleutherin is a naphthopyran derivative isolated from E. americana Merr. Et Heyne with anti-**fungal**, anti-viral, and anti-tumor activities. Isoeleutherin plays an important role in selective modulation of T helper cell-mediated immune responses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Isoeugenol acetate

(Acetyl isoeugenol)

Cat. No.: HY-N6805

Isoeugenol acetate (Acetyl isoeugenol), an essential oil constituent of nutmeg, clove, and cinnamon, shows excellent inhibitory effects against some metabolic enzymes such as acetylcholinesterase (AChE) enzymes (IC_{50}=77 nM; K_i=16 nM), α-glycosidase (IC_{50}=19.25 nM;...



Purity: 98.92%
Clinical Data: No Development Reported
Size: 5 mg

Isoflupredone

Cat. No.: HY-132269

Isoflupredone belongs to the class of corticosteroids and exerts its effect by binding to glucocorticoid and mineralocorticoid receptors of animals, such as horses. Isoflupredone can be used in wide range of conditions, such as infection and inflammatory diseases.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Isoformononetin

Cat. No.: HY-N7501

Isoformononetin is an analog of Daidzein (HY-N0019) and has **immunoprotective** effects. Isoformononetin inhibits the differentiation of Th17 and B-cells lymphopoesis to promote osteogenesis in estrogen-deficient bone loss conditions.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Isoforskolin

(Coleonol B)

Cat. No.: HY-N6927

Isoforskolin is the principle active component of C. forskohlii native to China. Isoforskolin reduces the secretion of lipopolysaccharide (LPS)-induced cytokines, namely **TNF-α**, **IL-1β**, **IL-6** and **IL-8**, in human mononuclear leukocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Isofraxidin

Cat. No.: HY-N0774

Isofraxidin, a coumarin component from Acanthopanax senticosus, inhibits **MMP-7** expression and cell invasion of human hepatoma cells. Isofraxidin inhibits the phosphorylation of **ERK1/2** in hepatoma cells.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Isoliensinine

Cat. No.: HY-N0770

Isoliensinine is a bisbenzylisoquinoline alkaloid extracted from the seed embryo of Nelumbo nucifera, with anti-oxidant and anti-inflammatory and anti-cancer activities. Isoliensinine induces apoptosis in triple-negative human breast cancer cells.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Isolindleyin

Cat. No.: HY-N6244

Isolindleyin, a butyrophenone, is a **tyrosinase** inhibitor, with a K_d of 54.8 μM for human tyrosinase. Isolindleyin exhibits anti-inflammatory, analgesic and anti-melanogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Isoliquiritigenin

(GU17; ISL; Isoliquiritigen)

Cat. No.: HY-N0102

Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza glabra, which inhibits **aldose reductase** with an IC_{50} of 320 nM. Isoliquiritigenin is a potent inhibitor of **influenza virus** replication with an EC_{50} of 24.7 μM.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Isoliquiritin

Cat. No.: HY-N0765

Isoliquiritin, isolated from Licorice Root, inhibits angiogenesis and tube formation. Isoliquiritin also exhibits antidepressant-like effects and antifungal activity.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Isolongifolene

((-)-Isolongifolene)

Cat. No.: HY-N7363

Isolongifolene ((-)-Isolongifolene) is a tricyclic sesquiterpene isolated from Murraya koenigii. Isolongifolene attenuates Rotenone-induced oxidative stress, mitochondrial dysfunction and apoptosis through the regulation of PI3K/AKT/GSK-3β signaling pathways.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Isomagnolone

Cat. No.: HY-N3472

Isomagnolone is isolated from Illicium burmanicum and has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Isomucronulatol

Cat. No.: HY-N2495

Isomucronulatol is a flavonoid isolated from the roots of A. membranaceus. Isomucronulatol exhibits inhibitory effects on LPS-stimulated production IL-12 p40 in vitro and has potential anti-inflammatory effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Isomucronulatol 7-O-glucoside

(Isomucronulatol 7-O-β-glucoside)

Cat. No.: HY-N6250

Isomucronulatol 7-O-glucoside is a flavonoid isolated from the roots of A. membranaceus. Isomucronulatol 7-O-glucoside exhibits weak inhibitory effects on LPS-stimulated production IL-12 p40 in vitro and has potential anti-inflammatory effect.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Isookanin

Cat. No.: HY-N7677

Isookanin can be used for the research of various illnesses including cancers, skin rashes, snake and insects bites, diabetes mellitus, diarrhoea. Isookanin acts as an anti-viral agent against HSV and varicella-zoster virus (VZV). Antioxidant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Isoorientin

(Homoorientin)

Cat. No.: HY-N0767

Isoorientin is a potent inhibitor of **COX-2** with an IC_{50} value of 39 μM.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Isopimpinellin

Cat. No.: HY-N0769

Isopimpinellin, an orally active compound isolated from the roots of Pimpinella saxifrage. Isopimpinellin blocks DNA adduct formation and skin tumor initiation by 7,12-dimethylbenz[a]anthracene. Isopimpinellin possesses anti-leishmania effect.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Isoquercetin

(Quercetin 3-glucoside)

Cat. No.: HY-N1445

Isoquercetin (Quercetin 3-glucoside) is a naturally occurring polyphenol that has antioxidant, anti-proliferative, and anti-inflammatory properties.



Purity: 99.87%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Isoquercitrin

(Isoquercitroside)

Cat. No.: HY-N0768

Isoquercitrin (Isoquercitroside) is an effective antioxidant and an eosinophilic inflammation suppressor.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Isorhamnetin

(3'-Methylquercetin)

Cat. No.: HY-N0776

Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of **MEK1** and **PI3K**.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Isorhamnetin 3-O-galactoside

(Cacticin)

Cat. No.: HY-N2082

Isorhamnetin 3-O-galactoside (Cacticin), a flavonoid glycoside isolated from Artemisia capillaris Thunberg, which ameliorates CCl4-induced hepatic damage by enhancing the anti-oxidative defense system and reducing the inflammatory signaling pathways.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Isorhapontigenin

Cat. No.: HY-N2593

Isorhapontigenin, an orally bioavailable dietary polyphenol isolated from the Chinese herb Gnetum cleistostachyum, displays anti-inflammatory effects. Isorhapontigenin induces **autophagy** and inhibits invasive bladder cancer formation.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Isoscabertopin

Cat. No.: HY-N2596

Isoscabertopin is a sesquiterpene lactone isolated from Elephantopus scaber L and shows **anti-tumor** activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Isoscoparin

Cat. No.: HY-N5080

Isoscoparin is a flavonoid that could be isolated from EtOAc extract of Gentiana algida Pall. Isoscoparin possesses antioxidant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Isosinensetin

Cat. No.: HY-N1941

Isosinensetin, a polymethoxylated flavone extracted from pericarpium citri reticulatae viride, exhibits inhibition on **P-glycoprotein (P-gp)** in MDR1-MDCKII cells.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Isotetrandrine

Cat. No.: HY-N6045

Isotetrandrine is a bioactive component in S. acutum.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Isothipendyl-d6

Cat. No.: HY-A0178S



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Isotoosendanin

Cat. No.: HY-N7694

Isotoosendanin is a limonoid that can be isolated from Melia toosendan fruit. Isotoosendanin displays significant anti-inflammatory and analgesic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Isovanillic acid

(3-Hydroxy-4-methoxybenzoic acid)

Cat. No.: HY-N6864

Isovanillic acid (3-Hydroxy-4-methoxybenzoic acid) is a phenolic acid isolated from isolated from S. frutescens, with Anti-inflammatory activity.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Isovitexin

(Saponaretin; Homovitexin)

Cat. No.: HY-N0773

Isovitexin is a flavonoid isolated from rice hulls of Oryza sativa, possesses anti-inflammatory and anti-oxidant activities; Isovitexin acts like a **JNK1/2** inhibitor and inhibits the activation of **NF-κB**.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Isoxicam

Cat. No.: HY-B1130

Isoxicam is an orally active, long-acting, non-steroidal anti-inflammatory agent for the research of arthritis. Isoxicam is a nonselective inhibitor of **COX-1** and **COX-2**.



Purity: 99.11%
Clinical Data: Launched
Size: 100 mg, 250 mg

IT1t

Cat. No.: HY-101458

IT1t is a potent **CXCR4** antagonist; inhibits CXCL12/CXCR4 interaction with an IC_{50} of 2.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IT1t dihydrochloride

Cat. No.: HY-101458A

IT1t dihydrochloride is a potent **CXCR4** antagonist; inhibits CXCL12/CXCR4 interaction with an IC_{50} of 2.1 nM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Itaconate-alkyne

(ITalk)

Cat. No.: HY-133870

Itaconate-alkyne (ITalk) is a specific bioorthogonal probe for quantitative and site-specific chemoproteomic profiling of Itaconation in living cells.



Purity: 96.66%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Itaconic acid

Cat. No.: HY-Y0520

Itaconic acid, a precursor of polymers, chemicals, and fuels, can be synthesized by many fungi. Itaconic acid also is a macrophage-specific metabolite. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Itch-Targeting Compound 1

Cat. No.: HY-U00361

Itch-Targeting Compound 1 is an anti-itching agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ITE

Cat. No.: HY-19317

ITE is a potent endogenous agonist of aryl hydrocarbon receptor (**AhR**), binding directly to **AHR**, with a K_i of 3 nM. ITE also has immunosuppressive activity.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ITK inhibitor 2

Cat. No.: HY-128726

ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (**ITK**) inhibitor extracted from patent WO2011065402A1, compound 4, with an IC_{50} of 2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ITK/TRKA-IN-1

Cat. No.: HY-141864

ITK/TRKA-IN-1 is a dual inhibitor of **IL-2-inducible T-cell kinase (ITK)** and **tropomyosin receptor kinase A (TRKA)** with an IC_{50} value of 1.0 nM and 96 % inhibition, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ivaltinostat formic

(CG-200745 formic)

Cat. No.: HY-16138A

Ivaltinostat (CG-200745) formic is an orally active, potent pan-**HDAC** inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

IX 207-887

Cat. No.: HY-106087

IX 207-887 is a novel antiarthritic agent which inhibits the release of **interleukin-1** (**IL-1**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ixekizumab

(LY2439821)

Cat. No.: HY-P9924

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin **IL-17A** (K_D<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members.

Ixekizumab

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Izencitinib

(TD-1473; JNJ-8398)

Cat. No.: HY-109148

Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted **JAK** inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Iα52

Cat. No.: HY-P1811

Iα52 is a naturally processed peptide encompassed the residues 52-68 of the murine I-Eα chain and may contribute to selection of immature T cells.

ASFEAQGALANIAVDKA

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

J-113863

Cat. No.: HY-103360

J-113863 is a potent and selective **CCR1 (CD18)** antagonist with IC_{50} values of 0.9 nM and 5.8nM for human and mouse **CCR1** receptors, respectively. J-113863 is also a potent antagonist of the human **CCR3** (IC_{50} of 0.58 nM) , but a weak antagonist of the mouse **CCR3** (IC_{50} of 460 nM).



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

J-2156 TFA

Cat. No.: HY-111615A

J-2156 TFA is a high potent, selective **somatostatin receptor type 4 (SST_4 receptor)** agonist with IC_{50}s of 0.05 nM and 0.07 nM for human and rat SST_4 receptors, respectively.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Jaceosidin

Cat. No.: HY-N0831

Jaceosidin is a flavonoid isolated from Artemisia vestita, induces apoptosis in cancer cells, activates **Bax** and down-regulates Mcl-1 and c-FLIP expression.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

JAK-2/3-IN-1

Cat. No.: HY-10652

JAK-2/3-IN-1 is a potent **JAK-2** and **JAK-3** inhibitor extracted from patent US8163732B2, compound 46, has K_is of <250 nM for both isoforms.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-1

Cat. No.: HY-13827

JAK-IN-1 is a **JAK1/2/3** inhibitor with IC_{50}s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-10

Cat. No.: HY-U00277

JAK-IN-10 is a **JAK** inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-11

Cat. No.: HY-U00318

JAK-IN-11 is a potent and selective **JAK** inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-14

Cat. No.: HY-139807

JAK-IN-14 is a potent and selective **JAK1** inhibitor, with an IC_{50} of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16).



Purity: 98.72%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

JAK-IN-3

Cat. No.: HY-111750

JAK-IN-3 (compound 22) is a potent **JAK** inhibitor, with IC_{50} values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-4

Cat. No.: HY-111749

JAK-IN-4 is a prodrug of a **JAK** inhibitor, effective in murine collagen induced arthritis model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-5

Cat. No.: HY-111471

JAK-IN-5 is an inhibitor of **JAK** extracted from patent US20170121327A1, compound example 283.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK-IN-5 hydrochloride

Cat. No.: HY-111471A

JAK-IN-5 hydrochloride is an inhibitor of **JAK** extracted from patent US20170121327A1, compound example 283.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK1-IN-7

Cat. No.: HY-126294

JAK1-IN-7 is a **Janus-associated kinase 1 (JAK1)** inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK1-IN-8

Cat. No.: HY-139423

JAK1-IN-8, a potent **JAK1** inhibitor (IC_{50}<500 nM), compound 28, extracted from patent WO2016119700A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK3 covalent inhibitor-1

Cat. No.: HY-119935

JAK3 covalent inhibitor-1 is a potent and selective **janus kinase 3 (JAK3)** covalent inhibitor with an IC_{50} of 11 nM and shows 246-fold selectivity vs other JAKs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3-IN-6

Cat. No.: HY-101976

JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC_{50} of 0.15 nM.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Jasminoside B

Cat. No.: HY-N4319

Jasminoside B is a natural compound with immunosuppressive activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Jatrorrhizine chloride

Cat. No.: HY-N0740

Jatrorrhizine chloride is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Jatrorrhizine hydroxide

Cat. No.: HY-N0749A

Jatrorrhizine hydroxide is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

JC-171

Cat. No.: HY-117432

JC-171 is a selective **NLRP3** inflammasome inhibitor, with an IC_{50} of 8.45 μM for inhibiting LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JC124

Cat. No.: HY-120007

JC124 is a specific **NLRP3** inflammasome inhibitor. JC124 has anti-inflammatory and neuroprotective effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Jedi2

Cat. No.: HY-131018

Jedi2 is a **Piezo1** activator, but not a specific Piezo2 activator. Jedi2 binds to the mouse Piezo1 proteins with a K_d of 2770μM.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Jervine

(11-Ketocyclopamine)

Cat. No.: HY-N0836

Jervine (11-Ketocyclopamine) is a potent **Hedgehog (Hh)** inhibitor with an IC_{50} of 500-700 nM. Jervine is a natural teratogenic sterodial alkaloid from rhizomes of Veratrum album. Jervine has anti-inflammatory and antioxidant properties.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

JFD01307SC

Cat. No.: HY-W028047

JFD01307SC is a **glutamine synthetase** inhibitor and anti-tuberculosis agent. JFD01307SC acts as a mimic of L-Glutamate and thus target enzymes involved in glutamine biosynthesis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Jionoside A1

Cat. No.: HY-N5045

Jionoside A1 isolated from Radix Rehmanniae Praeparata displays dose dependent immune-enhancement activity and possesses moderate protective activities on H_2O_2-treated SH-SY5Y cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JNJ-39758979 dihydrochloride

Cat. No.: HY-101189B

JNJ-39758979 dihydrochloride is a selective, orally active, and high-affinity **histamine H_4 receptor** antagonist, with K_is of 12.5, 5.3, and 25 nM for human, mouse, and monkey histamine H_4 receptor, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JNJ-42041935

Cat. No.: HY-12832

JNJ-42041935 is a potent, competitive and selective inhibitor of prolyl hydroxylase **PHD**; inhibits PHD1, PHD2, and PHD3 with pK_i values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

JNJ-55308942

Cat. No.: HY-123857

JNJ-55308942 is a high-affinity, selective, brain-penetrant **P2X7** functional antagonist (hP2X7: IC_{50}=10 nM, K_i=7.1 nM; rP2X7: IC_{50}=15 nM, K_i=2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult rodent brain.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

JNJ-7777120

Cat. No.: HY-13508

JNJ-7777120 is a selective H4R antagonist with Ki of 4 ±1 nM, exhibits >1000-fold selectivity over the other histamin receptors.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JR14a

Cat. No.: HY-138161

JR14a is a potent thiophene antagonist of **human complement C3a receptor**. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JSH-23

Cat. No.: HY-13982

JSH-23 is an **NF-κB** inhibitor which inhibits NF-κB transcriptional activity with an IC_{50} of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation.



Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

JTE-607

Cat. No.: HY-110133

JTE-607, a highly selective **inflammatory cytokine synthesis** inhibitor, protects from endotoxin shock in mice.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JTE-952

Cat. No.: HY-122906

JTE-952 is a potent, oral active and selective Type Ⅱ inhibitor of **colony stimulating factor-1 receptor** (**CSF-1R or cFMS**, type Ⅲ receptor tyrosine kinase), with IC_{50} values of 13 nM and 261 nM for CSF1R and TrkA , respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

JTS-653

Cat. No.: HY-19589

JTS-653 is a highly potent and selective transient receptor potential vanilloid 1 (**TRPV1**) antagonist in vitro and in vivo. JTS-653 attenuates chronic pain refractory to non-steroidal anti-inflammatory agents.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Juglanin

Cat. No.: HY-N3442

Juglanin, a natural occurring flavonoid, is a **JNK** acticator, with inflammation and anti-tumor activities. Juglanin can induce **apoptosis** and **autophagy** on human breast cancer cells.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

K-252a

(SF2370; Antibiotic K 252a; Antibiotic SF 2370)

Cat. No.: HY-N6732

K-252a, a staurosporine analog, inhibits **protein kinase**, with IC_{50} values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca^{2+}/calmodulin-dependent kinase type Ⅱ, and phosphorylase kinase, respectively.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

K-7174

Cat. No.: HY-12743

K-7174 is a novel cell adhesion inhibitor; inhibits the expression of vascular cell adhesion molecule-1 (VCAM-1) induced by either IL-1β or TNF-α.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

K-7174 dihydrochloride

Cat. No.: HY-12743A

K-7174 dihydrochloride is a novel cell adhesion inhibitor; inhibits the expression of vascular cell adhesion molecule-1 (VCAM-1) induced by either IL-1β or TNF-α.



Purity: 98.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

KA2507 monohydrochloride

Cat. No.: HY-138799A

KA2507 hydrochloride is a potent and highly selective inhibitor of **HDAC6** (IC_{50}=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Kadsurin

Cat. No.: HY-121271

Kadsurin, a natural compound from the stems of Kadsura heteroclita (Schizandraceae), results in significant decreases of CCL_4- induced lipid-peroxidation products, such as thiobarbituric acid reactive substances (TBA-RS), conjugated dienes and fluorescent products in...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kaempferol 3-O-sophoroside

Cat. No.: HY-N2055

Kaempferol 3-O-sophoroside, a derivative of Kaempferol, is isolated from the leaves of cultivated mountain ginseng (Panax ginseng) with anti-inflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kaempferol 3-O-β-D-glucuronide

(Kaempferol-3-glucuronide; Kaempferol-3-O-glucuronide)

Cat. No.: HY-N7176

Kaempferol 3-O-β-D-glucuronide (Kaempferol-3-glucuronide), one conjugated kaempferol metabolite, has anti-inflammatory effect.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Kaempferol-3-O-glucorhamnoside

Cat. No.: HY-N0208

Kaempferol-3-O-glucorhamnoside, a flavonoid derived from plant Thesium chinense Turcz, inhibits inflammatory responses via MAPK and NF-κB pathways in vitro and in vivo.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Kaempferol-7-O-β-D-glucopyranoside

Cat. No.: HY-N0627

Kaempferol-7-O-β-D-glucopyranoside is a flavonoid isolated from Malus pumila Mill. flowers, has antioxidative, anti-inflammatory and procoagulant activitives.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KAG-308

Cat. No.: HY-128686

KAG-308 is a potent selective and orally active agonist of **EP4 receptor** (a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF-α production.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Kakkalide

Cat. No.: HY-N4244

Kakkalide is an isoflavone derived from the flowers of Pueraria lobata. Kakkalide ameliorates endothelial insulin resistance by suppressing reactive oxygen species (ROS)-associated inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Kakkanin

Cat. No.: HY-N9375

Kakkanin comes from the roots of O. henryi and can be used for the research of anti-inflammatory.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kalii Dehydrographolidi Succinas

(Potassium dehydroandrographolide succinate)

Cat. No.: HY-N0677A

Kalii Dehydrographolidi Succinas (Potassium dehydroandrographolide succinate), extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used for the treatment of viral pneumonia and viral upper respiratory tract infections because of its...



Purity: 98.70%
Clinical Data: Launched
Size: 5 mg, 10 mg, 20 mg

Kamebakaurin

Cat. No.: HY-N6046

Kamebakaurin is a natural compound isolated from Isodon japonicus. Kamebakaurin is a potent inhibitor of **NF-κB** activation by directly targeting DNA-binding activity of p50.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Kansuinine B

Cat. No.: HY-126420

Kansuinine B inhibits IL-6-induced Stat3 activation. Kansuinine B possesses anti-viral activity and could be used in the study for COVID-19.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kansuinine E

Cat. No.: HY-N9376

Kansuinine E is a plant-derived **nitric oxide** inhibitor (IC_{50}=6.3 μM). Kansuinine E belongs to jatrophane-type diterpenoids and is isolated from the roots of E. kansui.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kartogenin

(KGN)

Cat. No.: HY-16268

Kartogenin (KGN) is an inducer of differentiation of human mesenchymal stem cells into chondrocytes, with an EC_{50} of 100 nM.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Kauran-16,17-diol

(ent-Kauran-16β,17-diol)

Cat. No.: HY-N7422

Kauran-16,17-diol (ent-Kauran-16β,17-diol), a natural diterpene, posseses anti-tumor and inducing-apoptosis activity, with a IC_{50} of 17 μM on inhibiting NO production in LPS-stimulated RAW 264.7 macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Kaurenoic acid

Cat. No.: HY-N1469

Kaurenoic acid is a diterpene from Sphagneticola trilobata, inhibits Inflammatory Pain by the inhibition of cytokine production and activation of the NO–cyclic GMP–PKG–ATP-sensitive potassium channel signaling pathway.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

KB-5492 anhydrous

Cat. No.: HY-19120

KB-5492 anhydrous is a potent and selective inhibitor of **sigma receptor**, inhibits specific [^{3}H]1,3-di(2-tolyl)guanidine (DTG) binding to the **sigma receptor** with an IC_{50} of 3.15 μM. KB-5492 anhydrous is an anti-ulcer agent.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 5 mg

KCL-440

Cat. No.: HY-15050

KCL-440 is a CNS-penetrated **PARP** inhibitor, with an IC_{50} of 68 nM. KCL-440 has strong inhibition of PARP-1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KDM2B-IN-1

Cat. No.: HY-139560

KDM2B-IN-1 is a **histone demethylase (kdm2b)** inhibitor and can be used for hyperproliferative diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KDM2B-IN-2

Cat. No.: HY-139561

KDM2B-IN-1, a potent **histone demethylase (kdm2b)** inhibitor with an IC_{50} of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-1 can be used for hyperproliferative diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Keap1-Nrf2-IN-1

Cat. No.: HY-126245

Keap1-Nrf2-IN-1 is a **Keap1 (Kelch-like ECH-associated protein 1)-Nrf2 (nuclear factor erythroid 2-related factor 2) protein-protein interaction** inhibitor, and with an IC_{50} of 43 nM for Keap1 protein.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Keap1-Nrf2-IN-1 TFA

Cat. No.: HY-126245A

Keap1-Nrf2-IN-1 TFA (compound35) is a **Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) protein-protein interaction** inhibitor, and with an IC_{50} of 43 nM for Keap1 protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ketoprofen

(RP-19583)

Cat. No.: HY-B0227

Ketoprofen (RP-19583) is a non-steroidal antiinflammatory agent, acting as a potent inhibitor of **COX**, with IC_{50}s of 2 nM and 26 nM for COX-1 and COX-2 in human blood monocytes, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Ketorolac

(RS37619)

Cat. No.: HY-B0580

Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective **COX** inhibitor, with IC_{50}s of 20 nM for COX-1 and 120 nM for COX-2.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ketorolac D4

Cat. No.: HY-B0580S1

Ketorolac D4 (RS37619 D4) is the deuterium labeled Ketorolac. Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective **COX** inhibitor, with IC_{50}s of 20 nM for COX-1 and 120 nM for COX-2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ketorolac tromethamine salt

(Ketorolac Tromethamine; Ketorolac tris salt; RS37619 tromethamine salt)

Cat. No.: HY-B0138

Ketorolac tromethamine salt (RS37619 tromethamine salt) is a non-steroidal anti-inflammatory agent, acting as a nonselective **COX** inhibitor, with IC_{50}s of 20 nM for COX-1 and 120 nM for COX-2.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Ketorolac-d5

Cat. No.: HY-B0580S

Ketorolac D5 is a deuterium labeled Ketorolac. Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective **COX** inhibitor, with IC_{50}s of 20 nM for COX-1 and 120 nM for COX-2.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Ketotifen fumarate

(HC 20511 fumarate)

Cat. No.: HY-B0157A

Ketotifen (HC 20511) fumarate is a second-generation noncompetitive **H1-antihistamine** and mast cell stabilizer, which is used to prevent asthma attacks.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Ketotifen-d3 fumarate

Cat. No.: HY-B0157AS

Ketotifen-d3 (HC 20511-d3) fumarate is the deuterium labeled Ketotifen fumarate. Ketotifen (HC 20511) fumarate is a second-generation noncompetitive **H1-antihistamine** and mast cell stabilizer, which is used to prevent asthma attacks.



Purity: >98%
Clinical Data:
Size: 5 mg, 50 mg

KG-501

(Naphthol AS-E phosphate)

Cat. No.: HY-103299

KG-501 is a **CREB** inhibitor, with an IC_{50} of 6.89 μM.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Kgp-IN-1

Cat. No.: HY-128523

Kgp-IN-1 is an **arginine-specific gingipain** (**Rgp**) inhibitor extracted from patent WO2017201322A1, compound 13-R.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kgp-IN-1 hydrochloride

Cat. No.: HY-128523A

Kgp-IN-1 hydrochloride is an **arginine-specific gingipain** (**Rgp**) inhibitor extracted from patent WO2017201322A1, compound 13-R.



Purity: 95.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ki20227

Cat. No.: HY-10408

Ki20227 is an orally active and highly selective **c-Fms tyrosine kinase (CSF1R)** inhibitor with **IC_{50}**s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, **VEGFR2** (vascular endothelial growth factor receptor-2), **c-Kit** (stem cell factor receptor) and **PDGFRβ** (platelet-derived growth factor...



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

KI696

Cat. No.: HY-101140

KI696 is a high affinity probe that disrupts the **Keap1/NRF2** interaction. KI696 is a potent and selective inhibitor of the **KEAP1/NRF2** interaction.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KI696 isomer

Cat. No.: HY-101140A

KI696 isomer is the less active isomer of KI696 (HY-101140). KI696 is a high affinity probe that disrupts the Keap1/NRF2 interaction.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Kif15-IN-1

Cat. No.: HY-15948

Kif15-IN-1 is an inhibitor of the mitotic **Kinesin family member 15 (Kif15)**, and is used for the research of cellular proliferative diseases.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Kif15-IN-2

Cat. No.: HY-15949

Kif15-IN-2 is an inhibitor of the mitotic **kinesin Kif15**, and is used for the research of cellular proliferative diseases.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KIF18A-IN-1

Cat. No.: HY-145034

KIF18A-IN-1 is a **mitotic kinesin KIF18A** inhibitor extracted from patent WO2021026098A1 example 100-13. KIF18A-IN-1 exhibits anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kifunensine

(FR-900494)

Cat. No.: HY-19332

Kifunensine, a potent and selective inhibitor of **class I α-mannosidases** isolated from Actinomycete, prevents α-mannosidases I from trimming mannose residues on glycoproteins. Kifunensine inhibits ERAD.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Kinsenoside

Cat. No.: HY-N2292

Kinsenoside is a main active component isolated from plants of the genus Anoectochilus, and exhibits many biological activities and pharmacological effects.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

KIRA-7

Cat. No.: HY-124646

KIRA-7, an imidazopyrazine compound, binds the **IRE1α kinase** (**IC_{50}** of 110 nM) to allosterically inhibit its RNase activity. KIRA-7 has an anti-fibrotic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KIRA6

Cat. No.: HY-19708

KIRA6 is an advanced small-molecule **IRE1α** RNase kinase inhibitor with an IC_{50} of 0.6 μM. KIRA6 can trigger an **apoptotic** response.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Kira8
(AMG-18)

Cat. No.: HY-114368

Kira8 (AMG-18) is a mono-selective **IRE1α** inhibitor that allosterically attenuates **IRE1α RNase activity** with an IC_{50} of 5.9 nM.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Kira8 Hydrochloride
(AMG-18 Hydrochloride)

Cat. No.: HY-114368A

Kira8 Hydrochloride (AMG-18 Hydrochloride) is a mono-selective **IRE1α** inhibitor that allosterically attenuates **IRE1α RNase activity** with an IC_{50} of 5.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kirenol

Cat. No.: HY-N0559

Kirenol is isolated from Siegesbeckia orientalis with anti-inflammatory and analgesic activity.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Kisspeptin-10, rat

Cat. No.: HY-P1197

Kisspeptin-10, rat is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, rat is a ligand for the rodent kisspeptin receptor (KISS1, GPR54). Kisspeptin-10 reduces Methotrexate-induced reproductive toxicity as a potential antioxidant compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kisspeptin-10, rat TFA

Cat. No.: HY-P1197A

Kisspeptin-10, rat TFA is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, rat TFA is a ligand for the rodent kisspeptin receptor (KISS1, GPR54). Kisspeptin-10 TFA reduces Methotrexate-induced reproductive toxicity as a potential antioxidant compound.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KLD-12

Cat. No.: HY-P2263

KLD-12 is a 12-residue self-assembling peptide that can enhance chondrogenic differentiation of bone marrow stromal cells (BMSCs). KLD-12 hydrogel can fill full-thickness osteochondral defects in situ and improve cartilage repair.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KML29

Cat. No.: HY-18977

KML29 is an extremely selective, orally active and irreversible **MAGL** inhibitor, with IC_{50} values of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Kobusin

Cat. No.: HY-N5101

Kobusin is a bisepoxylignan isolated from the Pnonobio biondii Pamp. Kobusin is an activator of CFTR and CaCCgie chloride channels and a inhibitor of **ANO1/CaCC (calcium-activated chloride channel) channel**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kongensin A

Cat. No.: HY-N3417

Kongensin A is a natural product isolated from Croton kongensis. Kongensin A is an effective, covalent **HSP90** inhibitor that blocks **RIP3**-dependent necroptosishas. Kongensin A is a potent **necroptosis** inhibitor and an **apoptosis** inducer.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Korepimedoside C

(Epimedin I)

Cat. No.: HY-N8086

Korepimedoside C (Epimedin I), a flavonol glycoside, is isolated from the aerial parts of Epimedium koreanum Nakai.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Koumine

Cat. No.: HY-N1440

Koumine is an alkaloid separated from Gelsemium elegans, shows potent anti-tumor activity. Koumine up-regulates the Bax/Bcl-2 ratio and caspase-3 expression in human breast cancer cells.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

KP136

(AL136)

Cat. No.: HY-U00168

KP136 (AL136) is an orally effective antiallergic agent. The **IC_{50}** is 76.1 μg/mL for **histamine release** and 63 ug/mL for **degranulation**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KP496

Cat. No.: HY-U00253

KP496 is a selective, dual antagonist for **Leukotriene D4 receptor** and **Thromboxane A2 receptor**.



Purity: 95.81%
Clinical Data: No Development Reported
Size: 5 mg

KPLH1130

Cat. No.: HY-128578

KPLH1130 is a specific pyruvate dehydrogenase kinase (**PDK**) inhibitor, blocks macrophage polarization and attenuates proinflammatory responses. KPLH1130 improves glucose tolerance in HFD-fed mice.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KRAS G13D peptide, 25 mer

Cat. No.: HY-P3129

KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine.

MTEYKLVVVGAGDVGKSALTIQLIQ

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRH-3955 hydrochloride

Cat. No.: HY-122058A

KRH-3955 hydrochloride is an orally bioavailable **CXCR4** antagonist. KRH-3955 hydrochloride inhibits SDF-1α binding to **CXCR4** with an **IC_{50}** of 0.61 nM. KRH-3955 hydrochloride is also a highly potent and selective inhibitor of **X4 HIV-1**, with an **EC_{50}** of 0.3 to 1.0 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRM-III

Cat. No.: HY-136427

KRM-III is a potent and orally active **T-cell antigen receptor (TCR)** inhibitor.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KRN2

Cat. No.: HY-112125

KRN2 is a selective inhibitor of **nuclear factor of activated T cells (NFAT5)**, with an **IC_{50}** of 100 nM. KRN2 has potential to treat NFAT5-mediated Chronic Arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRN2 bromide

Cat. No.: HY-112125A

KRN2 (bromide) is a selective inhibitor of **nuclear factor of activated T cells (NFAT5)**, with an **IC_{50}** of 0.1 μM.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KRN5

Cat. No.: HY-112126

KRN5, a derivative of KRN2, is an oral active **Nuclear factor of activated T cells 5 (NFAT5)** suppressor, with an IC_{50} of 750 nM. KRN5 has potential to treat NFAT5-mediated Chronic Arthritis.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KSPWFTTL

Cat. No.: HY-P3333

KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KSPWFTTL TFA

Cat. No.: HY-P3333A

KSPWFTTL TFA is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL TFA can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

KT5823

Cat. No.: HY-N6791

KT5823, a selective the cGMP-dependent protein kinase (**PKG**) inhibitor with an K_i value of 0.23 μM, it also inhibits **PKA** and **PKC** with K_i values of 10 μM and 4 μM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 100 μg

Kukoamine B

Cat. No.: HY-N2393

Kukoamine B is a component of Lycii Cortex, with anti-oxidant, anti-acute inflammatory and anti-diabetic properties.



Purity: 98.98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 20 mg

Kulactone

Cat. No.: HY-N9343

Kulactone, a natural bioflavonoid and an inhibitor against **jRdRp**, possesses antifungal, antibacterial and antiplasmodial activities. Kulactone exhibit no crossing through Blood Brain Barrier (BBB).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kurarinone

Cat. No.: HY-N2279

Kurarinone, a flavanoid derived from shrub Sophora flavescens, inhibits the process of experimental autoimmune encephalomyelitis via blocking Th1 and Th17 cell differentiation.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Kushenol B

Cat. No.: HY-N8092

Kushenol B is an isoprenoid flavonoid isolated from S. flavescens, has antimicrobial, anti-inflammatory and antioxidant activities. Kushenol B has inhibitory activity against **cAMP phosphodiesterase (PDE)**, with an IC_{50} of 31 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kushenol C

Cat. No.: HY-108966

Kushenol C, isolated from the roots of Sophora flavescens, shows anti-Inflammatory and anti-oxidative stress activities. Kushenol C inhibits **BACE1 (β-site APP cleaving enzyme 1)** with an IC_{50} of 5.45 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kushenol I

Cat. No.: HY-N2286

Kushenol I is a natural compound isolated from the roots of Sophora flavescens.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kuwanon A

Cat. No.: HY-N2300

Kuwanon A is a flavone derivative isolated from the root barks of the mulberry tree (Morus alba L.); inhibits nitric oxide production with an IC_{50} of 10.5 μM.



Purity: 96.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg

Kv3 modulator 1

Cat. No.: HY-111996

Kv3 modulator 1 is a **Kv3 voltage-gated potassium channel** modulator extracted from patent WO2018020263A1, Compound X. Kv3 modulator 1 has the potential for inflammatory pain treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kv3 modulator 2

Cat. No.: HY-128829

Kv3 modulator 2 (formula (I)) is a potent **Kv3 channels** modulator extracted from patent WO2018109484A1, compound formula (I) , has analgesic activity and is used in the prophylaxis or treatment of related disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kv3 modulator 3

Cat. No.: HY-128830

Kv3 modulator 3 (Compound 4) is a selective modulator of **Kv3.1** and/or **Kv3.2** and/or **Kv3.3 channels** extracted from patent WO2017098254A1, compound 4, has analgesic activity for use in the prophylaxis o or treatment of pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kv3 modulator 4

Cat. No.: HY-128831

Kv3 modulator 4 is a **Kv3.1** (pEC_{50}=5.45) and **Kv3.2** modulator extracted from patent WO2018020263A1, Cyclobutyl structure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KY-556

(N556)

Cat. No.: HY-U00148

KY-556 is a promising and orally-active pro-drug of disodium cromoglycate (DSCG) against allergic diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KYL peptide

Cat. No.: HY-P2264

KYL peptide, an antagonistic peptide, selectively targets **EphA4 receptor**. KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Kynurenic acid

(Quinurenic acid)

Cat. No.: HY-100806

Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting <b >NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of **GPR35/CXCR8**.



Purity: 99.03%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg, 500 mg

Kynurenic acid sodium

Cat. No.: HY-107512

Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting **NMDA, glutamate, α7 nicotinic acetylcholine receptor**. Kynurenic acid sodium is also an agonist of **GPR35/CXCR8**.



Purity: 99.76%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg

KZR-504

Cat. No.: HY-101786

KZR-504 is a highly selective inhibitor of immunoproteasome low molecular mass polypeptide 2 **(LMP2)**, with IC_{50}s of 51 nM, 4.274 μM for LMP2 and LMP7, respectively. KZR-504 is of interest for the treatment of autoimmune disease.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L 012 sodium salt

Cat. No.: HY-108537

L 012 sodium salt a luminol-based chemiluminescent (CL) probe, is widely used in vitro and in vivo to detect NADPH oxidase (Nox)-derived superoxide ($O2^{\bullet-}$) and identify Nox inhibitors.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

L 888607

Cat. No.: HY-111271

L 888607 is a potent, and selective **CRTH2** (also known as DP_2) agonist with a K_i of 0.8 nM.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L 888607 Racemate

Cat. No.: HY-111271A

L 888607 Racemate is a selective prostaglandin D_2 receptor subtype 1 **(DP1)** antagonist, with K_i**s** of 132 nM and 17 nM for DP1 and thromboxane A2 receptor (TP), respectively.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-(+)-Abrine

(L-Abrine; L-N-Methyltryptophan; N-α-Methyl-L-tryptophan) Cat. No.: HY-N1436

L-(+)-Abrine, a lethal albumin found in Abrus precatorius seeds, is an acute toxic alkaloid and chemical marker for abrin.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

L-161982

Cat. No.: HY-108559

L-161982 is a selective **EP4** receptor antagonist. L-161982 completely blocks PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. L-161982 alleviates collagen-induced arthritis in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-689502

Cat. No.: HY-U00261

L-689502 is a potent inhibitor of **HIV-I protease** with an IC_{50} of 1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-902688

Cat. No.: HY-119163

L-902688 is a potent, selective and orally active **EP4 receptor** agonist with a K_i of 0.38 nM and an EC_{50} of 0.6 nM. L-902688 shows >4,000-fold selective for **EP4** over other EP and prostanoid receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg

L-Alanyl-L-glutamine

Cat. No.: HY-W014102

L-Alanyl-L-glutamine, a glutamine dipeptide, is benefit for the antioxidant system, attenuating inflammation, and may modulate the heat shock protein (HSP) response in catabolic situations.



Purity: ≥97.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 100 mg

L-Cysteine methyl ester hydrochloride

Cat. No.: HY-B1038

L-Cysteine methyl ester hydrochloride is an antitussive, and an expectorant agent, used to relieve breathing difficulties caused by mucus.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

L-Glutathione reduced

(GSH; γ-L-Glutamyl-L-cysteinyl-glycine) Cat. No.: HY-D0187

L-Glutathione reduced (GSH; γ-L-Glutamyl-L-cysteinyl-glycine) is an endogenous antioxidant and is capable of scavenging oxygen-derived free radicals.



Purity: 99.83%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g

L-Histidine

Cat. No.: HY-N0832

L-Histidine is an essential amino acid for infants. L-Histidine is an inhibitor of **mitochondrial glutamine transport**.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

L-Homocysteine

Cat. No.: HY-W010347

L-Homocysteine, a homocysteine metabolite, is a homocysteine that has L configuration. L-Homocysteine induces upregulation of cathepsin V that mediates vascular endothelial inflammation in hyperhomocysteinaemia.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg

L-Homocystine

Cat. No.: HY-W011690

L-Homocystine is the oxidized member of the L-homocysteine. Homocysteine is a pro-thrombotic factor, vasodilation impairing agent, pro-inflammatory factor and endoplasmatic reticulum-stress inducer used to study cardiovascular disease mechanisms.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

L-Kynurenine

Cat. No.: HY-104026

L-Kynurenine is a metabolite of the amino acid L-tryptophan. L-Kynurenine is an **aryl hydrocarbon receptor** agonist.



Purity: 99.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 50 mg

L-Leucyl-L-Leucine methyl ester hydrobromide (LLOMe hydrobromide; Leu-Leu methyl ester hydrobromide; ...)

Cat. No.: HY-129905A

L-Leucyl-L-Leucine methyl ester (LLOMe) hydrobromide, a dipeptide condensation product of L-leucine methyl ester generated by human monocytes or polymorphonuclear leukocytes, selectively eliminates lymphocytes with cytotoxic potential.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

L-Leucyl-L-Leucine methyl ester hydrochloride (LLOMe hydrochloride; Leu-Leu methyl ester hydrochloride; ...)

Cat. No.: HY-129905

L-Leucyl-L-Leucine methyl ester (LLOMe) hydrochloride, a dipeptide condensation product of L-leucine methyl ester generated by human monocytes or polymorphonuclear leukocytes, selectively eliminates lymphocytes with cytotoxic potential.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Lysine

Cat. No.: HY-N0469

L-lysine is an essential amino acid with important roles in connective tissues and carnitine synthesis, energy production, growth in children, and maintenance of immune functions.



Purity: ≥97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

L-Lysine hydrochloride

Cat. No.: HY-N0470

L-lysine hydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

L-m-Tyrosine

Cat. No.: HY-W016443

L-m-Tyrosine is an unnatural amino acid, that has potential in the research of Parkinsons disease, Alzheimers disease, and arthritis.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

L-NIL

Cat. No.: HY-12116

L-NIL is an **inducible NO synthase** inhibitor, with an IC_{50} of 3.3 μM for miNOS.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

L-NIL dihydrochloride

Cat. No.: HY-12118

L-NIL dihydrochloride is an **inducible NO synthase** inhibitor, with an IC_{50} of 3.3 μM for miNOS.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Valyl-L-phenylalanine

(Valylphenylalanine; H-VAL-PHE-OH)

Cat. No.: HY-107378

L-Valyl-L-phenylalanine (Valylphenylalanine; H-VAL-PHE-OH) has been reported as biocompatible polymer.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

L002

Cat. No.: HY-100671

L002 is a potent, cell permeable, reversible and specific **acetyltransferase p300 (KAT3B)** inhibitor with an IC_{50} of 1.98 μM.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L48H37

Cat. No.: HY-126154

L48H37 is an analog of Curcumin (HY-N0005) with improved chemical stability. L48H37 is a potent and specific **myeloid differentiation protein 2 (MD2)** inhibitor and inhibits the interaction and signaling transduction of LPS-TLR4/MD2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lactoferricin B (4-14), bovine TFA

Cat. No.: HY-P2323

Lactoferricin B (4-14), bovine (TFA), a peptide corresponding to residues 4-14 of bovine lactoferrin, has antimicrobial activity against a wide range of microorganisms.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ladarixin

(DF 2156A free base)

Cat. No.: HY-19519

Ladarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual **CXCR1** and **CXCR2** antagonist. Ladarixin can be used for the research of COPD and asthma.
.



Purity: 98.05%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Ladarixin sodium

(DF 2156A)

Cat. No.: HY-19519A

Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual **CXCR1** and **CXCR2** antagonist. Ladarixin sodium can be used for the research of COPD and asthma.
.



Purity: 99.15%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lademirsen

(SAR339375; RG-012)

Cat. No.: HY-132599

Lademirsen (SAR339375; RG-012) is a highly specific antisense oligonucleotide (ASO) targeting **miR-21**. Lademirsen has the potential for Alport nephropathy research.

Lademirsen

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Laflunimus

(HR325)

Cat. No.: HY-101813

Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of **dihydroorotate dehydrogenase (DHODH)**.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lanoconazole

Cat. No.: HY-14282

Lanoconazole is a potent and orally active imidazole **antifungal** agent, shows a broad spectrum of activity against fungi in vitro and in vivo.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Lanolin

Cat. No.: HY-N7074

Lanolin is a yellow fat obtained from sheep's wool. Lanolin is used topically for sore, cracked nipples during breastfeeding.

Lanolin

Purity: >98%
Clinical Data: Phase 4
Size: 500 mg

Lanraplenib

(GS-9876)

Cat. No.: HY-109091

Lanraplenib (GS-9876) is a highly selective and orally active **SYK** inhibitor (IC_{50}=9.5 nM) in development for the treatment of inflammatory diseases.



Purity: 98.22%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lanraplenib monosuccinate

(GS-9876 monosuccinate)

Cat. No.: HY-109091A

Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active **SYK** inhibitor (IC_{50}=9.5 nM) in development for the treatment of inflammatory diseases.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Lanraplenib succinate

(GS-9876 succinate)

Cat. No.: HY-109091B

Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active **SYK** inhibitor (IC_{50}=9.5 nM) in development for the treatment of inflammatory diseases.



Purity: 98.21%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lansoprazole

(AG-1749)

Cat. No.: HY-13662

Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant **neutral sphingomyelinase (N-SMase)** inhibitor (exosome inhibitor).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Lansoprazole sodium

(AG-1749 sodium)

Cat. No.: HY-13662A

Lansoprazole sodium (AG 1749 sodium) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole sodium (AG 1749 sodium) is a potent brain penetrant **neutral sphingomyelinase (N-SMase)** inhibitor (exosome inhibitor).



Purity: >98%
Clinical Data: Launched
Size: 500 mg

Lansoprazole Sulfide D4

Cat. No.: HY-W013186S

Lansoprazole Sulfide D4 is a deuterium labeled Lansoprazole Sulfide. Lansoprazole Sulfide is an active metabolite of the **proton pump** inhibitor Lansoprazole.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lansoprazole-d4

(AG-1749-d4)

Cat. No.: HY-13662S

Lansoprazole D4 (AG-1749 D4) is a deuterium labeled Lansoprazole. Lansoprazole is a **proton pump** inhibitor which prevents the stomach from producing acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapachol

Cat. No.: HY-N6961

Lapachol is a naphthoquinone that was first isolated from Tabebuia avellanedae (Bignoniaceae).



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

Laquinimod

(ABR-215062)

Cat. No.: HY-13010

Laquinimod is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system.



Purity: 99.91%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg

Larazotide acetate

Cat. No.: HY-106268A

Larazotide acetate is a synthetic peptide. Larazotide acetate acts as a tight **junction** regulator and reverses leaky junctions to their normally closed state.



Purity: 99.68%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Laropiprant

(MK-0524)

Cat. No.: HY-50175

Laropiprant is a potent, selective **DP receptor** antagonist with K_i values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.



Purity: 99.73%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LAS101057

Cat. No.: HY-14390

LAS101057 is a potent, selective, and orally efficacious **A2B receptor** antagonist.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

LAS191954

Cat. No.: HY-101114

LAS191954 is a potent, selective and orally active **PI3Kδ** inhibitor for inflammatory diseases treatment, with an IC_{50} of 2.6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LASSBio-1632

Cat. No.: HY-131340

LASSBio-1632 is a new anti-asthmatic lead candidate associated with selective inhibition of **PDE4A** and **PDE4D** isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-α production in the lung tissue.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Latanoprost acid

Cat. No.: HY-113756A

Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective **prostanoid receptor (FP)** agonist that specifically activates the FP-PG receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Latanoprost lactone diol

Cat. No.: HY-125946

Latanoprost lactone diol is an intermediate in the synthesis of Latanoprost. Latanoprost is a prostaglandin F2α analogue and an agonist for the FP prostanoid receptor, and lowers intraocular-pressure (IOP).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Laurolitsine

((+)-Norboldine)

Cat. No.: HY-N2352

Laurolitsine ((+)-Norboldine) is an alkaloid isolated from the leaves of Peumus boldus Molina.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Laurolitsine hydrochloride

((+)-Norboldine hydrochloride)

Cat. No.: HY-N2352A

Laurolitsine hydrochloride is an alkaloid isolated from Phoebe formosana, and shows weak anti-inflammatory activity.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Lck Inhibitor

Cat. No.: HY-12072

Lck Inhibitor is a potent, orally active **Lck (lymphocyte specific kinase)** inhibitor with IC_{50}s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lck inhibitor 2

Cat. No.: HY-10644

Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lck-IN-1

Cat. No.: HY-138202

Lck-IN-1 is a potent lymphocyte protein tyrosine kinase **(Lck)** inhibitor extracted from patent WO2007013673A1, example 48.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LCMV GP (61-80)

Cat. No.: HY-P2560

LCMV GP (61-80) is a peptide fragment derived from lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP), and corresponds to amino acids 61-80. LCMV GP (61-80) is a specific epitope which can induce $CD4^+$ T-cell response.

GLKGPDIYKGVYQFKSVEFD

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LCMV gp33-41

Cat. No.: HY-P1569

LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes.

KAVYNFATM

Purity: 98.09%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

LCMV gp33-41 TFA

Cat. No.: HY-P1569A

LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes.

KAVYNFATM (TFA salt)

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

LDC1267

Cat. No.: HY-12494

LDC1267 is a highly selective **TAM (Tyro3, Axl and Mer)** kinase inhibitor with **IC_{50}**s of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LDC7559

Cat. No.: HY-111674

LDC7559 is a **gasdermin D (GSDMD)** inhibitor via blocking neutrophil extracellular trap (NET) in the late stages .



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Leachianone A

Cat. No.: HY-N2281

Leachianone A, isolated from Radix Sophorae, has anti-malarial, anti-inflammatory, and cytotoxic potent. Leachianone A induces **apoptosis involved both extrinsic and intrinsic pathways.**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

LEESGGGLVQPGGSMK

Cat. No.: HY-P3149

LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.

LEESGGGLVQPGGSMK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LEESGGGLVQPGGSMK acetate

Cat. No.: HY-P3149B

LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.

LEESGGGLVQPGGSMK (acetate)

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

LEESGGGLVQPGGSMK TFA

Cat. No.: HY-P3149A

LEESGGGLVQPGGSMK TFA, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK TFA can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.

LEESGGGLVQPGGSMK (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lenalidomide

(CC-5013)

Cat. No.: HY-A0003

Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Lenalidomide hydrochloride

(CC-5013 hydrochloride)

Cat. No.: HY-A0003A

Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Leniolisib

(CDZ173)

Cat. No.: HY-17635

Leniolisib (CDZ173) is a potent and selective **PI3Kδ** inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.



Purity: 99.25%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

LEO 39652

Cat. No.: HY-131707

LEO 39652 is a dual-soft **PDE4** inhibitor with IC_{50}s of 1.2 nM, 1.2 nM, 3.0 nM and 3.8 nM for **PDE4A**, **PDE4B**, **PDE4C** and **PDE4D**, respectively. LEO 39652 also inhibits **TNF-α** with an IC_{50} value of 6.0 nM. LEO 39652 is used for topical research of Atopic dermatitis (AD) .



Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Leonurine

(SCM-198)

Cat. No.: HY-N0741

Leonurine is an alkaloid isolated from Herba leonuri, with anti-oxidative and anti-inflammatory.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Leonurine hydrochloride

(SCM-198 hydrochloride)

Cat. No.: HY-N0741A

Leonurine hydrochloride is an alkaloid isolated from Herba leonuri, with anti-oxidative and anti-inflammatory.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Leucinostatin (mixture of A&B)

Cat. No.: HY-131152

Leucinostatin (mixture of A&B), the major components of an atypical nonapeptide complex produced by Paecilomyces lilacinus, are antibiotics.

Leucinostatin (mixture of A&B)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Leucocyanidin

Cat. No.: HY-119580

Leucocyanidin is an active anti-ulcerogenic ingredient was extracted from unripe plantain banana. Leucocyanidin demonstrates a significant protective effect against Aspirin-induced erosions in rat models.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Leukadherin-1

Cat. No.: HY-15701

Leukadherin-1, a specific agonist of the leukocyte surface integrin **CD11b/CD18**, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC_{50} of 4 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Leukotriene B4

(LTB4; 5(S),12(R)-DiHETE)

Cat. No.: HY-107608

Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 25 μg (297.2 μM * 250 μL in Ethanol)

Leukotriene C4

Cat. No.: HY-113446

Leukotriene C4 is the parent cysteinyl leukotriene produced by the LTC4 synthase catalyzed conjugation of glutathione to LTA4. Leukotriene C4 is produced by neutrophils, macrophages, mast cells, and by transcellular metabolism in platelets.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 25 μg (399.5 μM * 100 μL in Ethanol)

Leukotriene C4 D5

Cat. No.: HY-113446S

Leukotriene C4 D5 is the deuterium labeled Leukotriene C4. Leukotriene C4 is the parent cysteinyl leukotriene produced by the LTC4 synthase catalyzed conjugation of glutathione to LTA4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Leukotriene D4

Cat. No.: HY-113456

Leukotriene D4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A) produced by the metabolism of LTC4 by γ-glutamyl transpeptidase. Leukotriene D4 is the first cysteinyl-leukotriene metabolite of LTC4.



Purity: ≥98.0%
Clinical Data: Phase 4
Size: 10 μg (201.34 μM * 100 μL in Ethanol)

Leukotriene E4

(LTE4)

Cat. No.: HY-113465

Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Leukotriene F4

Cat. No.: HY-130440

Leukotriene F4 (LTF4), is a lipid that belongs to the Cysteinyl Leukotriene (CysTL) family. Leukotriene F4 induces bronchoconstriction with an ED_{50} of 16 μg/kg. The precursor of LTF4 is Leukotriene E4 (LTE4), which isformed from the action of a glutamyl transferase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Leupeptin hemisulfate

Cat. No.: HY-18234A

Leupeptin hemisulfate is a membrane-permeable **thiol protease** inhibitor that inhibits **Cathepsin B**, **Cathepsin H** and **Cathepsin L**, and also impairs amphisome-lysosome fusion. Leupeptin hemisulfate also exhibits anti-inflammatory effect.



Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Levalbuterol

((R)-Albuterol; (R)-Salbutamol; Levosalbutamol)

Cat. No.: HY-B1675

Levalbuterol ((R)-Albuterol; (R)-Salbutamol) is a short-acting **β2-adrenergic receptor** agonist and the active (R)-enantiomer of Salbutamol. Levalbuterol is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD.</br>.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Levocabastine hydrochloride

(R 50547 hydrochloride)

Cat. No.: HY-14277A

Levocabastine (R 50547) hydrochloride is a long acting, highly potent and selective **histamine H1-receptor** antagonist with anti-allergic activity.



Purity: ≥98.0%
Clinical Data: Launched
Size: 5 mg

Levocetirizine

((R)-Cetirizine)

Cat. No.: HY-B0814

Levocetirizine ((R)-Cetirizine) is a third-generation **peripheral H1-receptor** antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Levocetirizine dihydrochloride

((R)-Cetirizine dihydrochloride) Cat. No.: HY-W010841

Levocetirizine dihydrochloride ((R)-Cetirizine dihydrochloride) is a third-generation **peripheral H1-receptor** antagonist. Levocetirizine dihydrochloride is an antihistaminic agent which is the R-enantiomer of Cetirizine.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Levodropropizine

((S)-(-)-Dropropizine; DF-526) Cat. No.: HY-B1895

Levodropropizine (DF-526) is a histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive drug.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Levomenol

((-)-α-Bisabolol) Cat. No.: HY-N6967

Levomenol is a monocyclic sesquiterpene alcohol found in various plants and mainly in Matricaria chamomilla, which exerts antioxidant, anti-inflammatory, and anti-apoptotic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mL

Lexacalcitol

(KH1060) Cat. No.: HY-32340

Lexacalcitol (KH1060), a vitamin D analog, is a potent regulator of cell growth and immune responses. Lexacalcitol can be used for the research of graft rejection, psoriasis, cancer and auto-immune diseases.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Liarozole

(R75251) Cat. No.: HY-106019

Liarozole (R75251; R85246) is an imidazole derivative and orally active **retinoic acid (RA) metabolism-blocking agent (RAMBA)**.



Purity: 98.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Liarozole dihydrochloride

(R75251 dihydrochloride) Cat. No.: HY-106019C

Liarozole (R75251) dihydrochloride is an imidazole derivative and orally active **retinoic acid (RA) metabolism-blocking agent (RAMBA)**.



Purity: 98.66%
Clinical Data: Phase 3
Size: 1 mg

Licarin A

((+)-Licarin A) Cat. No.: HY-N2252

Licarin A ((+)-Licarin A), a neolignan, significantly and dose-dependently reduces TNF-α production (IC_{50}=12.6 μM) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects. Licarin A reduces **TNF-α** and **PGD2** production, and **COX-2** expression.



Purity: 98.16%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Licochalcone D

Cat. No.: HY-N4187

Licochalcone D, a flavonoid compound mainly existing in the root of Glycyrrhiza inflate, is a potent inhibitor of **NF-kappaB (NF-κB) p65**. Licochalcone D possesses antioxidant, anti-inflammatory, anti-cancer properties.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Licochalcone E

Cat. No.: HY-N4182

Licochalcone E, a flavonoid compound isolated from Glycyrrhiza inflate, inhibits NF-κB and AP-1 transcriptional activity through the inhibition of **AKT** and **MAPK** activation.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Licofelone

(ML-3000) Cat. No.: HY-B1452

Licofelone (ML-3000) is a dual **COX/5-lipoxygenase (5-LOX)** inhibitor (IC_{50}=0.21/0.18 μM, respectively) for the treatment of osteoarthritis. Licofelone exerts anti-inflammatory and anti-proliferative effects.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Licofelone-d4

Cat. No.: HY-B1452S

Licofelone-d4 (ML-3000-d4) is the deuterium labeled Licofelone. Licofelone (ML-3000) is a dual **COX/5-lipoxygenase (5-LOX)** inhibitor (IC_{50}=0.21/0.18 μM, respectively) for the treatment of osteoarthritis.



Purity: >98%
Clinical Data:
Size: 5 mg

Licogliflozin

(LIK066)

Cat. No.: HY-109092

Licogliflozin is a sodium glucose cotransporter (**SGLT1** and **SGLT2**) inhibitor.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Licoricidin

Cat. No.: HY-N3387

Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Licraside

Cat. No.: HY-N6987

Licraside is isolated from Glycyrrhiza uralesis Fish.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Liensinine perchlorate

Cat. No.: HY-N5014

Liensinine Perchlorate is a constituent of Nelumbo nucifera Gaertn, with ani-hypertension and anti-cancer activities. Liensinine Perchlorate induces colorectal cancer (CRC) cell **apoptosis**.



Purity: 99.22%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 20 mg

Lifitegrast

(SAR 1118; SHP-606)

Cat. No.: HY-19344

Lifitegrast (SAR 1118) is an integrin lymphocyte function-associated antigen-1 (**LFA-1; αLβ2**) antagonist; inhibits Jurkat T cell attachment to **ICAM-1** with an IC_{50} of 2.98 nM.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ligupurpuroside B

Cat. No.: HY-N2088

Ligupurpuroside B is a glycoside isolated from Ligustrum robustum, with antioxidant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ligupurpuroside C

Cat. No.: HY-N2089

Ligupurpuroside C is a natural phenylethanoid glycoside isolated from Kudingcha.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ligustilide

Cat. No.: HY-N0401

Ligustilide is is a bioactive phthalide derivative isolated from Angelica sinensis and Chuanxiong. Ligustilide exhibits neuroprotective, anti-cancer, anti-inflammatory, and vasodilator effects.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Ligustrazine

(Chuanxiongzine; Tetramethylpyrazine)

Cat. No.: HY-N0264

Ligustrazine (Chuanxiongzine), an alkylpyrazine isolated from Ligusticum wallichii (Chuan Xiong), is present in french fries, bread, cooked meats, tea, cocoa, coffee, beer, spirits, peanuts, filberts, dairy products and soy products as fragrance and flavouring...



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Limaprost

(17α,20-dimethyl-δ2-PGE1; ONO1206; OP1206)

Cat. No.: HY-B0683

Limaprost (OP1206) is a **PGE1** analogue and a potent and orally active vasodilator. Limaprost increases blood flow and inhibits platelet aggregation. Limaprost pain relief, has antianginal effects, and can be used for ischaemic symptoms research.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Limaprost-d3

Cat. No.: HY-B0683S

Limaprost-d3 (17α,20-dimethyl-δ2-PGE1-d3) is the deuterium labeled Limaprost. Limaprost (OP1206) is a **PGE1** analogue and a potent and orally active vasodilator. Limaprost increases blood flow and inhibits platelet aggregation.



Purity: >98%
Clinical Data:
Size: 500 μg, 5 mg

Linalyl acetate

Cat. No.: HY-N6948

Linalyl acetate is the principal components of many plant essential oils with potentially anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Linderane

Cat. No.: HY-N0688

Linderane, isolated from the root of Lindera strychnifolia, is an irreversible inhibitor **cytochrome P450 2C9 (CYP2C9)**. Linderane has the potential to relieve pain and cramp.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Linderene acetate

Cat. No.: HY-N6902

Linderene acetate, isolated from the root of Lindera strychnifolia, is a **prolyl endopeptidase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Linerixibat

(GSK2330672)

Cat. No.: HY-16643

Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active **apical sodium-dependent bile acid transporter (ASBT)** inhibitor with an IC_{50} of 42 nM **human ASBT**. Linerixibat can be used as lipid-lowering agent.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Linperlisib

(YY-20394)

Cat. No.: HY-102031

Linperlisib (YY-20394) is a potent, orally bioavailable and selective inhibitor of **PI3Kδ** extracted from patent WO 2015055071 A1, compound 10; has an IC_{50} of 6.4 nM.



Purity: 99.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lipoic acid

((R)-(+)-α-Lipoic acid; R-(+)-Thioctic acid)

Cat. No.: HY-18733

Lipoic acid ((R)-(+)-α-Lipoic acid) is an antioxidant, which is an essential cofactor of **mitochondrial** enzyme complexes. (R)-(+)-α-Lipoic acid is more effective than racemic Lipoic acid.



Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Lipopolysaccharides

(LPS)

Cat. No.: HY-D1056

Lipopolysaccharides (LPS) is an endotoxin derived from the outer leaflet of the outer membrane of Gram-negative bacteria. Lipopolysaccharides consists of an antigen O-specific chain, a core oligosaccharide and lipid A.

Purity: >98%
Clinical Data: Phase 4
Size: 5 mg, 10 mg

Lipopolysaccharides, Escherichiacoli (11C)

Cat. No.: HY-N9109

Lipopolysaccharides, Escherichiacoli (11C) consists of a hydrophobic lipid A, a core oligosaccharide (core OS), and a distal polysaccharide (O-PS). Lipopolysaccharides, Escherichiacoli (11C) can be used to induce inflammation.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lipoteichoic acid

Cat. No.: HY-N9481

Lipoteichoic acid, a cell wall component of Staphylococcus aureus, activates the complement system via **C3** induction and **CD55** inhibition.

Lipoteichoic acid

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Lipoxin A4

(LXA4)

Cat. No.: HY-113509

Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and **anti-inflammatory** properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 μg

Liquiritigenin

(4',7-Dihydroxyflavanone)

Cat. No.: HY-N0377

Liquiritigenin, a flavanone isolated from Glycyrrhiza uralensis, is a highly selective estrogen receptor β (**ERβ**) agonist with an $\mathbf{EC_{50}}$ of 36.5 nM for activation of the ERE tk-Luc.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Liquiritin

Cat. No.: HY-N0376

Liquiritin, a flavonoid isolated from Glycyrrhiza, is a potent and competitive **AKR1C1** inhibitor with $\mathbf{IC_{50}}$s of 0.62 μM, 0.61 μM, and 3.72μM for AKR1C1, AKR1C2 and AKR1C3, respectively. Liquiritin efficiently inhibits progesterone metabolism mediated by AKR1C1 in vivo.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Liquiritin apioside

Cat. No.: HY-N1471

Liquiritin apioside, a main flavonoid component of licorice, possesses antitussive effects.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Lirimilast

(BAY 19-8004)

Cat. No.: HY-19672

Lirimilast (BAY 19-8004) is a potent, selective and orally active **phosphodiesterase-4 (PDE4)** inhibitor with an $\mathbf{IC_{50}}$ value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD). Lirimilast has potently anti-inflammatory properties.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Liriope muscari baily saponins C

Cat. No.: HY-N0345

Liriope muscari baily saponins C is one of major active compounds of L. muscari (Decne.) Baily. Liriope muscari baily saponins C possesses strong anti-inflammatory, immunopharmacological and cardioprotective activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Lithospermic acid

((+)-Lithospermic acid)

Cat. No.: HY-N0823

Lithospermic acid ((+)-Lithospermic acid) is a plant-derived polycyclic phenolic carboxylic acid isolated from Salvia miltiorrhiza, and has the anti-oxidative and hepatoprotective activity on carbon tetrachloride (CCl_4)-induced acute liver damage in vitro and in vivo.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

LKKTETQ

Cat. No.: HY-P2463

LKKTETQ, a peptide segment, is the active site within the protein thymosin β_4 responsible for actin binding, cell migration and wound healing.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LKY-047

Cat. No.: HY-117026

LKY-047, a Decursin derivative, is a potent and selective reversible competitive **cytochrome P45022J2 (CYP2J2)** inhibitor with an $\mathbf{IC_{50}}$ of 1.7 μM. LKY-047 is inactive against other human P450s, such as CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LL-37, human acetate

Cat. No.: HY-P1222B

LL-37, human acetate is a 37-residue, amphipathic, cathelicidin-derived antimicrobial peptide, which exhibits a broad spectrum of antimicrobial activity. LL-37, human acetate could help protect the cornea from infection and modulates wound healing.

Purity: 99.50%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

LLO (91-99)

(Listeriolysin O (91-99))

Cat. No.: HY-P2455

LLO (91-99) (Listeriolysin O (91-99)), an exotoxin, is a class I MHC-restricted T-cell epitopes of listeriolysin (LLO). LLO (91-99) is an essential antigen for induction of T-cell mediated immunity in vivo.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LM-1484

Cat. No.: HY-101686

LM-1484 is an antagonist of CysLT1 receptor and displays a higher affinity for ^{3}H-LTC4 sites.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LMT-28

Cat. No.: HY-102084

LMT-28 is an orally active and the first synthetic **IL-6** inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LOC14

Cat. No.: HY-100432

LOC14 is a potent Protein disulfide isomerase (**PDI**) inhibitor with EC_{50} and K_d values of 500 nM and 62 nM, respectively. LOC14 exhibits high stability in mouse liver microsomes and blood plasma, low intrinsic microsome clearance, and low plasma-protein binding.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lodoxamide

(U-42585E free acid)

Cat. No.: HY-14270

Lodoxamide (U-42585E free acid) is an antiallergic compound acting as a mast-cell stabilizer for the treatment of asthma and allergic conjunctivitis.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Lodoxamide tromethamine

(U-42585E)

Cat. No.: HY-16289

Lodoxamide tromethamine (U-42585E) is a medication for the treatment of prophylaxis of mast cell-mediated allergic disease.



Purity: 99.37%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Loganic acid

Cat. No.: HY-N0513

Loganic acid is an iridoid isolated from cornelian cherry fruits. Loganic acid can modulate diet-induced atherosclerosis and redox status. Loganic acid has strong free radical scavenging activity and remarkable cyto-protective effect against heavy metal mediated toxicity.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Loganic acid 6′-O-β-D-glucoside

Cat. No.: HY-N9000

Loganic acid 6′-O-β-D-glucoside, a iridoidal glucoside, is isolated from the whole plant of Gentiana rhodantha (Gentianaceae). Loganic acid 6′-O-β-D-glucoside inhibits LPS-induced NO and TNF-α production in macrophage RAW264.7 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lonapalene

(RS4317)

Cat. No.: HY-U00156

Lonapalene (RS4317) is a topically effective **5-lipoxygenase** (**5-LO**) inhibitor.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Lonodelestat

(POL6014) Cat. No.: HY-P3293

Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of **human neutrophil elastase (hNE)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Loratadine

(Loratidine; SCH 29851) Cat. No.: HY-17043

Loratadine (SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Loratadine has anti-**dengue-virus (DENV)** activity. Loratadine can inhibit immunologic release of inflammatory mediators.



Purity: 99.60%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Loratadine-d4

(Loratidine-d4; SCH 29851-d4) Cat. No.: HY-17043S

Loratadine-d4 (Loratidine-d4) is the deuterium labeled Loratadine. Loratadine (SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Loratadine has anti-**dengue-virus (DENV)** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Loratadine-d5

(Loratidine-d5; SCH 29851-d5) Cat. No.: HY-17043S1

Loratadine-d5 (Loratidine-d5) is the deuterium labeled Loratadine. Loratadine (SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Loratadine has anti-**dengue-virus (DENV)** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lornoxicam

(Chlortenoxicam; Ro 13-9297) Cat. No.: HY-B0367

Lornoxicam (Chlortenoxicam), a COX-1 and COX-2 inhibitor, is a new nonsteroidal anti-inflammatory drug (NSAID). Target: COX Lornoxicam showed a balanced inhibition of COX-1/-2 exhibiting the lowest IC50 (0.005 microM/0.008 microM) of the large panel of NSAIDs tested.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Lorpucitinib

(JNJ-64251330) Cat. No.: HY-109182

Lorpucitinib is a Gut-Restricted **JAK** Inhibitor for the research of Inflammatory Bowel Disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Losmapimod

(GSK-AHAB; GW856553X; SB856553) Cat. No.: HY-10402

Losmapimod (GSK-AHAB) is a selective, potent, and orally active **p38 MAPK** inhibitor with **pK_i**s of 8.1 and 7.6 for p38α and p38β, respectively.



Purity: 98.06%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg

Losmiprofen

Cat. No.: HY-101642

Losmiprofen is a nonsteroidal antiinflammatory agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lotamilast

(RVT-501; E6005) Cat. No.: HY-12740

Lotamilast (RVT-501; E6005) is a selective phosphodiesterase 4 (**PDE4**) inhibitor with an **IC_{50}** of 2.8 nM.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Loteprednol Etabonate

Cat. No.: HY-17358

Loteprednol etabonate (LE) is an orally active "soft" steroid belonging to a unique class of glucocorticoids. Loteprednol etabonate (LE) exhibits anti-inflammatory activity and has been used in optometry and ophthalmology.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Loteprednol Etabonate D5

Cat. No.: HY-17358S

Loteprednol Etabonate D5 is a deuterium labeled Loteprednol etabonate. Loteprednol etabonate (LE) is an orally active "soft" steroid belonging to a unique class of glucocorticoids. Loteprednol etabonate (LE) exhibits anti-inflammatory activity and has been used in optometry and ophthalmology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Loureirin C

Cat. No.: HY-N2604

Loureirin C has anti-bacterial, anti-spasmodic, anti-inflammatory, analgesic, anti-diabetic, and anti-tumor activities.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Loxoprofen

Cat. No.: HY-B0578

Loxoprofen is a non-steroidal anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium is a nonselective **COX** inhibitor with IC_{50}s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Loxoprofen sodium

Cat. No.: HY-B0578A

Loxoprofen sodium is a non-steroidal anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium is a nonselective **COX** inhibitor with IC_{50}s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg

LP-935509

Cat. No.: HY-117626

LP-935509 is a selective, ATP-competitive and brain-penetrant inhibitor of **adapter protein-2 associated kinase 1 (AAK1)** with an IC_{50} and a K_i of 3.3 nM and 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC_{50}=14 nM) and a modest inhibitor of GAK (IC_{50}=320 nM).



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lp-PLA2-IN-2

Cat. No.: HY-133148

Lp-PLA2-IN-2 is a potent and selective **lipoprotein-associated phospholipase A2 (Lp-PLA2)** inhibitor, with an IC_{50} 0f 120 nM for recombinant human Lp-PLA2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LP117

Cat. No.: HY-U00438

LP117 is a novel and potent inhibitor of **5-Lipoxygenase (5-LO)** product synthesis with an IC_{50} of 1.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LP99

Cat. No.: HY-19553

LP99, an epigenetic probe, is a potent and selective inhibitor of the **BRD7** and **BRD9** bromodomains with a K_d of 99 nM against BRD9. LP99 disrupts the binding of BRD7 and BRD9 to chromatin in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LPA1 receptor antagonist 1

Cat. No.: HY-18076

LPA1 receptor antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 **(LPA1)** antagonist with an IC_{50} of 25 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LR-90

Cat. No.: HY-76383

LR-90 is an **advanced glycation end product (AGE)** inhibitor, inhibits inflammatory responses in human monocytes. LR-90 is also used in the research of diabetic animal model.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LS-102

Cat. No.: HY-135844

LS-102 is a selective E3 ubiquitin ligase **synoviolin (Syvn1)** inhibitor. LS-102 inhibits the autoubiquitination of synoviolin with an IC_{50} of 35 μM. LS-102 has the potential for rheumatoid arthritis treatment.



Purity: 96.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

LSP-249

Cat. No.: HY-126378

LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma **kallikrein** inhibitor under the study for angioedema, with an EC_{50} less than 100 nM in cell.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LT052

Cat. No.: HY-130622

LT052 is a highly selective **BET BD1** inhibitor with an IC_{50} of 87.7 nM. LT052 exhibits nanomolar BRD4 BD1 potency and 138-fold selectivity over BRD4 BD2 (IC_{50}=12.130 μM). LT052 has anti-inflammatory activity and can be used for acute gout arthritis research.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LTA4H-IN-1

Cat. No.: HY-137298

LTA4H-IN-1 is a potent inhibitor of **leukotriene A4 hydrolase (LTA4H)** extracted from patent WO2015092740A1, example 29, has an IC_{50} of 2 nM. LTA4H-IN-1 can be used for the research of inflammatory and autoimmune disorders.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LTB4-IN-1

Cat. No.: HY-U00299

LTB4-IN-1 (Compound 6) is a **leukotriene synthesis** (**LTB4**) inhibitor with an IC_{50} of 70 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LTD4 antagonist 1

Cat. No.: HY-U00359

LTD_4 antagonist 1 is a potent, orally active antagonist of **leukotriene D_4 (LTD_4)** with a K_i of 0.57 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LTV-1

Cat. No.: HY-18667

LTV-1 is a potent lymphoid tyrosine phosphatase (**LYP**) inhibitor in T cells with an IC_{50} of 508 nM. LTV-1 has the potential for autoimmunity treatment.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LTX-401 dihydrochloride

Cat. No.: HY-101949

LTX-401, an oncolytic amino acid derivative, targets the **Golgi apparatus**.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lucidenic acid D

(Lucidenic acid D2)

Cat. No.: HY-107260

Lucidenic acid D (Lucidenic acid D2) is a highly oxidized lanostane-type triterpenoid.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Lucidenic acid F

Cat. No.: HY-N9400

Lucidenic acid F, a natural triterpenoid, possesses anti-Inflammatory and anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lucyoside B

Cat. No.: HY-N4231

Lucyoside B inhibits the production of inflammatory mediators via both **NF-κB** and activator protein-1 pathways in activated macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lumacaftor

(VX-809; VRT 826809)

Cat. No.: HY-13262

Lumacaftor (VX-809; VRT 826809) is a **CFTR** modulator that corrects the folding and trafficking of CFTR protein.



Purity: 99.19%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lumiracoxib

(COX-189)

Cat. No.: HY-13507

Lumiracoxib is a potent,selective and orally active **COX-2** inhibitor with a K_i value of 0.06μM. Lumiracoxib acts as a nonselective **NSAID** with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg

Lumiracoxib-d6

Cat. No.: HY-13507S

Lumiracoxib-d6 (COX-189-d6) is the deuterium labeled Lumiracoxib. Lumiracoxib is a potent,selective and orally active **COX-2** inhibitor with a K_i value of 0.06μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Lup-20(29)-en-28-oic acid

Cat. No.: HY-N6049

Lup-20(29)-en-28-oic acid, a triterpenoid saponins of Pulsatilla koreana Root, possesses anti-inflammatory and anti-tumor effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lupenone

Cat. No.: HY-N2590

Lupenone, isolated from Rhizoma Musae, belongs to lupane type triterpenoids. Lupenone shows various pharmacological activities including anti-inflammatory, anti-virus, anti-diabetes, anti-cancer, improving Chagas disease without major toxicity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Lupeol acetate

Cat. No.: HY-126114

Lupeol acetate, a derivative of Lupeol, suppresses the progression of rheumatoid arthritis (RA) by inhibiting the activation of macrophages and osteoclastogenesis through downregulations of TNF-α, IL-1β, MCP-1, COX-2, VEGF and granzyme B.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lusutrombopag

(S-888711)

Cat. No.: HY-19883

Lusutrombopag is an orally bioavailable **thrombopoietin (TPO) receptor** agonist, used for treatment of chronic liver disease.



Purity: 99.09%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LUT014

Cat. No.: HY-111940

LUT014 is a **B-Raf** inhibitor with an IC_{50} of 11.7 nM, and developed to reduce dose-limiting acneiform lesions associated EGFR Inhibitors treatment. Extracted from patent WO 2019026065A2 .



Purity: 97.19%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Luteolin

(Luteoline; Luteolol; Digitoflavone)

Cat. No.: HY-N0162

Luteolin (Luteoline), a flavanoid compound, is a potent **Nrf2** inhibitor.



Purity: 98.15%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Luteolin 5-O-glucoside

Cat. No.: HY-N2008

Luteolin 5-O-glucoside, a major flavonoidfrom Cirsium maackii, possesses anti-inflammatory activity. Luteolin 5-O-glucoside inhibits LPS-induced **NO** production and t-BHP-induced **ROS** generation. Luteolin 5-O-glucoside suppresses the expression of iNOS and COX-2 in macrophages.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Luteolin 7-diglucuronide

Cat. No.: HY-N7269

Luteolin 7-diglucuronide is the major flavonoid isolated from Aloysia triphylla and Verbena officinalis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Luteolin-3-O-beta-D-glucuronide

Cat. No.: HY-N4099

Luteolin-3-O-beta-D-glucuronide is a luteolin glucosiduronic acid consisting of luteolin having a beta-D-glucosiduronic acid residue attached at the 3'-position.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Luteolin-7-rutinoside

Cat. No.: HY-N6647

Luteolin-7-rutinoside has both anti-arthritic and antifungal activities, can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Luteolinidin chloride

Cat. No.: HY-129997

Luteolinidin is a natural deoxyanthocyanidin, isolated from mosses and ferns. Luteolinidin is a potent CD38 inhibitor which can protect the heart against I/R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg

LXW7

Cat. No.: HY-P0178

LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an **integrin αvβ3** inhibitor. LXW7 has a high binding affinity to **αvβ3 integrin** with an IC_{50} of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LXW7 TFA

Cat. No.: HY-P0178A

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an **integrin αvβ3** inhibitor. LXW7 has a high binding affinity to **αvβ3 integrin** with an IC_{50} of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

LY 178002

Cat. No.: HY-101579

LY 178002 is a potent inhibitor of **5-lipoxygenase (5-LPO)**, **phospholipase A2**, with IC_{50} of 0.6 μM for 5-lipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on **cyclooxygenase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY 3000328

Cat. No.: HY-15533

LY 3000328 is a potent and selective **Cathepsin S (Cat S)** inhibitor with IC_{50}s of 7.7 and 1.67 nM for hCat S and mCat S, respectively.



Purity: 98.12%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

LY-311727

Cat. No.: HY-107393

LY-311727 is a potent **secretory non-pancreatic phospholipase A_2 ($sPLA_2$)** inhibitor (IC_{50} <1 μM for group IIA $sPLA_2$). $sPLA_2$ is an important proinflammatory enzyme.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

LY210073

Cat. No.: HY-U00263

LY210073 is a **Leukotriene B_4 (LTB_4)** receptor antagonist with an **IC_{50}** of 6.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY223982

(CGS23131; SKF107324)

Cat. No.: HY-112737

LY223982 is a potent and specific inhibitor of **leukotriene B4 receptor**, with an **IC_{50}** of 13.2 nM against [^{3}H]LTB4 binding to LTB4 receptor.



Purity: 100.0%
Clinical Data: No Development Reported
Size: 5 mg

LY255283

Cat. No.: HY-15744

LY255283 is a **LTB_4 receptor (BLT2)** antagonist, with an **IC_{50}** of ~100 nM for [^{3}H]LTB_4 binding to guinea pig lung membranes.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LY266097 hydrochloride

Cat. No.: HY-103094

LY266097 hydrochloride is a selective **5-HT2B** receptor antagonist with **pK_i**s of 7.7, 9.8, and 7.6 for **5-HT2A**, **5-HT2B**, **5-HT2C**, respectively. 5-HT2B receptor blockade contributes to the research in depression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY2955303

Cat. No.: HY-107765

LY2955303 is a potent and selective **retinoic acid receptor gamma** (**RARγ**) antagonist with a **K_i** of 1.09 nM.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

LY3200882

Cat. No.: HY-103021

LY3200882 is a potent, highly selective, ATP-competitive and orally active **TGF-β receptor type 1 (ALK5)** inhibitor with an **IC_{50}** of 38.2 nM. LY3200882 inhibits various pro-tumorigenic activities and is also used as an immune modulatory agent.



Purity: 99.60%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ly93

Cat. No.: HY-114307

Ly93 is a selective and orally active **sphingomyelin synthase 2 (SMS2)** inhibitor, with an **IC_{50}** of 91 nM.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lycorine

Cat. No.: HY-N0288

Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active **SCAP** inhibitor with a **K_d** value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Lycorine hydrochloride

Cat. No.: HY-N0289

Lycorine hydrochloride is the main active ingredient of the herbal medicine derived from Lycoris radia and is also a melanoma vasculogenic inhibitor and has anti-tumor activity. Lycorine hydrochloride effectively inhibits mitotic proliferation of Hey1B cells (**IC_{50}** of 1.2 μM).



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Lyn peptide inhibitor

Cat. No.: HY-P1111

Lyn peptide inhibitor is a potent and cell-permeable inhibitor of **Lyn-coupled IL-5 receptor** signaling pathway, while keeping other signals intact.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lyn peptide inhibitor TFA

Cat. No.: HY-P1111A

Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of **Lyn-coupled IL-5 receptor** signaling pathway, while keeping other signals intact.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LYP-IN-1

Cat. No.: HY-108944

LYP-IN-1 is a potent, selective and specific **LYP** inhibitor with a K_i and an IC_{50} of 110 nM and 0.259 μM, respectively. LYP-IN-1 also has selectivity for a large panel of PTPs, such as SHP1 (IC_{50}=5 μM) and SHP2 (IC_{50}=2.5 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lys-[Des-Arg9]Bradykinin TFA

Cat. No.: HY-103295A

Lys-[Des-Arg9]Bradykinin TFA, a naturally occurring kinin, is a potent and highly selective **bradykinin B1 receptor** agonist with a K_i of 0.12 nM, 1.7 nM and 0.23 nM for **human**, **mouse** and **rabbit B1 receptors**, respectively.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Lysionotin

Cat. No.: HY-107222

Lysionotin is a flavonoid isolated from few flower lysionotus herbs. Lysionotin efficiently inhibit **α-Toxin** (a pore-forming protein) expression and shows significant protection against S. aureus in vitro and in vivo.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lysostaphin

Cat. No.: HY-P2329

Lysostaphin is an antistaphylococcal agent. Lysostaphin has activities of three enzymes namely, glycylglycine endopeptidase, endo-β-N-acetyl glucosamidase and N-acteyl muramyl-L-alanine amidase.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

m-Coumaric acid

Cat. No.: HY-113357

m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

m-PEG5-succinimidyl carbonate

Cat. No.: HY-130150

m-PEG5-succinimidyl carbonate is a non-cleavable 5 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG5-succinimidyl carbonate is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG6-azide

Cat. No.: HY-115374

m-PEG6-azide is a non-cleavable 6 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG6-NHS ester

Cat. No.: HY-133066

m-PEG6-NHS ester is a non-cleavable 6 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). m-PEG6-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

m-PEG8-NHS ester

Cat. No.: HY-W019793

m-PEG8-NHS ester is a non-cleavable 8 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

M4284

Cat. No.: HY-120568

M4284 is a selective and orally active biphenyl mannoside **FimH** antagonist. M4284 has activities against different UPEC (Urinary tract infections (UTI) caused by uropathogenic E. coli) strains in different host genetic backgrounds and gut microbial community contexts.



Purity: 98.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg

Mabuterol-D9

Cat. No.: HY-13338S

Mabuterol-D9 is a deuterium labeled Mabuterol. Mabuterol is an agonist of the **β2-adrenergic receptor**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Macelignan

((+)-Anwulignan; Anwuligan)

Cat. No.: HY-N0064

Macelignan ((+)-Anwulignan; Anwuligan) is an orally active **lignan** isolated from Myristica fragrans. Macelignan possesses many pharmacological activities, including anti-inflammatory, anti-cancer, anti-diabetes, and neuroprotective activities.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Madecassic acid

Cat. No.: HY-N0569

Madecassic acid is isolated from Centella asiatica (Umbelliferae). Madecassic acid has anti-inflammatory properties caused by **iNOS**, **COX-2**, **TNF-alpha**, **IL-1beta**, and **IL-6** inhibition via the downregulation of **NF-κB** activation in RAW 264.7 macrophage cells.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Magnesium Lithospermate B

Cat. No.: HY-126415

Magnesium Lithospermate B, a derivative of caffeic acid tetramer, and is extracted from Salviae miltiorrhizae.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Magnolin

Cat. No.: HY-N1374

Magnolin, a major component of Magnolia flos (Shin-Yi), inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of **ERK1** and **ERK2** with IC_{50}s of 87 nM and 16.5 nM, respectively.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Magnolol

Cat. No.: HY-N0163

Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both **RXRα** and **PPARγ**, with EC_{50} values of 10.4 μM and 17.7 μM, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Mahanimbine

Cat. No.: HY-124557

Mahanimbine is an orally active alkaloid from curry leaves. Mahanimbine inhibits progression of high-fat diet (HFD)-induced metabolic complications in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mahanine

Cat. No.: HY-121368

Mahanine is a carbazole alkaloid with various biological properties. Mahanine is a potent anticancer agent against different types of cancer cells. Mahanine exhibits **antileishmanial** activity and can be used for Leishmania infection treatment research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mal-PEG1-acid

Cat. No.: HY-126960

Mal-PEG1-acid is is a non-cleavable 1 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG1-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

Maleimide-DOTA

(Maleimido-mono-amide-DOTA)

Cat. No.: HY-133540

Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 99.17%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Maltopentaose

(Maltopentose)

Cat. No.: HY-N1495

Maltopentaose is the shortest chain oligosaccharide that can be classified as maltodextrin and is also used in a study to investigate glycation and phosphorylation of α-lactalbumin.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Malvidin-3-glucoside chloride

(Malvidin-3-O-glucoside chloride; Oenin chloride)

Cat. No.: HY-125740

Malvidin-3-glucoside chloride (Malvidin-3-O-glucoside chloride), a major wine anthocyanin, is effective in promoting resilience against stress by modulating brain synaptic plasticity and peripheral inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Malvidin-3-O-arabinoside chloride

Cat. No.: HY-N9349

Malvidin-3-O-arabinoside chloride ameliorates ethyl carbamate-induced oxidative damage by stimulating AMPK-mediated **autophagy**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Manghaslin

Cat. No.: HY-N7993

Manghaslin is a flavonoid glycoside with anti-inflammatory activities. Manghaslin shows inhibitory activity against **AChE** with an IC_{50} of 94.92 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Manitimus

(FK778)

Cat. No.: HY-101603

Manitimus is an inhibitor of dehydroorotate dehydrogenase, and a potent immunosuppressive drug.



Purity: 99.57%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 20 mg

Manoalide

Cat. No.: HY-N7487

Manoalide is a potent Phospholipase A2 (**PLA2**) and Phospholipase C (**PLC**) inhibitor. Manoalide, a sesterpenoid compound, displays anti-inflammatory and antibacterial activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Maraviroc

(UK-427857)

Cat. No.: HY-13004

Maraviroc (UK-427857) is a selective **CCR5** antagonist with activity against human **HIV**.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Maraviroc-d6

Cat. No.: HY-13004S

Maraviroc-d6 (UK-427857-d6) is the deuterium labeled Maraviroc. Maraviroc (UK-427857) is a selective **CCR5** antagonist with activity against human **HIV**.



Purity: >98%
Clinical Data:
Size: 500 μg, 1 mg, 5 mg, 10 mg, 50 mg

MARCKS Peptide(151-175), Phosphorylated

Cat. No.: HY-P1834

MARCKS Peptide(151-175), Phosphorylated is a phosphorylated peptide corresponding to the basic effector domain of myristoylated alanine-rich protein kinase C substrate protein (MARCKS).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Maresin 1

Cat. No.: HY-116429

Maresin 1, produced by human Mφs from endogenous docosahexaenoic acid (DHA) and a specialized proresolving mediator, stimulates intracellular [Ca^{2+}] and secretion. Maresin 1 possesses anti-inflammatory activity.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 25 μg (277.4 μM * 250 μL in Ethanol)

MARK Substrate

Cat. No.: HY-P1583

MARK Substrate is a MARK substrate peptide.

NVKSKIGSTENLK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MART-1 (26-35) (human)

Cat. No.: HY-P0138

MART-1 (26-35) (human) is amino acid residue 26 to 35 of MART-1 protein.

EAAGIGILTV

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Maslinic acid

(Crategolic acid; 2α-Hydroxyoleanolic acid)

Cat. No.: HY-N0629

Maslinic acid can inhibit the DNA-binding activity of **NF-κB p65** and abolish the phosphorylation of **IκB-α**, which is required for p65 activation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Mast Cell Degranulating Peptide HR-2

Cat. No.: HY-P1807

Mast Cell Degranulating Peptide HR-2, a 14-membered linear peptide isolated from the venom of the giant hornet Vespa orientalis, is capable of degranulating mast cells and thus initiating histamine release.

FLPLILGKLVKGLL-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mavacoxib

Cat. No.: HY-119447

Mavacoxib is a selective, oral long-acting **cyclooxygenase-2 (COX-2)** inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MCC950

(CP-456773; CRID3)

Cat. No.: HY-12815

MCC950 (CP-456773; CRID3) is a potent and selective **NLRP3** inhibitor with IC_{50}s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MCC950 sodium

(CP-456773 sodium; CRID3 sodium salt)

Cat. No.: HY-12815A

MCC950 sodium (CP-456773 sodium; CRID3 sodium salt) is a potent, selective **NLRP3** inhibitor with IC_{50}s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MCL0020

Cat. No.: HY-107627

MCL0020 is a potent and selective **melanocortin MC4** receptor antagonist, with an IC_{50} of 11.63 nM. MCL0020 dose-dependently and significantly attenuates restraint stress-induced anorexia without affecting food intake.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MD2-IN-1

Cat. No.: HY-103483

MD2-IN-1 is an inhibitor of **Myeloid differentiation protein 2** (**MD2**) with a **KD** of 189 μM for the recombinant human MD2 (**rhMD2**).



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MD2-TLR4-IN-1

Cat. No.: HY-128598

MD2-TLR4-IN-1 (compound 22m) is an inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex, inhibiting lipopolysaccharides (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages with...



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MDL 19301

Cat. No.: HY-100286

MDL 19301 is a nonsteroidal, anti-inflammatory agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MDL-28170

(Calpain Inhibitor III)

Cat. No.: HY-18236

MDL-28170 (Calpain Inhibitor III) is a potent, selective and membrane-permeable cysteine protease inhibitor of **calpain** that rapidly penetrates the blood-brain barrier following systemic administration. MDL-28170 also block γ-secretase.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Me-triacetyl-β-D-glucopyranuronate-Ph-ald-NO2

Cat. No.: HY-131086

Me-triacetyl-β-D-glucopyranuronate-Ph-ald-NO2 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mebhydrolin

Cat. No.: HY-B1303A

Mebhydrolin is a specific **histamine H_1 receptor** antagonist.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Mebhydrolin napadisylate

(Mebhydroline 1,5-naphthalenedisulfonate salt)

Cat. No.: HY-B1303

Mebhydrolin napadisylate is a specific **histamine H_1 receptor** antagonist.



Purity: 99.93%
Clinical Data: Launched
Size: 100 mg

Meclofenamic acid

(Meclofenamate)

Cat. No.: HY-117275

Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective **fat mass and obesity-associated (FTO) enzyme** inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Meclofenamic acid sodium

(Meclofenamate sodium)

Cat. No.: HY-B1320

Meclofenamic acid (Meclofenamate) sodium is a nonsteroidal anti-inflammatory drug (NSAID) approved for use in arthritis (osteo and rheumatoid), analgesia (mild to moderate pain), dysmenorrhea, and heavy menstrual blood loss (menorrhagia).



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

MeCY5-NHS ester potassium

(Sulfo-Cyanine5 NHS ester potassium)

Cat. No.: HY-135413A

MeCY5-NHS ester (potassium) is a reactive dye and can be used for labeling protein nucleic acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Medrysone

(HMS; 6α-Methyl-11β-hydroxyprogesterone)

Cat. No.: HY-B1076

Medrysone is a corticosteroid, in ophthalmology for the treatment of eye inflammations.



Purity: 98.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Mefenamic acid

Cat. No.: HY-B0574

Mefenamic acid is a non-steroidal anti-inflammatory agent, acting as a competitive inhibitor of **hCOX-1** and **hCOX-2**, with IC_{50}s of 40 nM and 3 μM for hCOX-1 and hCOX-2, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Mefenamic acid D4

Cat. No.: HY-B0574S

Mefenamic acid D4 is a deuterium labeled Mefenamic acid. Mefenamic acid is a non-steroidal anti-inflammatory agent, acting as a competitive inhibitor of **hCOX-1** and **hCOX-2**, with IC_{50}s of 40 nM and 3 μM for hCOX-1 and hCOX-2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mefenamic Acid-d3

Cat. No.: HY-B0574S1

Mefenamic Acid-d3 is the deuterium labeled Mefenamic acid. Mefenamic acid is a non-steroidal anti-inflammatory agent, acting as a competitive inhibitor of **hCOX-1** and **hCOX-2**, with IC_{50}s of 40 nM and 3 μM for hCOX-1 and hCOX-2, respectively.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 25 mg

Mefloquine hydrochloride

(Mefloquin hydrochloride)

Cat. No.: HY-17437A

Mefloquine hydrochloride (Mefloquin hydrochloride), a quinoline antimalarial agent, is an anti-**SARS-CoV-2** entry inhibitor. Mefloquine hydrochloride is also a **K^+ channel (KvQT1/minK)** antagonist with an IC_{50} of ~1 μM.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

MEG hemisulfate

(Mercaptoethylguanidine hemisulfate)

Cat. No.: HY-138454

MEG (Mercaptoethylguanidine) hemisulfate is a potent and selective inhibitor of the **inducible NO synthase (iNOS)**, with EC_{50}s of 11.5, 110, and 60 μM for **iNOS**, **ecNOS**, and **bNOS** respectively in tissue homogenates.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Megastigm-7-ene-3,5,6,9-tetraol

(Megastigma-7-en-3,5,6,9-tetraol)

Cat. No.: HY-N3305

Megastigm-7-ene-3,5,6,9-tetraol (Megastigma-7-en-3,5,6,9-tetraol) is a diterpenoid analogue in the aerial parts of Isodon melissoides. Megastigm-7-ene-3,5,6,9-tetraol is also in Vigna luteola and has anti-inflammatory bioactivity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Megestrol

Cat. No.: HY-B1834

Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Melatonin

(N-Acetyl-5-methoxytryptamine)

Cat. No.: HY-B0075

Melatonin is a hormone made by the pineal gland that can activates **melatonin receptor**. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties.



Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Melatonin-d4

(N-Acetyl-5-methoxytryptamine-d4)

Cat. No.: HY-B0075S

Melatonin D4 is deuterium labeled Melatonin. Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Antioxidative and anti-inflammatory properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Melittin

Cat. No.: HY-P0233

Melittin is a **PLA_2** activator, stimulates the activity of the low molecular weight PLA_2, while it does not the increase activity of the high molecular weight PLA_2.

GIGAVLKVLTTGLPALISWIKRKRQQ-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Melittoside

Cat. No.: HY-N0915

Melittoside is a natural compound.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Meloxicam

Cat. No.: HY-B0261

Meloxicam is a non-steroidal antiinflammatory agent, inhibits **COX** activity, with IC_{50}s of 0.49 μM and 36.6 μM for COX-2 and COX-1, respectively.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Meloxicam-d3

Cat. No.: HY-B0261S

Meloxicam-d3 is deuterium labeled Meloxicam. Meloxicam is a non-steroidal antiinflammatory agent, inhibits COX activity, with IC_{50}s of 0.49 μM and 36.6 μM for COX-2 and COX-1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Menbutone

(Genabilic acid)

Cat. No.: HY-B1136

Menbutone is an oxobutyric acid derivative, and is a choleretic.Menbutone has a rapid onset of action, reaching its maximum plasma level within 1 hour and lasting for roughly 10 hours.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Menthone

Cat. No.: HY-N2381

Menthone, a monoterpene extracted from plants and Mentha oil with strong antioxidant properties. Menthone is a main volatile component of the essential oil, and has anti-Inflammatory properties in Schistosoma mansoni Infection.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Mequitazine

(LM-209)

Cat. No.: HY-B2168

Mequitazine is a potent, nonsedative and long-acting histamine H_1 antagonist.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mercaptoethylguanidine (MEG) (dihydrobromide)

Cat. No.: HY-115744

Mercaptoethylguanidine (MEG) dihydrobromide is selective inhibitor of the inducible **nitric oxide synthase** and **peroxynitrite** scavenger. Mercaptoethylguanidine (MEG) dihydrobromide has the potential for inflammatory bowel diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mesaconine

Cat. No.: HY-N1922

Mesaconinean, an ingredient from Aconitum carmichaelii Debx., has cardiac effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mesalamine impurity P

Cat. No.: HY-131265

Mesalamine impurity P is an impurity of Mesalamine (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific **PPARγ** agonist and also inhibits p21-activated kinase 1 (**PAK1**) and NF-κB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Meseclazone

(W2395; NSC297623)

Cat. No.: HY-U00157

Meseclazone (W2395;NSC297623) exhibits inhibitory potency of secondary phase ADP aggregation. Meseclazone possesses anti-inflammatory, analgesic and antipyretic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

meta-Fexofenadine

(meta-MDL-16455; meta-Terfenadine carboxylate) Cat. No.: HY-100657

meta-Fexofenadine (meta-MDL-16455) is an impurity of Fexofenadine. Fexofenadine, a H1R antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Metamizole sodium

Cat. No.: HY-B1279A

Metamizole sodium is a non-opioid compound with excellent analgesic and antipyretic effects. Metamizole (sodium) is a **cyclooxygenase-3 (COX-3)** inhibitor.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Metamizole sodium hydrate

Cat. No.: HY-B1279

Metamizole sodium hydrate is a potent analgesic drug that has been demonstrated to inhibit cyclooxygenase (COX).



Purity: ≥98.0%
Clinical Data: Launched
Size: 500 mg

Metaproterenol

(Orciprenaline) Cat. No.: HY-B1276A

Metaproterenol (Orciprenaline) is a direct-acting sympathomimetic and a **β2-adrenergic receptor (β2AR)** agonist with an IC_{50} of 68 nM. Metaproterenol also has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Metaproterenol hemisulfate

(Orciprenaline hemisulfate) Cat. No.: HY-B1276

Metaproterenol hemisulfate (Orciprenaline hemisulfate) is a direct-acting sympathomimetic and a **β2-adrenergic receptor (β2AR)** agonist with an IC_{50} of 68 nM. Metaproterenol hemisulfate also has anti-inflammatory activity.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Metaproterenol-d7 hemisulfate

Cat. No.: HY-B1276S

Metaproterenol-d7 (Orciprenaline-d7) hemisulfate is the deuterium labeled Metaproterenol hemisulfate. Metaproterenol hemisulfate (Orciprenaline hemisulfate) is a direct-acting sympathomimetic and a **β2-adrenergic receptor (β2AR)** agonist with an IC_{50} of 68 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Methapyrilene hydrochloride

(Thenylpyramine hydrochloride) Cat. No.: HY-B1483

Methapyrilene (Thenylpyramine) hydrochloride is an orally active **H1-receptor antihistamine** and an anticholinergic agent of the pyridine chemical class. Methapyrilene hydrochloride has hepatotoxicity and can be used as a hepatotoxin that cause periportal hepatic necrosis in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methazolamide

(L584601) Cat. No.: HY-B0553

Methazolamide (L584601) is a sulfonamide derivative used as a **carbonic anhydrase** inhibitor with a K_i of 14 nM for human carbonic anhydrase II.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Methotrexate

(Amethopterin; CL14377; WR19039) Cat. No.: HY-14519

Methotrexate (Amethopterin), an **antimetabolite** and **antifolate** agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Methotrexate disodium (Amethopterin disodium; CL14377 disodium; WR19039 disodium)

Cat. No.: HY-14519A

Methotrexate (Amethopterin) disodium, an **antimetabolite** and **antifolate** agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis.



Purity: 98.26%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Methotrexate metabolite

(DAMPA)

Cat. No.: HY-108251

Methotrexate metabolite (DAMPA), the active metabolite of Methotrexate. Methotrexate is a **folic acid** antagonist that is widely used as an immunosuppressant and chemotherapeutic agent.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

Methotrexate-d3

Cat. No.: HY-14519S

Methotrexate-d3 (Amethopterin-d3) is the deuterium labeled Methotrexate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methoxsalen

(8-Methoxypsoralen; Xanthotoxin; 8-MOP)

Cat. No.: HY-30151

Methoxsalen (8-Methoxypsoralen) is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450), is an agent used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing the skin to sunlight.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Methyl (E)-cinnamate

(Methyl (E)-3-phenylpropenoate)

Cat. No.: HY-W067056

Methyl (E)-cinnamate (EMC), a phytochemical constituent isolated from Alpinia katsumadai Hayata, is a natural flavor compound with anti-inflammatory properties. Methyl (E)-cinnamate is widely used in the food and commodity industry.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methyl 3,4-dihydroxybenzoate

(Protocatechuic acid methyl ester; Methyl protocatechuate)

Cat. No.: HY-Z0548

Methyl 3,4-dihydroxybenzoate (Protocatechuic acid methyl ester; Methyl protocatechuate) is a major metabolite of antioxidant polyphenols found in green tea. Antioxidant and anti-inflammatory effect.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Methyl 5-hydroxypyridine-2-carboxylate

Cat. No.: HY-W005963

Methyl 5-hydroxypyridine-2-carboxylate is a phenolic acid that can found in the stems of Mahonia fortune. Methyl 5-hydroxypyridine-2-carboxylate exhibits NO inhibitory effects in vitro.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 100 mg

Methyl aminolevulinate

Cat. No.: HY-A0169

Methyl aminolevulinate is an agent used as a **sensitizer** in photodynamic therapy (PDT). Methyl aminolevulinate is a prodrug that can be metabolized to Protoporphyrin IX.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Methyl aminolevulinate hydrochloride

Cat. No.: HY-A0169A

Methyl aminolevulinate hydrochloride is an agent used as a **sensitizer** in photodynamic therapy (PDT). Methyl aminolevulinate is a prodrug that can be metabolized to Protoporphyrin IX.



Purity: ≥95.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Methyl arachidate

(Methyl eicosanoate)

Cat. No.: HY-W004291

Methyl arachidate (Methyl eicosanoate), a natural compound, is a **leukotriene A4 hydrolase (LTA4H)** inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Methyl mycophenolate

Cat. No.: HY-113972

Methyl mycophenolate is a methyl ester of mycophenolic acid and is also found in marine-derived fungus Phaeosphaeria spartinae.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Methyl mycophenolate-d6

Cat. No.: HY-113972S

Methyl mycophenolate-d6 is the deuterium labeled Methyl mycophenolate. Methyl mycophenolate is a methyl ester of mycophenolic acid and is also found in marine-derived fungus Phaeosphaeria spartinae.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Methyl nicotinate

Cat. No.: HY-B1695

Methyl nicotinate, the methyl ester of Niacin found in alcoholic beverages, that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Methyl palmitate

Cat. No.: HY-N1482

Methyl palmitate, an acaricidal compound occurring in green walnut husks, inhibits phagocytic activity and immune response. Methyl palmitate also posseses anti-inflammatory and antifibrotic effects.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 500 mg

Methyl Salicylate

(Wintergreen oil)

Cat. No.: HY-Y0189

Methyl Salicylate (Wintergreen oil) is a topical analgesic and anti-inflammatory agent. Also used as a pesticide, a denaturant, a fragrance ingredient, and a flavoring agent in food and tobacco products. A systemic acquired resistance (SAR) signal in tobacco.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Methyl syringate

Cat. No.: HY-W002116

Methyl syringate, a chemical marker of asphodel monofloral honey, is an efficient phenolic mediator for bacterial and fungal laccases. Methyl syringate is a **TRPA1** agonist.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Methyl vanillate

Cat. No.: HY-75342

Methyl vanillate, one of the ingredients in Hovenia dulcis Thunb, is a **Wnt/β-catenin** pathway activator. A benzoate ester that is the methyl ester of vanillic acid. It has a role as an antioxidant and a plant metabolite.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

Methyl α-D-mannopyranoside

Cat. No.: HY-W039897

Methyl α-D-mannopyranoside could target macrophages in anti-tuberculosis inhalation therapy.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Methyl-3β-hydroxycholenate

Cat. No.: HY-100084

Methyl-3β-hydroxycholenate is a **ROR gamma** modulator extracted from patent US20110263046 A1, in figure 2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methyl-Hesperidin

Cat. No.: HY-N0165

Methyl-Hesperidin is a vasodilating agent.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 5 mg

Methylbenactyzium Bromide

Cat. No.: HY-B2070

Methylbenactyzium Bromide is a **muscarinic acetylcholine receptor** (**mAChR**) inhibitor.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg

Methylnissolin-3-O-glucoside

Cat. No.: HY-N2473

Methylnissolin-3-O-glucoside (Methylnissolin-3-O-β-D-glucoside) is a flavonoid from the roots of Astragalus membranaceus with anti-inflammatory effects.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Methylophiopogonanone A

Cat. No.: HY-N2437

Methylophiopogonanone A, a major homoisoflavonoid in Ophiopogon japonicas, has both anti-oxidative and anti-inflammatory properties.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Methylophiopogonone A

Cat. No.: HY-N2441

Methylophiopogonone A, a homoisoflavonoid isolated from the tuberous roots of Ophiopogon japonicas, shows anti-inflammatory activity.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Methylprednisolone

(U 7532)

Cat. No.: HY-B0260

Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical **COVID-19** by activating **ACE2** and reducing IL-6 levels.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Methylprednisolone succinate

(Methylprednisolone hydrogen succinate)

Cat. No.: HY-B1900

Methylprednisolone succinate is a synthetic glucocorticoid and widely used as an anti-inflammatory agent.



Purity: 99.55%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Methylsticin

Cat. No.: HY-N2465

Methylsticin is a kavalactone isolated from the kava roots. Methylsticin exhibit osteoclast formation inhibitory activity.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Methylsyringin

Cat. No.: HY-N10120

Methylsyringin exhibits **anti-inflammatory activity** in the LPS-stimulated RAW264.7 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methylthiouracil

(MTU)

Cat. No.: HY-B0513

Methylthiouracil is an antithyroid agent. Methylthiouracil suppresses the production **TNF-α** and **IL-6**, and the activation of **NF-κB** and **ERK1/2**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

MF-766

Cat. No.: HY-115487

MF-766 is a highly potent, selective and orally active **EP4** antagonist with a K_i of 0.23 nM. MF-766 behaves as a full antagonist with an IC_{50} of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay. MF-766 can be used for cancer and inflammation diseases research.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MF63

Cat. No.: HY-13283

MF63 is a selective mPGES-1 inhibitor with an IC50 of 0.9 nM and 1.3 nM for pig mPGES-1 and human mPGES-1 enzyme, respectively.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MGV354

Cat. No.: HY-111516

MGV354 is a **soluble guanylate cyclase** (**sGC**) activator with EC_{50}s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MHP

(Methyl caprooyl tyrosinate)

Cat. No.: HY-101572

MHP (Methyl caprooyl tyrosinate) is an activator of sphingosine kinase (**SPHK1**), and significantly stimulates CAMP mRNA and protein production. MHP (Methyl caprooyl tyrosinate) enhances antimicrobial defense and innate immunity.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Microcolin B

Cat. No.: HY-130999

Microcolin B is an extremely potent unusual acylpeptide, proline-containing potent immunosuppressant. Microcolin B is isolated from blue-green alga Lyngbya majuscule.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mifamurtide

(MTP-PE; L-MTP-PE; CGP 19835)

Cat. No.: HY-13682

Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide, an orphan drug, is a specific ligand of NOD2 used as an insulin sensitizer.



Purity: ≥98.0%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Mifamurtide sodium

(MTP-PE sodium; L-MTP-PE sodium; CGP 19835 sodium)

Cat. No.: HY-13682B

Mifamurtide sodium (MTP-PE sodium), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide sodium, an orphan drug, is a specific ligand of NOD2 used as an insulin sensitizer.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Mifamurtide TFA

(MTP-PE TFA; L-MTP-PE TFA; CGP 19835 TFA)

Cat. No.: HY-13682C

Mifamurtide TFA (MTP-PE TFA), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide TFA, an orphan drug, is a specific ligand of NOD2 used as an insulin sensitizer.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Milategrast

(E6007)

Cat. No.: HY-109151

Milategrast is useful as cell adhesion inhibitor or cell infiltration inhibitor. Milategrast in vitro inhibites the adhesion of Jurkat cells to human fibronectin with an IC_{50} of 5 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mimosine

Cat. No.: HY-N0928

Mimosine, a tyrosine analog , can act as an antioxidant by its potent iron-binding activity. Mimosine is a known chelator of Fe(III). Mimosine induces **apoptosis** through metal ion chelation, mitochondrial activation and ROS production in human leukemic cells.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Minocromil

(FPL59360)

Cat. No.: HY-U00258

Minocromil (FPL59360) is a new **Anti-asthmatic** agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Miravirsen

(SPC-3649)

Cat. No.: HY-132598

Miravirsen (SPC-3649), a β-d-oxy-locked nucleic acid-modified phosphorothioate antisense oligonucleotide, inhibit the biogenesis of **miR-122**. Miravirsen (SPC-3649) is used in the study for HCV infections.

Miravirsen

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mirtazapine

(Org3770; 6-Azamianserin)

Cat. No.: HY-B0352

Mirtazapine (Org3770) is a potent and orally active noradrenergic and specific serotonergic antidepressant (NaSSA) agent. Mirtazapine is also a **5-HT$_2$**, **5-HT$_3$**, **histamine H1 receptor** and **α2-adrenoceptor** antagonist with **pK$_i$** values of 8.05, 8.1, 9.3 and 6.95, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Misoprostol acid

Cat. No.: HY-118189

Misoprostol acid is an active metabolite of Misoprostol. Misoprostol is a synthetic analogue of **prostaglandin E1 (PGE1)**, extensively absorbed, and undergoes rapid de-esterification to Misoprostol acid in the gastrointestinal tract after oral administration.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Misoprostol acid-d5

Cat. No.: HY-118189S

Misoprostol acid D5 is deuterium labeled Misoprostol acid. Misoprostol acid is an active metabolite of Misoprostol.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Mito-TEMPO

Cat. No.: HY-112879

Mito-TEMPO is a mitochondria-targeted superoxide dismutase mimetic with superoxide and alkyl radical scavenging properties.



Purity: 98.35%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mitraphylline

Cat. No.: HY-N6946

Mitraphylline is the major pentacyclic oxindolic alkaloid presented in Uncaria tomentosa. Mitraphylline inhibits lipopolysaccharide-mediated activation of primary human neutrophils.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Mizolastine

Cat. No.: HY-B0164

Mizolastine is a histamine H1-receptor antagonist with IC50 of 47 nM used in the treatment of hay fever (seasonal allergic rhinitis), hives and other allergic reactions.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Mizolastine dihydrochloride

Cat. No.: HY-B0164A

Mizolastine dihydrochloride is a histamine H1-receptor antagonist with IC50 of 47 nM used in the treatment of hay fever (seasonal allergic rhinitis), hives and other allergic reactions.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Mizoribine

(NSC 289637; HE 69)

Cat. No.: HY-17470

Mizoribine (NSC 289637), an imidazole nucleoside, inhibits **HCV** RNA replication with IC$_{50}$ of approximately 100 μM for anti-HCV activity. Immunosuppressant.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

MJ33-OH

Cat. No.: HY-129944

MJ33-OH is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible **phospholipase A2 (PLA2)** inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MJ33-OH lithium

Cat. No.: HY-129944A

MJ33-OH lithium is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible **phospholipase A2 (PLA2)** inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6.



Purity: ≥90.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-0429

(L-000845704)

Cat. No.: HY-15102

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide **pan-integrin** antagonist with IC_{50} values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK-0812

Cat. No.: HY-50669

MK-0812 is a potent and selective **CCR2** antagonist with low nM affinity for CCR2.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-0812 Succinate

Cat. No.: HY-50669A

MK-0812 Succinate is a potent and selective **CCR2** antagonist with high affinity at CCR2.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK-2894

Cat. No.: HY-10413

MK-2894 is a potent, selective, orally active and high affinity (K_i=0.56 nM) full antagonist against **E prostanoid receptor 4 (EP4 receptor)** (IC_{50}=2.5 nM). MK-2894 possesses potent anti-inflammatory activity in animal models of pain/inflammation and can be used for the research of arthritis.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MK-2894 sodium salt

Cat. No.: HY-10414

MK-2894 sodium salt is a potent, selective, orally active and high affinity (K_i=0.56 nM) full antagonist against **E prostanoid receptor 4 (EP4 receptor)** (IC_{50}=2.5 nM).



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MK-447

Cat. No.: HY-100297

MK-447 is a free radical scavenger, also a nonsteroidal antiinflammatory agent, and enhances the formation of the endoperoxide, PGH_2, and other **prostaglandins**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-571 sodium salt

(L-660711 sodium salt)

Cat. No.: HY-19989A

MK-571 sodium salt is a selective, orally active **leukotriene D4 receptor** antagonist, with K_is of 0.22 and 2.1 nM in guinea pig and human lung membranes.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

MK-571-d6 sodium salt

Cat. No.: HY-19989AS

MK-571-d6 (L-660711-d6) sodium salt is the deuterium labeled MK-571 sodium salt. MK-571 sodium salt is a selective, orally active **leukotriene D4 receptor** antagonist, with K_is of 0.22 and 2.1 nM in guinea pig and human lung membranes.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

MK-7246

Cat. No.: HY-15853

MK-7246 is a potent and selective **CRTH2** antagonist with a K_i of 2.5±0.5 nM.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK-7246 S enantiomer

Cat. No.: HY-15853A

MK-7246 S enantiomer is the less active enantiomer of MK-7246. MK-7246 is a potent and selective CRTH2 antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-8318

Cat. No.: HY-112604

MK-8318 is a potent and selective **CRTh2 receptor** antagonist with a K_i of 5.0 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-8617

Cat. No.: HY-101023

MK-8617 is an orally active pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1-3 (**HIF PHD1-3**) with an **IC_{50}** of 1 nM for **PHD2**.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

MK2-IN-1 hydrochloride

Cat. No.: HY-12834A

MK2-IN-1 hydrochloride is a potent and selecitve MAPKAPK2(MK2) inhibitor(IC50=0.11 uM) with a non-ATP competitive binding mode.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK2-IN-3

Cat. No.: HY-131249

MK2-IN-3 is a potent and selective inhibitor of **MAPKAP-K2 (MK-2)**, with an **IC_{50}** of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC_{50}s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC_{50}s>200 μM).



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK2-IN-3 hydrate

Cat. No.: HY-112457

MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive **MAPKAP-K2 (MK-2)** inhibitor with an **IC_{50}** of 0.85 nM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML 145

Cat. No.: HY-107536

ML 145 is a selective and competitive human **GPR35/CXCR8** antagonist with an **IC_{50}/EC_{50}** of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC_{50}/EC_{50}=21.7 μM). ML 145 has no significant activity for GPR35 at either rodent ortholog.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML-030

Cat. No.: HY-103050

ML-030 is a potent **PDE4** inhibitor, with **IC_{50}** of 6.7 nM, 12.9 nM, 48.2 nM, 37.2 nM, 452 nM and 49.2 nM for PDE4A, PDE4A1, PDE4B1, PDE4B2, PDE4C1,and PDE4D2, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML355

Cat. No.: HY-12341

ML355 is a potent and selective inhibitor of **12-Lipoxygenase (12-LOX)** with an **IC_{50}** of 0.34 μM, shows excellent selectivity over related lipoxygenases and cyclooxygenases, and possesses favorable ADME properties.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML401

Cat. No.: HY-116814

ML401, a potent chemical probe, selectively antagonizes **EBI2** (also known as **GPR183**) with an **IC_{50}** of 1.03 nM. ML401 displays activity in a chemotaxis assay (IC_{50}=6.24 nM). ML401 shows good stability and no toxicity.



Purity: 99.87%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML604086

Cat. No.: HY-124416

ML604086 is a selective **CCR8** inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca^{2+} concentrations.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML604440

Cat. No.: HY-114170

ML604440 is a potent, specific and cell permeable proteasome β1i (**LMP2**) subunit inhibitor. ML604440 impairs MHC class I cell surface expression, IL-6 secretion and differentiation of naïve T helper cells to T helper 17 cells.



Purity: 99.67%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

MLKL-IN-1

Cat. No.: HY-139878

MLKL-IN-1 is a covalent **MLKL** inhibitor with a K_D of 50 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MLKL-IN-2

Cat. No.: HY-141889

MLKL-IN-2 is a **MLKL** inhibitor extracted from patent WO2021224505A1, compound (i).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MLN120B dihydrochloride

(ML120B dihydrochloride)

Cat. No.: HY-15473A

MLN120B dihydrochloride (ML120B dihydrochloride) is a potent, ATP competitive, and orally active inhibitor of **IKKβ** with an IC_{50} of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MLS-573151

(MLS000573151)

Cat. No.: HY-113849

MLS-573151 (MLS000573151) is a selective GTPase **Cdc42** inhibitor with an EC_{50} of 2 μM. MLS-573151 is inactive against other GTPases family members, such as Rab2, Rab7, H-Ras, Rac1, Rac 2 and RhoA wild-type. MLS-573151 acts by blocking the binding of GTP to Cdc42.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MLT-747

Cat. No.: HY-124587

MLT-747 is a potent, selective, allosteric inhibitor of **MALT1**, binds MALT1 in the allosteric Trp580 pocket, with an IC_{50} of 14 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MLT-748

Cat. No.: HY-115466

MLT-748 is a potent, selective and allosteric inhibitor of **MALT1**, binds MALT1 in the allosteric Trp580 pocket, with an IC_{50} of 5 nM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MLT-943

Cat. No.: HY-134820

MLT-943 is a potent, selective and orally active **MALT1 protease** inhibitor. MLT-943 inhibits stimulated-IL-2 secretion in PBMC or in whole blood with a similar IC_{50} across species (0.07-0.09 μM in PBMC, 0.6-0.8 μM in whole blood).



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MMG-11

Cat. No.: HY-112146

MMG-11 is a potent and selective human **TLR2** antagonist with low cytotoxicity. MMG-11 inhibits both TLR2/1 and TLR2/6 signaling with IC_{50}s of 1.7 μM for Pam_3CSK_4-induced hTLR2/1 and 5.7 μM for Pam_2CSK_4-induced hTLR2/6 responses.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

MMG-11 quarterhydrate

Cat. No.: HY-112146A

MMG-11 quarterhydrate is a potent and selective human **TLR2** antagonist with low cytotoxicity. MMG-11 quarterhydrate inhibits both TLR2/1 and TLR2/6 signaling with IC_{50}s of 1.7 μM for Pam_3CSK_4-induced hTLR2/1 and 5.7 μM for Pam_2CSK_4-induced hTLR2/6 responses.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mg

MMP13-IN-2

Cat. No.: HY-122624

MMP13-IN-2 is a potent, selective and orally active **MMP-13** inhibitor. MMP13-IN-2 exhibits excellent potency for MMP-13 (IC_{50}=0.036 nM) and selectivities (greater than 1,500-fold) over MMP-1, 3, 7, 8, 9, 14, and TACE.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MMP13-IN-3

Cat. No.: HY-124029

MMP13-IN-3 is a potent, selective, and orally active **MMP-13** inhibitor (IC_{50}=1 nM) for the potential treatment of osteoarthritis. MMP13-IN-3 is >1000 selective over other MMPs.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

MNK1/2-IN-5

Cat. No.: HY-139684

MNK1/2-IN-5 is a potent and selective **MNK1/2** inhibitor as a therapeutic agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MnTBAP chloride

Cat. No.: HY-126397

MnTBAP chloride is a superoxide dismutase (SOD) mimetic and peroxynitrite scavenger. MnTBAP chloride is a manganic porphyrin complex and has anti-oxidative property.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg

Mocravimod hydrochloride

(KRP-203)

Cat. No.: HY-13660

Mocravimod hydrochloride (KRP-203), an immunosuppressant, is a potent and orally active **S1PR1 (sphingosine 1-phosphate receptor type 1)** agonist.



Purity: 98.27%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Modipafant

(UK-80067)

Cat. No.: HY-108908A

Modipafant (UK-80067), the (+)-enantiomer of UK-74505, is a potent, orally active, and selective platelet-activating factor **(PAF)** antagonist. Modipafant exhibits approximately double the intrinsic potency of UK-74505.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mofezolac

Cat. No.: HY-120824

Mofezolac, a non-steroidal anti-inflammatory drug (NSAID), is a selective, reversible and orally active **COX-1** inhibitor with an IC_{50} of 1.44 nM. Mofezolac shows weak inhibitory activity on COX-2 (IC_{50} of 447 nM). Mofezolac can relieve pain and has anti-inflammatory activities.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mogroside II-A

Cat. No.: HY-N6915

Mogroside II-A is a natural product isolated from Siraitia grosvenorii.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Mometasone furoate

(Sch32088)

Cat. No.: HY-13693

Mometasone furoate (Sch32088) is a **glucocorticoid receptor** agonist with anti-inflammatory and anti-allergic activity.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Mometasone furoate-d3

(Sch32088-d3)

Cat. No.: HY-13693S

Mometasone furoate-d3 (Sch32088-d3) is a deuterium labeled Mometasone furoate. Mometasone furoate (Sch32088) is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Monascin

Cat. No.: HY-N6641

Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice). Monascin also exhibits anti-tumor-initiating activity and anti-inflammatory activity with oral administration.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg

Monobenzone

Cat. No.: HY-30272

Monobenzone is a potent skin depigmenting agent. Monobenzone induces depigmentation and active human vitiligo and exhibits good potential for vitiligo research.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Monocaprylin

(Glyceryl monocaprylate; Sefsol 318)

Cat. No.: HY-138650

Monocaprylin (Glyceryl monocaprylate), a monoglyceride of caprylic acid, exhibits an excellent **antibacterial** activity. Monocaprylin inhibits a variety of foodborne pathogenic and spoilage microorganisms and has the potential for an alternative food preservative research.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg

Monomelittoside

(Danmelittoside)

Cat. No.: HY-N0916

Monomelittoside is a natural compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Monomethyl fumarate

Cat. No.: HY-103252

Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease.



Purity: 97.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Monophosphoryl lipid A

(Glucopyranosyl lipid A)

Cat. No.: HY-130320

Monophosphoryl lipid A (Glucopyranosyl lipid A) is a **toll-like receptor 4** agonist. Monophosphoryl lipid A is derived from the cell wall of nonpathogenic Salmonella. Monophosphoryl lipid A can be used for the research of immunization and vaccine.



Purity: >98%
Clinical Data: Launched
Size: 5 mg

Monotropein

Cat. No.: HY-N0648

Monotropein is an iridoid glycoside isolated Morinda officinalis. Monotropein inhibits the expression of inflammatory mediators in dextran sulfate sodium (DSS)-induced colitis mouse model.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Montelukast

(MK0476 free base)

Cat. No.: HY-13315A

Montelukast is a potent, selective and orally active antagonist of **cysteinyl leukotriene receptor 1 (CysLT$_1$)**. Montelukast can be used for the reseach of asthma and liver injury.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Montelukast sodium

(MK0476)

Cat. No.: HY-13315

Montelukast sodium is a potent, selective and orally active antagonist of **cysteinyl leukotriene receptor 1 (Cysltr1)**. Montelukast sodium can be used for the reseach of asthma and liver injury.



Purity: 99.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Montelukast-d6

(MK0476-d6 free acid)

Cat. No.: HY-13315S

Montelukast-d6 (MK0476-d6 free acid) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of **cysteinyl leukotriene receptor 1 (Cysltr1)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Montelukast-d6 sodium

(MK0476-d6)

Cat. No.: HY-13315S1

Montelukast-d6 sodium (MK0476-d6) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of **cysteinyl leukotriene receptor 1 (Cysltr1)**. Montelukast sodium can be used for the reseach of asthma and liver injury.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Moracin M

Cat. No.: HY-122942

Moracin M, a phenolic component in the skin of Morus alba L., is a potent **phosphodiesterase-4 (PDE4)** inhibitor with IC_{50} values of 2.9, 4.5, >40, and >100 μM for PDE4D2, PDE4B2, PDE5A1, and PDE9A2, respectively. Moracin M has anti-inflammatory activity.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Moracin O

Cat. No.: HY-N3244

Moracin O is a 2-arylbenzofuran isolated from the Mori Cortex Radicis. Moracin O exhibits potent in vitro inhibitory activity against **hypoxia-inducible factor (HIF-1)**. Moracin O reduces oxygen-glucose deprivation (OGD)-induced **reactive oxygen species (ROS)** production.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Moracin P

Cat. No.: HY-N3243

Moracin P is a 2-arylbenzofuran isolated from the Mori Cortex Radicis. Moracin P exhibits potent in vitro inhibitory activity against **hypoxia-inducible factor (HIF-1)**. Moracin P reduces oxygen-glucose deprivation (OGD)-induced **reactive oxygen species (ROS)** production.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Morellic acid

Cat. No.: HY-N4094

Morellic acid is isolated from Garcinia Morella with an antiangiogenic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Morin monohydrate

Cat. No.: HY-N0151

Morin monohydrate, a plant-derived flavonoid, possesses low antioxidant activity. Morin is a fluorescing chelating agent used in aluminum speciation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Morusin

(Mulberrochromene)

Cat. No.: HY-N0622

Morusin is a prenylated flavonoid isolated from M. australis with various biological activities, such as antitumor, antioxidant, and anti-bacteria property. Morusin could inhibit **NF-κB** and **STAT3** activity.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Moslosooflavone

Cat. No.: HY-N2035

Moslosooflavone is a flavonoid isolated from Saussurea involucrata. Moslosooflavone has an anti-hypoxia and anti-inflammatory activities.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Moth Cytochrome C (MCC) (88-103)

Cat. No.: HY-P1735

Moth Cytochrome C (MCC) (88-103), derived from the carboxyl terminus of moth cytochrome c, induces positive selection of TCR transgenic thymocytes.

ANERADLIAYLKQATK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

mPGES1-IN-3

Cat. No.: HY-100864

mPGES1-IN-3 (Compound 17d) is a potent and selective microsomal prostaglandin E2 synthase-1 (**mPGES-1**) inhibitor, which exhibits excellent mPGES-1 enzyme (IC_{50}: 8 nM), cell (A549 IC_{50}: 16.24 nM) and human whole blood potency (IC_{50}: 249.9 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MPO-IN-1

Cat. No.: HY-139915

MPO-IN-1 is a potent, orally active, and irreversible indole-containing inhibitor of myeloperoxidase (**MPO**). MPO-IN-1 has IC_{50}s of 2.6 μM and 5.3 μM for MPO and thyroid peroxidase (TPO), respectively. MPO-IN-1 inhibits **MPO** activity in an acute mouse model of inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MreB Perturbing Compound A22 hydrochloride

(A22 hydrochloride)

Cat. No.: HY-118773

MreB Perturbing Compound A22 hydrochloride is a benzylisothiourea compound that interacts with the ATP binding site of MreB rapidly and reversibly.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MrgprX2 antagonist-1

Cat. No.: HY-145191

MrgprX2 antagonist-1 is an **MrgprX2** antagonist extracted from patent WO2021092264A1, example E23. MrgprX2 antagonist-1 can be used for the research of inflammatory disorders of the skin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MrgprX2 antagonist-2

Cat. No.: HY-145192

MrgprX2 antagonist-2 is an **MrgprX2** antagonist extracted from patent WO2021092262A1, example E163. MrgprX2 antagonist-2 can be used for the research of inflammatory disorders of the skin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MrgprX2 antagonist-3

Cat. No.: HY-145193

MrgprX2 antagonist-3 is an **MrgprX2** antagonist extracted from patent WO2021092240A1, example E117. MrgprX2 antagonist-3 can be used for the research of inflammatory disorders of the skin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MrgprX2 antagonist-4

Cat. No.: HY-145194

MrgprX2 antagonist-4 is an **MrgprX2** antagonist extracted from patent US20210128561A1, compound B-51 E117. MrgprX2 antagonist-4 can be used for the research of inflammatory disorders of the skin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MrgprX2 antagonist-5

Cat. No.: HY-145195

MrgprX2 antagonist-5 is an **MrgprX2** antagonist extracted from patent WO2020223255A1, example 16. MrgprX2 antagonist-5 can be used for the research of inflammatory disorders of the skin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MRS 1523

Cat. No.: HY-121119

MRS 1523 is a potent and selective **adenosine A_3 receptor** antagonist with K_i values of 18.9 nM and 113 nM for **human** and **rat A_3 receptors**, respectively. In rat this corresponds to selectivities of 140- and 18-fold vs A_1 and A_{2A} receptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MRS 1754

Cat. No.: HY-14121

MRS 1754 is a selective antagonist radioligand for **A_{2B} adenosine receptor** with very low affinity for A_1 and A_3 receptors of both humans and rats.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

MRS-1706

Cat. No.: HY-103186

MRS-1706 is a potent and selective **adenosine A_{2B} receptor** inverse agonist. MRS-1706 has K_i values of 1.39, 112, 157, and 230 nM for human A_{2B}, A_{2A}, A_1 and A_3 receptors respectively.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MRS1177

Cat. No.: HY-120090

MRS1177 is a potent and selective human Adenosine A3 receptor (**hA_3AR**) antagonist, with a **K_i** of 0.3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MRS1186

Cat. No.: HY-118678

MRS1186 is a potent and selective human Adenosine A3 receptor (**hA_3AR**) antagonist, with a **K_i** of 7.66 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MRS2698

Cat. No.: HY-111075

MRS2698 is a potent and highly selective **P2Y2 receptor** agonist with an **EC_{50}** of 8 nM. MRS2698 is >300-fold **P2Y2**-selective versus the P2Y4 and P2Y6 receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MRT67307

Cat. No.: HY-13018

MRT67307 is a dual inhibitor of the **IKKε** and **TBK-1** with **IC_{50}**s of 160 and 19 nM, respectively. MRT67307 also inhibits **ULK1** and **ULK2** with **IC_{50}**s of 45 and 38 nM, respectively. MRT67307 also blocks **autophagy** in cells.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MRT67307 hydrochloride

Cat. No.: HY-13018A

MRT67307 hydrochloride is a dual inhibitor of the **IKKε** and **TBK-1** with **IC_{50}**s of 160 and 19 nM, respectively. MRT67307 hydrochloride also inhibits **ULK1** and **ULK2** with **IC_{50}**s of 45 and 38 nM, respectively. MRT67307 hydrochloride also blocks **autophagy** in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MS402

Cat. No.: HY-120000

MS402 is a **BD1**-selective **BET BrD** inhibitor with **K_i**s of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for **BRD4(BD1)**, **BRD4(BD2)**, **BRD3(BD1)**, **BRD3(BD2)**, **BRD2(BD1)** and **BRD2(BD2)**, respectively. MS402 blocks Th17 cell differentiation and ameliorates colitis in mice.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MS417

(GTPL7512)

Cat. No.: HY-111139

MS417 is a selective BET-specific **BRD4** inhibitor, binds to BRD4-BD1 and BRD4-BD2 with **IC_{50}**s of 30, 46 nM and **K_d**s of 36.1, 25.4 nM, respectively, with weak selectivity at CBP BRD (**IC_{50}**, 32.7 μM).



Purity: 99.51%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

MSA-2

Cat. No.: HY-136927

MSA-2, a potent and orally available non-nucleotide **STING** agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows **EC_{50}**s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MSA-2 dimer

Cat. No.: HY-141514

MSA-2 dimer is a selective, orally active non-nucleotide **STING** agonist (**K_d**=145 μM) with long-term antitumor and immunogenic activity. MSA-2 dimer is bound to **STING** as a non-covalent dimer exhibiting higher permeability than cyclic dinucleotide.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MSC2360844

Cat. No.: HY-135827

MSC2360844 is a potent, orally active and selective **PI3Kδ** inhibitor, with an **IC_{50}** of 145 nM. MSC2360844 shows highly selective against a panel of 278 additional kinases.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MSC2360844 hemifumarate

Cat. No.: HY-135827A

MSC2360844 hemifumarate is a potent, orally active and selective **PI3Kδ** inhibitor, with an IC_{50} of 145 nM. MSC2360844 hemifumarate shows highly selective against a panel of 278 additional kinases.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MSX-122

Cat. No.: HY-13696

MSX-122 is an orally active partial antagonist of **CXCR4**, inhibiting **CXCR4/CXCL12** actions, with an IC_{50} of 10 nM. MSX-122 has anti-inflammatory and anti-metastatic activity.



Purity: 98.29%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MT-802

Cat. No.: HY-122562

MT-802 is a potent **BTK** degrader based on **Cereblon** ligand, with a DC_{50} of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia (CLL).



Purity: 98.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MTL-CEBPA

Cat. No.: HY-132607

MTL-CEPBA is a small activating RNA targeting for upregulation of **C/EBPα**. MTL-CEPBA has anti-inflammatory and anti-cancer activity.

MTL-CEBPA

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MTPPA

(M 5011)

Cat. No.: HY-101670

MTPPA is a drug for treating symptoms of inflammation and pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MUC5AC motif peptide

Cat. No.: HY-P0280

MUC5AC motif peptide is a 16-amino acid fragment of mucin 5.

GTTPSPVPTTSTTSAP

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Mulberrofuran Q

Cat. No.: HY-N5031

Mulberrofuran Q inhibits the formation of 12-hydroxy-5,8,10-heptadecatrienoic acid (HHT) and thromboxane B2 (cyclooxygenase products).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mulberroside A

Cat. No.: HY-N0619

Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.).



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Mupirocin calcium hydrate

Cat. No.: HY-N7068

Mupirocin calcium hydrate is an orally active antibiotic isolated from Pseudomonas fluorescens. Mupirocin calcium hydrate apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Muramyl dipeptide

(MDP)

Cat. No.: HY-127090

Muramyl dipeptide (MDP) is a synthetic **immunoreactive peptide**, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. Muramyl dipeptide is an inducer of **bone formation** through induction of **Runx2**.



Purity: ≥98.0%
Clinical Data: Phase 4
Size: 1 mg, 5 mg, 10 mg, 25 mg

Muscone

Cat. No.: HY-N0633

Muscone is the main active monomer of traditional Chinese medicine musk. Muscone inhibits **NF-κB** and **NLRP3** inflammasome activation. Muscone remarkably decreases the levels of inflammatory cytokines (**IL-1β**, **TNF-α** and **IL-6**), and ultimately improves cardiac function and survival rate.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

MW-150

(MW01-18-150SRM)

Cat. No.: HY-120111

MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of **p38α MAPK** with a K_i of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MW-150 dihydrochloride dihydrate

(MW01-18-150SRM dihydrochloride dihydrate)

Cat. No.: HY-120111B

MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) is a selective, CNS penetrant, and orally active inhibitor of **p38α MAPK** with a K_i of 101 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MW-150 hydrochloride

(MW01-18-150SRM hydrochloride)

Cat. No.: HY-120111A

MW-150 hydrochloride (MW01-18-150SRM hydrochloride) is a selective, CNS penetrant, and orally active inhibitor of **p38α MAPK** with a K_i of 101 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MY-5445

Cat. No.: HY-100933

MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, **phosphodiesterase type 5 (PDE5)**, with a K_i of 1.3 μM. MY-5445 inhibits human platelet aggregation.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

MYCi975

(NUCC-0200975)

Cat. No.: HY-129601

MYCi975 (NUCC-0200975) is an orally active **MYC** inhibitor, which disrupts MYC/MAX interaction, promotes MYC T58 phosphorylation and MYC degradation, and impairs MYC driven gene expression.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Mycophenolic acid

(Mycophenolate)

Cat. No.: HY-B0421

Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (**IMPDH**) inhibitor with an EC_{50} of 0.24 μM. Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including **influenza**.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Mycophenolic acid 13C,D3

(Mycophenolate 13C,D3)

Cat. No.: HY-B0421S1

Mycophenolic acid 13C,D3 (Mycophenolate 13C,D3) is deuterium labeled Mycophenolic acid 13C. Mycophenolic acid is an an immunosuppresant drug and has potent anti-proliferative activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Myelin Basic Protein (MBP) (68-82), guinea pig

Cat. No.: HY-P1048

Myelin Basic Protein (MBP) (68-82), guinea pig is a fragment of myelin basic protein (MBP).

YGSLPQKSQRSQDEN

Purity: 97.51%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Myelin Basic Protein(87-99)

Cat. No.: HY-P1052

Myelin Basic Protein(87-99) is an encephalitogenic peptide that induces basic protein-specific T cell proliferation. Myelin Basic Protein(87-99) causes a Th1 polarization in peripheral blood mononuclear cells with is implicated of multiple sclerosis (MS).

VHFFKNIVTPRTP

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Myelin Basic Protein(87-99) TFA

Cat. No.: HY-P1052A

Myelin Basic Protein(87-99) TFA is an encephalitogenic peptide that induces basic protein-specific T cell proliferation. Myelin Basic Protein(87-99) TFA causes a Th1 polarization in peripheral blood mononuclear cells with is implicated of multiple sclerosis (MS).

VHFFKNIVTPRTP (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55))

Cat. No.: HY-P1240

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination.

MEVGWYRSPFSRVVHLYRNGK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate (MOG (35-55) (acetate))

Cat. No.: HY-P1240B

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination.

MEVGWYRSPFSRVVHLYRNGK (acetate salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Myoseverin

Cat. No.: HY-W008956

Myoseverina, a microtubule-binding molecule, induces the reversible fission of multinucleated myotubes into mononucleated fragments.



Purity: 99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Myosin H Chain Fragment, mouse

Cat. No.: HY-P2464

Myosin H Chain Fragment, mouse is a fragment of the α-Myosin heavy chain peptide. Myosin H Chain Fragment can be used to induce experimental autoimmune myocarditis (EAM) mouse model.

Ac-RSLKLMATLFSTYASADR

Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Myrislignan

Cat. No.: HY-N0608

Myrislignan, a lignan isolated from Myristica fragrans Houtt, possesses anti-inflammatory activities. Myrislignan attenuates LPS-induced inflammation reaction in murine macrophage cells through inhibition of NF-kB signalling pathway activation.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

Myristoleic acid

Cat. No.: HY-113332

Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

M89

Cat. No.: HY-128347

M-89 is a highly potent and specific **menin** inhibitor, with a K_d of 1.4 nM for binding to menin. M-89 inhibits the **menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction** and has potential to treat MLL leukemia.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

N,N'-Dimethylthiourea (DMTU)

Cat. No.: HY-W027951

N,N'-Dimethylthiourea (DMTU), isolated from Allii Sativi Bulbus, is an orally active scavenger of hydroxyl radical (•OH) and blocks •OH production by activated neutrophils in vitro.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

N-(p-Coumaroyl) Serotonin

Cat. No.: HY-129440

N-(p-Coumaroyl) Serotonin is a polyphenol isolated from the seeds of safflower and has antioxidative, anti-atherogenic and anti-inflammatory properties. N-(p-Coumaroyl) Serotonin inhibits PDGF-induced on **phosphorylation of PDGF receptor** and Ca^{2+} release from sarcoplasmic reticulum.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 5 mg

N-5984

(KRP-204)

Cat. No.: HY-117378

N-5984 is a potent and selective agonist of β3-adrenergic receptor. N-5984 has the potential for developing as one of the clinically effective drugs for obesity and diabetes mellitus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-acetyl Dapsone (D4')

(MADDS D4')

Cat. No.: HY-G0016S1

N-acetyl Dapsone (D4') is the deuterium labeled N-acetyl Dapsone, which is a metabolite of Dapsone.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Acetyl sulfapyridine-d4

Cat. No.: HY-W011471S



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

N-Acetyl-Ser-Asp-Lys-Pro

(Ac-SDKP)

Cat. No.: HY-P0266

N-Acetyl-Ser-Asp-Lys-Pro, an endogenous tetrapeptide secreted by bone marrow, is a specific substrate for the N-terminal site of **ACE**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Acetyl-Ser-Asp-Lys-Pro acetate

(Ac-SDKP acetate)

Cat. No.: HY-P0266B

N-Acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) acetate is a specific substrate for the N-terminal active site of angiotensin-converting enzyme (ACE). N-Acetyl-Ser-Asp-Lys-Pro acetate is a natural inhibitor of pluripotent hematopoietic stem cell proliferation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

N-Acetyl-Ser-Asp-Lys-Pro TFA

(Ac-SDKP TFA)

Cat. No.: HY-P0266A

N-Acetyl-Ser-Asp-Lys-Pro (TFA), an endogenous tetrapeptide secreted by bone marrow, is a specific substrate for the N-terminal site of **ACE**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

N-Acetylcarnosine

(N-Acetyl-L-carnosine)

Cat. No.: HY-133026

N-Acetylcarnosine, a natural histidine-containing dipeptide, is a source of pharmacological principal L-carnosine. N-Acetylcarnosine is a potent ophthalmic drug in human cataracts.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

N-Acetylcysteine amide

Cat. No.: HY-110256

N-Acetylcysteine amide is a cell membranes and blood brain barrier permeant thiol antioxidant and neuroprotective agent, reduces **ROS** production.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Acetylhistamine

(N-Omega-acetylhistamine)

Cat. No.: HY-112175

N-Acetylhistamine is a histamine metabolite. N-acetylhistamine can be used as a potential biomarker of histidine metabolism for anaphylactoid reactions.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

N-Acetylpsychosine

(C2 Galactosylceramide (d18:1/2:0))

Cat. No.: HY-131992

N-Acetylpsychosine (C2 Galactosylceramide (d18:1/2:0)), α-galactosylated C2-ceramide, has immunostimulatory activity. N-Acetylpsychosine can be a useful tool to investigate the mechanism of apoptosis and the immune reponses induced by dendritic cells (DCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Arachidonylglycine

(NA-Gly)

Cat. No.: HY-103332

N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a **GPR18** agonist (EC_{50} = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits **GLYT2** (IC_{50} = 5.1 μM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

N-Boc-piperazine-C3-COOH

Cat. No.: HY-131184

N-Boc-piperazine-C3-COOH is a PROTAC linker, which refers to the alkyl/ether composition. Boc-N-piperazine-C3-COOH can be used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Butanoyl-DL-homoserine lactone

((Rac)-C4-HSL)

Cat. No.: HY-113764

N-Butanoyl-DL-homoserine lactone ((Rac)-C4-HSL) is a racemic mixture of N-Butanoyl-D-homoserine lactone and N-Butanoyl-L-homoserine lactone. N-Butanoyl-L-homoserine lactone is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Butanoyl-L-homoserine lactone

(C4-HSL; N-Butyryl-L-homoserine lactone)

Cat. No.: HY-114816

N-Butanoyl-L-homoserine lactone (C4-HSL) is a cleavable **ADC linker** used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has **antibacterial** activity and is used in antibacterial biofilm.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

N-Demethyl-α-obscurine

Cat. No.: HY-N7785

N-Demethyl-α-obscurine, a lycodine-type Lycopodium alkaloid, is isolated from Lycopodii Herba.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

N-Desmethyl diphenhydramine-d3 hydrochloride

Cat. No.: HY-139519S



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

N-Formyl-Met-Ala-Ser

Cat. No.: HY-P1756

N-Formyl-Met-Ala-Ser is a peptide, binds to **formyl peptide receptors** on neutrophils.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Formyl-Met-Leu-Phe

(fMLP; N-Formyl-MLF)

Cat. No.: HY-P0224

N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR). N-Formyl-Met-Leu-Ph is reported to inhibit **TNF-alpha** secretion.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

N-Formyl-Met-Leu-Phe-Lys

(fMLFK)

Cat. No.: HY-P1744

N-Formyl-Met-Leu-Phe-Lys (fMLFK) is a peptide, acts as a potent and selective agonist of **FPR1**, with EC_{50}s of 3.5 nM, 6.7 μM and 0.88 μM for FPR1, FPR2 and FPR2-D281$^{7.32}$G, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys

(For-Nle-Leu-Phe-Nle-Tyr-Lys-OH)

Cat. No.: HY-P1591

N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys TFA (For-Nle-Leu-Phe-Nle-Tyr-Lys-OH TFA) is a **formyl peptide receptor (FPR)** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys TFA

(For-Nle-Leu-Phe-Nle-Tyr-Lys-OH TFA) Cat. No.: HY-P1591A

N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys TFA (For-Nle-Leu-Phe-Nle-Tyr-Lys-OH TFA) is a **formyl peptide receptor (FPR)** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Glycolylneuraminic acid

(NeuGc; GcNeu) Cat. No.: HY-128965

N-Glycolylneuraminic acid is a nonhuman sialic acid molecule synthesized in pigs but not in humans. N-Glycolylneuraminic acid works as a decoy receptor of N-Glycolylneuraminic acid-binding **influenza A viruses (IAVs)**.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

N-Hydroxypipecolic acid

(1-Hydroxy-2-piperidinecarboxylic acid; NHP) Cat. No.: HY-N7378

N-Hydroxypipecolic acid (1-Hydroxy-2-piperidinecarboxylic acid), a plant metabolite and a systemic acquired resistance (SAR) regulator, orchestrates SAR establishment in concert with the immune signal salicylic acid.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg, 250 mg

N-Hydroxypipecolic acid potassium

(1-Hydroxy-2-piperidinecarboxylic acid potassium; ...) Cat. No.: HY-N7378A

N-Hydroxypipecolic acid potassium (1-Hydroxy-2-piperidinecarboxylic acid potassium), a plant metabolite and a systemic acquired resistance (SAR) regulator, orchestrates SAR establishment in concert with the immune signal salicylic acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Methylcytisine

(Caulophylline) Cat. No.: HY-N0443

N-Methylcytisine (Caulophylline), a tricyclic quinolizidine alkaloid, exerts hypoglycaemic, analgesic and anti-inflammatory activities.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

N-tert-Butyl-α-phenylnitrone

Cat. No.: HY-128463

N-tert-Butyl-α-phenylnitrone is a nitrone-based free radical scavenger that forms nitroxide spin adducts. N-tert-Butyl-α-phenylnitrone inhibits **COX2** catalytic activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg

N-trans-Feruloyltyramine

(N-feruloyltyramine; Moupinamide) Cat. No.: HY-N2410

N-trans-Feruloyltyramine (N-feruloyltyramine), an alkaloid from Piper nigru, is an inhibitor of **COX1** and **COX2**, with potential antioxidant properties. N-trans-Feruloyltyramine possesses anti-inflammatory activity.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

N1-Methylpseudouridine

(1-Methylpseudouridine) Cat. No.: HY-112582

N1-methyl-pseudouridine (1-Methylpseudouridine), a methylpseudouridine, outperforms 5 mC and 5 mC/N1-methyl-pseudouridine in translation.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

N3-PEG3-CH2CH2COOH

Cat. No.: HY-42490

N3-PEG3-CH2CH2COOH a PEG-based **PROTAC** linker can be used in the synthesis of BI-3663 (HY-111546), BI-4216 and BI-0319. Azido-PEG3-acid is also a non-cleavable 3 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N6,N6-Dimethyladenosine

Cat. No.: HY-101984

N6,N6-Dimethyladenosine is a modified ribonucleoside previously found in rRNA, and also exhibits in mycobacterium bovis Bacille Calmette-Guérin tRNA.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

N6-(2-Phenylethyl)adenosine

(N6-Phenethyladenosine; N6-Phenylethyladenosine)

Cat. No.: HY-101854



N6-(2-Phenylethyl)adenosine (N6-Phenethyladenosine), an adenosine derivative, is a potent **adenosine receptors (AR)** agonist with K_i values of 11.8 nM, 30.1 nM, 0.63 nM for rat A_1AR, human A_1AR and hA_3AR, respectively.

Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

N6-Etheno 2'-deoxyadenosine

Cat. No.: HY-111646



N6-Etheno 2'-deoxyadenosine is a reactive oxygen species (ROS)/reactive nitrogen species (RNS)-induced DNA oxidation product, used as a biomarker to evaluate chronic inflammation and lipid peroxidation in animal or human tissues.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

N6022

Cat. No.: HY-14984



N6022 is a potent, selective, reversible, and efficacious **S-Nitrosoglutathione reductase(GSNOR)** inhibitor with IC_{50} of 8 nM.

Purity: 99.89%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nabumetone

(BRL14777)

Cat. No.: HY-B0559



Nabumetone is an orally active non-acidic anti-inflammatory agent, acts as a potent and selective **COX-2** inhibitor, and is the prodrug of the active metabolite 6MNA.

Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Nafocare B1

(Methylfurylbutyrolactone)

Cat. No.: HY-100241



Nafocare B1 is a synthetic immune biological response modifier.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Naminterol

Cat. No.: HY-101822



Naminterol is a phenethanolamine derivative, is a **β_2 adrenoceptor** agonist with bronchodilatory properties. Naminterol is used for treatment of asthma.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Naproxen

((S)-Naproxen)

Cat. No.: HY-15030



Naproxen is a **COX-1** and **COX-2** inhibitor with IC_{50}s of 8.72 and 5.15 μM, respectively in cell assay.

Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Naproxen etemesil

(LT-NS 001; MX 1094)

Cat. No.: HY-19675



Naproxen etemesil is a lipophilic, non-acidic, inactive prodrug of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a **COX-1** and **COX-2** inhibitor with IC_{50}s of 8.72 and 5.15 μM, respectively in cell assay.

Purity: 99.89%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Naproxen sodium

Cat. No.: HY-15030A



Naproxen sodium is a **COX-1** and **COX-2** inhibitor with IC_{50}s of 8.72 and 5.15 μM, respectively in cell assay.

Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Naringenin

Cat. No.: HY-N0100



Naringenin is the predominant flavanone in grapefruit; displays strong anti-inflammatory and antioxidant activities. Naringenin has anti-**dengue virus (DENV)** activity.

Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

Naringenin chalcone

Cat. No.: HY-N3007

Naringenin chalcone is an intermediate in flavonol biosynthesis and is spontaneously metabolized into naringenin (NAR) by chalcone isomerase. Naringenin chalcone has anti-inflammatory and antiallergic activities.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Naringin

(Naringoside)

Cat. No.: HY-N0153

Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits. Naringin exhibits biological properties such as antioxidant, anti-inflammatory, and antiapoptotic activities.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 200 mg, 10 g

Narirutin

Cat. No.: HY-N0804

Narirutin, one of the active constituents isolated from Citrus unshiu, has antioxidant and anti-inflammatory activities. Narirutin is a **shikimate kinase** inhibitor with anti-tubercular potency.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Nasunin

(Delphinidin-3-(p-coumaroylrutinoside)-5-glucoside)

Cat. No.: HY-N9396

Nasunin, an antioxidant anthocyanin, possesses antiangiogenic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Natalizumab

Cat. No.: HY-108831

Natalizumab is a recombinant, humanized monoclonal antibody, binds to α4β1-**integrin** and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.

Natalizumab

Purity: ≥99.10%
Clinical Data: Launched
Size: 10 mg, 25 mg

Nav1.7-IN-8

Cat. No.: HY-141547

Nav1.7-IN-8 is a potent blockage of **NaV1.7** with high selectivity for the inhibition of **NaV1.7** over the subtypes hNaV1.1 and hNaV1.5. Nav1.7-IN-8 inhibits **CYP2C9** and **CYP3A4** with an IC_{50} of 0.17 μM and 0.077 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Navafenterol

(AZD-8871; LAS191351)

Cat. No.: HY-120802

Navafenterol (AZD-8871) is an inhaled dual-acting, potent, selective, and long-lasting **M3**-antagonist/**β2**-agonist (MABA) with long-lasting effects and favorable safety profile.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Navafenterol saccharinate

(AZD-8871 saccharinate; LAS191351 saccharinate)

Cat. No.: HY-120802A

Navafenterol (AZD-8871) saccharinate is an inhaled dual-acting, potent, selective, and long-lasting **M3**-antagonist/**β2**-agonist (MABA) with long-lasting effects and favorable safety profile.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Navarixin

(SCH 527123; MK-7123)

Cat. No.: HY-10198

Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both **CXCR1** and **CXCR2**, with K_d values of 41 nM for **cynomolgus CXCR1** and 0.20 nM, 0.20 nM, 0.08 nM for **mouse**, **rat** and **cynomolgus monkey CXCR2**, respectively.



Purity: 99.13%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NB-360

Cat. No.: HY-124322

NB-360 is a potent, brain penetrable, and orally bioavailable dual **BACE1/BACE2** inhibitor (IC_{50}: mouse and human BACE1=5 nM; BACE2=6 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NBI-74330

Cat. No.: HY-15320

NBI-74330 is a potent antagonist for **CXCR3**, and exhibits potent inhibition of (^{125}I)CXCL10 and (^{125}I)CXCL11 specific binding with K_i of 1.5 and 3.2 nM, respectively.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NCX1022

Cat. No.: HY-U00187

NCX1022 is an NO-releasing derivative of Hydrocortisone, which is the most widely used anti-inflammatory drug for the treatment of skin inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NDMC101

Cat. No.: HY-124958

NDMC101 is a potent **osteoclastogenesis** inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via **DPP4** inhibition.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NDT 9513727

Cat. No.: HY-110060

NDT 9513727 is a potent, selective, orally active and competitive inverse agonist of the **human C5aR (C5a receptor)**, with an IC_{50} of 11.6 nM. NDT 9513727 can be used for the research of human inflammatory diseases.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mg

NE 52-QQ57

Cat. No.: HY-101784

NE 52-QQ57 is a selective, and orally available **GPR4** antagonist with an IC_{50} of 70 nM. NE 52-QQ57 has anti-inflammatory activity.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nebentan

(YM598 free base)

Cat. No.: HY-106994

Nebentan (YM598 free base) is a potent, selective and orally active non-peptide **endothelin ET_A receptor** antagonist through the modification of Bosentan (HY-A0013).



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Nebentan potassium

(YM598)

Cat. No.: HY-106994A

Nebentan potassium (YM598) is a potent, selective and orally active non-peptide **endothelin ET_A receptor** antagonist through the modification of Bosentan (HY-A0013).



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Nec-4

Cat. No.: HY-18900

Nec-4, a tricyclic derivative, is a potent receptor interacting protein 1 **(RIP1)** inhibitor, with an IC_{50} of 2.6 μM, K_i of 0.46 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Necrostatin-34

Cat. No.: HY-132203

Necrostatin-34 (Nec-34), a **RIPK1** kinase inhibitor, stabilizes RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NecroX-5

Cat. No.: HY-104015

NecroX-5 is a derivative of the NecroX, reduces intracellular **calcium** concentration, and possesses anti-inflammatory and anti-cancer activity.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Nedocromil

(FPL 59002) Cat. No.: HY-13448

Nedocromil suppresses the action or formation of multiple mediators, including **histamine**, **leukotriene C_4** (LTC_4), and **prostaglandin D_2** (PGD_2).



Purity: 98.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Nedocromil sodium

(FPL 59002KP; Nedocromil disodium salt) Cat. No.: HY-16344

Nedocromil sodium suppresses the action or formation of multiple mediators, including **histamine**, **leukotriene C_4** (LTC_4), and **prostaglandin D_2** (PGD_2).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neflamapimod

(VX-745) Cat. No.: HY-10328

Neflamapimod (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of **p38α** inhibitor with an **IC_{50}** for p38α of 10 nM and for p38β of 220 nM. Neflamapimod (VX-745) possesses anti-inflammatory activity.



Purity: 99.32%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg

Negletein

(5,6-Dihydroxy-7-methoxyflavone) Cat. No.: HY-N4285

Negletein is a neuroprotectant enhances the action of nerve growth factor and induces neurite outgrowth in PC12 cells. Negletein shows promising anti-inflammatory activity via inhibition of **TNF-α** and **IL-1β** with IC_{50} values of 16.4 and 10.8 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Neoandrographolide

(Neoandrographiside) Cat. No.: HY-N0721

Neoandrographolide is a diterpenoid from the Andrographis paniculata (Acanthaceae).



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Neochlorogenic acid

(trans-5-O-Caffeoylquinic acid) Cat. No.: HY-N0722

Neochlorogenic acid is a natural polyphenolic compound found in dried fruits and other plants. Neochlorogenic acid inhibits the production of **TNF-α** and **IL-1β**. Neochlorogenic acid suppresses **iNOS and COX-2** protein expression.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Neocryptotanshinone

Cat. No.: HY-119720

Neocryptotanshinone, a fatty diterpenoids from Salvia Miltiorrhiza, inhibits lipopolysaccharide-induced inflammation by suppression of NF-κB and iNOS signaling pathways.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Neodiosmin

Cat. No.: HY-N4122

Neodiosmin is a flavone glycoside isolated from the leaves of Citrus aurantium..



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Neohesperidin

(Hesperetin 7-O-neohesperidoside) Cat. No.: HY-N0101

Neohesperidin is a flavonoid compound found in high amounts in Poncirus trifoliata with anti-oxidant and anti-inflammatory effects.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g, 5 g

Neohesperidin dihydrochalcone

(Neohesperidin DC; NHDC) Cat. No.: HY-N0154

Neohesperidin dihydrochalcone is a synthetic glycoside chalcone, is added to various foods and beverages as a low caloric artificial sweetener.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Neoisoastilbin

Cat. No.: HY-N5116

Neoisoastilbin possesses antioxidant, anti-hyperuricemic and anti-Inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neoliquiritin

Cat. No.: HY-N2123

Neoliquiritin is isolated from Glycyrrhiza uralensis with an anti-inflammatory activity.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 5 mg

Neophytadiene

Cat. No.: HY-N8534

Neophytadiene is a diterpene found in Turbinaria ornate, with anti-inflammatory antioxidant and cardioprotective properties.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neopterin

(D-(+)-Neopterin; D-erythro-Neopterin)

Cat. No.: HY-W040055

Neopterin (D-(+)-Neopterin), a catabolic product of guanosine triphosphate (**GTM**), serves as a marker of cellular immune system activation.



Purity: 98.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Neotuberostemonine

Cat. No.: HY-N3196

Neotuberostemonine, one of the main antitussive alkaloids in the root of Stemona tuberosa Lour, attenuates bleomycin-induced pulmonary fibrosis by suppressing the recruitment and activation of macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NEP(1-40)

Cat. No.: HY-P1242

NEP(1-40) is a **Nogo-66 receptor (NgR)** antagonist peptide, reversing the injury-induced shift in distribution of microglia morphologies by limiting myelin-based inhibition.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NEP(1-40) TFA

Cat. No.: HY-P1242A

NEP(1-40) TFA is a **Nogo-66 receptor (NgR)** antagonist peptide, reversing the injury-induced shift in distribution of microglia morphologies by limiting myelin-based inhibition.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nepafenac

(AHR 9434; AL 6515)

Cat. No.: HY-17357

Nepafenac(AHR 9434; AL 6515; Nevanac) is a selective COX-2 inhibitor; is prodrug of Amfenac. IC50 value: Target: COX-2 Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in opthamology to control pain following cataract surgery.



Purity: 99.51%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 100 mg

Nepetin

(6-Methoxyluteolin)

Cat. No.: HY-N2572

Nepetin (6-Methoxyluteolin) is a natural flavonoid isolated from Eupatorium ballotaefolium HBK with potent anti-inflammatory activities. Nepetin inhibits **IL-6**, **IL-8** and **MCP-1** secretion with IC_{50} values of 4.43 μM, 3.42 μM and 4.17 μM, respectively in ARPE-19 cells.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Nepitrin

(Nepetin-7-glucoside)

Cat. No.: HY-N5010

Nepitrin, isolated from Scrophularia striata, possess significant anti-inflammatory and anti-arthritic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Neriifolin

(17β-Neriifolin)

Cat. No.: HY-N8441

Neriifolin, a CNS-penetrating cardiac glycoside, is an inhibitor of the Na^+, K^+-ATPase. Neriifolin can target beclin 1, inhibits the formation of LC3-associated phagosomes and ameliorates experimental autoimmune encephalomyelitis (EAE) development.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 5 mg

Netropsin dihydrochloride

Cat. No.: HY-N6800A

Netropsin (dihydrochloride) is a small-molecule MGB (minor-groove binder), inhibits the catalytic activity of isolated topoisomerase and interferes with the stabilization of the cleavable complexes of topoisomerase II and I in nuclei.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg

Neurokinin antagonist 1

Cat. No.: HY-U00320

Neurokinin antagonist 1 is a **Neurokinin** antagonist extracted from patent WO1998045262A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nevadensin

Cat. No.: HY-N1377

Nevadensin is a naturally occurring selective inhibitor of human carboxylesterase 1 **(hCE1)** with an IC_{50} of 2.64 μM. Nevadensin has a variety of pharmacological effects such as anti-mycobacterium tuberculosis activities, antitussive, anti-inflammatory and anti-hypertensive.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Nezulcitinib

(TD-0903)

Cat. No.: HY-132849

Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (**JAK**) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NF-56-EJ40

Cat. No.: HY-130246

NF-56-EJ40 is a potent, high-affinity, and highly selective **human SUCNR1 (GPR91)** antagonist with an IC_{50} of 25 nM and a K_i of 33 nM, and shows almost no activity towards rat **SUCNR1**. NF-56-EJ40 has high affinity for **humanized rat SUCNR1** with a K_i value of 17.4 nM.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NF-κB activator 1

Cat. No.: HY-134476

NF-κB activator 1 is a potent **NF-κB** activator with an EC_{50} of 0.9 μM. NF-κB activator 1 induces superoxide dismutase (SOD)2 mRNA expression.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NF157

Cat. No.: HY-108672

NF157 is a highly selective nanomolar **P2Y11** antagonist with a pK_i of 7.35. The IC_{50}s are 463 nM, 1811 μM, 170 μM for P2Y11 (K_i=44.3 nM), P2Y1 (K_i=187 μM), P2Y2 (K_i=28.9 μM), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NF546

Cat. No.: HY-108661

NF546 is a selective non-nucleotide **P2Y11** agonist with a pEC_{50} of 6.27. NF546 stimulates release of interleukin-8 from human monocyte-derived dendritic cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NFAT Inhibitor

(VIVIT peptide)

Cat. No.: HY-P1026

NFAT Inhibitor (VIVIT peptide) is a cell-permeable peptide inhibitor of **nuclear factor of activated Tcells (NFAT)** that selectively inhibits calcineurin-mediated dephosphorylation of **NFAT**.

MAGPHPVIVITGPHEE

Purity: 98.89%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

NFAT Transcription Factor Regulator-1

Cat. No.: HY-112778

NFAT Transcription Factor Regulator-1 is an **IL-2 synthesis** inhibitor with an IC_{50} of 182 nM.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NG25

Cat. No.: HY-15434

NG25 is a potent dual **TAK1** and **MAP4K2** inhibitor, with IC_{50}s of 149 nM and 21.7 nM, respectively.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

NI-57

Cat. No.: HY-19537

NI-57 is an inhibitor of bromodomain and plant homeodomain finger-containing (**BRPF**) famlily of proteins, with IC_{50}s of 3.1, 46 and 140 nM for BRPF1, BRPF2 (BRD1) and BRPF3, respectively.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Niazinin

Cat. No.: HY-N8471

Niazinin is a thiocarbamate glycoside with antileishmanial activities, with an IC_{50} value of 5.25 μM. Niazinin also shows a binding affinity with the target protein **3CL protease**. Niazinin has promising leishmanicidal, anti-inflammatory and anti-pyretic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

NIBR0213

Cat. No.: HY-18166

NIBR-0213 is a potent and selective **S1P1** antagonist with efficacy in experimental autoimmune encephalomyelitis. NIBR-0213 displays potent and comparable potency on **human and rat S1P1** (IC_{50} of 2.0 nM and 2.3 nM, respectively) in GTPγ^{35}S assays.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NIBR189

Cat. No.: HY-12336

NIBR189 is a small molecule antagonist of the Epstein-Barr virus-induced gene 2 (EBI2; GPR183) receptor with IC50 of 16 nM(Binding) and 11 nM (Functional).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nicotinamide N-oxide

Cat. No.: HY-101407

Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the **CXCR2** receptor.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Nicotredole

(Tryptamide)

Cat. No.: HY-137394

Nicotredole (Tryptamide) is an orally active anti-inflammatory and analgesic agent. Nicotredole exhibits evident antiinflammatory effects of potency comparable with Phenylbutazone. Nicotredole has only weak ulcerogenic activity.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Nidufexor

(LMB763)

Cat. No.: HY-109096

Nidufexor (LMB763) is an orally-available **farnesoid X receptor** (**FXR**) agonist for the research of nonalcoholic steatohepatitis (NASH).



Purity: 98.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nifenazone

Cat. No.: HY-17475

Nifenazone is a pyrazole drug which can be used in the in the treatment of a variety of rheumatic disorders.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Nifeviroc

Cat. No.: HY-111069

Nifeviroc is an orally active **CCR5** antagonist. Nifeviroc is used for the study of HIV type-1 infection.
.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Niflumic acid

Cat. No.: HY-B0493

Niflumic acid, a Ca2+-activated Cl- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Niflumic Acid-d5

Cat. No.: HY-B0493S

Niflumic Acid-d5 is the deuterium labeled Niflumic acid. Niflumic acid, a Ca^{2+}-activated Cl^- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Nigakinone

Cat. No.: HY-N2128

Nigakinone is one of the most abundant alkaloids responsible for the major pharmacological activities of Kumu.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

NIK SMI1

Cat. No.: HY-112433

NIK SMI1 is a potent, selective NF-κB inducing kinase (**NIK**) inhibitor, which inhibits NIK-catalyzed hydrolysis of ATP to ADP with IC_{50} of 0.23±0.17 nM.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 1 g, 5 g

Nilofabicin

(CG-400549)

Cat. No.: HY-111071

Nilofabicin is an enoyl-(acyl-carrier protein) reductase (FabI) inhibitor. Nilofabicin had an MIC(90) of 0.5 microg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

NIM811

((Melle-4)cyclosporin; SDZ NIM811)

Cat. No.: HY-P0025

NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally bioavailable **mitochondrial permeability transition** and **cyclophilin** dual inhibitor, which exhibits potent in vitro activity against hepatitis C virus (HCV) .



Purity: 98.82%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Nimbin

Cat. No.: HY-N3187

Nimbin is a intermediate limonoid isolated from Azadirachta. Nimbin prevents **tau** aggregation and increases cell viability. Nimbin is effective inhibits the **envelope protein of dengue virus**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nimesulide

(R805)

Cat. No.: HY-B0363

Nimesulide is a selective **COX-2** inhibitor, with IC_{50}s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC_{50} >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Nimesulide D5

Cat. No.: HY-B0363S

Nimesulide D5 is a deuterium labeled Nimesulide. Nimesulide is a selective **COX-2** inhibitor, with IC_{50}s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC_{50} >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

NIR-H2O2

Cat. No.: HY-D1065

NIR-H2O2 is a cell-permeable near-infrared (NIR) fluorescent turn-on sensor. NIR-H2O2 has both absorption and emission in the NIR region. NIR-H2O2 responds to H_2O_2 with a large turn-on NIR fluorescence signal upon excitation in the NIR region.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nitecapone

(OR-462)

Cat. No.: HY-106842

Nitecapone (OR-462) is an orally active and short-acting **catechol-O-methyltransferase (COMT)** inhibitor with gastroprotective and antioxidant properties. Nitecapone (OR-462) scavenges reactive oxygen and nitric radicals and prevents lipid peroxidation.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Nitidine chloride

Cat. No.: HY-N0498

Nitidine chloride, a potential **anti-malarial** lead compound derived from Zanthoxylum nitidum (Roxb) DC, exerts potent anticancer activity through diverse pathways, including inducing **apoptosis**, inhibiting **STAT3** signaling cascade, **DNA topoisomerase 1 and 2A**, **ERK** and...



Purity: 99.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Nitrosoglutathione

(GSNO; RVC-588; S-Nitroso-L-glutathione)

Cat. No.: HY-D0845

Nitrosoglutathione (GSNO), a exogenous NO donor and a substrate for rat alcohol dehydrogenase class III isoenzyme, inhibits cerebrovascular angiotensin II-dependent and -independent AT1 receptor responses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nivalenol

Cat. No.: HY-N6801

Nivalenol, classified as type B trichotecenes toxins produced by Fusarium graminearum, is a fungal metabolite present in agricultural product. Nivalenol induces cell death through **caspase**-dependent mechanisms and via the intrinsic **apoptotic** pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nizatidine

Cat. No.: HY-B0310

Nizatidine is a potent and orally active **histamine H_2 receptor** antagonist, can be used for the research of stomach and intestines ulcers.



Purity: 99.19%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g

NLRP3-IN-4

Cat. No.: HY-132892

NLRP3-IN-4 is potent and orally active **NLRP3** inflammasome inhibitor with inflammatory activity for colitis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NLRP3-IN-5

Cat. No.: HY-145087

NLRP3-IN-5 is a **NLRP3 inflammasome** inhibitor (WO2016131098 (N-((4-chloro-2,6-dimethylphenyl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide)).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NLRP3-IN-NBC6

Cat. No.: HY-131040

NLRP3-IN-NBC6 is a potent, selective **NLRP3 inflammasome** inhibitor (IC_{50}= 574 nM) that acts independently of Ca^{2+}.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

NO-prednisolone

(NCX-1015)

Cat. No.: HY-101757

NO-prednisolone is a nitric oxide (NO)-releasing derivative of Prednisolone. NO-prednisolone potently stimulates **IL-10** production in vivo.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Nobiletin

Cat. No.: HY-N0155

Nobiletin is a poly-methoxylated flavone from the citrus peel that improves memory loss. Nobiletin is a **retinoid acid receptor-related orphan receptors (RORs)** agonist.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nociceptin(1-7)

Cat. No.: HY-P1319

Nociceptin (1-7) is the N-terminal bioactive fragment of nociceptin (HY-P0183). Nociceptin (1-7) is a potent **ORL_1 (NOP)** receptor agonist with antinociceptive activity. Nociceptin (1-7) combines with nociceptin reduces hyperalgesia in vivo.

FGGFTGA

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nociceptin(1-7) TFA

Cat. No.: HY-P1319A

Nociceptin (1-7) TFA is the N-terminal bioactive fragment of nociceptin (HY-P0183). Nociceptin (1-7) TFA is a potent **ORL_1 (NOP)** receptor agonist with antinociceptive activity. Nociceptin (1-7) TFA combines with nociceptin reduces hyperalgesia in vivo.

FGGFTGA (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NOD-IN-1

Cat. No.: HY-100691

NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (**NOD**)-like receptors, **NOD1** and **NOD2**, with **IC_{50}** of 5.74 μM and 6.45 μM, respectively.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Nodakenetin

Cat. No.: HY-N2276

Nodakenetin, isolated from Angelica decursiva, possesses antioxidant anti-inflammatory activities. Nodakenetin has the potential to be an antiarthritic and nerve tonic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nodakenin

Cat. No.: HY-N0825

Nodakenin is a major coumarin glucoside in the root of Peucedanum decursivum Maxim. Nodakenin inhibits acetylcholinesterase **(AChE)** activity with an **IC_{50}** of 84.7 μM.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Nodinitib-1

(ML130; CID-1088438)

Cat. No.: HY-18639

Nodinitib-1 (ML130;CID-1088438) is a **NOD1** inhibitor with an **IC_{50}** of 0.56 μM.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nonanal

Cat. No.: HY-N8016

Nonanal is a saturated fatty aldehyde with antidiarrhoeal activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

nor-NOHA acetate

(Nω-Hydroxy-nor-L-arginine acetate)

Cat. No.: HY-112885A

nor-NOHA acetate (Nω-Hydroxy-nor-L-arginine acetate) is a specific and reversible **arginase** inhibitor, induces apoptosis in ARG2-expressing cells under hypoxia but not normoxia. Anti-leukemic activity, effective in endothelial dysfunction, immunosuppression and metabolism.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Norathyriol

(Mangiferitin)

Cat. No.: HY-N1029

Norathyriol (Mangiferitin) is a natural metabolite of Mangifera. Norathyriol inhibits **α-glucosidase** in a noncompetitive manner with an **IC_{50}** of 3.12μM. Norathyriol inhibits **PPARα**, **PPARβ**, and **PPARγ** with **IC_{50}**s of 92.8 μM, 102.4 μM, and 153.5 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Norethindrone acetate

(19-Norethindrone acetate) Cat. No.: HY-B1710

Norethindrone acetate is a female hormone used for the research of endometriosis.



Purity: 99.41%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Norethindrone acetate-D8

(19-Norethindrone acetate-D8) Cat. No.: HY-B1710S

Norethindrone acetate-D8 (19-Norethindrone acetate-D8) is the deuterium labeled Norethindrone acetate. Norethindrone acetate is a female hormone used for the research of endometriosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Noricaritin

Cat. No.: HY-N1413

Noricaritin is a flavonoid sourced from roots of Epimedium brevicornu Maxim.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Norisoboldine

((+)-Laurelliptine) Cat. No.: HY-N0586

Norisoboldine is an orally active natural aryl hydrocarbon receptor (**AhR**) agonist. Norisoboldine, as a major isoquinoline alkaloid present in Radix Linderae, can be used for the research of Rheumatoid arthritis and Ulcerative colitis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Norisoboldine hydrochloride

((+)-Laurelliptine hydrochloride) Cat. No.: HY-N0586A

Norisoboldine hydrochloride is an orally active natural aryl hydrocarbon receptor (**AhR**) agonist. Norisoboldine hydrochloride, as a major isoquinoline alkaloid present in Radix Linderae, can be used for the research of Rheumatoid arthritis and Ulcerative colitis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NOS-IN-1

Cat. No.: HY-138564

NOS-IN-1 is a potent and orally active **NO synthase (NOS)** isoforms inhibitor with IC_{50}s of 0.1 μM, 1.1 μM, and 0.2 μM for **human iNOS (hiNOS)**, **heNOS** and **hnNOS**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

Nosantine racemate

(NPT 15392 racemate) Cat. No.: HY-101687

Nosantine racemate is the racemate of Nosantine. Nosantine is an inducer of **IL-2** or enhancer of **IL-2** induction by phytohemagglutinin (PHA).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nothofagin

Cat. No.: HY-113919

Nothofagin, a dihydrochalcone, is isolated from rooibos (Aspalathus linearis). Nothofagin downregulates NF-κB translocation through blocking **calcium** influx.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Notopterol

Cat. No.: HY-N0564

Notopterol is a coumarin extracted from N. incisum. Notopterol induces **apoptosis** and has antipyretic, analgesic and anti-inflammatory effects. Notopterol is used for acute myeloid leukemia (AML).



Purity: 99.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

NPD-1335

Cat. No.: HY-126250

NPD1335 is a Trypanosoma brucei phosphodiesterase B1 (**TbrPDEB1**) inhibitor with submicromolar activities against T. brucei parasites. NPD1335 displays a greatly improved cytotoxicity profile.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NR1H4 activator 1

Cat. No.: HY-125996

NR1H4 activator 1 is a potent and selective **Famesoid X Receptor (FXR)** agonist, extracted from patent WO2018152171A1, example 4. NR1H4 activator 1 shows strong FXR agonistic potency with a EC_{50} value of 1 nM in a Human FXR (NR1H4) Assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NS-2028

Cat. No.: HY-12379

NS-2028 is a highly selective soluble Guanylyl Cyclase (sGC) inhibitor with IC_{50} values of 30 nM and 200 nM for basal and NO-stimulated enzyme activity.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NS-3-008 hydrochloride

Cat. No.: HY-120897

NS-3-008 hydrochloride is an orally active transcriptional inhibitor of **G0/G1 switch 2 (G0s2)** with an IC_{50} of 2.25 μM. NS-3-008 hydrochloride can be used for chronic kidney disease.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NS-398

Cat. No.: HY-13913

NS-398 is a non-steroidal an-inflammatory agent with analgesic and antipyretic effects, and selectively inhibits prostaglandin G/H synthase 2/cyclooxygenase 2 (**COX-2**) activity, with an IC_{50} of 3.8 μM, and has no effect on COX-1 at 100 μM.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NS2 (114-121), Influenza

Cat. No.: HY-P2521

NS2 (114-121), Influenza, the 114-121 fragment of influenza nonstructural protein 2 (NS2), is a influenza-derived epitope. NS2 (114-121), Influenza can be used for the research of $CD8^+$ cytotoxic T lymphocyte (CTL) in antiviral immune responses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NS6180

Cat. No.: HY-15707

NS6180 is a novel potent and selective KCa3.1 channel inhibitor(IC50= 9 nM) prevents T-cell activation and inflammation.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NSC-60339

Cat. No.: HY-119172

NSC-60339, an **efflux pump** inhibitor and a substrate of AcrAB-TolC, is a polybasic terephthalic acid derivative studied as a potential cancer chemotherapeutic agent.



Purity: 95.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NSC117079

Cat. No.: HY-19819

NSC117079 is a novel **PHLPP** inhibitor.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nucleoprotein (396-404)

(NP 396)

Cat. No.: HY-P1571

Nucleoprotein (396-404) is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

FQPQNGQFI

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nucleoprotein (396-404) (TFA)

(NP 396 TFA)

Cat. No.: HY-P1571A

Nucleoprotein (396-404) TFA is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) TFA is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

FQPQNGQFI (TFA salt)

Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Nurr1 agonist 1

Cat. No.: HY-132909

Nurr1 agonist 1 is an inverse agonist tool for the neuroprotective transcription factor **Nurr1**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nusinersen

Cat. No.: HY-112980

Nusinersen is an antisense oligonucleotide drug that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein.

Nusinersen

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

NVS-PI3-4

Cat. No.: HY-133907

NVS-PI3-4 is a specific **PI3Kγ** inhibitor. NVS-PI3-4 can be used for the research of allergies, inflammatory and cancer diseases.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

NVS-ZP7-4

Cat. No.: HY-114395

NVS-ZP7-4 is a Zinc transporter SLC39A7 **(ZIP7)** inhibitor that is also the first reported chemical tool to probe the impact of modulating ER zinc levels and investigate ZIP7 as a novel druggable node in the Notch pathway.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nylidrin hydrochloride

(Buphenine hydrochloride)

Cat. No.: HY-B1404

Nylidrin hydrochloride was an effective inhibitor of IgE-mediated release of histamine from passively sensitized rat peritoneal mast cells and human basophils, and of IgG1-mediated release of histamine from passively sensitized guinea pig lung slices.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

O-Methyl Atorvastatin hemicalcium

Cat. No.: HY-135375

O-Methyl Atorvastatin (hemicalcium) is an impurity of Atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OATD-01

Cat. No.: HY-137464A

OATD-01 is a highly potent, first-in-class, orally active and selective **chitinase** inhibitor with low nanomolar activity toward **CHIT1** (hCHIT1,IC_{50}=23 nM). OATD-01 shows excellect PK profile in multiple species and is selectivity against a panel of other off-targets.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

OBAA

Cat. No.: HY-101015A

OBAA is a potent **phospholipase A2 (PLA2)** inhibitor with an IC_{50} of 70 nM. OBAA blocks Melittin-induced Ca^{2+} influx in Trypanosoma brucei with an IC_{50} of 0.4 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Obafistat

Cat. No.: HY-109154

Obafistat is a potent aldo-keto reductase **AKR1C3** inhibitor with an IC_{50} of 1.2 nM for human AKR1C3 (patent WO2017202817A1, example 4).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Obestatin(rat)

Cat. No.: HY-P1306

Obestatin(rat), encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain.

FNAPFDVGIKLSGAQYQQHGRAL-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Obestatin(rat) TFA

Cat. No.: HY-P1306A

Obestatin(rat) TFA, encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) TFA suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Obtucarbamate A

Cat. No.: HY-N3163

Obtucarbamate A isolated from Disporum cantoniense has antitussive activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ocarocoxib

Cat. No.: HY-139578

Ocarocoxib, a potent **COX-2 (cyclooxygenase-2)** inhibitor, is a non-steroidal anti-inflammatory for veterinary use.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Oclacitinib maleate

(PF-03394197 maleate)

Cat. No.: HY-13577A

Oclacitinib maleate (PF-03394197 maleate) is a novel **JAK** inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting **JAK1** (IC_{50}=10 nM).



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Oct3/4-inducer-1

Cat. No.: HY-18773

Oct3/4-inducer-1 (compound 2) is a potent **Oct3/4** inducer. Oct3/4-inducer-1 promotes expression and stabilization of Oct3/4, and enhances its transcriptional activity in diverse human somatic cells.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Octreotide

(SMS 201-995)

Cat. No.: HY-P0036

Octreotide is a somatostatin analog that binds to the **somatostatin receptor**, mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production.

Purity: 98.84%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg

Octreotide acetate

(SMS 201-995 acetate)

Cat. No.: HY-17365

Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits **growth hormone**, **glucagon**, and **insulin** more potently.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

OD36

Cat. No.: HY-19628

OD36 is a **RIPK2** inhibitor with an IC_{50} of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the **ALK2** kinase ATP pocket. OD36 shows **ALK2**-directed activity with K_Ds of 37 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Odatroltide

(DHDMIQK(KAP))

Cat. No.: HY-132828

Odatroltide, as a nanoscale P-selectin inhibitor, is a nano-delivery system of 6,7-dihydroxyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and KPAK to target the thrombus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oenothein B

Cat. No.: HY-N7765

Oenothein B is a dimeric macrocyclic ellagitannin and has widely pharmacological activities, including antioxidant, anti-inflammatory, antifungal, anti-HCV, and antitumor properties. Oenothein B is a potent and specific inhibitor of **poly(ADP-ribose) glycohydrolase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OGG1-IN-08

Cat. No.: HY-112902

OGG1-IN-08 is a potent **8-oxoguanine DNA glycosylase-1 (OGG1)** inhibitor with an IC_{50} value of 0.22 μM. OGG1-IN-08 decreases both the glycosylase and lyase activities of OGG1.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Oglemilast

(GRC 3886)

Cat. No.: HY-15178

Oglemilast (GRC 3886) is a potent and orally active **phosphodiesterase-4 (PDE4)** inhibitor with an IC_{50} of 0.5 nM for PDE4D3. Oglemilast inhibits pulmonary cell infiltration, including eosinophilia and neutrophilia in vitro and in vivo.



Purity: 98.20%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

Oglufanide

(H-Glu-Trp-OH; L-Glutamyl-L-tryptophan)

Cat. No.: HY-13718

Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits **vascular endothelial growth factor (VEGF)**. Oglufanide can stimulate the immune response to **hepatitic C virus (HCV)** and intracellular bacterial infections.



Purity: 99.49%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Okanin

Cat. No.: HY-N6673

Okanin, effective constituent of the flower tea Coreopsis tinctoria, attenuates LPS-induced microglial activation through inhibition of the **TLR4/NF-κB** signaling pathways.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 5 mg

Oleanolic acid derivative 1

Cat. No.: HY-18002

Oleanolic acid derivative 1 is an oleanolic acid derivative, which is a novel triterpenoid-steroid hybrid molecule.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Oleanolic acid derivative 2

Cat. No.: HY-18003

Oleanolic acid derivative 2 is an oleanolic acid derivative, which is a novel triterpenoid-steroid hybrid molecule.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Oleanolic acid hemiphthalate disodium salt

Cat. No.: HY-128695

Oleanolic acid hemiphthalate disodium salt is an anti-inflammatory agent.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Oleuropein

Cat. No.: HY-N0292

Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of **PPARγ** transcriptional activity.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Olodaterol

(BI1744)

Cat. No.: HY-14301

Olodaterol (BI1744) is a selective, long acting **β_2-adrenoceptor** (β_2-AR) agonist (**EC_{50}**=0.1 nM and **pK_i**= 9.14 for human β_2-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis.



Purity: 98.48%
Clinical Data: Launched
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Olodaterol hydrochloride

(BI1744 hydrochloride)

Cat. No.: HY-14301A

Olodaterol (BI1744) hydrochloride is a selective, long acting **β_2-adrenoceptor** (β_2-AR) agonist (**EC_{50}**=0.1 nM and **pK_i**= 9.14 for human β_2-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis.



Purity: 99.70%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Olopatadine hydrochloride

(ALO4943A; KW4679)

Cat. No.: HY-B0426A

Olopatadine hydrochloride (ALO4943A) is a histamine blocker used to treat allergic conjunctivitis.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Olopatadine-d3 hydrochloride

Cat. No.: HY-B0426AS

Olopatadine-d3 hydrochloride (ALO4943A-d3) is the deuterium labeled Olopatadine hydrochloride. Olopatadine hydrochloride (ALO4943A) is a histamine blocker used to treat allergic conjunctivitis.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Olutasidenib

(FT-2102)

Cat. No.: HY-114226

Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of **mutant Isocitrate dehydrogenase 1 (IDH1)**, with IC_{50} values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively .



Purity: 98.35%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Omalizumab

(Olizumab; rhuMab-E25)

Cat. No.: HY-P9950

Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a K_D of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a K_D of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research.

Olizumab

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Omaveloxolone

(RTA 408)

Cat. No.: HY-12212

Omaveloxolone (RTA 408) is an antioxidant inflammation modulator (AIM), which activates **Nrf2** and suppresses nitric oxide (NO). Omaveloxolone attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.



Purity: 99.40%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Omidenepag isopropyl

(DE-117)

Cat. No.: HY-111406

Omidenepag isopropyl is a selective **EP2** receptor agonist. Omidenepag isopropyl is converted to the active product Omidenepag during corneal penetration, and Omidenepag is a highly selective EP2 receptor agonist.



Purity: 98.07%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Omtriptolide

Cat. No.: HY-16363

Omtriptolide (PG490-88) is a derivative prodrug of triptolide purified from the Chinese herb.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Onilcamotide

Cat. No.: HY-P3315

Onilcamotide is a C-terminal peptide of RhoC protein. Onilcamotide is a cancer vaccine and has potential immunomodulating and antineoplastic activities.

ATRAGLQVRKNKRRRGCPIL

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ONO-RS-082

Cat. No.: HY-123070

ONO-RS-082 is an inhibitor of **phospholipase A** (**PLA**). ONO-RS-082 inhibits **PLA2** with the IC_{50} of 1.0 μM, but does not inhibit PLC even at 100 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ONO4057

(ONO-LB457)

Cat. No.: HY-U00252

ONO4057 is a **Leukotriene B_4 receptor** antagonist, with an IC_{50} of 0.7±0.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ONX-0914

(PR-957) Cat. No.: HY-13207

ONX-0914 (PR-957) is a selective inhibitor of low-molecular mass polypeptide-7 **(LMP7)**, the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 blocks cytokine production and attenuates progression of experimental arthritis.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ONX-0914 TFA

(PR-957 TFA) Cat. No.: HY-13207A

ONX-0914 (PR-957) TFA is a selective inhibitor of low-molecular mass polypeptide-7 **(LMP7)**, the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 TFA blocks cytokine production and attenuates progression of experimental arthritis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

OP-3633

Cat. No.: HY-125839

OP-3633 is a potent and selective steroidal **glucocorticoid receptor (GR)** antagonist with an IC_{50} of 29 nM, with inhibition of GR transcriptional activity. OP-3633 exhibits low progesterone receptor (PR) agonism and androgen receptor (AR) antagonism.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OP-5244

Cat. No.: HY-136978

OP-5244 is a potent and orally active inhibitor of **CD73**, with an IC_{50} of 0.25 nM. OP-5244 reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

OP-5244 sodium

Cat. No.: HY-136978A

OP-5244 sodium is a potent and orally active inhibitor of **CD73**, with an IC_{50} of 0.25 nM. OP-5244 sodium reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

OPC-167832

Cat. No.: HY-134940

OPC-167832 is a potent and orally active **dprE1** Inhibitor with an IC_{50} of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ophiopogonin D

Cat. No.: HY-N0515

Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C_{29} steroidal glycoside.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

opigolix

Cat. No.: HY-U00289

Opigolix is a Gonadotropin-releasing hormone (**GnRH**) receptor antagonist, used for the research of endometriosis and rheumatoid arthritis.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Oridonin

(NSC-250682; Isodonol) Cat. No.: HY-N0004

Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of **AKT**, with IC_{50}s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Orismilast

(LEO-32731) Cat. No.: HY-117960

Orismilast (LEO-32731) is a **PDE4** inhibitor used for the research of inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Osajin

(CID 95168; NSC 21565)

Cat. No.: HY-N3125

Osajin is the major bioactive isoflavone present in the fruit of Maclura pomifera with antitumor, antioxidant and anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Osilodrostat

(LCI699)

Cat. No.: HY-16276

Osilodrostat (LCI699) is a potent inhibitor of human **11β-hydroxylase** and **aldosterone synthase** with IC_{50} values of 2.5 and 0.7 nM, respectively.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ossirene

(AS101)

Cat. No.: HY-101019

Ossirene (AS101), an immunomodulatory tellurium compound, is a potent **IL-1β** inhibitor. Ossirene abolishes phosphorylation of STAT3 by inhibiting **IL-10**. Ossirene potently inhibits **Caspase-1** and is used for the autoimmune diseases and certain malignancies.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

OSS_128167

Cat. No.: HY-107454

OSS_128167 is a potent selective **sirtuin 6 (SIRT6)** inhibitor with IC_{50}s of 89 μM, 1578 μM and 751 μM for **SIRT6**, SIRT1 and SIRT2, respectively. OSS_128167 has anti-**HBV** activity that inhibits **HBV** transcription and replication.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Osteogenic Growth Peptide, OGP

Cat. No.: HY-P1563

Osteogenic Growth Peptide, OGP is a short, naturally occurring 14-mer growth factor peptide found in serum at μM concentrations.

ALKRQGRTLYGFGG

Purity: 98.35%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Osthole

(Osthol; NSC 31868)

Cat. No.: HY-N0054

Osthole (Osthol) is a natural antihistamine alternative. Osthole may be a potential inhibitor of **histamine H_1 receptor** activity. Osthole also suppresses the secretion of **HBV** in cells.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg, 1 g, 5 g

Otenaproxesul

(ATB-346)

Cat. No.: HY-15028

Otenaproxesul (ATB-346), an orally active non-steroidal anti-inflammatory drug (**NSAID**), inhibits **cyclooxygenase-1 and 2 (COX-1 and 2)**. Otenaproxesul possesses antiinflammatory and antinociceptive activities.



Purity: 98.35%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

OVA (241-270) (TFA)

Cat. No.: HY-P2495A

OVA (241-270) TFA, a non-specific cytotoxic T lymphocyte (CTL) peptide, is a fragmented peptide of OVA (ovalbumin) antigen.

SMLVLLPDEVSGLEQLESIINFEKLTEWTS (TFA salt)

Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

OVA (55-62)

Cat. No.: HY-P2494

OVA 55-62 is a fragmented peptide of OVA (ovalbumin) antigen and can bind to the mouse MHC class I molecule, H2-Kb.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OVA G4 peptide

Cat. No.: HY-P1771

OVA G4 peptide is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OVA G4 peptide TFA

Cat. No.: HY-P1771A

OVA G4 peptide TFA is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

OVA Peptide 323-339

Cat. No.: HY-P0286

OVA Peptide (323-339) represents a T and B cell epitope of Ovalbumin (Ova), which is important in the generation and development of immediate hypersensitivity responses in BALB/c mice.

ISQAVHAAHAEINEAGR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

OVA Peptide(257-264)

Cat. No.: HY-P1489

OVA Peptide(257-264) is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide from ovalbumin presented by the class I MHC molecule, H-2Kb.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OVA Peptide(257-264) acetate salt

Cat. No.: HY-P1489B

OVA Peptide(257-264) acetate salt is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide from ovalbumin presented by the class I MHC molecule H-2Kb.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OVA Peptide(257-264) TFA

Cat. No.: HY-P1489A

OVA Peptide(257-264) TFA is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide from ovalbumin presented by the class I MHC molecule, H-2Kb.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

OVA sequence (323-336)

Cat. No.: HY-P1870

OVA sequence (323-336) is a cognate helper T-lymphocyte peptide that is employed to enhance CTL epitope immunogenicity.

ISQAVHAAHAEINE

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OVA-E1 peptide

Cat. No.: HY-P2319

OVA-E1 peptide, is an antagonist variant of SIINFEKL [OVA (257-264). OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OVA-E1 peptide TFA

Cat. No.: HY-P2319A

OVA-E1 peptide TFA, is an antagonist variant of SIINFEKL [OVA (257-264). OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oxaceprol

(N-Acetyl-L-hydroxyproline)

Cat. No.: HY-17490

Oxaceprol (N-Acetyl-L-hydroxyproline), an orally active derivative of L-proline, possesses distinct anti-inflammatory activity. Oxaceprol is usually used for the research of osteoarthritis and rheumatoid arthritis.



Purity: ≥95.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Oxaprozin

(Oxaprozinum; Wy21743)

Cat. No.: HY-B0808

Oxaprozin is an inhibitor of both **COX-1** and **COX-2** with IC_{50}s of 2.2 μM and 36 μM for human platelet COX-1 and IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of **NF-κB**.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Oxatomide

Cat. No.: HY-123205

Oxatomide is a potent and orally active dual **H1-histamine receptor** and **P2X7 receptor** antagonist with antihistamine and anti-allergic activity. Oxatomide almost completely blocks the ATP-induced current in **human P2X7 receptors** (IC_{50} of 0.95 μM).



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Oxeladin citrate

Cat. No.: HY-B1216

Oxeladin citrate is a cough suppressant, is a highly potent and effective drug used to treat all types of cough of various etiologies.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Oxindole

(Indolin-2-one)

Cat. No.: HY-Y0061

Oxindole (Indolin-2-one) is an aromatic heterocyclic building block. 2-indolinone derivatives have become lead compounds in the research of kinase inhibitors.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Oxitropium Bromide

Cat. No.: HY-U00105

Oxitropium bromide is an **mAChR** antagonist used as an anticholinergic bronchodilator drug for the treatment of asthma and chronic obstructive pulmonary disease.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Oxolamine citrate

(SKF-9976 citrate; AF-438 citrate)

Cat. No.: HY-B1042

Oxolamine citrate (SKF-9976 citrate) is a cough suppressant that can be used for the research of respiratory tract diseases. Oxolamine citrate also exhibits anti-inflammatory effect.



Purity: 98.05%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Oxomemazine

Cat. No.: HY-136587

Oxomemazine is a phenothiazine-based **histamine H1-receptor** blocker with pronounced antimuscarinic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

Oxothiazolidinecarboxylic acid

Cat. No.: HY-133105

Oxothiazolidinecarboxylic acid, an antioxidant, is a prodrug of cysteine that is inert until metabolized to cysteine intracellulary, thus stimulating glutathione synthesis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg, 500 mg

OXSI-2

Cat. No.: HY-112386

OXSI-2 is a bioavailable, cell-permeable **Syk** inhibitor with an EC_{50} of 313 nM and an IC_{50} of 14 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oxymatrine

Cat. No.: HY-N0158

Oxymatrine, an alkaloid from the roots of Sophora species, with anti-inflammatory, antifibrosis, and antitumor effects, inhibits the **iNOS** expression and **TGF-β/Smad** pathway.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g

Oxypaeoniflorin

Cat. No.: HY-N0748

Oxypaeoniflorin, an anti-oxidant, is a monoterpene glycoside compound isolated from Paeoniae species. Oxypaeoniflorin has neuroprotective and anti-inflammatory effects.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Oxyphenbutazone

Cat. No.: HY-B1355A

Oxyphenbutazone is a phenylbutazone derivative, with anti-inflammatory effect. Oxyphenbutazone is a non-selective **COX** inhibitor. Oxyphenbutazone selectively kills non-replicating Mycobaterium tuberculosis.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

Oxypurinol

(Oxipurinol)

Cat. No.: HY-19657

Oxipurinol (Oxipurinol), the major active metabolite of Allopurinol, is an inhibitor of **xanthine oxidase**. Oxipurinol can be used to regulate blood urate levels and treat gout.



Purity: ≥98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg

Oxysophoridine

(Sophoridine N-oxide)

Cat. No.: HY-N1402

Oxysophoridine (Sophoridine N-oxide) is a bioactive alkaloid extracted from the Sophora alopecuroides Linn. Oxysophoridine (Sophoridine N-oxide) shows anti inflammatory, anti oxidative stress and anti **apoptosis** effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ozanimod

(RPC-1063)

Cat. No.: HY-12288

Ozanimod (RPC-1063) is a potent and selective **$S1P_1$** and **$S1P_5$ receptor** agonist with **EC_{50}**s of 410 pM and 11 nM in [^{35}S]-GTPγS binding, respectively.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

P-113

Cat. No.: HY-P2148

P-113 is an antimicrobial peptide (AMP) derived from the human salivary protein histatin 5. P-113 is active against clinically important microorganisms such as Pseudomonas spp., Staphylococcus spp., and C. albicans.

AKRHHGYKRKFH-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

p-Coumaric Acid Ethyl Ester (Ethyl (E)-p-hydroxycinnamate; Ethyl trans-4-hydroxycinnamate)

Cat. No.: HY-N3103

p-Coumaric Acid Ethyl Ester is the ethyl ester of p-Coumaric acid. p-Coumaric Acid is a potential immunosuppressive agent in treating autoimmune inflammatory diseases like rheumatoid arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

p2Ca

Cat. No.: HY-P0260

p2Ca, an 8-mer peptide, is a ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

P2X receptor-1

Cat. No.: HY-139627

P2X receptor-1 is a potential inhibitor of **P2X receptor** for the treatment of pain and inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

P2X3 antagonist 34

Cat. No.: HY-135976

P2X3 antagonist 34 is a potent, selective and orally active **P2X3 homotrimeric receptor** antagonist with **IC_{50}**s of 25 nM, 92 nM and 126 nM for **human P2X3**, **rat P2X3** and **guinea pig P2X3 receptors**, respectively.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

p38 MAPK-IN-1

Cat. No.: HY-12839

p38 MAPK-IN-1 (Compound 4) is a novel potent and selective inhibitor of **p38 MAPK** with **IC_{50}** of 68 nM. p38 MAPK-IN-1 shows sustained levels, low clearance and good bioavailability.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

p38α inhibitor 1

Cat. No.: HY-114423

p38α inhibitor 1 is a **p38α** inhibitor extracted from patent WO 2008076265 A1.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

p38α inhibitor 2

Cat. No.: HY-131335

p38α inhibitor 2 is a highly potent and selective **p38α MAPK** inhibitor, with a pIC_{50} of 9.6.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

P8RI

(D-P8RI)

Cat. No.: HY-P3325

P8RI (D-P8RI) is a biomimetic peptide of CD31 and a **CD31** agonist. P8RI binds to the juxtamembrane amino acid sequence of the ectodomain of CD31, shows an immunosuppressive effect through restoration of the CD31 inhibitory pathway.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PA-8

Cat. No.: HY-133529

PA-8 is a potent, selective and orally active **PACAP type I (PAC1) receptor** antagonist. PA-8 inhibits the phosphorylation of CREB induced by PACAP in **PAC1**-, but not VPAC1- or VPAC2-receptor. PA-8 also inhibits PACAP-induced cAMP elevation with an IC_{50} of 2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PAD2-IN-1

Cat. No.: HY-136557

PAD2-IN-1, a benzimidazole-based derivative, is a potent and selective **protein arginine deiminase 2 (PAD2)** inhibitor. PAD2-IN-1 shows superior selectivity for **PAD2** over PAD4 (95-fold) and PAD3 (79-fold).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Paeonolide

Cat. No.: HY-N2156

Paeonolide is a plant glycoside that contains a non-reducing end α-l-arabinopyranoside and is found in the roots of the widespread plant genus Paeonia.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PAF-AN-1

Cat. No.: HY-U00040

PAF-AN-1 is a platelet activating factor receptor (**PAF**) antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palbinone

Cat. No.: HY-N3115

Palbinone is a terpenoid isolated from the roots of Paeonia albiflora Pallas, potently inhibits **3α-hydroxysteroid dehydrogenase (3α-HSD)**, with an IC_{50} of 46 nM. Anti-inflammatory activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmatine

Cat. No.: HY-N0110A

Palmatine is an orally active and irreversible **indoleamine 2,3-dioxygenase 1 (IDO-1)** inhibitor. Palmatine can ameliorate DSS (Dextran Sulphate Sodium Salt)-induced colitis by mitigating colonic injury, preventing gut microbiota dysbiosis, and regulating tryptophan catabolism.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 20 mg

Palmitoyl Tetrapeptide-3

Cat. No.: HY-P0064

Palmitoyl Tetrapeptide-3 is a synthetic peptide, corrspending to 341-344 amino acid sequence of IgG human H-chain, with phagocytosis stimulating activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmitoylcarnitine chloride

Cat. No.: HY-101017

Palmitoylcarnitine chloride is a fatty acid-derived mitochondrial substrate, and selectively decreases cell survival in colorectal and prostate cancer cells by affecting on pro-inflammatory pathways, Ca^{2+} influx, and DHT-like effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg

Pam3CSK4

(Pam3Cys-Ser-(Lys)4)

Cat. No.: HY-P1180

Pam3CSK4 is a toll-like receptor 1/2 (**TLR1/2**) agonist with an EC_{50} of 0.47 ng/mL for human TLR1/2.

Pam_3C-SKKKK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Pam3CSK4 TFA

(Pam3Cys-Ser-(Lys)4 TFA)

Cat. No.: HY-P1180A

Pam3CSK4 TFA is a toll-like receptor 1/2 (**TLR1/2**) agonist with an EC_{50} of 0.47 ng/mL for human TLR1/2.

Pam_3C-SKKKK (TFA salt)

Purity: 98.76%
Clinical Data: No Development Reported
Size: 1 mg

Pam3CSK4-Biotin

(Pam3Cys-Ser-(Lys)4-Biotin)

Cat. No.: HY-P1405

Pam3CSK4-Biotin is biotinylated Pam3CSK4. Pam3CSK4-Biotin is a Toll-like receptor 1/2 (**TLR1/2**) agonist.

Pam3C-SKKKK-Biotin

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pamapimod

(Ro4402257; R1503)

Cat. No.: HY-10405

Pamapimod (Ro4402257) is a potent, selective and orally active **p38 MAPK** inhibitor with IC_{50}s of 14 nM and 480 nM and K_is of 1.3 nM and 120 nM for **p38α** and **p38β**, respectively. Pamapimod has no activity against p38δ or p38γ isoforms.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Pamapimod-d4

Cat. No.: HY-10405S

Pamapimod-d4 (Ro4402257-d4) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active **p38 MAPK** inhibitor with IC_{50}s of 14 nM and 480 nM and K_is of 1.3 nM and 120 nM for **p38α** and **p38β**, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

Pamidronic acid

Cat. No.: HY-B0012

Pamidronic acid is a drug used to treat a broad spectrum of bone absorption diseases.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Panaxydiol

Cat. No.: HY-N3114

Panaxydiol exhibits **histamine**-release inhibition activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pantoprazole

(BY1023; SKF96022)

Cat. No.: HY-17507

Pantoprazole (BY10232) is an orally active and potent **proton pump** inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H^+/K^+-**ATPase** inhibitor with an IC_{50} of 6.8 μM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pantoprazole sodium

(BY1023 sodium; SKF96022 sodium)

Cat. No.: HY-17507A

Pantoprazole sodium (BY10232 sodium) is an orally active and potent **proton pump** inhibitor (PPI). Pantoprazole sodium, a substituted benzimidazole, is a potent H^+/K^+-**ATPase** inhibitor with an IC_{50} of 6.8 μM.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Pantoprazole sodium hydrate

(BY1023 sodium hydrate; SKF96022 sodium hydrate) Cat. No.: HY-17507B

Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent **proton pump** inhibitor (PPI). Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent **H^+/K^+-ATPase** inhibitor with an **IC_{50}** of 6.8 μM.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

PAP-1

(5-(4-Phenoxybutoxy)psoralen) Cat. No.: HY-10015

PAP-1 (5-(4-Phenoxybutoxy)psoralen) is a potent, selective, and orally active **Kv1.3** blocker (**EC_{50}**=2 nM). PAP-1 blocks Kv1.3 in a use-dependent manner and acts by preferentially binding to the C-type inactivated state of the channel.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Papain

Cat. No.: HY-P1645

Papain is a cysteine protease of the peptidase C1 family, which is used in food, pharmaceutical, textile, and cosmetic industries.

Papain

Purity: >98%
Clinical Data: Phase 2
Size: 100 mg

Paquinimod

(ABR 25757) Cat. No.: HY-100442

Paquinimod (ABR 25757) is a specific inhibitor of **S100A8/S100A9**. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PAR-2-IN-1

Cat. No.: HY-138558

PAR-2-IN-1 is a protease-activated receptor-2 (PAR2) signaling pathway inhibitor with anti-inflammatory and anticancer effects.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PAR-4 Agonist Peptide, amide

(PAR-4-AP; AY-NH2) Cat. No.: HY-P1309

PAR-4 Agonist Peptide, amide (PAR-4-AP; AY-NH2) is a proteinase-activated receptor-4 (**PAR-4**) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PAR-4 Agonist Peptide, amide TFA

(PAR-4-AP TFA; AY-NH2 TFA) Cat. No.: HY-P1309A

PAR-4 Agonist Peptide, amide TFA (PAR-4-AP TFA; AY-NH2 TFA) is a proteinase-activated receptor-4 (**PAR-4**) agonist, which has no effect on either PAR-1 or PAR-2 and whose effects are blocked by a PAR-4 antagonist.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Parcetasal

(MR-897) Cat. No.: HY-U00100

Paclitaxal is a non-steroidal anti-inflammatory analgesic.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Parecoxib

(SC 69124) Cat. No.: HY-17474

Parecoxib (SC 69124) is a highly selective and orally active **COX-2** inhibitor, the prodrug of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis.



Purity: 98.34%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Parecoxib Sodium

(SC 69124A) Cat. No.: HY-17474A

Parecoxib Sodium (SC 69124A) is a highly selective and orally active **COX-2** inhibitor, the prodrug of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Parimifasor
(LYC30937)

Cat. No.: HY-109098

Parimifasor (LYC30937) is an immunomodulator, with anti-inflammatory activity.



Purity: 97.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Parstatin(human)

Cat. No.: HY-P1262

Parstatin(human), a cell-penetrating **PAR-1 thrombin receptor** agonist peptide, is a potent inhibitor of angiogenesis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Parstatin(human) TFA

Cat. No.: HY-P1262A

Parstatin(human) TFA, a cell-penetrating **PAR-1 thrombin receptor** agonist peptide, is a potent inhibitor of angiogenesis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Parstatin(mouse)

Cat. No.: HY-P1261

Parstatin(mouse), a cell-penetrating **PAR-1 thrombin receptor** agonist peptide, is a potent inhibitor of angiogenesis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Parstatin(mouse) TFA

Cat. No.: HY-P1261A

Parstatin(mouse) TFA, a cell-penetrating **PAR-1 thrombin receptor** agonist peptide, is a potent inhibitor of angiogenesis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pasakbumin B
(13α-(21)-Epoxyeurycomanone)

Cat. No.: HY-N4328

Pasakbumin B, a bioactive compound from Eurycoma longifolia Jack, exhibits potent antiulcer activity.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pasiniazid (Paraniazide; Pasiniazide; Isonicotinic acid hydrazide p-aminosalicylate)

Cat. No.: HY-B1048

Pasiniazid is an anti-TB and anti-leprosy drug, used to treat various types of TB and leprosy.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

PAT-048

Cat. No.: HY-123522

PAT-048 is a potent, selective and orally active **autotaxin** inhibitor, inhibits IL-6 mRNA expression, but shows no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in lung fibrosis model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PAT-1251

Cat. No.: HY-107422

PAT-1251 is a potent, selective and oral lysyl oxidase-like 2 (**LOXL2**) inhibitor, with IC_{50}s of 0.71 and 1.17 μM for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (IC_{50}s, 0.10, 0.12, and 0.16 μM, respectively); PAT-1251 is used in...



Purity: 95.11%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PAT-1251 Hydrochloride

Cat. No.: HY-107422A

PAT-1251 Hydrochloride is a potent, selective and oral lysyl oxidase-like 2 (**LOXL2**) inhibitor, with IC_{50}s of 0.71 and 1.17 μM for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (IC_{50}s, 0.10, 0.12, and 0.16 μM, respectively).



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

PAT-505

Cat. No.: HY-107781

PAT-505 is a potent, selective, noncompetitive and orally available **autotaxin** inhibitor, with an IC_{50} of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Patamostat

(E-3123)

Cat. No.: HY-114080

Patamostat (E-3123) is a potent **protease** inhibitor. Patamostat potently inhibits trypsin, plasmin and thrombin with IC_{50}s of 39 nM, 950 nM and 1.9 μM, respectively. Patamostat may possess suppressing effects on pathogenesis and development of acute pancreatitis.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Patamostat mesylate

(E-3123 mesylate)

Cat. No.: HY-114080A

Patamostat (E-3123) mesylate is a potent **protease** inhibitor. Patamostat mesylate potently inhibits trypsin, plasmin and thrombin with IC_{50}s of 39 nM, 950 nM and 1.9 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Patchouli alcohol

Cat. No.: HY-N0207

Patchouli alcohol is a natural tricyclic sesquiterpene extracted from Pogostemon cablin (Blanco) Benth, and exhibits anti-Helicobacter pylori and anti-inflammatory properties.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

PBP10

Cat. No.: HY-P1116

PBP10 is a cell permeable and selective gelsolin-derived peptide inhibitor of **formyl peptide receptor 2 (FPR2)** over FPR1.

RhB-QRLFQVKGRR-OH

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PBP10 TFA

Cat. No.: HY-P1116A

PBP10 is a cell permeable and selective gelsolin-derived peptide inhibitor of **formyl peptide receptor 2 (FPR2)** over FPR1.

RhB-QRLFQVKGRR-OH (TFA salt)

Purity: 98.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PCI 29732

Cat. No.: HY-18010

PCI 29732 is a potent, orally active, reversible BTK inhibitor with K_i^{app} values of 8.2, 4.6, and 2.5 nM for BTK, Lck and Lyn, respectively. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PCTR1

Cat. No.: HY-125445

PCTR1 is a potent monocyte/macrophage agonist, regulating key anti-inflammatory and pro-resolving processes during bacterial infection. PCTR1 is a member of the protectin family of specialized pro-resolving mediators (SPMs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD 404182

Cat. No.: HY-16958

PD 404182 is a potent and competitive inhibitor of human **dimethylarginine dimethylaminohydrolase 1 (DDAH1)**, with an IC_{50} of 9 μM. PD 404182 exhibits antiangiogenic and antiviral activity in vitro.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD 407824

Cat. No.: HY-18961

PD 407824 is a checkpoint kinase **Chk1** and **WEE1** inhibitor with IC_{50}s of 47 and 97 nM, respectively. PD 407824 is a chemical BMP sensitizer and increases the sensitivity of cells to sub-threshold amounts of BMP4.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD-1-IN-18

Cat. No.: HY-101098

PD-1-IN-18 is a **PD1** signaling pathway inhibitor, which acts as an immunomodulator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD-1/PD-L1-IN 5

Cat. No.: HY-129172A

PD-1/PD-L1-IN 5 is a **PD-1/PD-L1** protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC_{50} of ≤100 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD-1/PD-L1-IN 5 TFA

Cat. No.: HY-129172

PD-1/PD-L1-IN 5 TFA is a **PD-1/PD-L1** protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC_{50} of ≤100 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD-1/PD-L1-IN-NP19

Cat. No.: HY-131347

PD-1/PD-L1-IN-NP19 is a **PD-1/PD-L1** inhibitor, with an IC_{50} of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD1-PDL1-IN 1

Cat. No.: HY-101058

PD1-PDL1-IN 1 is a potent **programmed cell death 1 (PD-1)** inhibitor. PD1-PDL1-IN 1 is useful as immune modulator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDE IV-IN-1

Cat. No.: HY-U00352

PDE IV-IN-1 is an inhibitor of **phosphodiesterase IV**, used for the research of asthma, COPD or other inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDE1-IN-3

Cat. No.: HY-130262

PDE1-IN-3, compound 4 (WO2019156861), is a selective human **phosphodiesterase 1 (PDE1)** inhibitor. PDE1-IN-3 inhibits PDE4D and PDE6AB with IC_{50} values of 23.99 μM and 10 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDE12-IN-3

Cat. No.: HY-124768

PDE12-IN-3 is a **phosphodiesterase 12** (**PDE12**) inhibitor with a pXC_{50} of 7.68. Antiviral activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDE4B-IN-2

Cat. No.: HY-115687

PDE4B-IN-2 is an orally active and selective **PDE4B** inhibitor with an IC_{50} of 15 nM. PDE4B-IN-2 inhibits PDE4D (IC_{50}=1.7 μM). PDE4B-IN-2 exhibits potent anti-inflammatory effects.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

PDK4-IN-1

Cat. No.: HY-135954

PDK4-IN-1 is an anthraquinone derivative and a potent and orally active **pyruvate dehydrogenase kinase 4 (PDK4)** inhibitor with an IC_{50} value of 84 nM. PDK4-IN-1 potently represses cellular transformation and cellular proliferation and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PDK4-IN-1 hydrochloride

Cat. No.: HY-135954A

PDK4-IN-1 hydrochloride is an anthraquinone derivative and a potent and orally active **pyruvate dehydrogenase kinase 4 (PDK4)** inhibitor with an IC_{50} value of 84 nM.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PDM2

Cat. No.: HY-112629

PDM2 is a selective, high-affinity aryl hydrocarbon receptor (**AhR**) antagonist with an K_i of 1.2±0.4 nM.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Pectolinarigenin

Cat. No.: HY-N0493

Pectolinarigenin is a dual inhibitor of **COX-2/5-LOX**. Anti-inflammatory activity. Pectolinarigenin has potent inhibitory activities on melanogenesis.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Pectolinarin

Cat. No.: HY-N0314

Pectolinarin possesses anti-inflammatory activity. Pectolinarin inhibits secretion of **IL-6** and **IL-8**, as well as the production of **PGE2** and **NO**. Pectolinarin suppresses cell proliferation and inflammatory response and induces **apoptosis** via inactivation of the **PI3K/Akt** pathway.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Peficitinib

(ASP015K; JNJ-54781532)

Cat. No.: HY-19568

Peficitinib is an oral **JAK** inhibitor, with IC_{50}s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PEG4-aminooxy-MMAF

Cat. No.: HY-128968

PEG4-aminooxy-MMAF is a **drug-linker conjugate for ADC** with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4.



Purity: 97.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Pegaptanib sodium

Cat. No.: HY-109561

Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .

Pegaptanib (sodium)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Peimine

(Verticine; Dihydroisoimperialine)

Cat. No.: HY-N0212

Peimine(Dihydroisoimperialine; Verticine) is a natural compound with good anti-inflammatory effects in vivo. IC50 value: Target: Peimine (0-25 mg/L) significantly inhibited tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and increased IL-10 production.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Peiminine

(Verticinone; Raddeanine)

Cat. No.: HY-N0213

Peiminine(Verticinone; Raddeanine) is a natural compound with anti-inflammatory activity. IC50 value: Target: Peiminine and DXS significantly reduced alveolar inflammation and pulmonary interstitial inflammation in rats with bleomycin-induced lung injury.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Peimisine

(Ebeiensine)

Cat. No.: HY-N0214

Peimisine (Ebeiensine) non-competitively antagonizes tracheal smooth muscle **muscarinic M receptor** and inhibits smooth muscle contraction caused by Ach.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Peldesine

(BCX 34)

Cat. No.: HY-106934

Peldesine (BCX 34) is a potent, competitive, reversible and orally active **purine nucleoside phosphorylase (PNP)** inhibitor with IC_{50}s of 36 nM, 5 nM, and 32 nM for **human, rat, and mouse red blood cell (RBC) PNP**, respectively.



Purity: >98%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg

Peldesine dihydrochloride

(BCX 34 dihydrochloride)

Cat. No.: HY-106934A

Peldesine (BCX 34) dihydrochloride is a potent, competitive, reversible and orally active **purine nucleoside phosphorylase (PNP)** inhibitor with IC_{50}s of 36 nM, 5 nM, and 32 nM for **human, rat, and mouse red blood cell (RBC) PNP**, respectively.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Pelubiprofen

Cat. No.: HY-12383

Pelubiprofen, an orally active and non-steroidal anti-inflammatory drug, is a member of the 2-arylpropionic acid family and has relatively selective effects on **COX-2** activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pemirolast potassium

(TWT-8152; BMY 26517)

Cat. No.: HY-B0538A

Pemirolast potassium (TWT-8152) is a histamine H1 antagonist and mast cell stabilizer that acts as an antiallergic agent.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Penicillamine

(D-(-)-Penicillamine)

Cat. No.: HY-B0300

Penicillamine (D-(-)-Penicillamine) is the most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Pennogenin

Cat. No.: HY-N7798

Pennogenin is a bioactive component which can be isolated from T. govanianum rhizomes. Pennogenin exhibits significant in vitro inhibitory effect on release of ROS.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Penta-N-acetylchitopentaose

Cat. No.: HY-N7698A

Penta-N-acetylchitopentaose elicits plant defense systems. Penta-N-acetylchitopentaose is a substrate for the Rhizobium leguminosarum nodulation protein NodL.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 mg

Pentosan Polysulfate

Cat. No.: HY-A0203

Pentosan Polysulfate is an orally bioavailable medication with anti-inflammatory and pro-chondrogenic properties. Pentosan Polysulfate also displays a potent and selective anti-**HIV** activity. Pentosan Polysulfatecan be used for the research of interstitial cystitis.

Purity: >98%
Clinical Data: Launched
Size: 100 mg

Pentosan Polysulfate Sodium (W/W 43%)

Cat. No.: HY-A0203A

Pentosan Polysulfate Sodium is an orally bioavailable, semi-synthetic medication with anti-inflammatory and pro-chondrogenic properties. Pentosan Polysulfate Sodium also is a potent and selective anti-**HIV** agent.

Purity: >98%
Clinical Data: Launched
Size: 100 mg

Pepinh-TRIF TFA

Cat. No.: HY-P2565

Pepinh-TRIF (TFA) is a 30 aa peptide that blocks TIR-domain-containing adapter-inducing interferon-β (TRIF) signaling by interfering with **TLR-TRIF interaction**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Peptide 401

Cat. No.: HY-12537

Peptide 401, a potent mast cell degranulating factor from bee venom, suppresses the increased vascular permeability due to intradermal injection of various smooth muscle spasmogens (**histamine**, and **5-HT**).

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Peptide 78

Cat. No.: HY-P2642

Peptide 78, a chemotactic cytokine, a 78 amino acid protein member of the IL-8 or C-X-C chemokine supergene family. ENA-78 plays an important role in the elicitation of predominantly neutrophils (PMNs) into the joints of rheumatoid arthritis (RA).

TMRKPRSGNPDVAN

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Perakine

Cat. No.: HY-N2030

Perakine is an indole alkaloid with anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Perilla ketone

Cat. No.: HY-N9508

Perilla ketone is a naturally occurring xenobiotic compound. Perilla ketone is activated by pulmonary P450 cytochrome enzymes in the lung, resulting in severe pulmonary damage and development of diffuse pulmonary edema.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Peripheral Myelin P0 Protein (180-199), mouse

Cat. No.: HY-P2476

Peripheral Myelin P0 Protein (180-199), mouse, a neuritogenic peptide, is a purified component of murine peripheral nerve myelin.

SSKRGRQTPVLYAMLDHSRS

Purity: 99.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Peripheral Myelin Protein P2 (53-78), bovine

Cat. No.: HY-P2479

Peripheral Myelin Protein P2 (53-78), bovine is derived from bovine peripheral myelin P2 protein amino acid residues 53-78. Peripheral Myelin Protein P2 (53-78), bovine is a T cell epitope for the induction of experimental autoimmune neuritis (EAN) in Lewis rats.

TESPFKNTEISFKLGQEFEETTADNR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Periplocin

Cat. No.: HY-N1381

Periplocin is a cardiotonic steroid isolated from Periploca forrestii. Periplocin promotes tumor cell **apoptosis** and inhibits tumor growth. Periplocin has the potential to facilitate wound healing through the activation of Src/ERK and PI3K/Akt pathways mediated by Na/K-ATPase.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Periplogenin

Cat. No.: HY-N2414

Periplogenin is a naturally occurring furanocoumarin found in Angelica dahurica roots, with potent anti-psoriatic effects. Periplogenin induces adipocyte differentiation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Peritassine A

Cat. No.: HY-N3510

Peritassine A, an alkaloid that could be isolated from Tripterygium wilfordii Hook. f., possesses anti-HIV activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Peroxidase

Cat. No.: HY-125859

Peroxidase actively involves in oxidizing reactive oxygen species, innate immunity, hormone biosynthesis and pathogenesis of several diseases.

Peroxidase

Purity: >98%
Clinical Data: No Development Reported
Size: 15 KU

Petesicatib

Cat. No.: HY-109069

Petesicatib is a **cathepsin S** inhibitor, used in research of immune diseases.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

PF-00356231 hydrochloride

Cat. No.: HY-114091

PF-00356231 hydrochloride is a specific, non-peptidic, non-zinc chelating ligand and inhibitor of matrix metalloproteinase **MMP-12** (IC_{50}=1.4 μM). PF-00356231 hydrochloride binds to MMP-12 and forms PF-00356231/MMP-12 complex.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

PF-03654746

Cat. No.: HY-11045

PF-03654746 is a potent and selective **histamine H3 receptor** antagonist with high brain penetration. PF-03654746 reduces allergen-induced nasal symptoms, might be a novel therapeutic strategy to further explore allergic rhinitis.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

PF-03654746 Tosylate

Cat. No.: HY-11044

PF-03654746 Tosylate is a potent and selective **histamine H3 receptor** antagonist with high brain penetration. PF-03654746 Tosylate reduces allergen-induced nasal symptoms.



Purity: 99.65%
Clinical Data: Phase 2
Size: 1 mg

PF-03654764

Cat. No.: HY-123812

PF-03654764 is an orally active, selective histamine H_3 receptor antagonist with K_i values of 1.2 nM and 7.9 nM for human H_3 and rat H_3 in whole cell assay, respectively. The combination of PF-03654764 and Fexofenadine (HY-B0801A) has the potential for allergic rhinitis research.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

PF-03715455

Cat. No.: HY-18862

PF-03715455 is a potent inhaled **p38 MAPK** inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC_{50} values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC_{50}=1.7 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-04745637

Cat. No.: HY-120689

PF-04745637 is a potent and selective **TRPA1** antagonist with an IC_{50} of 17 nM for human TRPA1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-05381941

Cat. No.: HY-120823

PF-05381941 is a potent dual inhibitor of **TAK1/p38α**, with IC_{50}s of 156 and186 nM, respectively.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PF-06250112

Cat. No.: HY-117900

PF-06250112 is a potent, highly selective, orally bioavailable **BTK** inhibitor with an IC_{50} of 0.5 nM, shows inhibitory effect toward **BMX nonreceptor tyrosine kinase** and **TEC** with IC_{50}s of 0.9 nM and 1.2 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06260933

Cat. No.: HY-19562

PF-06260933 is an orally active and highly selective inhibitor of **MAP4K4** with IC_{50}s of 3.7 and 160 nM for kinase and cell, respectively.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-06263276

Cat. No.: HY-101024

PF-06263276 (PF 6263276) is a potent and selective **pan-JAK** inhibitor, with **IC_{50}**s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively.



Purity: ≥99.0%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

PF-06426779

Cat. No.: HY-123854

PF-06426779 is a potent and selective inhibitor of **interleukin1 receptor associated kinase 4 (IRAK4)**, with an **IC_{50}** of 0.3 nM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

PF-06747711

Cat. No.: HY-112706

PF-06747711 is a potent, selective, and orally active retinoic acid receptor-related orphan C2 (**RORC2**, also known as **RORγt**) inverse agonist, with an **IC_{50}** of 4.1 nM. Anti-skin inflammatory activity.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

PF-06795071

Cat. No.: HY-111512

PF-06795071 is a potent and selective covalent **MAGL** inhibitor with an **IC_{50}** of 3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06928215

Cat. No.: HY-114182

PF-06928215 is a **cGAS (cyclic GMP-AMP Synthase)** inhibitor with an **IC_{50}** of 4.9 μM. PF-06928215 has a high binding affinity of 0.2 μM (K_d).



Purity: 98.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

PF-07321332

Cat. No.: HY-138687

PF-07321332 is a potent and orally active **SARS-CoV 3C-like protease ($3CL^{PRO}$)** inhibitor . PF-07321332 targets to the SARS-CoV-2 virus and can be used for COVID-19 reseacrch.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PF-3644022

Cat. No.: HY-107427

PF-3644022 is a potent, selective, orally active and ATP-competitive **MAPKAPK2 (MK2)** inhibitor with an **IC_{50}** of 5.2 nM and a K_i of 3 nM. PF-3644022 also inhibits MK3 and **p38 regulated/activated kinase (PRAK)** with **IC_{50}**s of 53 nM and 5.0 nM, respectively.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-3845

Cat. No.: HY-14380

PF-3845 is a potent, selective, irreversible and orally active inhibitor of **fatty acid amide hydrolase (FAAH)**, with a K_i of 0.23 μM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-4136309

(INCB8761)

Cat. No.: HY-13245

PF-4136309 is a potent, selective, and orally bioavailable **CCR2** antagonist, with **IC_{50}**s of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.



Purity: 99.59%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-4191834

(PF-04191834)

Cat. No.: HY-117048

PF-4191834 (PF-04191834) is an orally active, noniron chelating, and non-redox inhibitor of the **5-Lipoxygenase (5-LOX)** (**IC_{50}**=229 nM), displays ~300-fold selectivity for 5-LOX over 12-LOX and 15-LOX, shows no activity toward the cyclooxygenase enzymes, and is effective...



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

PF-4693627

Cat. No.: HY-125415

PF-4693627 is a potent, selective and orally bioavailable microsomal prostaglandin E synthase-1 (**mPGES-1**) inhibitor (IC_{50}=3 nM) for the treatment of inflammation caused by osteoarthritis (OA) and rheumatoid arthritis (RA).



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mg

PF-4840154

Cat. No.: HY-18779

PF-4840154 is a potent, selective agonist of the rat and human **TrpA1** channel with EC_{50}s of 97 and 23 nM, respectively. PF-4840154 elicits TrpA1-mediated nocifensive behaviour in mouse.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-4878691

(3M-852A)

Cat. No.: HY-100176

PF-4878691 (3M-852A) is a potent, orally active, and selective **Toll-like receptor 7 (TLR7)** agonist modelled to dissociate its antiviral and inflammatory activities.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-543

(Sphingosine Kinase 1 Inhibitor II)

Cat. No.: HY-15425

PF-543 (Sphingosine Kinase 1 Inhibitor II) is a potent, selective, reversible and sphingosine-competitive **SPHK1** inhibitor with an IC_{50} of 2 nM and a K_i of 3.6 nM. PF-543 is >100-fold selectivity for **SPHK1** over SPHK2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-543 Citrate

(Sphingosine Kinase 1 Inhibitor II Citrate)

Cat. No.: HY-15425A

PF-543 Citrate (Sphingosine Kinase 1 Inhibitor II Citrate) is a potent, selective, reversible and sphingosine-competitive **SPHK1** inhibitor with an IC_{50} of 2 nM and a K_i of 3.6 nM. PF-543 Citrate is >100-fold selectivity for **SPHK1** over SPHK2.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-543 hydrochloride

(Sphingosine Kinase 1 Inhibitor II hydrochloride)

Cat. No.: HY-15425B

PF-543 hydrochloride (Sphingosine Kinase 1 Inhibitor II hydrochloride) is a potent, selective, reversible and sphingosine-competitive **SPHK1** inhibitor with an IC_{50} of 2 nM and a K_i of 3.6 nM. PF-543 hydrochloride is >100-fold selectivity for **SPHK1** over SPHK2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-610355

Cat. No.: HY-14296

PF-610355 is a long-acting inhaled β_2-**adrenoreceptor** agonist, with an EC_{50} of 0.26 nM. PF-610355 has the potential for the study of asthma and COPD.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-8380

Cat. No.: HY-13344

PF-8380 is a potent **autotaxin** inhibitor with an IC_{50} of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-8380 hydrochloride

Cat. No.: HY-13344A

PF-8380 hydrochloride is a potent **autotaxin** inhibitor with an IC_{50} of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.



Purity: 96.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-9184

Cat. No.: HY-19622

PF-9184 is a potent and highly selective inhibitor of human **microsomal prostaglandin E synthase-1 (mPGES-1)**, with an IC_{50} of 16.5 nM. PF-9184 inhibits IL-1β-induced PGE_2 synthesis in vitro.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PG-931

Cat. No.: HY-P1208

PG-931, an analog of SHU 9119 (HY-P0227), is a potent **melanocortin 4 (MC4) receptor** (IC_{50}=0.58 nM) agonist and is more selective than for the hMC3R (IC_{50}=55 nM) or the hMC5R (IC_{50}=2.4 nM). PG-931 can reverse haemorrhagic shock and prevent multiple organ damage in vivo.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PG-931 TFA

Cat. No.: HY-P1208A

PG-931 TFA, an analog of SHU 9119 (HY-P0227), is a potent **melanocortin 4 (MC4) receptor** (IC_{50}=0.58 nM) agonist and is more selective than for the hMC3R (IC_{50}=55 nM) or the hMC5R(IC_{50}=2.4 nM).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PG106

Cat. No.: HY-P1209

PG106 is a potent and selective **human melanocortin 3 (hMC3) receptor** antagonist (IC_{50}=210 nM) and has noactivity at hMC4 receptors (EC_{50}=9900 nM) and hMC5 receptor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PGD2-IN-1

Cat. No.: HY-101430

PGD2-IN-1 is an antagonist of **DP** extracted from patent WO 2006044732 A2, example 15 (d); has an IC_{50} of 0.3 nM.



Purity: 98.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PGS-IN-1

(KME-4)

Cat. No.: HY-101587

PGS-IN-1 is a potent inhibitor of **prostaglandin synthetase** (PGS) with an IC_{50} of 0.28 μM; also inhibits **5-lipoxygenase** with an IC_{50} of 1.05 μM.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

PH-797804

Cat. No.: HY-10403

PH-797804 is a ATP-competitive, selective **p38α/p38β** inhibitor (IC_{50}=26 nM and K_i=5.8 nM for p38α; K_i=40 nM for p38β) and does not inhibit JNK2.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

PHA 568487

Cat. No.: HY-107666

PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (**α-7 nAchR**).PHA 568487 reduces neuroinflammation and oxidative stress. PHA-568487 has rapid brain penetration.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

PHD-1-IN-1

Cat. No.: HY-136300

PHD-1-IN-1 is an orally active and potent **HIF prolylhydroxylase domain-1 (PHD-1)** inhibitor with an IC_{50} of 0.034 μM. PHD-1-IN-1 has a unique monodentate binding interaction with the active site Fe^{2+} ion and induces the formation of an "Arg367-out" pocket.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phellodendrine

Cat. No.: HY-N0427

Phellodendrine, a isoquinoline alkaloid, is one of important characteristic ingredients in the Phellodendri chinensis cortex. phellodendrine is against AAPH-induced oxidative stress through regulating the **AKT/NF-κB** pathway.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Phellopterin

Cat. No.: HY-N2110

Phellopterin is a natural product isolated from P. trifoliata. Phellopterin reduces TNF-alpha-induced VCAM-1 expression through regulation of the Akt and PKC pathway, which contributes to inhibit the adhesion of monocytes to endothelium.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Phenacetin
(Acetophenetidin)

Cat. No.: HY-B0476

Phenacetin (Acetophenetidin) is a non-opioid analgesic/antipyretic agent. Phenacetin is a selective **COX-3** inhibitor. Phenacetin is used as probe of cytochrome P450 enzymes CYP1A2 in human liver microsomes and in rats.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Phenamil methanesulfonate

Cat. No.: HY-108464A

Phenamil methanesulfonate, an analog of Amiloride (HY-B0285), is a more potent and less reversible **epithelial sodium channel (ENaC)** blocker with an IC_{50} of 400 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Phenanthrene

Cat. No.: HY-B1727

Phenanthrene is a polycyclic aromatic hydrocarbon (PAH) and has been frequently used as an indicator for monitoring PAH contaminated matrices. Phenanthrene induces oxidative stress and inflammation.



Purity: 99.80%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg

Phenanthrene-d10

Cat. No.: HY-B1727S

Phenanthrene-d10 is the deuterium labeled Phenanthrene. Phenanthrene is a polycyclic aromatic hydrocarbon (PAH) and has been frequently used as an indicator for monitoring PAH contaminated matrices. Phenanthrene induces oxidative stress and inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Phenethyl ferulate

Cat. No.: HY-W009248

Phenethyl ferulate is a major constituent ofQianghuo, shows inhibitory activity against **cyclooxygenase** (**COX**) and **5-lipoxygenase** (**5-LOX**) with IC_{50} values of 4.35 μM and 5.75 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phenidone

Cat. No.: HY-W010144

Phenidone, an orally active dual inhibitor of **cyclooxygenase (COX)** and **lipoxygenase (LOX)**, ameliorates rat paralysis in experimental autoimmune encephalomyelitis. Phenidone is a potent hypotensive agent in the spontaneously hypertensive rat.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Pheniramine Maleate

Cat. No.: HY-B0971

Pheniramine Maleate ia an antihistamine and vasoconstrictor.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Phenylbutazone

Cat. No.: HY-B0230

Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory drug (NSAID).



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Phenylbutazone(diphenyl-d10)

Cat. No.: HY-B0230S

Phenylbutazone-d10 (diphenyl) is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory drug (NSAID).



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg, 25 mg

Phenylethanolamine A

Cat. No.: HY-131103

Phenylethanolamine A acts as a **β-adrenergic** agonist. Phenylethanolamine A is a byproduct during the Ractopamine synthesis process.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phenylethanolamine A-D3

Cat. No.: HY-131103S

Phenylethanolamine A-D3 is a deuterium labeled Phenylethanolamine A. Phenylethanolamine A acts as a β-adrenergic agonist. Phenylethanolamine A is a byproduct during the Ractopamine synthesis process.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phenylpyropene C

(S14-95)

Cat. No.: HY-115734

Phenylpyropene C (S14-95), a **JAK/STAT** pathway inhibitor, can inhibit IFN-γ mediated expression of the reporter gene (IC_{50}=5.4~10.8 μM). Phenylpyropene C also is an inhibitor of **acyl-CoA**, with an IC_{50} of 16.0 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phillyrin

Cat. No.: HY-N0482

Phillyrin is isolated from Forsythia suspensa Vahl (Oleaceae), has antibacterial and anti-inflammatory activities. Phillyrin has potential inductive effects on rat **CYP1A2** and **CYP2D1** activities, without affecting CYP2C11 and CYP3A1/2 activities.



Purity: 98.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Phorbol 12-myristate 13-acetate

(Phorbol myristate acetate; PMA)

Cat. No.: HY-18739

Phorbol 12-myristate 13-acetate (PMA), a phorbol ester, is a dual **SphK** and **protein kinase C (PKC)** activator. Phorbol 12-myristate 13-acetate is a NF-κB activator. Phorbol 12-myristate 13-acetate induces differentiation in THP-1 cells.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Phosphoramidon Disodium

Cat. No.: HY-N2021A

Phosphoramidon Disodium is a **metalloprotease** inhibitor. Phosphoramidon inhibits endothelin-converting enzyme (**ECE**), neutral endopeptidase (**NEP**), and angiotensin-converting enzyme (**ACE**) with IC_{50} values of 3.5, 0.034, and 78 μM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Phthalide

Cat. No.: HY-W015820

Phthalide is a promising chemical scaffold with a potent anti-inflammatory efficacy. Phthalide can be used to synthesize a variety of phthalide derivatives including anti-inflammatory agent, antimicrobial, antioxidant.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Physalin F

Cat. No.: HY-N7696

Physalin F is a secosteroid with potent anti-inflammatory and immunomodulatory activities. Physalin F induces apoptosis of PBMC, decreasing the spontaneous proliferation and cytokine production caused by Human T-lymphotropic virus type 1 (HTLV-1) infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Physcion

(Parietin; Rheochrysidin)

Cat. No.: HY-N0108

Physcion (Parietin) is an anthraquinone isolated from traditional Chinese medicine Radix et Rhizoma Rhei, acts as an inhibitor of **6-phosphogluconate dehydrogenase**, with an IC_{50} and a K_d of 38.5 μM and 26.0 μM, respectively.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Physcion 8-O-β-D-glucopyranoside

Cat. No.: HY-N5091

Physcion 8-O-β-D-glucopyranosideis an anthraquinone compound isolated from Rumex japonicus Houtt. Physcion 8-O-β-D-glucopyranoside exerts anti-inflammatory and anti-cancer properties, can be for common malignancy cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Phytic acid (Inositol hexaphosphate; myo-Inositol, hexakis(dihydrogen phosphate))

Cat. No.: HY-N0814

Phytic acid is a phosphorus storage compound of seeds and cereal grains. Phytic acid is known as a food inhibitor, which has a strong ability to chelate multivalent metal ions, specially zinc, calcium, iron and as with protein residue.



Purity: ≥95.0%
Clinical Data: Launched
Size: 250 mg (757.5 mM * 500 μL in Water) ,

Phytic acid dodecasodium salt hydrate (Inositol hexaphosphate dodecasodium salt hydrate; ...)

Cat. No.: HY-N0814A

Phytic acid dodecasodium salt hydrate is a phosphorus storage compound of seeds and cereal grains.



Purity: ≥98.0%
Clinical Data: Phase 3
Size: 250 mg

Phytohemagglutinin (PHA-M)

Cat. No.: HY-N7038

Phytohemagglutinin (PHA-M), the major seed lectin of the common bean, Phaseolus vulgaris, accumulates in the parenchyma cells of the cotyledons. Phytohemagglutinin is a T-cell activator.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

Phytohemagglutinin P (PHA-P)

Cat. No.: HY-N7038A

Phytohemagglutinin P (PHA-P) is a mitogen known to selectively stimulate cells of hematogenous or lymphoid monocytic origin.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Phytolaccagenin

Cat. No.: HY-N1433

Phytolaccagenin, a triterpenoid saponin, is the active component of Radix Phytolaccae. Phytolcaccagenin has antifungal activity, anti-inflammatory activity and lower toxicity.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

PI-3065

Cat. No.: HY-12235

PI-3065 is a potent inhibitor of **PI3K p110δ**, with IC_{50} and K_i values of 5 nM and 1.5 nM, and exhibits less potent activity against p110α, p110β, p110γ with IC_{50}s of 910, 600, >10000 nM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PI3Kdelta inhibitor 1

Cat. No.: HY-112439

PI3Kdelta inhibitor 1 (Compound 5d) is a potent, selective and orally available **PI3Kδ** inhibitor with an IC_{50} of 1.3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kγ inhibitor 2

Cat. No.: HY-112286

PI3Kγ inhibitor 2 (Compound 16) is an orally bioavailable, CNS-penetrant, isoform selective **PI3Kγ** inhibitor with a K_i of 4 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kγ inhibitor 4

Cat. No.: HY-132299

PI3Kγ inhibitor 4 is a potent, selective and orally active inhibitor of **PI3Kγ**, with an IC_{50} of 40 nM. PI3Kγ inhibitor 4 shows 7, 43, and 18-fold selectivity for PI3Kγ over the α, β, and δ isoforms, respectively. PI3Kγ inhibitor 4 can be used for the research of airway inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kδ-IN-1

Cat. No.: HY-101921

PI3Kδ-IN-1 is a potent, selective, and efficacious **PI3Kδ** inhibitor with an IC_{50} of 1.7 nM.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Picfeltarraenin IA

Cat. No.: HY-N1474

Picfeltarraenin IA, a triterpenoid obtained from Picriafel-terrae Lour (P.fel-terrae), is an acetylcholinesterase (**AChE**) inhibitor. Picfeltarraenin IA can be used for the treatment of herpes infections, cancer and inflammation.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Picfeltarraenin IB

Cat. No.: HY-N2211

Picfeltarraenin IB, a triterpenoid obtained from Picriafel-terrae Lour (P.fel-terrae), is an acetylcholinesterase (**AChE**) inhibitor. Picfeltarraenin IB can be used for the treatment of herpes infections, cancer and inflammation.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Picfeltarraenin IV

Cat. No.: HY-N5076

Picfeltarraenin IV, a triterpenoid obtained from Picriafel-terrae Lour (P.fel-terrae), is an acetylcholinesterase (**AChE**) inhibitor. Picfeltarraenin IV can be used for the treatment of herpes infections, cancer and inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Piclamilast

(RP 73401; RPR 73401)

Cat. No.: HY-12887

Piclamilast (RP 73401) is a **phosphodiesterase 4 (PDE4)** inhibitor, with IC_{50} values of 16 nM and 2 nM in pig aorta and eosinophil soluble, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Piclidenoson

(IB-MECA; CF-101)

Cat. No.: HY-13591

Piclidenoson (IB-MECA) is a first-in-class, orally active and selective **A3 adenosine receptor (A3AR)** agonist. Piclidenoson exhibits antiproliferative effect and induces **apoptosis** in different cancer cell types like melanoma, leukemia.



Purity: 99.32%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Picrinine

Cat. No.: HY-N2074

Picrinine, an akuammiline alkaloid, is isolated from the leaves of Alstonia scholaris. Picrinine exhibits anti-inflammatory activity through inhibition of the 5-lipoxygenase enzyme.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Picroside I

(6'-Cinnamoylcatalpol)

Cat. No.: HY-N0407

Picroside I is the major ingredient of Picrorhiza kurroa. Picrorhiza kurroa is a high value medicinal herb due to rich source of hepatoprotective metabolites, Picroside-I and Picroside-II. Picroside I is a promising agent for the management of asthma.



Purity: 96.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Picroside II

Cat. No.: HY-N0408

Picroside II, an iridoid compound extracted from Picrorhiza, exhibits anti-inflammatory and anti-apoptotic activities. picroside II alleviates the inflammatory response in sepsis and enhances immune function by inhibiting the activation of **NLRP3** inflammasome and **NF-κB** pathways.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Picroside III

Cat. No.: HY-N0409

Picroside III is an iridoid glycoside isolated from Picrorhiza scrophulariiflora (PS), a traditional Chinese medicine.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Picroside IV

Cat. No.: HY-N5086

Picroside IV is an iridoid glycoside found in the underground parts of Picrorhiza scrophulariiflora. Picroside IV is a derivative of Catalpol (HY-N0820).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pidotimod

Cat. No.: HY-B0944

Pidotimod is an orally active dipeptide **immunostimulant** with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Pilloin

Cat. No.: HY-111927

Pilloin, a flavonoid isolated from Marrubium cylleneum, exerts a cytotoxic action targeted at the transformed lymphoblasts. Pilloin also possesses anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pimecrolimus

(SDZ-ASM 981)

Cat. No.: HY-13723

Pimecrolimus is an immunophilin ligand, which binds specifically to the cytosolic receptor, immunophilin macrophilin-12. Target: Others Pimecrolimus blocks T-lymphocyte activation pathway by inhibiting calcineurin function .



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Pinocembrin

((+)-Pinocoembrin; Dihydrochrysin; Galangin flavanone)

Cat. No.: HY-N0575

Pinocembrin ((+)-Pinocoembrin) is a flavonoid found in propolis, acts as a competitive inhibitor of **histidine decarboxylase**, and is an effective anti-allergic agent, with antioxidant, antimicrobial and anti-inflammatory properties.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Pinocembrin chalcone

(2',4',6'-Trihydroxychalcone)

Cat. No.: HY-N7515

Pinocembrin chalcone (2',4',6'-Trihydroxychalcone) is an **antibacterial** compound from Helichrysum Trilineatum. Pinocembrin chalcone can prevent gastric ulcers in rats.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pinostrobin

Cat. No.: HY-N2127

Pinostrobin is a flavonoid can be found in many plants, and has anti-oxidant, anti-inflammatory, anti-cancer and neuroprotective properties. Pinostrobin is a potent **PCSK9** inhibitor and inhibits the catalytic activity of PCSK9.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Piperine

(Bioperine; 1-Piperoylpiperidine)

Cat. No.: HY-N0144

Piperine, a natural alkaloid isolated from Piper nigrum L, inhibits **P-glycoprotein** and **CYP3A4** activities with an IC_{50} value of 61.94±0.054 μg/mL in HeLa cell.



Purity: 98.94%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 200 mg, 1 g, 5 g

Piperlonguminine

Cat. No.: HY-126562

Piperlonguminine is an alkaloid amide isolated from the Piper species. Piperlonguminine shows various biological properties, including anti-inflammatory, antitumor, neuroprotective, anti-platelet, anti-melanogenic, antifungal and antibacterial activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Piperoxan hydrochloride

(Benodaine hydrochloride)

Cat. No.: HY-100850

Piperoxan (Benodaine) hydrochloride is an α_2 adrenoceptor antagonist. Piperoxan hydrochloride is the first-generation antihistamine.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PIPES

(1,4-Piperazinediethanesulfonic acid)

Cat. No.: HY-D0875

PIPES (1,4-Piperazinediethanesulfonic acid) is an important component of PIPES buffer agent used in biochemistry.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Pirazolac

(ZK-76604)

Cat. No.: HY-100146

Pirazolac is a non-steroidal anti-inflammatory drug.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pirenzepine dihydrochloride

(LS519) Cat. No.: HY-17037

Pirenzepine dihydrochloride (LS519) is a selective **M1** muscarinic receptor antagonist.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Pirfenidone

(AMR69) Cat. No.: HY-B0673

Pirfenidone (AMR69) is an antifibrotic agent that attenuates **CCL2** and **CCL12** production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces **TGF-β2** protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Pirfenidone-d5

(AMR69-d5) Cat. No.: HY-B0673S

Pirfenidone D5 (AMR69 D5) is a deuterium labeled Pirfenidone. Pirfenidone is an antifibrotic agent that attenuates **CCL2** and **CCL12** production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces **TGF-β2** protein levels in human glioma cell lines.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Pirinixic acid

(Wy-14643) Cat. No.: HY-16995

Pirinixic acid (Wy-14643) is a potent agonist of **PPARα**, with **EC_{50}**s of 0.63 μM, 32 μM for murine **PPARα** and PPARγ, and 5.0 μM, 60 μM, 35 μM for human **PPARα**, PPARγ and PPARδ, respectively.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 250 mg

Pirolate

(CP-32387) Cat. No.: HY-100280

Pirolate is a **histamine H1** receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Piroxicam

(CP-16171) Cat. No.: HY-B0253

Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a **COX** inhibitor, with **IC_{50}**s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 10 g

Piroxicam D3

(CP-16171 D3) Cat. No.: HY-B0253S

Piroxicam D3 (CP-16171 D3) is deuterium labeled Piroxicam. Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC_{50}s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Pivanex

(AN-9; Pivalyloxymethyl butyrate) Cat. No.: HY-120508

Pivanex (AN-9), a derivative of Butyric acid, is an orally active **HDAC** inhibitor. Pivanex down-regulates **bcr-abl** protein and enhances **apoptosis**. Pivanex has antimetastic and antiangiogenic properties.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

PK68

Cat. No.: HY-128348

PK68 is a potent and selective type II inhibitor of **receptor-interacting kinase 1 (RIPK1)** with an **IC_{50}** of ~90nM, displays inhibition of RIPK1-dependent necroptosis.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PKA-IN-1

Cat. No.: HY-115732

PKA-IN-1 is a potent and selective cyclic AMP-dependent protein kinase (PKA) catalytic subunit (**cAK**) inhibitor with an **IC_{50}** of 0.03 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKC-IN-1

Cat. No.: HY-16903

PKC-IN-1 is a potent, ATP-competitive and reversible inhibitor of conventional **PKC** enzymes with K_is of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC_{50}s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε, respectively.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PKC-theta inhibitor 1

Cat. No.: HY-126328

PKC-theta inhibitor 1 is the **PKCθ** inhibitor with an K_i value of 6 nM, inhibits IL-2 production in vivo with an IC_{50} of 0.19 μM. PKC-theta inhibitor 1 demonstrates a reduction of symptoms in a mouse model of multiple sclerosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKR-IN-2

Cat. No.: HY-19702

PKR-IN-2 is a pyruvate kinase isoform **PKR** activator extracted from patent WO2014139144A1, compound 160. PKR-IN-2 can be used for the research of PKR function related diseases, including cancer, diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PL553

Cat. No.: HY-U00452

PL553 is a specific and high-affinity fluorigenic substrate of Leukotriene A4 hydrolase, with a λ_{max} of 210 nm and λ_{em} of 410 nm.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Plantamajoside

Cat. No.: HY-N0031

Plantamajoside is a phenylpropanoid glycoside isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside has protective effects on LPS-induced acute lung injury (ALI) mice model. Plantamajoside has the potential for the treatment of pulmonary inflammation.



Purity: 95.42%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Plantanone B

(Kaempferol 3-O-rhamnosylgentiobioside)

Cat. No.: HY-N8167

Plantanone B is a moderate **antioxidant-agent** with an IC_{50} of 169.8±5.2 μM. Plantanone B shows significant ovine COX-1 and moderate COX-2 inhibitory activities. Plantanone B has the potential for inflammation-related diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Platyconic acid A

Cat. No.: HY-N9377

Platyconic Acid A is an active component of changkil saponins from platycodon grandiflorum and can be used for the research of reducing airway inflammation.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 5 mg

Platycoside E

Cat. No.: HY-N3522

Platycoside E is a platycodigenin-type saponin isolated from the root of Platycodon grandiflorum with **haemolytic activity** and **adjuvant potential**. Platycoside E promotes the production of the sera OVA-specific **IgG2a** and **IgG2b** antibody in the ovalbumin (OVA)-immunized mice.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Plecanatide

Cat. No.: HY-108741

Plecanatide, an analogue of Uroguanylin, is an orally active **guanylate cyclase-C (GC-C) receptor** agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC_{50} of 190 nM in T84 cells assay.

Purity: 98.90%
Clinical Data: Launched
Size: 5 mg, 10 mg

Plecanatide acetate

Cat. No.: HY-108741A

Plecanatide acetate, an analogue of Uroguanylin, is an orally active **guanylate cyclase-C (GC-C) receptor** agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC_{50} of 190 nM in T84 cells assay.

Purity: 99.26%
Clinical Data: Launched
Size: 5 mg, 10 mg

Plerixafor

(AMD 3100; JM3100; SID791)

Cat. No.: HY-10046

Plerixafor (AMD 3100) is a selective **CXCR4** antagonist with an **IC_{50}** of 44 nM. Plerixafor, an immunostimulant and a **hematopoietic stem cell (HSC)** mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits **HIV-1** and **HIV-2** replication with an **EC_{50}** of 1-10 nM.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Plerixafor octahydrochloride (AMD3100 octahydrochloride; JM3100 octahydrochloride; SID791 octahydrochloride)

Cat. No.: HY-50912

Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective **CXCR4** antagonist with an **IC_{50}** of 44 nM.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PLP (139-151)

Cat. No.: HY-P0129

PLP (139-151) is amino acid residue 139 to 151 of myelin proteolipid protein (PLP) used to induce experimental autoimmune encephalomyelitis (EAE).

HCLGKWLGHPDKF

Purity: 98.34%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PLX647 dihydrochloride

Cat. No.: HY-13838A

PLX647 dihydrochloride is an orally active, highly specific dual **FMS** and **KIT** kinase inhibitor, with **IC_{50}**s of 28 and 16 nM, reapectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

pm26TGF-β1 peptide

Cat. No.: HY-P2294

pm26TGF-β1 peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide shows high affinity for the **TGF-β1 receptor**. pm26TGF-β1 peptide displays potent anti-inflammatory properties and does not exhibit neutrophils' chemoattraction.

ACESPLKRQCGGGS

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

pm26TGF-β1 peptide TFA

Cat. No.: HY-P2294A

pm26TGF-β1 TFA peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide TFA shows high affinity for the **TGF-β1 receptor**. pm26TGF-β1 peptide TFA displays potent anti-inflammatory properties and does not exhibit neutrophils' chemoattraction.

ACESPLKRQCGGGS (TFA salt)

Purity: 99.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

PMX 205

Cat. No.: HY-110136

PMX 205 is a potent **complement C5a receptor** (**C5aR**; **CD88**) antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PMX 205 Trifluoroacetate

Cat. No.: HY-110136A

PMX 205 Trifluoroacetate is a potent **complement C5a receptor** (**C5aR**; **CD88**) antagonist.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

PMX-53

(3D53)

Cat. No.: HY-106178

PMX-53 (3D53) is a synthetic peptidic and a potent and orally active **complement C5a receptor (CD88)** antagonist with an **IC_{50}** of 20 nM. PMX-53 is also a low-affinity **MrgX2** agonist that stimulates **MrgX2**-mediated mast cell degranulation.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

PNRI-299

Cat. No.: HY-15131

PNRI-299 is a selective **AP-1** transcription inhibitor with an **IC_{50}** of 20 uM. PNRI-299 is a selective **APE/Ref-1** inhibitor. PNRI-299 has no effect on NF-κB transcription or thioredoxin (up to 200 uM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PNU-120596

(NSC 216666)

Cat. No.: HY-12152

PNU-120596 (NSC 216666) is a potent and selective **α7 nAChR** positive allosteric modulator (PMA) with an EC_{50} of 216 nM. PNU-120596 is inactive against α4β2, α3β4, and α9α10 nAChRs. PNU-120596 has the potential for psychiatric and neurological disorders research.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PNU-159682 carboxylic acid

Cat. No.: HY-126666

PNU-159682 carboxylic acid (compound 53) is a potent **ADCs cytotoxin** and encodes a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pogostone

Cat. No.: HY-N1416

Pogostone is isolated from patchouli with anti-bacterial and anti-cancer activities.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Polaprezinc

(Zinc L-carnosine)

Cat. No.: HY-B0729

Polaprezinc is an orally bioavailable chelate composed of zinc and L-carnosine, with potential gastroprotective, anti-oxidant, anti-ulcer and anti-inflammatory activities.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

Poliumoside

Cat. No.: HY-N0033

Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens **aldose reductase** (**RLAR**) inhibitor, with IC_{50}s of 19.69 and 8.47 μM, respectively.



Purity: 95.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Poloxamer 407

Cat. No.: HY-D1005

Poloxamer 407 is a nonionic surfactant that is 100% active and relatively non-toxic to cells at low concentrations, and frequently used with dye AM esters such as Indo-1 AM, Fura-2 AM, Calcein AM, Fluo-3 AM, Fluo-4 AM, Quest Fluo-8™ AM and Quest Rhod-4™ AM, etc.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg

Poly-L-lysine hydrochloride

Cat. No.: HY-126437A

Poly-L-lysine hydrochloride is a nonspecific attachment factor for cells useful in promoting cell adhesion to solid substrates by enhancing electrostatic interaction between negatively charged ions of the cell membrane and the culture surface.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Polydatin

(Piceid)

Cat. No.: HY-N0120A

Polydatin (Piceid), extracted from the roots of Polygonum cuspidatum Sieb, a widely used traditional Chinese remedies, possesses anti-inflammatory activity in several experimental models. Polydatin (Piceid) inhibits G6PD and induces oxidative and ER stresses.



Purity: 98.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Polygalacic acid

Cat. No.: HY-N0801

Polygalacic acid, is a triterpene, isolated from the root of Polygala tenuifolia Willd.
Polygalacic acid inhibits **MMP** expression.
Polygalacic acid may have a therapeutic effect in Osteoarthritis (OA) treatment .



Purity: 98.92%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Polygalasaponin F

Cat. No.: HY-N0392

Polygalasaponin F, an oleanane-type triterpenoid saponin extracted from Polygala japonica, decreases the release of the inflammatory cytokine tumor necrosis factor a (TNFa).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Polygalasaponin V

Cat. No.: HY-N2169

Polygalasaponin V is a triterpenoid saponin isolated from the aerial parts of Polygala japonica. Polygala japonica has been a folk medicine herb used as expectorant, anti-inflammatory, antibacterial and antidepressant agents in the south of China.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Polygalaxanthone III

Cat. No.: HY-N1407

Polygalaxanthone III is extracted from polygala tenuifolia wild, has inhibitory effect towards **CYP450** enzyme. Polygalaxanthone III inhibits chlorzoxazone 6-hydroxylation catalyzed by CYP2E1 with an IC_{50} of 50.56 μM.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Polygodial

(Poligodial; Tadeonal)

Cat. No.: HY-108450

Polygodial (Poligodial) is an **antifungal** potentiator. Polygodial is a sesquiterpene with anti-hyperalgesic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Polyinosinic-polycytidylic acid sodium

(Poly(I:C) sodium)

Cat. No.: HY-135748

Polyinosinic-polycytidylic acid sodium (Poly(I:C) sodium) is a synthetic analog of double-stranded RNA and an agonist of **toll-like receptor 3 (TLR3)** and **retinoic acid inducible gene I (RIG-I)-like receptors** (**RIG-I** and **MDA5**).

Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

Polyketide synthase 13-IN-1

Cat. No.: HY-139594

Polyketide synthase 13-IN-1 (compound 32) is a **polyketide synthase 13** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Polyketide synthase 13-IN-2

Cat. No.: HY-139595

Polyketide synthase 13-IN-2 (comp 42) is a **polyketide synthase 13** inhibitor against Mycobacterium tuberculosis, with an MIC of 0.25 μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Polyketide synthase 13-IN-3

Cat. No.: HY-139596

Polyketide synthase 13-IN-3 (compound 41) is a **polyketide synthase 13** inhibitorwith a MIC of 0.0625-0.125 μg/mL against the M. tuberculosis strain H37Rv.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Polyphyllin G

Cat. No.: HY-N0817

Polyphyllin G is isolated from the rhizomes of Paris yunnanensis, with antimicrobial and anticancer activity. Polyphyllin G prevents the growth of both Gram-positive and Gram-negative bacteria with minimum inhibitory concentrations (MICs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Polyphyllin H

Cat. No.: HY-N2382

Polyphyllin H has been widely used in traditional Chinese medicinal preparations to treat inflammation, fracture and convulsion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Poncirin

Cat. No.: HY-N2258

Poncirin is isolated from Poncirus trifoliata with **anti-inflammory** activites. Poncirin significantly reduces mechanical hyperalgesia and allodynia in Complete Freund's Adjuvant (CFA)-induced inflammatory pain models.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ponesimod

(ACT-128800)

Cat. No.: HY-10569

Ponesimod (ACT-128800) is a potent, selective and orally active agonist of **$S1P_1$**, with an **IC_{50}** of 6 nM in a radioligand binding assay. Ponesimod activates $S1P_1$-mediated signal transduction with high potency (**EC_{50}**=5.7 nM).



Purity: 99.72%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ponicidin

(Rubescensine B)

Cat. No.: HY-N1535

Ponicidin (Rubescensine B) is a diterpenoid derived from Rabdosia rubescens, and exhibits immunoregulatory, anti-inflammatory, anti-viral and anti-cancer activity.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Posenacaftor

(PTI-801)

Cat. No.: HY-109187

Posenacaftor (PTI-801) is a **cystic fibrosis transmembrane regulator (CFTR) protein** modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor is used for the research of cystic fibrosis (CF).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Posenacaftor sodium

(PTI-801 sodium)

Cat. No.: HY-109187A

Posenacaftor (PTI-801) sodium is a **cystic fibrosis transmembrane regulator (CFTR) protein** modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor sodium is used for the research of cystic fibrosis (CF).



Purity: 99.65%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PPA-904

Cat. No.: HY-U00128

PPA-904 is a specific phenothiazine **photosensitizer** in photodynamic therapy (**PDT**) research, especially topical application for cutaneous leishmaniasis in vivo.



Purity: 97.97%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 20 mg

Ppc-1

Cat. No.: HY-117843

Ppc-1 is a **mitochondrial** uncoupler. Ppc-1 enhances **mitochondrial** oxygen consumption without adverse effects on ATP production. Ppc-1 is a cell-permeate **interleukin-2 (IL-2)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PPTN

Cat. No.: HY-110322A

PPTN is a potent, high-affinity, competitive and highly selective **P2Y14 receptor** antagonist with a **K_B** value of 434 pM. PPTN exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

PPTN hydrochloride

Cat. No.: HY-110322

PPTN hydrochloride is a potent, high-affinity, competitive and highly selective **P2Y14 receptor** antagonist with a **K_B** value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PR-39

Cat. No.: HY-P1259

PR-39, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric **proteasome** inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PR-39 TFA

Cat. No.: HY-P1259A

PR-39 TFA, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric **proteasome** inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Praeruptorin A

Cat. No.: HY-N6065

Praeruptorin A is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin A exerts anti-inflammatory effects in vitro through inhibition of **NF-κB** activation.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Pralnacasan

(VX-740; HMR 3480)

Cat. No.: HY-19676

Pralnacasan (VX-740) is a potent, selective, non-peptide and orally active **interleukin-1β converting enzyme (ICE, caspase 1)** inhibitor with a K_i of 1.4 nM. Pralnacasan inhibits proinflammatory cytokines **IL-18**, **IL-1β** , and **IFN-γ**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Pranlukast

(ONO-1078)

Cat. No.: HY-B0290

Pranlukast is a highly potent, selective and competitive antagonist of peptide **leukotriene**s. Pranlukast inhibits [^{3}H]LTE$_4$, [^{3}H]LTD$_4$, and [^{3}H]LTC$_4$ bindings to lung membranes with K_is of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Pranlukast hemihydrate

(ONO-1078 hemihydrate)

Cat. No.: HY-B0290A

Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide **leukotriene**s. Pranlukast inhibits [^{3}H]LTE$_4$, [^{3}H]LTD$_4$, and [^{3}H]LTC$_4$ bindings to lung membranes with K_is of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Pranlukast-d5

Cat. No.: HY-B0290S

Pranlukast-d5 (ONO-1078-d5) is the deuterium labeled Pranlukast. Pranlukast is a highly potent, selective and competitive antagonist of peptide **leukotriene**s.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Pranoprofen

Cat. No.: HY-B0336

Pranoprofen is a non-steroidal anti-inflammatory agent (**NSAID**) for the research of keratitis or other ophthalmology diseases. Pranoprofen inhibit **COX-1** and **COX-2** enzymes, thus blocking arachidonic acid converted to eicosanoids and reducing prostaglandins synthesis.



Purity: 99.37%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Precyasterone

Cat. No.: HY-N2200

Precyasterone is a natural product isolated from the dried roots of Cyathula capitata.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Prednisolone acetate

(Prednisolone 21-acetate)

Cat. No.: HY-B1214

Prednisolone acetate (Prednisolone 21-acetate) is an adrenal cortico hormones, with anti-inflammatory, anti-allergic and immune suppressive effects.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 250 mg, 500 mg

Prednisolone disodium phosphate

(Prednisolone 21-phosphate disodium)

Cat. No.: HY-B0645

Prednisolone disodium phosphate is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.



Purity: 99.21%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Prednisolone farnesylate

(PNF21)

Cat. No.: HY-U00169

Prednisolone farnesylate (PNF21) is a new transdermal corticosteroid with anti-inflammatory activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Prednisolone hemisuccinate

(Prednisolone 21-hemisuccinate)

Cat. No.: HY-B1087

Prednisolone hemisuccinate is a synthetic glucocorticoid, a derivative of cortisol, which is used to treat a variety of inflammatory and auto-immune conditions.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

Prednisolone Tebutate

Cat. No.: HY-U00098

Prednisolone tebutate is a synthetic glucocorticoid used as an antiinflammatory and immunosuppressant.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Prednisone

(Dehydrocortisone)

Cat. No.: HY-B0214

Prednisone (Adasone) is a synthetic corticosteroid agent that is particularly effective as an immunosuppressant compound. Target: Others Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Prednisone acetate

(Prednisone 21-acetate)

Cat. No.: HY-B1832

Prednisone acetate (Prednisone 21-acetate), the acetate salt form of prednisolone, is a **glucocorticoid receptor** agonist with anti-inflammatory and immunomodulating properties.



Purity: 99.71%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Prim-O-glucosylcimifugin

Cat. No.: HY-N0635

Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of **iNOS** and **COX-2** expression by through regulating JAK2/STAT3 signaling.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PRN694

Cat. No.: HY-12680

PRN694 is an irreversible, highly selective and potent covalent **interleukin-2-inducible T-cell kinase (ITK)** and **resting lymphocyte kinase (RLK)** dual inhibitor with IC_{50}s of 0.3 nM and 1.4 nM, respectively.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Proanthocyanidin A4

Cat. No.: HY-N4146

Proanthocyanidin A4 is a polyphenol found in a variety of plants. Proanthocyanidin A4 possesses anti-inflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Proanthocyanidins

Cat. No.: HY-N0794

Proanthocyanidins are a class of polyphenolic that are widely distributed in higher plants, consisted of an electrophilic flavanyl unit. Proanthocyanidins can be used as antioxidant and anti-cancers agent.



Purity: ≥95.0%
Clinical Data: Phase 4
Size: 10 mg, 50 mg, 100 mg

Procyanidin A1

(Proanthocyanidin A1)

Cat. No.: HY-N2344

Procyanidin A1 (Proanthocyanidin A1) is a procyanidin dimer, which inhibits degranulation downstream of protein kinase C activation or Ca^{2+} influx from an internal store in RBL-213 cells. Procyanidin A1 has antiallergic effects.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Procyanidin A2

Cat. No.: HY-N2343

Procyanidin A2 is a flavonoid found in cranberries and lingonberries, with anti-cancer, antioxidant, antimicrobial and anti-inflammation activity.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Procyanidin B1

Cat. No.: HY-N0795

Procyanidin B1 is a polyphenolic flavonoid isolated from commonly eaten fruits, binds to **TLR4/MD-2** complex, and has anti-inflammatory activity.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Procyanidol B4

((-)-Procyanidin B4)

Cat. No.: HY-107208

Procyanidol B4 ((-)-Procyanidin B4) is a flavanol. Anti-inflammatory properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Prodigiosin

(Prodigiosine)

Cat. No.: HY-100711

Prodigiosin (Prodigiosine) is a red pigment produced by bacteria as a bioactive secondary metabolite. Prodigiosin is a potent inhibitor of the **Wnt/β-catenin** pathway.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 100 μg

Prodigiosin hydrochloride

(Prodigiosine hydrochloride)

Cat. No.: HY-100711A

Prodigiosin (Prodigiosine) hydrochloride is a red pigment produced by bacteria as a bioactive secondary metabolite. Prodigiosin hydrochloride is a potent proapoptotic agent, and inhibits **Wnt/β-catenin** pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 μg, 250 μg, 1 mg

Proparacaine Hydrochloride

(Proxymetacaine Hydrochloride)

Cat. No.: HY-66012

Proparacaine Hydrochloride (Proxymetacaine Hydrochloride) is a derivative of lidocaine (HY-B0185), with immunomodulatory effect and glucocorticomimetic activity.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Propargyl-PEG3-acid

Cat. No.: HY-126975

Propargyl-PEG3-acid is a non-cleavable (3 unit PEG) ADC linker and also a PEG-based PROTAC linker that can be used to synthesis 6-OHDA-PEG3-yne. 6-OHDA-PEG3-yne contains 6-OHDA (HY-B1081, HY-B1081A) and Propargyl-PEG3-acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Propyphenazone

(4-Isopropylantipyrine; Isopropylphenazone)

Cat. No.: HY-A0273

Propyphenazone is a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity, Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 250 mg

Prostaglandin D2

(PGD2)

Cat. No.: HY-101988

Prostaglandin D2 (PGD2) is one of the major PGs actively produced in the brain of various mammals. Prostaglandin D2 is one of the most potent endogenous sleep promoting substances. PGD2 plays a protective role by suppressing inflammation.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 5 mg

PROTAC IDO1 Degrader-1

Cat. No.: HY-131911

PROTAC IDO1 Degrader-1 is the first potent **IDO1** (**indoleamine 2,3-dioxygenase 1**) degrader that hijacks IDO1 to **Cereblon** E3 ligase to introduce IDO1 into UPS and eventually achieve ubiquitination and degradation (DC_{50}=2.84 μM).

Purity: 98.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PROTAC IRAK4 degrader-3

Cat. No.: HY-135382A

PROTAC IRAK4 degrader-3 is a PROTAC-induced **IRAK4** degrader based on **von Hippel-Lindau**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC PD-1/PD-L1 degrader-1

Cat. No.: HY-131183

PROTAC PD-1/PD-L1 degrader-1, a **PD-1/PD-L1** PROTAC based on **Cereblon** E3 ligand, inhibits PD-1/PD-L1 interaction with an IC_{50} of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PROTAC RIPK degrader-2

Cat. No.: HY-111866

PROTAC RIPK degrader-2 is a nonpeptidic **PROTAC** based on **von Hippel-Lindau** ligand which potently targets serine-threonine kinase **RIPK2** and has highly selective for RIPK2 degradation.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Protease-Activated Receptor-1, PAR-1 Agonist

Cat. No.: HY-P2518

Protease-Activated Receptor-1, PAR-1 Agonist is a selective proteinase-activated receptor1 **(PAR-1)** agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Protease-Activated Receptor-3 (PAR-3) (1-6), human

Cat. No.: HY-P2519

Protease-Activated Receptor-3 (PAR-3) (1-6), human is a proteinase-activated receptor (**PAR-3**) agonist peptide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA

Cat. No.: HY-P2519A

Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA is a proteinase-activated receptor (**PAR-3**) agonist peptide.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Protein Kinase C (19-31)

(PKC (19-31))

Cat. No.: HY-P1746

Protein Kinase C (19-31), a peptide inhibitor of **protein kinase C (PKC)**, derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate peptide for testing...

RFARKGALRQKNV

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Protein Kinase C (19-31) (TFA)

(PKC (19-31) (TFA))

Cat. No.: HY-P1746A

Protein Kinase C (19-31) TFA, a peptide inhibitor of **protein kinase C (PKC)**, derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate peptide for testing...

RFARKGALRQKNV (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Protein Kinase C Peptide Substrate

(PKCε; PRKCE ; Peptide Epsilon)

Cat. No.: HY-P1803

Protein Kinase C Peptide Substrate is targeted to a specific cellular compartment in a manner dependent on second messengers and on specific adapter proteins in response to extracellular signals that activate G-protein-coupled receptors, tyrosine kinase receptors, or...

ERMRPRKRQGSVRRRV

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Protirelin

(Thyrotropin-releasing-hormone; TRH)

Cat. No.: HY-P0002

Protirelin is a highly conserved neuropeptide that exerts the hormonal control of thyroid-stimulating hormone (TSH) levels as well as neuromodulatory functions.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Protirelin acetate

(Thyrotropin-releasing-hormone acetate; TRH acetate)

Cat. No.: HY-P0002A

Protirelin Acetate is a highly conserved neuropeptide that exerts the hormonal control of thyroid-stimulating hormone (TSH) levels as well as neuromodulatory functions.



1.5 CH_3COOH

Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PROTO-1

Cat. No.: HY-18673

PROTO-1 shows significant protection of hair cells, with HC50(concentration that would produce 50% hair cell survival) of 1 μM-10 μM (1 μM≤HC50≤10 μM).



Purity: 98.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Protosappanin A

(PTA)

Cat. No.: HY-113573

Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses **JAK2/STAT3**-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3.



Purity: 99.98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

Protostemonine

Cat. No.: HY-N1954

Protostemonine is an active alkaloid mainly isolated from the roots of Stemona sesslifolia, with anti-inflammatory activity. Protostemonine has anti-inflammatory effects on asthma and gram-negative bacteria-induced acute lung injury.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Protostemotinine

Cat. No.: HY-N1955

Protostemotinine is an alkaloid isolated from the roots and rhizomes of Stemona sessilifolia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRT062607

(P505-15; PRT-2607; BIIB-057)

Cat. No.: HY-15322

PRT062607(P505-15; PRT-2607; BIIB-057) is a highly specific and potent inhibitor of Syk with IC50 of 1-2 nM; >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Prudomestin

Cat. No.: HY-N1547

Prudomestin, isolated from the heartwood of Prunus domestica, shows potent **xanthine oxidase (XO)** inhibitory activity (IC_{50}≈6 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Prunetin

Cat. No.: HY-N2597

Prunetin, an O-methylated isoflavone, possesses anti-inflammatory activity. Prunetin is a potent human aldehyde dehydrogenases inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PS10

Cat. No.: HY-121744

PS10 is a novel, potent and ATP-competitive pan-**PDK** inhibitor, inhibits all PDK isoforms with **IC_{50}** of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (**K_d**= 239 nM) than for Hsp90 (K_d= 47 μM).



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PS372424

Cat. No.: HY-111149

PS372424, a three amino-acid fragment of CXCL10, is a specific human **CXCR3** agonist with anti-inflammatory activity. PS372424 prevents human T-cell migration in a humanized model of arthritic inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PS372424 hydrochloride

Cat. No.: HY-111149A

PS372424 hydrochloride, a three amino-acid fragment of CXCL10, is a specific human **CXCR3** agonist with anti-inflammatory activity. PS372424 hydrochloride prevents human T-cell migration in a humanized model of arthritic inflammation.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PSB 0777 ammonium

Cat. No.: HY-136233

PSB 0777 ammonium is a potent and selective adenosine A_{2A} receptor full agonist with K_i values of 44.4 nM, 360 nM for rat and human A_{2A} receptors, respectively. PSB 0777 ammonium has K_i values of ≥10000 nM, 541 nM for rat and human A_1 receptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSB-10 hydrochloride

Cat. No.: HY-103177

PSB-10 hydrochloride is a potent and selective antagonist of **human adenosine A3 receptor (A_3AR)**, with a K_i of 0.44 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSB-603

Cat. No.: HY-103166

PSB-603 is a potent and selective adenosine A_{2B} receptor antagonist exhibiting a K_i value of 0.553 nM at the human A_{2B} receptor and virtually no affinity for the human and rat A_1 and A_{2A} and the human A_3 receptors up to a concentration of 10 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSB069

Cat. No.: HY-103262

PSB069 bearing a p-chlorophenylamino residue is a potent, well-tolerated and nonselective **NTPDases1, 2, 3** inhibitor(K_i=16~18 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pseudocoptisine acetate

(Isocoptisine acetate)

Cat. No.: HY-N6894

Pseudocoptisine (Isocoptisine) acetate is a quaternary alkaloid with benzylisoquinoline skeleton, was isolated from Corydalis Tuber. Pseudocoptisine acetate inhibits **acetylcholinesterase (AChE)** activity with an IC_{50} of 12.8 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pseudocoptisine chloride

(Isocoptisine chloride)

Cat. No.: HY-N6894A

Pseudocoptisine (Isocoptisine) chloride is a quaternary alkaloid with benzylisoquinoline skeleton, was isolated from Corydalis Tuber. Pseudocoptisine chloride inhibits **acetylcholinesterase (AChE)** activity with an IC_{50} of 12.8 μM.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pseudolaric Acid B

Cat. No.: HY-N6939

Pseudolaric Acid B is a diterpene isolated from the root of Pseudolarix kaempferi Gorden (pinaceae), has anti-cancer, antifungal, and antifertile activities, and shows immunosuppressive activity on T lymphocytes.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PSMα3

Cat. No.: HY-P2358

PSMα3 is a peptide for manipulating DCs to become tolerogenic for DC vaccination strategies.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PSMα3 TFA

Cat. No.: HY-P2358A

PSMα3 TFA is a peptide for manipulating DCs to become tolerogenic for DC vaccination strategies.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PTD-p65-P1 Peptide

Cat. No.: HY-P1832

PTD-p65-P1 Peptide is a nuclear transcription factor **NF-kappaB** inhibitor, composed of a membrane-translocating peptide sequence generated from antennapedia (PTD) conjugated with p65-P1, which selectively inhibits activation induced by various inflammatory stimuli.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PTD-p65-P1 Peptide TFA

Cat. No.: HY-P1832A

PTD-p65-P1 Peptide TFA is a nuclear transcription factor **NF-kappaB** inhibitor, composed of a membrane-translocating peptide sequence generated from antennapedia (PTD) conjugated with p65-P1, which selectively inhibits activation induced by various inflammatory stimuli.

Purity: 96.33%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Pterosin B

Cat. No.: HY-N1570

Pterosin B, a indanone found in bracken fern (Pteridium aquilinum), is an inhibitor of **salt-inducible kinase 3 (Sik3)** signaling. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice by inhibiting Sik3.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Pterostilbene

Cat. No.: HY-N0828

Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties.



Purity: 99.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 25 mg

PTPN22-IN-1

Cat. No.: HY-139693

PTPN22-IN-1 is a potent **PTPN22** inhibitor (IC_{50}=1.4 μM; K_i=0.50 μM). PTPN22-IN-1 exhibits >7-10 fold selectivity for PTPN22 over similar phosphatases. PTPN22-IN-1 augments antitumor immune responses. From WO2021007491A1 compound L-1.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Puerarin

Cat. No.: HY-N0145

Puerarin, an isoflavone extracted from Radix puerariae, is a **5-HT2C** receptor antagonist.



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Puerarin 6''-O-Xyloside

Cat. No.: HY-N2135

Puerarin 6''-O-Xyloside, isolated from radix of Pueraria lobata (Willd.), possesses snti-osteoporotic and anti-tumor activity. Puerarin 6''-O-Xyloside induces the mitochondria-mediated apoptosis pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pulegone

Cat. No.: HY-N1500

Pulegone, the major chemical constituent of Calamintha nepeta (L.) Savi essential oil which is an aromatic herb with a mint-oregano flavor, is one of avian repellents. The molecular target for the repellent action of Pulegone in avian species is nociceptive **TRP ankyrin 1 (TRPA1)**.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 5 mg

Pumaprazole

(BY-841)

Cat. No.: HY-19223

Pumaprazole is a reversible **proton pump** antagonist.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Punicalin

Cat. No.: HY-N0639

Punicalin is a hydrolyzable tannin isolated from Punica granatum L. or the leaves of Terminalia catappa L.. Punicalin is a anti-**hepatitis B virus (HBV)** agent and has anti-inflammatory activity.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Purpureaside C

Cat. No.: HY-N4148

Purpureaside C is a phenolic glycoside and has significant proinflammatory action.



Purity: 94.42%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Purpurogallin

Cat. No.: HY-12136

Purpurogallin is a naturally phenol extracted from the plants of Quercus spp, has potent **xanthine oxidase (XO)** inhibitory activity with an IC_{50} of 0.2 μM. Purpurogallin has antioxidant and anti-inflammatory effects.



Purity: 95.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PXS-4681A

Cat. No.: HY-117833

PXS-4681A is a potent, selective, irreversible and orally active **semicarbazide-sensitive amine oxidase (SSAO; VAP-1)** inhibitor with a K_i of 37 nM. PXS-4681A shows highly selectivity over related amine oxidases, ion channels, and seven-transmembrane domain receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PXS-4728A

(BI-1467335)

Cat. No.: HY-112726

PXS-4728A (BI-1467335) is a selective, orally active inhibitor of semicarbazide-sensitive amine oxidase (**SSAO**). PXS-4728A ameliorates chronic obstructive pulmonary disease in mice.



Purity: 99.66%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PXS-5120A

Cat. No.: HY-130242

PXS-5120A is a potent, irreversible fluoroallylamine inhibitor of **Lysyl Oxidase-like 2/3 (LOXL2/3)** with anti-fibrotic activity. PXS-5120A is >300-fold selective for **LOXL2** (K_i of 83 nM; pIC_{50} of 8.4) over **LOXL** (pIC_{50} of 5.8).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

PXS-5153A

Cat. No.: HY-114286

PXS-5153A is a potent, selective, orally active and fast-acting lysyl oxidase like 2/3 enzymatic **(LOXL2/LOXL3)** inhibitor, with an IC_{50} of <40 nM for LOXL2 across all mammalian species and an IC_{50} of 63 nM for human LOXL3. PXS-5153A could reduce crosslinks and ameliorates fibrosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PXS-5153A monohydrochloride

Cat. No.: HY-114286A

PXS-5153A monohydrochloride is a potent, selective, orally active and fast-acting lysyl oxidase like 2/3 enzymatic **(LOXL2/LOXL3)** inhibitor, with an IC_{50} of <40 nM for LOXL2 across all mammalian species and an IC_{50} of 63 nM for human LOXL3.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PY-60

Cat. No.: HY-141644

PY-60 is a robust and specific activator of **YAP** transcriptional activity that targets **annexin A2 (ANXA2)** with a K_d of 1.4 μM. PY-60 directly binds to ANXA2 and antagonizes its normal cellular function of repressing YAP activity.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pygenic acid A

Cat. No.: HY-N1823

Pygenic acid A is a natural compound that can be found in Prunella vulgaris. Pygenic acid A induces **apoptosis** in metastatic breast cancer cells. Pygenic acid A can be used for the research of diabetes, inflammatory diseases, and cancers.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pyributicarb

(TSH-888)

Cat. No.: HY-111202

Pyributicarb, a carbamate-type herbicide, is a potent activator of both **CYP3A4** gene and human **pregnane X receptor** (**hPXR**).



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Pyripyropene A

Cat. No.: HY-117832

Pyripyropene A is a potent and selective **sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2)** inhibitor, with an IC_{50} of 0.07 μM. Pyripyropene A attenuates hypercholesterolemia and atherosclerosis in vivo.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 250 μg

Pyrrolidinedithiocarbamate ammonium

(Ammonium pyrrolidinedithiocarbamate; PDTC ammonium; APDC) Cat. No.: HY-18738

Pyrrolidinedithiocarbamate ammonium (Ammonium pyrrolidinedithiocarbamate) is a selective and blood-brain barrier (BBB) permeable **NF-κB** inhibitor.



Purity: 99.04%
Clinical Data: Phase 3
Size: 100 mg

Pyrrolifene

Cat. No.: HY-U00081

Pyrrolifene is an analgesic with anti-inflammatory effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pyrroloquinoline quinone

(PQQ; Methoxatin) Cat. No.: HY-100196

Pyrroloquinoline quinone (PQQ), a redox co-factor, is an anionic, redox-cycling orthoquinone. Pyrroloquinoline quinone is isolated from cultures of methylotropic bacteria and tissues of mammals. Pyrroloquinoline quinone is an essential nutrient for mammals and is important for immune function.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pyrroloquinoline quinone disodium salt

(PQQ disodium salt; Methoxatin disodium salt) Cat. No.: HY-100196A

Pyrroloquinoline quinone disodium salt, a redox co-factor, is an anionic, redox-cycling orthoquinone. Pyrroloquinoline quinone disodium salt is isolated from cultures of methylotropic bacteria and tissues of mammals.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pyrrophenone

Cat. No.: HY-111376

Pyrrophenone is a potent and specific cytosolic phospholipase $A_2\alpha$ (**cPLA$_2\alpha$**) inhibitor with an IC_{50} value of 4.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

QAQ dichloride

Cat. No.: HY-110358

QAQ dichloride, a photoswitchable **voltage-gated Na_v** and **K_v** channels blocker, blocks channels in its trans form (of the azobenzene photoswitch), but not in its cis form.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

QL9

Cat. No.: HY-P0287

QL9 (QLSPFPFDL) is a high-affinity alloantigen for the 2C T cell receptor (TCR).

QLSPFPFDL

Purity: 98.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

QM385

Cat. No.: HY-114388

QM385 is a potent **sepiapterin reductase (SPR)** inhibitor with an **IC_{50}** of 1.49 nM, which blocks T-cell proliferation and autoimmunity at nanomolar potency and with good oral bioavailability.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

QNZ

(EVP4593) Cat. No.: HY-13812

QNZ (EVP4593) shows strong inhibitory effects on **NF-κB** transcriptional activation and **TNF-α** production with **IC_{50}**s of 11 and 7 nM, respectively. QNZ (EVP4593) is a neuroprotective inhibitor of **SOC** channel.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

QS-21

(Stimulon) Cat. No.: HY-101092

QS-21, an immunostimulatory saponin, could be used as a potent vaccine adjuvant. QS-21 stimulates **Th2** humoral and **Th1** cell-mediated immune responses through action on antigen presenting cells (APCs) and T cells.



Purity: 94.33%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Quadrol

(N,N,N′,N′-Tetrakis(2-hydroxypropyl)ethylenediamine; EDTP) Cat. No.: HY-B2149

Quadrol is an immunostimulant and has been implicated as a potentially useful agent in accelerated wound healing.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 10 g

Quebecol

Cat. No.: HY-N10059

Quebecol is a nutraceutical agent against periodontitis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Quercetagetin

(6-Hydroxyquercetin) Cat. No.: HY-N4149

Quercetagetin (6-Hydroxyquercetin) is a flavonoid. Quercetagetin is a moderately potent and selective, cell-permeable **pim-1** kinase inhibitor (IC_{50}, 0.34 μM). Anti-inflammatory and anticancer properties.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Quercetagitrin

(Quercetagetin-7-O-glucoside) Cat. No.: HY-N4150

Quercetagitrin (Quercetagetin-7-O-glucoside), isolated from the flowers of the African Marigold (Tagetes erecta), has anti-inflammatory activity.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Quercetin 3,3'-dimethyl ether

Cat. No.: HY-N9135

Quercetin 3,3'-dimethyl ether possesses antioxidant acticity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Quercetin 3-O-neohesperidoside

Cat. No.: HY-N7976

Quercetin 3-O-neohesperidoside, a flavonoid glycoside, has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Quercetin dihydrate

Cat. No.: HY-N0146

Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant **SIRT1** and a **PI3K** inhibitor with **IC_{50}s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively.**.



Purity: ≥97.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 500 mg

Quercetin pentaacetate

(Pentaacetylquercetin) Cat. No.: HY-124512

Quercetin pentaacetate could interact with F-protein with lower binding energy and better stability to block viral adhesion. Quercetin pentaacetate interacts with RSV and inhibit the viral adhesion on cell surface.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Quercitrin

(Quercetin 3-rhamnoside) Cat. No.: HY-N0418

Quercitrin is a natural compound found in Tartary buckwheat with a potential anti-inflammation effect that is used to treat heart and vascular conditions.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Quiflapon

(MK-591) Cat. No.: HY-10037

Quiflapon (MK-591) is a selective and specific **5-lipoxygenase-activating protein (FLAP)** inhibitor with an **IC_{50}** of 1.6 nM in a FLAP binding assay.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Quiflapon sodium

(MK-591 sodium)

Cat. No.: HY-50714

Quiflapon sodium (MK-591 sodium) is a selective and specific 5-Lipoxygenase-activating protein (**FLAP**) inhibitor. Quiflapon sodium is an orally active **Leukotriene biosynthesis** inhibitor. Induces **apoptosis**.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Quinaldopeptin

Cat. No.: HY-136295

Quinaldopeptin, a quinomycin antibiotic isolated from the culture of Streptoverticillium album strain, is highly active against Gram-positive bacteria and anaerobes and strongly cytotoxic against cultured B16 melanoma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Quinolinic acid

Cat. No.: HY-100807

Quinolinic acid is an endogenous N-methyl-D-aspartate (**NMDA**) **receptor** agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

Quinotolast sodium

(FR71021)

Cat. No.: HY-U00027

Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits **histamine**, **LTC_4** and **PGD_2** release in a concentration-dependent manner.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

R 59-022

(DKGI-I; Diacylglycerol kinase inhibitor I)

Cat. No.: HY-107613

R 59-022 (DKGI-I) is a **diacylglycerol kinase** inhibitor (**IC_{50}**=2.8 μM). R 59-022 is a **5-HTR** antagonist, and activates **protein kinase C (PKC)**.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

R-BC154 acetate

Cat. No.: HY-136214

R-BC154 acetate is a selective fluorescent **$\alpha_9\beta_1$** integrin antagonist. R-BC154 acetate acts as a useful high affinity, activation dependent integrin probe, which can be used to investigate α9β1 and α4β1 integrin binding activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

R112

Cat. No.: HY-16420

R112 is an ATP-competitive inhibitor of Syk kinase with a Ki of 96 nM. R112 inhibits Syk kinase activity with an IC50 of 226 nM.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

R243

Cat. No.: HY-122219

R243 is a potent and selective **CCR8** antagonist. R243 inhibits **CCL_1/CCR8** interaction and inhibits **CCR8** signaling and chemotaxis. R243 has antinociceptive and anti-inflammatory effects.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

R406

Cat. No.: HY-12067

R406 is an orally available and competitive **Syk/FLT3** inhibitor for ATP binding with a **K_i** of 30 nM, potently inhibits Syk kinase activity in vitro with an **IC_{50}** of 41 nM, measured at an ATP concentration corresponding to its K_m value.



Purity: 96.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

R406 free base

Cat. No.: HY-11108

R406 free base is an orally available and competitive **Syk/FLT3** inhibitor for ATP binding with a **K_i** of 30 nM, potently inhibits Syk kinase activity in vitro with an **IC_{50}** of 41 nM, measured at an ATP concentration corresponding to its K_m value.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rabdosiin

((+)-Rabdosiin)

Cat. No.: HY-N6880

Rabdosiin is a tetramer of caffeic acid isolated from the stem of Rabdosia japonica Hara. Rabdosiin possess anti-allergic activity, anti-HIV activity and inhibition on DNA topoisomerase.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Rabeprazole

(LY307640)

Cat. No.: HY-B0656

Rabeprazole (LY307640) is a second-generation proton **pump inhibitor** (**PPI**) that irreversibly inactivates gastric H^+/K^+-ATPase. Rabeprazole induces **apoptosis**. Rabeprazole acts as an uridine nucleoside ribohydrolase (**UNH**) inhibitor with an IC_{50} of 0.3 μM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Rabeprazole sodium

(LY307640 sodium)

Cat. No.: HY-B0656A

Rabeprazole sodium (LY307640 sodium) is a second-generation proton **pump inhibitor** (**PPI**) that irreversibly inactivates gastric H^+/K^+-ATPase. Rabeprazole sodium induces **apoptosis**.



Purity: 99.17%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Rabeprazole Sulfide

Cat. No.: HY-W003467

Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a **proton pump** inhibitor that suppresses gastric acid secretion through an interaction with (H^+/K^+)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of **H. pylori**.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Rabeprazole-d4

(LY307640-d4)

Cat. No.: HY-B0656S

Rabeprazole D4 (LY307640 D4) is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton **pump inhibitor** (**PPI**) that irreversibly inactivates gastric H^+/K^+-ATPase. Rabeprazole induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Raddeanoside R17

(Pulchinenoside E3)

Cat. No.: HY-N8096

Raddeanoside R17 (Pulchinenoside E3) is a saponin compound that can be isolated from the root of Pulsatilla koreana. Raddeanoside R17 shows anti-inflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RAGE antagonist peptide

Cat. No.: HY-P2268

RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4.

Ac-ELKVLMEKEL-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RAGE antagonist peptide TFA

Cat. No.: HY-P2268A

RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4.

Ac-ELKVLMEKEL-NH_2 (TFA salt)

Purity: 99.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Raleukin

(AMG-719)

Cat. No.: HY-108841

Raleukin (AMG-719) is a recombinant, nonglycosylated human **interleukin-1 receptor (IL-1R)** antagonist. Raleukin (AMG-719) is the first biological agent to block the pro-inflammatory effects.

Raleukin

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg

Ralimetinib

(LY2228820)

Cat. No.: HY-13241A

Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of **p38 MAPK α/β**, with IC_{50}s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ralimetinib dimesylate

(LY2228820 dimesylate)

Cat. No.: HY-13241

Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of **p38 MAPK α/β** with IC_{50}s of 5.3 and 3.2 nM, respectively.



Purity: 99.52%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ramatroban

(BAY u3405)

Cat. No.: HY-B0745

Ramatroban is a selective **thromboxane A_2** (TxA_2, IC_{50}=14 nM) antagonist, which also antagonizes **CRTH2** (IC_{50}=113 nM) by inhibiting **PGD_2** binding.



Purity: 99.10%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ramifenazone

(Isopropylaminoantipyrine)

Cat. No.: HY-B1137

Ramifenazone (Isopropylaminoantipyrine) is a pyrazole derivative and acts as a non-steroidal anti-inflammatory agent (**NSAID**). Ramifenazone has analgesic, antipyretic, anti-inflammatory and antimicrobial activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ramifenazone-d7

Cat. No.: HY-B1137S

Ramifenazone-d7 (Isopropylaminoantipyrine-d7) is the deuterium labeled Ramifenazone. Ramifenazone (Isopropylaminoantipyrine) is a pyrazole derivative and acts as a non-steroidal anti-inflammatory agent (**NSAID**).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 50 mg

Randialic acid B

Cat. No.: HY-N8152

Randialic acid B, a triterpenoid compound, is a **formyl peptide receptor 1 (FPR1)** antagonist. Randialic acid B blocks **FPR1** in human neutrophils and attenuates psoriasis-like inflammation in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rapanone

Cat. No.: HY-N8213

Rapanone is a natural benzoquinone. Rapanone exhibits a broad spectrum of biological actions, including anti-tumor, antioxidant, anti-inflammatory, antibacterial and antiparasitic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Raspberry ketone glucoside

Cat. No.: HY-N6069

Raspberry ketone glucoside is a natural product in raspberry fruit. Raspberry ketone glucosidev has the inhibitory effect on the melanin synthesis.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 100 mg

Razuprotafib

(AKB-9778)

Cat. No.: HY-109041

Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of **VE-PTP (vascular endothelial protein tyrosine phosphatase)** with an $IC_{50}$of 17 pM.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

RBN012759

Cat. No.: HY-136979

RBN012759 is a potent, selective and orally active inhibitor of **PARP14**, with an IC_{50} of <3 nM. RBN012759 displays 300-fold selectivity over the monoPARPs and 1000-fold selectivity over the polyPARPs.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RC-3095 TFA

Cat. No.: HY-P0107A

RC-3095 TFA is a selective **bombesin/gastrin** releasing peptide receptor (**GRPR**) antagonist. RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RCGD423

Cat. No.: HY-114775

RCGD423 is a **gp130** modulator, which prevents articular cartilage degeneration and promotes repair.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

rCRAMP (rat)

Cat. No.: HY-P2457

rCRAMP (rat) is the rat cathelin-related antimicrobial peptide. rCRAMP (rat) contributes to the antibacterial activity in rat brain peptide/protein extracts. rCRAMP (rat) is a potential key player in the innate immune system of rat CNS.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rebamipide

(OPC12759; Proamipide)

Cat. No.: HY-B0360

Rebamipide (OPC12759) is a mucoprotective agent. Rebamipide induces **COX-2** expression, increases **PGE2** levels, and enhances gastric mucosal defense in a COX-2-dependent manner.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Rebamipide mofetil

Cat. No.: HY-109158

Rebamipide mofetil is an orally active prodrug of Rebamipide (OPC12759). Rebamipide is a mucoprotective agent. Rebamipide induces **COX-2** expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rebamipide-d4

(OPC12759-d4; Proamipide-d4)

Cat. No.: HY-B0360S

Rebamipide D4 (OPC12759 D4) is deuterium labeled Rebamipide. Rebamipide is a mucoprotective agent. Rebamipide induces **COX-2** expression, increases **PGE2** levels, and enhances gastric mucosal defense in a COX-2-dependent manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Regaloside A

Cat. No.: HY-N7931

Regaloside A, a phenylpropanoid, shows significant DPPH radical scavenging activity of 58.0% at 160 ppm. Regaloside A has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Regaloside B

Cat. No.: HY-N7688

Regaloside B is a phenylpropanoid isolated from Lilium longiflorum. Regaloside B can inhibit the expression of **iNOS** and **COX-2**. Regaloside B has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Regaloside C

Cat. No.: HY-N7627

Regaloside C is a glycerol glucoside isolated from the bulbs of Lilium genus with anti-inflammatory activities. Regaloside C has cardiomyocyte protective activity by protecting the mitochondria in H_2O_2-induced heart H9C2 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Rehmannioside C

Cat. No.: HY-N2400

Rehmannioside C is an iridoid glucoside isolated from Radix Rehmanniae Praeparata.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rehmapicrogenin

Cat. No.: HY-N7630

Rehmapicrogenin, isolated from the root of Rehmannia glutinosa, exhibits potent anti-inflammatory effect by inhibiting iNOS, COX-2 and IL-6.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

rel-SB-612111 hydrochloride

Cat. No.: HY-18617

rel-SB-612111 hydrochloride is a novel and potent **human opiate receptor-like orphan receptor (ORL-1)** antagonist with a high affinity for hORL-1 (K_i=0.33 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

rel-α-Vitamin E

(rel-(+)-α-Tocopherol; rel-D-α-Tocopherol)

Cat. No.: HY-N0683A

rel-α-Vitamin E (rel-(+)-α-Tocopherol) is a vitamin with antioxidant properties and also a mixture.



Purity: ≥70.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Relenopride hydrochloride

(YKP10811 hydrochloride)

Cat. No.: HY-16729A

Relenopride (YKP10811) hydrochloride is a specific and selective **5-HT$_4$ receptor** agonist (K_i=4.96 nM). Relenopride hydrochloride has 120-fold and 6-fold lower affinity, respectively, for 5-HT$_{2A}$ (K_i=600 nM) and 5-HT$_{2B}$ receptors (K_i=31 nM) than for 5-HT$_4$.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Remibrutinib

Cat. No.: HY-128757

Remibrutinib, is a potent and orally active **bruton tyrosine kinase (BTK)** inhibitor with an **IC$_{50}$** value of 1 nM. Remibrutinib inhibits BTK activity with an **IC$_{50}$** value of 0.023 μM in blood. Remibrutinib has the potential for Chronic urticaria (CU) treatment.



Purity: 99.26%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Remlarsen

(MRG-201)

Cat. No.: HY-132602

Remlarsen (MRG-201), a miR-29b mimic, acts a **miR-29b** agonist. Remlarsen has the potential for preventiong formation of a fibrotic scar or cutaneous fibrosis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ReN-1869 hydrochloride

(NNC-05-1869 hydrochloride)

Cat. No.: HY-101724

ReN 1869 hydrochloride is a novel, selective **histamine H$_1$ receptor** antagonist, which demonstrates affinity to the histamine H$_1$ receptor (guinea pig brain) with K_i of 0.19±0.04 μM and the non-selective σ site (guinea pig brain) with K_i of 0.45 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Reparixin

(Repertaxin; DF 1681Y)

Cat. No.: HY-15251

Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors **CXCR1** and **CXCR2** activation with **IC$_{50}$**s of 1 and 100 nM, respectively.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Reparixin L-lysine salt

(Repertaxin L-lysine salt)

Cat. No.: HY-15252

Reparixin L-lysine salt is an allosteric inhibitor of **chemokine receptor 1/2 (CXCR1/2)** activation.



Purity: 99.93%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Reproxalap

(ADX-102; NS-2)

Cat. No.: HY-107150

Reproxalap (ADX-102) is a reactive aldehyde species (RASP) sequestering agent for the treatment of dry eye. Reproxalap (ADX-102) covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Resatorvid

(TAK-242; CLI-095)

Cat. No.: HY-11109

Resatorvid (TAK-242) is a selective **Toll-like receptor 4 (TLR4)** inhibitor. Resatorvid inhibits **NO, TNF-α** and **IL-6** production with **IC$_{50s}$** of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF.



Purity: 99.95%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Resiquimod

(R848; S28463) Cat. No.: HY-13740

Resiquimod is a Toll-like receptor 7 and 8 (**TLR7/TLR8**) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mg, 25 mg, 50 mg, 100 mg

Resiquimod-d5

(R848-d5; S28463-d5) Cat. No.: HY-13740S

Resiquimod-d5 (R848-d5) is deuterium labeled Resiquimod. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Reslizumab

(Sch 55700) Cat. No.: HY-P9949

Reslizumab (Sch 55700) is humanized monoclonal antibodies that target **interleukin-5 (IL-5)** for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of **IL-5**.

Reslizumab

Purity: ≥99.4%
Clinical Data: Launched
Size: 1 mg, 2 mg

Resolvin D1

(RvD1) Cat. No.: HY-125527

Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 25 μg (265.6 μM * 250 μL in Ethanol)

Resolvin D2

(RvD2) Cat. No.: HY-121636

Resolvin D2 is a metabolite of docosahexaenoic acid (DHA), with anti-inflammatory, anti-infective activities. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 25 μg, 50 μg

Resolvin D3

(RvD3) Cat. No.: HY-136540

Resolvin D3 (RvD3) is a docosahexaenoic acid (DHA) derived mediator. Resolvin D3 is dysregulated in arthritis and reduces arthritic inflammation.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 25 μg (265.6 μM * 250 μL in Ethanol)

Resolvin E1

(RvE1) Cat. No.: HY-114041

Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA).



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 μg (142.6 μM * 200 μL in Ethanol)

Resorcinol monoacetate

(Acetylresorcinol; Resorcin monoacetate) Cat. No.: HY-B0894

Resorcinol monoacetate (Acetylresorcinol) is an antiseptic and a disinfectant, is a chemical intermediate for the production of many other pharmaceuticals, and has the potential for acne, seborrheic dermatitis, eczema, psoriasis, and other skin disorders research.



Purity: 96.22%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Resorcinolnaphthalein

Cat. No.: HY-122445

ResorcinolnaphthaleIn is a specific **angiotensin-converting enzyme 2 (ACE2)** enhancer and activates ACE2 activity with an EC_{50} value of 19.5 μM. ResorcinolnaphthaleIn can be used for the investigation of hypertension and renal fibrosis.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Resveratrol

(trans-Resveratrol; SRT501) Cat. No.: HY-16561

Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Resveratrol analog 1

Cat. No.: HY-136203

Resveratrol analog 1 is an analog of Resveratrol (HY-16561), compound 48. Resveratrol is a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Resveratrol analog 2

Cat. No.: HY-136204

Resveratrol analog 2 is an **analog** of Resveratrol (HY-16561). Resveratrol is a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Reticuline

Cat. No.: HY-N1356

Reticuline shows anti-inflammatory effects through **JAK2/STAT3** and **NF-κB** signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3. Reticuline exhibits cardiovascular effects.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Retusin

(Quercetin-3,3',4',7-tetramethylether)

Cat. No.: HY-N6829

Retusin (Quercetin-3,3',4',7-tetramethylether), a natural compound isolated from the leaves of Talinum triangulare, possesses antiviral and anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Revefenacin

(TD-4208; GSK1160724)

Cat. No.: HY-15851

Revefenacin (TD-4208; GSK1160724) is a potent **mAChR** antagonist; has a high affinity on M3 receptor with a K_i of 0.18 nM.



Purity: 99.78%
Clinical Data: Launched
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RGD peptide (GRGDNP)

Cat. No.: HY-P1740

RGD peptide (GRGDNP) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RGD peptide (GRGDNP) (TFA)

Cat. No.: HY-P1740A

RGD peptide (GRGDNP) (TFA) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RGX-104

Cat. No.: HY-111498A

RGX-104 is an orally bioavailable and potent liver-X nuclear hormone receptor **(LXR)** agonist that modulates innate immunity via transcriptional activation of the ApoE gene.



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RGX-104 hydrochloride

Cat. No.: HY-111498

RGX-104 hydrochloride is a small-molecule **LXR** agonist that modulates innate immunity via transcriptional activation of the ApoE gene.



Purity: 99.96%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rhamnetin

Cat. No.: HY-N7036

Rhamnetin is a quercetin derivative found in Coriandrum sativum, inhibits secretory **phospholipase A2**, with antioxidant and anti-inflammatory activity.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rhamnocitrin

Cat. No.: HY-N1353

Rhamnocitrin is a flavonoid isolated from astragalus complanatus R. Br. (Sha-yuan-zi). Rhamnocitrin is a scavenger of DPPH with an IC_{50} of 28.38 mM. Rhamnocitrin has anti-oxidant, anti-inflammatory and an-tiatherosclerosis activity.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rhaponticin 2''-O-gallate

Cat. No.: HY-N8125

Rhaponticin 2''-O-gallate, as a stilbene glucoside gallate, inhibits NO production.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rhapontigenin

Cat. No.: HY-N2229

Rhapontigenin is a natural analog of resveratrol with anticancer, antioxidant, antifungal and antibacterial activities. Rhapontigenin is amechanism-based, potent and selective **cytochrome P450 1A1** inactivator (IC_{50} = 400 nM).



Purity: 99.66%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Rheb inhibitor NR1

Cat. No.: HY-124798

Rheb inhibitor NR1 is a **Rheb** inhibitor with an IC_{50} of 2.1μM in the Rheb-IVK assay. Rheb inhibitor NR1 also is a selective **mTORC1** inhibitor. NR1 inhibits the phosphorylation of ^{T389}pS6K1 and increases the phosphorylation of ^{S473}pAKT in a dose-dependent manner.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 5 mg

Rhein

(Rheic Acid; Rhubarb yellow; Monorhein)

Cat. No.: HY-N0105

Rhein is a lipophilic anthraquinone extensively found in medicinal herbs, and has many pharmacological effects, including epatoprotective, nephroprotective, anti-inflammatory, antioxidant, anticancer, and antimicrobial activities.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Rhodiocyanoside A

(Multifidin)

Cat. No.: HY-N5067

Rhodiocyanoside A is found to show antiallergic activity in a passive cutaneous anaphylaxis test in rat.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rhodojaponin II

Cat. No.: HY-N2151

Rhodojaponin II is a diterpenoid from the leaves of Rhododendron molle with anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rhodojaponin III

Cat. No.: HY-N2152

Rhodojaponin III is a diterpenoid from the leaves of Rhododendron molle with anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rhodojaponin V

Cat. No.: HY-N2154

Rhodojaponin V is a diterpenoid from the leaves of Rhododendron molle with anti-inflammatory activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rifalazil

(KRM-1648; ABI-1648)

Cat. No.: HY-105099

Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent **RNA polymerase** and kills bacterial cells by blocking off the β-subunit in RNA polymerase.



Purity: 98.44%
Clinical Data: Phase 3
Size: 50 mg, 100 mg, 250 mg

Rilapladib

(SB 659032)

Cat. No.: HY-102004



Rilapladib (SB 659032) is a selective **Lp-PLA$_2$** (lipoprotein-associated phospholipase A$_2$) inhibitor with an **IC$_{50}$** of 230 pM. Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist.

Purity: 99.93%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RIP1 kinase inhibitor 1

Cat. No.: HY-111409



RIP1 kinase inhibitor 1 (compound 22) is a highly potent, orally available, and brain-penetrating **RIP1 kinase** inhibitor (**pK$_i$**=9.04).

Purity: 99.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

RIP2 kinase inhibitor 1

Cat. No.: HY-133014



RIP2 kinase inhibitor 1 (compound 11) is a potent and selective **receptor interacting protein 2 (RIP2)** kinase inhibitor with an **IC$_{50}$** of 0.03 μM for RIP2 FP. RIP2 kinase inhibitor 1 is used for autoinflammatory disorders.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RIP2 Kinase Inhibitor 3

Cat. No.: HY-112907



RIP2 Kinase Inhibitor 3 is a highly potent and selective inhibitor of **receptor interacting protein-2 (RIP2) Kinase** with an **IC$_{50}$** of 1 nM .

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RIP2 Kinase Inhibitor 4

Cat. No.: HY-136010



RIP2 Kinase Inhibitor 4 is a potent and selective **RIPK2 PROTAC**. RIP2 Kinase Inhibitor 4 effectively degrades RIPK2 (**pIC$_{50}$** of 8) and inhibits the release of related TNF-α.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RIPA-56

Cat. No.: HY-101032



RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (**RIP1**) with an **IC$_{50}$** of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome.

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

RIPK-IN-4

Cat. No.: HY-107978



RIPK-IN-4 is a potent and selective **RIPK2** inhibitor with excellent oral bioavailability, and has an **IC$_{50}$** of 3 nM.

Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RIPK1-IN-3

Cat. No.: HY-126296



RIPK1-IN-3 (Example 38), a **RIPK1** inhibitor, extracted from patent WO2018148626A1, possesses anti-inflammatory proprieties.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RIPK1-IN-4

Cat. No.: HY-18901



RIPK1-IN-4 (compound 8) is a potent and selective type II kinase inhibitor of **receptor interacting protein 1 (RIP1)** kinase and binds to a DLG-out inactive form of RIP1 with an **IC$_{50}$**s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase.

Purity: 98.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RIPK3-IN-1

Cat. No.: HY-131064



RIPK3-IN-1 is a **RIPK3** type II DFG-out inhibitor with an **IC$_{50}$** of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC$_{50}$s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC$_{50}$ of 1.1 μM.

Purity: 98.82%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Risarestat

(CT 112)

Cat. No.: HY-16433

Risarestat (CT-112), an **aldose reductase** inhibitor, is developed for the treatment of diabetic complications.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ristomycin sulfate

Cat. No.: HY-131150

Ristomycin sulfate is a glycopeptide antibiotic isolated from Nocardia lurida.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ritlecitinib

(PF-06651600)

Cat. No.: HY-100754

Ritlecitinib (PF-06651600) is an orally active and selective **JAK3** inhibitor with an IC_{50} of 33.1 nM.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Rituximab

(Anti-Human CD20 type I, Chimeric Antibody)

Cat. No.: HY-P9913

Rituximab is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.

Purity: 99.85%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

RK-24466

(KIN 001-51)

Cat. No.: HY-108318

RK-24466 (KIN 001-51) is a potent and selective **Lck** inhibitor; inhibits Lck (64-509) and LckCD isoforms with IC_{50}s of less than 1 and 2 nM, respectively.



Purity: 98.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

RN486

Cat. No.: HY-18018

RN486 is a potent, selective and orally active **Btk** inhibitor with an IC_{50} of 4.0 nM and a K_d of 0.31 nM. RN486 is less active for other kinases. RN486 can be used for rheumatoid arthritis and systemic lupus erythematosus research.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

RNF5 inhibitor inh-02

Cat. No.: HY-123967

RNF5 inhibitor inh-02 is a potent inhibitor of **E3 ubiquitin ligase RNF5/RMA1**. RNF5 inhibitor inh-02 leads to significant F508del-CFTR rescue (EC_{50}=2.2 uM) in bronchial epithelial cells homozygous for the F508del mutation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ro 31-9790

(GI4747)

Cat. No.: HY-101703

Ro 31-9790 is a synthetic metalloproteinase (**MMP**) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ro 32-0432 hydrochloride

Cat. No.: HY-108601A

Ro 32-0432 hydrochloride is a potent, selective, ATP-competitive and orally active **PKC** inhibitor. The IC_{50} values of Ro 32-0432 hydrochloride for **PKCα**, **PKCβI**, **PKCβII**, **PKCγ** and **PKCε** are 9.3 nM, 28 nM, 30 nM, 36.5 nM and 108.3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Ro-24-0238

Cat. No.: HY-19084

Ro-24-0238 is an antagonist of **platelet activating factor (PAF)** and inhibitor of **thromboxane synthesis**, used for lessening the inflammation and damage resulting from a local release of PAF.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RO0270608

Cat. No.: HY-138542

RO0270608, the active metabolite of R411, is a dual **alpha4beta1-alpha4beta7 (α4β1/α4β7)** integrin antagonist. Antiinflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RO1138452

(CAY10441)

Cat. No.: HY-108912

RO1138452 is a potent and selective **IP (prostacyclin) receptor** antagonist. RO1138452 displays high affinity for IP receptors. In human platelets, **pK_i** is 9.3±0.1; in a recombinant IP receptor system, **pK_i** is 8.7±0.06.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ro24-7429

Cat. No.: HY-19149

Ro24-7429 is a potent and orally active HIV-1 transactivator protein **Tat** antagonist. Ro24-7429 is also a **runt-related transcription factor 1 (RUNX1)** inhibitor. Ro24-7429 has anti-HIV, antifibrotic and anti-inflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RO27-3225 TFA

Cat. No.: HY-P2242A

RO27-3225 TFA is potent and selective **melanocortin 4 receptor (MC4R)** agonist with an **EC_{50}** of 1 nM and 8 nM for **MC4R** and MC1R, respectively. RO27-3225 TFA shows ~30-fold selectivity for **MC4R** over MC3R. RO27-3225 TFA has neuroprotective and anti-inflammatory effects.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RO9021

Cat. No.: HY-16902

RO9021 is an orally bioavailable, novel ATP-competitive inhibitor of **SYK**, with an average **IC_{50}** of 5.6 nM.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Robinin

Cat. No.: HY-N1346

Robinin is present in flavonoid fraction of Vigna unguiculata leaf. Robinin inhibits upregulated expression of **TLR2** and **TLR4**. Robinin ameliorates oxidized low density lipoprotein (Ox-LDL) induced inflammatory insult through TLR4/NF-κB pathway.



Purity: 95.75%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Robotnikinin

Cat. No.: HY-100515

Robotnikinin is a small molecule capable of binding to and inhibiting the activity of **Sonic Hedgehog (Shh)** signaling up stream of Smo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Roburic acid

Cat. No.: HY-N0481

Roburic acid, a tetracyclic triterpenoid found in Gentiana macrophylla, acts as an inhibitor of **COX**, with **IC_{50}**s of 5 and 9 μM for COX-1 and COX-2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Robustine

Cat. No.: HY-N1343

Robustine, a furoquinoline alkaloid, from Dictamnus albus, exhibits inhibitory potency against human phosphodiesterase 5 (**hPDE5A**) in vitro.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

ROC-0929

Cat. No.: HY-145384

ROC-0929 (compound 13a) is a potent and selective inhibitor of **secreted phospholipases A_2 ($sPLA_2$s) with an IC_{50} of 80 nM, specially targeting hGX. Secreted phospholipases A2 (sPLA2s) are a family of disulfide-rich, Ca^{2+}-dependent enzymes that hydrolyze....**



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rocastine

(AHR-11325)

Cat. No.: HY-101745

Rocastine is a selective, nonsedating **H1** antagonist, acting as an antihistamine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ROCK inhibitor-2

Cat. No.: HY-119937

ROCK inhibitor-2 is a selective dual **ROCK1** and **ROCK2** inhibitor with IC_{50}s of 17 nM and 2 nM, respectively.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ROCK-IN-1

Cat. No.: HY-U00351

ROCK-IN-1 is a potent inhibitor of **ROCK**, with an IC_{50} of 1.2 nM for ROCK2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ROCK2-IN-2

Cat. No.: HY-103620

ROCK2-IN-2 is a selective **ROCK2** inhibitor extracted from patent US20180093978A1, Compound A-30, has an IC_{50} of <1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rofecoxib

(MK 966)

Cat. No.: HY-17372

Rofecoxib is a potent, specific and orally active **COX-2** inhibitor, with IC_{50}s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC_{50} > 50 μM in U937 cells and > 15 μM in...



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Rofecoxib-d5

Cat. No.: HY-17372S

Rofecoxib D5 (MK 966 D5) is the deuterium labeled Rofecoxib.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Roflumilast

Cat. No.: HY-15455

Roflumilast is a selective **PDE4** inhibitor with IC_{50}s of 0.7, 0.9, 0.7, and 0.2 nM for **PDE4A1**, **PDEA4**, **PDEB1**, and **PDEB2**, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Roflumilast Impurity E

Cat. No.: HY-100640

Roflumilast Impurity E is the impurity of Roflumilast. Roflumilast(Daliresp) is a drug which acts as a selective and long-acting inhibitor of the enzyme **PDE-4** with an IC_{50} value of 0.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Roflumilast N-oxide

Cat. No.: HY-100639

Roflumilast N-oxide is a **PDE type 4** inhibitor.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Roflumilast-d4

Cat. No.: HY-15455S

Roflumilast-d4 is the deuterium labeled Roflumilast. Roflumilast is a selective **PDE4** inhibitor with IC_{50}s of 0.7, 0.9, 0.7, and 0.2 nM for **PDE4A1**, **PDEA4**, **PDEB1**, and **PDEB2**, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Roquinimex

(Linomide; FCF89; ABR212616)

Cat. No.: HY-13743

Roquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.



Purity: 98.93%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ROR agonist-1

Cat. No.: HY-128353

ROR agonist-1 is a potent and orally bioavailable inverse agonist of the **retinoic acid receptor-related orphan receptor C2 (RORC2)**, inhibition of IL-17A production from human primary T_H 17 cells with a p**IC**$_{50}$ of 7.5.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt Inverse agonist 10

Cat. No.: HY-133552

RORγt Inverse agonist 10 is a potent and orally bioavailable **RORγt (retinoic acid receptor-related orphan nuclear receptor gamma t)** inverse agonist, with an **IC**$_{50}$ of 51 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt inverse agonist 13

Cat. No.: HY-131338

RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective **RORγt** inverse agonist, with improved drug-like properties, with an **IC**$_{50}$ of 63.8 nM.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RORγt inverse agonist 14

Cat. No.: HY-132195

RORγt inverse agonist 14 (8e) is a potent, orally active and selective **RORγt** inverse agonist (EC$_{50}$ of 2.5 nM) with anti-inflammatory activity. RORγt inverse agonist 14 is used in the study for rheumatoid arthritis and psoriasis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt Inverse agonist 2

Cat. No.: HY-111748

RORγt Inverse agonist 2 is a selective, orally active **RORγt** inverse agonist with an **EC**$_{50}$ of 119 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt inverse agonist 23

Cat. No.: HY-139847

RORγt inverse agonist 23 is a potent, selective, and orally available novel **retinoic acid receptor-related orphan receptor γt** inverse agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RORγt Inverse agonist 6

Cat. No.: HY-130243

RORγt Inverse agonist 6 (compound 43) is a **RORγt** inverse agonist for the study of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RORγt Inverse agonist 8

Cat. No.: HY-122737

RORγt Inverse agonist 8 is a potent, selective, orally bioavailable **RORγt** inverse agonist, with an **IC**$_{50}$ of 19 nM for human RORγt-LBD.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ROS 234 dioxalate

Cat. No.: HY-107563A

ROS 234 dioxalate is a potent **H3** antagonist, with a **pK**$_B$ of 9.46 for Guinea-pig ileum H_3-receptor, a **pK**$_i$ of 8.90 for Rat cerebral cortex H_3-receptor, and a **ED**$_{50}$ of 19.12 mg/kg (ip) in ex vivo of Rat cerebral cortex. ROS 234 dioxalate diaplays poor central access.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rosiglitazone

(BRL 49653) Cat. No.: HY-17386

Rosiglitazone (BRL 49653) is a selective, orally active **PPARγ** agonist with EC_{50}s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a K_d of approximately 40 nM.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 200 mg

Rosiglitazone hydrochloride

(BRL 49653 hydrochloride) Cat. No.: HY-17386A

Rosiglitazone hydrochloride (BRL 49653 hydrochloride) is a selective, orally active **PPARγ** agonist with EC_{50}s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone hydrochloride binds to PPARγ with a K_d of approximately 40 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Rosiglitazone maleate

(BRL 49653C) Cat. No.: HY-14600

Rosiglitazone maleate (BRL 49653C) is a potent and selective activator of **PPARγ**, with EC_{50}s of 30 nM, 100 nM and 60 nM for **PPARγ1**, **PPARγ2**, and **PPARγ**, respectively, and a K_d of appr 40 nM for **PPARγ**; Rosiglitazone maleate is also an modulator of **TRP channels**, inhibits TRP melastatin...



Purity: 99.75%
Clinical Data: Launched
Size: 50 mg, 200 mg

Rosiglitazone-d3

Cat. No.: HY-17386S

Rosiglitazone-d3 (BRL 49653-d3) is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active **PPARγ** agonist with EC_{50}s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Rosin

Cat. No.: HY-N0508

Rosin is isolated from pine wood or pine stumps, Rosin is a frequent contact **allergen** which induces allergic contact dermatitis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Rosmanol

Cat. No.: HY-N5015

Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.



Purity: 97.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Rotundic acid

Cat. No.: HY-N2217

Rotundic acid, a triterpenoid obtained from I. rotunda, induces DNA damage and cell apoptosis in hepatocellular carcinoma through **AKT/mTOR** and **MAPK** Pathways. Rotundic acid possesses anti-inflammatory and cardio-protective abilities.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Rovazolac

Cat. No.: HY-109073

Rovazolac is a **liver x receptor (LXR)** modulator extracted from patent WO2013130892A1.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Roxatidine Acetate Hydrochloride

(HOE 760) Cat. No.: HY-B0305A

Roxatidine Acetate Hydrochloride (HOE 760) is a selective **histamine H_2 receptor** antagonist, can be used for the research of gastric and duodenal ulcers.



Purity: 98.08%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Rozanolixizumab

(UCB7665) Cat. No.: HY-P9979

Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases.

Rozanolixizumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RP-54745

Cat. No.: HY-101716

RP-54745 is an inhibitor of macrophage stimulation and **interleukin-1** production, and a potential antirheumatic compound.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Rp-8-CPT-cAMPS

Cat. No.: HY-120994A

Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent **PKA I** and **II**. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rp-8-CPT-cAMPS sodium

Cat. No.: HY-120994

Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent **PKA I** and **II**. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RP101075

Cat. No.: HY-136576

RP101075, an active metabolite of Ozanimod, is a potent, orally active **S1PR** (sphingosine-1-phosphate receptor 1) agonist, with an EC_{50} of 0.27 nM. RP101075 displays >100-fold selectivity over S1PR5 (EC_{50}=5.9 nM) and >10000-fold over S1PR 2, 3, and 4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RP101442

Cat. No.: HY-136577

RP101442, an active metabolite of Ozanimod, is a selective, potent **S1PR1** (sphingosine-1-phosphate receptor 1) agonist, with EC_{50}s of 2.6 nM and 171 nM for S1PR1 and S1PR5, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RP101988

Cat. No.: HY-136578

RP101988, the major active metabolite of Ozanimod, is a selective, potent **S1PR1** (sphingosine-1-phosphate receptor 1) agonist, with EC_{50}s of 0.19 nM and 32.8 nM for S1PR1 and S1PR5, respectivlely.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RRx-001

Cat. No.: HY-16438

RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers **apoptosis** and overcomes drug resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity.



Purity: 99.71%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RS 09

Cat. No.: HY-P1439

RS09 is a LPS peptide mimic serves as a candidate to be considered as a new class of TLR4 agonist adjuvant. RS09 increases antibody production in a vaccine setting.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

RS 09 TFA

Cat. No.: HY-P1439A

RS 09 TFA is a TLR4 agonist. RS 09 TFA promotes NF-κB nuclear translocation and induces inflammatory cytokine secretion in RAW264.7 macrophages in vitro.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

RS 504393

Cat. No.: HY-15418

RS 504393 is a selective **CCR2** chemokine receptor antagonist (IC_{50} values are 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors respectively).



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

RS-25344 hydrochloride

Cat. No.: HY-108621

RS-25344 hydrochloride is a selective **cAMP-phosphodiesterase 4 (PDE 4; PDE IV)** inhibitor with an IC_{50} of 0.28 nM in human lymphocytes.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RS-601

Cat. No.: HY-U00072

RS-601 is a novel **leukotriene D4 (LTD4)/thromboxane A2 (TxA2)** dual receptor antagonist, with antiasthmatic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RSVA405

Cat. No.: HY-103238

RSVA405 is a potent, orally active activator of **AMPK**, with an EC_{50} of 1 μM. RSVA405 facilitates CaMKKβ-dependent activation of AMPK, inhibits **mTOR**, and promotes **autophagy** to increase Aβ degradation.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rubiadin

Cat. No.: HY-N0444

Rubiadin is a dihydroxy anthraquinone isolated from Rubia cordifolia. Rubiadin has a potent **antixidant** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Rubrofusarin

Cat. No.: HY-130307

Rubrofusarin is an orange polyketide pigment from Fusarium graminearum. Rubrofusarin is also an active ingredient of the Cassia species and ameliorates chronic restraint stress (CRS) -induced depressive symptoms through PI3K/Akt signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Rubropunctatin

Cat. No.: HY-N7766

Rubropunctatin, an orange azaphilone pigment, is isolated from the extracts of Monascus pilosus-fermented rice (red-mold rice). Rubropunctatin has anti-inflammatory, immunosuppressive and antioxidative effects, and also exhibits anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rupatadine

(UR-12592)

Cat. No.: HY-13511

Rupatadine (UR-12592) is a potent, orally active and long-lasting dual **PAF/H1** antagonist, with K_is of 0.55 μM and 0.1 μM, respectively. Rupatadine can be used for the research of allergic rhinitis and urticaria.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Rupatadine D4 fumarate

(UR-12592 D4 fumarate)

Cat. No.: HY-13511AS

Rupatadine D4 fumarate (UR-12592 D4 fumarate) is a deuterium labeled Rupatadine fumarate. Rupatadine Fumarate (UR-12592 Fumarate) is a potent dual **PAF/H1** antagonist with K_i of 0.55/0.1 μM(rabbit platelet membranes/guinea pig cerebellum membranes).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rupatadine Fumarate

(UR-12592 Fumarate)

Cat. No.: HY-13511A

Rupatadine (UR-12592) Fumarate is a potent, orally active and long-lasting dual **PAF/H1** antagonist, with K_is of 0.55 μM and 0.1 μM, respectively. Rupatadine Fumarate can be used for the research of allergic rhinitis and urticaria.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Rupintrivir

(AG7088)

Cat. No.: HY-106161

Rupintrivirvr (AG7088), an antiviral drug, is a potent, selective and irreversible inhibitor of **human rhinovirus (HRV) 3C protease**.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Rusalatide acetate

(TP508 amide acetate) Cat. No.: HY-105069A

Rusalatide acetate (TP508 amide acetate), a regenerative peptide, mitigates radiation-induced gastrointestinal damage by activating stem cells and preserving crypt integrity.

Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Rutaecarpine

(Rutecarpine) Cat. No.: HY-N0147

Rutaecarpine, an alkaloid of Evodia rutaecarpa, is an inhibitor of **COX-2** with an IC_{50} value of 0.28 μM.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Rutaevin

Cat. No.: HY-N2620

Rutaevin is isolated from the fruits of Euodia rutaecarpa. Rutaevin inhibits **NO production** in LPS-induced RAW 264.7 macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Rutin

(Rutoside; Quercetin 3-O-rutinoside) Cat. No.: HY-N0148

Rutin (Rutoside) is a flavonoid found in many plants and shows a wide range of biological activities including anti-inflammatory, antidiabetic, antioxidant, neuroprotective, nephroprotective, hepatoprotective and reducing Aβ oligomer activities.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

RV01

Cat. No.: HY-126241

RV01 is an analogue of resveratrol, inhibits DNA damage, reduces **acetaldehyde dehydrogenase 2 (ALDH2)** mRNA expression induced by ethanol, and exhibits hydroxyl radical scavenging activity. RV01 decreases **iNOS** expression, with anti-neuroinflammatory activity.



Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RVX-297

Cat. No.: HY-114504

RVX-297 is a potent, orally active **BET bromodomain** inhibitor with selectivity for **BD2**. RVX-297 shows IC_{50}s of 0.08, 0.05, and 0.02 μM for BRD2(BD2), BRD3(BD2), and BRD4(BD2), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types.



Purity: 96.59%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RWJ 50271

Cat. No.: HY-110086

RWJ 50271 is an selective and orally active inhibitor of **lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1)** interaction with an IC_{50} of 5.0 μM (HL60 cells). RWJ 50271 inhibits LFA-1/ICAM-1-mediated cell adhesion.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

RWJ 63556

Cat. No.: HY-U00022

RWJ 63556 is an orally active **COX-2 selective/5-lipoxygenase** inhibitor, with anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RWJ-67657

(JNJ 3026582) Cat. No.: HY-15505

RWJ-67657 (JNJ 3026582) is an orally active and selective **p38α** and **p38β MAPK** inhibitor with IC_{50}s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

S-(+)-Ketoprofen

((S)-Ketoprofen; Dexketoprofen) Cat. No.: HY-B2137

S-(+)-Ketoprofen is a potent inhibitor of both **COX-1** and **COX-2** with IC_{50}s of 1.9 and 27 nM, respectively.



Purity: 99.93%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg

S-1-Propenyl-L-cysteine

Cat. No.: HY-111827

S-1-Propenyl-L-cysteine is a stereoisomer of S-allyl-l-cysteine, extracted from garlic, with immunomodulatory effects and reduces blood pressure in a hypertensive animal model.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S-2474

Cat. No.: HY-19212

S-2474 is an inhibitor of **COX-2** and **5-lipoxygenase (5-LO)**, with IC_{50}s of 11 nM and 27 μM for COX-2 and COX-1 in human intact cells, and used as a nonsteroidal anti-inflammatory drug.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S-Adenosyl-L-methionine

(S-Adenosyl methionine; Ademetionine; AdoMet) Cat. No.: HY-B0617

S-Adenosyl-L-methionine (S-Adenosyl methionine) is produced endogenously from methionine and ATP by action of the enzyme methionine adenosyltransferase and is an important orally active methyl group donor.



Purity: ≥98.0%
Clinical Data: Launched
Size: 100 mg

S-Adenosyl-L-methionine tosylate (S-Adenosyl methionine tosylate; Ademetionine tosylate; AdoMet tosylate)

Cat. No.: HY-B0617A

S-Adenosyl-L-methionine tosylate (S-Adenosyl methionine tosylate) is produced endogenously from methionine and ATP by action of the enzyme methionine adenosyltransferase and is an important orally active methyl group donor.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

S-Adenosyl-L-methionine-d3

(S-Adenosyl methionine-d3; Ademetionine-d3; AdoMet-d3) Cat. No.: HY-B0617S

S-Adenosyl-L-methionine D3 (S-Adenosyl methionine D3) is a deuterium labeled S-Adenosyl-L-methionine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S-Allyl-L-cysteine

Cat. No.: HY-W013573

S-Allyl-L-cysteine, one of the organosulfur compounds found in AGE, possess various biological effects including neurotrophic activity, anti-cancer activity, anti-inflammatory activity.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

S-methyl-KE-298

(M-2) Cat. No.: HY-101671

S-methyl-KE-298 is an active metabolite of KE-298. KE-298 inhibits matrix metalloproteinase (MMP-1) production from rheumatoid arthritis (RA) synovial cells.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

S-Methylisothiourea sulfate

Cat. No.: HY-79457

S-Methylisothiourea sulfate is a potent, selective and competitive inhibitor of **inducible nitric oxide synthase (iNOS)**. S-Methylisothiourea sulfate exerts beneficial effects in rodent models of septic shock.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg

S18-000003

Cat. No.: HY-119366

S18-000003 is a potent, selective and orally active inhibitor of **retinoic acid receptor-related orphan receptor-gamma-t (RORγt)**, with an IC_{50} of <30 nM towards human RORγt in competitive binding assays.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S1p receptor agonist 1

Cat. No.: HY-101265

S1p receptor agonist 1 is a potent and orally active **S1P receptor** agonist, exhibits an activity of inducing S1P1 internalization (EC_{50}=9.83 nM). S1p receptor agonist 1 has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis).



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

S1P1 agonist III

Cat. No.: HY-12835

S1P1 Agonist III is a potent and orally active S1P1 agonist with EC50 of 18 nM; no activity on S1P3.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

S1PR1 modulator 1

Cat. No.: HY-126145

S1PR1 modulator 1 is a selective **S1PR1** inhibitor, with a **pIC$_{50}$** of 7.6, with >40- and >80-fold selectivity, over the other S1PR isoforms S1PR2/3/4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S1PR1-MO-1

Cat. No.: HY-U00366

S1PR-MO-1 is the modulator of **sphingosine-1-phosphate receptor**, used for research of hyperproliferative, inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S32826

Cat. No.: HY-103267A

S32826 is a potent **autotaxin** inhibitor, with an **IC$_{50}$** of 8.8 nM. S32826 shows similar inhibitory effects at various autotaxin isoforms (α, β and γ). S32826 inhibits LPA release from adipocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S32826 disodium

Cat. No.: HY-103267

S32826 disodium is a potent **autotaxin** inhibitor, with an **IC$_{50}$** of 8.8 nM. S32826 disodium shows similar inhibitory effects at various autotaxin isoforms (α, β and γ). S32826 disodium inhibits LPA release from adipocytes.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S3337

Cat. No.: HY-U00222

S3337 is an H^+, K^+-ATPase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Saccharin

Cat. No.: HY-Y0272

Saccharin is an orally active, non-caloric artificial sweeteners (NAS). Saccharin has **bacteriostatic** and microbiome-modulating properties.



Purity: 99.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Saccharin sodium hydrate

Cat. No.: HY-B1390B

Saccharin sodium hydrate is an orally active, non-caloric artificial sweeteners (NAS). Saccharin sodium hydrate has **bacteriostatic** and microbiome-modulating properties.



Purity: ≥98.0%
Clinical Data: Launched
Size: 500 mg, 1 g

Safranal

Cat. No.: HY-N7560

Safranal is an orally active main component of Saffron (Crocus sativus) and is responsible for the unique aroma of this spice. Safranal has neuroprotective and anti-inflammatory effects and has the potential for Parkinson's disease research.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 500 mg

SAHM1

Cat. No.: HY-P2203

SAHM1, a peptide mimetic of a dominant negative form of mastermind-like (MAML), inhibits canonical **Notch** transcription complex formation. SAHM1 can be used for the research of allergic airway inflammation in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Saikogenin A

Cat. No.: HY-N6584

Saikogenin A, extracted from a Chinese herbal plant called Tsai-Fu, is a dipeptidyl peptidase-IV (**DPP-IV**) inhibitor.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 5 mg

Saikogenin D

Cat. No.: HY-N4237

Saikogenin D is isolated from Bupleurum chinense, has anti-inflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Saikosaponin A

Cat. No.: HY-N0246

Saikosaponin A is an active component of Bupleurum falcatum, up-regulates **LXRα** expression, with potent anti-inflammatory activity.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Saikosaponin D

Cat. No.: HY-N0250

Saikosaponin D is a triterpene saponin isolated from Bupleurum, with anti-inflammatory, anti-bacterial, anti-tumor, and anti-allergic activities; Saikosaponin D inhibits **selectin**, **STAT3** and **NF-kB** and activates **estrogen receptor-β**.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Saikosaponin F

Cat. No.: HY-N2178

Saikosaponin F is a component found in Bupleurum (B.) falcatum L.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Saikosaponin G

Cat. No.: HY-N4216

Saikosaponin G is a triterpene glycoside isolated from Bupleuri Radix.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Saikosaponin H

Cat. No.: HY-N2603

Saikosaponin H is a saikosaponin derived from the herb Radix bupleuri.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sakuranetin

Cat. No.: HY-N3006

Sakuranetin is a rice flavonoid phytoalexin, shows strong antifungal activity. Sakuranetin has anti-inflammatory and antioxidative activities. Sakuranetin ameliorates LPS-induced acute lung injury.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Salbutamol hemisulfate

(Albuterol hemisulfate; AH-3365 hemisulfate)

Cat. No.: HY-B0436

Salbutamol Hemisulfate (Albuterol hemisulfate) is a short-acting β2 adrenergic receptor agonist Target: β2 Adrenergic Receptor Salbutamol Hemisulfate (Albuterol hemisulfate) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and...



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Salicin

(D-(−)-Salicin; Salicoside)

Cat. No.: HY-N0149

Salicin is a natural **COX** inhibitor.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Salicortin

Cat. No.: HY-123503

Salicortin, a phenolic glycoside, has been isolated from many plants such as Populus and Salix species. Salicortin inhibits osteoclast differentiation and bone resorption by down-regulating **JNK** and **NF-κB/NFATc1** signaling pathways.



Purity: >98%
Clinical Data:
Size: 100 μg, 1 mg, 5 mg

Salicylamide

(2-Hydroxybenzamide)

Cat. No.: HY-B0811

Salicylamide is an inhibitor of microsomal UDP-glucuronosyltransferase. Salicylamide is an analgesic and anti-pyretic agent.



Purity: 98.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 10 g

Salicylic acid

(2-Hydroxybenzoic acid)

Cat. No.: HY-B0167

Salicylic acid (2-Hydroxybenzoic acid) inhibits cyclo-oxygenase-2 (**COX-2**) activity independently of transcription factor (NF-κB) activation.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 10 g, 50 g

Salicylic acid-d6

(2-Hydroxybenzoic acid-d6)

Cat. No.: HY-B0167S

Salicylic acid-D6 (2-Hydroxybenzoic acid-D6) is a deuterium labeled Salicylic acid. Salicylic acid inhibits cyclo-oxygenase-2 (**COX-2**) activity independently of transcription factor (NF-κB) activation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Salmeterol

(GR33343X)

Cat. No.: HY-14302

Salmeterol (GR33343X) is a potent and selective human **β2 adrenoceptor** agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human **β2, β1 and β3 adrenoceptors** with **pEC_{50}**s of 9.6, 6.1, and 5.9, respectively.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Salmeterol xinafoate

(GR 33343X xinafoate)

Cat. No.: HY-17453

Salmeterol (GR 33343X) xinafoate is a potent and selective human **β2 adrenoceptor** agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human **β2, β1 and β3 adrenoceptors** with **pEC_{50}**s of 9.6, 6.1, and 5.9, respectively.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Salmeterol-D3

Cat. No.: HY-135119

Salmeterol-D3 is a deuterium labeled Salmeterol. Salmeterol is a potent and selective human **β2 adrenoceptor** agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human **β2, β1 and β3 adrenoceptors** with **pEC_{50}**s of 9.6, 6.1, and 5.9, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Salsalate

(Salicylsalicylic acid; Disalicylic acid)

Cat. No.: HY-B1245

Salsalate, a non-acetylated salicylate, is an effective antirheumatic drug that bypasses gastric absorption and also avoids cyclooxygenase inhibition. Salsalate has anti-inflammatory activity and reduces glucose levels, insulin resistance, and cytokine expression.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Salubrinal

Cat. No.: HY-15486

Salubrinal is a cell-permeable and selective inhibitor of **eIF2α dephosphorylation**. Salubrinal acts as a dual-specificity phosphatase 2 (**Dusp2**) inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Salviaflaside

Cat. No.: HY-N3010

Salviaflaside is a main bioactive component of Spica Prunellae.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Salvianolic acid A

Cat. No.: HY-N0318

Salvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation.



Purity: 99.75%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Salvigenin

Cat. No.: HY-N1318

Salvigenin is a natural polyphenolic compound, with neuroprotective effect. Salvigenin has antitumor cytotoxic and immunomodulatory properties.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Sampatrilat

(UK-81252)

Cat. No.: HY-123348

Sampatrilat (UK-81252) is a potent and orally active **vasopeptidase** inhibitor of **ACE** and neutral endopeptidase (**NEP**). Sampatrilat inhibits C-domain ACE (K_i=13.8 nM) 12.4-fold more potent than that for the N-domain (K_i=171.9 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sandaracopimaric acid

Cat. No.: HY-133594

Sandaracopimaric acid is a diterpenoid with anti-inflammatory effect. Sandaracopimaric acid reduces the contraction of phenylephrine-induced pulmonary arteries with an EC_{50} of 43.93 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sanggenon C

Cat. No.: HY-N0617

Sanggenon C is a flavanone Diels-Alder adduct compound, which is isolated from the root bark of Morus cathayana. Sanggenon C exerts protective effects against cardiac hypertrophy and fibrosis via suppression of the **calcineurin/NFAT2** pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sanggenon D

Cat. No.: HY-N0618

Sanggenon D is a Diels-Alder-type adduct from Chinese crude drug root bark of Morus cathayana. Sanggenon D possesses antioxidant and inhibits Pancreatic lipase (PL) with the an IC_{50} of 0.77 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Saponarin

Cat. No.: HY-N5083

Saponarin is a natural flavonoid isolated from Gypsophila trichotoma, with antioxidant, anti-inflammatory and hepatoprotective activities. Saponarin activates AMPK in a calcium-dependent manner, thus regulating gluconeogenesis and glucose uptake.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Saponins

(Saponin)

Cat. No.: HY-100597

Saponins are a class of chemical compounds of glycosides found in particular abundance in various plant species. In plants, saponins may serve as anti-feedants, and to protect the plant against microbes and fungi.

Saponins

Purity: ≥98.0%
Clinical Data: Phase 4
Size: 10 mg(10 mg × mL in Water), 100 mg

Sarilumab

(Anti-Human IL6Rα, Human Antibody)

Cat. No.: HY-P9916

Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a **interleukin-6 (IL-6) receptor** antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation.

Sarilumab

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Sarsasapogenin

(Parigenin; Sarsagenin)

Cat. No.: HY-N0073

Sarsasapogenin is a sapogenin from the Chinese medical herb Anemarrhena asphodeloides Bunge, with antidiabetic, anti-oxidative, anticancer and anti-inflamatory activities.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Sauchinone

Cat. No.: HY-N0613

Sauchinone is a diastereomeric lignan isolated from Saururus chinensis (Saururaceae). Sauchinone inhibits LPS-inducible iNOS, TNF-α and COX-2 expression through suppression of **I-κBα** phosphorylation and **p65** nuclear translocation.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

SB 239063

Cat. No.: HY-11068

SB 239063 is a potent, selective and orally active **p38 MAPK** inhibitor, exhibits an IC_{50} of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

SB 452533

Cat. No.: HY-108458

SB 452533 is a potent and selective **TRPV1** antagonist with the pK_b of 7.8.



Purity: 98.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SB-265610

Cat. No.: HY-50688

SB-265610 is a selective, competitive, nonpeptide and allosteric **CXCR2** antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis with IC_{50}s of 3.7 nM and 70 nM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg

SB-332235

Cat. No.: HY-16981

SB-332235 is a potent, orally active nonpeptide **CXCR2** antagonist, with an IC_{50} of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

SB-366791

Cat. No.: HY-12245

SB-366791 is a potent and selective vanilloid receptor (**VR1/TRPV1**) antagonist (IC_{50}=5.7 nM). SB-366791 can be used for the research of inflammation.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SB-423557

Cat. No.: HY-15106

SB-423557 is an orally active calcium-sensing receptor (**CaR**) antagonist (IC_{50}=520 nM), precursor of SB-423562 (IC_{50}=73 nM). SB-423557 is well tolerated in human and increases plasma concentrations of exogenous parathyroid hormone (PTH) and stimulates bone formation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB-423562

Cat. No.: HY-15105

SB-423562 is a short-acting calcium-sensing receptor **(CaR)** antagonist. SB-423562 has the potential for osteoporosis research.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SB-612111

Cat. No.: HY-18618

SB-612111 is a novel and potent **opiate receptor-like orphan receptor (ORL-1)** antagonist with a high affinity for hORL-1 (K_i=0.33 nM). SB-612111 exhibits selectivity for μ-, κ- and δ-receptors with K_i values of 57.6 nM, 160.5 nM and 2109 nM, respecticely.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

SB-657510

Cat. No.: HY-10656

SB-657510 is a selective **urotensin II (UII) receptor (UT)** antagonist. The K_i values are 61, 17, 30, 65 and 56 nM for human, monkey, cat, rat and mouse receptors, respectively.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

SB-747651A

Cat. No.: HY-114038

SB-747651A is an ATP-competitive **mitogen- and stress-activated kinase 1 (MSK1)** inhibitor with an IC_{50} of 11 nM. SB-747651A also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A can be used for inflammation research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SB-747651A dihydrochloride

Cat. No.: HY-110313

SB-747651A dihydrochloride is an ATP-competitive **mitogen- and stress-activated kinase 1 (MSK1)** inhibitor with an IC_{50} of 11 nM. SB-747651A dihydrochloride also inhibits PRK2, RSK1, p70S6K and ROCK-II.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

SB225002

Cat. No.: HY-16711

SB225002, a potent, selective and non-peptide **CXCR2** antagonist, inhibits ^{125}I-IL-8 binding to CXCR2 with an IC_{50} of 22 nM.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SB290157 trifluoroacetate

Cat. No.: HY-101502A

SB290157 trifluoroacetate is a potent and selective **C3a** receptor antagonist with an IC_{50} of 200 nM.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SC-236

Cat. No.: HY-W010983

SC-236 is an orally active **COX-2** specific inhibitor (IC_{50} = 10 nM) and a **PPARγ** agonist. SC-236 suppresses activator protein-1 (**AP-1**) through c-Jun NH2-terminal kinase. SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SC-26196

Cat. No.: HY-107410

SC-26196 is a potent, orally active Delta6 desaturase (**D6D, FADS2**) inhibitor (IC_{50}=0.2 μM in a rat liver microsomal assay). Antiinflammatory properties.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SC-58125

Cat. No.: HY-W013164

SC-58125 is a potent and selective inhibitor of **cyclooxygenase 2 (COX-2)**, with an IC_{50} of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SC57666

Cat. No.: HY-U00129

SC57666 is a selective **COX2** inhibitor with an IC_{50} of 26 nM.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

SC58451

Cat. No.: HY-U00239

SC58451 is a potent and selective **Cox-2** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SC79

Cat. No.: HY-18749

SC79, a unique specific and BBB permeable **Akt** activator, activates **Akt** in the cytosol and inhibits Akt membrane translocation. SC79 specifically binds to the PH domain of Akt.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SCH 546738

Cat. No.: HY-10017

SCH 546738 is a potent, orally active and non-competitive **CXCR3** antagonist, the affinity constant (K_i) of SCH 546738 binding to human CXCR3 receptor is determined to be 0.4 nM in multiple experiments.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SCH 563705

Cat. No.: HY-10011

SCH 563705 is a potent and orally available **CXCR2** and **CXCR1** antagonist, with IC_{50}s of 1.3 nM, 7.3 nM and K_is of 1 and 3 nM, respectively.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Schaftoside

Cat. No.: HY-N0703

Schaftoside is a flavonoid found in a variety of Chinese herbal medicines, such as Eleusine indica. Schaftoside inhibits the expression of TLR4 and Myd88. Schaftoside also decreases Drp1 expression and phosphorylation, and reduces mitochondrial fission.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Schisandrin

(Schizandrin; Schizandrol; Schizandrol-A)

Cat. No.: HY-N0691

Schisandrin (Schizandrin), a dibenzocyclooctadiene lignan, is isolated from the fruit of Schisandra chinensis Baill. Schisandrin exhibits antioxidant, hepatoprotective, anti-cancer and anti-inflammatory activities. Schisandrin also can reverses memory impairment in rats.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

Schisandrin A

(Schizandrin-A; Wuweizisu-A; Deoxyschizandrin)

Cat. No.: HY-N0693

Schisandrin A inhibits **CYP3A** activity with an IC_{50} of 6.60 μM and K_i of 5.83 μM, respectively.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Schisantherin A

(Gomisin-C; Schizantherin-A; Wuweizi ester-A)

Cat. No.: HY-N0694

Schisantherin A is a dibenzocyclooctadiene lignan. Schisantherin A inhibits **p65-NF-κB** translocation into the nucleus by IκBα degradation.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Schisantherin B

(Gomisin-B; Wuweizi ester-B; Schisantherin-B)

Cat. No.: HY-N0695

Schisantherin B (Gomisin-B; Wuweizi ester-B; Schisantherin-B) is a natural product.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Schisantherin E

(Schizantherin-E)

Cat. No.: HY-N0860

Schisantherin E is a natural compound isolated from the active fraction of the fruits of Schisandra sphenanthera Rehd. et Wils.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Schisanwilsonin C

(Arisanschinin K)

Cat. No.: HY-N2988

Schisanwilsonin C (Arisanschinin K) shows anti-HBV activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sciadopitysin

Cat. No.: HY-N2119

Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba. Sciadopitysi inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting **NF-κB** activation and reducing the expression of **c-Fos** and **NFATc1**.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Scopoletin

(Gelseminic acid; Chrysatropic acid) Cat. No.: HY-N0342

Scopoletin is an inhibitor of acetylcholinesterase (**AChE**).



Purity: 99.70%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 200 mg

Scutellarein

(6-Hydroxyapigenin; 4',5,6,7-Tetrahydroxyflavone) Cat. No.: HY-N0752

Scutellarin, a main active ingredient extracted from Erigeron breviscapus (Vant.) Hand-Mazz., has been wildly used to treat acute cerebral infarction and paralysis induced by cerebrovascular diseases.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Scutellarein tetramethyl ether

(4',5,6,7-Tetramethoxyflavone) Cat. No.: HY-N4314

Scutellarein tetramethyl ether (4',5,6,7-Tetramethoxyflavone) is a bioactive component of Siam weed extract. Scutellarein tetramethyl ether (4',5,6,7-Tetramethoxyflavone) exhibits anti-inflammatory activity through NF-κB pathway.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 1 mg

SD 0006

(SD-06) Cat. No.: HY-11087

SD 0006 (SD-06) is an orally active, selective, ATP-competitive and potent diaryl pyrazole inhibitor of **p38α MAP kinase**, with an IC_{50} of 110 nM for p38α.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SDKPDMAEIEKFDKSK

Cat. No.: HY-P3301

SDKPDMAEIEKFDKSK is a peptide derived from thymosin β4 (Tβ4).

SDKPDMAEIEKFDKSK

Purity: 99.80%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

SDMA

(Symmetric dimethylarginine; NG,NG'-Dimethyl-L-arginine) Cat. No.: HY-101410

SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (**NO**) synthase activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

SDZ 224-015

Cat. No.: HY-141622

SDZ 224-015 is an orally active inhibitor of the **interleukin-1 beta (IL-1β)** converting enzyme and **caspase-1**. SDZ 224-015 possesses anti-COVID-19 activity, targeting M^{pro} (IC_{50} of 30 nM).
.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SDZ-MKS 492

(MKS 492) Cat. No.: HY-100164

SDZ-MKS 492 (MKS 492) is a selective inhibitor of cyclic GMP-inhibited **phosphodiesterase (type III PDE)**. SDZ-MKS 492 inhibits antigen- or platelet activating factor (PAF)-induced bronchoconstriction and allergic reactions in guinea pigs and rats.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Se-DMC

Cat. No.: HY-139703

Se-DMC attenuates complete Freund's adjuvant (CFA)-induced inflammatory response, nociception, and neurobehavioral deficits in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Secalciferol

((24R)-24,25-Dihydroxyvitamin D3) Cat. No.: HY-32343

Secalciferol is a metabolite of Vitamin D, a possibly anti-inflammatory steroid which is involved in bone ossification. IC50 value: Target: In addition, it is known that Secalciferol mediates calcium and phosphorus homeostasis.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Secalciferol-d6

Cat. No.: HY-32343S

Secalciferol-d6 ((24R)-24,25-Dihydroxyvitamin D3-d6) is the deuterium labeled Secalciferol. Secalciferol is a metabolite of Vitamin D, a possibly anti-inflammatory steroid which is involved in bone ossification.



Purity: >98%
Clinical Data:
Size: 250 µg, 1 mg, 10 mg

Seclazone

Cat. No.: HY-119517

Seclazone, a heterocyclic compound, possesses anti-inflammatory, analgesic, antipyretic and diuretic properties. Seclazone is orally active.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Seco-DUBA

Cat. No.: HY-132180A

Seco-DUBA is a duocarmycin (DUBA) prodrug containing two hydroxyl groups, which can each be used for coupling to an antibody via a linker. Seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADCs).



Purity: 95.81%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Seco-DUBA hydrochloride

Cat. No.: HY-132180

Seco-DUBA hydrochloride is a toxin for ADC drug SYD985.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Secoisolariciresinol diglucoside

((S,S)-SDG; (S,S)-LGM2605)

Cat. No.: HY-105008

Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Secretin, porcine

(Porcine secretin acetate)

Cat. No.: HY-P1535

Secretin, porcine (Porcine secretin acetate) is a 27-amino acid peptide, acting on pancreatic acinar cells and ductal epithelial cells stimulating the production of bicarbonate rich fluid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Secretin, porcine TFA

(Porcine secretin TFA)

Cat. No.: HY-P1535A

Secretin, porcine TFA (Porcine secretin TFA) is a 27-amino acid peptide, acting on pancreatic acinar cells and ductal epithelial cells stimulating the production of bicarbonate rich fluid.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Secukinumab

(AIN457)

Cat. No.: HY-P9927

Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against **interleukin (IL)-17A**. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.

Purity: ≥99.20%
Clinical Data: Launched
Size: 1 mg, 5 mg

Sedanolide

Cat. No.: HY-N2114

Sedanolide, a natural compound occurring in edible umbelliferous plants, possesses anti-inflammatory and antioxidant activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Seletalisib

(UCB5857)

Cat. No.: HY-16754

Seletalisib (UCB5857) is potent and selective **PI3Kδ** inhibitor with an IC_{50} of 12 nM.



Purity: 98.50%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Selisistat

(EX-527)

Cat. No.: HY-15452

Selisistat (EX-527) is a potent and selective **SirT1** (Sir2 in Drosophila melanogaster) inhibitor with an IC_{50} of 123 nM for SirT1. Selisistat alleviates pathology in multiple animal and cell models of Huntington's disease.



Purity: 99.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Selnoflast

Cat. No.: HY-132831

Selnoflast (example 6) is a **NLRP3** inhibitor (extracted from patent WO2019008025).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Semapimod tetrahydrochloride

(CNI-1493; CPSI-2364 tetrahydrochloride)

Cat. No.: HY-15509A

Semapimod tetrahydrochloride (CNI-1493), an inhibitor of **proinflammatory cytokine** production, can inhibit **TNF-α**, **IL-1β**, and **IL-6**. Semapimod tetrahydrochloride inhibits TLR4 signaling (IC_{50}≈0.3 μM).



Purity: 98.43%
Clinical Data: No Development Reported
Size: 5 mg

Semicarbazide hydrochloride (Aminourea hydrochloride; Hydrazinecarboxamide hydrochloride)

Cat. No.: HY-Y0470

Semicarbazide hydrochloride, a derivative of urea, possesses antiviral, antiinfective and antineoplastic through binding to copper or iron in cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Senkyunolide I

Cat. No.: HY-N0745

Senkyunolide I, isolated from Ligusticum chuanxiong Hort, is an anti-migraine compound. Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sennoside D

Cat. No.: HY-N1973

Sennoside D is an anthraquinone glycoside, found in leaves and pods of Senna (Cassia angustifolia).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Seratrodast

(AA 2414)

Cat. No.: HY-B0774

Seratrodast(AA 2414) is an anti-asthmatic agent and a potent and selective thromboxane A2 receptor (TP) antagonist.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Serum CG probe 1

Cat. No.: HY-D1286

Serum CG probe 1 (formula (9)) is a compound for determining serum cholyglycine.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Serum CG probe 2

Cat. No.: HY-D1287

Serum CG probe 2 (formula (15)) is a compound for determining serum cholyglycine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sesamoside

Cat. No.: HY-N0412

Sesamoside is a iridoid isolated from the aerial part of Phlomis linearifolia. Sesamoside has antiodant and antiglycation activities.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Setipiprant

(ACT-129968; KYTH-105)

Cat. No.: HY-16635

Setipiprant is an orally available, selective CRTH2 antagonist. CRTH2 is a G protein-coupled receptor for PGD2.



Purity: 98.70%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SEW2871

Cat. No.: HY-W008947

SEW2871 is a highly selective, orally active **S1P1** agonist with an EC_{50} of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

SGC-CBP30

Cat. No.: HY-15826

SGC-CBP30 is a potent and highly selective **CBP/p300 bromodomain** (K_ds of 21 nM and 32 nM for **CBP** and **p300**, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of **BRD4 [BRD4(1)]** bound.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SGK1-IN-1

Cat. No.: HY-18607

SGK1-IN-1 is a highly active and selective inhibitor of **SGK-1**, with an IC_{50} of 1 nM.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SGK1-IN-2

Cat. No.: HY-135893

SGK1-IN-2 (14h) is a selective **SGK1 (serum and glucocorticoid regulated kinase 1)** inhibitor, with an IC_{50} of 5 nM at 10 μM ATP concentration.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Shionone

Cat. No.: HY-N0829

Shionone is the major triterpenoid isolated from Aster tataricus, has anti-tussive, anti-inflammatory activities. Shionone possesses a unique six-membered tetracyclic skeleton and 3-oxo-4-monomethyl structure.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

ShK-Dap22

Cat. No.: HY-P1274

ShK-Dap22 is a potent **Kv1.3**-specific immunosuppressive Polypeptide. ShK-Dap22 is a selective Kv1.3 channel blocker with IC_{50}s of 23 pM, 1.8 nM, 10.5 nM, 37 nM, and 39 nM for mKv1.3, mKv1.1, hKv1.6, mKv1.4, and rKv1.2 channels, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ShK-Dap22 TFA

Cat. No.: HY-P1274A

ShK-Dap22 TFA is a potent **Kv1.3**-specific immunosuppressive Polypeptide. ShK-Dap22 TFA is a selective Kv1.3 channel blocker with IC_{50}s of 23 pM, 1.8 nM, 10.5 nM, 37 nM, and 39 nM for mKv1.3, mKv1.1, hKv1.6, mKv1.4, and rKv1.2 channels, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SHR0302

Cat. No.: HY-112724

SHR0302 is a potent and orally active all members of the **JAK family** inhibitor, particularly **JAK1**. The selectivity of SHR0302 for **JAK1** is >10-fold for **JAK2**, 77-fold for **JAK3**, 420-fold for **Tyk2**.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

SHR168442

Cat. No.: HY-115879

SHR168442 is a modulator of retinoid-related orphan receptor gamma (RORγ) with an IC_{50} value of 0.035 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sialyl-Lewis X

(sLeX)

Cat. No.: HY-W020790

Sialyl-Lewis X (sLeX) is a sialylated fucosylated tetrasaccharide, an endogenous **antigen**. Sialyl-Lewis X is a high-affinity **ligand** for selectins (E-, P-, and L-selectin).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Siamenoside I

Cat. No.: HY-N0612

Siamenoside I is one of the mogrosides that has several kinds of bioactivities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Siegesbeckialide I

Cat. No.: HY-N10111

Siegesbeckialide I most potently inhibits LPS-induced NO production in RAW264.7 murine macrophages by directly binding to **IKKα/β**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Siltenzepine

Cat. No.: HY-101694

Siltenzepine is an anti-acid agent. It is used in the treatment of peptic ulcers.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Silybin

Cat. No.: HY-N0779A

Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces **apoptosis** and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity.



Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Silymarin

Cat. No.: HY-N7073

Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance.

Purity: ≥80.0%
Clinical Data: Launched
Size: 250 mg, 500 mg

Sinapine

Cat. No.: HY-N5077

Sinapine is an alkaloid isolated from seeds of the cruciferous species. Sinapine exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Sinapine hydroxide

Cat. No.: HY-N5077B

Sinapine hydroxide is an alkaloid isolated from seeds of the cruciferous species. Sinapine hydroxide exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sinefungin

(Adenosyl-Ornithine; A-9145; Antibiotic 32232RP)

Cat. No.: HY-101938

Sinefungin is a potent inhibitor of virion **mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase**, and viral multiplication. Sinefungin, a **SET7/9** inhibitor, ameliorates renal fibrosis by inhibiting H3K4 methylation.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg

Sinigrin hydrate

Cat. No.: HY-N2423

Sinigrin (hydrate) is a natural aliphatic glucosinolate present in plants of the Brassicaceae family. Sinigrin (hydrate) exhibits anti-cancer, antibacterial, antifungal, antioxidant and anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sinomenine

Cat. No.: HY-15122

Sinomenine, an alkaloid extracted from Sinomenium acutum, is a blocker of the **NF-κB** activation. Sinomenine also is an activator of **μ-opioid receptor**.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Sinomenine hydrochloride

(Cucoline hydrochloride)

Cat. No.: HY-15122A

Sinomenine hydrochloride (Cucoline hydrochloride), an alkaloid extracted from Sinomenium acutum, is a blocker of the **NF-κB** activation. Sinomenine also is an activator of **μ-opioid receptor**.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

SirReal2

Cat. No.: HY-100591

SirReal2 is a potent, isotype-selective **Sirt2** inhibitor with an IC_{50} value of 140nM and has very little effect on the activities of Sirt3-5. SirReal2 leads to tubulin hyperacetylation in HeLa cells and induces destabilization of the checkpoint protein BubR1.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SIRT-IN-1

Cat. No.: HY-16615

SIRT-IN-1 is a potent inhibitor of **SIRT1/2/3**, with IC_{50}**s** of 15, 10, 33 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SIRT-IN-2

Cat. No.: HY-16616

SIRT-IN-2 is a potent inhibitor of **SIRT1/2/3**, with IC_{50}**s** of 4, 4, 7 μM, respectively.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sirt2-IN-1

Cat. No.: HY-112427

Sirt2-IN-1 (Compound 9) is a **sirtuin 2** (**Sirt2**) inhibitor with an IC_{50} of 163 nM.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

SIS3 free base

Cat. No.: HY-100444

SIS3 free base is a potent and selective inhibitor of **Smad3** phosphorylation. SIS3 free base inhibits the myofibroblast differentiation of fibroblasts by TGF-β1. SIS3 free base does not affect the phosphorylation of Smad2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sitravatinib

(MGCD516; MG-516)

Cat. No.: HY-16961

Sitravatinib (MGCD516) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}**s** of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: 99.59%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Sitravatinib malate

(MGCD516 malate; MG-516 malate)

Cat. No.: HY-16961A

Sitravatinib malate (MGCD516 malate) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}**s** of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

SJ-3366

(IQP-0410)

Cat. No.: HY-118423

SJ-3366 (IQP-0410) is a potent inhibitor of HIV nonnucleoside reverse transcriptase. SJ-3366 (IQP-0410) inhibits HIV at sub-nanomolar concentrations primarily through a typical non-nucleoside mechanism.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SK1-IN-1

Cat. No.: HY-101805

SK1-IN-1 is a potent sphingosine kinase 1 (**SPHK1**) inhibitor with an IC_{50} of 58 nM.



Purity: 98.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Skepinone-L

(CBS3830)

Cat. No.: HY-15300

Skepinone-L (CBS3830) is a selective p38 mitogen-activated protein kinase inhibitor.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SKF-86002

Cat. No.: HY-12511

SKF-86002 is an orally active **p38 MAPK** inhibitor, with anti-inflammatory, anti-arthritic and analgesic activities. SKF-86002 inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production (IC_{50} = 1 μM).



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SKF-86002 dihydrochloride

Cat. No.: HY-108641

SKF-86002 dihydrochloride is an orally active **p38 MAPK** inhibitor, with anti-inflammatory, anti-arthritic and analgesic activities. SKF-86002 dihydrochloride inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production (IC_{50} = 1 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SKF96067

Cat. No.: HY-U00042

SKF96067 is a reversible inhibitor of the gastric **H^+/K^+-ATPase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Skimmianine

Cat. No.: HY-N2081

Skimmianine is a furoquinoline alkaloid present mainly in the Rutaceae family, with antispastic, anti-inflammatory activities and antiplatelet aggregation effect. Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Skimmin

(Umbelliferone glucoside)

Cat. No.: HY-N2263

Skimmin (Umbelliferone glucoside) is a coumarin found in Hydrangea paniculata, inhibits immune complex deposition, with anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Skullcapflavone II

Cat. No.: HY-N6624

Skullcapflavone II, a flavonoid derived from Scutellaria baicalensis, has anti-inflammatory, anti-microbial activities. Skullcapflavone II regulates osteoclast differentiation, survival, and function.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SLIGRL-NH2

(Protease-Activated Receptor-2 Activating Peptide)

Cat. No.: HY-P1308

SLIGRL-NH2 (Protease-Activated Receptor-2 Activating Peptide) is an agonist of Protease-Activated Receptor-2 (**PAR-2**).



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

SLIGRL-NH2 TFA

(Protease-Activated Receptor-2 Activating Peptide TFA)

Cat. No.: HY-P1308A

SLIGRL-NH2 TFA (Protease-Activated Receptor-2 Activating Peptide TFA) is an agonist of Protease-Activated Receptor-2 (**PAR-2**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SM 16

Cat. No.: HY-111482

SM 16 is a **ALK5/ALK4** kinase inhibitor with K_is of 10 and 1.5 nM, respectively.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SM-276001

Cat. No.: HY-123291

SM-276001 is a potent selective **TLR7** agonist that can induce antitumor immune responses. SM-276001 is an orally active **interferon** (**IFN**) inducer.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SM-324405

Cat. No.: HY-110207

SM-324405 is a **TLR7** agonistic antedrug (EC_{50} = 50 nM), with pEC_{50} values of 7.3 and 6.6 for human TLR7 and Rat TLR7, respectively. SM-324405 is used for immunotherapy of allergic diseases.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SMAP-29

Cat. No.: HY-P2460

SMAP-29, a promising **antiinfective** agent, is a broad spectrum antibacterial and antifungal α-helical cathelicidin-derived peptide. SMAP-29 acts by permeabilizing bacterial membranes and inducing remarkable changes in the surface morphology of susceptible microorganism.

RGLRRLGRKIAHGVKKYGPTVLRIIRIAG

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Smcy HY Peptide (738-746)

Cat. No.: HY-P1899

Smcy HY Peptide (738-746) is a H2-D^b-restricted peptide corresponding to amino acids 738-746 of Smcy protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SMS1-IN-1

Cat. No.: HY-135642

SMS1-IN-1, compound SAPA 1j, is a novel and the most potent **sphingomyelin synthase 1 (SMS1)** inhibitor with an IC_{50} value of 2.1 μM. SMS1-IN-1 has the potential for the treatment of atherosclerosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SMS2-IN-1

Cat. No.: HY-102041

SMS2-IN-1 is a potent and highly selective **sphingomyelin synthase 2 (SMS2)** inhibitor with an IC_{50} of 6.5 nM and a K_d of 37 nM. SMS2-IN-1 shows 150-fold selectivity for **SMS2** over SMS1 (IC_{50} of 1000 nM).



Purity: 98.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SMS2-IN-2

Cat. No.: HY-112713

SMS2-IN-2 is a potent, highly selective and orally active **sphingomyelin synthase 2 (SMS2)** inhibitor, with IC_{50}s of 100 nM and 56 μM for SMS2 and SMS1, respectively. Anti-chronic inflammatory activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Smyrindioloside

Cat. No.: HY-N1234

Smyrindioloside is a natural product isolated from the bark of Streblus indicus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SN50

Cat. No.: HY-P0151

SN50 is a cell permeable inhibitor of **NF-κB** translocation.

AAVALLPAVLLALLAPVQRKRQKLMP

Purity: 98.91%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sodium aescinate

Cat. No.: HY-N1404

Sodium aescinate is a triterpene saponin derived from Aesculus hippocastanum seeds, with anti-inflammatory and antioxidant activities. Sodium aescinate inhibits hepatocellular carcinoma growth by targeting CARMA3/NF-κB pathway.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Sodium diatrizoate

(Diatrizoic acid sodium salt; Sodium amidotrizoate)

Cat. No.: HY-B0926A

Sodium diatrizoate (Diatrizoic acid sodium salt) is an iodinated radiocontrast agent and has the potential for radiographic imaging of the airways. Sodium diatrizoate induces mitochondrial turnover and oxidative stress, and activating apoptosis by dysregulating calcium.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Sodium gualenate

(Guaiazulenesulfonate sodium)

Cat. No.: HY-B2191

Sodium gualenate (Guaiazulenesulfonate sodium) is a hydrophilic derivative of guaiazulene with excellent anti-inflammatory and wound-healing effects mainly used for the treatment of duodenal ulcer, gastric ulcer and gastritis.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Sodium Houttuyfonate

Cat. No.: HY-N6934

Sodium Houttuyfonate is an orally active compound synthesized by combining sodium bisulfite with houttuynia. Sodium Houttuyfonate exhibits antifungal, antibacterial, anti-inflammatory, and cardiovascular protective activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Sodium lauryl sulfoacetate

Cat. No.: HY-107789

Sodium lauryl sulfoacetate is a solid anionic surfactant of vegetable origin. Sodium lauryl sulfoacetate is an immunoadjuvant. Anti-immunosuppressive effect.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Sodium Salicylate (Salicylic acid sodium salt; 2-Hydroxybenzoic acid sodium salt)

Cat. No.: HY-B0167A

Sodium Salicylate (Salicylic acid sodium salt) inhibits cyclo-oxygenase-2 (**COX-2**) activity independently of transcription factor (NF-κB) activation. Sodium Salicylate is also a **S6K** inhibitor.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 10 g, 50 g

Sodium thiocyanate

(Thiocyanate sodium)

Cat. No.: HY-23119

Sodium thiocyanate reduces plasma levels of the pro-inflammatory cytokine **IL-6**, and increases the anti-inflammatory cytokine **IL-10** levels. Sodium thiocyanate also significantly reduces of **ROS** formation.

Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

Sofalcone

Cat. No.: HY-B2184

Sofalcone, a gastric **antiulcer** agent, is known to induce the expression of **Heme oxygenase-1** (**HO-1**) in gastric epithelium.



Purity: 99.12%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Solanesol

Cat. No.: HY-N0576

Solanesol is an aliphatic terpene alcohol mainly found in Solanaceous plants, with anti-inflammatory, neuroprotective, and antimicrobial activities.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg

Solasodine

(Purapuridine; Solancarpidine; Solasodin)

Cat. No.: HY-N0068

Solasodine (Purapuridine) is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

Solcitinib

(GSK-2586184; GLPG-0778)

Cat. No.: HY-16755

Solcitinib is an orally active, competitive, potent, selective **JAK1** inhibitor, with an IC_{50} of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.



Purity: 99.59%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Sootepin D

Cat. No.: HY-122521

Sootepin D (compound 6), a triterpene from the apical bud of Gardenia sootepensis, inhibits TNF-α-induced **NF-κB** activity with an IC_{50} of 8.3μM. Sootepin D has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sophocarpine

Cat. No.: HY-N0103

Sophocarpine is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Sophocarpine monohydrate

Cat. No.: HY-N0103A

Sophocarpine (monohydrate) is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Sophoricoside

Cat. No.: HY-N0423

Sophoricoside is an isoflavone glycoside isolated from Sophora japonica and has anti-inflammatory, anti-cancer and immunosuppressive effects.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Sordarin sodium

Cat. No.: HY-126396

Sordarin is a potent diphthamide-dependent **eEF2** inhibitor with **antifungal** properties. Sordarin targets eEF2 so as to inhibit protein translation by blocking eEF2-mediated translocation of tRNAs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sotirimod

(R850)

Cat. No.: HY-101589

Sotirimod is an immunostimulant, and can potentially treat for actinic keratosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sotrastaurin

(AEB071)

Cat. No.: HY-10343

Sotrastaurin (AEB071) is a potent and orally-active pan-**PKC** inhibitor, with K_is of 0.22 nM, 0.64 nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Soyasapogenol A

Cat. No.: HY-N6073

Soyasapogenol A, a triterpene compound, isolated from the roots of Abrus cantoniensis.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg

Soyasaponin II

Cat. No.: HY-122920

Soyasaponin II is a saponin with antiviral activity. Soyasaponin II inhibits the replication of HSV-1, HCMV, influenza virus, and HIV-1. Soyasaponin II shows potent inhibition on HSV-1 replication.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 1 mg

SP-100030

Cat. No.: HY-110177

SP-100030 is a potent **NF-κB** and **activator protein-1 (AP-1)** double inhibitor (IC_{50}s=50 and 50 nM, respectively). SP-100030 inhibits IL-2, IL-8, and TNF-alpha production in Jurkat and other T cell lines. SP-100030 decreases murine collagen-induced arthritis (CIA).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sp-8-CPT-cAMPS

Cat. No.: HY-120994B

Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent **protein kinas A (PKA I and PKA II)**. Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SP4206

Cat. No.: HY-119424

SP4206 is an **IL-2/IL-2Rα interaction** inhibitor. SP4206 binds with high affinity (K_d=70 nM) to **IL-2** and blocks binding to its natural receptor **IL-2Rα** (K_d=10 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Spantide I

Cat. No.: HY-P1194

Spantide I, a substance P analog, is a selective **NK_1 receptor** antagonist, with K_i values of 230 nM and 8150 nM for NK_1 and NK_2 receptor, respectively.

RPKPQQWFWLL-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Spantide I TFA

Cat. No.: HY-P1194A

Spantide I TFA, a substance P analog, is a selective **NK_1 receptor** antagonist, with K_i values of 230 nM and 8150 nM for NK_1 and NK_2 receptor, respectively.

RPKPQQWFWLL-NH_2 (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sparstolonin B

Cat. No.: HY-116213

Sparstolonin B acts as a selective **TLR2** and **TLR4** antagonist and selectively blocks TLR2- and TLR4-mediated inflammatory signaling. Sparstolonin B has anti-**HIV** and anticancer activities.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

SPB

Cat. No.: HY-104025

SPB is a drug-linker conjugate for ADC with potent anti-inflammatory activity by using Xanthotoxol, linked via the ADC linker.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

SPD304 dihydrochloride

Cat. No.: HY-111255A

SPD304 dihydrochloride is a selective **TNF-α** inhibitor, which promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor. SPD304 has an IC_{50} of 22 μM for inhibiting in vitro TNF receptor 1 (TNFR1) binding to TNF-α.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Specnuezhenide

((8E)-Nuezhenide)

Cat. No.: HY-N0665

Specnuezhenide ((8E)-Nuezhenide) is isolated from the fruits of Ligustrum lucidum. Specnuezhenide ((8E)-Nuezhenide) can inhibit IL-1β-induced inflammation in chondrocytes via inhibition of **NF-κB** and **wnt/β-catenin** signaling.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Sphinganine 1-phosphate

(D-erythro-Dihydrosphingosine 1-phosphate)

Cat. No.: HY-113116

Sphinganine 1-phosphate (D-erythro-Dihydrosphingosine 1-phosphate) is a polar sphingolipid metabolite that regulates cell migration, differentiation, survival and complex physiological processes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sphingomyelin

Cat. No.: HY-113498

Sphingomyelin is a eukaryotic sphingolipid and one of the major constituents of cell membranes and particularly abundant in the myelin sheath that surrounds neuronal axons.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Sphondin

Cat. No.: HY-N2429

Sphondin possesses an inhibitory effect on IL-1β-induced increase in the level of **COX-2** protein and PGE_2 release in A549 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Spiperone hydrochloride

(Spiroperidol hydrochloride)

Cat. No.: HY-B1371A

Spiperone hydrochloride (Spiroperidol hydrochloride) is a selective **dopamine D_2 receptor** (K_i values of 0.06 nM, 0.6 nM, 0.08 nM, ~350 nM, ~3500 nM for D_2, D_3, D_4, D_1 and D_5 receptors, respectively) and **5-HT_{2A}/5-HT_{1A} receptor** (K_is of 1 nM/49 nM)...



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mg

Spiraeoside

(Quercetin 4′-O-glucoside)

Cat. No.: HY-N8253

Spiraeoside, an orally active natural compound, exerts antioxidant activity, inhibits **reactive oxygen species (ROS)** and malondialdehyde production. Spiraeoside possesses antiallergic, anti-inflammatory and antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Spirofylline

Cat. No.: HY-100250

Spirofylline is a bronchodilator that has the potential for asthma and bronchitis and emphysema treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SPL-410

Cat. No.: HY-128356

SPL-410 is an orally active, highly potent and selective hydroxyethylamine based **SPPL2a (Signal Peptide Peptidase Like 2a)** inhibitor, with an IC_{50} of 9 nM.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

SPL-707

Cat. No.: HY-111360

SPL-707 is an orally active, selective **signal peptide peptidase-like 2a (SPPL2a)** inhibitor with an IC_{50} of 77 nM for hSPPL2a. SPL-707 inhibits **γ-secretase** (IC_{50}=6.1 μM) and **SPP** (IC_{50}=3.7 μM). SPL-707 has the potential for autoimmune diseases research by targeting B cells and dendritic cells.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

sPLA2 inhibitor 1

Cat. No.: HY-11059

sPLA2 inhibitor 1, a D-tyrosine derivative, is an orally active, potent **secretory phospholipase A_2 ($sPLA_2$)** inhibitor with an IC_{50} of 29 nM for human nonpancreatic secretory PLA_2 isoform IIa ($hnpsPLA_2$-IIa). sPLA2 inhibitor 1 has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Splenopentin diacetate

Cat. No.: HY-P0085

Splenopentin diacetate is a synthetic immunomodulating pentapeptide corresponding to the residues 32-36 of the splenic hormone splenin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SPR inhibitor 3

(SPRi3)

Cat. No.: HY-115510

SPR inhibitor 3 (SPRi3) is a potent sepiapterin reductase (SPR) inhibitor. SPR inhibitor 3 (SPRi3) displays high binding affinity to human SPR in a cell-free assay (IC_{50}=74 nM) and efficiently reduces biopterin levels in a cell-based assay (IC_{50}=5.2 μM).



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SR 11302

Cat. No.: HY-15870

SR 11302 is an **activator protein-1** (**AP-1**) transcription factor inhibitor. SR 11302 is a retinoid that specifically inhibits AP-1 activity without activating the transcription of retinoic acid response element (RARE).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

SR-31747

Cat. No.: HY-13751

SR-31747 is a **sigma** ligand with immunosuppressive and anti-inflammatory properties. SR-31747 blocks cell proliferation by inhibiting sterol isomerase.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SR-31747 free base

Cat. No.: HY-13751A

SR-31747 free base is a **sigma** ligand with immunosuppressive and anti-inflammatory properties. SR-31747 blocks cell proliferation by inhibiting sterol isomerase.



Purity: 95.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

SR-318

Cat. No.: HY-135674

SR-318 is a potent and highly selective **p38 MAPK** inhibitor with IC_{50}s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively. SR-318 potently inhibits the **TNF-α** release in whole blood with an IC_{50} of 283 nM. SR-318 has anti-cancer and anti-inflammatory activity.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SR-717

Cat. No.: HY-131454

SR-717 is a non-nucleotide **STING** agonist with EC_{50}s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SR-717 free acid

Cat. No.: HY-131454A

SR-717 free acid is a non-nucleotide **STING** agonist with EC_{50}s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 free acid is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR0987

Cat. No.: HY-101454

SR0987, a SR1078 analog, is a **RORγt** agonist, with an EC_{50} of 800 nM. SR0987 increases IL17 expression while repressing the expression of PD-1.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SR1001

Cat. No.: HY-13421

SR1001 is a selective ROR_{α} and $ROR_{\gamma t}$ inverse agonist with K_is 172 and 111 nM, respectively.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SR121566A

Cat. No.: HY-U00235

SR121566A is a novel non-peptide **Glycoprotein IIb/IIIa** (**GP IIb-IIIa**) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC_{50}s of 46±7.5, 56±6 and 42±3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR2211

Cat. No.: HY-16998

SR2211 is a potent, selective synthetic **RORγ** modulator and functions as an inverse agonist, with a K_i of 105 nM and an IC_{50} of ~320 nM.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Src Inhibitor 3

Cat. No.: HY-130254

Src Inhibitor 3 is a potent, orally active **c-terminal Src kinase (CSK)** with IC_{50} values below 3 nM and 4 nM in CSK HTRF and Caliper assay, respectively. Src Inhibitor 3 shows the ability to increase T cell proliferation induced by T cell receptor signaling.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SRS16-86

Cat. No.: HY-135430

SRS16-86 is a potent inhibitor of **ferroptosis**. SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SRT3109

Cat. No.: HY-15462

SRT3109 is an antagonist of **CXCR2**, with a pIC_{50} of 8.2, and used in the research of chemokine mediated diseases.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

SRT3190

Cat. No.: HY-13021

SRT3190 is an antagonist of **CXCR2**, used in the research of chemokine mediated diseases.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SSAA09E2

Cat. No.: HY-138067

SSAA09E2 is an inhibitor of **SARS-CoV** (Severe acute respiratory syndrome-Coronavirus) replication, acting by blocking early interactions of **SARS-S** with the receptor for **SARS-CoV**, Angiotensin Converting Enzyme-2 (ACE2) .



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SSAO inhibitor-1

Cat. No.: HY-139607

SSAO inhibitor-1 is a semicarbazide-sensitive amine oxidase (**SSAO**) inhibitor. SSAO inhibitor-1 has anti-inflammatory activity and can be used for liver diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SSK1

Cat. No.: HY-138936

SSK1, a senescence-specific killing compound, is a β-galactosidase-targeted prodrug attenuates inflammation. SSK1 is activated by lysosomal β-galactosidase and selectively killed senescent cells through the activation of **p38 MAPK** and induction of **apoptosis**.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

SSR240612

Cat. No.: HY-15039

SSR240612 is a potent, and orally active specific non-peptide **bradykinin B1 receptor** antagonist, with K_is of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes...



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

ST 2825

Cat. No.: HY-50937

ST 2825 is a specific **MyD88** dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Stachyanthuside A

Cat. No.: HY-N7679

Stachyanthuside A is an ellagic acid glycoside isolated from the leaves of Diplopanax stachyanthus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Stachyose hydrate

Cat. No.: HY-N0299

Stachyose hydrate act as a prebiotic to enhance the growth and activity of beneficial bacteria. Stachyose hydrate exhibit a hypoglycemic effect, and improve inflammation through modulating gut microbiota.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Stattic

Cat. No.: HY-13818

Stattic is a potent **STAT3** inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727). Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Stepharine

Cat. No.: HY-N9347

Stepharine, an natural alkaloid, directly interactes with **TLR4** and binds to the TLR4/MD2 complex (TLR4 inhibitor). Stepharine possesses anti-aging, anti-viral and anti-hypertensive effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Stigmasterol

(Stigmasterin)

Cat. No.: HY-N0131

Stigmasterol is a plant sterol which has been focused on the cholesterol-lowering activity and is valued as an anti-stiffness factor in the therapy of rheumatic diseases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg

Stigmasterol glucoside

Cat. No.: HY-N1200

Stigmasterol glucoside is a sterol isolated from P. urinaria with high antioxidant and anti-inflammatory activities, act as an inhibitor of **5α-reductase** with an IC_{50} of 27.2μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

STING ligand-1

Cat. No.: HY-114399

STING ligand-1 is a lead **STING** ligand with an IC_{50} of 68 nM for HAQ STING.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

STING-IN-2

Cat. No.: HY-138682

STING-IN-2 (C-170) is a potent and covalent **STING** inhibitor. STING-IN-2 efficiently inhibits both **mouse STING (mmSTING)** and **human STING (hsSTING)**. STING-IN-2 can be used for autoinflammatory disease research.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

STING-IN-3

Cat. No.: HY-138683

STING-IN-3 is an inhibitor of **stimulator of interferon genes (STING)**. STING-IN-3 efficiently inhibits both hsSTING and mmSTING through covalently target the predicted transmembrane cysteine residue 91 and thereby block the activation-induced palmitoylation of STING.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Stipuleanoside R2

Cat. No.: HY-N8816

Stipuleanoside R2 inhibits **NF-κB** activation stimulated by TNFα in a dose-dependent manner with IC_{50} value of 4.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Strictosamide

Cat. No.: HY-N1198

Strictosamide has important effects on inflammation and inflammatory pain. Strictosamide possesses **antiplasmodial** and **antifungal** activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Stylopine hydrochloride ((±)-Stylopine hydrochloride; Tetrahydrocoptisine hydrochloride)

Cat. No.: HY-N0924A

Stylopine hydrochloride (Tetrahydrocoptisine hydrochloride) is an alkaloid compound originally isolated from Corydalis tubers that exhibits anti-inflammatory and anti-parasitic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU0268

Cat. No.: HY-139056

SU0268 is a potent and specific inhibitor of **8-Oxoguanine DNA glycosylase 1 (OGG1)**. SU0268 regulates inflammatory responses during Pseudomonas aeruginosa infection.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SU1498

(AG 1498; Tyrphostin SU 1498)

Cat. No.: HY-19326

SU1498 (AG 1498) is a selective inhibitor of the **VEGFR2**; inhibits **Flk-1** with an IC_{50} of value of 700 nM.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

SU3327

Cat. No.: HY-107597

SU3327 is a potent, selective and substrate-competitive **JNK** inhibitor with an IC_{50} of 0.7 μM. SU3327 also inhibits protein-protein interactions between **JNK** and JNK Interacting Protein (JIP) with an IC_{50} of 239 nM. SU3327 shows less active against p38α and Akt kinase.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SU5201

Cat. No.: HY-21293

SU5201 is an inhibitor of interleukin-2 (**IL-2**) production.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Subasumstat

(TAK-981)

Cat. No.: HY-111789

Subasumstat (TAK-981) is a first in class and selective inhibitor of the **SUMOylation** enzymatic cascade, with potential immune-activating and antineoplastic activities.



Purity: 98.56%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Suberosin

Cat. No.: HY-N1196

Suberosin, isolated from Plumbago zeylanica, exhibits anti-inflammatory and anticoagulant activity.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Substance P Receptor Antagonist 1

Cat. No.: HY-U00382

Substance P Receptor Antagonist 1 has the potential function in central nervous system disorders, respiratory, inflammatory diseases and gastrointestinal disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Succinobucol

(AGI-1067; Probucol monosuccinate)

Cat. No.: HY-14937

Succinobucol is a phenolic antioxidant with anti-inflammatory and antiplatelet effects.



Purity: 99.93%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sucralfate

(Sucrose octasulfate-aluminum complex)

Cat. No.: HY-B0644

Sucralfate (Sucrose octasulfate-aluminum complex) is a potent and orally active **gastroprotectant** with no systemic effects.



Purity: >98%
Clinical Data: Launched
Size: 100 mg, 500 mg

Sudoxicam

Cat. No.: HY-106628

Sudoxicam is a reversible and orally active **COX** antagonist and a non-steroidal anti-inflammatory drug (NSAID) from the enol-carboxamide class. Sudoxicam has potent anti-inflammatory, anti-edema and antipyretic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulfapyridine

Cat. No.: HY-B0212

Sulfapyridine, a major metabolite of Sulfasalazine, is a sulfonamide antibiotic agent. Sulfapyridine inhibits **recombinant P. carinii dihydropteroate synthetase (DHPS)** with an IC_{50} of 0.18 μM. Sulfapyridine has antibacterial, anti-inflammatory and anti-rheumatic activities.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Sulfasalazine

(NSC 667219)

Cat. No.: HY-14655

Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress **NF-κB** activity. Sulfasalazine is a type 1 **ferroptosis** inducer.



Purity: 99.42%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Sulfinpyrazone

(G-28315)

Cat. No.: HY-B1271

Sulfinpyrazone (G-28315) is an orally active and potent **uricosuric agent** for chronic and intermittent gouty arthritis. Sulfinpyrazone has antithrombotic and platelet inhibitory effects.



Purity: 98.42%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Sulfo-PDBA-DM4

Cat. No.: HY-128954

Sulfo-PDBA-DM4 is a **drug-linker conjugate** composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody drug conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulfogaiacol

Cat. No.: HY-B2115

Sulfogaiacol is a antitussive agent. Sulfogaiacol is used for acute respiratory tract infections, cough and other conditions.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Sulforaphane

Cat. No.: HY-13755

Sulforaphane is an isothiocyanate present naturally in widely consumed vegetables. Sulforaphane increases tumor suppressor protein transcription and inhibits **histone deacetylase** activity.



Purity: 99.75%
Clinical Data: Phase 3
Size: 10 mg, 25 mg, 50 mg, 100 mg

Sulfosuccinimidyl oleate

(Sulfo-N-succinimidyl oleate)

Cat. No.: HY-112847

Sulfosuccinimidyl oleate (Sulfo-N-succinimidyl oleate) is a long chain fatty acid that inhibits fatty acid transport into cells. Sulfosuccinimidyl oleate is a potent and irreversible inhibitor of **mitochondrial respiratory chain**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulfosuccinimidyl oleate sodium

(Sulfo-N-succinimidyl oleate sodium)

Cat. No.: HY-112847A

Sulfosuccinimidyl oleate sodium (Sulfo-N-succinimidyl oleate sodium) is a long chain fatty acid that inhibits fatty acid transport into cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Sulfuretin

Cat. No.: HY-N1193

Sulfuretin inhibits the inflammatory response by suppressing the **NF-κB** pathway. Sulfuretin can be used for the research of allergic airway inflammation. Sulfuretin reduces oxidative stress, platelet aggregation, and mutagenesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulindac
(MK-231)

Cat. No.: HY-B0008

Sulindac (MK-231) is a non-steroidal antiinflammatory agent, acts as a **COX-2** inhibitor, and inhibits overexpression of COX-2.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sulprostone
(SHB 286; CP-34089; ZK-57671)

Cat. No.: HY-19360

Sulprostone (SHB 286) is a potent and selective **EP3 receptor** agonist. Sulprostone (SHB 286) is a prostaglandin E2 (PGE2) analogue and has antiulcer and nonsteroidal abortifacient effects.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SUN 1334H

Cat. No.: HY-U00084

SUN 1334H is a potent, orally active, highly selective **H1 receptor** antagonist, with K_i of 9.7 nM.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg

Suplatast (Tosilate)
(IPD 1151T)

Cat. No.: HY-17002

Suplatast Tosilate (IPD 1151T) is an orally active **Th2 cytokine** inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent.



Purity: 99.26%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Suprofen
(TN-762)

Cat. No.: HY-B0270

Suprofen (TN-762) is a non-steroidal anti-inflammatory drug (NSAID).



Purity: 99.44%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Suprofen-d3

Cat. No.: HY-B0270S

Suprofen-d3 (TN-762-d3) is the deuterium labeled Suprofen. Suprofen (TN-762) is a non-steroidal anti-inflammatory drug (NSAID).



Purity: >98%
Clinical Data:
Size: 2.5 mg, 25 mg

Suxibuzone

Cat. No.: HY-B1079

Suxibuzone is a drug used for joint and muscular pain, is a prodrug of the non steroidal anti inflammatory drug Phenylbutazone.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Swertiajaponin

Cat. No.: HY-N2204

Swertiajaponin is a tyrosinase inhibitor, forms multiple hydrogen bonds and hydrophobic interactions with the binding pocket of tyrosinase, with an IC_{50} of 43.47 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Swertianolin

Cat. No.: HY-N2192

Swertianolin, a xanthone isolated from Gentianella Acuta, inhibits **acetylcholinesterase (AChE)**. Swertianolin also exhibits anti-HBV and anti-bacterial activity.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Swertisin

Cat. No.: HY-N2189

Swertisin, a C-glucosylflavone isolated from Swertia japonica, is known to have antidiabetic, anti-inflammatory and antioxidant effects. Swertisin is an **adenosine A1 receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SX-682

Cat. No.: HY-119339

SX-682 is an orally bioavailable, potent allosteric inhibitor of **CXCR1** and **CXCR2**. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity.



Purity: 98.52%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Syk Inhibitor II

Cat. No.: HY-112390A

Syk Inhibitor II is a potent, high selective and ATP-competitive **Syk** inhibitor with an IC_{50} of 41 nM. Syk Inhibitor II inhibits **5-HT** release from RBL-cells with an IC_{50} of 460 nM. Syk Inhibitor II shows less potent against other kinases and has anti-allergic effect.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Syk-IN-1

Cat. No.: HY-12657

Syk-IN-1 (compound 4) is a potent **Syk** inhibitor, with an IC_{50} of 35 nM.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Syk-IN-4

Cat. No.: HY-131341

Syk-IN-4 is a potent, selective and orally bioavailable **SYK** inhibitor with an IC_{50} of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sylvestroside I

Cat. No.: HY-N3030

Sylvestroside I is an iridoid isolated from Acicarpa tribuloides.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Syringaldehyde

Cat. No.: HY-N1390

Syringaldehyde is a polyphenolic compound belonging to the group of flavonoids and is found in different plant species like Manihot esculenta and Magnolia officinalis. Syringaldehyde moderately inhibits **COX-2** activity with an IC_{50} of 3.5 μg/mL.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Syringyl Alcohol

(Syringic Alcohol)

Cat. No.: HY-N6654

Syringyl Alcohol (Syringic Alcohol) is a derivate of phenol.



Purity: 98.16%
Clinical Data:
Size: 10 mM × 1 mL, 250 mg

Syzalterin

Cat. No.: HY-N1187

Syzalterin is an inhibitor of **NO** production with an IC_{50} of 1.87 μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

T-26c

Cat. No.: HY-100518

T-26c is highly potent and selective **matrix metalloproteinase-13 (MMP-13)** inhibitor with an IC_{50} of 6.75 pM and more than 2600-fold selectivity over the other related metalloenzymes.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

T-peptide

Cat. No.: HY-P2251

T-peptide, a Tuftsin analog, can be used for the research of **human immunodeficiency virus (HIV)** infection. T-peptide prevents cellular immunosuppression and improves survival rate in septic mice. T-peptide also can inhibit the growth of residual tumor cells after surgical resection.

Ac-VQIVYKRRRRRRRRR-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

T6167923

Cat. No.: HY-19744

T6167923 is a potent and selective inhibitor of **MyD88-dependent signaling** pathways. T6167923 directly binds to Toll/IL1 receptor (TIR) domain of MyD88 and disrupts MyD88 homodimeric formation.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TA-02

Cat. No.: HY-100115

TA-02, an analog of SB 203580 (HY-10256), is a **p38 MAPK** inhibitor with an IC_{50} of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295).



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Tabersonine

Cat. No.: HY-N1431

Tabersonine is an indole alkaloid mainly isolated from Catharanthus roseus. Tabersonine disrupts Aβ(1-42) aggregation and ameliorates Aβ aggregate-induced cytotoxicity.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Tabersonine hydrochloride

Cat. No.: HY-N1431A

Tabersonine hydrochloride is an indole alkaloid mainly isolated from Catharanthus roseus. Tabersonine disrupts Aβ(1-42) aggregation and ameliorates Aβ aggregate-induced cytotoxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tacrolimus

(FK506; Fujimycin; FR900506)

Cat. No.: HY-13756

Tacrolimus (FK506), a macrocyclic lactone, binds to **FK506 binding protein (FKBP)** to form a complex. Tacrolimus inhibits **calcineurin phosphatase**, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tacrolimus monohydrate (FK506 monohydrate; Fujimycin monohydrate; FR900506 monohydrate)

Cat. No.: HY-13756A

Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to **FK506 binding protein (FKBP)** to form a complex and inhibits **calcineurin phosphatase**, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.



Purity: 99.37%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tacrolimus-13C,d2

(FK506-13C,d2; Fujimycin-13C,d2; FR900506-13C,d2)

Cat. No.: HY-13756S

Tacrolimus-13C,D2 (FK506-13C,D2) is a 13C-labeled and deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to **FK506 binding protein (FKBP)** to form a complex.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

TAK-020

Cat. No.: HY-132879

TAK-020 is a covalent **Btk** inhibitor, which becomes the clinical candidate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAK-615

Cat. No.: HY-117959

TAK-615 is a negative allosteric modulator (NAM) of the **LPA1** receptor for the research of pulmonary fibrosis. TAK-615 binds the LPA1 receptor with high affinity (K_d high affinity of 1.7 nM and K_d low affinity of 14.5 nM).



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAK-715

Cat. No.: HY-10456

TAK-715 is an orally active and potent **p38 MAPK** inhibitor with IC_{50}s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits **casein kinase I (CK1δ/ε)** to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

TAK-779

(Takeda 779)

Cat. No.: HY-13406

TAK-779 is a potent and selective nonpeptide antagonist of **CCR5** and **CXCR3**, with a K_i of 1.1 nM for CCR5, and effectively and selectively inhibits **R5 HIV-1**, with EC_{50} and EC_{90} of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

TAK-828F

Cat. No.: HY-111509

TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (**RORγt**) inverse agonist (binding IC_{50}=1.9 nM, reporter gene IC_{50}=6.1 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Takinib

(EDHS-206)

Cat. No.: HY-103490

Takinib (EDHS-206) is an orally active and selective **TAK1** inhibitor (IC_{50}=9.5 nM), more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Talabostat

(Val-boroPro; PT100)

Cat. No.: HY-13233

Talabostat (Val-boroPro; PT100) is an orally active and nonselective **dipeptidyl peptidase IV (DPP-IV)** inhibitor (IC_{50} < 4 nM; K_i = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein **(FAP)** (IC_{50} = 560 nM), inhibits DPP8/9 (IC_{50} = 4/11 nM; K_i =...



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Talabostat mesylate

(Val-boroPro mesylate; PT100 mesylate)

Cat. No.: HY-13233A

Talabostat mesylate (Val-boroPro mesylate; PT100 mesylate) is an orally active and nonselective **dipeptidyl peptidase IV (DPP-IV)** inhibitor (IC_{50} < 4 nM; K_i = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein **(FAP)** (IC_{50} = 560 nM), inhibits DPP8/9 (IC_{50} = 4/11...



Purity: 99.05%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Talarozole

(R115866)

Cat. No.: HY-14531

Talarozole (R115866) is an oral systemic all-trans **retinoic acid metabolism blocking agent (RAMBA)** which increases intracellular levels of endogenous all-trans retinoic acid (RA). Talarozole inhibits both **CYP26A1** and **CYP26B1** with IC_{50}s of 5.4 and 0.46 nM, respectively.



Purity: 99.78%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Talniflumate

(BA 7602-06)

Cat. No.: HY-103370

Talniflumate (BA 7602-06) is the prodrug of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase. Talniflumate is an orally active **Ca^{2+}-activated Cl^- channel (CaCC)** blocker.



Purity: 99.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tamarixetin

(4'-O-Methyl Quercetin)

Cat. No.: HY-N1181

Tamarixetin (4'-O-Methyl Quercetin) is a natural flavonoid derivative of quercetin, with anti-oxidative and anti-inflammatory effects. Tamarixetin protects against cardiac hypertrophy.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tangeretin

(Tangeritin; NSC53909; NSC618905)

Cat. No.: HY-N0133

Tangeretin (Tangeritin), a flavonoid from citrus fruit peels, has been proven to play an important role in anti-inflammatory responses and neuroprotective effects in several disease models, and is a **Notch-1** inhibitor.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tanimilast

(CHF-6001)

Cat. No.: HY-19929

Tanimilast (CHF-6001) is a novel highly potent and selective **phosphodiesterase 4** inhibitor(IC_{50}=0.026 ± 0.006 nM) with robust anti-inflammatory activity and suitable for topical pulmonary administration.Tanimilast is used for the research of obstructive lung diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tannic acid

Cat. No.: HY-B2136

Tannic acid is a novel **hERG channel** blocker with IC_{50} of 3.4 μM.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Tanzisertib

(CC-930)

Cat. No.: HY-15495

Tanzisertib (CC-930) is a potent **JNK1/2/3** inhibitor with IC_{50}s of 61/7/6 nM, respectively.



Purity: 99.84%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAPI-1

Cat. No.: HY-16657

TAPI-1 is a **TACE** (**ADAM17**) inhibitor and blocks the shedding of several cell surface proteins. TAPI-1 is also a metalloproteinase (**MMP**) inhibitor.



Purity: 97.01%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tapinarof

(WBI-1001; Benvitimod; GSK2894512)

Cat. No.: HY-109044

Tapinarof (WBI-1001) is a natural **aryl hydrocarbon receptor** (**AhR**) agonist with an EC_{50} of 13 nM. Tapinarof resolves skin inflammation in mice.



Purity: 99.65%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg

Taprenepag isopropyl

(PF-04217329)

Cat. No.: HY-19998

Taprenepag isopropyl is a highly selective EP_2 **receptor** agonist.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Taraxasterol

Cat. No.: HY-N1178

Taraxasterol is a pentacyclic triterpenoid isolated from Taraxacum officinale. Taraxasterol has a role as a metabolite and an anti-inflammatory agent.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Taraxasteryl acetate

Cat. No.: HY-N2478

Taraxasteryl acetate is isolated from P. sagittalis,and has a broad spectrum of **anti-inflammatory** activity. Taraxasteryl acetate relieves dextran, zymosan and arachidonic acid induced rat hind-paw edema.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Taraxerol

Cat. No.: HY-N2477

Taraxerol is isolated from Abroma augusta L, and has anti-inflammtory and anti-cancer effects. Taraxerol attenuates acute inlammation through inhibition of **NF-κB** signaling pathway. Taraxerol induces cell **apoptosis**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Taraxerone

Cat. No.: HY-N1177

Taraxerone is isolated from Sedum sarmentosum. Taraxerone enhances effects on alcohol dehydrogenase (**ADH**) and acetaldehyde dehydrogenase (**ALDH**) activities with EC_{50} values of 512.42 and 500.16 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tarenflurbil

((R)-Flurbiprofen; MPC7869)

Cat. No.: HY-10291

Tarenflurbil ((R)-Flurbiprofen) is the R-enantiomer of the racemate NSAID Flurbiprofen, Tarenflurbil ((R)-Flurbiprofen) inhibits the binding of [^{3}H]9-cis-RA to **RXRα** LBD with IC_{50} of 75 μM. Tarenflurbil can be used for Alzheimer's disease research.



Purity: 99.99%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 100 mg

TAS05567

Cat. No.: HY-120214

TAS05567 is a potent, highly selective, ATP-competitive and orally active **Syk** inhibitor with an IC_{50} of 0.37 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TASP0415914

Cat. No.: HY-120438

TASP0415914 is a potent and orally active **PI3Kγ** inhibitor with an IC_{50} of 29 nM. TASP0415914 also shows potent **Akt** inhibitory activities with an IC_{50} of 294 nM. TASP0415914 can be used for inflammatory diseases research.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAT-Gap19

Cat. No.: HY-P1136B

TAT-Gap19, a Cx mimetic peptide, is a specific **connexin43 hemichannel (Cx43 HC)** inhibitor. TAT-Gap19 does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 traverses the blood-brain barrier and alleviate liver fibrosis in mice.

YGRKKRRQRRRKQIEIKKFK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAT-Gap19 TFA

Cat. No.: HY-P1136C

TAT-Gap19 TFA, a Cx mimetic peptide, is a specific **connexin43 hemichannel (Cx43 HC)** inhibitor. TAT-Gap19 TFA does not inhibits the corresponding Cx43 GJCs. TAT-Gap19 TFA traverses the blood-brain barrier and alleviate liver fibrosis in mice.

YGRKKRRQRRRKQIEIKKFK (TFA salt)

Purity: 98.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Tauro-Obeticholic acid

Cat. No.: HY-135399

Tauro-Obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Taurochenodeoxycholic acid

(12-Deoxycholyltaurine)

Cat. No.: HY-N2027

Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces **apoptosis** and shows obvious anti-inflammatory and immune regulation properties.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Taurochenodeoxycholic acid sodium salt

(12-Deoxycholyltaurine sodium salt)

Cat. No.: HY-N1429

Taurochenodeoxycholic acid sodium salt (12-Deoxycholyltaurine sodium salt) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces **apoptosis** and shows obvious anti-inflammatory and immune regulation properties.



Purity: ≥95.0%
Clinical Data: Launched
Size: 100 mg

Taurocholic acid

(N-Choloyltaurine)

Cat. No.: HY-B1788

Taurocholic acid (N-Choloyltaurine) is a bile acid involved in the emulsification of fats.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Taurocholic acid sodium salt hydrate (Sodium taurocholate hydrate; N-Choloyltaurine sodium salt hydrate)

Cat. No.: HY-B1131

Taurocholic acid sodium salt hydrate (Sodium taurocholate hydrate) is a bile acid involved in the emulsification of fats.



Purity: 96.84%
Clinical Data: No Development Reported
Size: 50 mg

Taurodeoxycholate sodium salt

Cat. No.: HY-128853

Taurodeoxycholate sodium salt is a bile salt-related anionic detergent used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate (TDCA) inhibits various inflammatory responses .



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 500 mg

Taurodeoxycholic acid sodium hydrate

(Sodium taurodeoxycholate monohydrate)

Cat. No.: HY-B1899A

Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate) prevents apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tautomycetin

Cat. No.: HY-108542

Tautomycetin is a potent and specifical **PP1** inhibitor with the potential **apoptosis**-inducing activity. Tautomycetin inhibits purified PP1 and PP2A enzymes with **IC_{50}**s of 1.6 nM and 62 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 μg, 50 μg

Tautomycin

Cat. No.: HY-12728

Tautomycin, an antifungal antibiotic isolated from the bacterium Streptomyces verticillatus, is a potent and specific inhibitor of **protein phosphatases 1 and 2A** and induces contraction of smooth muscle under Ca^{2+}-free conditions, with **K_{iapp}** values of 0.16 nM and 0.4 nM for PP1...



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 μg

Tavilermide

(MIM-D3)

Cat. No.: HY-17622

Tavilermide is a selective, partial agonist of **TrkA**, or a nerve growth factor (NGF) mimetic.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Taxifolin

((+)-Dihydroquercetin; (+)-Taxifolin)

Cat. No.: HY-N0136

Taxifolin ((+)-Dihydroquercetin) exhibits important anti-**tyrosinase** activity. Taxifolin exhibits significant inhibitory activity against **collagenase** with an **IC_{50}** value of 193.3 μM. Taxifolin is an important natural compound with antifibrotic activity.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Tazanolast

(TO 188; Tazalest; Tazanol)

Cat. No.: HY-101810

Tazanolast is a selective mast-cell-stabilizing drug, on ozone-induced airway hyperresponsiveness in guinea pigs.



Purity: 99.50%
Clinical Data: Launched
Size: 1 mg

Tazarotene

(AGN 190168)

Cat. No.: HY-15388

Tazarotene (AGN 190168) is a selective retinoic acid receptor (**RAR**) agonist for the treatment of plaque psoriasis and acne vulgaris.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

TBK1/IKKε-IN-2

Cat. No.: HY-12453

TBK1/IKKε-IN-2 is a dual **TBK1** and **IKKε** inhibitor.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TC-S 7005

Cat. No.: HY-108597

TC-S 7005 is a **Polo-like kinases (Plks)** inhibitor with **IC_{50}**s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

TC-S 7009

Cat. No.: HY-18371

TC-S 7009 is a potent and selective **HIF-2α** inhibitor with a **K_d** of 81 nM. TC-S 7009 is more selective for **HIF-2α** than HIF-1α (K_d 5 μM). TC-S 7009 disrupts **HIF-2α** heterodimerization, decreases DNA-binding activity, and reduces **HIF-2α** target gene expression.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

TCJL37

Cat. No.: HY-16640

TCJL37 is a potent, selective, and orally bioavailable **TYK2** inhibitor with a K_i of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCS 2314

Cat. No.: HY-12308

TCS 2314 (compound 3) is orally active and selective **very late antigen-4 (VLA-4, α4β1, CD49d/CD29)** antagonist with an IC_{50} of 4.4 nM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

TD-0212

Cat. No.: HY-114412

TD-0212 (compound 35) is an orally active dual pharmacology **angiotensin II type 1 receptor (AT_1)** antagonist and **neprilysin (NEP)** inhibitor, with a **pK_i** of 8.9 for AT_1 and a **pIC_{50}** of 9.2 for NEP.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TD-0212 TFA

Cat. No.: HY-114412A

TD-0212 TFA is an orally active dual pharmacology **angiotensin II type 1 receptor (AT_1)** antagonist and **neprilysin (NEP)** inhibitor, with a **pK_i** of 8.9 for AT_1 and a **pIC_{50}** of 9.2 for NEP.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

TD-198946

Cat. No.: HY-15642

TD-198946, a thienoindazole derivative, is a potent chondrogenic agent.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Tea polyphenol

Cat. No.: HY-N1925

Tea polyphenol is the floorboard of phenolic compounds in tea. Tea polyphenol exhibits biological activity including antioxidant and anti-cancer activities, inhibition of cell proliferation, induction of apoptosis, cell cycle arrest and modulation of carcinogen metabolism.

Purity: ≥99.0%
Clinical Data: Phase 3
Size: 100 mg

Tectorigenin

Cat. No.: HY-N0792

Tectorigenin is a plant isoflavonoid originally isolated from the dried flower of Pueraria thomsonii Benth.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tectoruside

Cat. No.: HY-N7593

Tectoruside is a phenol acid glycoside of the rhizome of Iris dichotoma Pall. Iris dichotoma Pall, a traditional Chinese herbal medicine, has been used in several disorders such as inflammation, throat disorders, asthma and coughs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Tedalinab

(GRC-10693)

Cat. No.: HY-14900

Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 **(CB2)** agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TEI-9647

Cat. No.: HY-12398

TEI-9647, a Vitamin D_3 Lactone analogue, is a potent and specific **vitamin D receptor (VDR)** antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of $1\alpha,25(OH)_2D_3$.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

TEI-9648

Cat. No.: HY-12398A

TEI-9648, a Vitamin D_3 Lactone analogue, is a potent and specific **vitamin D receptor (VDR)** antagonist. TEI-9648 inhibits VDR/VDRE-mediated genomic actions of $1\alpha,25(OH)_2D_3$. TEI-9648 also inhibits HL-60 cell differentiation induced by of $1\alpha,25(OH)_2D_3$.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tellimagrandin II

(Eugeniin)

Cat. No.: HY-N9386

Tellimagrandin II (Eugeniin), the first intermediate in the $^4C_1$-glucose derived series of ellagitannins, also inhibits antibiotic resistance of drug-resistant Staphylococcus aureus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Temarotene

(Ro 15-0778)

Cat. No.: HY-U00011

Temarotene is an orally administered, particular arotinoid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Temocillin disodium

(BRL 17421 disodium)

Cat. No.: HY-139597

Temocillin disodium, a 6-α-methoxy penicillin, possesses antibacterial activity.



Purity: ≥90.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tenacissoside X

(Tenacissoside J)

Cat. No.: HY-N2545

Tenacissoside X (Tenacissoside J) is a compound isolated from Marsdenia tenacissima. Marsdenia tenacissima, a traditional Chinese herbal medicine, has long been used for the research of asthma, tracheitis, rheumatism, etc.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tenatoprazole

(TU-199)

Cat. No.: HY-17421

Tenatoprazole (TU-199) is an orally active imidazopyridine-based **proton pump** inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric **H^+/K^+-ATPase** activity with an IC_{50} of 6.2 μM.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

Tenidap

(CP-66248)

Cat. No.: HY-105028

Tenidap, a non-steroidal anti-inflammatory drug, is a selective **COX-1** inhibitor, with **IC_{50}** values of 0.03 μM and 1.2 μM for COX-1 and COX-2, respectively. Tenidap has anti-inflammatory and antirheumatic properties. Tenidap is also a specific SLC26A3 inhibitor.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tenofovir diphosphate

(TFV-DP)

Cat. No.: HY-136548

Tenofovir diphosphate (TFV-DP) is a competitive **DNA polymerases** inhibitor (with respect to dATP) and a substrate of HIV type 1 (**HIV-1**) **reverse transcriptase** (RT).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Tenofovir diphosphate triethylamine

(TFV-DP triethylamine)

Cat. No.: HY-136548A

Tenofovir diphosphate triethylamine (TFV-DP triethylamine) is a competitive **DNA polymerases** inhibitor (with respect to dATP) and a substrate of HIV type 1 (**HIV-1**) **reverse transcriptase** (RT).



Purity: 94.93%
Clinical Data: No Development Reported
Size: 1 mg

Tenosal

Cat. No.: HY-12384

Tenosal is a new compound obtained by esterifying salicylic acid with 2-thiophene-carboxylic acid and displays anti-inflammatory, analgesic and antipyretic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tenoxicam

(Ro-12-0068)

Cat. No.: HY-B0440

Tenoxicam (Ro-12-0068), an antiinflammatory agent with analgesic and antipyretic properties.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Tenuifoliside C

Cat. No.: HY-N2586

Tenuifoliside C, isolated from polygala tenuifolia willd, significantly inhibits chlorzoxazone 6-hydroxylation catalyzed by CYP2E1.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Tenuigenin

(Senegenin)

Cat. No.: HY-N0802

Tenuigenin is a major active component isolated from the root of the Chinese herb Polygala tenuifolia. Tenuigenin protects against S.aureus-induced pneumonia by inhibiting **NF-κB** activation. Tenuigenin has anti-inflammatory effect.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Tepilamide fumarate

(XP-23829)

Cat. No.: HY-109105

Tepilamide fumarate (XP-23829) is an oral fumaric acid ester, acts as a prodrug of monomethyl fumarate, and is used in the research of moderate to severe chronic plaque psoriasis.



Purity: 99.77%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Teplinovivint

Cat. No.: HY-137454

Teplinovivint is a potent **wnt/β-catenin** signaling pathway inhibitor. Teplinovivint has anti-inflammatory activity and has the potential for tendinopathy research.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Terbutaline sulfate

(Terbutaline hemisulfate)

Cat. No.: HY-B0802

Terbutaline sulfate is a β2-adrenergic receptor agonist; a fast-acting bronchodilator and a tocolytic to delay premature labor.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Terevalefim

(ANG-3777)

Cat. No.: HY-137455

Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the **c-Met receptor**.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Terfenadine

((±)-Terfenadine; MDL-991)

Cat. No.: HY-B1193

Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of **hERG** with an IC_{50} of 204 nM. Terfenadine, an **H1 histamine receptor** antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca^{2+} homeostasis.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Terfenadine-d3

Cat. No.: HY-B1193S

Terfenadine-d3 ((±)-Terfenadine-d3) is the deuterium labeled Terfenadine. Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of **hERG** with an IC_{50} of 204 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 2000 μg, 5 mg, 10 mg, 25 mg

Teriflunomide

(A77 1726)

Cat. No.: HY-15405

Teriflunomide is the active metabolite of leflunomide, an approved therapy for rheumatoid arthritis. It inhibits **pyrimidine synthesis** and therefore potently decreases T cell and B cell proliferation.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Teriflunomide impurity 3

(4-Amino-N-(4-trifluoromethylphenyl)benzamide)

Cat. No.: HY-134753

Teriflunomide impurity 3 (4-Amino-N-(4-trifluoromethylphenyl)benzamide) is a selective **COX-1** inhibitor with an IC_{50} of 30 μM. Teriflunomide impurity 3 is less active against COX-2 (IC_{50}>100 μM).



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Terlipressin

Cat. No.: HY-12554

Terlipressin is a vasopressin analogue with potent vasoactive properties. Terlipressin is a highly selective **vasopressin V1 receptor** agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Terlipressin acetate

Cat. No.: HY-12554A

Terlipressin acetate is a vasopressin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective **vasopressin V1 receptor** agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding.



Purity: 99.76%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Terminolic acid

Cat. No.: HY-N7652

Terminolic acid is a pentacyclic triterpenoid glucoside isolated from Combretum racemosum.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Terpin hydrate

(Terpin monohydrate; cis-Terpin hydrate)

Cat. No.: HY-B1063

Terpin hydrate is an expectorant, commonly used to loosen mucus in patients presenting with acute or chronic bronchitis, and related conditions.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Terpinen-4-ol

(4-Carvomenthenol)

Cat. No.: HY-W017316

Terpinen-4-ol (4-Carvomenthenol), a naturally occurring monoterpene, is the main bioactive component of tea-tree oil. Terpinen-4-ol suppresses inflammatory mediator production by activated human monocytes.



Purity: ≥96.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg

Terpinen-4-ol-d7

Cat. No.: HY-W017316S

Terpinen-4-ol-d7 (4-Carvomenthenol-d7) is the deuterium labeled Terpinen-4-ol. Terpinen-4-ol (4-Carvomenthenol), a naturally occurring monoterpene, is the main bioactive component of tea-tree oil.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

Terreic acid

Cat. No.: HY-110013

Terreic acid, a quinone epoxide **antibiotic**, acts as an effective **Btk** inhibitor. Terreic acid blocks the interaction between PKC and the pleckstrin homology domain of Btk.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tesmilifene fumarate

(DPPE fumarate)

Cat. No.: HY-101179

Tesmilifene fumarate (DPPE fumarate), an H_{1c} **receptor** antagonist, potentiates a wide range of cytotoxics and even to offer some protection of normal cells.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

TET 830 modified/T-helper epitope from tetanus toxoid

Cat. No.: HY-P2514

TET 830 modified/T-helper epitope from tetanus toxoid is a modified T-helper epitope from tetanus toxoid. TET 830 modified/T-helper epitope from tetanus toxoid induces T-cells responses and is used as a helper peptide in vaccinations.

AQYIKANSKFIGITEL

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tetra-N-acetylchitotetraose

Cat. No.: HY-N7698

Tetra-N-acetylchitotetraose elicits plant defense systems. Tetra-N-acetylchitotetraose is a component of the hpo-chitoo gosacchaπdes (LCOs) secreted from Rhizobia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Tetrahydrobiopterin

((Rac)-Sapropterin)

Cat. No.: HY-107383

Tetrahydrobiopterin ((Rac)-Sapropterin) is a **cofactor** of the **aromatic amino acid hydroxylases enzymes** and also acts as an essential **cofactor** for all **nitric oxide synthase** (NOS) isoforms.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tetrahydrocurcumin

(HZIV 81-2)

Cat. No.: HY-N0893

Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit **CYP2C9** and **CYP3A4**.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Tetrahydrocurcumin D6

(HZIV 81-2 D6)

Cat. No.: HY-N0893S

Tetrahydrocurcumin D6 (HZIV 81-2 D6) is a deuterium labeled Tetrahydrocurcumin. Tetrahydrocurcumin is a Curcuminoid which displays inhibitory activity for CYP2C9 and CYP3A4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tetrahydromagnolol

(Magnolignan)

Cat. No.: HY-116637

Tetrahydromagnolol (Magnolignan), a main metabolite of Magnolol, is a potent and selective **cannabinoid CB2 receptor** agonist with an EC_{50} of 170 nM and a K_i of 416 nM. Tetrahydromagnolol possesses 20-fold more selective for **CB2 receptor** than CB1 receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Tetramethylcurcumin

(FLLL31)

Cat. No.: HY-N2521

Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of **STAT3** by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Tetrandrine

(NSC-77037; d-Tetrandrine)

Cat. No.: HY-13764

Tetrandrine (NSC-77037; d-Tetrandrine) is a bis-benzyl-isoquinoline alkaloid, which inhibits voltage-gated Ca^{2+} **current** (ICa) and Ca^{2+}-activated K^+ **current**.



Purity: 99.90%
Clinical Data: Launched
Size: 100 mg, 250 mg

Tetroxoprim

(HE 781)

Cat. No.: HY-107033

Tetroxoprim is an antimicrobial **DHFR** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TG 100572 Hydrochloride

Cat. No.: HY-10185

TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

TG4-155

Cat. No.: HY-18971

TG4-155 is a potent, brain-permeant and selective **EP2 receptor** antagonist with a K_i of 9.9 nM. TG4-155 shows low nanomolar antagonist activity against only EP2 and DP1.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TGFBR1-IN-1

Cat. No.: HY-129171

TGFBR1-IN-1 is an **ALK5** inhibitor extracted from patent WO2018004290A1, Compound 33, has an IC_{50} of 10-100 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TGFβRI-IN-3

Cat. No.: HY-132290

TGFβRI-IN-3 inhibits **TGFβR1** at an IC_{50} of 0.79 nM with 2000-fold selectivity against MAP4K4. TGFβRI-IN-3 represents a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TGN-020

Cat. No.: HY-W008574

TGN-020 is a selective **Aquaporin 4 (AQP4)** inhibitor with an IC_{50} of 3.1 μM. TGN-020 is an alkyl chain-based **PROTAC linker** that can be used in the synthesis of PROTACs.TGN-020 alleviates edema and inhibits glial scar formation after spinal cord compression injury in rats.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

TH1020

Cat. No.: HY-116961

TH1020 is a potent and selective **toll-like receptor 5 (TLR5)/flagellin complex** antagonist with an IC_{50} of 0.85 μM. TH1020 inhbits flagellin-induced **TLR5** signaling. TH1020 is inactive against TLR2, TLR3, TLR4, TLR7 and TLR8.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TH5487

Cat. No.: HY-125276

TH5487 is a potent 8-oxoguanine DNA glycosylase 1 (**OGG1**) inhibitor with an IC_{50} of 342 nM. TH5487 stops OGG1 from recognizing its DNA substrate, inhibits **DNA** repair and modifies OGG1 chromatin dynamics, which results in the inhibition of proinflammatory pathway genes.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Thalidomide D4

Cat. No.: HY-14658S

Thalidomide D4 is a deuterium labeled Thalidomide. Thalidomide inhibits **cereblon (CRBN)**, a part of the **cullin-4 E3 ubiquitin ligase** complex CUL4-RBX1-DDB1, with a K_d of ~250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Thalidomide-NH-PEG8-Ts

Cat. No.: HY-131912

Thalidomide-NH-PEG8-Ts is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the Thalidomide based cereblon ligand and 8-unit PEG linker used in PROTAC technology, such as IDO1 PROTAC degrader (HY-131911).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-amido-PEG2-C2-NH2 (Cereblon Ligand-Linker Conjugates 10; E3 Ligase Ligand-Linker Conjugates 24)

Cat. No.: HY-112617

Thalidomide-O-amido-PEG2-C2-NH2 incorporates an E3 ligase ligand and a linker, can be an immunomodulater for the treatment of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-amido-PEG2-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 10 TFA; ...)

Cat. No.: HY-112617A

Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in **PROTAC** technology.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

THI0019

Cat. No.: HY-117388

THI0019 is a potent **integrin α4β1 (VLA-4)** agonist with an EC_{50} range of 1-2 μM. THI0019 induces stem/progenitor cells adhesion. THI0019 also regulates adhesion mediated by α4β7, α5β1 and αLβ2.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Thiarabine
(OSI-7836)

Cat. No.: HY-16496

Thiarabine (OSI-7836) shows potent anti-tumor activity and inhibition of **DNA** synthesis.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg

Thiazolidinone-Derivatives-1

Cat. No.: HY-100284

Thiazolidinone-Derivatives-1 is an antiulcer agent which inhibits the secretion of gastric acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thiocolchicoside

Cat. No.: HY-N0301

Thiocolchicoside is a competitive **γ-aminobutyric acid type A (GAB_AA) receptor** antagonist and **glycine receptor** agonist in the central nervous system. Thiocolchicoside is a semisynthetic sulfur derivative of colchicoside.



Purity: 99.23%
Clinical Data: Phase 4
Size: 5 mg, 10 mg, 20 mg

Thiodigalactoside
(TDG)

Cat. No.: HY-130208

Thiodigalactoside (TDG) is an orally active and potent **galectin (GAL)** inhibitor with K_d values of 24 μM, 49 μM for GAL1 and GAL3, respectively. Thiodigalactoside, a non-metabolizable disaccharide, has anti-inflammatory and anti-cancer activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Thioflosulide
(L-745337)

Cat. No.: HY-19217

Thioflosulide (L-745337) is a selective **cyclooxygenase-2 (COX2)** inhibitor, with an IC_{50} of 2.3 nM, and shows anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thiomandelic acid

Cat. No.: HY-129629

Thiomandelic acid is a broad spectrum inhibitor of Zinc -lactamases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thioredoxin reductase peptide

Cat. No.: HY-P1948

Thioredoxin reductase peptide corresponds to residues 53–67 in thioredoxin reductase (TrxR), used in thioredoxin reductase research. Thioredoxin reductase acts as a reductant of disulfide-containing proteins and plays crucial role in cellular antioxidant defense.

WGLGGTCVNVGCIPK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thonzylamine
(Neohetramine)

Cat. No.: HY-B1317

Thonzylamine is an orally active H_1 **histamine receptor** antagonist, exhibits good antihistaminic and antianaphylactic properties. Thonzylamine can be used for the research of hypersensitivity diseases, nasal congestion, allergic conjunctivitis and other allergic diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thromboxane B2

Cat. No.: HY-113331

Thromboxane B2 is a prostaglandin derivative that is released during anaphylaxis. Thromboxane B2 induces arterial contraction and platelet aggregation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thromboxane B2-D4

Cat. No.: HY-113331S

Thromboxane B2-D4 is the deuterium labeled Thromboxane B2. Thromboxane B2 is a prostaglandin derivative that is released during anaphylaxis. Thromboxane B2 induces arterial contraction and platelet aggregation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thymol

Cat. No.: HY-N6810

Thymol is the main monoterpene phenol occurring in essential oils isolated from plants belonging to the Lamiaceae family, and other plants such as those belonging to the Verbenaceae, Scrophulariaceae, Ranunculaceae and Apiaceae families.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Thymopentin

Cat. No.: HY-N7122

Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Thymopentin acetate

Cat. No.: HY-N7122A

Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Thymoquinone

Cat. No.: HY-D0803

Thymoquinone is a nature product isolated from N. sativa. Thymoquinone possess antioxidant, anti-inflammatory, anti-cancer, antitumor activities and hepatoprotective properties.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 100 mg

Thymus factor X

(TFX-Jelfa)

Cat. No.: HY-P0001

Thymic factor X (TFX-Jelfa) is an aqueous extract from juvenile calf thymuses and a natural stimulator of lymphocyte function.

Thymus factor X

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thymus peptide C

Cat. No.: HY-P0070

Thymus peptide C is a hormonal drug derived from the thymus glands of young calves, which works as a substitute for the physiological functions of the thymus.

thymus peptide C

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Tiaprofenic acid

Cat. No.: HY-106579

Tiaprofenic acid is an orally active nonsteroidal anti-inflammatory drug **(NSAID)** with anti-inflammatory and analgesic potency. Tiaprofenic acid inhibits prostaglandin synthesis by suppressing **cyclo-oxygenase (COX)**.



Purity: 99.33%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Tiaprofenic acid D3

Cat. No.: HY-106579S

Tiaprofenic acid D3 is a deuterium labeled Tiaprofenic acid. Tiaprofenic acid is a nonsteroidal anti-inflammatory drug (NSAID) mainly used in the treatment of rheumatic diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tibenelast sodium

(LY 186655)

Cat. No.: HY-101705

Tibenelast sodium is a **phosphodiesterase** inhibitor.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TIE-2/VEGFR-2 kinase-IN-1

Cat. No.: HY-112294

TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tigloidin

(Tigloyl pseudotropine; Tiglylpseudotropine; Tiglyssin)

Cat. No.: HY-U00082

Tigloidin is an analogue of atropine, with anticholinergic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tilianin

Cat. No.: HY-N2555

Tilianin is an active flavonoid glycoside found in many medical plants, with potential anti-hypertensive, myocardial-protective, anti-diabetic, anti-hyperlipidemic, anti-inflammatory and antioxidant effects.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Tilmacoxib

(JTE522; JTP19605; RWJ57504)

Cat. No.: HY-U00197

Tilmacoxib (JTE522) is a highly selective, time-dependent and irreversible human **COX-2** inhibitor with an IC_{50} of 85 nM in an enzyme assay.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Tilpisertib

Cat. No.: HY-137456

Tilpisertib is a **serine/threonine kinase** inhibitor (WO2017007689).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tiludronate disodium

(Tiludronic Acid disodium)

Cat. No.: HY-A0213A

Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties.



Purity: ≥98.0%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Timapiprant

(OC000459)

Cat. No.: HY-15342

Timapiprant (OC000459) is a potent, selective, and orally active D prostanoid receptor 2 (DP_2, also known as **CRTH2**) antagonist.



Purity: 99.48%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Timapiprant sodium

(OC000459 sodium)

Cat. No.: HY-15342A

Timapiprant sodium (OC000459 sodium) is a potent, selective, and orally active D prostanoid receptor 2 (DP_2, also known as **CRTH2**) antagonist.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Timegadine

(SR1368)

Cat. No.: HY-100125

Timegadine, a new antiinflammatory agent, is found to be a potent, competitive inhibitor of **cyclo-oxygenase** (**COX**) and **lipo-oxygenase**, with IC_{50}s ranging from 5 nM (washed rabbit platelets) to 20 μM (rat brain) for COX and 100 μM for lipo-oxygenase both in the cytosol fraction...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Timobesone

Cat. No.: HY-U00111

Timobesone is a topical corticosteroid but never marketed.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Timosaponin B III

Cat. No.: HY-N6806

Timosaponin B III is a major bioactive steroidal saponin isolated from Anemarrhena asphodeloides Bge, and exhibits anti-inflammatory, anti-platelet aggregative and anti-depressive effects.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Timosaponin BII

(Prototimosaponin A III) Cat. No.: HY-N0812

Timosaponin BII (Prototimosaponin A III) is a steroid saponin found in the rhizomes of Anemarrhena asphodeloides. Timosaponin BII has neuronal protective, anti-inflammatory and antioxidant activities.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Timosaponin C

(Anemarsaponin C) Cat. No.: HY-N7006

Timosaponin C is isolated from Rhizoma Anemarrhenae. Timosaponin C shows weaker NO inhibition in N9 microglial cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tinoridine hydrochloride

(Y-3642 hydrochloride) Cat. No.: HY-111354

Tinoridine hydrochloride is a nonsteroidal anti-inflammatory drug and also has potent radical scavenger and antiperoxidative activity.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tiopinac

(RS 40974) Cat. No.: HY-U00063

Tiopinac (RS 40974), a dibenzthiepin, is an orally active and highly potent anti-inflammatory and anti-pyretic agent.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

Tipelukast

(KCA 757; MN 001) Cat. No.: HY-14938

Tipelukast (KCA 757) is a sulfidopeptide **leukotriene receptor** antagonist, an orally bioavailable anti-inflammatory agent and used for the treatment of asthma.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Tirucallol

Cat. No.: HY-N2556

Tirucallol, a tetracyclic triterpene, is isolated from Euphorbia lacteal latex. Tirucallol has topical anti-inflammatory effect. Tirucallol can suppress ear edema in the mouse model and inhibit nitrite production in lipopolysaccharide-stimulated macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

TK05

Cat. No.: HY-117143

TK05 is a potent and selective inhibitor of **leukotriene C_4 synthase (LTC4S)** with an **IC_{50}** of 95 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TLK117

(TER117) Cat. No.: HY-13634B

TLK117, the active metabolite of TLK199, selective inhibits **Glutathione S-transferase P1–1 (GSTP1-1)** with a **K_i** of 0.4 μM for GSTP. TLK117 also competitively inhibits **glyoxalase I** with a **K_i** of 0.56 μM.



Purity: 98.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

TLR1

Cat. No.: HY-W011400

TLR1 (compound 4a) is a low molecular weight, cell-penetrating **Toll/IL-1 receptor/resistance (TIR) domain/BB-Loop** mimic. TLR1 inhibits IL-1 receptor-mediated responses.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 500 μg (33 mM * 50 μL in Ethanol)

TLR4-IN-C34

Cat. No.: HY-107575

TLR4-IN-C34 is an orally active **TLR4** inhibitor and reduces systemic inflammation in models of endotoxemia and necrotizing enterocolitis.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

TLR4-IN-C34-C2-amide-C6-OH

Cat. No.: HY-145245

TLR4-IN-C34-C2-amide-C6-OH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg, 500 mg

TLR4-IN-C34-C2-COOH

Cat. No.: HY-W092043

TLR4-IN-C34-C2-COO is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg, 500 mg, 1 g

TLR7 agonist 2

Cat. No.: HY-103039

TLR7 agonist 2 is a potent and selective **Toll-like Receptor 7** (**TLR7**) agonist with a **LEC** of 0.4 μM.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

TLR7 agonist 3

Cat. No.: HY-117602

TLR7 agonist 3 (Compound 2) is a potent agonist of toll-like receptor 7 (TLR7). TLR7 has an important role in immune activation processes and represents an emerging drug discovery target for the development of immunomodulators.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TLR7/8 agonist 1 dihydrochloride

Cat. No.: HY-103698A

TLR7/8 agonist 1 dihydrochloride is a toll-like receptor **TLR7/TLR8** dual-agonistic imidazoquinoline.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TLR7/8-IN-1

Cat. No.: HY-139323

TLR7/8-IN-1 is a crystalline from of a **TLR7/TLR8** inhibitor extracted from patent WO2019220390, compound 2b. TLR7/8-IN-1 can be used for the research of autoimmune disease.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TLR8 agonist 2

Cat. No.: HY-141454

TLR8 agonist 2 is a potent and selective **TLR8** agonist with an EC_{50} of 3 nM for human TLR8. TLR8 agonist 2 shows less active against human TLR7 (EC_{50} of 33.33 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TLR8 agonist 2 hydrochloride

Cat. No.: HY-141454A

TLR8 agonist 2 hydrochloride is a potent and selective **TLR8** agonist with an EC_{50} of 3 nM for human TLR8. TLR8 agonist 2 hydrochloride shows less active against human TLR7 (EC_{50} of 33.33 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TMP778

Cat. No.: HY-102075A

TMP778 is a potent and selevtive **RORγt** inverse agonist, with an IC_{50} of 7 nM in FRET assay.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TMP780

Cat. No.: HY-102075B

TMP780 is an inverse agonist of **RORγt** with an IC_{50} of 13 nM. RORγt is a tractable drug target for the treatment of cutaneous inflammatory disorders.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TMP920

Cat. No.: HY-117819

TMP920 is a highly potent and selective **RORγt** antagonist. TMP920 inhibits RORγt binding to the SRC1 peptide with an IC_{50} of 0.03 μM.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TMRM

Cat. No.: HY-D0984

TMRM is a cell-permeant cationic lipophilic red fluorescent dye (λ_{ex}=530 nm, λ_{em}=592 nm).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TNF-α (10-36), human

Cat. No.: HY-P1825

TNF-α (10-36), human is a peptide of human TNF-α.

DKPVAHVVANPQAEGQLQWLNRRANAL

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TNF-α (10-36), human TFA

Cat. No.: HY-P1825A

TNF-α (10-36), human (TFA) is a peptide of human TNF-α.

DKPVAHVVANPQAEGQLQWLNRRANAL (TFA salt)

Purity: 97.70%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

TNF-α (31-45), human

Cat. No.: HY-P1860

TNF-α (31-45), human is a peptide of tumor necrosis factor-α.

RRANALLANGVELRD

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TNF-α (31-45), human TFA

Cat. No.: HY-P1860A

TNF-α (31-45), human (TFA) is a peptide of tumor necrosis factor-α.

RRANALLANGVELRD (TFA salt)

Purity: 98.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

TNF-α (46-65), human

Cat. No.: HY-P1875

TNF-α (46-65), human is a peptide of TNF-α.

NQLVVPSEGLYLIYSQVLFK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TNF-α-IN-1

Cat. No.: HY-112275

TNF-α-IN-1 is a **TNF-α** inhibitor extracted from patent US20030096841A1, compound example I-7.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 250 mg

TNF-α-IN-2

Cat. No.: HY-134471

TNF-α-IN-2 is a potent and orally active inhibitor of **tumor necrosis factor alpha (TNFα)**, with an IC_{50} of 25 nM in the HTRF assay. TNF-α-IN-2 distorts the TNFα trimer upon binding, leading to aberrant signaling when the trimer binds to TNFR1.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tocainide hydrochloride

Cat. No.: HY-B1798A

Tocainide hydrochloride is a **sodium channel** blocker, it blocks the sodium channels in the pain-producing foci in the nerve membranes. Tocainide hydrochloride is a primary amine analog of lidocaine, can be used for the treatment of tinnitus.



Purity: 98.38%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg

Tocilizumab

(Anti-Human IL6R, Humanized Antibody) Cat. No.: HY-P9917

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (**IL-6R**) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling.

Tocilizumab

Purity: 99.67%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg

Tofacitinib

(Tasocitinib; CP-690550) Cat. No.: HY-40354

Tofacitinib is an orally available **JAK3/2/1** inhibitor with IC_{50}s of 1, 20, and 112 nM, respectively.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tofacitinib citrate

(Tasocitinib citrate; CP-690550 citrate) Cat. No.: HY-40354A

Tofacitinib citrate is an orally available **JAK1/2/3** inhibitor with IC_{50}s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

TOK-8801

Cat. No.: HY-100162

TOK-8801 is a synthesized dihydroimidazothiazole carboxamide and is under development as an immunomodulator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tokinolide B

Cat. No.: HY-N1145

Tokinolide B is isolated from the rhizomes of Ligusticum porter.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tolfenamic Acid

(GEA 6414) Cat. No.: HY-B0335

Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits **COX-2**, with an IC_{50} of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 10 g

Tolfenamic Acid-D4

Cat. No.: HY-B0335S

Tolfenamic Acid-D4 (GEA 6414-D4) is the deuterium labeled Tolfenamic Acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Toll-like receptor modulator

Cat. No.: HY-10018

Toll-like receptor modulator is a modulator of **TLR7/8**, which modulates immune function.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tolmetin

Cat. No.: HY-B1799

Tolmetin is an orally active and potent **COX** inhibitor with IC_{50}s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin is a non-steroidal anti-inflammatory drug (NSAID).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg

Tolmetin sodium dihydrate

Cat. No.: HY-B1489

Tolmetin sodium dihydrate is an orally active and potent **COX** inhibitor with IC_{50}s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin sodium dihydrate is a non-steroidal anti-inflammatory drug (NSAID).



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Tolmetin-d3

Cat. No.: HY-B1799S

Tolmetin-d3 is the deuterium labeled Tolmetin. Tolmetin is an orally active and potent **COX** inhibitor with **IC_{50}**s of 0.35 μM and 0.82 μM human COX-1 and COX-2, respectively. Tolmetin is a non-steroidal anti-inflammatory drug (NSAID).



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Toltrazuril sulfoxide

Cat. No.: HY-136438

Toltrazuril sulfoxide is a short-lived **intermediary metabolite** of Toltrazuril (HY-B0175), and then can be metabolized to the reactive toltrazuril sulfone (TZR-SO2) in vivo. Toltrazuril is an **antiprotozoal agent** that acts upon Coccidia parasites.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Toltrazuril sulfoxide-d3

Cat. No.: HY-136438S

rac Toltrazuril-d3 Sulfoxide is the deuterium labeled Toltrazuril sulfoxide. Toltrazuril sulfoxide is a short-lived **intermediary metabolite** of Toltrazuril (HY-B0175), and then can be metabolized to the reactive toltrazuril sulfone (TZR-SO2) in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Tomatidine

Cat. No.: HY-N2149

Tomatidine acts as an anti-inflammatory agent by blocking **NF-κB** and **JNK** signaling. Tomatidine activates **autophagy** either in mammal cells or C elegans.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Tomatidine hydrochloride

Cat. No.: HY-N2149A

Tomatidine hydrochloride acts as an anti-inflammatory agent by blocking **NF-κB** and **JNK** signaling. Tomatidine hydrochloride activates **autophagy** either in mammal cells or C elegans.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Tonabersat

(SB-220453)

Cat. No.: HY-15204

Tonabersat (SB-220453) is a **gap-junction** modulator. Tonabersat prevents inflammatory damage in the central nervous system.



Purity: 99.68%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Toosendanin

Cat. No.: HY-N0263

Toosendanin, a triterpenoid extracted from the bark of fruit of Melia toosendan Sieb et Zucc, possesses analgesic, insecticidal and anti-inflammatory activities.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Tormentic acid

Cat. No.: HY-N4137

Tormentic acid, a triterpene isolated from Rosa rugosa, exerts anti-inflammatory, antihyperlipidemic, and anti-atherogenic properties.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Toxicarol isoflavone

Cat. No.: HY-N1135

Toxicarol isoflavone is an isoflavone extracted from Millettia brandisiana.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 1 mg

TP-008

Cat. No.: HY-125851

TP-008 is a potent, selective and orally active **(Activin-Like Kinase 5) ALK5** inhibitor with **pIC_{50}** and **pEC_{50}** values of 7.6 and 6.63, respectively. TGFβRI-IN-2 can produce observed cardiac toxicity in vivo at high dose.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TP-064

Cat. No.: HY-114965

TP-064 is a potent and selective **proteinarginine methyltransferase 4 (PRMT4; CARM1)** inhibitor (IC_{50} <10 nM). TP-064 inhibits dimethylation of BAF155 (IC_{50} of 340 nM) and MED12 (IC_{50} of 43 nM). TP-064 is inactive against the other family members except for PRMT6 (IC_{50} of 1.3 μM).



Purity: 98.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

TPCA-1

Cat. No.: HY-10074

TPCA-1 is a potent and selective inhibitor of **IKK-2** with IC_{50} of 17.9 nM. TPCA-1 is an effective inhibitor of **STAT3** phosphorylation, DNA binding, and transactivation.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 100 mg

TPI-1

Cat. No.: HY-100463

TPI-1, also known as Tyrosine Phosphatase Inhibitor 1, is a **SHP-1** inhibitor; inhibits recombinant SHP-1 with an IC_{50} of 40 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tpl2 Kinase Inhibitor 1

Cat. No.: HY-12358

Tpl2 Kinase Inhibitor 1 (Compound 1) is a potent and selective **Tpl2** (**COT kinase**, **MAP3K8**) inhibitor, plays an important role in the regulation of the inflammatory response and the progression of some cancers.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

TPPU

Cat. No.: HY-101294

TTPU is a soluble epoxide hydrolase (**sEH**) inhibitor with IC_{50} values of 37 and 3.7 nM for monkey and human sEH, respectively.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TQS

Cat. No.: HY-107682

TQS is a α7 nicotinic acetylcholine receptor (**nAChR**) positive allosteric modulator. TQS can be used for the research of neuroinflammatory pain.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TR-14035

Cat. No.: HY-15770

TR-14035 is a orally active dual $\alpha_4\beta_7/\alpha_4\beta_1$ **integrin** antagonist, with IC_{50} s of 7 nM and 87 nM for $\alpha_4\beta_7$ and $\alpha_4\beta_1$, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases.



Purity: 95.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tr-PEG2-OH

Cat. No.: HY-114995

Tr-PEG2-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Tr-PEG2-OH is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tr-PEG3-OH

Cat. No.: HY-120258

Tr-PEG3-OH is a non-cleavable 3 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tr-PEG4-OH

Cat. No.: HY-126883

Tr-PEG4-OH is a non-cleavable 4 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tr-PEG5-OH

Cat. No.: HY-120845

Tr-PEG5-OH is a non-cleavable 5 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). Tr-PEG5-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tr-PEG6-OH

Cat. No.: HY-129311

Tr-PEG6-OH is a non-cleavable 6 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tr-PEG8-OH

Cat. No.: HY-130165

Tr-PEG8-OH is a non-cleavable 8 unit PEG **ADC** linker used in the synthesis of antibody-drug conjugates (ADCs). Tr-PEG8-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trabectedin

(Ecteinascidin 743; ET-743)

Cat. No.: HY-50936

Trabectedin (Ecteinascidin 743; ET-743) is a tetrahydroisoquinoline alkaloid with potent antitumor activity.



Purity: 99.84%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg

Trabectedin D3

(Ecteinascidin 743 D3; ET-743 D3)

Cat. No.: HY-50936S

Trabectedin D3 (Ecteinascidin 743 D3) is deuterium labeled Trabectedin. Trabectedin is a tetrahydroisoquinoline alkaloid with potent antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 2 mg, 5 mg

Trabodenoson

(INO-8875)

Cat. No.: HY-106007

Trabodenoson (INO-8875), an adenosine mimetic, is a highly selective **Adenosine A1 receptor** agonist. Trabodenoson (INO-8875) is used in the study for Primary Open-Angle Glaucoma.
.



Purity: 98.14%
Clinical Data: Phase 3
Size: 5 mg

TRAF-STOP inhibitor 6877002

Cat. No.: HY-110247

TRAF-STOP inhibitor 6877002, is a selective inhibitor of **CD40-TRAF6** interaction, compound VII, shows inhibition of **NF-κB** activation in RAW cells, extracted from patent WO2014033122A1.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Tranilast

(MK-341; SB 252218)

Cat. No.: HY-B0195

Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of **prostaglandin D2** (**PGD2**, IC_{50}= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects.



Purity: 99.46%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tranilast sodium

(MK-341 sodium; SB 252218 sodium)

Cat. No.: HY-B0195A

Tranilast sodium (MK-341 sodium) acts as an anti-atopic agent. Tranilast suppresses production of **prostaglandin D2** (**PGD2**, IC_{50}= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects.



Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg

trans-Benzylideneacetone

(trans-Benzalacetone)

Cat. No.: HY-W012595A

trans-Benzylideneacetone (trans-Benzalacetone), a metabolite of gram-negative entomopathogenic bacterium Xenorhabdus nematophila, is an enzyme inhibitor against **phospholipase A2** (**PLA2**). trans-Benzylideneacetone is an immunosuppressant.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 500 mg

trans-Chalcone

Cat. No.: HY-Y0598

trans-Chalcone, isolated from Aronia melanocarpa skin, is a biphenolic core structure of flavonoids precursor. trans-Chalcone is a potent **fatty acid synthase (FAS)** and **α-amylase** inhibitor.



Purity: 97.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

trans-Tranilast

(trans-MK-341; trans-SB 252218)

Cat. No.: HY-18706

trans-Tranilast (trans-MK-341) is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

trans-Trimethoxyresveratrol (trans-trismethoxy Resveratrol; E-Resveratrol Trimethyl Ether; Tri-O-methylresveratrol)

Cat. No.: HY-N1408

Trans-Trimethoxyresveratrol is a derivative of Resveratrol (RSV),and it may be a more potent anti-inflammatory, antiangiogenic and vascular-disrupting agent when compared with resveratrol.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

trans-Urocanic acid

((E)-Urocanic acid; trans-UCA)

Cat. No.: HY-113008B

trans-urocanic acid (trans-UCA), a natural epidermal constituent, inhibits human natural killer cell (NK) activity in vitro. trans-urocanic acid is active in regulating an immune function.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Transdermal Peptide Disulfide

(TD 1 Disulfide(peptide))

Cat. No.: HY-P1565

Transdermal Peptide Disulfide (TD 1 Disulfide(peptide)) is a 11-amino acid peptide, binds to**Na^+/K^+-ATPase beta-subunit (ATP1B1)**, and mainly interacts with the C-terminus of **ATP1B1**. Transdermal Peptide Disulfide can enhance the transdermal delivery of many macromolecules.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRAP-6 (PAR-1 agonist peptide; Thrombin Receptor Activator Peptide 6)

Cat. No.: HY-P0078

TRAP-6 (PAR-1 agonist peptide), a peptide fragment, is a selective **protease activating receptor 1 (PAR1)** agonist. TRAP-6 activates human platelets via the **thrombin receptor**. TRAP-6 shows no activity at PAR4.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg

TRAP-6 amide

Cat. No.: HY-P2321

TRAP-6 amide is a **PAR-1 thrombin receptor** agonist peptide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRAP-6 amide TFA

Cat. No.: HY-P2321A

TRAP-6 amide TFA is a **PAR-1 thrombin receptor** agonist peptide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Traumatic Acid

Cat. No.: HY-119358

Traumatic Acid is a monounsaturated dicarboxylic acid isolated from Phaseolus vulgaris. Traumatic Acid can cause a decrease in membrane phospholipid peroxidation and show antioxidant and stimulatory effects on **collagen biosynthesis**.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Trehalose 6-behenate

Cat. No.: HY-101871

Trehalose 6-behenate is a Th1/Th17 skewing vaccine adjuvant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Treprostinil

(UT-15)

Cat. No.: HY-100441

Treprostinil (UT-15) is a potent **DP1** and **EP2** agonist with EC_{50} values of 0.6±0.1 and 6.2±1.2 nM, respectively.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Treprostinil palmitil

(INS-1009)

Cat. No.: HY-109163

Treprostinil palmitil (TP) is the prodrug of **DP1** and **EP2** agonist, Treprostinil (UT-15), whose EC_{50} values were 0.6 and 6.2 nM, respectively. Treprostinil palmitil is a pure prodrug and possesses no inherent binding to G-protein coupled receptors including prostanoid receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Treprostinil sodium

(UT-15 sodium)

Cat. No.: HY-16504

Treprostinil (UT-15) sodium is a potent **DP1** and **EP2** agonist with EC_{50} values of 0.6±0.1 and 6.2±1.2 nM, respectively.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH

Cat. No.: HY-145255

Tri(TLR4-IN-C34-C2-amide-C3-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH

Cat. No.: HY-145253

Tri(TLR4-IN-C34-C2-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Triamcinolone

Cat. No.: HY-B0328

Triamcinolone is a long-acting synthetic corticosteroid. Triamcinolone is a **corticosteroid hormone receptor** agonist and an anti-inflammatory agent. Target: Glucocorticoid Receptor Dimethyl fumarate is an anti-inflammatory.



Purity: 99.15%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Triamcinolone acetonide

Cat. No.: HY-B0636

Triamcinolone acetonide is a more potent type of triamcinolone, being about 8 times as effective as prednisone.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Triamcinolone Benetonide

Cat. No.: HY-U00043

Triamcinolone benetonide is a synthetic glucocorticoid corticosteroid with anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Triamcinolone hexacetonide

Cat. No.: HY-U00103

Triamcinolone hexacetonide is a commonly used long-acting steroids in treatment of subacute and chronic inflammatory joint diseases.



Purity: 98.02%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg

Tricarballylic acid

Cat. No.: HY-W020215

Tricarballylic acid, a conjugate acid of a tricarballylate, is a competitive inhibitor of the enzyme **aconitate hydratase** (aconitase; EC 4.2.1.3) with a K_i value of 0.52 mM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 g

Tricarbonyldichlororuthenium(II) dimer

(CORM-2) Cat. No.: HY-W033577

Tricarbonyldichlororuthenium(II) dimer is a pharmacological donor of CO releasing.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg

Trifarotene

(CD5789) Cat. No.: HY-100256

Trifarotene (CD5789) is a potent and selective **RARγ** agonist. Trifarotene (CD5789) shows 65-fold and 16-fold selectivitiy for the **RARγ** (EC_{50}=7.7 nM) over **RARα** (EC_{50}=500 nM) and **RARβ** (EC_{50}=125 nM), respectively.



Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Triflusal

Cat. No.: HY-B0531

Triflusal irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1. Target: COX Triflusal at 10 mM, 100 mM and 1 M decreases LDH efflux in rat brain slices after anoxia/reoxygenation by 24%, 35% and 49% respectively.



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Trifolirhizin

Cat. No.: HY-N0616

Trifolirhizin is a pterocarpan flavonoid isolated from the roots of Sophora flavescens. Trifolirhizin possesses potent **tyrosinase** inhibitory activity with an IC_{50} of 506 μM. Trifolirhizin exhibits potential anti-inflammatory and anticancer activities.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Triglycidyl isocyanurate

(TGIC; Teroxirone) Cat. No.: HY-W011434

Triglycidyl isocyanurate (TGIC; Teroxirone) is a triazene triepoxide with antiangiogenic and antineoplastic activities. Triglycidyl isocyanurate inhibits the growth of non-small-cell-lung cancer cells via **p53** activation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Trimetazidine-N-oxide

Cat. No.: HY-135408

Trimetazidine-N-oxide is the major active metabolite of Trimetazidine. Trimetazidine is a selective **long chain 3-ketoyl coenzyme A thiolase** inhibitor with an IC_{50} of 75 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trimethylamine N-oxide

Cat. No.: HY-116084

Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the **ROS/NLRP3 inflammasome**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Triolein

Cat. No.: HY-N1981

Triolein is a symmetrical triacylglycerol, reduces **MMP-1** upregulation, with strong antioxidant and anti-inflammatory properties.



Purity: ≥80.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Trioxsalen

(Trisoralen; Trioxysalen; TMP) Cat. No.: HY-B1157

Trioxsalen (Trisoralen), a psoralen derivative, is a photochemical DNA crosslinker. Trioxsalen only works after photoactivation with near ultraviolet light. Trioxsalen is a photosensitizer that can be used for the research of vitiligo and hand eczema.



Purity: 99.03%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Tripelennamine hydrochloride

Cat. No.: HY-17428

Tripelennamine hydrochloride, a H1-receptor antagonist, is a psychoactive drug and member of the pyridine andethylenediamine classes that is used as an antipruritic and first-generation antihistamine.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g, 5 g

Triphala

Cat. No.: HY-114335

Triphala, an Ayurvedic polyherbal formulation comprising of equiproportional fruit parts of Terminalia chebula, Terminalia bellerica, and Phyllanthus emblica. Triphala inhibits **NF-κB** activation. Triphala exerts **antifungal** action.

Triphala

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg(10 mg × mL in Water)

Triprolidine hydrochloride

Cat. No.: HY-B1808A

Triprolidine hydrochloride, a first-generation antihistamine, is an orally active **histamine H1** antagonist. Triprolidine hydrochloride can be used for the research of allergic rhinitis. Triprolidine hydrochloride exhibits spinal motor and sensory block in rats.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Triprolidine hydrochloride monohydrate

Cat. No.: HY-B1301

Triprolidine hydrochloride monohydrate, a first-generation antihistamine, is an oral active **histamine H1** antagonist. Triprolidine hydrochloride monohydrate can be used for the research of allergic rhinitis.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Tripterin

(Celastrol)

Cat. No.: HY-13067

Tripterin (Celastrol) is a **proteasome** inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified **20S proteasome** with **IC_{50}** of 2.5 μM.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Triptonide

(NSC 165677; PG 492)

Cat. No.: HY-32736

Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a **Wnt** signaling inhibitor with an **IC_{50}** of appropriately 0.3nM.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg

Triptoquinone B

((+)-Triptoquinone B)

Cat. No.: HY-N1120

Triptoquinone B ((+)-Triptoquinone B), a sesquiterpene alkaloid, is an **interleukin-1** inhibitor. Triptoquinone B shows potent inhibitory activities against interleukin 1α and β releases for human peripheral mononuclear cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tris(2,4-di-tert-butylphenyl)phosphate

Cat. No.: HY-136177

Tris(2,4-di-tert-butylphenyl)phosphate is an active compound from the leaves of Vitex negundo L. shows anti-inflammatory activity with evidence of inhibition for **secretory Phospholipase A_2** (**$sPLA_2$**) through molecular docking.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg

Tritoqualine

(Inhibostamin; Hypostamine)

Cat. No.: HY-U00065

Tritoqualine is used as a **histidine decarboxylase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Troleandomycin

(Triacetyloleandomycin)

Cat. No.: HY-108881

Troleandomycin (Triacetyloleandomycin), a macrolide acrolide antibiotic, is a selective **CYP3A** inhibitor. Troleandomycin is an oral corticosteroid for asthma study.



Purity: ≥80.0%
Clinical Data: Launched
Size: 1 mg, 5 mg

Troxerutin

(Trihydroxyethylrutin)

Cat. No.: HY-N0139

Troxerutin, also known as vitamin P4, is a tri-hydroxyethylated derivative of natural bioflavonoid rutins which can inhibit the production of **reactive oxygen species** (**ROS**) and depress ER stress-mediated **NOD** activation.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 5 g

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Troxipide

Cat. No.: HY-B0758

Troxipide is an orally active defensive factor-enhancing therapeutic agent for gastritis and gastric ulcer (GU). Troxipide is a non-antisecretory gastro protective agent with antiulcer, anti-inflammatory and mucus-secreting properties.



Purity: 99.39%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

TRPV antagonist 1

Cat. No.: HY-U00330

TRPV antagonist 1 is a transient receptor potential vanilloid **(TRPV)** antagonist, with an **IC_{50}** of < 250 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TRPV4 agonist-1

Cat. No.: HY-114400A

TRPV4 agonist-1 is a transient receptor potential vanilloid 4 (TRPV4) agonist with an EC_{50} of 60 nM in the hTRPV4 Ca^{2+} assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TRPV4 agonist-1 free base

Cat. No.: HY-114400

TRPV4 agonist-1 free base is a transient receptor potential vanilloid 4 (**TRPV4**) agonist with an **EC_{50}** of 60 nM in the hTRPV4 Ca^{2+} assay.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Trypan red

(C.I. 22850)

Cat. No.: HY-D0983

Trypan red is a vital stain.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Tryptanthrin

Cat. No.: HY-N6607

Tryptanthrin is a potent and orally active cellular **Leukotriene (LT) biosynthesis** inhibitor. Tryptanthrin inhibits LT formation in human whole blood (**IC_{50}** = 10 μM) and reduces LTB4 levels in the rat pleurisy model.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Tsugaric acid A

Cat. No.: HY-N4096

Tsugaric acid A can significantly inhibit superoxide anion formation. Tsugaric acid A also protects human keratinocytes against damage induced by ultraviolet B (UV B) light. Tsugaric acid A can protect keratinocytes from photodamage.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

TTP 22

Cat. No.: HY-15479

TTP 22 is a potent **CK2** inhibitor, with an **IC_{50}** of 100 nM and a **K_i** of 40 nM.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tubeimoside III

Cat. No.: HY-N2542

Tubeimoside III, a triterpenoid saponin, shows anti-inflammatory, anti-tumor, anti-tumorigenic activities, and acute toxicity in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Tuberculosis inhibitor 3

Cat. No.: HY-114147

Tuberculosis inhibitor 3 (compound 2i) displays potent anti-TB activity (MIC < 0.016 μg/mL) against drug-sensitive/resistant MTB strains. Tuberculosis inhibitor 3 (compound 2i) shows acceptable PK profiles with oral bioavailability.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tuftsin

Cat. No.: HY-P0240

Tuftsin is a tetrapeptide. Tuftsin is a macrophage/microglial activator.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Tuftsin diacetate

Cat. No.: HY-P0240A

Tuftsin diacetate, a tetrapeptide, is a **macrophage/microglial** activator.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tulobuterol

(C-78 free base)

Cat. No.: HY-B1810

Tulobuterol (C-78 free base) is a long-acting **β_2-adrenoceptor** agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma.



Purity: >98%
Clinical Data: Launched
Size: 50 mg, 100 mg

Tulobuterol hydrochloride

(C-78)

Cat. No.: HY-W011733

Tulobuterol hydrochloride (C-78) is a long-acting **β_2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma.**.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Tulobuterol-D9 hydrochloride

(C-78-D9)

Cat. No.: HY-B1810S

Tulobuterol-D9 hydrochloride (C-78-D9) is the deuterium labeled Tulobuterol. Tulobuterol (C-78 free base) is a long-acting **β_2-adrenoceptor** agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tumulosic acid

Cat. No.: HY-N9366

Tumulosic acid, a triterpenoid, inhibits **KLK5 protease** activity (**IC_{50}**= 14.84 μM). Tumulosic acid suppresses the proteolytic processing of LL-37 in keratinocytes at ≤10 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tunicamycin

Cat. No.: HY-A0098

Tunicamycin is a mixture of homologous nucleoside antibiotic that inhibits **N-linked glycosylation** and blocks **GlcNAc phosphotransferase (GPT)**.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg

Turanose

Cat. No.: HY-113334

Turanose is an isomer of Sucrose that naturally exists in honey. Turanose has anti-inflammatory and regulates adipogenesis effect. Turanose has potential for obesity and related chronic diseases research.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Tussilagone

Cat. No.: HY-N1388

Tussilagone, a major active component in Tussilago farfara, has anti-inflammatory effect. Tussilagone ameliorates inflammatory responses in dextran sulphate sodium-induced murine colitis.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

TXNIP-IN-1

Cat. No.: HY-115688

TXNIP-IN-1 is **TXNIP-TRX (thioredoxin-interacting protein- thioredoxin) complex** inhibitor extracted from patent US20200085800A1, Compound 1.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

TY-51469

Cat. No.: HY-12370

TY-51469 is a **chymase** inhibitor with IC_{50}s for simian and human chymases of 0.4 and 7.0 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TyK2-IN-2

Cat. No.: HY-101762

TyK2-IN-2 (Compoud 18) is a potent and selective **TYK2** inhibitor with IC_{50}s of 7 nM, 0.1 μM and 0.05 μM for **TYK2 JH2**, **IL-23** and **IFNα**, respectively. TyK2-IN-2 also inhibits **phosphodiesterase 4 (PDE4)** with an IC_{50} of 62 nM.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Tyk2-IN-3

Cat. No.: HY-18709

Tyk2-IN-3 is a **Tyk2 pseudokinase** inhibitor, with an IC_{50} of 485 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyk2-IN-5

Cat. No.: HY-111745

Tyk2-IN-5 (compound 6) is a highly potent, selective and orally active **Tyk2** inhibitor and targets the JH2 domain, with a K_i of 0.086 nM for Tyk2 JH2 and an IC_{50} of 25 nM for IFNα.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyk2-IN-7

Cat. No.: HY-126242S

Tyk2-IN-7 (Compound 48) is a **TYK2 JH2** inhibitor, binds to TYK2 JH2 domain with IC_{50} and $K_{i,app}$ of 0.00053 μM and 0.00007 μM, respectively.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Type A Allatostatin I

Cat. No.: HY-P1882

Type A Allatostatin I is a tridecapeptide. Allatostatins are pleiotropic neuropeptides for inhibition of juvenile hormone synthesis in insects.

APSGAQRLYGFGL-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Typhaneoside

Cat. No.: HY-N0712

Typhaneoside, extracted from Typha angustifolia L., Typhaneoside can inhibit the excessive **autophagy** of hypoxia/reoxygenation cells and increase the phosphorylation of Akt and mTOR.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Tyrosinase-related Protein 2 (TRP-2) (181-188)

Cat. No.: HY-P2527

Tyrosinase-related Protein 2 (TRP-2) (181-188) is a tyrosinase-related protein 2 (TRP-2)-derived peptide, corresponding to residues 180-188. Tyrosinase-related Protein 2 (TRP-2) (181-188) is the major reactive epitope within TRP-2 recognized by anti-B16 CTLs.

VYDFFVWL

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)

Cat. No.: HY-P1590

Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

VLPQDKE-pY-pY-KVKEPGE

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tyrosol

Cat. No.: HY-N0474

Tyrosol is a derivative of phenethyl alcohol. Tyrosol attenuates pro-inflammatory cytokines from cultured astrocytes and **NF-κB** activation. Anti-oxidative and anti-inflammatory effects.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Tyrphostin A1

(Tyrphostin 1; AG9)

Cat. No.: HY-16668

Tyrphostin A1(AG9) inhibits CD40L-stimulated IL-12 production in macrophage cultures and antigen-induced generation of Th1 cells.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 100 mg

Tyrphostin AG1296

(AG1296)

Cat. No.: HY-13894

Tyrphostin AG1296 is a potent and selective inhibitor of **platelet-derived growth factor receptor (PDGFR)**, with an IC_{50} of 0.8 μM.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

U-73122

Cat. No.: HY-13419

U-73122 is a **phospholipase C (PLC)** and **5-LO (5-lipoxygenase)** inhibitor with an $IC_{50}$of 1-2.1 μM for PLC.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UbcH5c-IN-1

Cat. No.: HY-103046

UbcH5c-IN-1 (compound 6d) is a potent and selective small-molecule inhibitor of Ubiquitin-conjugating enzyme **UbcH5c**, with a K_d of 283 nM for E2 UbcH5c-IN-1 by covalent binding with Cys85.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UC-1728

(t-TUCB)

Cat. No.: HY-114266

UC-1728 is a potent rabbit soluble epoxide hydrolase **(sEH)** inhibitor, with an IC_{50} of 2 nM on rabbit liver.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UC-514321

Cat. No.: HY-120395

UC-514321, a structural analog of NSC370284 with higher activity, directly targets **STAT3/5** and represses **TET1** expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

UCB-9260

Cat. No.: HY-133122

UCB-9260, an orally active compound, inhibits **TNF signaling** by stabilising an asymmetric form of the trimer. UCB-9260 is selective for TNF over other superfamily members, and binds TNF with a similar K_d of 13nM.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UCB9608

Cat. No.: HY-112613

UCB9608 is a potent, selective and orally active **PI4KIIIβ** inhibitor, with an IC_{50} of 11 nM, selective over PI3KC2 α, β, and γ lipid kinases. UCB9608 improves metabolic stability and exhibits excellent pharmacokinetic profile, acts as a potent immunosuppressive agent.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UCM 608

(2-Phenylmelatonin)

Cat. No.: HY-101074

UCM 608 is a high affinity melatonin (**MT**) membrane receptor agonist. The pKi values for **MT1** and **MT2** are 10.7 and 10.4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ufenamate

(Flufenamic acid butyl ester; Butyl flufenamate)

Cat. No.: HY-100009

Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory agent. Ufenamate can be used for the research of skin diseases, such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliaria and atopic dermatitis.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UK 356618

Cat. No.: HY-107394

UK 356618 (Compound 4j) is a potent and selective inhibitor of **matrix metalloprotease-3 (MMP-3)** with an IC_{50} of 5.9 nM. UK 356618 is less potent against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14 compared with **MMP-3**.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

UK-370106

Cat. No.: HY-107639

UK-370106 is a potent and highly selective **MMP-3** (IC_{50} of 23 nM) and **MMP-12** (IC_{50} of 42 nM) inhibitor with >1200-fold higher potency than MMP-1, MMP-2, MMP-9, and MMP-14, and about 100-fold than MMP-13 and MMP-8.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

UK-371804

Cat. No.: HY-101214

UK-371804 is a urokinase-type plasminogen activator (**uPA**) inhibitor with a K_i of 10 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UK-432097

Cat. No.: HY-107046

UK-432097 is a highly potent and selective A_{2A}**AR** agonist with a pK_i of 8.4 for human A_{2A}AR. UK-432097 has anti-inflammatory and anti-aggregatory properties. UK-432097 has the potential for COPD (Chronic Obstructive Pulmonary Disease) research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ulmoidol

Cat. No.: HY-N10150

Ulmoidol prevents neuroinflammation by targeting the **PU.1** transcriptional signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Umeclidinium bromide

(GSK573719A)

Cat. No.: HY-12100

Umeclidinium bromide is a novel **mAChR** antagonist. The affinity (K_i) of Umeclidinium bromide for the cloned human M1-M5 mAChRs ranges from 0.05 to 0.16 nM.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Umirolimus

Cat. No.: HY-122402

Umirolimus, a macrocyclic triene lactone Rapamycin derivative, is powerful immunosuppressant and anti-inflammatory agent. Umirolimus has highly lipophilicity and can be used drug-eluting stent (DES) applications.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC3230

Cat. No.: HY-110150

UNC3230 is a potent, selective and ATP-competitive **PIP5K1C** inhibitor with an IC_{50} of ~41 nM. UNC3230 also inhibits **PIP4K2C** and does not inhibit any of the other lipid kinases that regulate phosphoinositide levels. UNC3230 has antinociceptive and anticancer effects.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UP202-56

Cat. No.: HY-U00226

UP202-56 is an adenosine analogue, which is an adenosinergic agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Upadacitinib

(ABT-494)

Cat. No.: HY-19569

Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (**JAK1**) inhibitor (IC_{50}=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UPF-523

(AIDA)

Cat. No.: HY-101311

UPF-523 (AIDA), a rigid (carboxyphenyl) glycine derivative, is a relatively potent and selective antagonist of group I metabotropic glutamate receptors **(mGlu1a)** with an **IC_{50}** of 214 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

URAT1 inhibitor 1

Cat. No.: HY-114309

URAT1 inhibitor 1 (1g) is a **uric acid transporter 1 (URAT1)** inhibitor, with an **IC_{50}** of 32 nM. URAT1 inhibitor 1 has potential to treat hyperuricemia associated with gout.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

URB937

Cat. No.: HY-116477

URB937 is an orally active and peripherally restricted **FAAH** inhibitor (**IC_{50}**=26.8 nM) and increases anandamide levels. URB937 fails to affect FAAH activity in the brain (not penetrate the blood-brain barrier).



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Uric acid

Cat. No.: HY-B2130

Uric acid, scavenger of **oxygen radical**, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation.



Purity: 99.96%
Clinical Data: Phase 3
Size: 500 mg, 1 g

Uridine 5'-diphosphate sodium salt

Cat. No.: HY-W010820

Uridine 5'-diphosphate sodium salt is a potent, selective **$P2Y_6$** receptor native agonist (**EC_{50}**=300 nM; **pEC_{50}**=6.52) and a potent **$P2Y_{14}$** antagonist (**pEC_{50}**=7.28).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Uridine triphosphate

(UTP; Uridine 5'-triphosphate)

Cat. No.: HY-107372

Uridine triphosphate (UTP;Uridine 5'-triphosphate) is a nucleotide that regulates the functions of the pancreas in endocrine and exocrine secretion, proliferation, channels, transporters, and intracellular signaling under normal and disease states.



Purity: ≥98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Uridine triphosphate trisodium salt (UTP trisodium salt;

Uridine 5'-triphosphate trisodium salt)

Cat. No.: HY-W013093

Uridine triphosphate trisodium salt is a nucleotide that regulates the functions of the pancreas in endocrine and exocrine secretion, proliferation, channels, transporters, and intracellular signaling under normal and disease states.



Purity: ≥96.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg

Uridine-5'-diphosphate disodium salt

Cat. No.: HY-W010832

Uridine-5'-diphosphate disodium salt is a potent, selective **$P2Y_6$** receptor native agonist (**EC_{50}**=300 nM; **pEC_{50}**=6.52 for human $P2Y_6$ receptor).



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Urolithin B

Cat. No.: HY-126307

Urolithin B is one of the gut microbial metabolites of ellagitannins, and has anti-inflammatory and antioxidant effects.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Usaramine N-oxide

Cat. No.: HY-N6827

Usaramine N-oxide, a flavonoid isolated from Crotalaria pallida, possesses anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ustekinumab

(Anti-Human IL-12/IL-23, Human Antibody) Cat. No.: HY-P9909

Ustekinumab is an anti-**IL-12/IL-23** IgG1κ human monoclonal antibody.

Ustekinumab

Purity: 98.42%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 25 mg, 50 mg

UTL-5g

(GBL-5g) Cat. No.: HY-117082

UTL-5g (GBL-5g), an anti-inflammatory **TNF-α** inhibitor, has chemoprotective and liver radioprotective effects. UTL-5g lowers hepatotoxicity, nephrotoxicity, and myelotoxicity induced by Cisplatin through TNF-α inhibition among other factors.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Uty HY Peptide (246-254)

Cat. No.: HY-P1917

Uty HY Peptide (246-254), derived from the ubiquitously transcribed tetratricopeptide repeat gene on the Y chromosome (UTY) protein as an H-Y epitope, H-YD^b, is a male-specific transplantation antigen H-Y.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Uty HY Peptide (246-254) (TFA)

Cat. No.: HY-P1917A

Uty HY Peptide (246-254) TFA, derived from the ubiquitously transcribed tetratricopeptide repeat gene on the Y chromosome (UTY) protein as an H-Y epitope, H-YD^b, is a male-specific transplantation antigen H-Y.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Uvaol

Cat. No.: HY-N1109

Uvaol, a triterpene present in olives and virgin olive oil, possesses anti-inflammatory properties and antioxidant effects. Uvaol attenuates pleuritis and eosinophilic inflammation in ovalbumin-induced allergy in mice.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

V116517

Cat. No.: HY-12914

V116517 is a potent, orally active transient receptor potential vanilloid **(TRPV1)** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VAF347

Cat. No.: HY-135750

VAF347 is a cell permeable and highly affinity **aryl hydrocarbon receptor (AhR)** agonist and induces **AhR** signaling. VAF347 inhibits the development of $CD14^+CD11b^+$ monocytes from granulo-monocytic (GM stage) precursors. VAF347 has anti-inflammatory effects.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Valategrast

(R-411 free base) Cat. No.: HY-14190

Valategrast (R-411 free base) is a potent and orally active **integrin α4β1 (VLA-4)** and **α4β7** dual antagonist. Valategrast has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment.



Purity: 98.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Valdecoxib

(SC 65872) Cat. No.: HY-15762

Valdecoxib is a highly potent and selective inhibitor of **COX-2**, with IC_{50}s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Valencene

Cat. No.: HY-N6636

Valencene is a sesquiterpene isolated from Cyperus rotundus, possesses antiallergic, antimelanogenesis, anti-infammatory, and antioxidant activitivies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Valeriandoid F

Cat. No.: HY-N8174

Valeriandoid F is an iridoid, which potently inhibits NO production with an IC_{50} value of 0.88 μM. Valeriandoid F has anti-inflammatory and antiproliferative activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Valrubicin

(AD-32)

Cat. No.: HY-13772

Valrubicin is a chemotherapy agent, inhibits TPA- and PDBu-induced **PKC** activation with IC_{50}s of 0.85 and 1.25 μM, respectively, and has antitumor and antiinflammatory activity.



Purity: 99.60%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Vamorolone

(VBP15)

Cat. No.: HY-109017

Vamorolone (VBP15) is a first-in-class, orally active **dissociative steroidal anti-inflammatory** drug and membrane-stabilizer. Vamorolone improves muscular dystrophy without side effects. Vamorolone shows potent **NF-κB** inhibition and substantially reduces hormonal effects.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Vanillic acid

Cat. No.: HY-N0708

Vanillic acid is a flavoring agent found in edible plants and fruits. Vanillic acid inhibits **NF-κB** activation. Anti-inflammatory, antibacterial, and chemopreventive effects.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Vanilloid receptor antagonist 1

Cat. No.: HY-114017

Vanilloid receptor antagonist 1 is a potent vanilloid receptor **TRPV1** antagonist extracted from patent US8349852B2, compound B8.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Vanin-1-IN-1

Cat. No.: HY-129035

Vanin-1-IN-1 is an inhibitor of vanin-1 enzyme which is a cell surface associated, giycosyiphosphatidyS inositol (GPi) anchored protein and plays an important role in metabolism and inflammation.



Purity: 99.91%
Clinical Data:
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vapendavir diphosphate

(BTA798 diphosphate)

Cat. No.: HY-106254A

Vapendavir diphosphate (BTA798 diphosphate) is a potent **enteroviral** capsid binder (CB). Vapendavir diphosphate (BTA798 diphosphate) possesses potent antiviral activity for enterovirus 71 (EV71) replication, with EC_{50} values of 0.5-1.4 μM in different EV71 strains.



Purity: 98.08%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Varespladib

(LY315920)

Cat. No.: HY-13402

Varespladib (LY315920) is a potent and selective **group IIA, secretory phospholipase A_2 ($sPLA_2$)** inhibitor with an IC_{50} of 9 nM.



Purity: 98.68%
Clinical Data: Phase 3
Size: 5 mg, 10 mg

Varespladib methyl

(A-002; LY333013)

Cat. No.: HY-17448

Varespladib methyl (A-002; LY333013) is a selective inhibitor of group II secretory phospholipase A2 (**PLA2**).



Purity: 99.45%
Clinical Data: Phase 3
Size: 1 mg

Varespladib sodium

(LY315920 sodium)

Cat. No.: HY-13402A

Varespladib sodium (LY315920 sodium) is a potent and selective **group IIA, secretory phospholipase A_2 ($sPLA_2$)** inhibitor with an IC_{50} of 9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vasicine

(Peganine) Cat. No.: HY-N1103

Vasicine (peganine) is a quinazoline alkaloid isolated from Justicia adhatoda. Vasicine (peganine) possesses anti- tuberculosis activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vasicine hydrochloride

(Peganine hydrochloride) Cat. No.: HY-N1103A

Vasicine hydrochloride (peganine hydrochloride) is a quinazoline alkaloid isolated from Justicia adhatoda. Vasicine (peganine) possesses anti-tuberculosis activity.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Vazegepant hydrochloride

(Zavegepant hydrochloride; BHV-3500 hydrochloride) Cat. No.: HY-132131

Vazegepant (BHV-3500) hydrochloride is a highly soluble **CGRP** receptor antagonist (**hCGRP** K_i= 0.023 nM). Vazegepant hydrochloride is the first intranasal gepant for migraine.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Vebicorvir

(ABI-H0731) Cat. No.: HY-109195

Vebicorvir (ABI-H0731) is a first-generation **hepatitis B virus (HBV) core protein** inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC_{50}s from 1.84μM to 7.3μM.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vedolizumab

(Anti-Human lymphocyte α4β7 integrin, Humanized Antibody) Cat. No.: HY-P9911

Vedolizumab is a humanized monoclonal antibody that targets the α4β7 **integrin** for the treatment of ulcerative colitis and Crohn's disease.

Vedolizumab

Purity: 99.64%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Veledimex

(INXN-1001; RG-115932) Cat. No.: HY-16785

Veledimex (INXN-1001), a synthetic analog of the insect molting hormone ecdysone, is an orally active activator ligand for a proprietary gene therapy promoter system.



Purity: 99.19%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Veledimex racemate

(INXN-1001 racemate; RG-115932 racemate) Cat. No.: HY-16785A

Veledimex racemate (INXN-1001 racemate) is the racemate of veledimex. Veledimex is an orally available, small-molecule activator ligand for the RheoSwitch Therapeutic System.



Purity: 97.82%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Veliflapon

(BAY X 1005; DG-031) Cat. No.: HY-14165

Veliflapon (BAY X 1005; DG-031) is an orally active and selective **5-lipoxygenase activating protein (FLAP)** inhibitor. Veliflapon inhibits the synthesis of the **leukotrienes B4** and **C4**.



Purity: 98.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

Velsecorat

(AZD7594; AZ13189620) Cat. No.: HY-111453

AZD7594 is a potent selective nonsteroidal **glucocorticoid receptor** modulator, with an IC_{50} of 0.9 nM.



Purity: 99.60%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Velutin

Cat. No.: HY-N1098

Velutin is an aglycone extracted from Korean Mistletoe, with inhibitory activity against melanin biosynthesis. Velutin reduces osteoclast differentiation and down-regulates HIF-1α through the NF-κB pathway.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Vemircopan

Cat. No.: HY-139588

Vemircopan is a **complement factor D** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Veratric acid

(3,4-Dimethoxybenzoic acid)

Cat. No.: HY-N2007

Veratric acid (3,4-Dimethoxybenzoic acid) is an orally active phenolic compound derived from vegetables and fruits, has antioxidant and anti-inflammatory activities.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Verbascose

Cat. No.: HY-N9369

Verbascose, an alacto-oligosac-charides (GOS), has potent immunostimulatory activity. Verbascose acts as a potential natural immunomodulatory agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Verbascoside

(Acteoside; Kusaginin; TJC160)

Cat. No.: HY-N0021

Verbascoside is isolated from Lantana camara, acts as an ATP-competitive inhibitor of **PKC**, with an IC_{50} of 25 μM, and has antitumor, anti-inflammatory and antineuropathic pain activity.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Verbenalin

Cat. No.: HY-N2014

Verbenalin is Verbena glycoside, with anti-inflammatory, anti-fungal anti-virus activities. Verbenalin can be used for the research of prostatitis. Verbenalin can reduce cerebral ischemia-reperfusion injury.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Vercirnon

(GSK-1605786; CCX282-B; Traficet-EN)

Cat. No.: HY-15724

Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of **CCR9**. Vercirnon inhibits CCR9-mediated Ca^{2+} mobilization and chemotaxis on Molt-4 cells with IC_{50} values of 5.4 and 3.4 nM, respectively.



Purity: 98.19%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vercirnon sodium

(GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium)

Cat. No.: HY-15724A

Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of **CCR9**. Vercirnon sodium inhibits CCR9-mediated Ca^{2+} mobilization and chemotaxis on Molt-4 cells with IC_{50} values of 5.4 and 3.4 nM, respectively.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Verminoside

Cat. No.: HY-N1094

Verminoside is an iridoid isolated from Kigelia africana, exhibits anti-inflammatory and remarkable antioxidant activity with a radical-scavenging activity of 2.5 μg/mL. The genotoxicity of Verminoside on human lymphocytes is associated with elevated levels of **PARP-1** and **p53** proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vesatolimod

(GS-9620)

Cat. No.: HY-15601

Vesatolimod (GS-9620) is a potent, selective and orally active agonist of **Toll-Like Receptor (TLR7)** with an EC_{50} of 291 nM.



Purity: 99.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VGX-1027

(GIT 27)

Cat. No.: HY-15507

VGX-1027 is an orally active isoxazole compound that exhibits various immunomodulatory properties. VGX-1027 targets macrophages, reducing the production of the proinflammatory mediators TNF-α, IL-1β, IL-10.



Purity: 99.93%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg

Vialinin A

(Terrestrin A)

Cat. No.: HY-103435

Vialinin A (Terrestrin A) is a p-terphenyl compound with **antioxidant** properties. Vialinin A is a potent inhibitor of TNF-α, USP4, USP5, and sentrin/SUMO-specific protease 1 (SENP1). Vialinin A (Terrestrin A) can be used for autoimmune diseases and cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vidofludimus

(4sc-101; SC12267)

Cat. No.: HY-14908

Vidofludimus(4SC-101; SC12267) is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.



Purity: 98.88%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vidupiprant

(AMG 853)

Cat. No.: HY-14973

Vidupiprant (AMG 853) is a phenylacetic acid derivative. Vidupiprant is a potent and orally active **CRTH2 (DP2)** and **prostanoid D receptor (DP or DP1)** dual antagonist with **IC_{50}**s of 3 nM and 4 nM in buffer, and 8 nM and 35 nM in human plasma, respectively.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

Vilanterol

(GW642444)

Cat. No.: HY-14300

Vilanterol (GW642444) is a long-acting **β_2-adrenoceptor** (β_2-AR) agonist with 24 h activity. The **pEC_{50}**s for β_2-AR,β_1-AR and β_3-AR is 10.37±0.05, 6.98±0.03 and 7.36±0.03, respectively.



Purity: 96.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vilanterol trifenatate

(GW642444 trifenatate)

Cat. No.: HY-14300A

Vilanterol trifenatate (GW642444 trifenatate) is a long-acting **β_2-adrenoceptor** (β_2-AR) agonist with inherent 24-hour activity. The **pEC_{50}**s for β_2-AR, β_1-AR and β_3-AR are 10.37, 6.98 and 7.36, respectively.



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Villosolside

Cat. No.: HY-N2367

Villosolside is an iridoid glucoside that can be isolated from the roots of Patrinia scabra. Villosolside has **anti-inflammatory** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vimirogant

(VTP-43742)

Cat. No.: HY-103637

Vimirogant (VTP-43742) is a potent, selective, and orally active **RORγt** inhibitor (K_i=3.5 nM; **IC_{50}**=17 nM). Vimirogant exhibits >1000-fold selectivity versus the RORα and RORβ isotypes.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg

Vimirogant hydrochloride

(VTP-43742 hydrochloride)

Cat. No.: HY-103637A

Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active **RORγt** inhibitor (K_i=3.5 nM; **IC_{50}**=17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Vinaginsenoside R3

Cat. No.: HY-N4264

Vinaginsenoside R3 is a saponin composition of roots of Panax ginseng. Ginsengs have been not only used as therapeutic agents with tonic, anti-fatigue, and anti-gastric ulcer effect but also marketed as dietary supplements and raw materials of health food.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vinaginsenoside R4

Cat. No.: HY-N4265

Vinaginsenoside R4, isolated from the leaves of hydroponic Panax ginseng. It has an inhibitory effect on melanin biosynthesis without any cytotoxic effects on the melan-a cells, and enhances the depigmentation on the zebrafish.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vincosamide

Cat. No.: HY-N1089

Vincosamide, an alkaloid from Psychotria leiocarpa extract, inhibits the **acetylcholinesterase** (**AChE**) activity with anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vinpocetine

(Ethyl apovincaminate)

Cat. No.: HY-13295

Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na^+ channels. The **IC_{50}** value of Vinpocetine on direct **IKK** inhibition in the cell-free system is 17.17 μM.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Violanthin

Cat. No.: HY-N6895

Violanthin is isolated from the aerial parts of Piper bavinum, has potent antioxidant and antibacterial activities. Violanthin inhibits acetylcholinesterase (**AChE**) with an **IC_{50}** value of 79.80 μM.



Purity: 95.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Visnagin

Cat. No.: HY-N1082

Visnagin, an antioxidant furanocoumarin derivative, possess anti-inflammatory and analgesic properties. Visnagin has substantial potential to prevent Cerulein induced acute pancreatitis (AP). Visnagin possess promising vasodilator effects in vascular smooth muscles.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 5 mg

Visomitin

(SKQ1)

Cat. No.: HY-100474

Visomitin (SKQ1) is a mitochondrial-targeted antioxidant with the high mitochondrion membrane penetrating ability and potent antioxidant capability.



Purity: 98.06%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vitamin B15

(Pangamic Acid)

Cat. No.: HY-N7384

Vitamin B15 (Pangamic Acid) is a natural, ubiquitously in plant seeds substance and can used be as an agent stimulating cellular respiration. Vitamin B15 contains D-gluconodimethyl amino acetic acid. Vitamin B15 is also a immune-correcting agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VKGILS-NH2

Cat. No.: HY-P1310

VKGILS-NH2 is a reversed amino acid sequence control peptide for SLIGKV-NH2 (protease-activated receptor 2 (PAR2) agonist). VKGILS-NH2 has no effect on DNA synthesis in cells.

Purity: 99.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

VKGILS-NH2 TFA

Cat. No.: HY-P1310A

VKGILS-NH2 TFA is a reversed amino acid sequence control peptide for SLIGKV-NH2 (protease-activated receptor 2 (PAR2) agonist). VKGILS-NH2 TFA has no effect on DNA synthesis in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Voclosporin

(ISAtx-247)

Cat. No.: HY-106638

Voclosporin (ISAtx-247) is a **calcineurin (PP2B)** (CN) inhibitor.



Purity: 98.04%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VPC 23019

Cat. No.: HY-108490

VPC 23019, an aryl amide-containing Sphingosine 1-phosphate (S1P) analog, is a competitive antagonist at the **S1P1** and **S1P3 receptors** (**pK_i**= 7.86 and 5.93, respectively) and an agonist at the **S1P4** and **S1P5** receptors (**pEC_{50}**= 6.58 and 7.07, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

VRT-043198

Cat. No.: HY-112226

VRT-043198, the drug metabolite of VX-765 (Belnacasan), is a potent, selective and blood-brain barrier permeable inhibitor of **interleukin-converting enzyme/caspase-1** subfamily caspases.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VTX-27

Cat. No.: HY-112782

VTX-27 is a selective protein kinase C θ **(PKC θ)** inhibitor, with K_is of 0.08 nM and 16 nM for PKC θ and PKC δ.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VU0359595

(CID-53361951; ML-270)

Cat. No.: HY-101293

VU0359595 (CID-53361951; ML-270) is a potent and selective pharmacological phospholipase D1 (**PLD1**) inhibitor with an IC_{50} of 3.7 nM. VU0359595 is >1700-fold selective for PLD1 over PLD2 (IC_{50} of 6.4 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VU6015929

Cat. No.: HY-135401

VU6015929 is a potent, selective and orally active dual **discoidin domain receptor 1/2 (DDR1/2)** inhibitor with IC_{50}s of 4.67 nM and 7.39 nM, respectively. VU6015929 potently blocks collagen-induced **DDR1** activation and collagen-IV production.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VUF10460

Cat. No.: HY-101420

VUF10460 is a non-imidazole histamine **H4** receptor agonist; binds to rat H4 receptor with a pK_i of 7.46.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VX-702

Cat. No.: HY-10401

VX-702 is a highly selective inhibitor of **p38α MAPK**, 14-fold higher potency against the p38α versus p38β.



Purity: 99.44%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

W-54011

Cat. No.: HY-16992A

W-54011 is a potent and orally active non-peptide **C5a receptor** antagonist. W-54011 inhibits the binding of ^{125}I-labeled **C5a** to human neutrophils with a K_i value of 2.2 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Warangalone

(Scandenolone)

Cat. No.: HY-N1074

Warangalone is an anti-malarial compound which can inhibit the growth of both strains of parasite **3D7** (chloroquine sensitive) and **K1** (chloroquine resistant) with IC_{50}s of 4.8 μg/mL and 3.7 μg/mL, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

WAY-204688

(SIM-688)

Cat. No.: HY-19498

WAY-204688 is an **estrogen receptor** (**ER-α**) selective, orally active inhibitor of **NF-κB** transcriptional activity with an IC_{50} of 122±30 nM for NF-κB-luciferase (NF-κB-luc) in HAECT-1 cells.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 1 mg

WAY-600

Cat. No.: HY-15272

WAY-600 is a potent, ATP-competitive, and selective **mTOR** inhibitor with an IC_{50} of 9 nM for recombinant mTOR enzyme. WAY-600 blocks mTOR complex 1/2 (**mTORC1/2**) assemble and activation.



Purity: 95.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

WAY127093B racemate

Cat. No.: HY-101749

WAY127093B racemate is the racemate of WAY127093B. WAY127093B is an orally active **phosphodiesterase IV** inhibitor in guinea pigs and rats.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Wedelolactone

Cat. No.: HY-N0551

Wedelolactone, a natural product from Ecliptae herba, suppresses LPS-induced **caspase-11** expression by directly inhibiting the IKK Complex. Wedelolactone inhibits **5-lipoxygenase** (**5-Lox**) (IC_{50}~2.5 μM) activity by an oxygen radical scavenging mechanism.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

WHI-P97

Cat. No.: HY-11067

WHI-P97 is a potent and selective **JAK-3** inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Wilforgine

Cat. No.: HY-N1072

Wilforgine is a bioactive sesquiterpene alkaloid in Tripterygium wilfordii Hook. F.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Wilforlide A

(Regelide; Abruslactone A)

Cat. No.: HY-N0476

Wilforlide A is a **bioactive triterpene** isolated from Tripterygium wilfordii Hook f. Wilforlide A has anti-inflammatory and immune suppressive effects.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Wilfortrine

Cat. No.: HY-N3506

Wilfortrine is a bioactive sesquiterpene alkaloid. Wilfortrine exhibits immunosuppresive effects. Wilfortrine also can inhibit leukaemia cell growth in mice and shows anti-HIV activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Withaferin A

Cat. No.: HY-N2065

Withaferin A is a steroidal lactone isolated from Withania somnifera, inhibits **NF-kB** activation and targets **vimentin**, with potent antiinflammatory and anticancer activities. Withaferin A is an inhibitor of endothelial protein C receptor **(EPCR)** shedding.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

WKYMVM

Cat. No.: HY-P1120

WKYMVM is a potent N-formyl peptide receptor (**FPR1**) and **FPRL1/2** agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg

WKYMVM TFA

Cat. No.: HY-P1120A

WKYMVM (TFA) is a potent N-formyl peptide receptor (**FPR1**) and **FPRL1/2** agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WKYMVM-NH2 TFA

Cat. No.: HY-P1121A

WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Wogonin

Cat. No.: HY-N0400

Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of **CDK8** and **Wnt**, and exhibits anti-inflammatory and anti-tumor effects.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Wogonoside

Cat. No.: HY-N0399

Wogonoside, a flavonoid glycoside isolated from Huangqin, possesses anti-inflammatory effects. Wogonoside induces autophagy in breast cancer cells by regulating MAPK-mTOR pathway.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

WS3

Cat. No.: HY-12462

WS3 is a novel proliferative molecule that promotes pancreatic **β cell proliferation** in rodent and human primary islets. WS3 can be used for the research of type 1 diabetes.</br>.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

WS6

Cat. No.: HY-12461

WS6 is a novel small molecule that promotes β cell proliferation in rodent and human primary islets with EC50 of 0.28 uM(R7T1 cell viability). EC50 value: 0.28 uM Target: β cell proliferation agonist in vitro: WS6 induced up to 4% of rat β cells to proliferate, with an EC50 of 0.4 μM.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Wushanicaritin

Cat. No.: HY-N4111

Wushanicaritin exhibits significant antioxidant activity (IC_{50}=35.3 μM) in DPPH radical scavenging activity tests. Antitumor effects and anti-inflammatory property.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg

Wy 49051

Cat. No.: HY-101830

Wy 49051 is a potent, orally active **H1 receptor** antagonist, with **IC_{50}** of 44 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Xanthatin

Cat. No.: HY-N3032

Xanthatin is isolated from Xanthium strumarium leaves.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Xanthine

Cat. No.: HY-W017389

Xanthine, a plant alkaloid found in tea, coffee, and cocoa, is a mild stimulant of the central nervous system. Xanthine also acts as an intermediate product on the pathway of purine degradation.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 500 mg, 1 g

Xanthoangelol

Cat. No.: HY-111588

Xanthoangelol, extracted from Angelica keiskei, suppresses obesity-induced inflammatory responses. Xanthoangelol possesses antibacterial activity. Xanthoangelol inhibits monoamine oxidases. Xanthoangelol induces apoptosis in neuroblastoma and leukemia cells.



Purity: 98.36%
Clinical Data: No Development Reported
Size: 1 mg

Xanthone

Cat. No.: HY-N0126

Xanthone is isolated from Mangosteen and is known to control cell division and growth, apoptosis, inflammation, and metastasis in different stages of carcinogenesis.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 100 mg

Xanthopterin (hydrate)

Cat. No.: HY-119674A

Xanthopterin hydrate, an unconjugated pteridine compound, is the main component of the yellow granule in the Oriental hornet bear wings, produces a characteristic excitation/emission maximum at 386/456 nm.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Xanthotoxol

(8-Hydroxypsoralen)

Cat. No.: HY-30152

Xanthotoxol (8-Hydroxypsoralen) is a biologically active linear furocoumarin, shows strong pharmacological activities as anti-inflammatory, antioxidant, **5-HT** antagonistic, and neuroprotective effects.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

XVA143

Cat. No.: HY-139202

XVA143, an α/β I-like allosteric antagonist, inhibits **LFA-1** dependent firm adhesion, while at the same time it enhances adhesion in shear flow and rolling both in vitro and in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

XY018

Cat. No.: HY-120210

XY018 is a potent **ROR-γ**-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC_{50}, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD).



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Y-320

Cat. No.: HY-15898

Y-320 is a new phenylpyrazoleanilide immunomodulator; inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Yadanziolide B

Cat. No.: HY-N8399

Yadanziolide B, a natural quassinoid, is a potential **H5N1** neuraminidase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Yangonin

Cat. No.: HY-N0919

Yangonin exhibits affinity for the human recombinant cannabinoid **CB1 receptor** with an IC_{50} and a K_i of 1.79 μM and 0.72 μM, respectively.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

YKL-05-099

Cat. No.: HY-101147

YKL-05-099 is a salt-inducible kinase (**SIK**) inhibitor. YKL-05-099 binds to **SIK1** and **SIK3** with IC_{50}s of ~10 and ~30 nM, respectively. YKL-05-099 has slightly less potent SIK2-inhibitory (IC_{50}=40 nM).



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

YKL-06-061

Cat. No.: HY-120056

YKL-06-061 is a potent, selective, second-generation **salt-inducible kinase (SIK)** inhibitor with IC_{50} values of 6.56 nM/1.77 nM/20.5 nM for SIK1/2/3, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

YKL-06-062

Cat. No.: HY-129141

YKL-06-062 is a second-generation **salt-inducible kinase (SIK)** inhibitor with an IC_{50} of 2.12 nM/1.40 nM/2.86 nM, respectively. YKL-06-062 is the structural analog of YKL-06-062.



Purity: 95.26%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

YM-264

Cat. No.: HY-101833

YM-264 is a selective, potent and orally active **platelet-activating factor (PAF)** antagonist with a pKi value of 8.85 for rabbit platelet membranes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YM-341619

(AS1617612)

Cat. No.: HY-134771

YM-341619 (AS1617612) is a potent and orally active **STAT6** inhibitor with an IC_{50} of 0.70 nM. YM-341619 inhibits Th2 differentiation in mouse spleen T cells induced by IL-4 (IC_{50}=0.28 nM) without affecting Th1 cell differentiation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YM-58483

(BTP2)

Cat. No.: HY-100831

YM-58483 (BTP2) is the first selective and potent inhibitor of **CRAC channels** and subsequent Ca^{2+} signals. YM-584832 is a blocker of store-operated Ca^{2+} entry (**SOCE**).



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

YM-90709

Cat. No.: HY-19969

YM-90709 is a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

YM158 free base

(YM-57158)

Cat. No.: HY-U00355

YM158 free base is a potent and selective LTD_4 and TXA_2 **receptor** antagonist with pA_2 values of about 8.87 and 8.81, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Yohimbic acid

Cat. No.: HY-121936

Yohimbic acid is an amphoteric demethylated derivative of Yohimbine. Yohimbic acid exhibits vasodilatory action. Yohimbic acid also can be used for the research of osteoarthritis (OA).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

YQ128

Cat. No.: HY-130252

YQ128 is a potent and selective second-generation **NLRP3 (NOD-like receptor P3) inflammasome** inhibitor with an IC_{50} of 0.30 μM. YQ128 significantly and selectively suppresses the production of **IL-1β**, but not TNF-α, and it can cross the BBB to reach the CNS.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Yubeinine

Cat. No.: HY-107276

Yubeinine is an alkaloid with tracheal relaxant effects.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Z-Asp-CH2-DCB

Cat. No.: HY-113953

Z-Asp-CH2-DCB is an irreversible broad spectrum **caspase** inhibitor. Z-Asp-CH2-DCB also inhibits proteases with caspase-like activity.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Z-LVG-CHN2

Cat. No.: HY-108137

Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of **cysteine proteinase**. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Z62954982

(ZINC08010136)

Cat. No.: HY-115376

Z62954982 (ZINC08010136) is a potent, selective and cell-permeable **Rac1** (IC_{50}=12 μM) inhibitor that is 4 times more effective than NSC23766 (HY-15723A) (IC_{50}=50 μM).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg (99.87 mM * 120.5 μL in DMSO)

Zabedosertib

(BAY 1834845)

Cat. No.: HY-139374

Zabedosertib (BAY 1834845) is a **IRAK4** inhibitor with immunomodulatory potential. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zafirlukast

(ICI 204219)

Cat. No.: HY-17492

Zafirlukast (ICI 204219) is a potent orally active **leukotriene D_4 (LTD_4) receptor** antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Zafirlukast-d7

Cat. No.: HY-17492S

Zafirlukast-d7 (ICI 204219-d7) is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active **leukotriene D_4 (LTD_4) receptor** antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Zaldaride maleate

(CGS-9343B; KW 5617)

Cat. No.: HY-105118A

Zaldaride maleate (CGS-9343B) is a potent, orally active and selective inhibitor of **calmodulin**. Zaldaride maleate (CGS-9343B) inhibits CaM (calmodulin)-stimulated cAMP phosphodiesterase activity, with an IC_{50} of 3.3 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Zaloglanstat

(ISC-27864; GRC-27864)

Cat. No.: HY-139589

Zaloglanstat (ISC-27864) is the inhibitor of the **microsomal prostaglandin E synthase-1 (mPGES-1)**, and can be used to study asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases, etc.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zaltoprofen

(CN100)

Cat. No.: HY-B0619

Zaltoprofen (CN100), a non-steroidal anti-inflammatory drug (NSAID), is a preferential and orally active **COX-2** inhibitor, with IC_{50}s of 1.3 and 0.34 μM for **COX-1** and **COX-2**, respectively.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

ZAP-180013

Cat. No.: HY-136179

ZAP-180013 is a **zeta-chain-associated protein kinase 70 (ZAP-70)** inhibitor with an IC_{50} of 1.8 μM. ZAP-180013 inhibits the interaction of **ZAP-70** SH2 domain with immunoreceptor tyrosine-based activation motif (ITAMs).



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Zardaverine

Cat. No.: HY-15485

Zardaverine is a newly developed dual-selective PDE3/4 inhibitor with IC50 values of 0.5 uM and 0.8 uM respectively.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Zastaprazan

Cat. No.: HY-139557

Zastaprazan is a **proton pump** inhibitor (WO2018008929). Zastaprazan can be used for the research of gastrointestinal inflammatory diseases or gastric acid-related diseases.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Zauategrast
(CT7758) Cat. No.: HY-70073

Zauategrast (CT7758) is a potent and oral-effective **α_4-integrin** inhibitor.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Zauategrast ethyl ester
(CDP323; UCB1184197) Cat. No.: HY-75385

Zauategrast ethyl ester (CDP323), the ethyl ester prodrug of CT7758, is a **α4β1/α4β7** integrin antagonist used for the treatment of inflammatory and autoimmune disorders.



Purity: 99.06%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Zauategrast ethyl ester sulfate
(CDP323 sulfate; UCB1184197 sulfate) Cat. No.: HY-75385A

Zauategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester prodrug of CT7758, is a **α4β1/α4β7** integrin antagonist used for the treatment of inflammatory and autoimmune disorders.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

ZD8321
Cat. No.: HY-U00256

ZD8321 is a potent inhibitor of human **Neutrophil elastase** (**NE**) with a K_i of 13±1.7 nM.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zeaxanthin
Cat. No.: HY-120318

Zeaxanthin, a diet-obtained carotenoid, presents in the macula region of the eye. Zeaxanthin shows antioxidant effects.



Purity: ≥95.0%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Zectivimod
Cat. No.: HY-139555

Zectivimod is a **sphingosine-1-phosphate receptor** agonist. Zectivimod can be used for the research of autoimmune diseases, chronic inflammatory diseases and immunoregulation disorders.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ZED-1227
Cat. No.: HY-19359

ZED-1227 is a specific and orally active **transglutaminase 2 (TG2)** inhibitor, with an **IC_{50}** of 45 nM. ZED-1227 can block inflammation-induced TG2 expression and activity. ZED-1227 can be used for the research of celiac disease (CeD).



Purity: 99.97%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Zetomipzomib
(KZR-616) Cat. No.: HY-114419

Zetomipzomib (KZR-616), a first-in-class inhibitor of the **immunoproteasome**, selectively targets the LMP7 (IC_{50}: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC_{50}: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. Zetomipzomib has the potential for the research of multiple autoimmune diseases.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg

Zetomipzomib maleate
(KZR-616 maleate) Cat. No.: HY-114419A

Zetomipzomib (KZR-616) maleate, a first-in-class **immunoproteasome** inhibitor, selectively targets the LMP7 (IC_{50}: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC_{50}: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ziconotide
(SNX-111) Cat. No.: HY-P0062

Ziconotide (SNX-111), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide reduces synaptic transmission, and can be used for chronic pain research.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ziconotide acetate

(SNX-111 acetate) Cat. No.: HY-P0062B

Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research.



Purity: 99.64%
Clinical Data: Launched
Size: 5 mg, 10 mg

Ziconotide TFA

(SNX-111 TFA) Cat. No.: HY-P0062A

Ziconotide TFA (SNX-111 TFA), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide TFA reduces synaptic transmission, and can be used for chronic pain research.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Zileuton

(A 64077; Abbott 64077) Cat. No.: HY-14164

Zileuton is a potent and selective inhibitor of **5-lipoxygenase** with antiasthmatic properties.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Zileuton sodium

(A 64077 sodium; Abbott 64077 sodium) Cat. No.: HY-14164A

Zileuton sodium (A 64077 sodium) is a potent and selective inhibitor of **5-lipoxygenase**, exhibiting inflammatory activities.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Zileuton-d4

Cat. No.: HY-14164S

Zileuton-d4 (A 64077-d4) is the deuterium labeled Zileuton. Zileuton (A 64077) is a potent and selective inhibitor of **5-lipoxygenase** with antiasthmatic properties.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Zimlovisertib

(PF-06650833) Cat. No.: HY-19836

Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of **interleukin-1 receptor associated kinase 4 (IRAK4)** with IC_{50}s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively.



Purity: 99.84%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Zingerone

(Vanillylacetone; Gingerone) Cat. No.: HY-14621

Zingerone (Vanillylacetone) is a nontoxic methoxyphenol isolated from Zingiber officinale, with potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, antispasmodic and anti-tumor properties.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Ziritaxestat

(GLPG1690) Cat. No.: HY-101772

Ziritaxestat (GLPG1690) is a first-in-class **autotaxin (ATX)** inhibitor, with an IC_{50} of 131 nM and a K_i of 15 nM.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ziyuglycoside II

Cat. No.: HY-N0332

Ziyuglycoside II is a triterpenoid saponin compound extracted from Sanguisorba officinalis L.. Ziyuglycoside II induces reactive oxygen species (**ROS**) production and **apoptosis**. Anti-inflammation and anti-cancer effect.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

ZK 216348

((+)-ZK 216348) Cat. No.: HY-123352

ZK 216348 ((+)-ZK 216348) is a nonsteroidal selective **glucocorticoid receptor** agonist with an IC_{50} of 20.3 nM. ZK 216348 also binds to Progesterone and mineralocorticoid receptors with IC_{50}s of 20.4 nM and 79.9 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZK-261991

Cat. No.: HY-15333

ZK-261991 is an orally active **VEGFR** tyrosine kinase inhibitor with an IC_{50} of 5 nM for VEGFR2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZK-90055 hydrochloride

Cat. No.: HY-U00293

ZK-90055 hydrochloride is a **β2 adrenergic receptor** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZK824190

Cat. No.: HY-126361

ZK824190 is an orally available and selective **urokinase plasminogen activator** (**uPA**) inhibitor as a potential treatment for multiple sclerosis. IC_{50}s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZK824859

Cat. No.: HY-114330

ZK824859 is an oral available and selective urokinase plasminogen activator (**uPA**) inhibitor with IC_{50}s of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZK824859 hydrochloride

Cat. No.: HY-114330A

ZK824859 hydrochloride is an oral available and selective urokinase plasminogen activator (**uPA**) inhibitor with IC_{50}s of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ZL0420

Cat. No.: HY-112149

ZL0420 is a potent and selective bromodomain-containing protein 4 (**BRD4**) inhibitor with IC_{50} values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

ZL0454

Cat. No.: HY-112150

ZL0454 is a potent and selective **Bromodomain-containing protein 4 (BRD4)** inhibitor with an IC_{50} of 49 and 32 nM for BD1 and BD2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZL0580

Cat. No.: HY-126428

ZL0580, a structurally close analog of ZL0590, induces epigenetic suppression of **HIV** via selectively binding to BD1 domain of **BRD4**.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zomepirac sodium salt

(McN-2783-21-98)

Cat. No.: HY-B0890

Zomepirac sodium salt (McN-2783-21-98) is a potent **prostaglandin biosynthesis** inhibitor. Zomepirac sodium salt is a non-steroidal anti-inflammatory drug (NSAID). Zomepirac sodium salt can cause immune-mediated liver injury.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg

Zomepirac-d4 sodium salt

Cat. No.: HY-B0890S

Zomepirac-d4 sodium salt is the deuterium labeled Zomepirac sodium salt. Zomepirac sodium salt (McN-2783-21-98) is a potent **prostaglandin biosynthesis** inhibitor. Zomepirac sodium salt is a non-steroidal anti-inflammatory drug (NSAID).



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 5 mg, 10 mg, 25 mg

Zunsemetinib

(ATI-450; CDD-450)

Cat. No.: HY-139553

Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (**MK2**) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

[D-p-Cl-Phe6,Leu17]-VIP

Cat. No.: HY-P1159

[D-p-Cl-Phe6,Leu17]-VIP is a competitive and selective antagonist of **vasoactive intestinal peptide (VIP) receptor**, with the IC_{50} of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP has no activity on glucagon, secretin or GRF receptors.

HSDAV-(Cl-Phe)-TDNYTRLRKQLAVKKYLNSILN-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[D-p-Cl-Phe6,Leu17]-VIP TFA

Cat. No.: HY-P1159A

[D-p-Cl-Phe6,Leu17]-VIP TFA is a competitive and selective antagonist of **vasoactive intestinal peptide (VIP) receptor**, with the IC_{50} of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP TFA has no activity on glucagon, secretin or GRF receptors.

HSDAV-(Cl-Phe)-TDNYTRLRKQLAVKKYLNSILN-NH_2 (TFA salt)

Purity: 99.26%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

[D-Trp8]-γ-MSH

Cat. No.: HY-P1217

[D-Trp8]-γ-MSH is a potent and selective agonist of **melanocortin 3 (MC3) receptor**, with IC_{50}s of 6.7 nM, 600 nM and 340 nM for **hMC3**, **hMC4** and **hMC5**, respectively in CHO cells.

YVMGHFRWDRFG

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[D-Trp8]-γ-MSH TFA

Cat. No.: HY-P1217A

[D-Trp8]-γ-MSH TFA is a potent and selective agonist of **melanocortin 3 (MC3) receptor**, with IC_{50}s of 6.7 nM, 600 nM and 340 nM for **hMC3**, **hMC4** and **hMC5**, respectively in CHO cells.

YVMGHFRWDRFG (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Des-Arg9]-Bradykinin

Cat. No.: HY-P0298

[Des-Arg9]-Bradykinin is a **Bradykinin** (B_1) receptor agonist that displays selectivity for B_1 over B_2 receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Des-Arg9]-Bradykinin acetate

Cat. No.: HY-P0298A

[Des-Arg9]-Bradykinin acetate is a **Bradykinin B_1 receptor** agonist that displays selectivity for B_1 over B_2 receptors.



Purity: 96.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

[Lys5,MeLeu9,Nle10]-NKA(4-10)

Cat. No.: HY-P1279

[Lys5,MeLeu9,Nle10]-NKA(4-10) is a highly selective and potent NK_2 receptor agonist, with an IC_{50} of 6.1 nM.

DKFVG{N(Me)Leu}{Nle}-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Nphe1]Nociceptin(1-13)NH2

Cat. No.: HY-P1320

[Nphe1]Nociceptin(1-13)NH2, a novel **nociceptin/orphanin FQ (NC)** endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity.

Bn-GGGFTGARKSARK-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Nphe1]Nociceptin(1-13)NH2 TFA

Cat. No.: HY-P1320A

[Nphe1]Nociceptin(1-13)NH2, a novel **nociceptin/orphanin FQ (NC)** endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity.

Bn-GGGFTGARKSARK-NH_2 (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

{Boc}-Phe-Leu-Phe-Leu-Phe

Cat. No.: HY-P2355

{Boc}-Phe-Leu-Phe-Leu-Phe ({Boc}-FLFLF) is a formyl peptide receptor (**FPR**) family antagonist that preferentially inhibits activity triggered through the formyl peptide receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

{Boc}-Phe-Leu-Phe-Leu-Phe TFA

Cat. No.: HY-P2355A

{Boc}-Phe-Leu-Phe-Leu-Phe TFA is a formyl peptide receptor (**FPR**) family antagonist that preferentially inhibits activity triggered through the formyl peptide receptor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α,β-Methylene ATP trisodium

Cat. No.: HY-108652

α,β-Methylene ATP trisodium, a phosphonic analog of ATP, is a P2X3 and P2X7 receptor ligand. α,β-Methylene ATP trisodium is a highly selective agonist for P2X1 and P2X3, with practically no activity at P2X2,4-7.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

α,β-Methylene-ATP dilithium

Cat. No.: HY-134440

α,β-Methylene ATP dilithium, a phosphonic analog of ATP, is a P2X3 and P2X7 receptor ligand. α,β-Methylene ATP dilithium is a highly selective agonist for **P2X1** and **P2X3**, with practically no activity at P2X2,4-7.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-2,3-sialyltransferase-IN-1

(Lith-O-Asp analog)

Cat. No.: HY-112535

α-2,3-sialyltransferase-IN-1 (Lith-O-Asp analog) is a noncompetitive **α-2,3-sialyltransferase** inhibitor with an IC_{50} of 6 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

α-Amyrin acetate

Cat. No.: HY-N2842

α-Amyrin acetate, a natural triterpenoid, has anti-inflammatory activity, antispasmodic profile and the relaxant effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

α-Amyrin palmitate

Cat. No.: HY-N2843

α-Amyrin palmitate is isolated from Santalum album (sandalwood). α-Amyrin palmitate can be used for the study of arthritis in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

α-CGRP, rat

Cat. No.: HY-P0203

α-CGRP, rat, a neuropeptide (calcitonin gene-related peptide (CGRP)), is a potent vasodilator, with the potential in cardiovascular, pro-inflammatory and metabolic studies.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-CGRP, rat TFA

Cat. No.: HY-P0203A

α-CGRP, rat TFA, a neuropeptide (calcitonin gene-related peptide (CGRP)), is a potent vasodilator, with the potential in cardiovascular, pro-inflammatory and metabolic studies.

Purity: 99.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-D-Glucose-1-phosphate disodium

Cat. No.: HY-128747

α-D-Glucose-1-phosphate disodium is used as a starting material for synthesis of glucuronic acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-D-Glucose-1-phosphate disodium hydrate

Cat. No.: HY-128747A

α-D-Glucose-1-phosphate disodium hydrate is used as a starting material for synthesis of glucuronic acid.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

α-Galactosylceramide

(α-GalCer; KRN7000)

Cat. No.: HY-102022

α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent **NKT cell** agonist and binds effectively to CD1d.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

α-Humulene

(Humulene; α-Caryophyllene)

Cat. No.: HY-N6968

α-Humulene is a main constituent of Tanacetum vulgare L. (Asteraceae) essential oil with anti-inflammation (IC_{50}=15±2 μg/mL). α-Humulene inhibits **COX-2** and **iNOS** expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-Lipoic Acid

(Thioctic acid; (±)-α-Lipoic acid; DL-α-Lipoic acid)

Cat. No.: HY-N0492

α-Lipoic Acid is an antioxidant, which is an essential cofactor of **mitochondrial** enzyme complexes. α-Lipoic Acid inhibits **NF-κB**-dependent **HIV-1** LTR activation. α-Lipoic Acid induces endoplasmic reticulum (ER) stress-mediated **apoptosis** in hepatoma cells.



Purity: 98.03%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

α-Lipoic Acid-d5 (Thioctic acid-d5; (±)-α-Lipoic acid-d5; DL-α-Lipoic acid-d5)

Cat. No.: HY-N0492S

α-Lipoic Acid-d5 (Thioctic acid-d5) is the deuterium labeled α-Lipoic Acid. α-Lipoic Acid is an antioxidant, which is an essential cofactor of **mitochondrial** enzyme complexes. α-Lipoic Acid inhibits **NF-κB**-dependent **HIV-1** LTR activation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

α-MSH

(α-Melanocyte-Stimulating Hormone)

Cat. No.: HY-P0252

α-MSH (α-Melanocyte-Stimulating Hormone), an endogenous neuropeptide, is an endogenous **melanocortin receptor 4 (MC4R)** agonist with anti-inflammatory and antipyretic activities. α-MSH is a post-translational derivative of pro-opiomelanocortin (POMC).

Ac-SYSMEHFRWGKPV-NH_2

Purity: 98.02%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

α-MSH TFA

(α-Melanocyte-Stimulating Hormone TFA)

Cat. No.: HY-P0252A

α-MSH (α-Melanocyte-Stimulating Hormone) TFA, an endogenous neuropeptide, is an endogenous **melanocortin receptor 4 (MC4R)** agonist with anti-inflammatory and antipyretic activities. α-MSH TFA is a post-translational derivative of pro-opiomelanocortin (POMC).

Ac-SYSMEHFRWGKPV-NH_2 (TFA salt)

Purity: 99.48%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

α-Terpineol

Cat. No.: HY-N5142

α-Terpineol is isolated from Eucalyptus globulus Labill, exhibits strong antimicrobial activity against periodontopathic and cariogenic bacteria. α-Terpineol possesses antifungal activity against T. mentagrophytes, and the activity might lead to irreversible cellular disruption.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

α-Truxillic acid

Cat. No.: HY-114771

α-Truxillic acid is form by the dimerization of two molecules of α-trans-cinnamic acid, with anti-inflammatory activities.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

α-Zearalenol

Cat. No.: HY-N6710

α-Zearalenol is a Mycotoxin with high affinity for the estrogen receptors (**ER**), α-Zearalenol is the derivative of zearalenone (ZEN), causes reproductive disorders in animals, due to its xenoestrogenic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

α-Chaconine

Cat. No.: HY-129113

α-Chaconine inhibits the expressions of **COX-2**, **IL-1β**, **IL-6**, and **TNF-α** at the transcriptional level. α-Chaconine inhibits the LPS-induced expressions of **iNOS** and **COX-2** at the protein and mRNA levels and their promoter activities in RAW 264.7 macrophages. Anti-inflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Aminoarteether

(SM934 free base)

Cat. No.: HY-137553

β-Aminoarteether (SM934 free base) is an Artemisinin derivative with orally active. β-Aminoarteether can be used for inflammation and autoimmune disease research, such as lupus diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Amyrenonol

(11-Oxo-β-amyrin)

Cat. No.: HY-N2920

β-Amyrenonol (11-Oxo-β-amyrin), an oleanolic-type triterpenoid in licorice roots, is a precursor of Glycyrrhetinic acid. β-Amyrenonol has anti-proliferative and anti-inflammatory activities, and β-Amyrenonol could function as the skeleton for the synthesis of many triterpenoids.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

β-Anhydroicaritin

Cat. No.: HY-N1940

β-Anhydroicaritin is isolated from Boswellia carterii Birdware, has important biological and pharmacological effects, such as antiosteoporosis, estrogen regulation and antitumor properties.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

β-CGRP, human

(Human β-CGRP; CGRP-II (Human))

Cat. No.: HY-P1548

β-CGRP, human (Human β-CGRP) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC_{50}s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-CGRP, human acetate

(Human β-CGRP acetate; CGRP-II (Human) (acetate))

Cat. No.: HY-P1548B

β-CGRP, human acetate (Human β-CGRP acetate) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC_{50}s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-CGRP, human TFA

(Human β-CGRP TFA; CGRP-II (Human) (TFA))

Cat. No.: HY-P1548A

β-CGRP, human TFA (Human β-CGRP TFA) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC_{50}s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.

Purity: 99.01%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

β-Elemonic acid

Cat. No.: HY-N2454

β-Elemonic acid is a triterpene isolated from Boswellia papyrifera. β-Elemonic acid induces cell **apoptosis**, reactive oxygen species (**ROS**) and **COX-2** expression and inhibits **prolyl endopeptidase**. β-Elemonic acid exhibits anticancer and anti-inflammatory effects.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

β-Hederin

Cat. No.: HY-N7489

β-Hederin, a saponin isolated from Hedera helix L.(Araliaceae), possesses **antileishmanial** activity. β-Hederin exhibits IC_{50} values of 1.5 μM, 68 nM and 4.57 μM in L. Mexicana promastigotes, L. mexicana amastigotes and THP1 cells, respectively.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Tocotrienol

Cat. No.: HY-108693

β-Tocotrienol is one form of vitamin E. β-Tocotrienol is a less potent antioxidant than α-tocotrienol.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

γ-Asarone

Cat. No.: HY-N7937

γ-Asarone, a phenylpropene, shows strong correlation with the biological activities (anti-oxidative, anti-inflammatory and neurotrophic effects).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

γ-Globulins from human blood

Cat. No.: HY-118870

γ-Globulins from human blood are a class of proteins in the blood. γ-Globulin is a protein fraction of blood serum containing many antibodies that protect against bacterial and viral infectious diseases. γ-Globulins from human blood is used for common variable immunodeficiency.

γ-Globulins from human blood

Purity: ≥99.0%
Clinical Data: Launched
Size: 10 mg, 50 mg, 250 mg

γ-Linolenic acid ethyl ester

(Ethyl γ-linolenate)

Cat. No.: HY-108396

γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a **leukotriene B_4 receptor 4 (LTB_4)** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

γ-Tocopherol

(D-γ-Tocopherol; (+)-γ-Tocopherol)

Cat. No.: HY-N7148

γ-Tocopherol (D-γ-Tocopherol) is a potent **cyclooxygenase (COX)** inhibitor. γ-Tocopherol is a naturally occurring form of Vitamin E in many plant seeds, such as corn oil and soybeans. γ-Tocopherol possesses antiinflammatory properties and anti-cancer activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

γ-Tocopherol-d4

Cat. No.: HY-N7148S1

γ-Tocopherol-d4 (D-γ-Tocopherol-d4) is the deuterium labeled γ-Tocopherol. γ-Tocopherol (D-γ-Tocopherol) is a potent **cyclooxygenase (COX)** inhibitor. γ-Tocopherol is a naturally occurring form of Vitamin E in many plant seeds, such as corn oil and soybeans.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

γ-Tocotrienol

Cat. No.: HY-108694

γ-Tocotrienol is an active form of vitamin E.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

δ-Amyrenone

(Delta-Amyrone)

Cat. No.: HY-N1037

δ-Amyrenone (Delta-Amyrone) is a pentacyclic triterpene compound from S. lineare, with anti-inflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ε-Viniferin

(epsilon-Viniferin)

Cat. No.: HY-N3841

ε-Viniferin, the dimer of Resveratrol and isolated from **Vitis vinifera**, displays a potent inhibitory for all the **CYP** activities, with K_i values from 0.5-20 μM. ε-Viniferin possesses potent antioxidant capacity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

κ-Carrageenan

Cat. No.: HY-138962

κ-Carrageenan is a natural polymer which predominantly available in red seaweeds. κ-Carrageenan is an effective drug carrier to deliver curcumin in cancer cells and to induce **apoptosis**.

k-Carrageenan

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg